

National Healthcare Safety Network (NHSN)

Patient Safety Component Manual

Table of Contents

Chapter 1: National Healthcare Safety Network (NHSN) Overview
Chapter 2: Identifying Healthcare-associated Infections (HAI) for NHSN Surveillance
Chapter 3: Patient Safety Monthly Reporting Plan and Annual Surveys
Chapter 4: Bloodstream Infection Event (Central Line-Associated Bloodstream Infection and non- central line-associated Bloodstream Infection)
Chapter 6: Pneumonia (Ventilator-associated [VAP] and non-ventilator-associated Pneumonia [PNEU]) Event
Chapter 7: Urinary Tract Infection (Catheter-Associated Urinary Tract Infection [CAUTI] and non- catheter-associated Urinary Tract Infection [UTI]) and Other Urinary System Infection (USI) Events
Chapter 9: Surgical Site Infection (SSI) Event
Chapter 10: Ventilator-Associated Event (VAE)
Chapter 11: Pediatric Ventilator-Associated Event (PedVAE)
Chapter 12: Multidrug-Resistant Organism & <i>Clostridioides difficile</i> Infection (MDRO/CDI) Module
Chapter 14: Antimicrobial Use and Resistance (AUR)
Chapter 15: CDC Locations and Descriptions and Instructions for Mapping Patient Care Locations
Chapter 16: General Key Terms
Chapter 17: CDC/NHSN Surveillance Definitions for Specific Types of Infections

Please Note: The NHSN Patient Safety Component Manual is updated annually based on subject matter expert review and user feedback. Over time, certain chapters have been retired or moved to other components. To avoid confusion, the chapters in the PSC manual do not shift to account for these changes; therefore, chapters 5, 8, and 13 are not listed in the Table of Contents or included in this document.

National Healthcare Safety Network (NHSN) Overview

CDC's NHSN is a secure, web-based surveillance application that is the nation's most widely used healthcare-associated infection (HAI) tracking system. The application is managed and maintained by the Division of Healthcare Quality Promotion (DHQP) at the Centers for Disease Control and Prevention (CDC).

While ensuring data security, integrity, and confidentiality, NHSN gives healthcare facilities the ability to see their data in real-time and share that information with clinicians and facility leadership, as well as with other facilities (for example, a multihospital system) and partners such as health departments or quality improvement organizations. CDC provides the standard national measures for HAIs as well as analytic tools that enable each facility to assess its progress and identify where additional efforts are needed. In addition, NHSN is the conduit for facilities to comply with Centers for Medicare and Medicaid Services (CMS) infection reporting requirements.


NHSN provides medical facilities, states, regions, and the nation with data collection and reporting capabilities needed to:

- identify infection prevention problems by facility, state, or specific quality improvement project
- benchmark progress of infection prevention efforts
- comply with state and federal public reporting mandates, and ultimately,
- drive national progress toward elimination of HAIs.

[NHSN Fact Sheet](#)

NHSN includes the following components: Patient Safety, Long-term Care Facility, Outpatient Dialysis, Healthcare Personnel Safety, Biovigilance, Outpatient Procedure, Neonatal, Medication Safety, and Healthcare Preparedness (Figure 1).

Figure 1: NHSN Components



The **Patient Safety Component (PSC)** includes modules that focus on events associated with medical devices, surgical procedures, antimicrobial agents used during healthcare, and multidrug resistant organisms.

- Device-associated Modules:
 - Bloodstream Infection (CLABSI – Central line-associated bloodstream infection)
 - Urinary Tract Infection (CAUTI – Catheter-associated urinary tract infection)
 - Pediatric Ventilator-associated Events (PedVAE) (NICU and pediatric locations only)
 - Ventilator-associated Events (VAE) (adult locations only)
 - Pneumonia (VAP – Ventilator-associated Pneumonia) - in pediatric locations (in-plan* or off-plan*), or NICU and adult locations (off-plan* only)
- Procedure-associated Module:
 - Surgical Site Infection (SSI)
- Antimicrobial Use and Resistance Module (AUR)
- Multidrug-Resistant Organism and *Clostridioides difficile* Infection (MDRO/CDI) Module
- Hospital Respiratory Data (HRD) Module

***Note:** “In-plan” surveillance means that the facility has committed to following the NHSN surveillance protocol, in its entirety, for that particular event, as shown in the facility’s NHSN monthly reporting plan. “Off-plan” surveillance is surveillance that is done because a facility has decided to track a particular event for internal use. Data that are entered into NHSN “off-plan” are not included in NHSN annual reports or other NHSN publications. A facility makes no commitment to follow the NHSN protocol for “off-plan” events. Further, “off-plan” data cannot be uploaded into NHSN via Clinical Document Architecture (CDA) and must be manually entered. Instructions and standardized surveillance methods and definitions for each module of the Patient Safety Component are provided in this manual and on the NHSN website (www.cdc.gov/nhsn).

The NHSN **Long-term Care Facility Component** provides long-term care facilities (LTCFs) with standardized surveillance methods and definitions for four modules: 1) Respiratory Pathogens and Vaccination (RPV); 2) Multidrug resistant organism (MDRO) and *Clostridioides difficile* Infection (CDI) Laboratory-identified (LabID) Events; 3) Urinary Tract Infections (UTI); and 4) Prevention Process Measures. The component is accessible to nursing homes, skilled nursing facilities, chronic care facilities, assisted living and residential care facilities, intermediate care facilities for individuals with intellectual disabilities, psychiatric residential treatment facilities, and State Veteran’s Homes. LTCF surveillance protocols, training materials, data collection forms, instructions, and other supporting materials are provided on the Long-term Care Facility Component website: <https://www.cdc.gov/nhsn/ltc/index.html>.

Outpatient hemodialysis centers have surveillance options that are tailored for the specific facility patient population and clinical setting within the **Dialysis Component**. The Dialysis component consists of the following: 1) Dialysis Event (Outpatient Hemodialysis and Acute Kidney Injury (AKI)); 2) Prevention Process Measures; and 3) Summary Data. These modules focus on monitoring and reporting adverse events for the purpose of evaluating prevention efforts among hemodialysis patients. Facilities that treat hemodialysis outpatients should refer to the Dialysis Component protocol, instructions and standardized surveillance methods and definitions at www.cdc.gov/nhsn/dialysis/index.html.

There are two modules in the **Healthcare Personnel Safety (HPS) Component** of NHSN: The Healthcare Personnel Exposure Module and the Healthcare Personnel Vaccination Module. These modules may be used separately or simultaneously. Data collected in this surveillance component can assist healthcare facilities, health systems, and public health agencies to review data on blood/body fluid exposures and antiviral medication use for exposures to influenza, and to monitor influenza and COVID-19 vaccination coverage among healthcare personnel.

The Healthcare Personnel Exposure Module includes Blood/Body Fluid Exposure Only; Blood/Body Fluid Exposure with Exposure Management; and Influenza Exposure Management. This module was retired in June 2025, but facilities can continue to access their historical exposure data for analysis.

The Healthcare Personnel Vaccination Module includes the Influenza Vaccination Summary and COVID-19 Vaccination Summary. Information on reporting influenza vaccination data for healthcare personnel is found here: <https://www.cdc.gov/nhsn/hps/vaccination/index.html>. Information on reporting COVID-19 vaccination data for healthcare personnel is found here: <https://www.cdc.gov/nhsn/hps/weekly-covid-vac/index.html>.

The **NHSN Biovigilance Component**, Hemovigilance Module facilitates national surveillance of transfusion-related recipient adverse events. The Hemovigilance Module is designed for transfusion service staff to collect data on annual facility and transfusion service characteristics, individual reports on adverse transfusion reactions, and yearly counts of transfused or discarded components. The Hemovigilance Module surveillance protocol, training materials, data collection forms, instructions, and other supporting materials are provided on the Hemovigilance Module website: <https://www.cdc.gov/nhsn/biovigilance/blood-safety/index.html>.

The **Outpatient Procedure Component (OPC)** includes two modules that focus on adverse events associated with surgical procedures performed in Ambulatory Surgery Centers (ASCs). The two modules include Same Day Outcome Measures and Surgical Site Infections.

- Same Day Outcome Measures (OPC-SDOM) are a grouping of outpatient care quality indicators that represent a broad range of risks encountered by patients accessing care in various outpatient settings. The four individual outcome measures are:
 - Patient Burn
 - Patient Fall
 - Wrong Site, Wrong Side, Wrong Patient, Wrong Procedure, Wrong Implant
 - All-Cause Hospital Transfer/Admission
- Surgical Site Infection (OPC-SSI) - SSI surveillance for outpatient operative procedures using the Outpatient Procedure Component (OPC).

The OPC surveillance protocols, training materials, data collection forms, instructions, and other supporting materials are provided on the Outpatient Procedure Component website: <https://www.cdc.gov/nhsn/ambulatory-surgery/index.html>.

The **Neonatal Component** includes one module, Late-Onset Sepsis/ Meningitis (LOS/MEN). This module will track late-onset sepsis and meningitis events in very low birthweight neonates housed in Level II/III, Level III, and Level IV nursery locations. The following events will be tracked in the LOS/MEN module:

- Late-Onset Sepsis Event: In an eligible infant, a recognized pathogen or common commensal identified from one or more blood specimens by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment. Under this major type of infection, there are two specific types of infection (see below).
 - NLCBI 1
 - NLCBI 2
- Meningitis Event: In an eligible infant, a recognized pathogen or common commensal identified from a CSF specimen by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment. Under this major type of infection, there are two specific types of infection (see below).
 - NLCM 1
 - NLCM 2

The LOS/MEN surveillance protocols, training materials, data collection forms, instructions, and other supporting materials are provided on the Neonatal Component website:

<https://www.cdc.gov/nhsn/neonatal/index.html>.

The **Medication Safety Component** (MSC) comprises a single module, the Glycemic Control Module. This module focuses on surveillance, measurement, and benchmarking of inpatient medication-related hypoglycemia and hyperglycemia events within healthcare facilities using the Fast Healthcare Interoperability Resources (FHIR) data- exchange standard. Manual and CDA reporting are not available for the Medication Safety Component.

As NHSN gains more experience with the MSC, new areas of focus that can be supported by digital quality measurement will be added. All inpatient facilities enrolled in NHSN are eligible to enroll and participate in the MSC. Long-term care facilities (LTCFs) and outpatient dialysis facilities are not yet eligible to participate in the Medication Safety Component.

The Medication Safety Component protocol is available at the NHSN website:

<https://www.cdc.gov/nhsn/medication-safety-component/index.html>.

The **Healthcare Preparedness Component** is designed to collect data on hospital readiness, operational and critical infrastructure status. The Healthcare Preparedness component will provide NHSN users with resources that support the collection of standardized data on hospital readiness and resource availability. These resources are designed to assess the operational status of U.S. healthcare facilities under normal conditions and during emergencies, including natural disasters and public health crises.

The first module in this component is the Daily Facility Operating Status. The Daily Facility Operating Status module allows facilities to enter daily status updates on evacuation status and critical elements such as power, water, and structural integrity. The report from the module enhances situational awareness and informs coordination and response efforts at the federal, state, and local levels.

The Daily Facility Operating Status module is available for optional reporting of critical infrastructure information for acute care or other short-term stay hospitals. Facilities report every 12 hours during normal operations and during emergency events. The data elements in this module include the overall facility operating status (normal, contingency, emergency) and the following:

- Structural
- Evacuation
- Power
- Water
- Sewer
- Immediate needs

The Daily Facility Operating Status protocols, training materials, data collection forms, instructions, and other supporting materials are provided on the Healthcare Preparedness Component website.

Surveillance Techniques

Surveillance for healthcare associated conditions/infections require a combination of active, concurrent, prospective, or retrospective approaches and surveillance techniques and resources. Trained Infection Preventionists (IPs) and designees shall seek out infections/conditions by screening a variety of data sources, such as laboratory, pharmacy, admission/discharge/transfer, radiology/imaging, and pathology databases, as well as patient charts, including history and physical exam notes, nurses'/ physicians' notes, temperature charts, etc. Others may be trained to screen data sources for these events, but the IP must make the final determination. Laboratory-based surveillance should not be used alone, unless all possible criteria for identifying an infection are solely determined by laboratory evidence (for example, LabID event detection in the MDRO/CDI Module). Retrospective chart reviews should be used only when patients are discharged before all information can be gathered. NHSN forms should be used to collect all required data, using the NHSN definitions of each data field. To minimize the IP's data collection burden, others may be trained to collect the denominator data and process of care data; additionally, electronic capture of data is an option for reporting as an aide to optimizing available resources.

Procedure-Associated Module

Surgical site infection (SSI) monitoring is offered through this module. SSI surveillance requires active, patient-based, prospective surveillance techniques (see Surveillance Techniques above).

Concurrent and post-discharge surveillance methods should be used to detect SSIs following inpatient operative procedures and post-discharge surveillance for outpatient operative procedures. These methods may include 1) direct examination of patients' wounds during hospitalization, or follow-up visits to either surgery clinics or physicians' offices, 2) review of medical records or surgery clinic patient records, 3) visits to the ICU and wards; interview primary care staff, 4) surgeon surveys by mail or telephone, and 5) patient surveys and/or reports (though patients may have a difficult time assessing their infections). Any combination of these methods (or other methods identified by the facility) with the capacity to identify all SSIs is acceptable for use; however, NHSN criteria for SSI must be used. See Surgical Site Infection Event (SSI) protocol for additional examples of concurrent and post-discharge surveillance methods (www.cdc.gov/nhsn/pdfs/pscmanual/9pscscsscurrent.pdf). To minimize IPs' workload of collecting denominator data, operating room data may be downloaded (see file specifications at <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/ImportingProcedureData.pdf>).

Device-Associated Module

Medical instrumentation increases the risk of developing an HAI and most patients admitted to a healthcare facility will have a medical device used in the course of their admission. Such devices include, but are not limited to, vascular access devices, indwelling urinary catheters, and ventilators. NHSN enables facilities to monitor for infections associated with the use of these medical devices and to monitor processes related to their use which might increase infection risk. Specifically, NHSN allows facilities to perform surveillance on central line-associated bloodstream infection (CLABSI), catheter-associated urinary tract infection (CAUTI), ventilator-associated events (VAE and PedVAE), and/or ventilator-associated pneumonia (VAP). See the Dialysis Component for detailed instructions for Dialysis Event (DE) surveillance of hemodialysis outpatients (www.cdc.gov/nhsn/dialysis/index.html).

Device-associated denominator data should be collected for CLABSI, CAUTI, VAE, PedVAE, and VAP surveillance (see the CLABSI, CAUTI, VAE, PedVAE, and PNEU protocols for guidance) at the same time each day, or by weekly sampling methods in certain locations. When denominator data are available from electronic databases (for example, ventilator days from respiratory therapy), these sources may be used as long as the counts are not substantially different (+/- 5%) from manually collected counts that have been validated for a minimum of three months. See the respective device-associated event protocols for detailed surveillance instructions.

Antimicrobial Use and Resistance (AUR) Module

The use of antimicrobial agents has a direct effect on antimicrobial resistance patterns of pathogens. The observed increase in multidrug resistance is in part due to inappropriate prescription of, as well as only partial completion of courses of antibiotics.

The AUR Module allows facilities to collect information on the amount of antimicrobials that are used for patient care within their systems, as well as to collect data on the prevalence of drug-resistant organisms in their inpatient and outpatient areas. Electronic capture and reporting of microbiology and pharmacy data are the only available options for reporting data into this module.

See the [Antimicrobial Use and Resistance](#) protocol for detailed surveillance instructions.

Multidrug-resistant Organism and *Clostridioides difficile* Infection (MDRO/CDI) Module

The NHSN MDRO/CDI Module offers a means for facilities to meet criteria and metrics that are outlined in several organizational guidelines to control and measure the spread of MDROs and CDI within their healthcare system. The module has two separate and independent reporting options, Laboratory-identified (LabID) Event and Infection Surveillance, that may be tailored to meet the needs of participating NHSN facilities.

In addition, the following process measures are available: (1) adherence to hand hygiene; (2) adherence to contact precautions when caring for patients infected or colonized with an MDRO or *C. difficile*; and (3) adherence to active surveillance testing (AST) of MRSA and/or VRE. Active surveillance testing outcome measures is also available in locations where AST adherence is being performed and enables facilities to use the results of AST to monitor the incidence and prevalence of positive MRSA and/or VRE cultures. See the [MDRO/CDI](#) protocol for detailed surveillance instructions.

Identifying Healthcare-associated Infections (HAI) for NHSN Surveillance

The purpose of Chapter 2 is to standardize the classification of an infection as present on admission (POA) or a healthcare-associated infection (HAI), using objective surveillance definitions and guidance for NHSN surveillance. The intention of this chapter is to align criteria and definitions and decrease subjectivity while maintaining epidemiologic standardization and clinical relevance. A variety of scenarios to include repeat infections of the same type, concurrent infections of differing types, and pathogen assignment in multi-pathogen infections are addressed. See [Appendix](#) Flow Diagram for NHSN Event Determination.

Table of Contents

General Instructions	1
Infection Window Period (IWP).....	3
Infection Window Period Special Considerations	4
Date of Event (Event Date)	7
Location of Attribution (LOA)	9
Transfer Rule (Exception to Location of Attribution)	9
Repeat Infection Timeframe (RIT)	11
Secondary BSI Attribution Period (SBAP)	15
Secondary BSI Attribution Period Tables.....	17
Pathogen Assignment Guidance.....	19
Appendix: Flow Diagram for NHSN Event Determination	29

General Instructions

1. The guidance found in this Chapter is not applicable when performing surgical site infection (SSI), ventilator-associated event (VAE), pediatric ventilator-associated event (PedVAE), or laboratory-identified (LabID) event surveillance. Infection window period (IWP), date of event (DOE), present on admission (POA), healthcare-associated infection (HAI), repeat infection timeframe (RIT), and secondary BSI attribution period (SBAP) definitions as defined in this chapter **do not** apply to [SSI](#), [VAE](#), [PedVAE](#), or [LabID](#) events ([Table 1](#)).

Refer to Chapters 9, 10, 11, and 12 for guidance specific to these event determinations.

Table 1: Module Exceptions to application of Chapter 2 Timeframes (Page 2-2)

Concept	SSI	LabID	VAE	PedVAE
Infection Window Period	Not Applicable	Not Applicable	Not Applicable	Not Applicable
Date of Event				
Present on Admission				
Healthcare-associated Infection				
Repeat Infection Timeframe				
Secondary BSI Attribution Period				

2. Organisms that primarily cause community-associated infections and are not known to (or rarely) cause healthcare-associated infections, are excluded and cannot be used to meet any NHSN definition.
 - **Fungi:** *Blastomyces*, *Histoplasma*, *Coccidioides*, *Paracoccidioides*, *Cryptococcus*, *Pneumocystis*
 - **Vector-borne bacteria:** *Anaplasma spp.*, *Ehrlichia spp.*, *Borrelia spp.*, *Rickettsia spp.*

Additionally, refer to the individual event protocols for pathogen exclusions specific to the event being reported for example, bloodstream infection (BSI), urinary tract infection (UTI), pneumonia (PNEU), endocarditis (ENDO), gastrointestinal tract (GIT), and intraabdominal (IAB) infections.

3. If the date of specimen collection is on or after the date of documentation of evidence of consent **AND** the patient is being supported for organ donation purposes, an event identified using the specimen culture result or microbiologic non-culture based diagnostic test result should not be reported as an HAI. For criteria without a specimen collected, if the date of event (DOE) is on or after the date of documentation of evidence of consent **AND** the patient is being supported for organ donation purposes, the event identified should not be reported as an HAI. The patient should, however, still be included in device and patient day denominator data collection.
4. Hospice, palliative, or comfort care patients are not excluded from any type of NHSN surveillance.
5. Identification of organisms from specimens collected post-mortem are only eligible for use in meeting the central nervous system (CNS)/intracranial (IC) infection definition using brain tissue or dura specimen obtained during post-mortem examination (autopsy) and the pneumonia (PNEU) infection definition using lung tissue specimen obtained by transthoracic or transbronchial biopsy immediately post-mortem (most likely collected at bedside shortly after death). For all other NHSN definitions autopsy specimens/reports are not eligible for use.
6. Infections occurring in newborns with date of event on hospital day 1 or day 2 are considered POA. Infections with a date of event on day 3 or later, are an HAI. Infections acquired as a result of passage through the birth canal and transplacentally-acquired viral, parasite and spirochete infections are excluded (for example, but not limited to herpes simplex, toxoplasmosis, rubella, CMV, or syphilis). Exception: See guidance about non-reporting of CLABSIs with Group B *Streptococcus* during a neonate's first 6 days of life found in the Comments and Reporting

Instructions section of the Bloodstream Infection Event (Central Line-Associated Bloodstream Infection and Non-central line-associated Bloodstream Infection) protocol.

7. Reactivation of a **latent** infection (for example but not limited to herpes, shingles, syphilis, or tuberculosis) is not considered to be an HAI.
8. For purposes of NHSN surveillance, if an observation patient is admitted to an inpatient location, the patient must be included in all surveillance events designated in the monthly reporting plan and included in patient and device day counts. The patient is being housed, monitored, and cared for in an inpatient location and therefore is at risk for acquisition of an HAI.

Infection Window Period

The infection window period (IWP) is defined as the 7-days during which all site-specific infection criteria must be met. It includes the collection date of the **first positive diagnostic test that is used as an element** to meet the site-specific infection criterion, the 3 calendar days before and the 3 calendar days after ([Table 2](#)). For purposes of defining the IWP the following examples are considered diagnostic tests:

- laboratory specimen collection
- imaging test
- procedure or exam

Table 2: Infection Window Period

Infection Window Period		3 days before
	Date of first positive diagnostic test that is used as an element of the site-specific criterion OR In the absence of a diagnostic test, use the date of the first documented <u>localized</u> sign or symptom that is used as an element of the site-specific criterion	3 days after

It is important to use the first diagnostic test that creates an infection window period during which all elements of the criterion can be found. See example below.

Example

When meeting pneumonia (PNEU) definition using the PNU2 criterion, identification of an eligible organism from blood or from a site-specific specimen and an imaging test may be available. Both the organism identification and the imaging test are diagnostic tests. Use the first diagnostic test for which all elements of the PNU2 criterion occur within the IWP.

In this example below, Option 1 uses the imaging test (not the blood culture) to set the IWP. This is the first diagnostic test that creates an IWP in which all elements of PNU2 criterion occur.

Hospital Day = (HD)

Infection window period (IWP)		Option 1: Correct diagnostic test use – HD 3 imaging test		Option 2: Incorrect diagnostic test use – HD 6 blood culture	
Present on Admission (POA)		HD	IWP	HD	IWP
Healthcare-associated Infection (HAI)		-2		-2	
		-1		-1	
		1		1	
		2 POA	New onset cough	2	New onset cough
		3	Imaging test: New infiltrate	3 HAI	Imaging test: New infiltrate
		4	Fever > 38.0 C	4	Fever > 38.0 C
		5	Fever > 38.0 C	5	Fever > 38.0 C
		6	Blood culture: <i>A. baumannii</i>	6	Blood culture: <i>A. baumannii</i>
		7	Imaging test: Infiltrate Rales, Fever > 38.0 C	7	Imaging test: Infiltrate Rales, Fever > 38.0 C
		8	Cough, Rales	8	Cough, Rales
		9		9	
		10		10	
		11		11	
		12		12	
		13		13	
		14		14	
		15		15	
		16		16	
		17		17	

Infection Window Period Special Considerations

1. Infection criteria that do not include a diagnostic test:

For site-specific infection criteria **that do not include a diagnostic test**, the date of the first documented localized sign or symptom that is used as an element of the site-specific infection criterion is used to define the infection window period (IWP), for example, diarrhea, site-specific pain, or purulent drainage. A non-specific sign or symptom such as fever is not considered localized and therefore is not used to define the IWP.

For example, when meeting endometritis (EMET) using criterion 2, there is no diagnostic test as a part of this criterion. The date of the first documented localized sign or symptom, purulent drainage or pain or tenderness, that is used as an element to meet EMET criterion 2 is to be used to set the IWP. Fever is not a localized sign.

EMET-Endometritis

Endometritis must meet at least **one** of the following criteria:

1. Patient has organism(s) identified from endometrial fluid or tissue by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
2. Patient has **suspected endometritis** with at least **two** of the following signs or symptoms: fever ($>38.0^{\circ}\text{C}$), pain or tenderness (uterine or abdominal) *, or purulent drainage from uterus.

* With no other recognized cause

2. More than one criterion can be met:

When more than one criterion of a site-specific infection definition is met, identify the IWP that results in the **earliest date of event**.

Example

A patient has purulent drainage noted at a superficial wound site on hospital day 2. It is documented on day 3 that the wound site is painful, and swelling is present. *S. aureus* is identified from a wound specimen with collection date on day 4. SKIN definition can be met using criterion 2a with pain, swelling and positive culture from the site-specific specimen (diagnostic test) and met using criterion 1 with purulent drainage (sign). Using the sign of infection, purulent drainage, to set the IWP results in criterion 1 being met and provides the earliest date of event.

Hospital Day = (HD)

Infection window period (IWP)		SKIN Criterion 1: Correct Determination		SKIN Criterion 2a: Incorrect Determination	
Date of event (DOE)		HD	IWP	HD	IWP
		-2		-2	
		-1		-1	
		1		1	
		2	Purulent Drainage from wound (SKIN criterion 1)	2	
		DOE			
		3		3	Pain, Swelling (SKIN Criteria 2a)
				DOE	
		4		4	Drainage Culture: <i>S. aureus</i>
		5		5	
		6		6	
		7		7	
		8		8	
		9		9	
		10		10	
		11		11	
		12		12	
		13		13	
		14		14	
		15		15	
		16		16	
		17		17	

3. Endocarditis:

When meeting the endocarditis ([ENDO](#)) definition, the IWP is lengthened to accommodate the **extended** diagnostic timeframe that is frequently required to reach a clinical determination of endocarditis. The ENDO IWP is 21 days and includes the 10 calendar days before and the 10 calendar days after the first positive diagnostic test that is used as an element of the ENDO infection criterion.

4. Osteomyelitis:

When meeting the osteomyelitis ([BONE](#)) definition, the IWP is lengthened to accommodate the extended diagnostic timeframe that is frequently required to reach a clinical determination of osteomyelitis and the extended antimicrobial treatment associated with the condition. The BONE IWP is 21 days and includes the 10 calendar days before and the 10 calendar days after the first positive diagnostic test that is used as an element of the BONE infection criterion.

Date of Event (Event Date)

The date of event (DOE) is the date the first element used to meet an NHSN site-specific infection criterion occurs for the first time within the seven-day infection window period ([Table 3](#) and [Table 4](#)).

An infection is considered **present on admission (POA)** if the date of event of the NHSN site-specific infection criterion occurs during the POA timeframe, which is defined as the day of admission to an inpatient location (calendar day 1), the 2 days before admission, and the calendar day after admission. For purposes of NHSN surveillance and determination of the repeat infection timeframe (as defined below) if the DOE is determined to be either of the two days prior to inpatient admission, then the date of event will be hospital day 1.

An infection is considered a **healthcare-associated infection (HAI)** if the date of event of the NHSN site-specific infection criterion occurs on or after the 3rd calendar day of admission to an inpatient location where day of admission is calendar day 1.

Note:

Accurate determination of DOE is critical because DOE is used to determine:

- if an event is HAI or POA
- location of attribution
- device association
- day 1 of the Repeat Infection Timeframe

Table 3: Date of Event and Classification Determination

Hospital Day	Date of Event Assignment for RIT	Classification
2 days before admit	Hospital Day 1	POA
1 day before admit	Hospital Day 1	
1	Hospital Day 1	
2	Hospital Day 2	
3	Hospital Day 3	HAI
4	Hospital Day 4	
5	Hospital Day 5	

Table 4: Infection Window Period and Date of Event

Note the date of event is the date the **first** element used to meet the site-specific infection criterion occurs for the **first** time in the IWP. In the first example, it is day 2, the date the fever occurs for the first time in the IWP, this results in a POA determination. In the second example, it is day 4, the date of the diagnostic test, which is the first element in the IWP, and this results in an HAI determination. Date of event may be, but is not always, the date of the diagnostic test which is used to set the IWP.

Hospital Day = (HD)			
Infection window period (IWP)			
Date of event (DOE)			
Example 1: POA Determination		Example 2: HAI Determination	
HD	IWP	HD	IWP
1		1	
2 DOE	Fever > 38.0 C	2	
3		3	
4	Urine culture: >100,000 CFU/ ml <i>E. coli</i>	4 DOE	Urine culture: >100,000 CFU/ ml <i>E. coli</i>
5		5	Fever > 38.0 C
6		6	Fever > 38.0 C
7		7	
8		8	
9		9	
10		10	
11		11	
12		12	
13		13	
14		14	
15		15	
16		16	
17		17	
	UTI-POA Date of Event: HD 2 Pathogen: <i>E. coli</i>		UTI-HAI Date of Event: HD 4 Pathogen: <i>E. coli</i>

Notes:

- Acceptable documentation includes patient-reported signs or symptoms within the POA timeframe, documented in the medical record by a healthcare professional. Information communicated verbally from facility to facility, or information found in another facility's medical record cannot be used unless also documented in the current facility's medical record (except for post-discharge SSI surveillance). For example, the following would be eligible for use if documented in the current facility's medical record:
 - patient states measured fever > 38.0°C or >100.4°F occurring in the POA timeframe
 - nursing home reports fever > 38.0° C or >100.4°F prior to arrival to the hospital and occurring in the POA timeframe
 - patient complains of dysuria
 - copy of laboratory test result from another facility
- Physician diagnosis can be accepted as evidence of an infection only when physician diagnosis is an element of the specific infection definition. Note that only the EAR (ear, mastoid infection) and UR (upper respiratory tract infection, pharyngitis, laryngitis, epiglottitis) definitions include physician diagnosis as an element.
 - For example, physician diagnosis is not an element of any UTI definition; therefore, physician diagnosis of a UTI may not be used to satisfy the UTI definition.
 - For example, physician diagnosis is an element of EAR definition; therefore, physician diagnosis of otitis interna may be used to satisfy the inner ear infection definition.

Location of Attribution (LOA)

The inpatient location where the patient was assigned on the [date of event \(DOE\)](#) is the location of attribution (LOA) (see date of event definition). Non-bedded patient locations, for example, Operating Room (OR) or Interventional Radiology (IR) are not eligible for assignment of LOA for HAI events. Location of attribution must be assigned to a location where denominator data (for example, patient days, device days) can be collected.

Transfer Rule (Exception to Location of Attribution)

If the date of event is on the date of transfer or discharge, or the next day, the infection is attributed to the transferring/discharging location. This is called the **Transfer Rule**. If the patient was in multiple locations within the transfer rule time frame, attribute the infection to the **first** location in which the patient was housed the **day before** the infection's date of event. See examples below.

- When the transfer rule is invoked following facility discharge from one facility and admission to another, receiving facilities should share information regarding the HAI with the transferring facility. Such information should include all information necessary to determine that HAI criteria are met. Sharing of HAI data between facilities promotes consistency and accuracy in reporting HAI data. Surveillance after the patient is discharged from the facility is not required. However, if discovered,

any infection with a DOE on the day of discharge or the next day is attributable to the discharging location and should be included in any data reported to NHSN for that location.

- In certain situations, a patient may be discharged and readmitted to the same facility on either the date of discharge or the next day. This commonly occurs during the transfer rule and POA timeframe, where a single diagnostic test can result in both a POA event and a HAI event.
 - For example, a patient is initially admitted to a facility from 4/1 to 4/7. Subsequently, the same patient is readmitted on 4/8 and presents with a fever of 101°F, along with the collection of a urine culture that is positive with $\geq 10^5$ CFU/ml *Escherichia coli*. In this case, due to the occurrence of the positive urine culture and fever on the day following discharge from the first admission, it can be classified as a HAI UTI event for the first admission and a POA UTI event for the second admission.
- **Note:** Although the transfer rule does not apply to SSI or LabID events, facilities should always share information of potential HAI events that may occur before or following transfers between facilities. Refer to Chapter 9 and Chapter 12 for guidance regarding SSI and LabID events.

- **Location Example:**

Date	Patient Location	Location of Attribution
3/22	Unit A	
3/23	Unit A Unit B	
3/24 Date of Event	Unit B	Unit A
3/25	Unit B	

- **Facility Example:**

Date	Patient Location	Location of Attribution
3/22	Facility 1	
3/23	Facility 1 Facility 2	
3/24 Date of Event	Facility 2	Facility 1
3/25	Facility 2	

○ **Multiple transfers within the same facility during the same admission example:**

In instances where a patient has been transferred to more than one location on the date of an infection, or the day before, attribute the infection to the **first** location in which the patient was housed the **day before** the infection's date of event.

Date	Patient Location	Location of Attribution
3/22	Unit A	
3/23	Unit A Unit B Unit C	
3/24 Date of Event	Unit C Unit D	Unit A
3/25	Unit D	

Repeat Infection Timeframe

The Repeat Infection Timeframe (RIT) is a 14-day timeframe during which no new infections of the same type are reported.

- **The RIT applies to both POA and HAI determinations.**
 - Note: To establish a POA RIT, the event must first fully meet NHSN criteria.
- The date of event is Day 1 of the 14-day RIT.
- If criteria for the same type of infection are met and the date of event is within the 14-day RIT, a new event is not identified or reported.
 - The original date of event and the original 14-day RIT are maintained.
 - Additional pathogens recovered during the RIT from the **same type of infection** are added to the event and the pathogens are not required to match.
 - Device association determination and location of attribution do not change. See examples in [Table 5](#) and [Table 6](#) below.
- The RIT will apply at the level of specific type of infection with the exception of BSI, UTI, and PNEU where the RIT will apply at the major type of infection.

Specific Type Example:

- Patients will have no more than one SKIN infection reported in a SKIN RIT, but may have overlapping or simultaneous SKIN RIT and decubitus ulcer infection (DECU) RIT

Major Type Examples:

- Patients will have no more than one BSI reported in a BSI RIT laboratory-confirmed bloodstream infection (LCBI 1, LCBI 2, and LCBI-3) or mucosal barrier

- injury laboratory confirmed bloodstream infection (MBI-LCBI 1, MBI-LCBI 2, and MBI-LCBI 3)
 - Patients will have no more than one PNEU reported in a PNEU RIT (PNU1, PNU2, PNU3).
 - Patients will have no more than one UTI reported in a UTI RIT (symptomatic urinary tract infection [SUTI] or asymptomatic bacteremic urinary tract infection [ABUTI])
- The RIT applies during a patient's single admission, including the day of discharge and the day after, in keeping with the [Transfer Rule](#).
 - If a patient is readmitted to the same facility within the transfer rule timeframe, an RIT does not carry over from one admission to another.
 - Note: If an Inpatient Rehabilitation Facility (IRF) is located inside of an Acute Care Hospital (ACH), movement between the ACH and the IRF location is considered a location transfer and is treated as a single facility continuous stay with one admission and discharge. Billing status requiring a transferred patient to be given a new visit/encounter number, does not impact the continuous stay determination from an NHSN surveillance perspective. Therefore, the original RIT continues without interruption.
- The RIT for endocarditis (ENDO) and osteomyelitis (BONE) is extended to include the remainder of the patient's current admission.

In the example below ([Table 5](#)), the date of event is hospital day 4. The 14-day RIT is hospital day 4 through day 17. On hospital day 12, within the RIT, a urine culture with > 100,000 CFU/ml *S. aureus* is identified. The urine pathogen identified from the hospital day 12 culture is added to the originally identified infection on hospital day 4. Determination of a new infection or continuation of ongoing infection is not required. The original date of event and the RIT are maintained.

Table 5: Repeat Infection Timeframe

Hospital Day = (HD)	HD	RIT	IWP
Infection window period (IWP)	1		
Date of event (DOE)	2		
Repeat infection timeframe (RIT)	3		
	4	1	Urine culture: >100,000 CFU/ ml <i>E. coli</i>
	5	2	Fever > 38.0 C
	6	3	Fever > 38.0 C
	7	4	
	8	5	
	9	6	Urine culture: No growth
	10	7	
	11	8	
	12	9	Urine culture: >100,000 CFU/ ml <i>S. aureus</i> , Fever > 38.0 C
	13	10	
	14	11	
	15	12	
	16	13	
	17	14	
			UTI HAI Date of Event: HD 4 Pathogens: <i>E. coli</i> , <i>S. aureus</i>

In the example below ([Table 6](#)) a non-catheter associated UTI is identified with date of event on day 4. This sets an RIT day 4 -17. On day 5 an indwelling urinary catheter is inserted. On day 8, within the RIT, a urine culture with > 100,000 CFU/ml *E. coli* is identified. The *E. coli* is added to the originally identified day 4 event. The device association **does not** change, and the date of event and RIT are maintained.

Table 6. Repeat Infection Timeframe

Hospital Day = (HD)		
Infection window period (IWP)		
Date of event (DOE)		
Repeat infection timeframe (RIT)		

HD	RIT	IWP
1		No indwelling urinary catheter
2		No indwelling urinary catheter
3		No indwelling urinary catheter
4 DOE	1	Urine culture: > 100,000 CFU/ml <i>S. aureus</i> ; dysuria
5	2	Indwelling urinary catheter inserted
6	3	Indwelling urinary catheter
7	4	Indwelling urinary catheter
8	5	Indwelling urinary catheter Urine culture: > 100,000 CFU/ml <i>E. coli</i> Fever 39.0° C
9	6	
10	7	
11	8	
12	9	
13	10	
14	11	
15	12	
16	13	
17	14	
		Non-Catheter associated SUTI DOE: HD 4 Pathogens: <i>S. aureus</i>, <i>E. coli</i>
Note: Meeting an event within the RIT does not alter the original determination. Date of event, device association, and RIT do not change.		

Secondary BSI Attribution Period

The Secondary BSI Attribution Period*(SBAP) is the period in which a blood specimen must be collected for a secondary bloodstream infection to be attributed to a primary site infection. This period includes the infection window period combined with the repeat infection timeframe (RIT). The SBAP is 14-17 days in length depending upon the date of event. (Refer to [Appendix](#), Secondary Bloodstream Infection (BSI) Guide of the BSI Event Protocol).

A bloodstream infection can only be determined secondary to another site of infection if the following requirements are met[†]:

An NHSN site-specific definition must be met; either one of the [CDC/NHSN Surveillance Definitions for Specific Types of Infections](#) (defined in Chapter 17), or [UTI](#), [PNEU](#) or [SSI](#) definition.

AND

One of the following scenarios must be met:

Scenario 1: At least one organism from the blood specimen matches an organism identified from the site-specific infection that is used as an element to meet the NHSN site-specific infection criterion and the blood specimen is collected in the secondary BSI attribution period (infection window period + repeat infection timeframe).

OR

Scenario 2: An organism identified in the blood specimen is an element that is used to meet the NHSN site-specific infection criterion and therefore is collected during the site-specific infection window period.

[†]Exception:

Necrotizing enterocolitis (NEC) criteria does not include a site-specific specimen, or an organism identified from a blood specimen; however, an exception for assigning a BSI secondary to NEC is provided.

A BSI is considered secondary to NEC if the patient meets one of the two NEC criteria **AND** an organism identified from a blood specimen collected during the secondary BSI attribution period is an LCBI pathogen, or the same common commensal which is identified from two or more blood specimens drawn on separate occasions collected on the same or consecutive calendar days.

Determination of a **secondary** BSI to a primary site of infection does not set an RIT for all subsequent BSIs. If a positive blood culture occurs during a site-specific infection's secondary BSI attribution period and the positive blood culture cannot be used as an element to meet the infection definition or does not have at least one matching pathogen to the site-specific infection culture used to meet the site-specific infection criterion, the BSI must be evaluated as a new BSI event.

***Notes:**

- When meeting the endocarditis (ENDO) or osteomyelitis (BONE) definition, the secondary BSI attribution period includes the 21-day infection window period and all subsequent days of the patient's current admission.
 - As a result of this lengthy secondary BSI attribution period, secondary BSI pathogen assignment for ENDO and BONE, is limited to organism(s) identified in the blood specimen(s) that match the organism(s) used to meet the ENDO or BONE definition.

Example 1: If the ENDO definition was met using a site-specific specimen (cardiac vegetation) or using a blood specimen where *S. aureus* was the identified organism and subsequently a blood specimen collected during the ENDO secondary BSI attribution period (but outside of the IWP) is positive for *S. aureus* and *E. coli*, while the *S. aureus* can be assigned to the ENDO event, it cannot be assumed the *E. coli* can be assigned as a secondary BSI pathogen. The blood organism (*E. coli*) does not match the organism (*S. aureus*) used to meet the ENDO definition. If the blood specimen can be used to meet an ENDO definition criterion both organisms can be assigned. Otherwise, the *E. coli* will need to be investigated as a separate BSI and be identified as a secondary BSI to another site-specific infection or determined to be a primary BSI.

Example 2: If the BONE definition was met using a site-specific specimen (bone culture) or using a blood specimen with *Pseudomonas aeruginosa* as the identified organism and subsequently a blood specimen collected during the BONE secondary BSI attribution period is positive for *Pseudomonas aeruginosa* and *E. coli*, while *Pseudomonas aeruginosa* can be assigned to the BONE event, it cannot be assumed the *E. coli* can be assigned as a secondary BSI pathogen. The blood organism (*E. coli*) does not match the organism (*Pseudomonas aeruginosa*) used to meet BONE definition. If the blood specimen can be used to meet a BONE definition criterion both organisms can be assigned. Otherwise, the *E. coli* will need to be investigated as a separate BSI and identified as a secondary BSI to another site-specific infection or determined to be a primary BSI.

Secondary BSI Attribution Period Tables:

In the example below ([Table 7](#)), the Date of Event is hospital day 4. The 14-day RIT is hospital day 4 through day 17. *S. aureus* is identified in the urine during the SUTI RIT; therefore, this organism is added to the SUTI-1 event. The Secondary BSI Attribution Period is the Infection Window Period combined with the Repeat Infection Timeframe; in this example it is 17 days. The blood culture collected on hospital day 10 has a matching pathogen to the site-specific culture used to meet the SUTI definition, and therefore, a secondary BSI is identified.

Table 7: Secondary BSI Attribution Period

Hospital Day = (HD)			
Infection window period (IWP)			
Date of event (DOE)			
Repeat infection timeframe (RIT)			
Secondary BSI Attribution Period (SBAP)			

HD	RIT	IWP	UTI SBAP
1			1
2			2
3			3
4	1	Urine culture: >100,000 CFU/ ml <i>E. coli</i>	4
5	2	Fever > 38.0 C	5
6	3	Fever > 38.0 C	6
7	4		7
8	5		8
9	6		9
10	7	Blood culture: <i>E. coli</i>	10
11	8		11
12	9	Urine culture: >100,000 CFU/ ml <i>S. aureus</i> , Fever > 38.0 C	12
13	10		13
14	11		14
15	12		15
16	13		16
17	14		17
		UTI: <i>E. coli</i> , <i>S. aureus</i> Secondary BSI: <i>E. coli</i> Date of Event: HD 4	

In the example below ([Table 8](#)), the Date of Event is hospital day 4. The 14-day RIT is hospital day 4 through day 17. The secondary BSI Attribution Period is 17 days in length. The blood culture collected on hospital day 5 is used as an element to meet the PNU2 infection definition and therefore a secondary BSI is identified.

Table 8: Secondary BSI Attribution Period

Hospital Day (HD)	HD	RIT	IWP	PNEU SBAP
	1			1
Infection window period (IWP)	2			2
	3			3
Date of event (DOE)	4	1	Imaging test: Worsening infiltrate	4
Repeat infection timeframe (RIT)	5	2	Blood culture: <i>S. aureus</i> Fever > 38.0°C, new onset cough	5
	6	3	Fever > 38.0°C, rales	6
	7	4	Imaging test: Infiltrate persists	7
	8	5		8
	9	6		9
	10	7		10
	11	8		11
	12	9		12
	13	10		13
	14	11		14
	15	12		15
	16	13		16
	17	14		17
			PNU2 & Secondary BSI Date of Event: HD 4 Pathogen: <i>S. aureus</i>	

Pathogen Assignment Guidance

The following provides guidance for reporting pathogens associated with site-specific infections that are identified during the RIT or during the secondary BSI attribution period.

- Eligible pathogens identified following the initial secondary BSI during the RIT from the same type of infection are added to the event.
- Report all site-specific pathogens before secondary BSI pathogens.
- If at least one BSI pathogen with a collection date in the secondary BSI attribution period matches an organism from a specimen (either a site-specific specimen or a blood specimen) that was used to meet a site-specific infection criterion, additional eligible BSI pathogens from **the same blood specimen** are also considered secondary to the event and are reported with the event.
- BSI pathogens may be assigned to more than one infection source at the same time in the following scenarios.
 - 1) Secondary BSI pathogen assigned to two different site-specific infections (see [Example 1](#))
OR
 - 2) Secondary BSI pathogen assigned to a site-specific infection and assigned as pathogen to a primary BSI event (see [Example 2a](#)).

MBI-RIT Exception: An MBI-LCBI designation will not change to an LCBI event if the following criteria are met:

1. The blood culture with the non-MBI organism is collected during an existing BSI (MBI-LCBI) RIT
- AND**
2. The blood culture with the non-MBI organism is deemed secondary to an NHSN site-specific infection (see [Example 2b](#)).

Example 1:

K. pneumoniae is identified in a blood culture during the SBAP of a SUTI with *K. pneumoniae*. The patient also has documentation of fever (>38.0° C) and abdominal pain with an abdominal abscess seen on imaging. These three elements, when combined with a positive blood culture, meet IAB criterion 3b. Both UTI and IAB HAIs are identified, each with a secondary BSI and *K. pneumoniae* as the pathogen.

Example 1

Hospital Day (HD)
Infection window period (IWP)
Date of event (DOE)
Repeat infection timeframe (RIT)
Secondary BSI Attribution Period (SBAP)

UTI				IAB		
HD	RIT	IWP	SBAP	HD	IWP	SBAP
1			1	1		
2			2	2		
3			3	3		
4	1	Urine culture: >100,000 CFU/ ml <i>K. pneumoniae</i>	4	4		
5	2	Fever > 38.0 C	5	5		
6	3		6	6		1
7	4		7	7		2
8	5		8	8	Fever > 38.0 C, Abdominal pain	3
9	6		9	9	CT scan: Abdominal abscess	4
10	7	Blood culture: <i>K. pneumoniae</i>	10	10	Blood culture: <i>K. pneumoniae</i>	5
11	8		11	11		6
12	9		12	12		7
13	10		13	13		8
14	11		14	14		9
15	12		15	15		10
16	13		16	16		11
17	14		17	17		12
18				18		13
19				19		14
20				20		15
21				21		16
22				22		
		UTI: <i>K. pneumoniae</i> Secondary BSI: <i>K. pneumoniae</i> Date of Event: HD 4			HAI-IAB Secondary BSI Date of Event: HD 8 Pathogen: <i>K. pneumoniae</i>	

Example 2a:

On day 4 of the hospital admission, *S. aureus* is identified in a blood culture meeting LCBI 1 criterion. On day 8 the patient has a fever > 38.0° C, and *E. coli* is identified in a urine culture meeting the SUTI definition. On hospital day 13, a blood culture positive for *E. coli* is identified. **Because the blood culture occurs within both the LCBI RIT and the SUTI secondary BSI attribution period, the pathogen, *E. coli* is assigned to both events.**

Hospital Day (HD)
Infection window period (IWP)
Date of event (DOE)
Repeat infection timeframe (RIT)
Secondary BSI Attribution Period (SBAP)

LCBI			UTI & Secondary BSI			
HD	RIT	IWP	HD	RIT	IWP	SBAP
1			1			
2			2			
3			3			
4	1	Blood Culture: <i>S. aureus</i>	4			
5	2		5			
6	3		6			1
7	4		7			2
8	5		8	1	Fever > 38.0 C	3
9	6		9	2	Urine Culture: > 100,000 CFU/ml <i>E. coli</i>	4
10	7		10	3		5
11	8		11	4		6
12	9		12	5		7
13	10	Blood Culture: <i>E. coli</i>	13	6	Blood Culture: <i>E. coli</i>	8
14	11		14	7		9
15	12		15	8		10
16	13		16	9		11
17	14		17	10		12
18			18	11		13
19			19	12		14
20			20	13		15
21			21	14		16
22			22			
LCBI Date of Event: HD 4 Pathogens: <i>S. aureus</i> , <i>E. coli</i>			UTI and Secondary BSI Date of event: HD 8 Pathogen: <i>E. coli</i>			

Example 2b:

On day 7 of hospital admission, *E. faecalis* is identified in a blood culture meeting MBI-LCBI 1 criterion. During the BSI RIT of the MBI-LCBI 1 event, a blood culture with a non-MBI organism (*Staphylococcus aureus*) is collected but is deemed secondary to a SKIN 2a. Because the *Staphylococcus aureus* (a non-MBI organism) is secondary to the SKIN 2a, the MBI-LCBI 1 designation **will not** change to an LCBI 1. Two separate events meet definitions: MBI-LCBI with *E. faecalis*, and a SKIN 2a with *S. aureus* an element of the definition.

Hospital Day = (HD)						
Infection window period (IWP)						
Date of event (DOE)						
Repeat infection timeframe (RIT)						
Secondary BSI Attribution Period (SBAP)						
MBI LCBI 1			SKIN-2a			
HD	RIT	IWP	HD	RIT	IWP	SBAP
1			1			
2			2			
3			3			
4			4			
5		WBC- 400 cells/mm ³	5			
6			6			
7	1	Blood Culture: <i>E. faecalis</i>	7			
8	2		8			1
9	3		9			2
10	4	WBC- 300 cells/mm ³	10	1	Erythema, Pain	3
11	5		11	2	Skin culture: <i>S. aureus</i>	4
12	6		12	3		5
13	7		13	4		6
14	8		14	5		7
15	9		15	6		8
16	10		16	7		9
17	11		17	8		10
18	12		18	9		11
19	13		19	10	Blood culture: <i>S. aureus</i>	12
20	14		20	11		13
21			21	12		14
22			22	13		15
23			23	14		16
MBI LCBI 1 Date of Event: HD 7 Pathogen: <i>E. faecalis</i>			SKIN-2a & Secondary BSI Date of Event: HD 10 Pathogen: <i>S. aureus</i>			

Pathogen Assignment - Special Considerations

Pathogens excluded from specific infection definitions (for example, yeast in UTI, Example 3 or *Enterococcus* spp. in PNEU, Example 4) are also excluded as pathogens for BSIs secondary to that type of infection (specifically they cannot be added to one of these infections as a pathogen). The excluded organism must be accounted for as either:

- 1) A primary bloodstream infection (BSI/CLABSI)

OR

- 2) A secondary BSI attributed to another primary infection (for example, to an IAB or SINU), in accordance with Appendix, Secondary BSI Guide of the [BSI Event protocol](#)

Example 3:

A SUTI with *Enterococcus faecalis* is identified and a subsequent blood culture with yeast and *E. faecalis* is collected during the SUTI secondary BSI attribution period. A BSI secondary to SUTI is identified.

***E. faecalis* is already documented as a pathogen, but the yeast will not be reported as a secondary BSI pathogen, because yeasts are excluded as organisms in the UTI definition.** In this example, no other primary source of infection for which the yeast BSI can be assigned as secondary is identified. Therefore, a primary BSI with yeast only is identified.

Note: The *E. faecalis* is not assigned as a pathogen for the primary BSI because if an excluded organism had not been identified, a primary BSI would not have been reported.

Example 3

Hospital Day = (HD)
Infection window period (IWP)
Date of event (DOE)
Repeat infection timeframe (RIT)
Secondary BSI Attribution Period (SBAP)

UTI & Secondary BSI				LCBI			
HD	RIT	IWP	SBAP	HD	RIT	IWP	SBAP
1			1	1			
2			2	2			
3 DOE	1	Dysuria	3				
4	2	Urine culture: >100,000 CFU/ ml <i>E. faecalis</i>	4	4			
5	3		5	5			
6	4		6	6			
7	5		7	7			
8	6		8	8			1
9	7		9	9			2
10	8		10	10			3
11	9	Blood culture: <i>E. faecalis</i> , yeast	11	11 DOE	1	Blood culture: <i>E. faecalis</i> , yeast	4
12	10		12	12	2		5
13	11		13	13	3		6
14	12		14	14	4		7
15	13		15	15	5		8
16	14		16	16	6		9
17	15			17	7		10
18	16			18	8		11
19	17			19	9		12
20	18			20	10		13
21	19			21	11		14
22	20			22	12		15
23	21			23	13		16
24	22			24	14		17
		UTI & Secondary BSI Date of Event: HD 3 Pathogen: <i>E. faecalis</i>				Primary BSI Date of Event: HD 11 Pathogen: yeast	

Example 4:

A PNU2 with *Acinetobacter baumannii* cultured from blood is identified. The positive chest imaging result is the diagnostic test that is used to define the infection window period. A subsequent blood culture with *Enterococcus faecalis* and *A. baumannii* is collected during the secondary BSI attribution period of this PNU2 event. ***Enterococcus faecalis* will not be reported as a pathogen for the PNU2 because *Enterococcus* spp. are excluded as organisms in the PNEU definition.** Another primary source of infection, SUTI, is found and *Enterococcus faecalis* is assigned as a secondary BSI pathogen.

Hospital Day = (HD)
Infection window period (IWP)
Date of event (DOE)
Repeat infection timeframe (RIT)
Secondary BSI Attribution Period (SBAP)

PNEU & Secondary BSI				UTI & Secondary BSI			
HD	RIT	IWP	SBAP	HD	RIT	IWP	SBAP
1				1			
2				2			
3				3			
4				4			
5			1	5			
6			2	6			
7	1	New onset cough	3	7			
DOE							
8	2	Imaging test: New infiltrate	4	8			1
9	3	Fever > 38.0 C	5	9	1	Fever > 38.0 C	2
				DOE			
10	4	Fever > 38.0 C	6	10	2	Fever > 38.0 C	3
11	5	Blood culture: <i>A. baumannii</i> Imaging test: Infiltrate	7	11		Urine culture: >100,000 CFU/ ml <i>E. faecalis</i>	4
12	6	Blood culture: <i>A. baumannii</i> , <i>E. faecalis</i>	8	12	3	Blood culture: <i>A. baumannii</i> , <i>E. faecalis</i>	5
13	7		9	13	4		6
14	8		10	14	5		7
15	9		11	15	6		8
16	10		12	16	7		9
17	11		13	17	8		10
18	12		14	18	9		11
19	13		15	19	10		12
20	14		16	20	11		13
21				21	12		14
22				22	13		15
					14		16
		PNU2 & Secondary BSI Date of Event = HD 7 Pathogen = <i>A. baumannii</i>				UTI & Secondary BSI Date of Event = HD 9 Pathogen: <i>E. faecalis</i> & <i>A. baumannii</i>	

Example 5:

A SUTI with *Enterococcus faecalis* is identified and a blood culture with *E. faecalis* collected on hospital day 11 within the SUTI secondary BSI attribution period is also identified. On hospital day 15 (also within the SUTI RIT and secondary BSI attribution period), a blood culture growing *Staphylococcus aureus* is identified. **Because the blood growing *S. aureus* does not have at least one pathogen that matches the urine culture used to meet the SUTI criterion the BSI cannot be attributed as secondary to the SUTI. The BSI will need to be investigated as a new BSI event** and either assigned as a secondary BSI to another primary site of infection or determined to be a primary BSI.

Note: The secondary BSI attribution period for a primary site of infection does not establish a repeat infection timeframe for all subsequent BSIs.

Hospital Day = (HD)
Infection window period (IWP)
Date of event (DOE)
Repeat infection timeframe (RIT)
Secondary BSI Attribution Period (SBAP)

HD	RIT	IWP	SBAP
1			1
2			2
3 DOE	1	Dysuria	3
4	2	Urine Culture: > 100,000 CFU/ml <i>E. faecalis</i>	4
5	3		5
6	4		6
7	5		7
8	6		8
9	7		9
10	8		10
11	9	Blood Culture: <i>E. faecalis</i>	11
12	10		12
13	11		13
14	12		14
15	13	*Blood Culture: <i>S. aureus</i>	15
16	14		16
		UTI & Secondary BSI DOE: HD 3 Pathogen: <i>E. faecalis</i>	
* The blood growing <i>S. aureus</i> does not have at least one pathogen that matches the urine culture used to meet the SUTI criterion the BSI cannot be attributed as secondary to the SUTI. The <i>S. aureus</i> will need to be investigated as a new BSI event.			

- When identifying a BSI which appears to fall within a BSI-RIT, it is important to verify the initial BSI was indeed a primary BSI and not a secondary BSI to site-specific event. Only primary BSIs create a BSI RIT, therefore, incorrectly establishing a BSI-RIT for a secondary BSI event can result in the inaccurate assignment of a BSI pathogen(s) and the identification of a true CLABSI event will likely be missed ([see Example 6](#)).

Example 6:

Initially a BSI was identified as POA and therefore not further investigated. Upon identification of a subsequent BSI, it cannot be assumed that the POA BSI set a BSI RIT. Instead, it must be verified that the initial BSI was indeed a primary BSI and not a secondary BSI to a site-specific infection. In the example below, upon further review the initial BSI was determined to be a secondary BSI to a SKIN infection. The SKIN Secondary BSI Attribution Period does not capture all subsequent BSIs. In this example it can only account for BSIs that have at least one matching pathogen to the site-specific specimen (wound drainage) used to meet SKIN. The BSI on hospital day 9 does not match and it also was determined not to be secondary to another site-specific infection and therefore a CLABSI is identified.


Hospital Day = (HD)
Infection window period (IWP)
Date of event (DOE)
Repeat infection timeframe (RIT)
Secondary BSI Attribution Period (SBAP)

Incorrect Determination: POA BSI			
HD	CL	IWP	RIT
-2			
-1			
1			
2 DOE	CL placed CL day 1	Blood culture: <i>S. aureus</i>	1
3	CL day 2		2
4	CL day 3		3
5	CL day 4		4
6	CL day 5		5
7	CL day 6		6
8	CL day 7		7
9	CL day 8	Blood culture: <i>S. epidermidis</i> x2	8
10	CL day 9	Hypotension	9
11	CL day 10		10
12	CL day 11		11
13	CL day 12		12
14	CL day 13		13
15	CL day 14		14
16	CL day 15		
17	CL day 16		
18	CL day 17		
19	CL day 18		
20	CL day 19		
21	CL day 20		
22	CL day 21		
		POA LCBI 1 Date of Event = HD 2 Pathogen = <i>S. aureus</i> <i>S. epidermidis</i>	

Correct Determination: Secondary BSI & Primary BSI						
SKIN					LCBI	
HD	CL	IWP	RIT	SBAP	IWP	RIT
-2						
-1						
1				1		
2	CL placed CL day 1	Blood culture: <i>S. aureus</i>		2		
3 DOE	CL day 2	Pain, Erythema	1	3		
4	CL day 3	Wound drainage culture: <i>S. aureus</i>	2	4		
5	CL day 4		3	5		
6	CL day 5		4	6		
7	CL day 6		5	7		
8	CL day 7		6	8		
9	CL day 8		7	9	Blood culture: <i>S. epidermidis</i> x2	1
10	CL day 9	Hypotension	8	10	Hypotension	2
11	CL day 10		9	11		3
12	CL day 11		10	12		4
13	CL day 12		11	13		5
14	CL day 13		12	14		6
15	CL day 14		13	15		7
16	CL day 15		14	16		8
17	CL day 16					9
18	CL day 17					10
19	CL day 18					11
20	CL day 19					12
21	CL day 20					13
22	CL day 21					14
		HAI SKIN w/ Secondary BSI Date of Event = HD 3 Pathogen = <i>S. aureus</i>			HAI LCBI 2 Date of Event = HD 9 Pathogen: <i>S. epidermidis</i>	

The complete set of CDC/NHSN HAI site-specific infection criteria and the comments and reporting instructions integral to the correct application of the criteria can be found in [Chapter 17, CDC/NHSN Surveillance Definitions](#) for Specific Types of Infections, PNEU ([Chapter 6](#)), and UTI ([Chapter 7](#)).

Appendix: Flow Diagram for NHSN Event Determination



Patient Safety Component Monthly Reporting Plan and Annual Surveys

Monthly Reporting Plan (MRP)

The *Patient Safety Monthly Reporting Plan* form (CDC [57.106](#)) is used by NHSN facilities to inform CDC which Patient Safety modules are used by that facility during a given month. This allows CDC to select the data that should be included in the aggregate data analysis used for creating national benchmarks. Data submitted to NHSN may represent either “in-plan” or “off-plan” surveillance. “In-plan” surveillance means that the facility has committed to following the NHSN surveillance protocol, in its entirety, for that particular event, as shown in the facility’s NHSN MRP. “Off-plan” surveillance is surveillance that is done because a facility has decided to track a particular event for internal use. Each participating facility must enter a MRP to indicate the module(s) used, if any, and the events, locations and/or procedures that will be monitored in-plan. The modules and locations selected for the month represent in-plan surveillance and indicate that the NHSN surveillance protocols will be used in their entirety, for that surveillance.

- Only “in-plan” surveillance data are submitted to The Centers for Medicare and Medicaid Services (CMS) in accordance with CMS’s Quality Reporting Programs and included in NHSN annual reports or other NHSN publications.
- “Off-plan” surveillance is surveillance performed because a facility is tracking a particular event for internal use. A facility makes no commitment to follow the NHSN protocol for “off-plan” events and such data are not included in CMS Quality Reporting Programs, NHSN annual reports, or other NHSN publications.

The MRP must be completed for every month for which data are entered into NHSN; a facility may choose the option “No NHSN Patient Safety Modules Followed this Month.” The MRP should reflect reporting requirements (for example, local, state, or CMS mandates) when applicable to the facility. The MRP indicates data that NHSN should submit to CMS as part of the CMS Quality Reporting Programs.

Instructions for completing the [Patient Safety Monthly Reporting Plan](#) form can be found in the Table of Instructions.

Annual Facility Survey

One or more annual facility surveys must be completed upon enrollment in NHSN, activation of an NHSN component, and/or identification of select CMS-certified units. Thereafter, at the beginning of each year, a new facility survey(s) must be completed to reflect data from the prior calendar year. For example, at the beginning of 2026, an acute care hospital completes a 2025 Annual Hospital Survey containing data from 2025.

Surveys must be completed by March 1st each year. If no completed annual facility survey is submitted by March 1st, no MRPs can be entered until the applicable annual survey(s) is complete.

The Patient Safety Component has separate surveys for the following types of facilities:

- Hospital (includes the following hospital types: general, acute care; critical access; oncology; orthopedic; pediatric; women's; women's and children's; military; psychiatric; and Veterans Affairs): ***Patient Safety Component – Annual Hospital Survey*** ([57.103](#))
- Long-term Acute Care (LTAC) Hospital: ***Patient Safety Component – Annual Facility Survey for LTAC*** ([57.150](#))
- Inpatient Rehabilitation Facility (includes free-standing rehabilitation facilities and CMS-certified inpatient rehabilitation units located within a hospital): ***Patient Safety Component – Annual Facility Survey for IRF*** ([57.151](#))

Instructions for completing the Annual Survey form can be found in the Table of Instructions. A link to the Table of Instructions form is included on each of the annual survey forms.

Bloodstream Infection Event (Central Line-Associated Bloodstream Infection and Non-central Line Associated Bloodstream Infection)

Table of Contents

Introduction.....	2
Settings	2
Key Terms and Abbreviations.....	2
Definitions Specific to Bloodstream Infection (BSI) / Central Line Associated Bloodstream Infection (CLABSI)	
Surveillance	3
Laboratory Confirmed Bloodstream Infection (LCBIs) Hierarchy; Types of LCBIs	3
Types of Central Lines for NHSN reporting purposes.....	5
Devices Not Considered Central Lines for NHSN Reporting Purposes	6
Table 1: Laboratory-Confirmed Bloodstream Infection Criteria:	6
Table 2: Mucosal Barrier Injury Laboratory-Confirmed Bloodstream Infection (MBI-LCBI)	9
Reporting Instructions: See below for a Summary of CLABSI Exclusions and Reporting Requirements.	11
Reporting Instructions.....	12
Blood Specimen Collection	14
Table 3: Examples of Associating the Use of Central Lines to BSI Events (CLABSI)	15
Pathogen Exclusions and Reporting Considerations	17
Table 4: Reporting Speciated and Unspeciated Organisms Identified from Blood Specimens.....	18
Table 5: Examples Illustrating the MBI-LCBI Criteria for Neutropenia	18
Monthly Summary Data	19
Table 6: Examples of Denominator Day counts for Device Days	20
Table 7: Denominator Data Collection Methods.....	22
Data Analyses	25
Table 8: CLABSI Measures Available in NHSN	28
References	29
Appendix: Secondary BSI Guide (not applicable to Ventilator-associated Events [VAE]).....	30
Table B1: Secondary BSI Guide: List of all NHSN primary site-specific definitions available for making secondary BSI determinations using Scenario 1 or Scenario 2	34
Secondary BSI Reporting Instructions	35
Pathogen Assignment.....	37
Figure B1: Secondary BSI Guide for eligible organisms	45
Figure B2: VAE Guidance for Secondary BSI Determination	46

Disclaimer: The appearance of any product or brand names in this training protocol is for educational purposes only and is not meant to serve as an official endorsement of any such product or brand by the Centers for Disease Control and Prevention (CDC) or the United States Government. CDC and the United States Government, by mentioning any particular product or brand, is neither recommending that product or brand nor recommending against the product's or brand's use.

Bloodstream Infection Event (Central Line-Associated Bloodstream Infection and Non-central Line Associated Bloodstream Infection)

Introduction

Although a 10% decrease in CLABSIs has occurred in hospitals across the U.S. from 2023-2024, an estimated 18,100 central line-associated bloodstream infections (CLABSI) still occur in intensive care units and wards of U.S. acute care facilities each year.¹ CLABSIs are serious infections typically causing a prolongation of hospital stay, increased cost, and risk of mortality.

CLABSIs can be prevented through proper insertion techniques and management of the central line which are addressed in the CDC's Healthcare Infection Control Practices Advisory Committee (CDC/HICPAC) *Guidelines for the Prevention of Intravascular Catheter-Related Infections, 2011*.²

Settings

Surveillance may occur in any inpatient location where denominator data can be collected, which can include critical/intensive care units (ICU), specialty care areas (SCA), neonatal units including neonatal intensive care units (NICUs), step down units, wards, and long-term acute care units. A complete listing of inpatient locations and instructions for mapping can be found in [the CDC Locations and Descriptions](#) chapter.

Note: CLABSI surveillance after patient discharge from a facility is not required. However, if discovered, any CLABSI with a date of event (DOE) on the day of or the day after discharge is attributed to the discharging location and should be communicated to that facility to encourage appropriate NHSN reporting of CLABSIs. (See [Transfer Rule, Chapter 2](#)). Do not collect or report additional central line days after discharge.

Key Terms and Abbreviations

Refer to the NHSN Patient Safety Manual, [Chapter 2 Identifying Healthcare Associated Infections in NHSN](#) and [Chapter 16 NHSN Key Terms](#) for definitions of the following universal concepts for conducting HAI surveillance.


- I. Date of event (DOE)
- II. Healthcare associated infection (HAI)
- III. Infection window period (IWP)
- IV. Present on admission (POA)
- V. Repeat infection timeframe (RIT)
- VI. Secondary BSI attribution period (SBAP)
- VII. Location of Attribution (LOA)
- VIII. Transfer rule

Definitions Specific to Bloodstream Infection (BSI) / Central Line Associated Bloodstream Infection (CLABSI) Surveillance:

Primary bloodstream infection (BSI): A Laboratory Confirmed Bloodstream Infection (LCBI) that is not secondary to an infection at another body site (see Appendix: Secondary BSI Guide and CDC/NHSN Surveillance Definitions for Specific Types of Infection [Ch-17], urinary tract infection (UTI) [Ch-7], pneumonia (PNEU) [Ch-6], and surgical site infection (SSI) [Ch- 9]).

Laboratory Confirmed Bloodstream Infection (LCBIs) Hierarchy; Types of LCBIs

(see [Table 1](#) and [Table 2](#)):



Secondary BSI: A BSI that is thought to be seeded from a site-specific infection at another body site (see Appendix: Secondary BSI Guide and CDC/NHSN Surveillance Definitions for Specific Types of Infection, UTI, PNEU, and SSI).

Secondary BSI Attribution Period (SBAP): The period in which a blood specimen must be collected for a secondary BSI to be attributed to a primary site of infection. This period includes the Infection Window Period (IWP) combined with the Repeat Infection Timeframe (RIT). The SBAP is 14-17 days in length depending upon the date of event (See Secondary BSI Attribution period, Chapter 2).

Infusion: The administration of any solution through the lumen of a catheter into a blood vessel. Infusions include continuous infusion (for example, nutritional fluids or medications), intermittent infusion (for example, IV flush), IV antimicrobial administration, and blood transfusion or hemodialysis treatment.

Access: The performance of any of the following activities during the current inpatient admission:

- Line placement
- Use of (entering the line with a needle or needleless device) any central line for:
 - Infusion
 - Withdrawal of blood
- Use for hemodynamic monitoring

Notes:

1. If a patient is admitted to an *inpatient* location with a central line (CL) already in place, and it is the patient's only CL, the day of ***first access*** in an inpatient location begins the central line day count (CL Day for making central line-associated determinations). De-accessing any type of central line (for example, removal of port needle but port remains in body) does not remove the patient from CLABSI surveillance or device day counts for reporting denominator summary data.
2. An inpatient location, for making determinations about central line access, includes but is not limited to, any department or unit within the facility that provides service to inpatients [for example, inpatient Dialysis, Operating Room (OR), Interventional Radiology, Gastroenterology Lab (GI), Cardiac Catheterization lab (CC), wards, ICUs, etc.].
3. Include any inpatient receiving dialysis in CLABSI surveillance conducted in the patient's assigned inpatient location, regardless of whether the patient only has one CL and dialysis staff are the only providers to access it during dialysis treatment.

Examples: *CLABSIs in the following examples will be attributed to Unit A*

- Patient on Unit A receives onsite dialysis by contracted dialysis staff
- Dialysis staff travels to Unit A to provide dialysis to a Unit A patient
- Patient in Unit A for inpatient care is transported to dialysis unit within the facility for dialysis

Because CLABSI events cannot be attributed to a non-bedded inpatient location (inpatient location where denominator data is not collected but inpatient care is provided, for example, OR, IR, or inpatient dialysis), such events must be attributed to the inpatient location housing the patient.

Central line (CL): An intravascular catheter that terminates at, in, or close to the heart, **or** in one of the great vessels **AND** is used for infusion, withdrawal of blood, or hemodynamic monitoring. Consider the following great vessels when making determinations about CLABSI events and counting CL device days:

- Aorta
- Pulmonary artery
- Superior vena cava
- Inferior vena cava
- Brachiocephalic veins
- Internal jugular veins
- Subclavian veins
- External iliac veins
- Common iliac veins
- Femoral veins
- In neonates, the umbilical artery/vein

Notes:

1. Neither the type of device nor the insertion site is used to determine if a device is considered a central line for NHSN reporting purposes. Any intravascular catheter (such as introducers, midlines, or arterial catheters) depending on the location of the tip and its use, may be considered a CL.
2. At times, a CL may migrate from its original central location after confirmation of proper placement. NHSN does not require ongoing verification of proper line placement. Therefore, once a line has been designated a CL it remains a CL, regardless of migration, until removed from the body or patient discharge, whichever comes first. CL days are included for any CLABSI surveillance conducted in that location.
3. A non-lumened intravascular catheter that terminates at or close to the heart or in a great vessel that is not used for infusion, withdrawal of blood or hemodynamic monitoring is not considered a CL for NHSN reporting purposes (for example, non-lumened pacemaker wires.)
 - There are some pacemaker wires that do have lumens, which may be considered a central line.

Types of Central Lines for NHSN reporting purposes:

1. Permanent central line: Includes:
 - a. Tunneled catheters, including tunneled dialysis catheters
 - b. Implanted catheters (including ports)
2. Temporary central line: A non-tunneled, non-implanted catheter
3. Umbilical catheter: A vascular catheter inserted through the umbilical artery or vein in a neonate. All umbilical catheters are central lines

Eligible Central Line: A CL that has been **in place** for **more than two consecutive calendar days** (on or after CL Day 3), following the *first access* (as defined above) of the central line, in an inpatient location, during the current admission. Such lines are eligible for CLABSI events and remain eligible for CLABSI events until the day after removal from the body or patient discharge, whichever comes first. (See [Table 3](#) for examples).

Eligible BSI Organism: Any organism that is eligible for use to meet LCBI or MBI-LCBI criteria. In other words, an organism that is not an excluded pathogen for use in meeting LCBI or MBI-LCBI criteria. All organisms may not be included in the [NHSN Terminology Browser](#). Contact NHSN for guidance regarding organisms that are not found in the browser.

Central line-associated BSI (CLABSI): A laboratory confirmed bloodstream infection where an eligible BSI organism is identified, and an eligible central line is present on the LCBI DOE or the day before.

Central line days: The number of days a central line is accessed to determine if an LCBI is a CLABSI.

Denominator device days: The count of central lines on an inpatient unit that is recorded in the monthly denominator summary data. This count begins on the first day the central line is present, regardless of access.

Devices **Not** Considered Central Lines for NHSN Reporting Purposes:

- Arterial catheters unless in the pulmonary artery, aorta, or umbilical artery
- Arteriovenous fistula
- Arteriovenous graft
- Extracorporeal life support (ECMO)
- Hemodialysis reliable outflow (HERO) dialysis catheter
- Intra-aortic balloon pump (IABP) devices
- Peripheral IV
- Midlines unless the central line definition is met
- Total Artificial Heart (TAH)
- Ventricular Assist Device (VAD)

Table 1: Laboratory-Confirmed Bloodstream Infection Criteria:

Must meet **one** of the following LCBI criteria:

Criterion	<i>Comments and reporting instructions that follow the site-specific criteria provide further explanation and are integral to the correct application of the criteria.</i> Once an LCBI determination is made, proceed to the MBI-LCBI definitions, and determine if the corresponding MBI-LCBI criteria are also met (for example, after meeting LCBI 2, investigate for potential MBI-LCBI 2)
LCBI 1 If LCBI 1 criterion is met, consider MBI-LCBI 1	Patient of any age has a recognized bacterial or fungal pathogen, not included on the NHSN common commensal list: 1. Identified from one or more blood specimens obtained by a culture OR 2. Identified to the genus or species level by non-culture based microbiologic testing (NCT)* methods (for example, T2 Magnetic Resonance [T2MR] or next-generation sequencing [NGS]). Note: <i>If blood is collected for culture within 2 days before, or 1 day after the NCT, disregard the result of the NCT and use only the result of the CULTURE to make an LCBI surveillance determination. If no blood is collected for culture within this time period, use the result of the NCT for LCBI surveillance determination.</i> AND Organism(s) identified in blood is not related to an infection at another site (See Appendix: Secondary BSI Guide). *For the purposes of meeting LCBI 1, NCT is defined as a methodology that identifies an organism directly from a blood specimen without inoculation of the blood specimen to any culture media.

	Notes: 1. If a patient meets both LCBI 1 and LCBI 2 or LCBI 3 criteria, report LCBI 1 with the recognized pathogen entered as pathogen #1 and the common commensal as pathogen #2. 2. An eligible organism in the blood specimen is the only element needed to meet LCBI 1 criterion; therefore, the LCBI 1 DOE <u>will always be</u> the collection date of the first positive blood specimen used to set the BSI IWP.																											
LCBI 2 If LCBI 2 criterion is met, consider MBI-LCBI 2	Patient of any age has at least <u>one</u> of the following signs or symptoms: fever (>38.0°C), chills, or hypotension AND Organism(s) identified in blood is not related to an infection at another site (See Appendix: Secondary BSI Guide). AND The same NHSN common commensal is identified by culture from two or more blood specimens collected on separate occasions (see Blood Specimen Collection). For common commensal organisms, refer to the NHSN Terminology Browser. Notes: 1. Criterion elements must occur within the 7-day IWP (as defined in Chapter 2) which includes the collection date of the positive blood specimen, the 3 calendar days before and the 3 calendar days after. 2. The two matching common commensal specimens represent a single element for use in meeting LCBI 2 criterion, and the collection date of the first specimen is used to determine the BSI IWP. 3. At least one element (specifically, a sign or symptom of fever, chills, or hypotension) is required to meet LCBI 2 criterion; the LCBI 2 DOE will always be the date the first element occurs for the first time during the BSI IWP, whether that be a sign or symptom or the positive blood specimen. <table><tr><td></td><td>6/1</td><td>Fever > 38.0 °C</td><td>LCBI 2 DOE = 6/1</td></tr><tr><td></td><td>6/2</td><td>No LCBI element</td><td></td></tr><tr><td></td><td>6/3</td><td>No LCBI element</td><td></td></tr><tr><td rowspan="2">Single element</td><td>6/4</td><td><i>S. epidermidis</i> (1 of 2)</td><td>Date of 1st diagnostic test = 6/4</td></tr><tr><td>6/5</td><td><i>S. epidermidis</i> (2 of 2)</td><td></td></tr><tr><td></td><td>6/6</td><td>No LCBI element</td><td></td></tr><tr><td></td><td>6/7</td><td>No LCBI element</td><td></td></tr></table>		6/1	Fever > 38.0 °C	LCBI 2 DOE = 6/1		6/2	No LCBI element			6/3	No LCBI element		Single element	6/4	<i>S. epidermidis</i> (1 of 2)	Date of 1st diagnostic test = 6/4	6/5	<i>S. epidermidis</i> (2 of 2)			6/6	No LCBI element			6/7	No LCBI element	
	6/1	Fever > 38.0 °C	LCBI 2 DOE = 6/1																									
	6/2	No LCBI element																										
	6/3	No LCBI element																										
Single element	6/4	<i>S. epidermidis</i> (1 of 2)	Date of 1st diagnostic test = 6/4																									
	6/5	<i>S. epidermidis</i> (2 of 2)																										
	6/6	No LCBI element																										
	6/7	No LCBI element																										

LCBI 3 If LCBI 3 criterion is met, consider MBI-LCBI 3	Patient ≤ 1 year of age has at least one of the following signs or symptoms: fever ($>38.0^{\circ}\text{C}$), hypothermia ($<36.0^{\circ}\text{C}$), apnea, or bradycardia AND Organism(s) identified in blood is not related to an infection at another site (See Appendix: Secondary BSI Guide). AND The same NHSN common commensal is identified by a culture from two or more blood specimens collected on separate occasions (see Blood Specimen Collection). For common commensal organisms, refer to the NHSN Terminology Browser. Notes: 1. Criterion elements must occur within the 7-day IWP (as defined in Chapter 2) which includes the collection date of the positive blood specimen, the 3 calendar days before and the 3 calendar days after. 2. The two matching common commensal specimens represent a single element for use in meeting LCBI 3 criterion, and the date of the first is used to determine the BSI IWP. At least one element (specifically, a sign or symptom of fever, hypothermia, apnea, or bradycardia) is required to meet LCBI 3 criterion; the LCBI 3 DOE will always be the date the first element occurs for the first time during the BSI IWP whether that be a sign or symptom or the positive blood specimen. <table border="1" data-bbox="349 1375 1323 1692"> <tr> <td></td><td>5/31</td><td>No LCBI element</td><td></td></tr> <tr> <td></td><td>6/1</td><td>No LCBI element</td><td></td></tr> <tr> <td></td><td>6/2</td><td>No LCBI element</td><td></td></tr> <tr> <td rowspan="2">Single element</td><td>6/3</td><td><i>S. epidermidis</i> (1 of 2)</td><td rowspan="2">Date of 1st diagnostic test = 6/3 LCBI DOE = 6/3</td></tr> <tr> <td>6/4</td><td><i>S. epidermidis</i> (2 of 2)</td></tr> <tr> <td></td><td>6/5</td><td>Apnea documented</td><td></td></tr> <tr> <td></td><td>6/6</td><td>No LCBI element</td><td></td></tr> </table>		5/31	No LCBI element			6/1	No LCBI element			6/2	No LCBI element		Single element	6/3	<i>S. epidermidis</i> (1 of 2)	Date of 1st diagnostic test = 6/3 LCBI DOE = 6/3	6/4	<i>S. epidermidis</i> (2 of 2)		6/5	Apnea documented			6/6	No LCBI element	
	5/31	No LCBI element																									
	6/1	No LCBI element																									
	6/2	No LCBI element																									
Single element	6/3	<i>S. epidermidis</i> (1 of 2)	Date of 1st diagnostic test = 6/3 LCBI DOE = 6/3																								
	6/4	<i>S. epidermidis</i> (2 of 2)																									
	6/5	Apnea documented																									
	6/6	No LCBI element																									

Table 2: Mucosal Barrier Injury Laboratory-Confirmed Bloodstream Infection (MBI-LCBI)

An MBI-LCBI is a subset of the LCBI criteria; therefore, a BSI event must fully meet an LCBI criterion before evaluating for the corresponding MBI-LCBI criterion.

The MBI-LCBI DOE will always be the date the prerequisite LCBI criteria are met. Abnormal ANC and WBC values reflect risk factors for acquiring an MBI-LCBI, not symptoms of infection and therefore are not used in DOE determinations.

Must meet **one** of the following MBI-LCBI criteria

MBI-LCBI 1	MBI-LCBI 2	MBI-LCBI 3
Patient of any age fully meets LCBI 1 criterion	Patient of any age fully meets LCBI 2 criterion	Patient ≤1 year of age fully meets LCBI 3 criterion
with at least one blood specimen	with at least two matching blood specimens	
with ONLY MBI organisms (see NHSN Terminology Browser)*	with ONLY Viridans Group <i>Streptococcus</i> and/or <i>Rothia spp.</i> alone but no other organisms†	
identified by culture or non-culture based microbiologic testing method	identified by culture	
AND		
Patient meets at least <u>one</u> of the following:		
1. Is an allogeneic hematopoietic stem cell transplant recipient within the past year with one of the following documented during same hospitalization as positive blood specimen: a. Grade III or IV gastrointestinal graft versus host disease [GI GVHD] OR b. ≥1-liter diarrhea in a 24-hour period (or ≥20 mL/kg in a 24-hour period for patients <18 years of age) with onset on or within the 7 calendar days before the date the positive blood specimen was collected. OR		
2. Is neutropenic, defined as at least two separate days with ANC [†] and/or WBC values <500 cells/mm ³ collected within a 7-day time period which includes the collection date of the positive blood specimen, the 3 calendar days before and the 3 calendar days after (See Table 5).		

Notes:

1. If a patient meets both MBI-LCBI 1 and MBI-LCBI 2 or MBI-LCBI 3 criteria (specifically has Viridans Group *Streptococcus* or *Rothia* spp. and only MBI organisms in the blood specimen), report organisms as MBI-LCBI 1 with the recognized pathogen as pathogen #1 and the common commensal as pathogen #2.
2. Any combination of ANC and/or WBC values can be used to meet neutropenic criteria provided they are collected on separate days within the 7-day period that includes the date of the positive blood specimen, the 3 calendar days before and the 3 calendar days after.
3. When a blood specimen positive for a non-MBI organism is collected during the BSI RIT of an MBI-LCBI, the initial MBI-LCBI event is edited to an LCBI and the identified non-MBI organism is added.

* Refer to the [NHSN Terminology Browser](#) for eligible MBI organisms.

†Eligible positive blood specimens must be collected on separate occasions and limited to the following:

- Viridans Group *Streptococcus* identified in at least two sets of blood specimens
- *Rothia* spp. identified in at least two sets of blood specimens
- Viridans Group *Streptococcus* and *Rothia* spp. identified in at least two sets of blood specimens

†Formula for calculating ANC if not provided by your laboratory:

- The ANC is not always reported directly in the chart
- The WBC in the chart is usually reported in terms of a thousand cells/mm³ and can be used to calculate the ANC

$$\text{ANC} = \text{Absolute Segs} + \text{Absolute Bands}$$

OR

$$\text{ANC} = \text{WBC} \times \% \text{Segs} + \% \text{Bands} \div 100$$

Example:

WBC	Segs	Bands
2 k/mm ³	20%	20%

$$\text{ANC} = 2000 \times (20 + 20) \div 100 = 800 \text{ cells/mm}^3$$

Reporting Instructions: See below for a Summary of CLABSI Exclusions and Reporting Requirements

When a **BSI event in the presence of a central line** meets one of the CLABSI exclusions listed below the following guidelines are applied:

- The event is reported to NHSN but is NOT considered central line associated.
- **The Central Line field is marked “Yes”** if an eligible central line has been on the BSI DOE and is still in place on the BSI DOE or the day before.
- The events do not contribute to the CLABSI SIR measure.
- In each instance where the date of event of subsequent positive blood specimens is outside of the established BSI RIT, meeting the exclusion criteria, the subsequent positive blood must be investigated as primary or secondary to another site-specific infection. The CLABSI exclusion criteria must be met again in a new BSI IWP to determine if the positive blood specimen is central line associated.

Note: Meeting LCBI criteria in all situations noted below will result in setting a BSI RIT and any associated device days should be included in the denominator summary data counts.

- Extracorporeal life support (ECLS or ECMO):** A BSI meeting LCBI criteria with an eligible central line where extracorporeal life support (for example, extracorporeal membrane oxygenation [ECMO]) is present for more than 2 days on the BSI DOE and is still in place on the DOE or the day before, is considered an LCBI. Report such events, marking the ECMO field as “Yes.”
- Ventricular Assist Device (VAD):** A BSI meeting LCBI criteria with an eligible central line where a VAD is present for more than 2 days on the BSI DOE and is still in place on the DOE or the day before, is considered an LCBI. Report such events, marking the VAD field as “Yes.”
- Total Artificial Heart (TAH):** A BSI meeting LCBI criteria with an eligible central line where a TAH is present for more than 2 days on the BSI DOE and is still in place on the DOE or the day before, is considered an LCBI. Report such events, marking the TAH field as “Yes.”
- Patient Injection:** A BSI meeting LCBI criteria that is accompanied by documentation of observed or suspected patient injection into the vascular access line, within the BSI IWP, will be considered an LCBI for NHSN reporting purposes. This exclusion is very specific to **“INJECTION”**. Manipulating or tampering with the line (such as biting, picking at, sucking on, etc.) DOES NOT meet the intent of this exclusion. The documentation must specifically state the patient was “observed injecting...” or “suspected of injecting...” the device. Insinuations or descriptive events that suggest such behavior DO NOT meet the intent of this exclusion. Report such events, marking the Patient Injection field as “Yes.”
- Epidermolysis bullosa (EB):** If during the current admission, there is documentation of a diagnosis of EB report such an event, marking the EB field as “Yes.”

Note: The Epidermolysis bullosa (EB) CLABSI exclusion is limited to the genetic forms of EB in the pediatric population.

- f. **Munchausen Syndrome by Proxy (MSBP):** If during the current admission, there is documentation or a diagnosis of known or suspected MSBP, also known as factitious disorder, imposed on another (FDIA), report such an event, marking the MSBP fields as “Yes.”
- g. **Pus at the vascular access site:** Occasionally, a patient with both an eligible central line and another vascular access device will have pus at the other access site. If there is pus at the site of one of the following vascular access devices and a specimen collected from that site has at least one matching organism to an organism identified in the blood during the BSI IWP, report such events marking the “pus at the vascular access site” field as “Yes.” Vascular access devices included in this exception are limited to:
- Arterial catheters unless in the pulmonary artery, aorta or umbilical artery
 - Arteriovenous fistulae
 - Arteriovenous grafts
 - Hemodialysis reliable outflow (HERO) dialysis catheters
 - Intra-aortic balloon pump (IABP) devices
 - Non-accessed CL (those neither inserted nor used during current admission)
 - Peripheral IV
 - Midlines unless the central line definition is met

Reporting Instructions:

1. Group B *Streptococcus*: Group B *Streptococcus* identified from blood, with a date of event during the first 6 days of life, is not reported as a CLABSI. A BSI RIT is set, and any associated device days should be included in the denominator summary data counts.
2. Do not report an LCBI that has a DOE within a BSI RIT. Any additional organisms identified meeting LCBI criteria are added to the initial BSI event. See RIT guidance in [Chapter 2](#), Identifying Healthcare associated Infections or [Chapter 16](#), Key Terms.
3. Do not report an MBI-LCBI that has a DOE within a BSI RIT. Any additional organisms identified meeting MBI-LCBI criteria are added to the initial BSI event. See RIT guidance in [Chapter 2](#), Identifying Healthcare associated Infections.
4. A common commensal identified in a single blood specimen is considered a contaminant. A single common commensal organism is not used to meet LCBI 2 or 3 criteria or secondary BSI attribution. Additionally, it does not prevent a case from meeting MBI-LCBI criteria when the organism requirements call for “only” a specific organism or type of organism (for example, “only intestinal organisms from the MBI list”).
5. Only primary BSIs create a 14-day BSI RIT:

Primary BSI example: Patient has a positive blood specimen identifying *Staphylococcus aureus* on hospital day 6, which is not secondary to another site-specific source of infection. A subsequent positive blood specimen is collected on hospital day 12 that identifies *Pseudomonas aeruginosa*. Because the date of event is during the BSI RIT, no new BSI event is reported, and *Pseudomonas* is added to the initial BSI event.

6. **Secondary BSIs do not create a 14-day BSI RIT:**

Secondary BSI example: A symptomatic urinary tract infection (SUTI) with *Enterococcus faecalis* is identified and *E. faecalis* is also identified from a blood specimen on hospital day 11. Because the positive blood culture is collected during the SUTI secondary BSI attribution period, the positive *E. faecalis* blood specimen is deemed secondary to the SUTI. Since the BSI is secondary to the SUTI, a SUTI RIT is set, not a BSI RIT. On hospital day 15 (also within the SUTI RIT and secondary BSI attribution period), a blood culture growing *Staphylococcus aureus* is collected. Because the blood growing *S. aureus* does not have at least one organism that matches the organism used to meet the SUTI criterion, the BSI cannot be attributed as secondary to the SUTI. Additionally, there is no BSI RIT established; therefore, the BSI will need to be investigated as a new BSI event and either assigned as primary or secondary to another site-specific infection.

Note: The secondary BSI attribution period of a primary source of infection is not a “catch all” for subsequent BSIs.

7. There is no expectation that positive blood specimens collected during the present on admission (POA) time period are investigated. If identified, they are not reported to NHSN. However, if a subsequent positive blood specimen is collected within 14 days of a positive blood specimen collected during the POA time period, it is imperative that a determination is made for the original blood specimen in order to make the correct determination about the subsequent blood specimen.

Example 1: A patient has a positive blood specimen with *Escherichia coli* (*E. coli*) that is a POA on 6/1. On 6/10, a subsequent positive blood specimen with *Klebsiella pneumoniae* is identified. The 6/1 blood specimen is investigated and if determined a primary BSI, sets a 14-day BSI RIT (6/1-6/14). Therefore, the 6/10 specimen is not a new BSI event and *K. pneumoniae* is added to the POA BSI event if reported.

Example 2: A patient has a positive blood specimen that identifies *Staphylococcus aureus* present on admission 6/1. On 6/10, a subsequent positive blood specimen with *Klebsiella pneumoniae* is collected. To make the correct determination about the second blood specimen, the initial POA BSI event must be investigated to determine if it is primary or secondary to another site. In reviewing the chart, a right elbow culture from 5/31, is also positive for *S. aureus*, plus the symptoms needed to meet Joint or Bursa infection (JNT) criterion 3c are documented making the 6/1 BSI secondary to JNT. The POA primary JNT infection creates a 14-day JNT RIT (6/1-6/14) during which no new JNT infections are reported. Additionally, since the subsequent blood specimen does not contain at least one matching pathogen to the specimen used to meet the JNT criterion, the positive blood with *K. pneumoniae* cannot be attributed to the original JNT event and must be investigated as a primary or secondary BSI.

Blood Specimen Collection

The “two or more blood specimens drawn on separate occasions” criterion is met if there is blood collected from at least two separate blood draws* on the same or consecutive calendar days.

*Two separate blood draws mean the blood cultures are assigned separate specimen numbers, processed individually, and are reported separately in the final laboratory report.

1. Specimen Collection Considerations: Blood specimens drawn through central lines can have a higher rate of contamination than blood specimens collected through peripheral venipuncture.^{3,4} However, all positive blood specimens, regardless of the site from which they are drawn or the purpose for which they are collected, must be included when conducting in-plan CLABSI surveillance (for example, weekly blood cultures performed in hematology and oncology locations).
2. Catheter tip cultures cannot be used in place of blood specimens for meeting LCBI criteria.
3. In MBI-LCBI 1, 2 and 3, “no other organisms” means there is no identification of a non-MBI-LCBI pathogen (such as *S. aureus*) or 2 matching common commensals (such as coagulase-negative staphylococci) collected from the blood on separate occasions that would otherwise meet LCBI criteria. If this occurs, the infection does not meet MBI-LCBI criteria.
4. When a blood specimen positive for an organism not included on the NHSN MBI organism list is collected during the BSI RIT of an MBI-LCBI, the initial MBI-LCBI event is edited to an LCBI and the identified non-MBI organism is added.

MBI-RIT Exception: An MBI-LCBI designation will not change to an LCBI event if the following criteria are met:

1. The blood culture with the non-MBI organism is collected during an existing BSI (MBI-LCBI) RIT
- AND**
2. The blood culture with the non-MBI organism is deemed secondary to an NHSN site-specific infection

See Example 5 in the Secondary BSI Guide section of this protocol and [Chapter 2](#) Pathogen Assignment (Example 2b).

Table 3: Examples of Associating the Use of Central Lines to BSI Events (CLABSI):

This table provides examples that illustrate:

- Device association as determined by the presence of an eligible CL on the BSI DOE or the day before.
- The goal of NHSN HAI surveillance is to identify risks to the patient that are the result of device use in general; therefore, NHSN does not require association of a BSI with a specific device when more than one line is present.

Note: The procedure for de-accessing a port involves ensuring patency of the line prior to removal of the needle which involves blood withdrawal, an IV flush and injection of an anticoagulant.

Date	31-Mar	1-Apr	2-Apr	3-Apr	4-Apr	5-Apr	6-Apr
Patient A:							
Port Status	Port in	Port in	Port in	Port in	Port in	Port in	Port in
Accessed	No	No	Yes	Yes	Yes De-accessed	No	No
Eligible for CLABSI event	No	No	No	No	Yes-eligible CL	Yes-eligible CL	Yes-eligible CL
			CL Day 1	CL Day 2	CL Day 3	CL Day 4	CL Day 5
Patient A becomes eligible for a CLABSI on 4/4 because an accessed port is in place for some portion of > 2 consecutive calendar days making it an eligible CL on 4/4 (CL Day 3). The patient remains eligible for a CLABSI event the day of or the day after device removal or patient discharge, whichever comes first.							

Date	31-Mar	1-Apr	2-Apr	3-Apr	4-Apr	5-Apr	6-Apr
Patient B:							
CL/Port Status	CL/Port in	CL/Port in	CL/Port in	CL/Port in	CL/Port in CL/Port out	No device	No device
Accessed	No	No	Yes	Yes	Removed	-	-
Eligible for CLABSI event	No	No	No	No	Yes-eligible CL	Yes-eligible CL	No
	-	-	CL Day 1	CL Day 2	CL Day 3	-	-
Patient B is eligible for a CLABSI on 4/4 (CL Day 3) through 4/5. An accessed device (CL or port) is in place > 2 consecutive calendar days making it an eligible CL on 4/4 (CL Day 3). A BSI with a DOE on the day of or the day after device removal or patient discharge is considered device associated (CLABSI).							

Date	31-Mar	1-Apr	2-Apr	3-Apr	4-Apr	5-Apr	6-Apr
Patient C: CL Status	CL in	CL in	CL in/ CL out	CL in	CL in	CL in/ CL out	No device
Accessed	Yes	Yes	Removed	Placed	Yes	Removed	-
Eligible for CLABSI event	Yes-eligible CL	Yes- eligible CL	Yes- eligible CL	Yes- eligible CL	Yes- eligible CL	Yes- eligible CL	Yes- eligible CL
	CL Day 3	CL Day 4	CL Day 5	CL Day 6	CL Day 7	CL Day 8	-

Patient C is admitted to an inpatient location on 3/29 with a central line in place. Patient C is eligible for a CLABSI on 3/31 (CL Day 3) through 4/6 because an accessed CL is in place > 2 consecutive calendar days. A BSI with a DOE on the day of or the day after device removal or patient discharge is considered a device-associated infection (CLABSI). The patient remains eligible for a CLABSI event through 4/6 because a full calendar day did not pass without a CL in place, therefore, device counts continue uninterrupted.

Date	31-Mar	1-Apr	2-Apr	3-Apr	4-Apr	5-Apr	6-Apr
Patient D: CL Status	CL in	CL in	CL in/ CL out	No device	CL in	CL in	CL in
Accessed	Yes	Yes	Removed	-	Placed	Yes	Yes
Eligible for CLABSI event	Yes-eligible CL	Yes-eligible CL	Yes-eligible CL	Yes-eligible CL	No	No	Yes-eligible CL
	CL Day 3	CL Day 4	CL Day 5		CL Day 1	CL Day 2	CL Day 3

Patient D is admitted to an inpatient location on 3/29 with a central line in place. Patient D is eligible for a CLABSI 3/31 (CL Day 3) through 4/3. An accessed CL had been in place > 2 consecutive calendar days, however, a full calendar day passed (4/3) with no CL in place, therefore, device day counts start over at CL Day 1 when a new line is placed. After 4/3, the patient will not be eligible for a CLABSI event again until 4/6 when the new CL becomes an eligible CL (CL Day 3).

Date	31-Mar	1-Apr	2-Apr	3-Apr	4-Apr	5-Apr	6-Apr
Patient E: CL Status	No device	CL in	CL in	CL in	CL in	CL in	CL in
Accessed	-	Placed	Yes	Yes	Yes	Yes	Yes
Eligible for CLABSI event	-	No	No	Yes-eligible CL	Yes-eligible CL	Yes-eligible CL	Yes-eligible CL
	-	CL Day 1	CL Day 2	CL Day 3	CL Day 4	CL Day 5	CL Day 6

Patient E is eligible for a CLABSI on 4/3 (CL Day 3) through 4/6. Line placement is considered access and begins device day counts for making a CLABSI determination. An accessed device is in place > 2 consecutive calendar days making it an eligible CL on 4/3 (CL Day 3).

BOLD = change in status

Pathogen Exclusions and Reporting Considerations:

The term “recognized pathogen” in LCBI 1 criterion refers to any organism that is not an NHSN common commensal (Refer to the [NHSN Terminology Browser](#) for common commensals used for NHSN reporting purposes).

Exceptions:

- Organisms that are parasites and viruses are excluded as LCBI pathogens. This exclusion applies to meeting a primary BSI only. Viruses and parasites are eligible for use in secondary BSI determinations.
 - Organisms belonging to the following genera are excluded as LCBI pathogens: *Salmonella*, *Shigella*, *Yersinia*, *Campylobacter*, *Listeria*, *Vibrio*, STEC: Shiga toxin-producing *E. coli*, ETEC: Enterotoxigenic *E. coli*, EPEC: Enteropathogenic *E. coli*, EIEC: Enteroinvasive *E. coli*, EAEC: Enteroaggregative *E. coli*, DAEC: Diffusely adherent *E. coli*, *C. difficile*, or *Giardia*. These organisms are eligible for use in secondary BSI determinations but are not reported as the sole pathogen in a primary BSI.
 - Organisms that primarily cause community-associated infections and are not known to (or rarely) cause healthcare-associated infections, are excluded and cannot be used to meet any NHSN definition.
 - **Fungi:** *Blastomyces*, *Histoplasma*, *Coccidioides*, *Paracoccidioides*, *Cryptococcus*, *Pneumocystis*
 - **Vector-borne bacteria:** *Anaplasma spp.*, *Ehrlichia spp.*, *Borrelia spp.*, *Rickettsia spp.*
1. Business rules written into the pathogen fields of the NHSN application prevent entry of a common commensal as pathogen #1 when attempting to report both a recognized pathogen and common commensal identified in an LCBI 1 or MBI-LCBI 1 event. To save the event successfully, enter the recognized pathogen as pathogen # 1 and the common commensal as pathogen #2.
 2. For LCBI criteria 2 and 3, if the common commensal is identified to the species level for one blood specimen, and a companion blood specimen is identified with only a descriptive name, which is complementary to the companion culture (in other words, to the genus level), then it is assumed the organisms are the same (see [Table 4](#)).
 - Colony morphology, biotype, and antibiogram comparisons should not be used to determine the “sameness” of organisms because laboratory testing capabilities and protocols vary between facilities.
 - To reduce reporting variabilities due to differences in laboratory practice only genus and species identification should be used, and they should only be reported once.
 - An organism identified to the species level should be reported along with the antibiogram, if available. If antibiograms are available and the sensitivities differ for the same organisms in separate specimens, always report the more resistant panel.

Table 4: Reporting Speciated and Unspeciated Organisms Identified from Blood Specimens

Culture Report	Companion Culture Report	Report as...
Coagulase-positive staphylococci	<i>S. aureus</i>	<i>S. aureus</i>
<i>S. epidermidis</i>	Coagulase-negative staphylococci	<i>S. epidermidis</i>
<i>Enterococcus</i> spp.	<i>E. faecium</i>	<i>E. faecium</i>
<i>Bacillus</i> spp. (not anthracis)	<i>B. cereus</i>	<i>B. cereus</i>
<i>S. salivarius</i>	<i>Strep viridans</i>	<i>S. salivarius</i>

Note: When identification to the species level is not provided, the genus of the organism will be reported to NHSN. When identification to the genus level is not provided, report the organism as available on the NHSN organism list (for example, Gram-positive bacillus).

Table 5: Examples Illustrating the MBI-LCBI Criteria for Neutropenia

		Day -7	Day -6	Day -5	Day -4	Day -3	Day -2	Day -1	Day 1*	Day 2	Day 3	Day 4
Pt. A	WBC	100	800	400	300	ND	ND	320 [†]	400 [†] + BC* x 1 <i>Candida</i> spp.	ND	550	600
Pt. B	ANC	ND	410	130	ND	ND	120 [†]	110 [†]	ND +BC* x 2 viridans strep plus fever >38°C	110	300	320
Pt. C	WBC	100	800	400	300	ND	ND	ND	600 + BC* x 1 <i>Candida</i> spp.	230 [†]	ND	400 [†]

ND = not done; *Collection date of positive blood specimen; Italics = ANC/WBC < 500 cells/mm³; † ANC/WBC < 500 cells/mm³ used to meet neutropenia for MBI-LCBI criteria

Rationale for Table 5:

Patient A meets MBI-LCBI 1 criterion with neutropenia: Positive blood specimen with intestinal organism (*Candida* spp.) and neutropenia*. In this case, the WBC values on Day 1 = 400, and Day -1 = 320 are used.

Patient B meets MBI-LCBI 2 criterion with neutropenia: At least two positive blood specimens with *viridans group streptococci*, fever >38°C and neutropenia*. In this case, the ANC values on day -1 = 110 and Day -2 = 120 are used.

Note: Any two of Days -2, -1, 2, 3, and 4 could be used to meet this requirement since WBC and/or ANC values of $<500\text{cells/mm}^3$ were present on those days.

Patient C meets MBI-LCBI 1 criterion with neutropenia: Positive blood specimen with intestinal organism (*Candida* spp.) and neutropenia*. In this case, WBC values on Day 2 = 230 and Day 4 = 400 are used.

*Neutropenia is defined as: 2 separate days of ANC or WBC $<500\text{ cells/mm}^3$ occurring on the collection date of the positive blood specimen (Day 1) or during the 3 days before or the 3 days after Day 1.

Monthly Summary Data

Numerator Data: The [Primary Bloodstream Infection \(BSI\) form \(CDC 57.108\)](#) is used to collect and report each CLABSI that is identified during the month selected for surveillance. For CLABSI surveillance, all LCBI and MBI-LCBI that are identified as central-line associated must be included. The [Instructions for Completion of Primary Bloodstream Infection \(BSI\) form](#) contains brief instructions for collection and entry of each data element on the form. The *Primary BSI* form includes patient demographic information and whether a central line was present, and, if so, the type of central line the patient had if appropriate to the location; these data will be used to calculate line-specific infection rates. Additional data include the specific criteria met for identifying the primary BSI, whether the patient died, organisms identified from blood specimens, and the organisms' antimicrobial susceptibilities.

Reporting Instruction:

During the month of surveillance, if no CLABSI events are identified, the "Report No Events" box must be checked on the appropriate denominator summary screen, (for example, Denominators for Intensive Care Unit [ICU]/other locations [not NICU or SCA], etc.

Table 6: Examples of Denominator Day counts for Device Days

This table provides examples that illustrate:

- Denominator device day counts for a central line present on an inpatient location at the time of the device day count.

Note: If the central line is in place at the time of the denominator device count, it is included in the daily denominator device day count.

Date	31-Mar	1-Apr	2-Apr	3-Apr	4-Apr	5-Apr	6-Apr
Patient A:	Inpatient Location ICU CL inserted	ICU CL in	ICU CL in	ICU CL in	ICU CL in	ICU CL in	ICU CL in
Denominator Day Counts for Device Days	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7
Patient A has a CL inserted in the ICU. Because the CL is inserted in an inpatient location, Day 1 begins the denominator day count for device days. Patient A has 7 denominator device days for 3/31-4/6.							

Date	31-Mar	1-Apr	2-Apr	3-Apr	4-Apr	5-Apr	6-Apr
Patient B:	ED CL in place at time of admission	Patient admitted to inpatient location ICU CL in	ICU CL in	ICU CL in	ICU CL in	Inpatient Location CL in	Inpatient Location CL in
Denominator Day Counts for Device Days	-	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6
Patient B has a central line at the time of admission. Because Patient B is admitted to the emergency department on 3/31, the denominator day count for device days does not begin until the patient is transferred to the inpatient location on 4/1. Patient B has 6 denominator device days for 4/1-4/6.							

Date	31-Mar	1-Apr	2-Apr	3-Apr	4-Apr	5-Apr	6-Apr
Patient C:	Inpatient Location ICU CL in place at time of admission	ICU CL in	ICU CL in/ CL out	ICU CL in	ICU CL in	ICU CL in/ CL out	ICU No device
Denominator Day Counts for Device Days	Day 1	Day 2	Day 3*	Day 4	Day 5	Day 6*	-

Patient C has a central at the time of admission to ICU. Because Patient C is admitted to ICU on 3/31, the denominator day count for device days begins on the date of admission (3/31). Because there is no device on 4/6, the denominator device day count will end on 4/5. Patient C has 6 denominator device days for 3/31-4/5.

Date	31-Mar	1-Apr	2-Apr	3-Apr	4-Apr	5-Apr	6-Apr
Patient D:	Inpatient Location ICU No device	Inpatient Location ICU CL inserted	ICU CL in	ICU CL in	ICU CL in	ICU CL in	ICU CL in
Denominator Day Counts for Device Days	-	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6

Patient D does not have a central line in place at the time of admission to ICU. Because there is no central line in place on admission, the denominator day count for device days does not begin until the central line is placed in the inpatient location on 4/1. Patient D has 6 denominator device days for 4/1-4/6.

Date	31-Mar	1-Apr	2-Apr	3-Apr	4-Apr	5-Apr	6-Apr
Patient E:	Inpatient Location ICU Patient admitted with non- accessed port	Inpatient Location ICU Port not accessed	ICU Port not accessed	ICU Port accessed	ICU Port accessed	ICU Port accessed	ICU Port accessed
Denominator Day Counts for Device Days	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7

Patient E has a non-accessed port at the time of admission to ICU. The denominator device day count begins on the date the patient is admitted to ICU (3/31). Accessing the port on 4/3 does not change the denominator day count for device days. Patient E has 7 denominator device days for 3/31-4/6.

Table 7: Denominator Data Collection Methods

Denominator Data: Device days and patient days are used for denominator reporting. Device-day denominator data that are collected differ according to the patient location. The following methods can be used for the collection of denominator data:

Data Collection Method	Details
Manual, Daily	Denominator data (patient days and device days) should be collected at the same time, every day, for each location performing surveillance to ensure that differing collection methods don't inadvertently result in device days being greater than patient days. - For locations other than specialty care areas/oncology (SCA/ONC) and NICUs, the number of patients with at least one central line of any type, is collected daily, at the same time each day during the month and is recorded on the Denominators for Intensive Care Unit (ICU)/Other Locations (Not NICU or SCA/ONC) form (CDC 57.118). Only the totals for the month are entered into NHSN. Notes: - Only one central line per patient is counted per calendar day regardless of the number of central lines present. - All central lines on inpatient units should be included in device day counts regardless of access. - For specialty care areas/oncology, the number of patients with at least one central line are separated into those with permanent central lines and those with temporary central lines. The number of patients with at least one central line of either or both type(s), is collected daily, at the same time each day during the month and is recorded on the Denominators for Specialty Care Area (SCA)/Oncology (ONC) form (CDC 57.117). Only the totals for the month are entered into NHSN. Temporary and permanent lines are reported separately in this location because permanent lines are more commonly used in this patient population and may be associated with a lower BSI rate when compared to temporary central lines. Notes: - Only one central line per patient is counted per calendar day regardless of the number of central lines present. - All central lines on inpatient units should be included in device day counts regardless of access.

Data Collection Method	Details
	3. If a patient has both a temporary and a permanent central line, only report the temporary line because it is associated with a higher risk of bloodstream infection. The Instructions for Completion of Denominators for Intensive Care Unit (ICU)/Other Locations (Not NICU and SCA/ONC) and Instructions for Completion of Denominators for Specialty Care Areas (SCA)/Oncology (ONC) contain brief instructions for collection and entry of each data element on the form. - In NICUs, the number of patients with at least one central line is stratified by <u>birth weight</u> in five categories because the risk of BSI varies by birth weight. These data are reported on the Denominators for Neonatal Intensive Care Unit (NICU) form (CDC 57.116). Note: - Report only birth weight when entering BSI denominator data. The infant's weight at the time of BSI identification is <u>not</u> used and should not be reported. For example, a neonate weighs 1006 grams at birth but remains in the NICU for two months and has a body weight of 1650 grams when a CLABSI develops; enter the birth weight of 1006 grams on the BSI form. - All central lines on inpatient units should be included in device day counts regardless of access. The Instructions for Completion of Denominators for Neonatal Intensive Care Unit (NICU) form contains brief instructions for collection and entry of each data element on the forms.
Manual, sampled once/week (collected at the same time on the same designated day, once per week)	- To reduce staff time spent collecting surveillance data, once weekly sampling of denominator data to generate estimated central line days, may be used as an alternative to daily collection in non-oncology ICUs and wards (see Notes below). Sampling may <u>not</u> be used in SCA/ONC locations or NICUs. During the month, the number of patients in the location (patient-days) and the number of patients with at least one central line of any type (central line days) is collected on a designated day each week (for example, every Tuesday), and at the same time each day. - Evaluations of this method have repeatedly shown the use of Saturday or Sunday generate the least accurate estimates of denominator data; therefore, weekend days should not be selected as the designated denominator data collection day.⁶⁻⁸ If the designated day is missed, collect the denominator data on the next available weekday.

Data Collection Method	Details
	- The following must be collected and entered into NHSN: - The monthly total for patient-days, collected daily - The sampled total for patient-days - The sampled total central line-days When these data are entered, the NHSN application will calculate an estimate of central line-days. Notes: - To ensure the accuracy of estimated denominator data obtained by sampling, only ICU and ward location types with an average of 75 or more central line-days per month are eligible to use this method. A review of each location's central line denominator data for the past twelve months in NHSN will help determine which locations are eligible. - The accuracy of estimated denominator data generated by sampling can be heavily influenced by incorrect or missing data. Careful implementation of data collection following the guidance in this protocol is essential to avoid erroneous fluctuations in rates or standard infection ratios (SIRs).
Electronic	For <u>any</u> location, denominator data from electronic sources (in other words, central line days from electronic charting may be used only after a validation of a minimum of 3 consecutive months proves the data to be within 5% (+/-) of the manually collected once-a-day counts. When converting from one electronic counting system to another electronic counting system, the new electronic system should be validated against manual counts as above. If electronic counts for the new electronic system are not within 5% of manual counts, resume manual counting and continue working with IT staff to improve design of electronic denominator data extraction (while reporting manual counts) until concurrent counts are within 5% for 3 consecutive months. Notes: This guideline is important because validating a new electronic counting system against an existing electronic system can magnify errors and result in inaccurate denominator counts. Perform the validation of electronic counts separately for each location conducting CLABSI surveillance.

Data Analyses:

All data that are entered into NHSN can be analyzed at event or summary level. The data in NHSN can be visualized and analyzed in various ways, for example, descriptive analysis reports for both the denominator and numerator data.

Types of CLABSI Analysis Reports

Standardized Infection Ratio (SIR):

The standardized infection ratio (SIR) is calculated by dividing the number of observed events by the number of predicted events. The number of predicted events is calculated using probabilities estimated from statistical models constructed from national NHSN data, which represents the baseline population. There are three NHSN baseline periods, 2006-2008, 2015 and 2022 baselines. For the 2 more recent baselines, please see the SIR guides:

For the 2015 baseline model details: <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/nhsn-sir-guide.pdf>

For the 2022 baseline model details: <https://www.cdc.gov/nhsn/2022rebaseline/sir-guide.pdf>

$$\text{SIR} = \frac{\text{Observed (O) HAIs}}{\text{Predicted (P) HAIs}}$$

While SIRs can be calculated for single locations, the measure also allows you to summarize your data across multiple locations, adjusting for differences in the incidence of infection among the location types. For example, you can obtain one CLABSI SIR adjusting for all locations reported. Similarly, you can obtain one CLABSI SIR for all ICUs in your facility. In addition, IRF units within Acute Care Hospitals will be separated from all other ACH locations.

For more information on using the CLABSI SIR reports, please see the troubleshooting guide:

https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/clabsicauti_sirtroubleshooting.pdf.

For further information regarding the p-value and 95% confidence interval, see the following guide:

<https://www.cdc.gov/nhsn/ps-analysis-resources/keys-to-success.html>

Note: The SIR will be calculated only if the number of predicted events (numPred) is ≥ 1 to help enforce a minimum precision criterion.

Standardized Utilization Ratio (SUR):

The SUR, or standardized utilization ratio, is a summary measure used to track device use at a national, state, local, or facility level over time. The SUR adjusts for various facility and/or location-level factors that contribute to device use. The method of calculating an SUR is similar to the method used to calculate the Standardized Infection Ratio (SIR), a summary statistic used in NHSN to track healthcare-associated infections (HAIs). In device-associated HAI data analysis, the SUR compares the actual number of device days reported to what would be predicted, given the standard population (specifically, the NHSN baseline), adjusting for several factors that have been found to be significantly associated with differences in device utilization.

In other words, an SUR greater than 1.0 indicates that more device days were observed than predicted; conversely, an SUR less than 1.0 indicates that fewer device days were observed than predicted. SURs are currently calculated in NHSN for the following device types: central lines, urinary catheters, and ventilators.

More information regarding the 2015 and 2022 SUR calculations can be found at:

<https://www.cdc.gov/nhsn/2015rebaseline/index.html>

<https://www.cdc.gov/nhsn/2022rebaseline/analysis-resources.html>

Rates and Ratios:

The CLABSI rate per 1000 central line days is calculated by dividing the number of CLABSIs by the number of central line days and multiplying the result by 1000. The Central Line Utilization Ratio is calculated by dividing the number of central line days by the number of patient days. These calculations will be performed separately for different types of ICUs, specialty care areas, oncology units, and other locations in the institution. Separate rates and ratios will also be calculated for different types of central lines in specialty care areas/oncology locations and for birth weight categories in NICUs.

$$\text{CLABSI Rate} = \frac{\text{No. of CLABSIs}}{\text{No. of Central Line Days}} * 1000$$

Device Utilization Ratio

The Central Line Utilization Ratio is calculated by dividing the number of central line catheter days by the number of patient days.

These calculations will be performed separately for the different types of ICUs, specialty care areas, and other locations in the institution, except for neonatal locations. DURs are useful for the purposes of tracking device use over shorter periods of time and for internal trend analyses.

$$\text{DUR} = \frac{\text{No. of Central Line Days}}{\text{No. of Patient Days}}$$

Descriptive analysis

Descriptive analysis output options of numerator and denominator data, such as line listings, frequency tables, and bar and pie charts are available in the NHSN application. CLABSI SIRs, rates, and run charts are also available. A line list, frequency table, and rate table are also available to analyze pathogens and antimicrobial susceptibility data reported for CLABSIs. Guides on using NHSN analysis features are available from: <https://www.cdc.gov/nhsn/ps-analysis-resources/reference-guides.html>.

NHSN Group Analysis:

NHSN Group Users can perform the same analysis as facility level users in NHSN. A few helpful tools in NHSN for groups are listed in the resources below. These tools are guides on how to start and join a Group; how to create a template to request data from facilities; how to determine the level of access granted by the facility following the previous steps, and how to analyze the facilities data.

Group Analysis Resources:

NHSN Group Users Page: <https://www.cdc.gov/nhsn/group-users/index.html>

Group User's Guide to the Membership Rights Report: <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/GroupAnalysisWebinar.pdf>

Group User's Guide to the Line Listing- Participation Alerts: <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/group-alerts.pdf>

Data Quality Resources

Data Quality Website: <https://www.cdc.gov/nhsn/ps-analysis-resources/data-quality/index.html>

Data Quality Manual: https://www.cdc.gov/nhsn/pdfs/pscmanual/Instructions_DQ.pdf

Data Quality Training: <https://www.cdc.gov/nhsn/training/analysis/index.html>

Verifying BSI Events Contributing to CLABSI Numerator: <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/bsi-excluded-linelist-508.pdf>

Additional Resources

Analysis Resources: <https://www.cdc.gov/nhsn/ps-analysis-resources/index.html>

Analysis Reference Guides: <https://www.cdc.gov/nhsn/PS-Analysis-resources/reference-guides.html>

NHSN Training: <https://www.cdc.gov/nhsn/training/index.html>

Table 8: CLABSI Measures Available in NHSN

<u>Measure</u>	<u>Exclusions</u>	<u>Calculation</u>	<u>Application</u>
CLABSI SIR	MBI-LCBIs, ECMO, VAD, MSBP, EB, TAH, Patient self-injection, and Pus at vascular site	$\frac{\text{The number of Observed CLABSIs}}{\text{The number of Predicted CLABSIs}}$	Both location specific and summarized measure
MBI-LCBI SIR (ACH Only)	ECMO, VAD, MSBP, EB, TAH, Patient self-injection, and Pus at vascular site	$\frac{\text{The number of Observed MBI – LCBIs}}{\text{The number of Predicted MBI – LCBIs}}$	Both location specific and summarized measure
CLABSI Rates	MBI-LCBIs, ECMO, VAD, MSBP, EB, TAH, Patient self-injection, and Pus at vascular site	$\left(\frac{\text{The number of CLABSIs for a location}}{\text{The number of Central Line Days for that location}} \right) \times 1000$	Location specific measure only
MBI-LCBI Rates	ECMO, VAD, MSBP, EB, TAH, Patient self-injection, and Pus at vascular site	$\left(\frac{\text{The number of MBI_LCBIs for a location}}{\text{The number of Central Line Days for that location}} \right) \times 1000$	Location specific measure only
Central Line SUR		$\frac{\text{The number of Observed Central Line Days}}{\text{The number of Predicted Central Line Days}}$	Both location specific and summarized measure
DUR		$\frac{\text{Central Line Days for a location}}{\text{The Patient Days for that location}}$	Location specific measure only

References

- ¹CDC National and State Healthcare-Associated Infections Progress Report, published April 2024, available at <https://www.cdc.gov/healthcare-associated-infections/php/data/progress-report.html>
- ² O’Grady, NP., Alexander, M., Burns, LA., Dellinger, EP., Garland, J., Heard, SO., Maki, DG., et al. “Guidelines for the Prevention of Intravascular Catheter-related Infections”. *Clinical Infectious Diseases* 52 (a): (2011): 1087-99.
- ³Boyce JM, Nadeau J, Dumigan D, Miller D, Dubowsky C, Reilly L, Hannon CV. Obtaining blood cultures by venipuncture versus from central lines: impact on blood culture contamination rates and potential effect on central line-associated bloodstream infection reporting. *Infect Control Hosp Epidemiol.* 2013 Oct;34(10):1042-7. doi: 10.1086/673142. Epub 2013 Aug 21. PMID: 24018920.
- ⁴Doern GV, Carroll KC, Diekema DJ, Garey KW, Rupp ME, Weinstein MP, Sexton DJ. Practical Guidance for Clinical Microbiology Laboratories: A Comprehensive Update on the Problem of Blood Culture Contamination and a Discussion of Methods for Addressing the Problem. *Clin Microbiol Rev.* 2019 Oct 30;33(1):e00009-19. doi: 10.1128/CMR.00009-19. PMID: 31666280; PMCID: PMC6822992.
- ⁵ Lee, A., Mirrett, S., Reller, LB., Weinstein, MP. “Detection of Bloodstream Infections In Adults: How Many Blood Cultures are Needed?” *Journal of Clinical Microbiology*, Nov; 45(11): (2007): 3546-8.
- ⁶ Klevens, RM., et al. “Sampling for Collection of Central Line Day Denominators in Surveillance for Healthcare-associated Bloodstream Infections”. *Infection Control Hospital Epidemiology.* 27: (2006):338-42.
- ⁷ Thompson, ND., et al.” Evaluating the Accuracy of Sampling to Estimate Central Line–Days: Simplification of NHSN Surveillance Methods”. *Infection Control Hospital Epidemiology.* 34(3): (2013): 221-228.
- ⁸ See, I., et al. ID Week 2012 (Abstract #1284): Evaluation of Sampling Denominator Data to Estimate Urinary Catheter- and Ventilator-Days for the NHSN. San Diego, California. October 19, 2012.

Appendix: Secondary BSI Guide (not applicable to Ventilator-associated Events [VAE])

The purpose of using the CDC/NHSN infection criteria is to identify and consistently categorize infections that are healthcare-associated into major infection and site-specific infection types. LCBI criteria include the caveat that organism(s) identified from the blood cannot be related to infection at another and must be a primary BSI. One must be sure there is no other CDC/NHSN defined primary site-specific infection that may have seeded the bloodstream secondarily; otherwise, the bloodstream infection may be misclassified as a primary BSI and erroneously associated with the use of a central line, specifically called a CLABSI. For locations performing in-plan VAE surveillance, refer to [Figure B2](#) in this appendix, as well as the VAE chapter for specific guidance on assigning a secondary BSI to a VAE. When conducting BSI surveillance, the PNEU definitions as well as UTI, SSI and all definitions found in Chapter 17 are available for attributing a secondary BSI for any patient in any location.

Example: A ventilated patient in an adult location where VAE surveillance is being conducted can have a secondary BSI assigned to VAE or PNEU. A ventilated patient in a neonatal location where in-plan PedVAP surveillance is not an option can have a secondary BSI assigned to PNEU.

Secondary BSI Scenarios: For the purposes of NHSN reporting, for a bloodstream infection to be determined secondary to another site of infection, the following requirements must be met: *

An NHSN site-specific definition must be met; either one of the CDC/NHSN Surveillance Definitions for Specific Types of Infections (defined in Chapter 17), or UTI, PNEU or SSI definitions.

AND

One of the following scenarios must be met:

Scenario 1: At least one organism from the blood specimen matches an organism identified from the site-specific specimen that is used as an element to meet the NHSN site-specific infection criterion AND the blood specimen is collected during the secondary BSI attribution period (infection window period + repeat infection timeframe) [†].

OR

Scenario 2: An organism identified in the blood specimen is an element that is used to meet a NHSN site-specific infection criterion and therefore is collected during the site-specific infection window period.

Exception to Scenarios 1 & 2: Necrotizing Enterocolitis (NEC)

The Necrotizing Enterocolitis (NEC) criteria include neither a site-specific specimen (to apply Scenario 1) nor an organism identified from blood specimen (to apply Scenario 2). A BSI is considered secondary to NEC if the patient meets one of the two NEC criterion below AND an organism identified from blood specimen collected during the secondary BSI attribution period is an LCBI pathogen, or the same common commensal is identified from two or more blood specimens drawn on separate occasions collected on the same or consecutive calendar days.

Necrotizing enterocolitis in infants (≤ 1 year of age) must meet one of the following criteria:

1. Infant has at least **one** of the clinical and **one** of the imaging test findings from the lists below:

At least one clinical sign:

- a. bilious aspirate** (see **Note**)
- b. vomiting
- c. abdominal distention
- d. occult or gross blood in stools (with no rectal fissure)

And at least one imaging test finding which if equivocal is supported by clinical correlation

(specifically, physician documentation or physician designee of antimicrobial treatment for NEC):

- a. Pneumatosis intestinalis
- b. Portal venous gas (Hepatobiliary gas)
- c. Pneumoperitoneum

2. Surgical NEC: Infant has at least **one** of the following surgical findings:

- a. surgical evidence of extensive bowel necrosis (>2 cm of bowel affected)
- b. surgical evidence of pneumatosis intestinalis with or without intestinal perforation

NEC Exception Notes:

- Bilious aspirate from a transpyloric feeding tube should be excluded
- Pneumatosis is considered an equivocal abdominal imaging finding for Necrotizing enterocolitis.
 - Examples of abdominal imaging include KUB, ultrasound, or an abdominal x-ray
- NEC criteria cannot be met in patients > 1 year of age. Review Gastrointestinal tract infection (GIT) for eligibility.

Endocarditis and Osteomyelitis Exception Note:

- **The Endocarditis (ENDO) and osteomyelitis (BONE) criteria have different rules** for infection window period, RIT, pathogen assignment and secondary BSI attribution period. (See ENDO and BONE criteria in Ch. 17)

Applying Secondary BSI Attribution Using Scenario 1 or Scenario 2

Below are examples with guidance on how to distinguish between a primary or secondary BSI. The definition of “matching organisms”, important notes, and reporting instructions are also provided. See [Figure B1](#): Secondary BSI Guide for algorithmic display of the following instructions.

Scenario 1: An organism identified from the site-specific infection is used as an element to meet the site-specific infection criterion, **AND** the blood specimen contains at least one matching organism to that site-specific specimen. The positive blood specimen must be collected during the site-specific infection’s secondary BSI attribution period.

For your convenience, a list of infection criteria that include a blood specimen with at least one matching pathogen to the site-specific specimen that is used as an element to meet the definition are included in [Table B1](#)). Table B1 lists the **only** site-specific infections eligible for secondary BSI attribution.

Example A: Patient meets NHSN criteria for a symptomatic urinary tract infection (suprapubic tenderness and $\geq 10^5$ CFU/ml of *Escherichia coli*) and blood specimen collected during the symptomatic urinary tract infection (SUTI) secondary BSI attribution period is positive for *Escherichia coli*. This is a SUTI with a secondary BSI and the reported organism is *Escherichia coli*.

Example B: Patient meets NHSN criteria for a symptomatic urinary tract infection (suprapubic tenderness and $\geq 10^5$ CFU/ml of *Escherichia coli*) and blood specimen collected during the SUTI secondary BSI attribution period grows *E. coli* and *Pseudomonas aeruginosa*. This is a SUTI with a secondary BSI and the reported organisms are *E. coli* and *P. aeruginosa* since both site and blood specimens are positive for at least one matching pathogen. Please see a detailed scenario in Pathogen Assignment [Example 6](#).

Example C: Patient meets NHSN criteria for a symptomatic urinary tract infection (suprapubic tenderness and $\geq 10^5$ CFU/ml of *Escherichia coli*) and a single blood specimen collected during the SUTI secondary BSI attribution period is positive for *E. coli* and *Staphylococcus epidermidis*. This is a SUTI with a secondary BSI and the reported organism is only *E. coli* since the single common commensal *S. epidermidis* positive blood specimen does not meet BSI criteria.

Scenario 2: An organism identified from a blood specimen is an element used to meet the site-specific infection criterion and is collected during the site-specific infection window period.

A list of site-specific infections that include a positive blood culture as an element are included in [Table B1](#)). Table B1 lists the **only** site-specific infections eligible for secondary BSI attribution.

Example D: Patient becomes febrile ($> 38.0^\circ\text{C}$) and complains of nausea and abdominal pain. CT scan performed on the same day shows an intraabdominal abscess and a blood specimen collected the same day results in the identification of *Bacteroides fragilis*. Because the patient meets intraabdominal infection criterion 3b (IAB 3b), where identification of an organism from the blood specimen is a required element, along with at least two signs and symptoms and a CT scan showing an intraabdominal abscess, the BSI is considered secondary to an IAB 3b infection.

Example E: Patient is febrile, has a new onset of cough, and has a positive chest imaging test indicating the presence of a new infiltrate that is persistent. Blood specimens collected identified *Pseudomonas aeruginosa*. Because the patient can meet the PNU2 definition using the identification of organisms from a blood specimen as one of the elements of the infection criterion, and there is a new and persistent infiltrate on chest imaging test, fever, plus new onset of cough, the BSI is considered secondary to PNEU (PNU2).

***Example F:** Following a COLO procedure, on day 10 of the SSI surveillance period the patient becomes febrile ($>38.0^\circ\text{C}$) and complains of nausea and abdominal pain. A CT scan performed indicates an abscess in the intraabdominal cavity definitive for infection. The following day cultures are performed that showed *Escherichia coli* from a T-tube drainage specimen and

Bacteroides fragilis from a blood specimen. Although the organisms in the site-specific specimen culture and blood culture do not match at least one organism, the blood culture is considered secondary to IAB because the patient meets IAB criterion 3b with fever, nausea, and abdominal pain. Also, the CT scan results are definitive for an intraabdominal infection, and there is an MBI organism identified in the blood specimen. The organism identified in the blood specimen is used as an element to meet the Organ/Space SSI site-specific infection criterion and is collected during the SSI surveillance period. The patient also meets IAB criterion 3a with fever, nausea, abdominal pain, and the organism (*Escherichia coli*) identified from the site-specific specimen culture. Although the organism identified (*Escherichia coli*), differs from the organism used to meet IAB criterion 3b (*Bacteroides fragilis*), the BSI is considered secondary to the organ/space SSI IAB and both organisms (*Escherichia coli* and *Bacteroides fragilis*) would be listed as the IAB infection pathogens.

***Example G:** Patient is febrile with a new onset of cough and has a positive chest imaging test indicating the presence of a new infiltrate that is persistent. Blood and bronchoalveolar lavage (BAL) specimens are collected that identifies *Klebsiella pneumoniae* > 10⁴ CFU/ml from the BAL and *Pseudomonas aeruginosa* from the blood. Although the organisms in the blood specimen and site-specific specimen do not match for at least one organism, the patient can meet PNU2 using either the identification of an organism from blood specimen or the BAL specimen as one of the elements of the infection criterion. The positive blood culture or BAL specimen plus the new and persistent infiltrate on chest imaging test, fever, and new onset of cough are used to fully meet the PNU2 definition. The blood culture is considered a secondary BSI to PNEU and both organisms are listed as PNEU pathogens.

**In situations where an NHSN infection definition can be met using more than one criterion of the infection definition, it is possible that identification of an organism from the blood and site-specific specimens may not match, and a BSI may still be considered a secondary BSI.*

Reporting Guidance - When Scenario 1, 2, or the NEC Exception Cannot Be Applied:

If the organism identified from the blood specimen does not match the organism from the site-specific specimen, and that blood specimen cannot be used to meet the site-specific infection criteria, that blood specimen cannot be considered a secondary BSI, and in this scenario, the positive blood specimen is considered a primary BSI.

Example 1: Patient has pustules on their abdomen along with tenderness and swelling. Purulent material is obtained from the pustules and is positive for *Streptococcus* Group B. A blood specimen collected the same day identifies methicillin resistant *Staphylococcus aureus*. Because the organisms from the pustules and blood specimens do not match, and SKIN does not include a positive blood specimen as an element, both a site-specific infection, SKIN (criterion 1 and 2a), and a primary BSI is reported.

Example 2: A patient has an abscess in the soft tissue around a percutaneous endoscopic gastrostomy (PEG) tube, identified by CT scan, and there is purulent drainage noted from the site. There is no site-specific specimen collected, or other sites of infection identified, however, a blood specimen is positive for *Staphylococcus aureus*. Since there are no site-specific cultures collected, ST criterion 1 is not met which means a blood specimen cannot be deemed secondary. Therefore, the positive blood specimen must be investigated as primary BSI. The patient has an ST infection (criterion 2), and a primary BSI with the pathogen *Staphylococcus aureus*.

Table B1: Secondary BSI Guide: List of all NHSN primary site-specific definitions available for making secondary BSI determinations using Scenario 1 or Scenario 2

Scenario 1	Scenario 2																																																																																																						
A positive blood specimen must contain at least one eligible matching organism to the site-specific specimen	Positive blood specimen must be an element of the site-specific definition																																																																																																						
And the blood specimen is collected in the site-specific secondary BSI attribution period	And blood specimen is collected in the site-specific infection window period																																																																																																						
And an eligible <u>organism identified from the site-specific specimen</u> is used as an element to meet the site-specific definition	And an eligible <u>organism identified in a blood specimen</u> is used as an element to meet the site-specific definition																																																																																																						
<table> <tr> <th>Site</th><th>Criterion</th></tr> <tr><td>ABUTI</td><td>ABUTI</td></tr> <tr><td>BONE</td><td>1</td></tr> <tr><td>BRST</td><td>1</td></tr> <tr><td>CARD</td><td>1</td></tr> <tr><td>CIRC</td><td>2 or 3</td></tr> <tr><td>CONJ</td><td>1a</td></tr> <tr><td>DECU</td><td>1</td></tr> <tr><td>DISC</td><td>1</td></tr> <tr><td>EAR</td><td>1, 3, 5 or 7</td></tr> <tr><td>EMET</td><td>1</td></tr> <tr><td>ENDO</td><td>1</td></tr> <tr><td>EYE</td><td>1</td></tr> <tr><td>GE</td><td>2a</td></tr> <tr><td>GIT</td><td>2a, 2b (only yeast)</td></tr> <tr><td>IAB</td><td>1 or 3a</td></tr> <tr><td>IC</td><td>1</td></tr> <tr><td>JNT</td><td>1</td></tr> <tr><td>LUNG</td><td>1</td></tr> <tr><td>MED</td><td>1</td></tr> <tr><td>MEN</td><td>1</td></tr> <tr><td>ORAL</td><td>1, 3a, 3d (only yeast)</td></tr> <tr><td>OREP</td><td>1</td></tr> <tr><td>PJI</td><td>1 or 3e</td></tr> <tr><td>PNEU</td><td>2 or 3</td></tr> <tr><td>SA</td><td>1</td></tr> <tr><td>SINU</td><td>1</td></tr> <tr><td>SSI</td><td>SI, DI or OS</td></tr> <tr><td>SKIN</td><td>2a</td></tr> <tr><td>ST</td><td>1</td></tr> <tr><td>UMB</td><td>1a</td></tr> <tr><td>UR</td><td>1a or 3a</td></tr> <tr><td>USI</td><td>1</td></tr> <tr><td>SUTI</td><td>1a, 1b or 2</td></tr> <tr><td>VASC <i>only as SSI</i></td><td>1</td></tr> <tr><td>VCUF</td><td>3</td></tr> </table>	Site	Criterion	ABUTI	ABUTI	BONE	1	BRST	1	CARD	1	CIRC	2 or 3	CONJ	1a	DECU	1	DISC	1	EAR	1, 3, 5 or 7	EMET	1	ENDO	1	EYE	1	GE	2a	GIT	2a, 2b (only yeast)	IAB	1 or 3a	IC	1	JNT	1	LUNG	1	MED	1	MEN	1	ORAL	1, 3a, 3d (only yeast)	OREP	1	PJI	1 or 3e	PNEU	2 or 3	SA	1	SINU	1	SSI	SI, DI or OS	SKIN	2a	ST	1	UMB	1a	UR	1a or 3a	USI	1	SUTI	1a, 1b or 2	VASC <i>only as SSI</i>	1	VCUF	3	<table> <tr> <th>Site</th><th>Criterion</th></tr> <tr><td>ABUTI</td><td>ABUTI</td></tr> <tr><td>BONE</td><td>3a</td></tr> <tr><td>BURN</td><td>1</td></tr> <tr><td>DISC</td><td>3a</td></tr> <tr><td>ENDO</td><td>4a, 4b, 4c, 4d (titer excluded), 4f, 5a, 5b, 5c, 5d (titer excluded), 5f, 6e, or 7f plus other criteria as listed</td></tr> <tr><td>GIT</td><td>1b or 2c</td></tr> <tr><td>IAB</td><td>2b or 3b</td></tr> <tr><td>JNT</td><td>3c</td></tr> <tr><td>MEN</td><td>2c or 3c</td></tr> <tr><td>OREP</td><td>3a</td></tr> <tr><td>PNEU</td><td>2 or 3</td></tr> <tr><td>SA</td><td>3a</td></tr> <tr><td>UMB</td><td>1b</td></tr> <tr><td>USI</td><td>3b or 4b</td></tr> </table>	Site	Criterion	ABUTI	ABUTI	BONE	3a	BURN	1	DISC	3a	ENDO	4a, 4b, 4c, 4d (titer excluded), 4f, 5a, 5b, 5c, 5d (titer excluded), 5f, 6e, or 7f plus other criteria as listed	GIT	1b or 2c	IAB	2b or 3b	JNT	3c	MEN	2c or 3c	OREP	3a	PNEU	2 or 3	SA	3a	UMB	1b	USI	3b or 4b
Site	Criterion																																																																																																						
ABUTI	ABUTI																																																																																																						
BONE	1																																																																																																						
BRST	1																																																																																																						
CARD	1																																																																																																						
CIRC	2 or 3																																																																																																						
CONJ	1a																																																																																																						
DECU	1																																																																																																						
DISC	1																																																																																																						
EAR	1, 3, 5 or 7																																																																																																						
EMET	1																																																																																																						
ENDO	1																																																																																																						
EYE	1																																																																																																						
GE	2a																																																																																																						
GIT	2a, 2b (only yeast)																																																																																																						
IAB	1 or 3a																																																																																																						
IC	1																																																																																																						
JNT	1																																																																																																						
LUNG	1																																																																																																						
MED	1																																																																																																						
MEN	1																																																																																																						
ORAL	1, 3a, 3d (only yeast)																																																																																																						
OREP	1																																																																																																						
PJI	1 or 3e																																																																																																						
PNEU	2 or 3																																																																																																						
SA	1																																																																																																						
SINU	1																																																																																																						
SSI	SI, DI or OS																																																																																																						
SKIN	2a																																																																																																						
ST	1																																																																																																						
UMB	1a																																																																																																						
UR	1a or 3a																																																																																																						
USI	1																																																																																																						
SUTI	1a, 1b or 2																																																																																																						
VASC <i>only as SSI</i>	1																																																																																																						
VCUF	3																																																																																																						
Site	Criterion																																																																																																						
ABUTI	ABUTI																																																																																																						
BONE	3a																																																																																																						
BURN	1																																																																																																						
DISC	3a																																																																																																						
ENDO	4a, 4b, 4c, 4d (titer excluded), 4f, 5a, 5b, 5c, 5d (titer excluded), 5f, 6e, or 7f plus other criteria as listed																																																																																																						
GIT	1b or 2c																																																																																																						
IAB	2b or 3b																																																																																																						
JNT	3c																																																																																																						
MEN	2c or 3c																																																																																																						
OREP	3a																																																																																																						
PNEU	2 or 3																																																																																																						
SA	3a																																																																																																						
UMB	1b																																																																																																						
USI	3b or 4b																																																																																																						

Secondary BSI Reporting Instructions:

- For reporting secondary BSI for possible VAP (PVAP), see [Figure B2](#) and [Chapter 10](#).
- Do **not** report secondary bloodstream infection for vascular (VASC) infections, ventilator-associated conditions (VAC), infection-related ventilator-associated complications (IVAC), or pneumonia 1 (PNU1).
- When a BSI is suspected to be secondary to a lower respiratory tract infection, the BSI can be determined secondary to VAE or PNEU definitions. (See [Figure B2](#)).
- Site-specific organism exclusions apply to secondary BSI attribution as well.

A **matching organism** is defined as one of the following:

1. If genus and species are identified in both specimens, they must be the same.
 - a. **Example:** An intraabdominal specimen is used as an element to meet an IAB definition and is growing *Enterobacter cloacae*. A blood specimen with a collection date in the IAB secondary BSI attribution period is growing *Enterobacter cloacae*. These are considered matching organisms.
 - b. **Example:** An intraabdominal specimen is used as an element to meet an IAB definition and is growing *Enterobacter aerogenes*. A blood specimen with a collection date during the IAB secondary BSI attribution period is growing *Enterobacter cloacae*. These are NOT considered matching organisms as the species, aerogenes and cloacae, are different.
2. Organisms must at least match to the genus level and at that level the organisms must be the same.
 - a. **Example:** A surgical wound growing *Pseudomonas* species is used to meet deep incisional SSI criteria and a blood specimen growing *Pseudomonas aeruginosa* is collected in the SSI secondary BSI attribution period. The organisms are considered matching at the genus level, and therefore the BSI is secondary to the SSI.
 - b. **Example:** A PCR identifying *Enterococcus faecalis* in CSF meets the MEN definition. A subsequent blood culture collected in the MEN secondary BSI attribution period is identified as *Enterococcus* species. The organisms are considered matching at the genus level *Enterococcus*, and therefore the BSI is secondary to MEN.
3. There are two exceptions to the matching organisms definition:
 - a. Infections meeting LCBI 2 criterion with *Staphylococcus* or *Streptococcus*
Example (Staphylococcus): A patient has a fever and a previous chest tube site that is reddened and swollen, and a culture is collected from the soft tissue site. A culture of the chest tube site is positive for *Staphylococcus* species therefore; the ST 1 definition is met. The next day, two blood culture sets are collected, and both blood cultures are positive for coagulase-negative *Staphylococcus*. The site-specific and blood organisms are NOT considered matching, because *Staphylococcus* species could be a coagulase-negative or a coagulase-positive *Staphylococcus*. Therefore, the BSI is not considered secondary to the ST 1.

Example (*Streptococcus*): A patient has a fever and a previous chest tube site that is reddened and swollen, and a culture is collected from the soft tissue site. The chest tube site culture is reported positive for *Streptococcus* species; therefore, the ST 1 definition is met. The next day, two blood culture sets are collected, and both blood cultures are positive for *Streptococcus*, viridans group. The site-specific and blood organisms are NOT considered matching, because *Streptococcus* species could represent a *Streptococcus*, viridans group or non- *Streptococcus*, viridans group. Therefore, the BSI is not considered secondary to the ST 1.

- b. In cases where an organism is identified only as “yeast” or “yeast not otherwise specified,” the organism can be considered a match to other yeasts, when the yeast is collected during the required timeframe, whether more fully identified or not.

Example: A tissue culture from the ulcer margin of a decubiti is reported positive for yeast is used as an element to meet the DECU definition. A blood specimen collected in the secondary BSI attribution period of the DECU is reported as *Candida albicans*. In this example, the two organisms are considered matching organisms as the organisms are complementary (specifically, *Candida* is a type of yeast).

Note: This exception is limited to yeast and does not apply to identification of organisms identified as Gram positive cocci, Gram negative rods, etc.

Yeasts isolated from non-sterile sites are commonly not identified to the genus or genus and species level.

Example: A culture of tissue from the ulcer margin of a decubiti reported positive for a Gram-negative rod is used as an element to meet DECU definition. A blood specimen collected in the secondary BSI attribution period of the DECU is reported as *E. coli*. In this example the two organisms are NOT considered matching organisms.

Notes:

1. Antibiograms of the blood and potential primary site isolates do not have to match.
2. If the blood specimen alone does not meet BSI criteria (for example, only one blood specimen positive for a common commensal), that specimen may not be used to meet secondary BSI criteria (see [Scenario 1c](#)).

Pathogen Assignment

- Additional pathogens identified from secondary BSIs, should be added to the pathogens reported for the primary infection type. The Secondary BSI data collection field should be checked yes.

MBI-RIT Exception: An MBI-LCBI designation will not change to an LCBI event if the following criteria are met:

- The blood culture with the non-MBI organism is collected during an existing BSI (MBI-LCBI) RIT*

AND

- The blood culture with the non-MBI organism is deemed secondary to an NHSN site-specific infection*

See Example 5 in the Secondary BSI Guide section of this protocol and [Chapter 2](#) Pathogen Assignment (Example 2b)

- If at least one BSI pathogen with a collection date in the secondary BSI attribution period matches an organism from a specimen that was used to meet a site-specific infection criterion (either a site-specific specimen or a blood specimen) the BSI is considered secondary to the event. However, if no matching pathogen is identified, the subsequent BSI pathogen must be evaluated and deemed primary or secondary to another site-specific infection.

Example: A patient with a primary UTI with *Escherichia coli* and a secondary BSI with *Escherichia. coli* has a subsequent positive blood specimen with *yeast*. *Yeast* is an excluded pathogen for meeting UTI criteria; therefore, the subsequent blood must be evaluated as primary or secondary to another site-specific infection.

- A secondary BSI pathogen may be assigned to two different primary sites of infection (for example, UTI and an IAB infection). In Example 1 below, two primary sites of infection have been identified, and a blood culture is collected within both the SUTI and the IAB secondary BSI attribution period. The blood culture pathogen matches the pathogens for both primary sites of infection (SUTI and IAB). Therefore, the pathogen is reported for both primary sites of infection as a secondary bloodstream infection.

Example 1: Pathogen Assignment

Hospital Day (HD)	UTI SBAP	UTI RIT	UTI Infection Window Period	IAB Infection Window Period	IAB RIT	IAB SBAP
1						
2						
3						
4		1	Urine culture: >100,000 cfu/ml <i>K. pneumoniae</i>			
5		2	Fever > 38.0 C			
6		3				
7		4				
8		5		Fever >38.0 C, Abdominal pain		
9		6		CT scan: Abdominal abscess		
10		7	Blood culture: <i>K. pneumoniae</i>	Blood culture: <i>K. pneumoniae</i>		
11		8				
12		9				
13		10				
14		11				
15		12				
16		13				
17		14				
18						
19						
20						
21						
22						
23						
			SUTI & Secondary BSI DOE = HD 4 Pathogen: <i>K. pneumoniae</i>	IAB & Secondary BSI DOE = HD 8 Pathogen: <i>K. pneumoniae</i>		

Infection Window Period

(First positive diagnostic test, 3 days before and 3 days after)

Repeat Infection Timeframe (RIT)

(date of event = day 1)

Secondary BSI Attribution Period (SBAP) (Infection Window Period + RIT)**Date of Event (DOE)**

Date the first element occurs for the first time within the infection window

Example 2: Pathogen Assignment (continued)

Pathogens excluded from specific infection definitions (for example, yeast in UTI, or *Enterococcus* spp. for PNEU) are also excluded as pathogens for BSIs secondary to that type of infection (they cannot be added as a pathogen based on the infection type). In example 2 below, the excluded organism must be accounted for as either 1) a primary bloodstream infection (BSI/CLABSI) or, 2) a secondary bloodstream infection attributed to another primary infection (for example, IAB, SINU).

A blood culture with yeast and *E. faecalis* is collected during the SUTI RIT. A BSI secondary to a SUTI (*E. faecalis*) is identified. *E. faecalis* is already documented as the SUTI pathogen, however, the yeast cannot be reported as a secondary BSI pathogen, because yeasts are excluded organisms in the UTI definition. Since there is no other primary source of infection for which the yeast BSI can be assigned as secondary, a primary BSI with yeast is identified.

Note: The *Enterococcus faecalis* is not reported as a pathogen for the primary BSI because if an excluded UTI organism, yeast, had not been identified, a primary BSI would not have been reported.

Hospital Day (HD)	UTI SBAP	UTI RIT	UTI Infection Window Period	BSI Infection Window Period	BSI RIT
1					
2					
3		1	Dysuria		
4		2	Urine culture: > 100,000 cfu/ml <i>E. faecalis</i>		
5		3			
6		4			
7		5			
8		6			
9		7			
10		8			
11		9	Blood culture: <i>E. Faecalis</i> / Yeast	Blood culture: <i>E. faecalis</i> / Yeast	1
12		10			2
13		11			3
14		12			4
15		13			5
16		14			6
17					7
18					8
19					9
20					10
21					11
22					12
23					13
24					14
25					
			UTI & Secondary BSI DOE = HD 3 Pathogen: <i>E. faecalis</i>	Primary BSI DOE = HD 11 Pathogen: Yeast	

Infection Window Period
(First positive diagnostic test, 3 days before and 3 days after)

Repeat Infection Timeframe (RIT)
(date of event = day 1)

Secondary BSI Attribution Period (SBAP)
(Infection Window Period + RIT)

Date of Event (DOE)
Date the first element occurs for the first time within the infection window period

Example 3: Pathogen Assignment (continued)

Hospital Day (HD)	IAB SBAP	IAB RIT	IAB Infection Window Period	IAB Infection Window Period
1	Admit		Abdominal pain & distention	
2	PICC placed			
3				
4			US guided drainage-5L purulent peritoneal fluid: <i>Klebsiella pneumoniae</i> and <i>E. coli</i>	
5				
6				
7				
8				
9				
10				Abdominal pain
11				CTS multiple liver abscesses Blood culture: <i>C. glabrata</i> , <i>L. casei</i>
12				
13				jaundice, fever
14				
15				
			IAB 1 DOE = HD 4 Pathogens: <i>K. pneumoniae</i> , <i>E. coli</i>	IAB 3b & Secondary BSI DOE = HD 4 Pathogens: <i>C. glabrata</i> , <i>L. casei</i>

Infection Window Period

(First positive diagnostic test, 3 days before and 3 days after)

Repeat Infection Timeframe (RIT)

(date of event = day 1)

Secondary BSI Attribution Period (SBAP)

(Infection Window Period + RIT)

Date of Event (DOE)

Date the first element occurs for the first time within the infection window period

Only one infection of a specific type (or major type: BSI, UTI and PNEU) is reported during an RIT for that specific type of event. However, a new event of the same specific type (or major type: BSI, UTI and PNEU) can be identified during a RIT if all required elements of the new event occur within a new IWP; the DOE of the new event must be within the RIT of the initial event. In example 3, IAB criteria 1 is met on hospital day 4 using organisms identified from purulent fluid. During the IAB RIT (hospital day 4-hospital day 17), IAB criteria 3b is met (on hospital day 10) using two symptoms, positive imaging evidence of an abscess and a positive blood specimen. Because the positive blood specimen was used to re-meet an IAB criterion during the IAB RIT, the blood specimen is considered secondary to IAB. The pathogens, in this case, do not have to match because another definition (IAB 3b) is fully met within a new IAB IWP (hospital day 8-hospital day 14). Because the DOE (hospital day 10) occurs within the RIT of the initial IAB 1, a new event is not reported. The DOE, RIT, and device association are not changed. Any additional organisms identified (*C. glabrata* and *L. casei*) are added to the initial IAB event if reported.

Example 4: Pathogen Assignment (continued)

Hospital Day (HD)	GIT SBAP	GIT RIT	GIT Infection Window Period	GIT Infection Window Period
1	Admit		Fever & vomiting	
2	PICC placed			
3				
4			CT bowel abscess	
5				
6			Blood culture: <i>Enterococcus faecalis</i> X2	
7				
8				
9				
10				
11				Blood culture: <i>Candida glabrata</i>
12				
13				Abscess drainage: <i>Candida glabrata</i> Abdominal pain and nausea
14				
15				
			GIT-2c & Secondary BSI DOE= HD 1 Pathogen: <i>E. faecalis</i>	GIT-2a & Secondary BSI DOE = HD 1 Pathogen: <i>C. glabrata</i>

Infection Window Period

(First positive diagnostic test, 3 days before and 3 days after)

Repeat Infection Timeframe (RIT)

(date of event = day 1)

Secondary BSI Attribution Period (SBAP)

(Infection Window Period + RIT)

Date of Event (DOE)

Date the first element occurs for the first time within the infection window period

Only one infection of a specific type (or major type for BSI, UTI and PNEU) is reported during an RIT for that type of event. However, a new event of the same specific type (or major type for BSI, UTI and PNEU) can be identified during an RIT if all required elements occur within a new IWP and the DOE is within the RIT of the initial event. In example 4, GIT criterion 2c is met on hospital day-1 using two symptoms, positive imaging, evidence of an abscess, and a positive blood specimen for *Enterococcus faecalis*. GIT 2a is met during the GIT RIT (two symptoms and positive abscess). The positive blood specimen occurs within the GIT secondary BSI attribution period and matches the organism identified from the abscess culture, *Candida glabrata*. Therefore, the positive blood culture is considered secondary to the GIT infection. The pathogens, in this case, do not have to match because another definition (GIT 2a) is fully met within a new GIT IWP (hospital day 8-hospital day 14). Because the DOE (hospital day 11) occurs within the RIT of the initial GIT 2c, a new event is not reported. The DOE, RIT, and device association are not changed but any additional organism identified (*C. glabrata*) is added to the initial GIT event if reported. This scenario is applicable to any site-specific infection definition from Chapter 17 or major infection type including BSI, UTI or PNEU.

Example 5: Pathogen Assignment (continued)

Hospital Day	RIT	Infection Window Period	Infection Window Period	RIT	SBAP
1					
2					
3					
4					
5		WBC – 400 cells/mm ³			
6					
7	1	Blood culture: <i>E. faecalis</i>			
8	2				
9	3				
10	4	WBC – 300 cells/mm ³	Erythema, Pain	1	
11	5		Skin culture: <i>Staphylococcus aureus</i>	2	
12	6			3	
13	7			4	
14	8			5	
15	9			6	
16	10			7	
17	11			8	
18	12			9	
19	13		Blood culture: <i>Staphylococcus aureus</i>	10	
20	14			11	
21				12	
22				13	
23				14	
24					
25					
26					
		MBI-LCBI 1 Date of Event = HD 7 Pathogen: <i>E. faecalis</i>	SKIN 2a & Secondary BSI Date of Event = HD 10 Pathogen: <i>Staphylococcus aureus</i>		

Infection Window Period
(First positive diagnostic test, 3 days
before and 3 days after)

**Repeat Infection Timeframe
(RIT)**
(date of event = day 1)

**Secondary BSI Attribution
Period (SBAP)**
(Infection Window Period + RIT)

Date of Event (DOE)
Date the first element occurs for the first
time within the infection window period

A non-MBI organism is NOT assigned to an MBI-LCBI (primary BSI) event when a blood culture with a non-MBI organism is collected during a BSI (MBI-LCBI)-RIT and deemed secondary to an NHSN site-specific infection. The MBI-LCBI designation will not change to an LCBI event. On day 7 of hospital admission, *Enterococcus faecalis* is identified in a blood culture meeting MBI-LCBI 1 criteria. During the BSI RIT of the

MBI-LCBI 1 event, a blood culture with a non-MBI organism (*Staphylococcus aureus*) is collected but is deemed secondary to a SKIN 2a. Because the *Staphylococcus aureus* (a non-MBI organism) is secondary to SKIN 2a, the MBI-LCBI 1 designation **will not** change to an LCBI 1.

Example 6: Pathogen Assignment (continued)

HD	UTI SBAP	RIT	UTI IWP	BSI IWP
1				
2				
3				
4 DOE		1	Urine culture: >100,000 cfu/ml <i>Escherichia coli</i>	
5		2	Suprapubic tenderness	
6		3		
7		4		
8		5		
9	Blood culture: <i>E. coli</i> / <i>Pseudomonas aeruginosa</i>	6	Blood culture: <i>E. coli</i> / <i>Pseudomonas aeruginosa</i>	
10		7		
11		8		
12 DOE		9	Blood culture: <i>Pseudomonas aeruginosa</i>	Blood culture: <i>Pseudomonas aeruginosa</i>
13		10		
14		11		
15		12		
16		13		
17		14		
			SUTI & Secondary BSI Date of Event: HD 4 Pathogen: <i>E. coli</i> / <i>Pseudomonas aeruginosa</i>	Primary BSI DOE = HD 12 Pathogen: <i>Pseudomonas aeruginosa</i>


Infection Window Period
(First positive diagnostic test, 3 days
before and 3 days after)

**Repeat Infection Timeframe
(RIT)**
(date of event = day 1)

**Secondary BSI Attribution
Period (SBAP)**
(Infection Window Period + RIT)


Patient meets NHSN criteria for a symptomatic urinary tract infection (suprapubic tenderness and $\geq 10^5$ CFU/ml of *Escherichia coli*) and blood specimen collected during the SUTI secondary BSI attribution period grows *E. coli* and *Pseudomonas aeruginosa*. This is a SUTI with a secondary BSI and the reported organisms are *E. coli* and *P. aeruginosa* since both site and blood specimens are positive for at least one matching pathogen. A second blood specimen is collected during the SUTI secondary BSI attribution period grows *P. aeruginosa*. Because this blood specimen does not contain at least one matching pathogen from the site-specific specimen, it cannot be deemed secondary to the SUTI event and is an LCBI 1. The reported organism is *P. aeruginosa*.

Figure B1: Secondary BSI Guide for eligible organisms*‡
(Not applicable to Ventilator-associated Events [VAE], See [Figure B2](#))



***Exception:** The necrotizing enterocolitis (NEC) definition does not include criteria for a matching site-specific specimen, nor an organism identified from a blood specimen, however an exception for assigning a BSI secondary to NEC is provided. A BSI is considered secondary to NEC if the patient meets one of the two NEC criteria **AND** an organism identified from a blood specimen, collected during the secondary BSI attribution period, is an LCBI pathogen or the same common commensal is identified from 2 or more blood specimens drawn on separate occasions on the same or consecutive days.

Figure B2: VAE Guidance for Secondary BSI Determination



*Secondary BSIs may be reported for possible VAP (PVAP) events, provided that at least one organism identified from the blood specimen matches an organism identified from an appropriate respiratory tract specimen (including respiratory secretions, pleural fluid, and lung tissue). The respiratory tract specimen must have been collected on or after the 3rd day of mechanical ventilation and within 2 calendar days before or after the day of onset of worsening oxygenation to be considered for use in meeting the PVAP definition. In addition, the organisms identified from blood must have been collected during the 14-day event period, where day 1 is the day of onset of worsening oxygenation.

- In cases where PVAP is met with only the histopathology criterion and no culture or non-culture based testing is performed on an eligible respiratory specimen, and there is also a positive blood specimen, a secondary BSI to VAE is not reported.
- In cases where a culture or non-culture based testing of respiratory secretions, pleural fluid, or lung tissue is performed and does not identify an organism that matches an organism identified from blood, a secondary BSI to VAE is not reported.

Note: Any *Candida* species or yeast not otherwise specified, any coagulase-negative *Staphylococcus* species, and any *Enterococcus* species identified from blood cannot be deemed secondary to a PVAP, unless the organism was also identified from pleural fluid or lung tissue.

Pneumonia (Ventilator-associated [VAP] and non-ventilator-associated Pneumonia [PNEU]) Event

Table of Contents

Introduction.....	1
Settings	2
Key Terms and Abbreviations	2
Definitions Specific to PNEU/VAP Surveillance.....	3
Guidance for Determination of Eligible Imaging Test Evidence	3
General Comments Applicable to All Pneumonia Specific Site Criteria.....	4
Reporting Instructions	5
Table 1: Specific Site Algorithms for Clinically Defined Pneumonia (PNU1).....	6
Table 2: Specific Site Algorithm for Pneumonia with Common Bacterial or Filamentous Fungal Pathogens and Specific Laboratory Findings (PNU2).....	7
Table 3: Specific Site Algorithm for Viral, Legionella, and other Bacterial Pneumonias with Definitive Laboratory Findings (PNU2).....	8
Table 4: Specific Site Algorithm for Pneumonia in Immunocompromised Patients (PNU3)	9
Figure 1: Pneumonia Flow Diagram for Patients of Any Age.....	10
Figure 2: Pneumonia Flow Diagram, Alternative Criteria for Infants and Children	11
Footnotes to Algorithms and Flow Diagrams	12
Table 5: Threshold values for cultured specimens used in the diagnosis of pneumonia	15
Numerator Data.....	17
Denominator Data	17
Data Analyses.....	18
Table 6: VAP Measures Available in NHSN	19
References	20

Introduction

In 2015 CDC conducted a point-prevalence survey in a sample of acute care hospitals in U.S. and determined that of the 427 healthcare-associated infections identified, pneumonia was the most common infection with 32% of those being ventilator associated.¹ Patients receiving invasive mechanical ventilation are at risk for numerous complications, including pneumonia. Ventilator-associated pneumonia (VAP) and other healthcare-associated pneumonias are important, common healthcare-associated infections, but national surveillance for VAP has long been a challenge because of the lack of objective, reliable definitions. Due to these challenges, in January 2013 the National Healthcare Safety Network (NHSN) replaced surveillance for ventilator-associated pneumonia (VAP) in adult inpatient locations with surveillance for ventilator-associated events (VAE).² Based on discussions with an expert working group in 2012-2013, NHSN also discontinued in-plan VAP surveillance in neonatal locations. As of January 2014, in-plan VAP surveillance is only available in pediatric inpatient locations.

Settings

PNEU/VAP surveillance may occur in any inpatient location where denominator data can be collected, such as critical/intensive care units (ICUs), specialty care areas (SCA), step-down units, wards, inpatient rehabilitation locations, and long-term acute care locations. A complete listing of inpatient locations and instructions for mapping are found in [Chapter 15 CDC Locations and Descriptions](#).

- In-plan PNEU/VAP surveillance is restricted to pediatric ventilator-associated pneumonia (pedVAP) surveillance for mechanically ventilated patients (regardless of age) in inpatient pediatric locations only (excludes neonatal locations).
- Off-plan PNEU/VAP surveillance can be conducted as follows:
 - Ventilator-associated pneumonia (VAP) surveillance for mechanically ventilated adult, pediatric, and neonatal patients in any inpatient location
 - Non-ventilator-associated pneumonia (PNEU) surveillance for non-mechanically ventilated adult, pediatric, and neonatal patients in any inpatient location
- PNEU definitions are also available for secondary bloodstream infection (BSI) assignment when conducting BSI surveillance in ventilated and non-ventilated patients of any age in any inpatient location.

Note: Post-discharge surveillance for pedVAPs is not required. However, if discovered, any pedVAP with a date of event (DOE) on the day of discharge or day after discharge is attributed to the discharging location and should be included in any pedVAPs reported to NHSN by the discharging location. No additional ventilator days are reported.

Key Terms and Abbreviations

Refer to the NHSN Patient Safety Manual, [Chapter 2 Identifying Healthcare-associated Infections \(HAI\) for NHSN Surveillance](#) and [Chapter 16 General Key Terms](#) for definitions of the following universal concepts for conducting HAI surveillance.

- | | |
|------|---|
| I | Date of event (DOE) |
| II | Healthcare associated infection (HAI) |
| III | Infection window period (IWP) |
| IV | Present on admission (POA) |
| V | Repeat infection timeframe (RIT) |
| VI | Secondary BSI attribution period (SBAP) |
| VII | Location of attribution (LOA) |
| VIII | Transfer rule |

Definitions Specific to PNEU/VAP Surveillance

Pneumonia (PNEU) is identified by using a combination of imaging, clinical, and laboratory criteria. The following pages detail the various criteria that may be used for meeting the surveillance definition of healthcare-associated pneumonia (Tables [1](#), [2](#), [3](#), and [4](#) and Figures [1](#) and [2](#)), general comments applicable to all site-specific criteria, footnotes applicable to specific elements, and reporting instructions.

Ventilator: Any device used to support, assist, or control respiration (inclusive of the weaning period) through the application of positive pressure to the airway when delivered via an artificial airway, specifically an oral/nasal endotracheal or tracheostomy tube.

Ventilation and lung expansion devices that deliver positive pressure to the airway (for example, CPAP, BiPAP, Bi-level, IPPB, and PEEP) via non-invasive means (for example, nasal prongs, nasal mask, full face mask, total mask, etc.) are not considered ventilators unless positive pressure is delivered via an artificial airway (oral/nasal endotracheal or tracheostomy tube).

Ventilator-associated pneumonia (VAP): A pneumonia where the patient is on mechanical ventilation for > 2 consecutive calendar days on the date of event, with day of ventilator placement being Day 1*

AND

the ventilator was in place on the date of event or the day before.

*If the ventilator was in place prior to inpatient admission, the ventilator day count begins with the admission date to the first inpatient location.

If a break in mechanical ventilation occurs for at least one full calendar day, ventilator day count for ventilator association starts anew upon reintubation and/or re-initiation of mechanical ventilation.

Guidance for Determination of Eligible Imaging Test Evidence

- If only one imaging test is available, it is acceptable for this to satisfy the imaging requirement for PNEU/VAP POA determinations regardless of whether the patient has underlying pulmonary or cardiac disease.
- When multiple imaging test results are available, persistence of imaging test evidence of pneumonia is a requirement for all patients, not just those with underlying cardiac or pulmonary disease.
- The date of the first eligible imaging test will be utilized when determining if the PNEU/VAP criteria are met within the IWP. All elements of PNEU/VAP definition must be present within the Infection Window Period (IWP). The exception may occur when identifying persistence of imaging test evidence of pneumonia, as the second imaging test must occur within seven days of the first but is not required to occur within the IWP.
- Refer to [Footnotes](#) 1, 2, and 13 for additional guidance.

General Comments Applicable to All Pneumonia Specific Site Criteria

1. Physician diagnosis of pneumonia alone is not an acceptable criterion for present on admission (POA) or healthcare-associated (HAI) pneumonia.
2. Although specific criteria are included for infants and children and immunocompromised patients, all patients may meet any of the other pneumonia site-specific criteria.
3. Pneumonia due to gross aspiration (for example, in the setting of intubation in the field, emergency department, or operating room) that meets the PNEU/VAP definition with a date of event during the HAI timeframe is considered healthcare associated.
4. Multiple episodes of healthcare-associated pneumonia may occur in critically ill patients with lengthy hospital stays. When determining whether to report multiple episodes of healthcare-associated pneumonia in a single patient, follow the Repeat Infection Timeframe (RIT) guidance found in [Chapter 2](#).
5. Excluded organisms that cannot be used to meet the PNEU/VAP definition are as follows:
 - a. "Normal respiratory flora," "normal oral flora," "mixed respiratory flora," "mixed oral flora," "altered oral flora," or other similar results indicating isolation of commensal flora of the oral cavity or upper respiratory tract. **Note:** A report of "flora" does not exclude the use of an eligible organism isolated or identified from the specimen. Only the "flora" is excluded from use.
 - b. The following organisms, unless identified from lung tissue or pleural fluid (where specimen was obtained during thoracentesis or within 24 hours of chest tube placement; pleural fluid specimens collected after a chest tube is repositioned or from a chest tube in place > 24 hours are not eligible):
 - i. Any *Candida* species as well as a report of "yeast" that is not otherwise specified
 - ii. Any coagulase-negative *Staphylococcus* species
 - iii. Any *Enterococcus* species
6. If the excluded pathogens, any *Candida* species* or yeast not otherwise specified, any coagulase-negative *Staphylococcus* species, and any *Enterococcus* species, are identified from blood they can only be attributed as a secondary BSI to PNEU if PNU2 or PNU3 is met with a matching organism identified from lung tissue or pleural fluid (where specimen was obtained during thoracentesis or within 24 hours of chest tube placement; pleural fluid specimens collected after a chest tube is repositioned or from a chest tube in place > 24 hours are not eligible) and the blood specimen collection date is within the Secondary BSI Attribution Period (SBAP).

*The exception to this is any *Candida* species or yeast not otherwise specified identified from blood can be attributed as a secondary BSI to PNEU if PNU3 is met using the blood specimen and a sputum, endotracheal aspirate, bronchoalveolar lavage (BAL), or protected specimen brushing with matching *Candida* species, and both specimens have a collection date in the IWP.

7. Organisms that primarily cause community-associated infections and are not known to (or rarely) cause healthcare-associated infections, are excluded and cannot be used to meet any NHSN definition.
 - **Fungi:** *Blastomyces*, *Histoplasma*, *Coccidioides*, *Paracoccidioides*, *Cryptococcus*, *Pneumocystis*
 - **Vector-borne bacteria:** *Anaplasma spp.*, *Ehrlichia spp.*, *Borrelia spp.*, *Rickettsia spp.*
8. Abbreviations used in the PNEU laboratory criteria:
 - BAL – bronchoalveolar lavage
 - EIA – enzyme immunoassay
 - IFA – immunofluorescent antibody
 - LRT – lower respiratory tract
 - PMN – polymorphonuclear leukocyte
 - RIA – radioimmunoassay

Reporting Instructions

- There is a hierarchy of specific type of infection within the major type pneumonia (PNEU) since pathogens cannot be reported for PNU1. If the patient meets criteria for more than one specific type during the IWP or the RIT, report only one:
 - If a patient meets criteria for both PNU1 and PNU2, report PNU2.
 - If a patient meets criteria for both PNU2 and PNU3, report PNU3.
 - If a patient meets criteria for both PNU1 and PNU3, report PNU3.
- Pathogens and secondary bloodstream infections can only be reported for PNU2 and PNU3 specific events.
- Report concurrent LUNG and PNEU as PNEU (unless the LUNG is a surgical site organ/space infection, in which case, report both PNEU and SSI-LUNG).

Table 1: Specific Site Algorithms for Clinically Defined Pneumonia (PNU1)

NOTE: The PNEU Algorithms (PNU1,2,3) and Flowcharts include [FOOTNOTE](#) references. The interpretation and guidance provided in the **FOOTNOTES** are an important part of the algorithms and must be incorporated into the decision-making process when determining if a PNEU definition is met.

Imaging Test Evidence	Signs/Symptoms
Two or more serial chest imaging test results with at least <u>one</u> of the following (1,2,13):	For ANY PATIENT, at least <u>one</u> of the following: • Fever ($> 38.0^{\circ}\text{C}$ or $> 100.4^{\circ}\text{F}$) • Leukopenia ($\leq 4000 \text{ WBC/mm}^3$) or leukocytosis ($\geq 12,000 \text{ WBC/mm}^3$) • For adults ≥ 70 years old, altered mental status with no other recognized cause And at least <u>two</u> of the following (from separate bullets): • New onset of purulent sputum (3) or change in character of sputum (4), or increased respiratory secretions, or increased suctioning requirements • Dyspnea, or tachypnea (5), or new onset or worsening cough • Rales (6) or bronchial breath sounds • Worsening gas exchange (for example, O_2 desaturations [for example, $\text{PaO}_2/\text{FiO}_2 \leq 240$] (7), increased oxygen requirements, or increased ventilator demand)
New and persistent or Progressive and persistent • Infiltrate • Consolidation • Cavitation • Pneumatoceles, in infants ≤ 1 year old	ALTERNATE CRITERIA, for infants ≤ 1 year old: Worsening gas exchange (for example, O_2 desaturations [for example, pulse oximetry $< 94\%$], increased oxygen requirements, or increased ventilator demand) And at least <u>three</u> of the following (from separate bullets): • Temperature instability • Leukopenia ($\leq 4000 \text{ WBC/mm}^3$) <u>or</u> leukocytosis ($\geq 15,000 \text{ WBC/mm}^3$) and left shift ($\geq 10\%$ band forms) • New onset of purulent sputum (3) or change in character of sputum (4), or increased respiratory secretions, or increased suctioning requirements • Apnea, tachypnea (5), nasal flaring with retraction of chest wall, or nasal flaring with grunting • Wheezing, rales (6), or rhonchi • Cough • Bradycardia ($< 100 \text{ beats/min}$) or tachycardia ($> 170 \text{ beats/min}$)
Note: In patients <i>without</i> underlying pulmonary or cardiac disease (such as respiratory distress syndrome, bronchopulmonary dysplasia, pulmonary edema, or chronic obstructive pulmonary disease), <u>at least one definitive</u> imaging test result is acceptable. (1)	ALTERNATE CRITERIA, for child > 1 year old or ≤ 12 years old, at least <u>three</u> of the following (from separate bullets): • Fever ($> 38.0^{\circ}\text{C}$ or $> 100.4^{\circ}\text{F}$) or hypothermia ($< 36.0^{\circ}\text{C}$ or $< 96.8^{\circ}\text{F}$) • Leukopenia ($\leq 4000 \text{ WBC/mm}^3$) or leukocytosis ($\geq 15,000 \text{ WBC/mm}^3$) • New onset of purulent sputum (3) or change in character of sputum (4), or increased respiratory secretions, or increased suctioning requirements • Dyspnea, or apnea, or tachypnea (5), or new onset or worsening cough • Rales (6) or bronchial breath sounds • Worsening gas exchange (for example, O_2 desaturations [for example, pulse oximetry $< 94\%$], increased oxygen requirements, or increased ventilator demand)

Table 2: Specific Site Algorithm for Pneumonia with Common Bacterial or Filamentous Fungal Pathogens and Specific Laboratory Findings (PNU2)

NOTE: The PNEU Algorithms (PNU1,2,3) and Flowcharts include [FOOTNOTE](#) references. The interpretation and guidance provided in the **FOOTNOTES** are an important part of the algorithms and must be incorporated into the decision-making process when determining if a PNEU definition is met.

Imaging Test Evidence	Signs/Symptoms	Laboratory
Two or more serial chest imaging test results with at least <u>one</u> of the following (1,2,13): New and persistent or Progressive and persistent • Infiltrate • Consolidation • Cavitation • Pneumatocoles, in infants ≤ 1 year old Note: In patients without underlying pulmonary or cardiac disease (such as respiratory distress syndrome, bronchopulmonary dysplasia, pulmonary edema, or chronic obstructive pulmonary disease), at least one definitive chest imaging test result is acceptable. (1)	At least <u>one</u> of the following: • Fever ($> 38.0^{\circ}\text{C}$ or $> 100.4^{\circ}\text{F}$) • Leukopenia (≤ 4000 WBC/mm³) or leukocytosis ($\geq 12,000$ WBC/mm³) • For adults ≥ 70 years old, altered mental status with no other recognized cause And at least <u>one</u> of the following: • New onset of purulent sputum (3) or change in character of sputum (4), or increased respiratory secretions, or increased suctioning requirements • Dyspnea, or tachypnea (5), or new onset or worsening cough • Rales (6) or bronchial breath sounds • Worsening gas exchange (for example, O₂ desaturations [for example, PaO₂/FiO₂ ≤ 240] (7), increased oxygen requirements, or increased ventilator demand)	At least <u>one</u> of the following: • Organism identified from blood (8,12) • Organism identified from pleural fluid (9,12) • Positive quantitative culture or corresponding semi-quantitative culture result (9) from minimally contaminated LRT specimen (<i>specifically, BAL, protected specimen brushing, or endotracheal aspirate</i>) • Positive quantitative culture or corresponding semi-quantitative culture result (9) of lung tissue • $\geq 5\%$ BAL-obtained cells contain intracellular bacteria on direct microscopic exam (for example, Gram stain) • Histopathologic exam shows at least <u>one</u> of the following evidences of pneumonia: ○ Abscess formation or foci of consolidation with intense PMN accumulation in bronchioles and alveoli ○ Evidence of lung parenchyma invasion by fungal hyphae or pseudohyphae

Table 3: Specific Site Algorithm for Viral, Legionella, and other Bacterial Pneumonias with Definitive Laboratory Findings (PNU2)

NOTE: The PNEU Algorithms (PNU1,2,3) and Flowcharts include [FOOTNOTE](#) references. The interpretation and guidance provided in the **FOOTNOTES** are an important part of the algorithms and must be incorporated into the decision-making process when determining if a PNEU definition is met.

Imaging Test Evidence	Signs/Symptoms	Laboratory
Two or more serial chest imaging test results with at least <u>one</u> of the following (1,2,13): New and persistent or Progressive and persistent • Infiltrate • Consolidation • Cavitation • Pneumatocoles, in infants ≤ 1 year old Note: In patients <i>without</i> underlying pulmonary or cardiac disease (such as respiratory distress syndrome, bronchopulmonary dysplasia, pulmonary edema, or chronic obstructive pulmonary disease), <u>at least one definitive</u> chest imaging test result is acceptable. (1)	At least <u>one</u> of the following: • Fever ($> 38.0^{\circ}\text{C}$ or $> 100.4^{\circ}\text{F}$) • Leukopenia (≤ 4000 WBC/mm³) or leukocytosis ($\geq 12,000$ WBC/mm³) • For adults ≥ 70 years old, altered mental status with no other recognized cause And at least <u>one</u> of the following: • New onset of purulent sputum (3) or change in character of sputum (4), or increased respiratory secretions, or increased suctioning requirements • Dyspnea, or tachypnea (5), or new onset or worsening cough • Rales (6) or bronchial breath sounds • Worsening gas exchange (for example, O₂ desaturations [for example, PaO₂/FiO₂ ≤ 240] (7), increased oxygen requirements, or increased ventilator demand)	At least <u>one</u> of the following: • Virus, <i>Bordetella</i>, <i>Legionella</i>, <i>Chlamydia</i>, or <i>Mycoplasma</i> identified from respiratory secretions or tissue by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment (for example, not Active Surveillance Culture/Testing (ASC/AST)) • Fourfold rise in paired sera (IgG) for pathogen (for example, influenza viruses, <i>Chlamydia</i>) • Fourfold rise in <i>Legionella pneumophila</i> serogroup 1 antibody titer to $\geq 1:128$ in paired acute and convalescent sera by indirect IFA • Detection of <i>Legionella pneumophila</i> serogroup 1 antigens in urine by RIA or EIA

Table 4: Specific Site Algorithm for Pneumonia in Immunocompromised Patients (PNU3)

NOTE: The PNEU Algorithms (PNU1,2,3) and Flowcharts include **FOOTNOTE** references. The interpretation and guidance provided in the **FOOTNOTES** are an important part of the algorithms and must be incorporated into the decision-making process when determining if a PNEU definition is met.

Imaging Test Evidence	Signs/Symptoms	Laboratory
Two or more serial chest imaging test results with at least <u>one</u> of the following (1,2,13): New and persistent or Progressive and persistent • Infiltrate • Consolidation • Cavitation • Pneumatoceles, in infants ≤ 1 year old Note: In patients <i>without</i> underlying pulmonary or cardiac disease (such as respiratory distress syndrome, bronchopulmonary dysplasia, pulmonary edema, or chronic obstructive pulmonary disease), <u>at least one definitive</u> chest imaging test result is acceptable. (1)	Patient who is immunocompromised (see definition in footnote 10) has at least <u>one</u> of the following: • Fever ($> 38.0^{\circ}\text{C}$ or $> 100.4^{\circ}\text{F}$) • For adults ≥ 70 years old, altered mental status with no other recognized cause • New onset of purulent sputum (3), or change in character of sputum (4), or increased respiratory secretions, or increased suctioning requirements • Dyspnea, or tachypnea (5), or new onset or worsening cough • Rales (6) or bronchial breath sounds • Worsening gas exchange (for example, O_2 desaturations [for example, $\text{PaO}_2/\text{FiO}_2 \leq 240$] (7), increased oxygen requirements, or increased ventilator demand) • Hemoptysis • Pleuritic chest pain	At least <u>one</u> of the following: • Identification of matching <i>Candida</i> spp. from blood and one of the following respiratory specimens: sputum, endotracheal aspirate, BAL, or protected specimen brushing (11,12); blood specimen and respiratory specimen must have collection dates that occur within the same IWP • Evidence of fungi (excluding any <i>Candida</i> and yeast not otherwise specified) from minimally contaminated LRT specimen (specifically BAL, protected specimen brushing or endotracheal aspirate) from one of the following: – Direct microscopic exam – Positive culture of fungi – Non-culture diagnostic laboratory test OR Any of the following from: LABORATORY CRITERIA DEFINED UNDER PNU2

Figure 1: Pneumonia Flow Diagram for Patients of Any Age

NOTE: The PNEU Algorithms (PNU1,2,3) and Flowcharts include [FOOTNOTE](#) references. The interpretation and guidance provided in the **FOOTNOTES** are an important part of the algorithms and must be incorporated into the decision-making process when determining if a PNEU definition is met.





Figure 2: Pneumonia Flow Diagram, Alternative Criteria for Infants and Children

NOTE: The PNEU Algorithms (PNU1,2,3) and Flowcharts include **FOOTNOTE** references. The interpretation and guidance provided in the **FOOTNOTES** are an important part of the algorithms and must be incorporated into the decision-making process when determining if a PNEU definition is met.



Footnotes to Algorithms and Flow Diagrams

1. **Imaging - Persistence:** To help confirm difficult cases, multiple imaging test results spanning over several calendar days must be considered when determining if there is imaging test evidence of pneumonia. Pneumonia may have rapid onset and progression but does not resolve quickly. Imaging test evidence of pneumonia will persist. Rapid imaging resolution suggests that the patient does not have pneumonia, but rather a non-infectious process such as atelectasis or congestive heart failure.
 - The diagnosis of healthcare-associated pneumonia may be quite clear on the basis of signs, symptoms, and a single definitive chest imaging test result. Therefore, in a patient without underlying pulmonary or cardiac disease and when there is only one imaging test available, if the imaging finding is an eligible and definitive finding, the imaging test evidence requirement can be met.
 - In patients without underlying disease, if more than one imaging test is available the serial imaging test results (within a 7-day timeframe) must also be evaluated and must demonstrate persistence of eligible and definitive findings.
 - In patients with underlying pulmonary or cardiac disease (such as interstitial lung disease, congestive heart failure, etc.), the diagnosis of pneumonia may be particularly difficult. For example, imaging findings of pulmonary edema from decompensated congestive heart failure may simulate the presentation of pneumonia. Therefore, in patients with underlying disease, serial chest imaging test results (within a 7-day timeframe) must be examined and must demonstrate persistence of eligible and definitive findings to help separate infectious from non-infectious pulmonary processes.
2. **Imaging - Alternative Descriptors:** Note that there are many ways of describing the imaging appearance of pneumonia. Examples include, but are not limited to, “air-space disease,” “focal opacification,” “patchy areas of increased density.” Although perhaps not specifically delineated as pneumonia by the radiologist, in the appropriate clinical setting these alternative descriptive wordings should be seriously considered as potentially positive findings. If provided and the findings are not documented as attributed to another issue (for example, pulmonary edema, chronic lung disease), they are eligible for meeting imaging test evidence of pneumonia.
3. **New onset of purulent sputum:** Purulent sputum is defined as secretions from the lungs, bronchi, or trachea that contain ≥ 25 neutrophils and ≤ 10 squamous epithelial cells per low power field (x100). Refer to the table below if your laboratory reports these data semi-quantitatively or uses a different format for reporting Gram stain or direct examination results (for example, “many WBCs” or “few squamous epithelial cells”). This laboratory confirmation is required since written clinical descriptions of purulence are highly variable.

How do I use the purulent respiratory secretions criterion if ...	Instruction
My laboratory reports counts of “white blood cells” or “polymorphonuclear leukocytes” or “leukocytes” rather than counts of “neutrophils”?	Assume that counts of cells identified by these other descriptors (for example, “white blood cells”) are equivalent to counts of neutrophils, unless the laboratory tells you this is not the case.
My laboratory reports semi-quantitative results (not quantitative results) for numbers of neutrophils and squamous epithelial cells?	Check with the laboratory to get information about what quantitative ranges the semi-quantitative reports correspond to.
My laboratory cannot provide additional information on how its semi-quantitative reporting corresponds to quantitative reporting ranges for neutrophils and squamous epithelial cells?	Use the following direct examination results to meet the purulent respiratory secretions criterion: many, heavy, numerous 4+, or ≥ 25 neutrophils per low power field (lpf) [x100], AND no, rare, occasional, few, 1+ or 2+, or ≤ 10 squamous epithelial cells per lpf [x100].
My laboratory reports <u>only</u> the numbers of neutrophils present, without reporting the number of squamous epithelial cells?	In this situation, the purulent secretions criterion may be met using the specified quantitative and semi-quantitative thresholds for neutrophils alone (specifically many, heavy, numerous, 4+, or ≥ 25 neutrophils per lpf [x100]).
My laboratory uses different reporting thresholds for neutrophils and squamous epithelial cells (for example, maximum report of ≥ 20 neutrophils per low power field [x100], or minimum report of ≤ 15 squamous epithelial cells per low power field [x100])?	In this situation, the purulent secretions criterion may be met using the laboratory’s specified maximum quantitative threshold for neutrophils, and/or minimum quantitative threshold for squamous epithelial cells.
My laboratory processes respiratory specimens such as bronchoalveolar lavage fluid using a centrifugation procedure (for example, “cytospin”), and there is no quantitation or semi-quantitation of neutrophils or white blood cells in the direct examination report?	In this situation, a report indicating the presence of white blood cells, without quantitation, is sufficient to meet the purulent secretions criterion.

4. **Change in character of sputum:** Refers to the color, consistency, odor, and quantity of sputum.
5. **Tachypnea:** Defined by age-based respiration rates (breaths per minute) in the table below.

Age Group	Respiration Rate
Adults	> 25 breaths per minute
Children > 1 year old	> 30 breaths per minute
Children 2 months – 12 months old	> 50 breaths per minute
Infants < 2 months old	> 60 breaths per minute
Premature infants born at < 37 weeks gestation and until the 40 th week	> 75 breaths per minute

6. **Rales:** May also be described as “crackles.”
7. **PaO₂/FiO₂ ≤ 240:** This measure of arterial oxygenation is defined as the ratio of the arterial tension (PaO₂) to the inspiratory fraction of oxygen (FiO₂).
8. **Organism identified from blood:** Any coagulase-negative *Staphylococcus* species, any *Enterococcus* species, and any *Candida* species or yeast not otherwise specified that are identified from blood cannot be deemed secondary to a PNEU event unless the organism was also identified from lung tissue or pleural fluid (where specimen was obtained during thoracentesis or within 24 hours of chest tube placement; a pleural fluid specimen collected after a chest tube is repositioned or from a chest tube in place > 24 hours is not eligible). This applies when meeting PNU2 or when meeting PNU3 (for patients meeting the immunocompromised definition) with the laboratory findings found in PNU2.

Exception: Identification of matching *Candida* spp. from blood and sputum, endotracheal aspirate, BAL, or protected specimen brushing with specimen collection dates in the same IWP can be used to satisfy PNU3 definition for patients meeting the immunocompromised definition (see [footnote 10](#)).

9. **Organism identified from minimally contaminated LRT specimens, pleural fluid, and lung tissue (Table 2):**

Refer to threshold values in [Table 5](#) for cultured specimens (lung tissue, BAL, protected specimen brushing, or endotracheal aspirate) with growth of eligible pathogens.

Notes:

- A specimen that is not obtained through an artificial airway (specifically an endotracheal tube or a tracheostomy) from a ventilated patient is not considered minimally contaminated and is not eligible for use in meeting the laboratory criteria for PNEU (PNU2 or PNU3 when using the laboratory findings found in PNU2). Sputum or tracheal secretions collected from a non-ventilated patient are not minimally contaminated specimens.
- The following organisms can only be used to meet PNEU definitions when identified from lung tissue or pleural fluid obtained during thoracentesis or within 24 hours of chest tube placement (not from a chest tube that has been repositioned or from a chest tube that has been in place > 24 hours):

- Any coagulase-negative *Staphylococcus* species
- Any *Enterococcus* species
- Any *Candida* species or yeast not otherwise specified
 - Exception: Identification of matching *Candida* spp. from blood and sputum, endotracheal aspirate, BAL, or protected specimen brushing with specimen collection dates in the same IWP can be used to satisfy PNU3 definition for immunocompromised patients (see [footnote 10](#)).

Table 5: Threshold values for cultured specimens used in the diagnosis of pneumonia

Specimen collection/technique	Values*
Lung tissue†	$\geq 10^4$ CFU/g tissue
Bronchoscopically (B) obtained specimens	
Bronchoalveolar lavage (B-BAL)	$\geq 10^4$ CFU/ml
Protected BAL (B-PBAL)	$\geq 10^4$ CFU/ml
Protected specimen brushing (B-PSB)	$\geq 10^3$ CFU/ml
Nonbronchoscopically (NB) obtained (blind) specimens	
NB-BAL	$\geq 10^4$ CFU/ml
NB-PSB	$\geq 10^3$ CFU/ml
Endotracheal aspirate (ETA)	$\geq 10^5$ CFU/ml

CFU = colony forming units, g = gram, ml = milliliter

*Consult with your laboratory to determine if reported semi-quantitative results match the quantitative thresholds. In the absence of additional information available from your laboratory, a semi-quantitative result of “moderate” or “heavy” or “many” or “numerous” growth, or 2+, 3+, or 4+ growth is considered to correspond.

†Lung tissue specimens obtained by either open or closed lung biopsy methods. For post-mortem specimens, only lung tissue specimens obtained by transthoracic or transbronchial biopsy that are collected immediately post-mortem are eligible for use.

10. Immunocompromised patients include only

- those with neutropenia defined as absolute neutrophil count or total white blood cell count (WBC) $< 500/\text{mm}^3$
- those with leukemia, lymphoma, or who are HIV positive with CD4 count < 200 cells/ mm^3
- those who have undergone splenectomy
- those who have a history of solid organ or hematopoietic stem cell transplant
- those on cytotoxic chemotherapy
- those on enteral or parenteral administered steroids (excludes inhaled and topical steroids) daily for > 14 consecutive days on the date of event

11. **Identification of matching *Candida* spp. from blood and respiratory specimens for PNU3 (Table 4):** Sputum obtained by any method (such as deep cough, induction, aspiration, or lavage) are acceptable specimens. Any quantity of organism identified is acceptable, to include all non-quantitative, semi-quantitative, and quantitative results.
12. **Organism identified from blood (Table 2), organism identified from pleural fluid (Table 2), and identification of matching *Candida* spp. from blood and respiratory specimens for PNU3 (Table 4):** Identification of organism by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment (for example, not Active Surveillance Culture/Testing (ASC/AST)).
13. **Imaging - Equivocal Results:** If the imaging test result is equivocal for pneumonia, first check to see if subsequent imaging test results are definitive. For example, if a chest imaging test result states infiltrate vs. atelectasis and a subsequent imaging test result is definitive for infiltrate, the equivocal imaging test would be eligible for use. If a chest imaging test result states infiltrate vs. atelectasis and a subsequent imaging test result is definitive for atelectasis, the equivocal imaging test would not be eligible for use. In the absence of finding a subsequent imaging test result that clarifies the equivocal finding, if there is clinical correlation then the equivocal imaging test is eligible for use. See [Chapter 16](#) for definitions of Equivocal imaging and Clinical correlation.

Numerator Data

The *Pneumonia (PNEU)* form ([CDC 57.111](#)) is used to collect and report each VAP that is identified during the month selected for surveillance. The [Instructions for Completion of Pneumonia \(PNEU\)](#) form contains brief instructions for collection and entry of each data element on the form. The pneumonia form includes patient demographic information and information on whether or not mechanically assisted ventilation was present. Additional data include the specific criteria met for identifying pneumonia, whether the patient developed a secondary bloodstream infection, whether the patient died, the organisms identified from culture or non-culture based microbiologic testing methods, and the organisms' antimicrobial susceptibilities.

Reporting Instruction: If no VAPs are identified during the month of surveillance, the “*Report No Events*” box must be checked on the appropriate denominator summary screen, for example, Denominators for Intensive Care Unit (ICU)/Other Locations (Not NICU or SCA/ONC), etc.

Denominator Data

Device days and patient days are used for denominators (see [Chapter 16](#)). Ventilator days, which are the number of patients managed with a ventilatory device, are collected daily, at the same time each day, according to the chosen location using the appropriate form ([CDC 57.116](#) [NICU], [57.117](#) [Specialty Care Areas], and [57.118](#) [ICU/Other Locations]). These daily counts are summed and only the total for the month is entered into NHSN. Ventilator days and patient days are collected for each of the locations where VAP is monitored. When denominator data are available from electronic sources, these sources may be used as long as the counts are within +/- 5% of manually collected counts, validated for a minimum of three consecutive months. Validation of electronic counts should be performed separately for each location conducting VAP surveillance.

When converting from one electronic counting system to another electronic counting system, the new electronic system should be validated against manual counts as above. If electronic counts for the new electronic system are not within 5% of manual counts, resume manual counting and continue working with IT staff to improve design of electronic denominator data extraction (while reporting manual counts) until concurrent counts are within 5% for 3 consecutive months.

Note: This guideline is important because validating a new electronic counting system against an existing electronic system can magnify errors and result in inaccurate denominator counts.

Data Analyses

All data that is entered into NHSN can be analyzed at event or summary level. The data in NHSN can be visualized and analyzed in various ways, specifically, descriptive analysis reports for both the denominator and numerator data.

Types of VAP Analysis Reports

VAP Rate

The VAP rate per 1000 ventilator days is calculated by dividing the number of VAPs by the number of ventilator days and multiplying the result by 1000 (ventilator days).

$$\text{VAP Rate per 1000 ventilator days} = \frac{\text{No. of VAPs}}{\text{No. of Ventilator Days}} * 1000$$

Device Utilization Ratio

The Ventilator Utilization Ratio is calculated by dividing the number of ventilator days by the number of patient days. These calculations will be performed separately for the different types of ICUs, SCAs, and other locations in the institution.

$$\text{DUR} = \frac{\text{No. of Ventilator Days}}{\text{No. of Patient Days}}$$

Descriptive Analysis Output Options

Descriptive analysis output options of numerator and denominator data, such as line listings, frequency tables, and bar and pie charts are also available in the NHSN application.

Line List: [Creating a Line List](#)

Frequency Tables: [Creating a Frequency Table](#)

Bar Chart: [Creating a Bar Chart](#)

Pie Chart: [Creating a Pie Chart](#)

Rate Table: [Creating a Rate Table](#)

Analysis Resources Links

[Analysis Resources Website](#)

[Analysis Quick Reference Guides](#)

Data Quality Resources Links

[Data Quality Website](#)

[Data Quality Manual](#)

[Data Quality Training](#)

Table 6: VAP Measures Available in NHSN

<u>Measure</u>	<u>Calculation</u>	<u>Application</u>
VAP Rates	$\frac{\text{The number of VAPs for a location}}{\text{The number of Ventilator Days for that location}} \times 1000$	Location specific measure only
DUR	$\frac{\text{The number of Ventilator Days for a location}}{\text{The number of Patient Days for that location}}$	Location specific measure only

NHSN Group Analysis

NHSN Group Users can perform the same analysis as facility level users in NHSN. A few helpful tools in NHSN for groups are listed in the resources below. These tools are guides on how to start and join a Group; how to create a template to request data from facilities; how to determine the level of access granted by the facility following the previous steps, and how to analyze the facilities data.

Group Analysis Resources

NHSN Group Users Page:

<https://www.cdc.gov/nhsn/group-users/index.html>

Group User's Guide to the Membership Rights Report:

<https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/membership-rights-508.pdf>

Group User's Guide to the Line Listing - Participation Alerts:

<https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/group-alerts.pdf>

References

¹Magill SS, O’Leary E, Janelle SJ, et al. Changes in Prevalence of Health Care–Associated Infections in U.S. Hospitals. *N Engl J Med*. 2018;379(18):1732-1744.

²Magill SS, Klompas M, Balk R, et al. Developing a new, national approach to surveillance for ventilator-associated events. *Crit Care Med*. 2013;41(11):2467-2475.

Urinary Tract Infection (Catheter-Associated Urinary Tract Infection [CAUTI] and Non-Catheter-Associated Urinary Tract Infection [UTI]) Events

Table of Contents

Introduction	1
Definitions	2
Identifying a CAUTI	3
Figure 1. Indwelling Urinary Catheter Utilization Timeline, CAUTI Eligibility	4
Figure 2. Indwelling Urinary Catheter Utilization Timeline, Non-CAUTI Eligibility	4
Table 1. Urinary Tract Infection Criteria	5
Figure 3. Identifying SUTI and ABUTI Flowchart	10
Monthly Summary Data	11
Table 2: Denominator Data Collection Methods	11
Data Analyses	14
Table 3. CAUTI Measures Available in NHSN	17
References	18

Introduction

Catheter-associated urinary tract infections (CAUTIs) remain a significant concern in acute care hospitals and continue to represent a major source of preventable harm. In 2023, acute care hospitals reported more than 17,000 CAUTI events occurring over 23 million urinary catheter device-days¹. Virtually all healthcare-associated UTIs are caused by instrumentation of the urinary tract.

Approximately 12%-16% of adult hospital inpatients will have an indwelling urinary catheter (IUC) at some time during their hospitalization, and each day the indwelling urinary catheter remains, a patient has a 3%-7% increased risk of acquiring a catheter-associated urinary tract infection (CAUTI).²⁻³

CAUTIs can lead to such complications as prostatitis, epididymitis, and orchitis, cystitis, pyelonephritis, gram-negative bacteremia, endocarditis, vertebral osteomyelitis, septic arthritis, endophthalmitis, and meningitis in patients. Complications associated with CAUTIs cause discomfort to the patient, prolonged hospital stays, and increased costs and mortality.⁴ It has been estimated that each year, more than 13,000 deaths are associated with UTIs.⁵

Prevention of CAUTIs is discussed in the CDC/HICPAC document, *Guideline for Prevention of Catheter-associated Urinary Tract Infection*.⁶

Settings: CAUTI surveillance may occur in any inpatient location(s) where denominator data can be collected, such as critical intensive care units (ICU), specialty care areas (SCA), step-down units, wards, inpatient rehabilitation locations, and long-term acute care locations. Neonatal ICUs may participate, but only off plan (not as a part of their monthly reporting plan). A complete listing of inpatient locations and instructions for mapping are located in the [CDC Locations and Descriptions](#) chapter.

- **Note:** Post-discharge surveillance for CAUTI is not required. However, if a post-discharge CAUTI is discovered, any CAUTI with a date of event (DOE) on the day of discharge or the next day is attributable to the discharging location and should be included in any CAUTI reported to NHSN for that location (see Transfer Rule [Chapter 2](#)). No additional indwelling urinary catheter (IUC) days are reported.

Refer to the NHSN Patient Safety Manual, [Chapter 2 Identifying Healthcare Associated Infections in NHSN](#) and [Chapter 16 NHSN Key Terms](#) for definitions of the following universal concepts for conducting HAI surveillance.

- I. Date of event (DOE)
- II. Healthcare associated infection (HAI)
- III. Infection window period (IWP)
- IV. Present on admission (POA)
- V. Repeat infection timeframe (RIT)
- VI. Secondary BSI attribution period (SBAP)
- VII. Location of Attribution (LOA)
- VIII. Transfer rule

Definitions

Urinary Tract Infections (UTIs): For NHSN reporting, UTIs are defined by Symptomatic Urinary Tract Infection (SUTI) and Asymptomatic Bacteremic UTI (ABUTI) criteria (see [Table 1](#)).

- **Note:** UTI is a primary site of infection; it is **never** considered secondary to another site of infection.

Indwelling Urinary Catheter (IUC): A drainage tube that is inserted into the urinary bladder through the urethra, is left in place, and is connected to a drainage bag (including leg bags). IUCs are often called Foley catheters. IUCs used for intermittent or continuous irrigation are also included in CAUTI surveillance. Urinary devices not meeting the IUC definition may include but are not limited to condom, straight in-and-out catheters, nephrostomy tubes, ileoconduits, or suprapubic catheters. If these devices are present in addition to an IUC, the patient remains eligible for a CAUTI.

Catheter-associated UTI (CAUTI): A UTI where an indwelling urinary catheter (IUC) was in place for more than two consecutive days in an inpatient location on the date of event or the day before, with day of device placement being Day 1*. If an IUC was in place for more than two consecutive days in an inpatient location and then removed, the date of event for the UTI must be the day of device discontinuation or the next day for the UTI to be catheter-associated.

*If the IUC was in place prior to inpatient admission, the catheter day count that determines catheter-association begins with the admission date to the first inpatient location allowing for consistency with device denominator count collection (see [Table 2 Denominator Data Collection Methods](#)).

Spinal Cord Injury-associated Neurogenic Bladder (SCI-NB): For NHSN reporting, neurogenic bladder is a condition in which there is dysfunction or damage to the nerves that control the bladder as a result of a spinal cord injury. To answer “Yes” to the ‘Neurogenic bladder’ field within the NHSN application you must enter:

- One ICD-10-CM diagnosis code that indicates a diagnosis of spinal cord injury (SCI)
- AND**
- One ICD-10-CM diagnosis code that indicates a diagnosis of neurogenic bladder (NB)

In tandem, these diagnostic codes define SCI-NB for NHSN surveillance purposes. For a complete list of eligible ICD-10-CM codes please visit the Urinary Tract Infection (UTI) Events section of the NHSN website under “[Supporting Materials](#)”.

Identifying a CAUTI

NHSN surveillance is aimed at identifying risk to the patient that is the result of indwelling urinary catheter use. IUC device days are counted by calendar day, not to be mistaken as 24-hours. If an IUC is present for any part of a calendar day, it will count as a device day even if it was removed and a new one was inserted. The device day count is only interrupted and starts anew if a full calendar day passes with no IUC present.

Example

Two patients, A and B, are in an inpatient unit and had indwelling urinary catheters (IUCs) inserted on the same day. Later, on Hospital Day 4, both patients had their IUCs removed. The device utilization for Patients A and B varied for the remainder of their admissions (see Figure 1 below).

Figure 1. Indwelling Urinary Catheter Utilization Timeline, CAUTI Eligibility

	March 29 th	March 30 th	March 31 st	April 1 st	April 2 nd	April 3 rd	April 4 th	April 5 th
Patient A	IUC Inserted (Day 1)	IUC (Day 2)	IUC (Day 3)	IUC Removed (Day 4)	IUC Inserted (Day 5)	IUC Inserted (Day 6)	IUC Removed (Day 7)	No IUC
Patient B	IUC Inserted (Day 1)	IUC (Day 2)	IUC (Day 3)	IUC Removed (Day 4)	No IUC	IUC Inserted (Day 1)	IUC (Day 2)	IUC (Day 3)

- **Rationale (Patient A):** A UTI with a date of event on or between March 31st and April 5th, would be a CAUTI since the patient had an IUC in place for greater than two consecutive days. Please note, a UTI with a date of event on April 5th does qualify as a CAUTI, even though the IUC was removed the day prior (see [Table 1](#)).
- **Rationale (Patient B):** A UTI with a date of event on or between March 31st and April 2nd, would be a CAUTI since the patient had an IUC in place for greater than two consecutive days. A UTI with a date of event on April 2nd does qualify as a CAUTI, even though the IUC was removed the day prior (see [Table 1](#)). Additionally, Patient B becomes eligible again for a CAUTI on April 5th.

Example

A patient in an inpatient unit has an indwelling urinary catheter (IUC) inserted, and the following day is found to be the UTI date of event (see Figure 2 below).

Figure 2. Indwelling Urinary Catheter Utilization Timeline, Non-CAUTI Eligibility

January 22 nd	January 23 rd	January 24 th	January 25 th
IUC Inserted (Day 1)	IUC Date of Event (Day 2)	IUC (Day 3)	IUC (Day 4)

- **Rationale:** The IUC on the date of event has not been in place for more than two consecutive days in an inpatient location, therefore this UTI event is not catheter-associated (see [Table 1](#)).

Note: The examples above were created to depict various catheter-association scenarios. Please refer to [Chapter 2 Identifying HAIs in NHSN](#) when making a present on admission (POA) or healthcare-associated infection (HAI) determination.

Table 1. Urinary Tract Infection Criteria

Note: All elements of the UTI criterion must occur during the IWP (see IWP Definition [Chapter 2 Identifying HAIs in NHSN](#)).

Criterion	Urinary Tract Infection
	Symptomatic UTI (SUTI) Must meet at least <u>one</u> of the following criteria:
SUTI 1a Catheter-associated Urinary Tract Infection (CAUTI) in any age patient	Patient must meet 1, 2, <u>and</u> 3 below: 1. Patient had an indwelling urinary catheter that had been in place for more than 2 consecutive days in an inpatient location on the date of event AND was either: • Present for any portion of the calendar day on the date of event[†], OR • Removed the day before the date of event[‡] 2. Patient has at least <u>one</u> of the following signs or symptoms: • fever (>38.0°C) • suprapubic tenderness* • costovertebral angle pain or tenderness* • urinary urgency[^] • urinary frequency[^] • dysuria[^] 3. Patient has a urine culture with no more than two species of organisms identified, at least one of which is a bacterium of ≥100,000 CFU/ml (see Comments below). [†] When entering event into NHSN choose “INPLACE” for Risk Factor for IUC [‡] When entering event into NHSN choose “REMOVE” for Risk Factor for IUC * With no other recognized cause [^] These symptoms cannot be used when an indwelling urinary catheter (IUC) is in place. An IUC in place could cause patient complaints of “frequency,” “urgency,” or “dysuria”.


Criterion	Urinary Tract Infection (UTI)
SUTI 1b Non-Catheter-associated Urinary Tract Infection (Non-CAUTI) in any age patient	Patient must meet 1, 2, <u>and</u> 3 below: - One of the following is true: - Patient has/had an indwelling urinary catheter, but it has/had not been in place for more than two consecutive days in an inpatient location on the date of event[†] OR - Patient did not have an indwelling urinary catheter in place on the date of event nor the day before the date of event[†] - Patient has at least <u>one</u> of the following signs or symptoms: - fever (>38°C) - suprapubic tenderness* - costovertebral angle pain or tenderness* - urinary frequency^ - urinary urgency^ - dysuria^ - Patient has a urine culture with no more than two species of organisms identified, at least one of which is a bacterium of ≥100,000 CFU/ml (see Comments below). [†] When entering event into NHSN choose “NEITHER” for Risk Factor for IUC * With no other recognized cause ^These symptoms cannot be used when an indwelling urinary catheter (IUC) is in place. An IUC in place could cause patient complaints of “frequency,” “urgency,” or “dysuria”.

Criterion	Urinary Tract Infection (UTI)
SUTI 2 CAUTI or Non-CAUTI in patients 1 year of age or less	Patient must meet 1, 2, <u>and</u> 3 below: 1. Patient is ≤ 1 year of age (with[*] or without an indwelling urinary catheter) 2. Patient has at least <u>one</u> of the following signs or symptoms: • fever ($>38.0^{\circ}\text{C}$) • hypothermia ($<36.0^{\circ}\text{C}$) • apnea[*] • bradycardia[*] • lethargy[*] • vomiting[*] • suprapubic tenderness^{*^} 3. Patient has a urine culture with no more than two species of organisms identified, at least one of which is a bacterium of $\geq 100,000$ CFU/ml (see Comments below). [*] If patient had an indwelling urinary catheter (IUC) in place for more than two consecutive days in an inpatient location and the IUC was in place on the date of event or the previous day, the CAUTI criterion is met. If no such IUC was in place, UTI (non-catheter associated) criterion is met. [*]With no other recognized cause
Comments	Mixed flora cannot be reported as a pathogen for a UTI event. Additionally, “mixed flora” represents at least two species of organisms and cannot be used to meet the NHSN UTI criteria. Any additional organisms recovered from the same culture would be in addition to the mixed flora, meaning there are at least three organisms present making the culture ineligible for use to meet NHSN UTI criteria. The following excluded organisms cannot be used to meet the UTI definition: • Any yeast or yeast species yeast • mold • dimorphic fungi or • parasites

	An acceptable urine specimen may include the above organisms if no more than one bacterium with $\geq 100,000$ CFU/ml is also present. Additionally, these non-bacterial organisms identified from a blood culture cannot be deemed secondary to a UTI since the above non-bacterial organisms are excluded as organisms in the UTI definition. ➤ Suprapubic tenderness documentation - whether elicited by palpation (tenderness-sign) or provided as a subjective complaint of suprapubic pain (pain-symptom) - found in the medical record is acceptable to meet SUTI criterion if documented in the medical record during the Infection Window Period. ➤ Lower abdominal pain or bladder or pelvic discomfort are examples of symptoms that can be used as suprapubic tenderness. Generalized "abdominal pain" in the medical record is too general and not to be interpreted as suprapubic tenderness as there are many causes of abdominal pain. ➤ Lower back pain (left, right, or bilateral) or flank pain (left, right, or bilateral) are examples of symptoms that can be used as costovertebral angle pain or tenderness. Generalized "low back pain" is not to be interpreted as costovertebral angle pain or tenderness. ➤ Fever and hypothermia are non-specific symptoms of infection and cannot be excluded from UTI determination because they are clinically deemed due to another recognized cause.
--	--

Criterion	Urinary Tract Infection (UTI)
Asymptomatic Bacteremic Urinary Tract Infection (ABUTI) (Any age patient)	
	Patient must meet 1, 2, <u>and</u> 3 below: 1. Patient with* or without an indwelling urinary catheter has <u>no</u> signs or symptoms of SUTI 1 or 2 regardless of age. 2. Patient has a urine culture with no more than two species of organisms identified, at least one of which is a bacterium of $\geq 100,000$ CFU/ml (see Comments below). 3. Patient has recognized pathogen(s) identified** from blood specimen with at least <u>one</u> matching bacterium to the $\geq 100,000$ CFU/ml bacterium identified in the urine specimen OR Patient is eligible to meet LCBI 2 with chills or hypotension (not fever) and common commensal(s) in the blood and urine specimens match. *Patient had an IUC in place for more than two consecutive days in an inpatient location on the date of event, and an IUC was in place on the date of event or the day before. ** Organisms identified by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment (e.g., not Active Surveillance Culture/Testing (ASC/AST)). Note: Catheter-associated ABUTIs are reportable if CAUTI is in the facility's reporting plan for the location.
Comments	Mixed flora cannot be reported as a pathogen for a UTI event. Additionally, "mixed flora" represents at least two species of organisms and cannot be used to meet the NHSN UTI criteria. Any additional organisms recovered from the same culture would be in addition to the mixed flora, meaning there are at least three organisms present making the culture ineligible for use to meet NHSN UTI criteria. Additionally, the following excluded organisms cannot be used to meet the UTI definition: • Any yeast or yeast species • mold • dimorphic fungi or • parasites An acceptable urine specimen may include these excluded organisms if no more than one bacterium with $\geq 100,000$ CFU/ml is also present. Additionally, these non-bacterial organisms identified from blood cannot be deemed secondary to a UTI since they are excluded as organisms in the UTI definition.

Figure 3. Identifying SUTI and ABUTI Flowchart



Monthly Summary Data

Numerator Data: The [Urinary Tract Infection \(UTI\) form \(CDC 57.114\)](#) is used to collect and report each CAUTI that is identified during the month selected for surveillance. The [Instructions for Completion of Urinary Tract Infection form](#) include brief instructions for collection and entry of each data element on the form. The UTI form includes patient demographic information and information on whether an indwelling urinary catheter was present. Additional data include the specific criteria met for identifying the UTI, whether the patient developed a secondary bloodstream infection, whether the patient died, and the organisms isolated from cultures and their antimicrobial susceptibilities.

Reporting Instructions:

If no CAUTIs are identified during the month of surveillance, the “Report No Events” box must be checked on the appropriate denominator summary screen, (for example, [Denominators for Intensive Care Unit \(ICU\)/Other Locations \(Not NICU or SCA/ONC\)](#)).

Denominator Data: Device days and patient days are used for denominators (see [Key Terms](#) chapter). The method of collecting device-day denominator data may differ depending on the location of patients being monitored. The following methods may be used:

Table 2: Denominator Data Collection Methods

Denominator Data Collection Method	Details
Manual, Daily (specifically, collected at the same time every day of the month)	Denominator data (patient days and device days) should be collected at the same time, every day, for each location performing surveillance to ensure that differing collection methods don’t inadvertently result in device days being greater than patient days. The Instructions for Completion of Denominators for Intensive Care Unit (ICU)/Other Locations (Not NICU and SCA/ONC) and Instructions for Completion of Denominators for Specialty Care Areas (SCA)/Oncology (ONC) contain brief instructions for collection and entry of each data element on the form. Indwelling urinary catheter days, which are the number of patients with an indwelling urinary catheter device, are collected daily, at the same time each day, according to the chosen location using the appropriate form (CDC 57.117 and 57.118). These daily counts are summed and only the total for the month is entered into NHSN. Indwelling urinary catheter days and patient days are collected separately for each of the locations monitored.

Denominator Data Collection Method	Details
Manual, sampled once/week (collected at the same time on the same designated day, once per week)	To maximize staff resources on time spent collecting surveillance data, once/week sampling of denominator data to generate estimated urinary catheter days may be used as an alternative to daily collection in non-oncology ICUs and wards (see Notes below). Sampling may not be used in SCA/ONC locations or NICUs. During the month, the number of patients in the location (patient-days) and the number of patients with an indwelling urinary catheter (urinary catheter-days) is collected on a designated day each week (for example, every Tuesday), at the same time each day. Evaluations of this method have repeatedly shown that collecting weekly denominator data on Saturday or Sunday generates the least accurate estimates of denominator data, therefore, Saturday and Sunday should not be selected.⁷⁻⁹ If the designated sampling collection day is missed, collect the data the next available day instead. The following must be collected and entered NHSN: 1. The monthly total for patient-days, collected daily 2. The sampled total patient-days 3. The sampled total urinary catheter-days When these data are entered, the NHSN application will calculate an estimate of urinary catheter-days. Notes: • To ensure the accuracy of estimated denominator data obtained by sampling, only ICUs and ward locations with an average of 75 or more urinary catheter-days per month are eligible to use the sampling method. A review of each location's urinary catheter denominator data for the past 12 months in NHSN will help determine which locations are eligible to use the sampling method. • The accuracy of estimated denominator data generated by sampling can be heavily influenced by incorrect or missing data. Using the guidance in this protocol is essential to avoid erroneous fluctuations in rates or Standardized Infection Ratios (SIRs) when implementing data collection by sampling.

Denominator Data Collection Method	Details
Electronic	For <i>any</i> location, denominator data from electronic sources (for example, urinary catheter days from electronic charting), may be used after validation of a minimum of three consecutive months proves the electronic data to be within 5% (+/-) of the manually-collected, once a day counts. Perform the validation of electronic counts separately for each location conducting CAUTI surveillance. When converting from one electronic counting system to another electronic counting system, the new electronic system should be validated against manual counts as above. If electronic counts for the new electronic system are not within 5% of manual counts, resume manual counting and continue working with IT staff to improve design of electronic denominator data extraction (while reporting manual counts) until concurrent counts are within 5% for 3 consecutive months. Note: This guideline is important because validating a new electronic counting system against an existing electronic system can magnify errors and result in inaccurate denominator counts. • Perform the validation of electronic counts separately for each location conducting CAUTI surveillance.

Data Analyses

All CAUTI data entered into NHSN can be analyzed at event (for example, CAUTI event) or summary level (for example, location or facility level). You can visualize both with descriptive reports (line lists, frequency tables, bar/pie charts, rate tables, and run charts) and with risk-adjusted summary metrics (SIR, SUR).

Before running reports in NHSN, generate data sets. This process freezes your NHSN data at a point in time and copies those data into defined data sets. When you want updates reflected in NHSN reports, regenerate data sets.

Types of CAUTI Analysis Reports

Standardized Infection Ratio (SIR)

The Standardized Infection Ratio (SIR) is a summary metric used to track HAI incidence over time at a national, state, or local level. The SIR adjusts for various facility and/or patient-level factors that contribute to HAI risk within each facility. In HAI data analysis, the SIR compares the observed (numerator) number of HAIs to the number predicted (denominator), given the standard population (i.e., NHSN baseline), adjusting for several risk factors that have been found to be significantly associated with differences in infection incidence. The number of predicted CAUTI events is calculated using negative binomial regression (2015 or 2022 NHSN baselines) to estimate expected counts from facility denominator (i.e., urinary catheter days) and risk-factor data.

For more information on the SIR, exclusion factors and the CAUTI parameter estimates, refer to the appropriate SIR guide:

- 2015 Baseline: <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/nhsn-sir-guide.pdf>
- 2022 Baseline: <https://www.cdc.gov/nhsn/2022rebaseline/sir-guide.pdf>

The SIR is calculated by dividing the number of observed infections by the number of predicted infections.

$$\text{SIR} = \frac{\text{Observed (O) HAIs}}{\text{Predicted (P) HAIs}}$$

A SIR greater than 1.0 indicates that more HAIs were observed than predicted; conversely, a SIR less than 1.0 indicates that fewer HAIs were observed than predicted.

Note: In order to enforce a minimum precision criterion, SIRs are only calculated when the number of predicted infections is at least 1.0. This rule was instituted to avoid the calculation and interpretation of statistically imprecise SIRs, which typically have extreme values.

While the CAUTI SIR can be calculated for single locations, the measure also allows you to summarize your data by multiple locations, adjusting for differences in the incidence of infection among the location types. For example, you will be able to obtain one CAUTI SIR adjusting for all locations reported. Similarly, you can obtain one CAUTI SIR for all ICUs in your facility.

For more information on using the CAUTI SIR reports, please see the troubleshooting guide:

https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/clabscauti_sirtroubleshooting.pdf.

For further information regarding the p-value and 95% confidence interval, please see the guide below:

<https://www.cdc.gov/nhsn/ps-analysis-resources/keys-to-success.html>

Standardized Utilization Ratio (SUR)

The SUR, or Standardized Utilization Ratio is a summary metric used to track device use at a national, state, local, or facility level over time. The SUR adjusts for various facility and/or location-level factors that contribute to device use. The method of calculating an SUR is similar to the method used to calculate the Standardized Infection Ratio (SIR), a summary metric used in NHSN to track HAIs in device-associated HAI data analysis. The SUR compares the observed (numerator) number of device days reported to what would be predicted (denominator), given the standard population (specifically, the NHSN baseline), adjusting for factors that have been found to be significantly associated with differences in device utilization.

More information regarding the CAUTI 2015 and 2022 baseline SUR model and the parameter estimates, refer to:

- <https://www.cdc.gov/nhsn/2015rebaseline/index.html>
- <https://www.cdc.gov/nhsn/2022rebaseline/analysis-resources.html>

The SUR is calculated by dividing the number of observed indwelling-urinary catheter (IUC) days by the number of predicted IUC days.

$$\text{SUR} = \frac{\text{Observed (O) Catheter Days}}{\text{Predicted (P) Catheter Days}}$$

A SUR greater than 1.0 indicates that more device days were observed than predicted; conversely, a SUR less than 1.0 indicates that fewer device days were observed than predicted.

Note: In order to enforce a minimum precision criterion, SURs are only calculated when the number of predicted device-days is at least 1.0.

Rates and Ratios

The CAUTI rate per 1000 urinary catheter days is calculated by dividing the number of CAUTIs by the number of catheter days and multiplying the result by 1000.

$$\text{CAUTI Rate per 1000 IUC Days} = \frac{\text{No. of CAUTI Events}}{\text{No. of IUC Days}} \cdot 1000$$

Device Utilization Ratio (DUR)

The Urinary Catheter Utilization Ratio is calculated by dividing the number of urinary catheter days by the number of patient days.

$$\text{DUR} = \frac{\text{No. of Urinary Catheter Days}}{\text{No. of Patient Days}}$$

These calculations will be performed separately for the different types of ICUs, specialty care areas, and other locations in the institution, except for neonatal locations. DURs are useful for the purposes of tracking device use over shorter periods of time and for internal trend analyses.

Descriptive Analysis

Descriptive analysis output options of numerator and denominator data, such as line listings, frequency tables, and bar and pie charts are available in the NHSN application. SIRs, SURs and CAUTI rates and run charts are also available. Guides on using NHSN analysis features are available at: www.cdc.gov/nhsn/PS-Analysis-resources/reference-guides.html.

NHSN Group Analysis

NHSN Group Users can perform the same analysis as facility level users in NHSN. A few helpful tools in NHSN for groups are listed in the resources below. These tools are guides on how to start and join a Group; how to create a template to request data from facilities; how to determine the level of access granted by the facility following the previous steps, and how to analyze the facilities data.

Group Analysis Resources

- NHSN Group Users Page:
 - <https://www.cdc.gov/nhsn/group-users/index.html>
- Group User's Guide to the Membership Rights Report:
 - <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/GroupAnalysisWebinar.pdf>
- Group User's Guide to the Line Listing- Participation Alerts: <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/group-alerts.pdf>

Data Quality Resources

- Data Quality Website: <https://www.cdc.gov/nhsn/ps-analysis-resources/data-quality/index.html>
- Data Quality Manual: https://www.cdc.gov/nhsn/pdfs/pscmanual/Instructions_DQ.pdf
- Data Quality Training: <https://www.cdc.gov/nhsn/training/analysis/index.html>

Additional Resources

- Analysis Resources:
 - <https://www.cdc.gov/nhsn/ps-analysis-resources/index.html>
- Analysis Reference Guides:
 - <https://www.cdc.gov/nhsn/PS-Analysis-resources/reference-guides.html>
- NHSN Training:
 - <https://www.cdc.gov/nhsn/training/index.html>
- Data Quality Website:
 - <https://www.cdc.gov/nhsn/ps-analysis-resources/data-quality/index.html>

Table 3. CAUTI Measures Available in NHSN

<u>Measure</u>	<u>Calculation</u>	<u>Application</u>
CAUTI SIR	$\frac{\text{Observed (O) HAIs}}{\text{Predicted (P) HAIs}}$	Both location specific and summarized measure
CAUTI Rates*	$\frac{\text{No. of CAUTIs}}{\text{No. IUC Days}} \cdot 1000$	Location specific measure only
Indwelling Urinary Catheter (IUC) SUR*	$\frac{\text{Observed (O) IUC Days}}{\text{Predicted (P) IUC Days}}$	Both location specific and summarized measure
DUR	$\frac{\text{No. of IUC Days}}{\text{No. of Patient Days}}$	Location specific measure only

*Rates do not account for factors that could contribute to differences in risk of CAUTI/device use between facilities and locations. Therefore, comparing rates should be used with caution.

References

¹2023 National and State Healthcare-Associated Infections Progress Report. Centers for Disease Control and Prevention (CDC) website. <https://www.cdc.gov/hai/data/portal/progress-report.html>. Published November 2024. Accessed November 21, 2025.

²McGuckin M. *The patient survival guide: 8 simple solutions to prevent hospital and healthcare-associated infections*. New York, NY: Demos Medical Publishing; 2012.

³Lo E, Nicolle LE, Coffin SE, Gould C, Maragakis LL, Meddings J, et al. Strategies to prevent catheter-associated urinary tract infections in acute care hospitals: 2014 update. *Infection Control and Hospital Epidemiology* 2014; 35:464-79.

⁴Scott R. The Direct Medical Costs of Healthcare-Associated Infections in U.S. Hospitals and the Benefits of Prevention, 2009. Division of Healthcare Quality Promotion, National Center for Preparedness, Detection, and Control of Infectious Diseases, Coordinating Center for Infectious Diseases, Centers for Disease Control and Prevention, February 2009.

⁵Klevens, R., Edward, J., et al. Estimating Healthcare-associated Infections and Deaths in U.S. Hospitals. *Public Health Reports*. 2007;122: 160-166.

⁶Gould, CV., Umscheid, CA., Agarwal, RK., Kuntz, G., Pegues, DA. "Guideline for Prevention of Catheter-associated Urinary Tract Infections". *Infection Control and Hospital Epidemiology*. 2010;31: 319-26.

⁷Klevens, R., et al. Sampling for Collection of Central Line Day Denominators in Surveillance for Healthcare-associated Bloodstream Infections. *Infection Control and Hospital Epidemiology*. 2006;27: 338-42.

⁸Thompson, N., et al. Evaluating the Accuracy of Sampling to Estimate Central Line—Days: Simplification of NHSN Surveillance Methods. *Infection Control and Hospital Epidemiology*. 2013;34(3): 221-228.

⁹See, I., et al. ID Week 2012 (Abstract #1284): Evaluation of Sampling Denominator Data to Estimate Urinary Catheter and Ventilator Days for the NHSN. San Diego, California. October 19, 2012.

Surgical Site Infection Event (SSI)

Table of Contents

Introduction	1
Settings	2
Requirements.....	2
Surveillance Methods	3
Operative Procedure Codes.....	3
Definition of an NHSN Operative Procedure	4
SSI Event Details.....	5
Denominator for Procedure Required Details	7
Table 1. Surgical Site Infection Criteria	11
Table 2. Surveillance Periods for SSI Following Selected NHSN Operative Procedure Categories.....	16
Table 3. Specific Sites of an Organ/Space SSI	17
SSI Event (Numerator) Reporting.....	18
Table 4. NHSN Principal Operative Procedure Category Selection List	24
Denominator for Procedure Reporting.....	25
Data Analyses.....	28
Table 5: Inclusion Criteria of SSI in SIR Models.....	31
Table 6: Universal Exclusion Criteria for NHSN Operative Procedures.....	32
References	34
APPENDIX A.....	35
APPENDIX B.....	42

Introduction:

The CDC healthcare-associated infection (HAI) prevalence survey found that there were an estimated 110,800 surgical site infections (SSIs) associated with inpatient surgeries in 2015¹. Based on the 2024 HAI data results published in the NHSN's HAI Progress Report, no significant changes in the SSI standardized infection ratio (SIR) related to all NHSN operative procedure categories combined compared to the previous year². Additional SSI HAI data can be found in the annual HAI Progress Report².

While advances have been made in infection control practices, including improved operating room ventilation, sterilization methods, barriers, surgical technique, and availability of antimicrobial prophylaxis, SSIs remain a substantial cause of morbidity, prolonged hospitalization, and mortality. It is reported, SSI accounts for 20% of all HAIs and is associated to

a 2-to 11-fold increase in the risk of mortality with 75% of SSI-associated deaths directly attributable to the SSI^{3,4}. SSI is the most costly HAI type with an estimated annual cost of \$3.3 billion, and extends hospital length of stay by 9.7 days, with cost of hospitalization increased by more than \$20,000 per admission^{3,5}.

Surveillance of SSI with feedback of appropriate data to surgeons has been shown to be an important component of strategies to reduce SSI risk⁶⁻⁹. A successful surveillance program includes the use of epidemiologically-sound infection definitions and effective surveillance methods, stratification of SSI rates according to risk factors associated with SSI development, and data feedback^{7,8}. The *CDC and Healthcare Infection Control Practices Advisory Committee Guideline for the Prevention of Surgical Site Infection*, provides evidence-based strategies for SSI prevention⁹. Most recently, the *Strategies to prevent surgical site infections in acute-care hospitals: 2022 Update* was published providing acute-care hospitals with recommendations for SSI prevention¹⁰.

Settings:

Surveillance of surgical patients will occur in any inpatient facility and/or hospital outpatient procedure department (HOPD) where the selected NHSN operative procedure(s) are performed.

Note: Ambulatory Surgery Centers (ASCs) that report to NHSN must use the Outpatient Procedure Component (OPC) to perform SSI surveillance. For purposes of NHSN surveillance and reporting this is defined as any distinct entity that operates exclusively for the purpose of providing surgical services to patients not requiring hospitalization and in which the expected duration of services would not exceed 24 hours following an admission.

Requirements:

- Perform surveillance for SSI following at least one NHSN operative procedure category (using the associated NHSN operative procedure codes) as indicated in the *Patient Safety Monthly Reporting Plan* ([CDC 57.106](#)).
- Collect SSI event (numerator) and operative procedure (denominator) data on all procedures included in the selected operative procedure categories indicated on the facility's Monthly Reporting Plan.
- All procedures included in the NHSN Monthly Reporting Plan are monitored for superficial incisional, deep incisional, and organ/space SSI events and the type of SSI reported must reflect the deepest tissue level where SSI criteria are met during the surveillance period.
- SSI events and the procedures to which they are linked are reported to NHSN regardless of noted evidence of infection at time of surgery.
- An SSI event is attributed to the facility in which the NHSN operative procedure is performed.

Surveillance Methods:

SSI monitoring requires active, patient-based, prospective surveillance. Concurrent and post-discharge surveillance methods should be used to detect SSIs following inpatient and outpatient operative procedures.

These methods include [but are not limited to]:

- Review of medical records or surgery clinic patient records
 - Admission, readmission, ED, and OR logs
 - Patient reported signs and symptoms of SSI
 - Lab, imaging, other diagnostic test reports
 - Clinician/healthcare professional notes
 - ICD-10-CM Infection Diagnosis Codes to prompt further review
- Visit the ICU and wards – talk to primary care staff
- Surgeon surveys by mail or telephone
- Patient surveys by mail or telephone (though patients may have a difficult time assessing their infections).

Any combination of these methods (or other methods identified by the facility) with the capacity to identify all SSIs is acceptable for use; however, NHSN criteria for SSI must be used. To minimize Infection Preventionists' (IPs) workload of collecting denominator data, operative procedure data may be imported. See file specifications at:

<https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/ImportingProcedureData.pdf>.

Operative Procedure Codes:

Operative procedure codes are used in health care settings to communicate uniform information. This wide use of operative procedure codes allows NHSN to incorporate the operative procedure codes to standardize NHSN SSI surveillance reporting. The operative procedure codes are **required** to determine the correct NHSN operative procedure category to be reported. Entering the operative procedure code into the NHSN application remains optional but is recommended.

NHSN uses the following operative procedure coding systems:

- *International Classification of Diseases, 10th Revision Clinical Modifications/Procedure Coding System* (ICD-10-CM/PCS), as defined by the ICD-10 Coordination and Maintenance Committee of the National Center for Health Statistics and the Centers for Medicare and Medicaid Services (CMS).
- *Current Procedural Terminology* (CPT), as defined by the American Medical Association (AMA).

The mapping for [ICD-10-PCS](#) and [CPT](#) NHSN operative procedures is found in the “[Operative Procedure Code Documents](#)” section of the Surgical Site Infection (SSI) Events page on the NHSN website. The mapping documents include a general definition for each NHSN operative procedure category as well as a description for each individual operative procedure code.

Note: For in-plan reporting purposes, only NHSN operative procedures are included in SSI surveillance. An infection associated with a procedure that is not included in one of the NHSN operative procedure categories is not considered an NHSN SSI, although the infection may be investigated as a healthcare-associated infection (HAI). SSI events can only be attributed to NHSN operative procedures.

Definition of an NHSN Operative Procedure:

An NHSN Operative Procedure is a procedure:

- that is included in the [ICD-10-PCS](#) and/or [CPT](#) NHSN operative procedure code mapping
And
- takes place during an operation where at least one incision (including laparoscopic approach and cranial Burr holes) is made through the skin or mucous membrane, or entry is through an existing incision (such as an incision from a prior operative procedure)
And
- takes place in an operating room (OR), defined as a patient care area that met the Facilities Guidelines Institute’s (FGI) or American Institute of Architects’ (AIA) criteria for an operating room when it was constructed or renovated¹¹. This may include an OR, C-section room, interventional radiology room, or a cardiac catheterization lab.

SSI Event Details

The infection window period (IWP), present on admission (POA), healthcare-associated infection (HAI), and repeat infection timeframe (RIT) definitions do not apply to the SSI surveillance. For additional information on the POA designation not applying to SSI surveillance, see SSI Event Reporting Instruction #2. For details related to infection present at time of surgery (PATOS), see SSI Event Reporting Instruction #3.

Surveillance Period for SSI:

The timeframe following an NHSN operative procedure for monitoring and identifying an SSI event. The surveillance period is determined by the NHSN operative procedure category (for example, COLO has a 30-day SSI surveillance period and KPRO has a 90-day SSI surveillance period, see [Table 2](#)). Superficial incisional SSIs are monitored for a 30-day period for all procedure categories. Secondary incisional SSIs are monitored for a 30-day period regardless of the surveillance period for the primary site.

Each trip to the OR for an NHSN operative procedure sets an SSI surveillance period for the surgical site.

- If a patient returns to the OR for an **NHSN operative procedure** and the same surgical space is entered, the surveillance period for the prior NHSN operative procedure ends and a new SSI surveillance period begins at the conclusion of the procedure.
- If within the surveillance period following an NHSN operative procedure a **non-NHSN operative procedure** is performed, and all three tissue levels are entered, the SSI surveillance period for the NHSN operative procedure ends at the conclusion of the non-NHSN operative procedure. The SSI surveillance period continues for the tissue levels not entered during the non-NHSN operative procedure. No new surveillance period is set following a non-NHSN operative procedure.

Date of Event (DOE) for SSI:

For an SSI, the DOE is the date when the first element used to meet the SSI infection criterion occurs for the first time during the SSI surveillance period. The DOE must occur within the SSI surveillance period to meet SSI criteria. The type of SSI (superficial incisional, deep incisional, or organ/space) reported, and the DOE assigned must reflect the deepest tissue level where SSI criteria are met during the surveillance period. Synonym: infection date.

Timeframe for SSI elements:

The Infection Window Period (IWP), Present on Admission (POA), Healthcare-associated Infection (HAI), and Repeat Infection Timeframe (RIT) definitions do not apply to SSI surveillance. SSI surveillance is based on a 30- or 90-day SSI surveillance period, which is determined by the NHSN operative procedure category and the tissue level of SSI event. **SSI guidelines do not offer a strict timeframe for elements of criteria to occur** but historically, all elements used to meet an SSI criterion *generally* occur within a 7-10 day timeframe. To ensure that all elements associate to the SSI, the elements must be relational to one another. Each case differs based on the individual elements occurring and the type of SSI but the DOE for an SSI must occur within the appropriate 30- or 90-day SSI surveillance period.

Secondary BSI Scenarios for SSI:

For a bloodstream infection to be determined secondary to an SSI, one of the following scenarios must be met:

Scenario 1 (All levels of SSI): At least one organism from the blood specimen matches an organism identified from the site-specific specimen that is used as an element to meet the NHSN SSI criterion AND the blood specimen is collected during the secondary BSI attribution period. The secondary BSI attribution period for SSI is a 17-day period that includes the SSI DOE, 3 days prior, and 13 days after.

OR

Scenario 2 (Organ/Space SSI Only): An organism identified in the blood specimen is an element that is used to meet the NHSN Organ/Space SSI site-specific infection criterion and is collected during the timeframe for SSI elements.

For detailed instructions on determining whether identification of organisms from a blood specimen represents a secondary BSI, refer to the Secondary BSI Guide (Table B1 found within the [BSI Event Protocol](#)).

Denominator for Procedure Required Details

Additional guidance can be found within the Instructions for [Completion of Denominator for Procedure Form](#) (CDC 57.121).

ASA physical status:

Assessment by the anesthesiologist of the patient's preoperative physical condition using the American Society of Anesthesiologists' (ASA) Physical Status Classification System¹². Patients are assigned an ASA score of 1-6 at time of surgery. Patients with an ASA score of 1-5 are eligible for NHSN SSI surveillance. Patients that are assigned an ASA score of 6 (a declared brain-dead patient whose organs are being removed for donor purposes) are **not** eligible for NHSN SSI surveillance.

Diabetes:

The NHSN SSI surveillance definition of diabetes indicates that the patient has a diagnosis of diabetes requiring management with insulin or a non-insulin anti-diabetic agent. This includes:

- Patients with "insulin resistance" who are on management with anti-diabetic agents.
- Patients with gestational diabetes.
- Patients who are noncompliant with their diabetes medications.

The ICD-10-CM diagnosis codes that reflect the diagnosis of diabetes are also acceptable for use to answer YES to the diabetes field question on the denominator for procedure entry if the codes are documented during the admission where the procedure is performed. These codes are found on the Surgical Site Infection (SSI) Events page section of the NHSN website under "[Operative Procedure Code Documents](#)".

Some patients may receive diabetic medications for indications other than diabetes. For purposes of NHSN reporting, the Diabetes field = NO, if there is no diagnosis of diabetes.

Duration of operative procedure:

The interval in hours and minutes between the Procedure/Surgery Start Time and the Procedure/Surgery Finish Time, as defined by the Association of Anesthesia Clinical Directors (AACD)¹³:

- Procedure/Surgery Start Time (PST): Time the procedure is begun (for example, incision for a surgical procedure).
- Procedure/Surgery Finish (PF): Time when all instrument and sponge count are completed and verified as correct, all postoperative radiologic studies to be done in the OR are completed, all dressings and drains are secured, and the physicians/surgeons have completed all procedure-related activities on the patient.

Emergency operative procedure:

A procedure that is documented per the facility's protocol to be an Emergency or Urgent procedure.

General anesthesia:

The administration of drugs or gases that enter the general circulation and affect the central nervous system to render the patient pain free, amnesic, unconscious, and often paralyzed with relaxed muscles. This does not include conscious sedation.

Height:

The patient's most recent height documented in the medical record in feet (ft.) and inches (in.), or meters (m).

Outpatient Status:**NHSN Inpatient Operative Procedure**

An NHSN operative procedure performed on a patient whose date of admission to the healthcare facility and the date of discharge are different calendar days.

NHSN Outpatient Operative Procedure

An NHSN operative procedure performed on a patient whose date of admission to the healthcare facility and date of discharge are the same calendar day.

Closure Technique:**Non-primary Closure**

The closure of the surgical wound in a way which leaves the skin level completely open following the surgery. Closure of any portion of the skin represents primary closure (see Primary Closure definition below). For surgeries with non-primary closure, the deep tissue layers may be closed by some means (with the skin level left open), or the deep and superficial layers may both be left completely open. Wounds with non-primary closure may or may not be described as "packed" with gauze or other material, and may or may not be covered with plastic, "wound vacs," or other synthetic devices or materials.

Examples:

- Laparotomy in which the incision was closed to the level of the deep tissue layers, sometimes called "fascial layers" or "deep fascia," but the skin level was left open.
- The abdomen is left completely open after the surgery (an "open abdomen").

Primary Closure

The closure of the skin level during the original surgery, regardless of the presence of wires, wicks, drains, or other devices or objects extruding through the incision. This category includes surgeries where the skin is closed by some means. Thus, if any portion of the incision is closed at the skin level, by any manner, a designation of primary closure should be assigned to the surgery.

Note: When a procedure has multiple incision/laparoscopic trocar sites and any of the incisions are closed primarily then the procedure technique is recorded as primary closed.

Scope:

An instrument used to reach and visualize the site of the operative procedure. In the context of an NHSN operative procedure, use of a scope involves creation of several small incisions to perform or assist in the performance of an operation rather than use of a traditional larger incision (specifically, open approach).

Procedure codes provide a reliable identification of the procedure approach. The fifth character of the ICD-10-PCS codes indicates the approach to reach the procedure site:

ICD-10 5th Character	Approach	NHSN Scope Designation
0	Open	NO
3	Percutaneous (Included only in CRAN and VSHN categories- procedures with BURR holes)	NO
4	Percutaneous endoscopic	YES
7	Via natural or artificial opening	NO
8	Via natural or artificial opening with endoscopic	NO
F	Via natural or artificial opening with percutaneous endoscopic assistance	YES

For CPT codes, the scope question can be answered based on the procedure code description. Using HYST code 58570 as an example, the procedure code description indicates Laparoscopy, surgical, with total hysterectomy. Laparoscopy is **Scope = YES**.

HYST	58570	Laparoscopy, surgical, with total hysterectomy, for uterus 250 g or less
------	-------	--

Note: Scope is reported based on the primary incision site. If an **open and scope** code is assigned to procedures in the same NHSN procedure category, then the procedure should be reported to NHSN as **Scope = NO**. The **open** designation is considered a higher risk procedure.

Trauma:

Blunt or penetrating injury occurring prior to the start of the procedure. Complex trauma cases may require multiple trips to the OR during the same admission to repair the initial trauma. In such cases, Trauma = Yes.

Weight:

The patient's most recent weight documented in the medical record in pounds (lbs.) or kilograms (kg) prior to or otherwise closest to the procedure.

Wound class:

An assessment of the degree of contamination of a surgical wound at the time of the surgical procedure. Wound class is assigned by a person involved in the surgical procedure (for example, surgeon, circulating nurse, etc.) based on the wound class schema that is adopted within each organization [NHSN does not offer guidance on which wound class should be assigned]. The four wound classifications available within the NHSN application are the standard designations endorsed by the Association of periOperative Registered Nurses [[AORN](#)]: Clean (C), Clean-Contaminated (CC), Contaminated (CO), and Dirty/Infected (D).¹⁴

The following operative procedure categories cannot be recorded as clean (C) within the application: APPY, BILI, CHOL, COLO, REC, SB, and VHYS. If a clean (C) wound class was assigned to a procedure in one of these procedure categories, the procedure cannot be included in the denominator for procedure data. The IP should not modify the wound class.

Table 1. Surgical Site Infection Criteria

Criterion	Surgical Site Infection (SSI)
	Superficial incisional SSI Must meet the following criteria:
	Date of event occurs within 30 days following the NHSN operative procedure (where day 1 = the procedure date) AND involves only skin and subcutaneous tissue of the incision AND patient has at least <i>one</i> of the following: - purulent drainage from the superficial incision. - organism(s) identified from an aseptically-obtained specimen from the superficial incision or subcutaneous tissue by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment (for example, not Active Surveillance Culture/Testing [ASC/AST]) - a superficial incision that is deliberately opened, re-accessed or aspirated by a surgeon, physician* or physician designee AND the surgeon, physician*, or physician designee initiates or continues antibiotic or antifungal therapy on or in the two calendar days following the date of deliberate opening, re-access, aspiration with a duration of two calendar days or longer AND patient has at least one of the following signs or symptoms: new or worsening localized pain or tenderness; localized swelling; erythema; or heat - diagnosis of a superficial incisional SSI by a physician* or physician designee * The term physician for the purpose of application of the NHSN SSI criteria may be interpreted to mean a surgeon, infectious disease physician, emergency physician, other physician on the case, or physician's designee (Advanced Practice Nurse [APN], Physician's Assistant [PA]).

	Superficial incisional SSI
Comments	There are two specific types of superficial incisional SSIs: 1. Superficial Incisional Primary (SIP) – a superficial incisional SSI that is identified in the primary incision in a patient that has had an operation with one or more incisions (for example, C-section incision or chest incision for CBGB) 2. Superficial Incisional Secondary (SIS) – a superficial incisional SSI that is identified in the secondary incision in a patient that has had an operation with more than one incision (for example, donor site incision for CBGB) Note: Refer to SSI Event Reporting Instruction #7 for NHSN operative procedure categories with secondary incision sites available for SSI attribution.
Reporting Instructions for Superficial incisional SSI	<u>The following do not qualify as criteria for meeting the NHSN definition of superficial incisional SSI:</u> • Diagnosis/treatment of cellulitis ALONE does not meet superficial incisional SSI criterion 'd'. • A stitch abscess ALONE (minimal inflammation and discharge confined to the points of suture penetration/staple penetration site). • A localized stab wound or pin site infection; depending on the depth, these infections might be considered either an HAI skin (SKIN) or soft tissue (ST) infection. Notes: • For the purpose of NHSN surveillance, the term “incision” refers to the incision made for the primary surgical procedure and the term “stab wound” refers to an incision made at another site, generally to accommodate a drain. For an NHSN operative procedure, a laparoscopic trocar site is considered a surgical incision and not a stab wound. If a surgeon uses a laparoscopic trocar site to place a drain at the end of a procedure this is considered a surgical incision.

	Deep incisional SSI Must meet the following criteria:
	Date of event occurs within 30 or 90 days following the NHSN operative procedure (where day 1 = the procedure date) according to the list in Table 2 AND involves deep soft tissues of the incision (for example, fascial and muscle layers) AND patient has at least <u>one</u> of the following: a. purulent drainage from the deep incision b. organism(s) identified from the deep soft tissues of the incision by a culture- or nonculture- based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment (for example, not Active Surveillance Culture/Testing [ASC/AST]) c. a deep incision that is deliberately opened[†], re-accessed, or aspirated by a surgeon, physician[‡] or physician designee or spontaneously dehisces[¶] AND the surgeon, physician[‡], or physician designee initiates or continues antibiotic or antifungal therapy on or in the two calendar days following the date of deliberate opening, re-access, aspiration or spontaneous dehiscence[¶] with a duration of two calendar days or longer AND patient has at least <u>one</u> of the following signs or symptoms: fever (>38°C); new or worsening localized pain or tenderness d. an abscess, or other evidence of infection involving the deep incision detected on gross anatomical exam, histopathologic exam, or imaging test <i>†Excludes any known multi-part/multi-phase procedures that occur over more than one operative episode [during the same admission] that is documented in the medical record by a surgeon prior to or during the first operative procedure [for example, a plan to return to OR that is documented in the operative narrative of the first procedure would be eligible for use].</i> <i>‡The term physician for the purpose of application of the NHSN SSI criteria may be interpreted to mean a surgeon, infectious disease physician, emergency physician, other physician on the case, or physician's designee (Advanced Practice Nurse [APN], Physician's Assistant [PA]).</i>

	¶ Spontaneous dehiscence is defined as a re-opening of a surgical incision that is not due to external factors such as direct trauma.
Comments	Deep incisional SSI
	There are two specific types of deep incisional SSIs: 1. Deep Incisional Primary (DIP) – a deep incisional SSI that is identified in a primary incision in a patient that has had an operation with one or more incisions (for example, C-section incision or chest incision for CBGB) 2. Deep Incisional Secondary (DIS) – a deep incisional SSI that is identified in the secondary incision in a patient that has had an operation with more than one incision (for example, donor site incision for CBGB) Note: Refer to SSI Event Reporting Instruction #7 for NHSN operative procedure categories with secondary incision sites available for SSI attribution.

	Organ/Space SSI Must meet the following criteria:
	Date of event occurs within 30 or 90 days following the NHSN operative procedure (where day 1 = the procedure date) according to the list in Table 2 AND involves the organ/space tissues (deeper than the fascia/muscle) AND patient has at least <u>one</u> of the following: - purulent drainage from a drain placed into the organ/space (for example, closed suction drainage system, open drain, T-tube drain, CT-guided drainage) - organism(s) identified from fluid or tissue in the organ/space by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment (for example, not Active Surveillance Culture/Testing [ASC/AST]) - an abscess or other evidence of infection involving the organ/space detected on: - gross anatomical exam <u>or</u> - histopathologic exam <u>or</u> - imaging test evidence definitive or equivocal for infection AND meets at least <u>one</u> eligible [per Appendix A] criterion for a specific organ/space infection site listed in Table 3. These criteria are found in the Surveillance Definitions for Specific Types of Infections (Chapter 17).
Comments	Examples of gross anatomic evidence of organ/space infection: - An intraabdominal abscess will require an invasive procedure to actually visualize the abscess. - Visualization of pus or purulent drainage (includes from a drain). - Abdominal, pelvic or uterine pain or tenderness post Cesarean section (CSEC) or hysterectomy (HYST or VHYS) is sufficient gross anatomic evidence of infection without an invasive procedure to meet <u>general Organ/Space SSI criterion 'c'</u> when a Chapter 17 Reproductive Tract Infection criteria is met. Allowing the documentation of abdominal pain or tenderness as gross anatomic evidence of infection to meet general Organ/Space SSI criterion 'c' enables the user to report an SSI-OREP, SSI-EMET or SSI-VCUF event. Abdominal pain or tenderness <u>cannot</u> be applied as 'other evidence of infection on gross anatomic exam' to meet Deep Incisional SSI criterion 'c' or to meet any Chapter 17 site-specific criterion (for example, OREP '2').

Table 2. Surveillance Periods for SSI Following Selected NHSN Operative Procedure Categories. Day 1 = the date of the procedure.

30-day Surveillance			
Category	Operative Procedure	Category	Operative Procedure
AAA	Abdominal aortic aneurysm repair	LAM	Laminectomy
AMP	Limb amputation	LTP	Liver transplant
APPY	Appendix surgery	NECK	Neck surgery
AVSD	Shunt for dialysis	NEPH	Kidney surgery
BILI	Bile duct, liver or pancreatic surgery	OVRV	Ovarian surgery
CEA	Carotid endarterectomy	PRST	Prostate surgery
CHOL	Gallbladder surgery	REC	Rectal surgery
COLO	Colon surgery	SB	Small bowel surgery
CSEC	Cesarean section	SPLE	Spleen surgery
GAST	Gastric surgery	THOR	Thoracic surgery
HTP	Heart transplant	THYR	Thyroid and/or parathyroid surgery
HYST	Abdominal hysterectomy	VHYS	Vaginal hysterectomy
KTP	Kidney transplant	XLAP	Exploratory laparotomy
90-day Surveillance			
Category	Operative Procedure		
BRST	Breast surgery		
CARD	Cardiac surgery		
CBGB	Coronary artery bypass graft with both chest and donor site incisions		
CBGC	Coronary artery bypass graft with chest incision only		
CRAN	Craniotomy		
FUSN	Spinal fusion		
FX	Open reduction of fracture		
HER	Herniorrhaphy		
HPRO	Hip prosthesis		
KPRO	Knee prosthesis		
PACE	Pacemaker surgery		
PVBY	Peripheral vascular bypass surgery		
VSHN	Ventricular shunt		

Notes:

- Superficial incisional SSIs are monitored for a 30-day period for all procedure categories.
- Secondary incisional SSIs are monitored for a 30-day period regardless of the surveillance period for the primary incision site.

Table 3. Specific Sites of an Organ/Space SSI

Category	Specific Site	Category	Specific Site
BONE	Osteomyelitis	MED	Mediastinitis
BRST	Breast abscess or mastitis	MEN	Meningitis or ventriculitis
CARD	Myocarditis or pericarditis	ORAL	Oral cavity infection (mouth, tongue, or gums)
DISC	Disc space infection	OREP	Deep pelvic tissue infection or other infection of the male or female reproductive tract
EAR	Ear, mastoid infection	PJI	Periprosthetic joint infection
EMET	Endometritis	SA	Spinal abscess/infection
ENDO	Endocarditis	SINU	Sinusitis
GIT	Gastrointestinal (GI) tract infection	UR	Upper respiratory tract, pharyngitis, laryngitis, epiglottitis
IAB	Intraabdominal infection, not specified elsewhere	USI	Urinary System Infection
IC	Intracranial infection	VASC	Arterial or venous infection
JNT	Joint or bursa infection	VCUF	Vaginal cuff infection
LUNG	Other infection of the lower respiratory tract		

Criteria for these sites can be found in Chapter 17, [Surveillance Definitions for Specific Types of Infections](#).

[Appendix A](#) contains a complete list of all NHSN operative procedure categories and the corresponding site-specific SSIs that may be attributable to each category.

SSI Event (Numerator) Reporting

Numerator Data:

All patients having any of the procedures included in the selected NHSN operative procedure category(s) are monitored for SSI. The [Surgical Site Infection \(SSI\)](#) form is completed for each SSI. If no SSI events are identified during the surveillance month, check the “Report No Events” field in the Missing PA Events tab of the Incomplete/Missing List in the NHSN application.

The [Instructions for Completion of the Surgical Site Infection Form \(CDC 57.120\)](#) include brief instructions for collection and entry of each data element on the form. The [SSI form](#) includes patient demographic information and specific event details that pertain to the SSI event.

SSI Event Reporting Instructions:

1. **Excluded organisms:** Organisms that primarily cause community-associated infections and are not known to (or rarely) cause healthcare-associated infections or surgical site infections, are excluded and cannot be used to meet any NHSN definition.
 - **Fungi:** *Blastomyces*, *Histoplasma*, *Coccidioides*, *Paracoccidioides*, *Cryptococcus*, *Pneumocystis*
 - **Vector-borne bacteria:** *Anaplasma spp.*, *Ehrlichia spp.*, *Borrelia spp.*, *Rickettsia spp.*In addition, organisms associated with latent infections (for example, herpes, shingles, syphilis, or tuberculosis) are excluded from meeting SSI criteria.
2. **Attributing SSI to an NHSN operative procedure when there is evidence of infection at the time of the primary surgery:** The present on admission (POA) definition does not apply to the SSI protocol. If evidence of infection is present at the time of the procedure and the patient meets SSI criteria within the SSI surveillance period following the procedure, an SSI is attributed to the procedure (for guidance on PATOS determination, see [SSI Event Reporting Instruction #3](#)).
3. **Infection present at time of surgery (PATOS):** PATOS is a YES/NO field found on the SSI event form. PATOS denotes there was evidence of infection visualized (seen) during the surgical procedure to which a subsequent SSI is attributed. The evidence of infection must be noted intraoperatively and documented within the narrative portion of the operative note or report of surgery to be eligible for PATOS (pre/post op diagnoses, ‘indication for surgery’, and other headings routinely included in an operative note are not eligible with answering PATOS).

Key points for consideration:

- a) Only select PATOS = YES when it applies to the depth of the SSI that is being attributed to the procedure. Examples:
 - When a patient has documentation of an intraabdominal infection at time of surgery and then later returns with an organ/space SSI, PATOS = YES.

- When a patient has documentation of an intraabdominal infection at time of surgery and then later returns with a superficial or deep incisional SSI, PATOS = NO.
- b) Examples of verbiage that is considered evidence of infection include but are not limited to: abscess, infection, purulence/pus, phlegmon, osteomyelitis, “feculent peritonitis”, or a sinus tract [for HPRO/KPRO procedures ONLY]. A ruptured appendix is evidence of infection at the organ/space level.
- c) Examples of verbiage that is **not** considered evidence of infection include but are not limited to: colon perforation, contamination, necrosis, gangrene, fecal spillage, nicked bowel during procedure, murky fluid, or documentation of inflammation.
- d) The use of the ending “itis” in an operative note/report of surgery does not automatically meet PATOS, as it may only reflect inflammation which is not infectious in nature (for example, diverticulitis, peritonitis, and appendicitis).
- e) Pathology report findings and imaging test findings cannot be used for PATOS determination.
- f) Identification of an organism using culture or non-culture based microbiologic testing method or on a pathology report from a surgical specimen cannot be used for PATOS determination.
- g) Wound class assignment cannot be used for PATOS determination.
- h) Trauma resulting in a contaminated case does not automatically meet the PATOS requirement. For example, a fresh gunshot wound to the abdomen may be a trauma with a high wound class but there would not be time for infection to develop.
- i) For C-Section [CSEC] procedures ONLY: chorioamnionitis [including suspected chorioamnionitis] documented in the operative narrative is eligible for use for PATOS at the organ/space tissue level.

Examples of PATOS application:

- A patient undergoes an XLAP where there is a finding of a ruptured appendix and an APPY is performed. Two weeks later the patient meets criteria for an organ/space IAB SSI. The PATOS field is selected as YES since a ruptured appendix is noted at time of surgery in the same tissue level as the subsequent SSI.
- During a COLO procedure the surgeon documents multiple abscesses in the intraabdominal cavity. Patient returns three weeks later and meets criteria for a superficial incisional SSI. The PATOS field is selected as NO since there was no documentation of evidence of infection of the superficial tissues at time of the COLO.
- During a CSEC the surgeon nicks the bowel and there is contamination of the intraabdominal cavity. One week later the patient meets criteria for an organ/space

OREP SSI. The PATOS field is selected as NO since there is no documentation of evidence of infection at the time of the CSEC. The colon nick is a complication but there is not infection present at time of surgery.

- Patient undergoes an AMP due to chronic ischemia. The patient returns two weeks later and meets criteria for a deep incisional SSI. The PATOS field is selected as NO since there is not documentation of evidence of infection at time of the AMP. Chronic ischemia is not sufficient for evidence of infection.

Note: For more information about PATOS, see Quick Learn titled [“Surgical Site Infection \(SSI\) Event PATOS – Infection Present at Time of Surgery”](#).

4. **Multiple tissue levels are involved in the infection:** The type of SSI (superficial incisional, deep incisional, or organ/space) reported must reflect the deepest tissue level where SSI criteria are met during the surveillance period. The DOE assigned is the date of the first element used to meet the SSI criteria at the deepest tissue level that is met.
 - Report infection that meets criteria for organ/space SSI as an organ/space SSI, regardless of superficial or deep tissue involvement.
 - Report infection that meets criteria for deep incisional SSI as a deep incisional SSI, regardless of superficial tissue involvement.
 - If a patient meets criteria for a deep incisional SSI on day 10 of the SSI surveillance period and a week later (day 17 of the SSI surveillance period) the patient meets criteria for an organ/space SSI, the DOE assigned is the date of the organ/space SSI.
 5. **Attributing SSI to a NHSN procedure when several are performed on different dates:** Each trip to the OR for an NHSN operative procedure sets an SSI surveillance period. When a patient has several NHSN operative procedures performed on different dates, attribute the SSI to the most recently performed NHSN operative procedure [for which the patient is in an SSI surveillance period for]
- Note:** For multiple NHSN operative procedures performed within a 24-hour period, see Denominator Reporting Instruction #7.
6. **Attributing SSI to NHSN procedures that involve multiple primary incision sites:** When multiple primary incision sites of the same NHSN operative procedure become infected, report as a single SSI, and assign the type of SSI (superficial incisional, deep incisional, or organ/space) that represents the deepest tissue level where SSI criteria are met at any of the involved primary incision sites during the surveillance period. Examples:

- If one laparoscopic incision meets criteria for a superficial incisional SSI and another laparoscopic incision meets criteria for a deep incisional SSI, report one deep incisional SSI.
 - If one or more laparoscopic incision sites meet criteria for superficial incisional SSI but the patient also has an organ/space SSI related to the procedure, report one organ/space SSI.
 - If an operative procedure is limited to a single breast and involves multiple incisions in that breast that become infected, report a single SSI.
 - In a colostomy formation or reversal (take down) procedure, the stoma and other abdominal incision sites are considered primary incisions. If both the stoma and another abdominal incision site develop superficial incisional SSI, report as one SSI (SIP).
7. **Attributing SSI to NHSN operative procedures that have secondary incision sites:** Certain procedures can involve secondary incisions (specifically, BRST, CBGB, CEA, FUSN, PVBY, REC, and VSHN). Secondary incision sites are monitored for Superficial Incisional Secondary (SIS) SSI and Deep Incisional Secondary (DIS) SSI. The surveillance period for all secondary incision sites is 30 days, regardless of the required deep incisional or organ/space SSI surveillance period for the primary incision site(s) ([Table 2](#)). Procedures meeting this designation are reported as one operative procedure, although up to two SSI events can be reported linked to the procedure (a primary incision site SSI and a secondary incision site SSI). For example:
- A saphenous vein harvest incision site in a CBGB procedure is considered the secondary incision site. One CBGB procedure is reported, the saphenous vein harvest site is monitored for 30 days following surgery for SSI, and the chest incision is monitored for 90 days following surgery for SSI. If the patient meets criteria for an SSI at the saphenous vein harvest site (such as a superficial incisional SSI) and meets criteria for an SSI at the chest site (such as a deep incisional SSI) two SSIs are reported and linked to the CBGB procedure.
 - A tissue harvest site (for example, Transverse Rectus Abdominis Myocutaneous [TRAM] flap) in a BRST procedure is considered the secondary incision site. One BRST procedure is reported, and if the secondary incision site becomes infected, report as either SIS or DIS as appropriate.
8. **SSI detected at another facility:** An SSI event is reported by the facility where the NHSN operative procedure was performed. When a potential SSI is detected at a facility other than the one where the procedure was performed, enough detail is provided to the reporting facility in the event an SSI should be reported to NHSN. If an SSI is determined, the reporting facility should indicate **Detected = RO** (patient readmission to a facility

other than where procedure was performed) on the SSI event form when reporting the SSI.

9. **SSI attribution after multiple categories of NHSN procedures are performed during a single trip to the OR:** When more than one NHSN operative procedure category is performed through a single incision/laparoscopic site(s) during a single trip to the operating room, attribute the SSI to the procedure associated to the infection. When attribution is not clear, use the NHSN Principal Operative Procedure Category Selection Lists ([Table 4](#)) to select the operative procedure to which the SSI should be attributed. For example, when a patient meets criteria for an SSI after a single trip to the OR in which both a COLO and SB were performed, and the source of the SSI is not apparent, assign the SSI to the COLO procedure per [Table 4](#).

The final decision for **SSI attribution lies with the local facility based on the full details of the case as documented in the medical record**. It is critical that documentation is included which supports the SSI attribution.

10. **SSI following invasive manipulation or accessions of the operative site:** An SSI will **NOT** be attributed when the following 3 criteria are ALL met:

- during the post-operative period there is no suspicion or evidence of infection related to the surgical site/space.
And
- an invasive manipulation or accessions of the site/space is performed for diagnostic or therapeutic purposes (for example, needle aspiration, accessions of ventricular shunts, accessions of breast expanders).
And
- an infection subsequently develops in a tissue level which was entered during the manipulation/accessions.

Notes:

- Suspicion or evidence of infection may include signs and symptoms of infection (for example, fever or pain) depending on the site of the procedure.
- Tissue levels not manipulated/accessed are still eligible for SSI. For example, a superficial debridement following a COLO procedure, where the muscle/fascia and organ/space is not entered, a subsequent deep incisional or organ/space SSI following the debridement may be an SSI attributable to the COLO procedure.
- This reporting instruction does NOT apply to closed manipulation (for example, closed reduction of a dislocated hip after an orthopedic procedure).

- Invasive manipulation does not include wound packing or changing of wound packing materials as part of postoperative care.
- Routine flushing of catheters as part of the facility's standard care and maintenance is not considered invasive manipulation.
- Each trip to the OR for an NHSN operative procedure sets an SSI surveillance period for the surgical site.

11. Reporting instructions for post-operative infection scenarios: An SSI should be reported to NHSN without regard to post-operative accidents, falls, inappropriate showering or bathing practices, or other occurrences that may or may not be attributable to patients' intentional or unintentional postoperative actions. An SSI should also be reported regardless of the presence of certain skin conditions (for example, dermatitis, blister, impetigo) noted near an incision, and regardless of the possible occurrence of a "seeding" event from an unrelated procedure (for example, dental work). This instruction concerning various postoperative circumstances is necessary to reduce subjectivity and data collection burden.

Table 4. NHSN Principal Operative Procedure Category Selection List

(The categories with the highest risk of SSI are listed before those with lower risks.)

Priority	Category	Abdominal Operative Procedures
1	LTP	Liver transplant
2	COLO	Colon surgery
3	BILI	Bile duct, liver or pancreatic surgery
4	SB	Small bowel surgery
5	REC	Rectal surgery
6	KTP	Kidney transplant
7	GAST	Gastric surgery
8	AAA	Abdominal aortic aneurysm repair
9	HYST	Abdominal hysterectomy
10	CSEC	Cesarean section
11	XLAP	Laparotomy
12	APPY	Appendix surgery
13	HER	Herniorrhaphy
14	NEPH	Kidney surgery
15	VHYS	Vaginal hysterectomy
16	SPLE	Spleen surgery
17	CHOL	Gall bladder surgery
18	OVRY	Ovarian surgery
Priority	Category	Thoracic Operative Procedures
1	HTP	Heart transplant
2	CBGB	Coronary artery bypass graft with donor incision(s)
3	CBGC	Coronary artery bypass graft, chest incision only
4	CARD	Cardiac surgery
5	THOR	Thoracic surgery
Priority	Category	Neurosurgical (Brain/Spine) Operative Procedures
1	VSHN	Ventricular shunt
2	CRAN	Craniotomy
3	FUSN	Spinal fusion
4	LAM	Laminectomy
Priority	Category	Neck Operative Procedures
1	NECK	Neck surgery
2	THYR	Thyroid and or parathyroid surgery

Denominator for Procedure Reporting

Denominator Data:

Denominator data are collected for each individual NHSN operative procedure category selected for monitoring on the [Patient Safety Monthly Reporting Plan](#). For all patients having any of the procedures included in the NHSN operative procedure category(s) for which SSI surveillance is being performed during the month, complete the [Denominator for Procedure](#) form. An operative procedure code (ICD-10-PCS and/or CPT) is required to determine the correct NHSN operative procedure category to be reported. The [Instructions for Completion of the Denominator for Procedure Form \(57.121\)](#) include brief instructions for collection and entry of each data element on the form.

Denominator Reporting Instructions:

1. **Different operative procedure categories performed during same trip to the OR:** When procedures in more than one NHSN operative procedure category are performed during the same trip to the operating room through the same or different incisions, a [Denominator for Procedure](#) form is completed for each NHSN operative procedure category being monitored in the Monthly Reporting Plan.

For example:

- If a CARD and CBGC are performed through the same incision during the same trip to the operating room, and both procedures are monitored in the Monthly Reporting Plan, complete a [Denominator for Procedure](#) form for each procedure.
- If following a motor vehicle accident, a patient has an FX and SPLE performed during the same trip to the operating room, and both procedures are monitored in the Monthly Reporting Plan, complete a [Denominator for Procedure](#) form for each procedure.

EXCEPTION: If a patient has both a CBGC and CBGB during the same trip to the operating room, report only as a CBGB. Only report as a CBGC if there is only a chest incision. CBGB and CBGC are never reported for the same patient for the same trip to the operating room.

2. **Duration of the operative procedures when more than one category of NHSN operative procedure is performed through the same incision:** If more than one NHSN operative procedure category is performed through the same incision during the same trip to the OR, record the combined duration of all procedures, which is the time from procedure/surgery start time to procedure/surgery finish time. For example, if a CBGC and a CARD are performed on a patient during the same trip to the operating room, the time from start time to finish time is reported for both operative procedures.

3. **Duration of operative procedures if patient has two different NHSN operative procedures performed via separate incisions on the same trip to the OR:** Try to determine the correct duration for each separate procedure (if this is documented); otherwise, take the time for both procedures and split it evenly between the two. For example, if an AMP and SPLE are performed during the same trip to the OR.
4. **Same operative procedure category but different ICD-10-PCS or CPT codes during same trip to the OR:** If procedures of different ICD-10-PCS or CPT codes from the same NHSN operative procedure category are performed through the same incision/laparoscopic sites, record one procedure for that category. For example, a facility is performing surveillance for CARD procedures and a patient undergoes a replacement of both the mitral and tricuspid valves during the same trip to the operating room (two CARD procedure codes are assigned). Complete one CARD [Denominator for Procedure](#) form because both procedures are in the same operative procedure category (CARD).
5. **For revision HPRO and KPRO procedures:** If total or partial revision HPRO or KPRO is performed, determine if any of the ICD-10-PCS/CM diagnosis or procedure codes indicating infection (see link below) were assigned to the index joint in the 90 days prior to and including the index HPRO or KPRO revision. If any of the specified codes are assigned to the procedure, indicate on the [Denominator for Procedure](#) form that the revision was associated with 'prior infection at index joint' = YES. The 'prior infection at index joint' variable only applies to *revision* HPRO and KPRO. The cases designated 'prior infection at index joint' = YES should be validated before the procedure is submitted to NHSN. This validation is necessary to ensure the code is aligned with the index joint revision. The ICD-10-PCS/CM code mapping guidance is found on the NHSN website in the SSI section under "[Operative Procedure Code Documents](#)."
6. **Same NHSN operative procedure category via separate incisions:** For operative procedures that can be performed via separate incisions during same trip to the operating room (specifically the following, AMP, BRST, CEA, FUSN, FX, HER, HPRO, KPRO, LAM, NEPH, OVRY, PVBY), separate [Denominator for Procedure](#) forms are completed. To document the duration of the procedures, indicate the procedure/surgery start time to procedure/surgery finish time for each procedure separately or, alternatively, take the total time for the procedures and split it evenly between procedures. [Appendix B](#) provides guidance for the 12 NHSN operative procedure categories that can have multiple procedures reported per category per patient per calendar day.

Notes:

- A COLO procedure with a colostomy formation is considered one COLO procedure with multiple primary incision sites.
- Laparoscopic hernia repairs are considered one HER procedure, regardless of the number of hernias repaired in a trip to the OR. In most cases there will be only one incision time documented for this procedure. If more than one time is documented, total the durations. Open (specifically, non-laparoscopic) hernia repairs are reported as one

HER procedure for each hernia repaired via a separate incision, (specifically, if two incisions are made to repair two defects, then two HER procedures are reported). It is anticipated that separate incision times will be recorded for these procedures. If not, take the total time for both procedures and split it evenly between the two.

7. More than one operative procedure through same incision/surgical space within 24 hours:

When a patient has more than one operative procedure via the same incision or into the same surgical space and the second procedure start time is within 24 hours of the first procedure finish time, report one [Denominator for Procedure](#) form for the original procedure, combining the durations for both procedures based on the procedure start times and finish times for both procedures.

- For example, a patient has a CBGB lasting 4 hours and returns to the OR six hours later for another operative procedure via the same incision (for example, CARD). The second operation has duration of 1.5 hours. Record the operative procedure as one CBGB and the duration of operation as 5 hour 30 minutes. If the wound class has changed, report the higher wound class. Do not report the CARD procedure in your denominator data.

Notes:

- If the first procedure is **not** an NHSN operative procedure, this guidance does not apply.
- If the second procedure is **not** an NHSN operative procedure, this guidance does still apply
- When the patient returns to the OR within 24 hours of the end of the first procedure assign the surgical wound closure technique that applies when the patient leaves the OR from the first operative procedure.
- If the ASA class has changed in the second procedure, report the higher ASA class.
- The surveillance period for the procedure reported begins at the completion of the second procedure.

8. Patient expires in the OR: If a patient expires in the operating room, do not complete a [Denominator for Procedure](#) form. This operative procedure is excluded from the denominator.

9. HYST or VHYS: For the purpose of NHSN SSI reporting, hysterectomy procedure codes that involve an incision made into the abdomen, including trocar insertion, are listed in the abdominal hysterectomy (HYST) category. The correct CPT hysterectomy procedure codes should be assigned by a medical record coder using current guidelines and conventions. Hysterectomy procedures should be designated as a HYST or VHYS, based on the approach of the procedure (5th character of the ICD-10 operative procedure code) the facility's medical coder assigns to the hysterectomy procedure.

Procedure	ICD-10 5 th Character	Approach
HYST	0	Open
	4	Percutaneous endoscopic
	F	Via natural or artificial opening with percutaneous endoscopic assistance
VHYS	7	Via natural or artificial opening
	8	Via natural or artificial opening with endoscopic

Data Analyses

Once procedure (denominator) and SSI (numerator) data are collected and entered into NHSN, the data can be analyzed/visualized in various ways including with descriptive analysis reports and standardized infection ratio (SIR) reports.

Types of SSI Analyses Reports

Descriptive analysis reports

Descriptive analysis report options, such as line listings, frequency tables, and bar and pie charts are available for numerator and denominator data.

Line lists, frequency tables, and rate tables are also available to analyze pathogens and antimicrobial susceptibility data reported for each SSI. See the NHSN Analysis website for quick reference guides on how to access, generate and interpret SSI data using any of these report types: <https://www.cdc.gov/nhsn/ps-analysis-resources/reference-guides.html>

SSI Basic Rate Index Reports

SSI rates per 100 operative procedures are calculated by dividing the number of SSIs by the number of operative procedures and multiplying the results by 100. SSIs will be included in the numerator of a rate based on the date of procedure, not the date of event (DOE), because the procedure bears the risk for infection. SSI rate calculations can be performed separately for the different types of operative procedures and stratified by the basic risk index using the Rate Table reports located in the SSI subfolder of the All Procedure-Associated Events folder in the HAI Detailed Reports (Line List, Rate Tables, etc.) folder in the Analysis Reports feature of the NHSN application. The universal exclusion criteria and SIR inclusion criteria do not apply in the calculation of the SSI rate. The SSI rate includes PATOS events and outpatient procedures but excludes procedures with non-primary closure techniques. Additional information regarding the basic risk index calculation can be found in the paper:

<https://www.cdc.gov/nhsn/pdfs/datastat/2009NHSNReport.pdf>

SSI SIR Reports

The SIR is calculated by dividing the number of observed infections by the number of predicted infections. The SIR will be calculated only if the number of predicted HAIs (“numPred” in the NHSN application) is ≥ 1 to help enforce a minimum precision criterion.

$$SIR = \frac{\text{Observed (O)HAIs}}{\text{Predicted (P)HAIs}}$$

The number of predicted infections is calculated using SSI probabilities estimated from multivariate logistic regression models constructed from NHSN data during a baseline time period, which represents a standard population’s SSI experience. There are three NHSN baseline periods, 2006-2008, 2015 and 2022 baselines. For the 2 more recent baselines, the procedures/SSI occurring in adults are modeled separately from those occurring in pediatrics. Also, the procedures/SSI occurring in inpatient setting are modeled separate from those occurring in hospital outpatient procedure department (HOPD) setting.

The SSI SIR can be generated for individual procedures for different summary time periods. While the SSI SIR can be calculated for single procedure categories and for specific surgeons, the measure also allows you to summarize your data across multiple procedure categories while adjusting for differences in the estimated probability of infection among the patients included across the procedure categories. For example, you will be able to obtain one SSI SIR adjusting for all procedures reported. Alternatively, you can obtain one SSI SIR for a single procedure category such as colon surgery only within your facility.

Additional Notes about SSI SIRs

Inclusion Notes	Original Baseline for SSI SIR 2006-2008 (Baseline Set 1 or BS1)	2015 Baseline (Baseline Set 2 or BS2) 2022 Baseline (Baseline Set 3 or BS3)
Closure technique	SIR calculation includes only procedures reported with a primary closure (PRI) method	SIR calculation includes procedures with either primary (PRI) and non-primary closure (OTH) methods
Infection present at time of infection (PATOS)	SIR calculation <u>includes</u> PATOS events and associated procedure	SIR calculation <u>excludes</u> PATOS events and associated procedure

SSI SIR Models and Reports

There are three main SSI SIR Models available from NHSN, each briefly described in the table below. SSIs are included in the numerator of an SIR based on the date of procedure, not the date of event. This is because the procedure carries the risk for the infection/SSI.

The first two models, the All-SSI SIR and the Complex A/R SSI SIR models, are available for all NHSN operative procedures/SSI occurring in both adults and pediatric patients, while the third model, the Complex 30-day SSI SIR is available for colon and abdominal hysterectomy procedures/SSI occurring in adults only. Please see the NHSN SIR Guide for more model specific information:

For the 2015 baseline model details: <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/nhsn-sir-guide.pdf>

For the 2022 baseline model details: <https://www.cdc.gov/nhsn/2022rebaseline/sir-guide.pdf>

Table 5: Inclusion Criteria of SSI in SIR Models

All SSI SIR Model	- Includes separate models for inpatient and hospital outpatient procedures (under the 2015 baseline) - Includes Superficial, Deep & Organ/Space SSIs - Superficial & Deep incisional SSIs limited to primary incisional SSIs only - Includes SSIs identified on admission, readmission & via post-discharge surveillance - Separate models for patient population (pediatric data is separated from adult data)
Complex A/R SSI Model	- Includes <u>only</u> Deep incisional primary SSIs & Organ/Space SSIs - Includes <u>only</u> SSIs identified on Admission/Readmission to facility where procedure was originally performed - Includes <u>only</u> inpatient procedures - Used for the HAI Progress Report, published annually by CDC - Separate models for patient population (pediatric data is separated from adult data)
Complex 30-day SSI model (used for CMS IPPS)	- Includes only in-plan, inpatient COLO and HYST procedures in adult patients (specifically, ≥ 18 years of age) - Includes only deep incisional primary SSIs and organ/space SSIs with an event date within 30 days of the procedure - Includes SSIs identified on admission, readmission & via post-discharge surveillance - Used only for CMS IPPS reporting and for public reporting on Hospital Compare - Details of the SSI SIR models can be found in the SSI section of the SIR Guide: https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/nhsn-sir-guide.pdf

For more information on how to generate a line listing report to determine SSI inclusion criteria, please see the quick reference guide: <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/ssi-events-line-list-qrg.pdf>

In addition to the SSI inclusion criteria listed above, there are a set of universal exclusion criteria that are applied to all procedures and associated events prior to the SIR calculation. Any procedure that meets any of the exclusion criteria is universally excluded from any SSI SIR calculation. The “Line List of Procedures Excluded from the SIR” is an NHSN analysis report that is intended to assist users in reviewing the procedures that are excluded from the SIRs and the reasons for the exclusion. Please refer to this quick reference guide, <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/line-list-procedures-excluded-sir.pdf> to generate and interpret this report. This list of universal exclusion criteria, also called the universal exclusion criteria, applies to procedures regardless of the SSI model. Often, the reason for procedure exclusion from SIRs is due to data quality issues, which can be addressed, if applicable.

Table 6: Universal Exclusion Criteria for NHSN Operative Procedures

Universal Exclusion Criteria Variables	Definition of Variables
exclMissingVarInd	Procedure is excluded for missing risk factors used in risk adjustment of applicable procedure category for SSI models
exclMissingVarList	List of missing risk factors used in risk adjustment of applicable procedure category for SSI models
exclDurThresholdInd	Procedure excluded due to procedure duration being less than 5 minutes or exceeding the IQR5 value. Please see the list of procedure duration cutoff points in the SSI section of the SIR Guide: https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/nhsn-sir-guide.pdf
exclAgeGT109Ind	Procedure is excluded if the patient's age at time of procedure is 109 years or older
exclOutpatientInd	Procedure excluded because it was reported as an outpatient procedure; Note: all outpatient procedures are excluded from the inpatient SSI SIRs calculated using the 2015 baseline. There is separate SIR reports for procedures performed in Hospital Outpatient Procedure Departments (HOPD).
exclPedIndcmpx30d	Procedures performed in pediatric patients are excluded from the Complex 30-day model
exclSexInd	Procedure excluded because sex was missing or not reported
exclInvalidJointRepHemi	Procedure is excluded if procedure code is KPRO or HPRO and (procedure type is a hemi joint replacement reported as a total revision or a total joint replacement reported as a partial revision) and procedure date is January 1, 2015-December 31, 2015.
exclBMIThresholdInd	Procedure is excluded if the adult patient's BMI is less than 12 or greater than 60. In pediatric patients < 18 years procedure is excluded if the biological plausibility value (BIV) for BMI is extreme based on the child's weight, height, sex, and age. The calculation of the BIV for BMI in pediatric patients is described in CDC's Growth Chart Training*. For instructions on how to enter height and weight on denominator form, please see: https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/Reporting-Height-and-Weight-for-Procedures-508.pdf

*This BMI exclusion applies to all procedures on pediatric patients 2 years and older and less than 18, in both applicable SSI models (All SSI and Complex A/R). CDC Growth Charts are used to assess BMI in pediatric patients, calculated using height, weight, age and sex. More information can be found here: <https://www.cdc.gov/nccdphp/dnpao/growthcharts/resources/sas.htm>. Pediatric procedures with a calculated biological plausibility value of not equal to 0, is excluded from the SSI SIR.

NHSN Group Analysis:

NHSN Group Users can perform the same analysis as facility level users in NHSN. A few helpful tools in NHSN for groups are listed in the resources below. These tools are guides on how to start and join a Group; how to create a template to request data from facilities; how to determine the level of access granted by the facility following the previous steps, and how to analyze the facilities data.

Group Analysis Resources:

- NHSN Group Users weblink: <https://www.cdc.gov/nhsn/group-users/index.html>
- Group User's Guide to the Membership Rights Report:
 - <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/membership-rights-508.pdf>
- Group User's Guide to the Line Listing- Participation Alerts:
 - <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/group-alerts.pdf>
- Group User's Guide to Generating Participation Alerts
 - <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/participationalerts-dataset-508.pdf>
 - <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/group-alerts.pdf>

Additional Resources:

- Analysis Resources:
 - <https://www.cdc.gov/nhsn/ps-analysis-resources/index.html>
 - <https://www.cdc.gov/nhsn/PS-Analysis-resources/reference-guides.html>
- NHSN Training: <https://www.cdc.gov/nhsn/training/index.html>

References

- ¹Magill, SS, O'Leary, E, Janelle, SJ, et al., "Changes in Prevalence of Health Care-Associated Infection in U.S. Hospitals". *N Engl J Med*, 379(18): (2018): 1732-44.
- ²CDC National and State Healthcare-Associated Infections Progress Report, published December 2025, available from: https://www.cdc.gov/healthcare-associated-infections/php/data/progress-report.html?CDC_AAref_Val=https://www.cdc.gov/hai/data/portal/progress-report.html#cdc_report_pub_study_section_2-2022-hai-progress-report
- ³Ban, KA, Minei JP, Laronga C, et al., "American College of Surgeons and Surgical Infection Society: Surgical Site Infection Guidelines, 2016 Update". *J Am Coll Surg*, 224(1): (2017): 59-74.
- ⁴Awad, SS, "Adherence to surgical care improvement project measures and post-operative surgical site infections". *Surgical Infect (Larchmt)*, 13(4): (2012): 234-7.
- ⁵Zimlichman, E, Henderson D, Tamir O, et al., "Health care-associated infections. a meta-analysis of costs and financial impact on the US health care system". *JAMA Intern Med*, 173(22): (2013): 2039-46.
- ⁶Condon, RE, Schulte WJ, Malangoni MA, et al., "Effectiveness of a surgical wound surveillance program". *Arch Surg*, 118(3): (1983): 303-7.
- ⁷Consensus paper on the surveillance of surgical wound infections. The Society for Hospital Epidemiology of America; The Association for Practitioners in Infection Control; The Centers for Disease Control; The Surgical Infection Society. *Infect Control Hosp Epidemiol*, 13(10): (1992): 599-605.
- ⁸Haley, RW, Culver, DH, White, JW, et al., "The efficacy of infection surveillance and control programs in preventing nosocomial infections in US hospitals". *Am J Epidemiol*, 121(2): (1985):182-205.
- ⁹Berríos-Torres, SI, Umscheid CA, Bratzler DW, et al. "Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection". *JAMA Surg*, 152(8): (2017):784-91.
- ¹⁰Calderwood, MS, Anderson, DJ, Bratzler, DW, et al. "Strategies to prevent surgical site infections in acute-care hospitals: 2022 Update". *Infection Control & Hospital Epidemiology*, 44: (2023):695–720.
- ¹¹The Facility Guidelines Institute, Guidelines for Design and Construction of Hospitals. 2022, St. Louis, MO: Facility Guidelines Institute.
- ¹²American Society of Anesthesiologists. *ASA Physical Status Classification System*. Available from: <https://www.asahq.org/standards-and-practice-parameters/statement-on-asa-physical-status-classification-system>.
- ¹³Donham, RT, Mazzei WJ, and Jones RL, "Association of Anesthesia Clinical Directors' Procedure Times Glossary". *Am J Anesthesiol*, 23(5S): (1996):S1-S12.
- ¹⁴Herman TF, Bordon B. Wound classification. StatPearls. April 24, 2023. Accessed October 21, 2025. <https://www.ncbi.nlm.nih.gov/books/NBK554456/>

APPENDIX A

Specific event types available for SSI attribution by NHSN procedure category

Operative Procedure Category	Specific Event Type
AAA - Abdominal aortic aneurysm repair	DIP - Deep Incisional Primary ENDO - Endocarditis GIT - Gastrointestinal tract IAB - Intraabdominal, not specified elsewhere SIP - Superficial Incisional Primary VASC - Arterial or venous infection
AMP - Limb amputation	BONE - Osteomyelitis DIP - Deep Incisional Primary JNT - Joint or bursa SIP - Superficial Incisional Primary
APPY - Appendix surgery	DIP - Deep Incisional Primary GIT - Gastrointestinal tract IAB - Intraabdominal, not specified elsewhere SIP - Superficial Incisional Primary
AVSD - AV shunt for dialysis	DIP - Deep Incisional Primary SIP - Superficial Incisional Primary VASC - Arterial or venous infection
BILI - Bile duct, liver or pancreatic surgery	DIP - Deep Incisional Primary GIT - Gastrointestinal tract IAB - Intraabdominal, not specified elsewhere SIP - Superficial Incisional Primary
BRST - Breast surgery	BRST - Breast abscess or mastitis DIP - Deep Incisional Primary DIS - Deep Incisional Secondary SIP - Superficial Incisional Primary SIS - Superficial Incisional Secondary
CARD - Cardiac surgery	BONE - Osteomyelitis CARD - Myocarditis or pericarditis DIP - Deep Incisional Primary ENDO - Endocarditis IAB - Intraabdominal, not specified elsewhere LUNG - Other infections of the lower respiratory tract MED - Mediastinitis SIP - Superficial Incisional Primary VASC - Arterial or venous infection

Operative Procedure Category	Specific Event Type
CBGB - Coronary bypass with chest & donor incisions	BONE - Osteomyelitis CARD - Myocarditis or pericarditis DIP - Deep Incisional Primary DIS - Deep Incisional Secondary ENDO - Endocarditis IAB - Intraabdominal, not specified elsewhere LUNG - Other infections of the lower respiratory tract MED - Mediastinitis SIP - Superficial Incisional Primary SIS - Superficial Incisional Secondary VASC - Arterial or venous infection
CBGC - Coronary bypass graft with chest incision	BONE - Osteomyelitis CARD - Myocarditis or pericarditis DIP - Deep Incisional Primary ENDO - Endocarditis IAB - Intraabdominal, not specified elsewhere LUNG - Other infections of the lower respiratory tract MED - Mediastinitis SIP - Superficial Incisional Primary VASC - Arterial or venous infection
CEA - Carotid endarterectomy	DIP - Deep Incisional Primary DIS - Deep Incisional Secondary SIP - Superficial Incisional Primary SIS - Superficial Incisional Secondary VASC - Arterial or venous infection
CHOL - Gallbladder surgery	DIP - Deep Incisional Primary GIT - Gastrointestinal tract IAB - Intraabdominal, not specified elsewhere SIP - Superficial Incisional Primary
COLO - Colon surgery	DIP - Deep Incisional Primary GIT - Gastrointestinal tract IAB - Intraabdominal, not specified elsewhere OREP - Deep pelvic tissue infection or other infection of the male or female reproductive tract SIP - Superficial Incisional Primary USI - Urinary System Infection

Operative Procedure Category	Specific Event Type
CRAN - Craniotomy	BONE - Osteomyelitis DIP - Deep Incisional Primary IC - Intracranial infection MEN - Meningitis or ventriculitis SINU - Sinusitis SIP - Superficial Incisional Primary
CSEC - Cesarean section	DIP - Deep Incisional Primary EMET - Endometritis GIT - Gastrointestinal tract IAB - Intraabdominal, not specified elsewhere OREP - Deep pelvic tissue infection or other infection of the male or female reproductive tract SIP - Superficial Incisional Primary USI - Urinary System Infection
FUSN - Spinal fusion	BONE - Osteomyelitis DIP - Deep Incisional Primary DIS - Deep Incisional Secondary DISC - Disc space infection IAB - Intraabdominal, not specified elsewhere IC - Intracranial infection LUNG - Other infections of the lower respiratory tract MEN - Meningitis or ventriculitis SA - Spinal abscess/infection SIP - Superficial Incisional Primary SIS - Superficial Incisional Secondary
FX - Open reduction of fracture	BONE - Osteomyelitis DIP - Deep Incisional Primary JNT - Joint or bursa SIP - Superficial Incisional Primary
GAST - Gastric surgery	DIP - Deep Incisional Primary GIT - Gastrointestinal tract IAB - Intraabdominal, not specified elsewhere LUNG - Other infections of the lower respiratory tract SIP - Superficial Incisional Primary
HER - Herniorrhaphy	DIP - Deep Incisional Primary IAB - Intraabdominal, not specified elsewhere SIP - Superficial Incisional Primary

Operative Procedure Category	Specific Event Type
HPRO - Hip prosthesis	BONE - Osteomyelitis DIP - Deep Incisional Primary PJI - Periprosthetic joint infection SIP - Superficial Incisional Primary
HTP - Heart transplant	BONE - Osteomyelitis CARD - Myocarditis or pericarditis DIP - Deep Incisional Primary ENDO - Endocarditis IAB - Intraabdominal, not specified elsewhere LUNG - Other infections of the lower respiratory tract MED - Mediastinitis SIP - Superficial Incisional Primary VASC - Arterial or venous infection
HYST - Abdominal hysterectomy	DIP - Deep Incisional Primary IAB - Intraabdominal, not specified elsewhere OREP - Deep pelvic tissue infection or other infection of the male or female reproductive tract SIP - Superficial Incisional Primary VCUF - Vaginal cuff infection
KPRO - Knee prosthesis	BONE - Osteomyelitis DIP - Deep Incisional Primary PJI - Periprosthetic joint infection SIP - Superficial Incisional Primary
KTP - Kidney transplant	DIP - Deep Incisional Primary IAB - Intraabdominal, not specified elsewhere OREP - Deep pelvic tissue infection or other infection of the male or female reproductive tract SIP - Superficial Incisional Primary USI - Urinary System Infection VASC - Arterial or venous infection
LAM - Laminectomy	BONE - Osteomyelitis DIP - Deep Incisional Primary DISC - Disc space infection IAB - Intraabdominal, not specified elsewhere IC - Intracranial infection MEN - Meningitis or ventriculitis SA - Spinal abscess/infection SIP - Superficial Incisional Primary

Operative Procedure Category	Specific Event Type
LTP - Liver transplant	DIP - Deep Incisional Primary GIT - Gastrointestinal tract IAB - Intraabdominal, not specified elsewhere SIP - Superficial Incisional Primary VASC - Arterial or venous infection
NECK - Neck surgery	DIP - Deep Incisional Primary EAR - Ear, mastoid infection ORAL - Oral cavity infection (mouth, tongue, or gums) SIP - Superficial Incisional Primary UR - Upper respiratory tract infection, pharyngitis, laryngitis, epiglottitis
NEPH - Kidney surgery	DIP - Deep Incisional Primary IAB - Intraabdominal, not specified elsewhere OREP - Deep pelvic tissue infection or other infection of the male or female reproductive tract SIP - Superficial Incisional Primary USI - Urinary System Infection
OVRY - Ovarian surgery	DIP - Deep Incisional Primary IAB - Intraabdominal, not specified elsewhere OREP - Deep pelvic tissue infection or other infection of the male or female reproductive tract SIP - Superficial Incisional Primary USI - Urinary System Infection
PACE - Pacemaker surgery	CARD - Myocarditis or pericarditis DIP - Deep Incisional Primary ENDO - Endocarditis IAB - Intraabdominal, not specified elsewhere SIP - Superficial Incisional Primary VASC - Arterial or venous infection
PRST - Prostate surgery	DIP - Deep Incisional Primary IAB - Intraabdominal, not specified elsewhere OREP - Deep pelvic tissue infection or other infection of the male or female reproductive tract SIP - Superficial Incisional Primary USI - Urinary System Infection

Operative Procedure Category	Specific Event Type
PVBY - Peripheral vascular bypass surgery	DIP - Deep Incisional Primary DIS - Deep Incisional Secondary SIP - Superficial Incisional Primary SIS - Superficial Incisional Secondary VASC - Arterial or venous infection
REC - Rectal surgery	DIP - Deep Incisional Primary DIS - Deep Incisional Secondary GIT - Gastrointestinal tract IAB - Intraabdominal, not specified elsewhere OREP - Deep pelvic tissue infection or other infection of the male or female reproductive tract SIP - Superficial Incisional Primary SIS - Superficial Incisional Secondary USI - Urinary System Infection
SB - Small bowel surgery	DIP - Deep Incisional Primary GIT - Gastrointestinal tract IAB - Intraabdominal, not specified elsewhere OREP - Deep pelvic tissue infection or other infection of the male or female reproductive tract SIP - Superficial Incisional Primary USI - Urinary System Infection
SPLE - Spleen surgery	DIP - Deep Incisional Primary IAB - Intraabdominal, not specified elsewhere SIP - Superficial Incisional Primary
THOR - Thoracic surgery	BONE - Osteomyelitis BRST - Breast abscess or mastitis DIP - Deep Incisional Primary IAB - Intraabdominal, not specified elsewhere LUNG - Other infections of the lower respiratory tract SIP - Superficial Incisional Primary
THYR - Thyroid and/or parathyroid surgery	DIP - Deep Incisional Primary EAR - Ear, mastoid infection GIT - Gastrointestinal tract SIP - Superficial Incisional Primary UR - Upper respiratory tract infection, pharyngitis, laryngitis, epiglottitis

Operative Procedure Category	Specific Event Type
VHYS - Vaginal hysterectomy	DIP - Deep Incisional Primary IAB - Intraabdominal, not specified elsewhere OREP - Deep pelvic tissue infection or other infection of the male or female reproductive tract SIP - Superficial Incisional Primary USI - Urinary System Infection VCUF - Vaginal cuff infection
VSHN - Ventricular shunt	BONE - Osteomyelitis DIP - Deep Incisional Primary DIS - Deep Incisional Secondary IAB - Intraabdominal, not specified elsewhere IC - Intracranial infection LUNG – Other infections of the lower respiratory tract MEN - Meningitis or ventriculitis SA - Spinal abscess/infection SIP - Superficial Incisional Primary SIS - Superficial Incisional Secondary
XLAP - Exploratory laparotomy	DIP - Deep Incisional Primary EMET - Endometritis GIT - Gastrointestinal tract IAB - Intraabdominal, not specified elsewhere OREP - Deep pelvic tissue infection or other infection of the male or female reproductive tract SIP - Superficial Incisional Primary USI - Urinary System Infection

APPENDIX B

Guidance for Multiple Procedure Reporting

This table addresses the 12 NHSN operative procedure categories that are included in [Denominator for Reporting Instruction #6 - Same NHSN operative procedure category via separate incisions](#): AMP, BRST, CEA, FUSN, FX, HER, HPRO, KPRO, LAM, NEPH, OVRY, PVBY. The instruction provides guidance on correct procedure reporting when multiple procedures from one of these categories (procedures from the same category) are performed via separate incisions per patient per calendar day. The table includes the maximum number of procedures per day per patient and an explanation.

Operative Procedure Category	Maximum # Of Procedures Per Day	Explanation
AMP - Limb amputation	4	Corresponds to the four (4) extremities (left arm, left leg, right arm, right leg). In instances where multiple AMP procedures are performed on the same extremity only one AMP procedure should be reported for that extremity.
BRST - Breast surgery	2	Corresponds to the left breast and right breast.
CEA - Carotid endarterectomy	2	Corresponds to the left artery and right artery.
FUSN - Spinal fusion	4	Corresponds to the four (4) anatomical spinal levels (cervical, thoracic, lumbar, sacral). When more than one anatomical spinal level is fused, report the NHSN spinal level and approach in which the most vertebrae were fused. The number of FUSN procedures reported depends on various factors: - When a spinal fusion procedure is performed on one spinal level/contiguous spinal levels, this is considered one FUSN procedure for reporting purposes although multiple joints may be fused and multiple procedures codes are assigned. - When an anterior and posterior incision are made to access one spinal level/contiguous spinal levels (such as C3-C5 spinal fusion with anterior and posterior approach) one FUSN procedure is reported. Indicate 'Anterior and Posterior' approach on the denominator for procedure form.

Operative Procedure Category	Maximum # Of Procedures Per Day	Explanation
		When distinct levels/sections of the spine are fused using different incisions on non-contiguous spinal levels (such as an incision made in the cervical spine and an incision made in the lumbar spine) enter as separate denominators (two FUSN denominator for procedure forms should be completed).
FX - Open reduction of fracture	4	Corresponds to the four (4) extremities (right arm, right leg, left arm, left leg). In instances where multiple FX procedures are performed on the same extremity only one FX procedure should be reported for that extremity.
HER - Herniorrhaphy	5	Corresponds to five (5) hernias. Laparoscopic hernia repairs are considered one HER procedure, regardless of the number of hernias repaired in that trip to the OR. In most cases there will be only one incision time documented for this procedure. If more than one time is documented, total the durations. Open (specifically, non-laparoscopic) hernia repairs are reported as one HER procedure for each hernia repaired via a separate incision. For example: - If one incision is made to repair two defects, then report one HER procedure. - If two incisions are made to repair two defects, then report two HER procedures. It is anticipated that separate incision times will be recorded for these procedures. If not, take the total time for both procedures and split it evenly between the two.
HPRO - Hip prosthesis	2	Corresponds to the left hip and right hip.
KPRO - Knee prosthesis	2	Corresponds to the left knee and right knee.
LAM - Laminectomy	2	Corresponds to two (2) LAM procedures [each at different spinal levels].
NEPH - Kidney surgery	2	Corresponds to the left kidney and right kidney.
OVRY - Ovarian surgery	2	Corresponds to the left ovary and right ovary.
PVBY - Peripheral vascular bypass surgery	4	Corresponds to four (4) PVBY procedures.

Ventilator-Associated Event (VAE)

For use in adult locations only

Table of Contents

Introduction	1
Settings	3
Inclusion and Exclusion Criteria.....	3
Definitions	3
Table 1: Definitions of routes of administration.....	13
Table 2: Instructions for using the purulent respiratory secretions criterion, based on laboratory reporting of respiratory secretion direct examination results.....	15
Reporting Instructions	17
Table 3: Threshold values for cultured specimens used in the PVAP definition	19
Figure 1: Ventilator-Associated Events (VAE) Surveillance Algorithm.....	21
Numerator and Denominator Data.....	22
Data Analyses.....	24
Table 4: VAE Measures Available in NHSN	28
References	29
Appendix. List of Antimicrobial Agents Eligible for IVAC, PVAP.....	30
VAE Frequently Asked Questions (FAQs)	32

Introduction

Mechanical ventilation is an essential, life-saving therapy for patients with critical illness and respiratory failure. Studies have estimated that more than 300,000 patients receive mechanical ventilation in the United States each year [1-3]. These patients are at high risk for complications and poor outcomes, including death [1-5]. Ventilator-associated pneumonia (VAP), sepsis, acute respiratory distress syndrome (ARDS), pulmonary embolism, barotrauma, and pulmonary edema are among the complications that can occur in patients receiving mechanical ventilation. Such complications can lead to longer duration of mechanical ventilation, longer stays in the intensive care unit (ICU) and hospital, increased healthcare costs, and increased risk of disability and death. Mortality in patients with acute lung injury on mechanical ventilation has been estimated to range from 24% in persons 15-19 years of age to 60% for patients 85 years and older [4].

Surveillance for ventilator-associated events in the National Healthcare Safety Network (NHSN) prior to 2013 was limited to VAP. For the year 2012, VAP incidence for various types of hospital units ranged from 0.0-4.4 per 1,000 ventilator days [6]. However, there is currently no valid, reliable definition for VAP, and even the most widely used VAP criteria and definitions are neither sensitive nor specific [7-10].

A particular difficulty with many commonly used VAP definitions, including the NHSN PNEU definitions (revised in 2002), is that they require radiographic findings of pneumonia. Evidence suggests that chest radiograph findings do not accurately identify VAP. The subjectivity and variability inherent in chest radiograph technique, interpretation, and reporting make chest imaging ill-suited for inclusion in a

definition algorithm to be used for the potential purposes of public reporting, inter-facility comparisons, and pay-for-reporting and pay-for-performance programs. Another major limitation of the available VAP definitions is their reliance on specific clinical signs or symptoms, which are subjective and may be poorly or inconsistently documented in the medical record. The NHSN PNEU protocol includes multiple definition pathways and special criteria for selected patient populations (for example, children, immunocompromised patients), increasing its complexity.

The limitations of VAP surveillance definitions have implications for prevention. Valid and reliable surveillance data are necessary for assessing the effectiveness of prevention strategies. It is notable that some of the most effective measures for improving outcomes of patients on mechanical ventilation do not specifically target pneumonia prevention [11-14].

In 2011, CDC convened a Working Group composed of members of several stakeholder organizations to address the limitations of the NHSN PNEU definitions and propose a new approach to surveillance for Ventilator-Associated Events (VAE) for NHSN [15]. The organizations represented in the Working Group include: the Critical Care Societies Collaborative (the American Association of Critical-Care Nurses, the American College of Chest Physicians, the American Thoracic Society, and the Society for Critical Care Medicine), the American Association for Respiratory Care, the Association of Professionals in Infection Control and Epidemiology, the Council of State and Territorial Epidemiologists, the Healthcare Infection Control Practices Advisory Committee's Surveillance Working Group, the Infectious Diseases Society of America, and the Society for Healthcare Epidemiology of America.

The VAE surveillance definition algorithm developed by the Working Group and implemented in the NHSN in January 2013 is based on objective, streamlined, and potentially automatable criteria that identify a broad range of conditions and complications occurring in mechanically ventilated adult patients [16]. Several modifications to the VAE definitions have been made since January 2013. These modifications address issues raised by NHSN users and discussed with the Working Group. There are three definition tiers within the VAE algorithm: 1) Ventilator-Associated Condition (VAC); 2) Infection-related Ventilator-Associated Complication (IVAC); and 3) Possible VAP (PVAP). Data indicate that streamlined, objective algorithms to detect ventilator-associated complications (similar to the VAC tier of the VAE algorithm) are easily implemented, can make use of electronic health record systems to automate event detection, and identify events that are clinically important and associated with outcomes such as ICU and hospital length of stay and mortality [16,17]. Research suggests that most VACs are due to pneumonia, ARDS, atelectasis, and pulmonary edema [16]. These are significant clinical conditions that may be preventable. VAE rates and event characteristics in adult inpatient locations reporting data to NHSN in 2014 have been published [18].

NOTE: The VAE definition algorithm is for use in surveillance. It is not a clinical definition algorithm and is not intended for use in the clinical management of patients. Examples provided throughout this protocol and in the VAE "Frequently Asked Questions" are for illustration purposes only and are not intended to represent actual clinical scenarios.

Settings

Inpatient locations eligible to participate in VAE surveillance are those adult locations in acute care hospitals, long term acute care hospitals, and inpatient rehabilitation facilities where denominator data (ventilator and patient days) can be collected for patients. Such locations may include critical/intensive care units (ICU), specialty care areas (SCA), step-down units, and wards. A complete listing of adult inpatient locations can be found in [Chapter 15 CDC Locations and Descriptions](#).

Non-acute care mapped locations in acute care facilities (chronic care units in acute care facilities) are not eligible to participate in VAE surveillance.

It is not required to monitor for VAEs after discharge if a patient is transferred to another facility while still on mechanical ventilation. However, if discovered, any VAE with a date of event on the day of discharge or the day after discharge is attributed to the discharging location and should be included in any VAEs reported to NHSN by the discharging location. No additional ventilator days are reported.

Inclusion and Exclusion Criteria

Patients INCLUDED in VAE surveillance:

- All patients in the adult inpatient locations found in Chapter 15, regardless of patient's age
- Patients on a [ventilator](#) (as defined below) who are receiving:
 - a conventional mode of mechanical ventilation (for example, synchronized intermittent mandatory ventilation)
 - Airway Pressure Release Ventilation (APRV) or related modes (see "Frequently Asked Questions [FAQ]" number [no.] 14 at the end of this protocol)
- Patients on a [ventilator](#) (as defined below) who are receiving a conventional mode of mechanical ventilation, or APRV or related modes:
 - while in the prone position
 - while receiving nitric oxide therapy, helium-oxygen mixtures (heliox), or epoprostenol therapy

Patients EXCLUDED from VAE surveillance:

- All patients in the neonatal and pediatric inpatient locations found in Chapter 15, regardless of patient's age
- Patients on high-frequency ventilation, extracorporeal life support, or paracorporeal membrane oxygenation are excluded from VAE surveillance during periods of time when the support is in place for the entire calendar day (see FAQ no. 14 at the end of this protocol)

Definitions

Ventilator: A device used to support, assist, or control respiration (inclusive of the weaning period) through the application of positive pressure to the airway when delivered via an artificial airway, specifically oral/nasal endotracheal or tracheostomy tube.

Ventilation and lung expansion devices that deliver positive pressure to the airway (for example, CPAP, BiPAP, Bi-level, IPPB, and PEEP) via non-invasive means (for example, nasal prongs, nasal mask, full face mask, total mask, etc.) are not considered ventilators unless positive pressure is delivered via an artificial airway (oral/nasal endotracheal or tracheostomy tube).

VAE: VAEs are identified by using a combination of objective criteria: deterioration in respiratory status after a period of stability or improvement on the ventilator, evidence of infection or inflammation, and laboratory evidence of respiratory infection, and are categorized into the following 3 tiers: ventilator-associated condition (VAC), infection-related ventilator-associated complication (IVAC), and possible ventilator-associated pneumonia (PVAP). The following pages outline the criteria that must be used for meeting each of the VAE surveillance definitions ([Figure 1](#)).

Patients must be mechanically ventilated for at least 4 calendar days to fulfill VAE criteria (where the day of intubation and initiation of mechanical ventilation is day 1). The earliest date of event for VAE (the date of onset of worsening oxygenation) is day 3 of mechanical ventilation. Line lists of VAE data elements demonstrating scenarios that meet and do not meet the VAE definitions are presented in FAQ no. 2 at the end of this protocol.

Positive End-Expiratory Pressure (PEEP): “A technique used in respiratory therapy in which airway pressure greater than atmospheric pressure is achieved at the end of exhalation by the introduction of a mechanical impedance to exhalation” [19]. In patients on mechanical ventilation, PEEP is one of the key parameters that can be adjusted depending on the patient’s oxygenation needs and is typically in the range of 0 to 15 cmH₂O. A sustained increase in the daily minimum PEEP of ≥ 3 cmH₂O following a period of stability or improvement on the ventilator is one of two criteria that can be used in meeting the VAC definition. For the purposes of VAE surveillance, PEEP values from 0 to 5 cmH₂O are considered equivalent.

Fraction of Inspired Oxygen (FiO₂): The fraction of oxygen in inspired gas. For example, the FiO₂ of ambient air is 0.21; the oxygen concentration of ambient air is 21%. In patients on mechanical ventilation, the FiO₂ is one of the key parameters that can be adjusted depending on the patient’s oxygenation needs and is typically in the range of 0.30 (oxygen concentration of 30%) to 1.0 (oxygen concentration of 100%). A sustained increase in the daily minimum FiO₂ of ≥ 0.20 (20 points) following a period of stability or improvement on the ventilator is one of the two criteria that can be used in meeting the VAC definition.

Daily Minimum PEEP: The lowest value of PEEP during a calendar day that is set on the ventilator and *maintained for > 1 hour*. This requirement that the daily minimum PEEP be the lowest setting maintained for > 1 hour will ensure that units monitoring and recording PEEP settings hourly or more frequently than once per hour are able to apply the VAE surveillance PEEP criterion in a standardized way.

If ventilator settings are monitored and recorded less frequently than once per hour (for example, every 2 hours or every 4 hours), the daily minimum PEEP is simply the lowest value of PEEP set on the ventilator during the [calendar day](#).

EXAMPLE: PEEP is set at the following values through the course of a calendar day:

Time	00:00	04:00	08:00	12:00	16:00	20:00
PEEP (cmH ₂ O)	5	8	5	8	8	10

In this example, the daily minimum PEEP is 5 cmH₂O. PEEP settings are being monitored and recorded every 4 hours; therefore, the lowest recorded PEEP setting for the calendar day is the value used in VAE surveillance.

If there is no documentation of values maintained for > 1 hour (for example, the lowest value of PEEP is set late in the calendar day, mechanical ventilation is discontinued early in the calendar day, PEEP settings are changed very frequently throughout the calendar day), the daily minimum PEEP will default to the lowest value of PEEP set on the ventilator during the calendar day (regardless of how long that setting was maintained).

- For example, a patient who is intubated and started on mechanical ventilation at 23:30 on June 1, with a PEEP setting of 10 cmH₂O from 23:30 to 00:00, would have a daily minimum PEEP of 10 cmH₂O on June 1 for the purposes of VAE surveillance.

In units tracking PEEP settings every hour or more frequently than every hour, there must be sufficient consecutive recordings of a specific PEEP setting to meet the minimum required duration of > 1 hour.

- In units tracking PEEP every 15 minutes, 5 consecutive recordings of PEEP at a certain level would be needed to meet the required > 1 hour minimum duration (for example, at 09:00, 09:15, 09:30, 09:45, and 10:00).
- In units tracking PEEP every 30 minutes, 3 consecutive recordings of PEEP at a certain level would be needed to meet the required > 1 hour minimum duration (for example, at 09:00, 09:30, and 10:00).
- In units tracking PEEP every hour, 2 consecutive recordings of PEEP at a certain level would be needed to meet the required > 1 hour minimum duration (for example, at 09:00 and 10:00).

EXAMPLE: The patient is intubated at 18:00. PEEP is set at the following values through the remainder of the calendar day:

Time	18:00	19:00	20:00	21:00	22:00	23:00
PEEP (cmH ₂ O)	10	8	5	5	8	8

In this example, the daily minimum PEEP for the purposes of VAE surveillance is 5 cmH₂O. PEEP settings are being monitored and recorded every hour. There are two consecutive hours where the PEEP setting is noted to be 5 cmH₂O (20:00 and 21:00), and therefore required minimum duration of > 1 hour is met.

EXAMPLE: The patient is intubated at 18:00. PEEP is set at the following values through the remainder of the calendar day:

Time	18:00	19:00	20:00	21:00	22:00	23:00
PEEP (cmH ₂ O)	8	8	5	8	5	8

In this example, the daily minimum PEEP for the purposes of VAE surveillance is 8 cmH₂O. PEEP settings are being monitored and recorded every hour. Although the lowest PEEP is 5 cmH₂O, it is recorded at two non-consecutive time points only (20:00, then 22:00), and so the required > 1 hour minimum duration is not met. There are two consecutive hours where the PEEP setting is

noted to be 8 cmH₂O (18:00 and 19:00), and therefore the required minimum duration of > 1 hour is met to allow use of this setting as the daily minimum value for VAE surveillance.

EXAMPLE: You are reviewing a patient's ventilator settings on Wednesday morning to determine the daily minimum PEEP values for Monday and Tuesday. The MICU monitors and records PEEP settings for mechanically ventilated patients every 30 minutes. You see that the lowest PEEP setting on Monday (5 cmH₂O) was recorded at 23:30 when the episode of mechanical ventilation was initiated for this patient. The patient remained at this PEEP setting for an additional 30 minutes on Tuesday morning and was then maintained on PEEP 10 cmH₂O for the rest of the day on Tuesday. What do you record as the daily minimum PEEP for Monday and for Tuesday? In this example, the only PEEP setting recorded on Monday was 5 cmH₂O. Because there is no value on Monday that has been maintained for > 1 hour, the lowest (and only) setting of 5 cmH₂O is recorded as the daily minimum PEEP for that calendar day. On Tuesday, the daily minimum PEEP should be recorded as 10 cmH₂O, which is the lowest PEEP setting maintained for > 1 hour on Tuesday.

Day	Time	PEEP (cmH ₂ O)
Monday	23:30	5
Tuesday	00:00	5
Tuesday	00:30	5
Tuesday	01:00	10
Tuesday	01:30	10
Tuesday	02:00 through 23:30	10

Note: For the purposes of VAE surveillance, PEEP values between 0 cmH₂O and 5 cmH₂O will be considered equivalent. This means that patients with daily minimum PEEP values from 0 to 5 cmH₂O must then have an increase in the daily minimum PEEP to at least 8 cmH₂O, sustained for at least 2 calendar days, to meet the VAC definition.

Daily minimum PEEP determinations are made using documented PEEP settings specific to the calendar day and independently of the PEEP settings recorded on the previous calendar day or the next calendar day.

EXAMPLE: You are reviewing a patient's ventilator data on Thursday morning to determine the daily minimum PEEP values for Tuesday and Wednesday. The medical ICU (MICU) monitors and records PEEP every 8 hours. You see that the lowest PEEP on Tuesday is 5 cmH₂O, last recorded at 23:30. The first recorded PEEP on Wednesday, at 07:30, is 8 cmH₂O and the patient remains at that PEEP for the remainder of the calendar day on Wednesday. What do you record as the daily minimum PEEP for Tuesday and for Wednesday? On Tuesday, the daily minimum PEEP is 5 cmH₂O, as it is the lowest value recorded on that calendar day. On Wednesday, the daily minimum PEEP is 8 cmH₂O, as it is the lowest value recorded on that calendar day. Only PEEP values documented during the given calendar day are taken into consideration when determining the daily minimum PEEP for that calendar day.

Day	Time	PEEP (cmH ₂ O)
Tuesday	07:30	8
Tuesday	15:30	5

Day	Time	PEEP (cmH ₂ O)
Tuesday	23:30	5
Wednesday	07:30	8
Wednesday	15:30	8
Wednesday	23:30	8

Daily Minimum FiO₂: The lowest value of FiO₂ during a calendar day that is set on the ventilator and *maintained for > 1 hour*. This requirement that the daily minimum FiO₂ be the lowest setting maintained for > 1 hour will ensure that units monitoring and recording FiO₂ settings hourly or more frequently than once per hour are able to apply the VAE surveillance FiO₂ criterion in a standardized way.

If ventilator settings are monitored and recorded less frequently than once per hour (for example, every 2 hours or every 4 hours), the daily minimum FiO₂ is simply the lowest value of FiO₂ set on the ventilator during the [calendar day](#).

EXAMPLE: FiO₂ is set at the following values through the course of a calendar day:

Time	14:00	16:00	18:00	20:00	22:00	00:00
FiO ₂	1.0	0.60	0.40	0.50	0.55	0.60

In this example, the patient was intubated at 14:00. The daily minimum FiO₂ is 0.40. FiO₂ settings are being monitored and recorded every 2 hours; therefore, the lowest recorded FiO₂ setting for the calendar day is the value used in VAE surveillance.

If there is no documentation of values maintained for > 1 hour (for example, the lowest value of FiO₂ is set late in the calendar day, mechanical ventilation is discontinued early in the calendar day, FiO₂ settings are changed very frequently throughout the calendar day), the daily minimum FiO₂ will default to the lowest FiO₂ set on the ventilator during the calendar day (regardless of how long that setting was maintained).

- For example, a patient who is intubated and started on mechanical ventilation at 23:30 on June 1, with a FiO₂ setting of 0.30 from 23:30 to 00:00, would have a daily minimum FiO₂ of 0.30 on June 1 for the purposes of VAE surveillance.

In units tracking FiO₂ settings every hour or more frequently than every hour, there must be sufficient consecutive recordings of a specific FiO₂ setting to meet the minimum required duration of > 1 hour.

- In units tracking FiO₂ every 15 minutes, 5 consecutive recordings of FiO₂ at a certain level would be needed to meet the required > 1 hour minimum duration (for example, 09:00, 09:15, 09:30, 09:45, and 10:00).
- In units tracking FiO₂ every 30 minutes, 3 consecutive recordings of FiO₂ at a certain level would be needed to meet the required > 1 hour minimum duration (for example, 09:00, 09:30, and 10:00).
- In units tracking FiO₂ every hour, 2 consecutive recordings of FiO₂ at a certain level would be needed to meet the required > 1 hour minimum duration (for example, 09:00 and 10:00).

EXAMPLE: The patient is intubated at 18:00. FiO₂ is set at the following values through the remainder of the calendar day:

Time	18:00	19:00	20:00	21:00	22:00	23:00
FiO ₂	1.0	0.8	0.5	0.5	0.8	0.8

In this example, the daily minimum FiO₂ for the purposes of VAE surveillance is 0.5. FiO₂ settings are being monitored and recorded every hour. There are two consecutive hours where the FiO₂ setting is noted to be 0.5 (20:00 and 21:00), and therefore the required minimum duration of > 1 hour is met.

EXAMPLE: The patient is intubated at 18:00. FiO₂ is set at the following values through the remainder of the calendar day:

Time	18:00	19:00	20:00	21:00	22:00	23:00
FiO ₂	0.8	0.8	0.5	0.8	0.5	0.8

In this example, the daily minimum FiO₂ for the purposes of VAE surveillance is 0.8. FiO₂ settings are being monitored and recorded every hour. Although the lowest FiO₂ is 0.5, it is recorded at two non-consecutive time points only (20:00, and then 22:00), and so the required > 1 hour minimum duration is not met. There are two consecutive hours where the FiO₂ setting is noted to be 0.8 (18:00 and 19:00), and therefore the required minimum duration of > 1 hour is met to allow use of this setting as the daily minimum value for VAE surveillance.

EXAMPLE: You are reviewing a patient's ventilator settings on Friday morning to determine the daily minimum FiO₂ value for Thursday. The patient was intubated and initiated on mechanical ventilation at 21:45 hours on Thursday. The ICU monitored and recorded FiO₂ settings for the patient every 15 minutes during the remainder of the day on Thursday. Based on the information recorded in the table below, what should you record as the daily minimum FiO₂ for Thursday? In this example, since there is no setting that is maintained for > 1 hour during the calendar day, the daily minimum FiO₂ for Thursday is 0.70 (70%). This is the lowest value of FiO₂ set on the ventilator during the calendar day.

Day	Time	FiO ₂
Thursday	21:45	Intubated; 1.0
	22:00	1.0
	22:15	0.90
	22:30	0.90
	22:45	0.70
	23:00	0.80
	23:15	0.85
	23:30	0.85
	23:45	0.85

Daily minimum FiO₂ determinations are made using documented FiO₂ settings specific to the calendar day and independently of the FiO₂ settings recorded on the previous calendar day or the next calendar day.

EXAMPLE: You are reviewing a patient's ventilator data on Thursday morning to determine the daily minimum FiO₂ values for Tuesday and Wednesday. The medical ICU (MICU) monitors and records FiO₂ every 8 hours. You see that the lowest FiO₂ on Tuesday is 0.70 (70%), last recorded at 23:30. The first recorded FiO₂ on Wednesday, at 07:30, is 0.90 (90%) and the patient remains at that FiO₂ for the remainder of the calendar day on Wednesday. What do you record as the daily minimum FiO₂ for Tuesday and for Wednesday? On Tuesday, the daily minimum FiO₂ is 0.70 (70%), as it is the lowest value recorded on that calendar day. On Wednesday, the daily minimum FiO₂ is 0.90 (90%), as it is the lowest value recorded on that calendar day. Only FiO₂ values documented during the given calendar day are taken into consideration when determining the daily minimum FiO₂ for that calendar day.

Day	Time	FiO ₂
Tuesday	07:30	0.75
Tuesday	15:30	0.70
Tuesday	23:30	0.70
Wednesday	07:30	0.90
Wednesday	15:30	0.90
Wednesday	23:30	0.90

Baseline Period: The baseline period of stability or improvement on the ventilator is defined as the 2 calendar days immediately preceding the first day of increased daily minimum PEEP or FiO₂, and must be characterized by ≥ 2 calendar days of stable or decreasing daily minimum FiO₂ or PEEP values (specifically the daily minimum PEEP or FiO₂ on the second day of the baseline period of stability or improvement must be equal to or less than the daily minimum PEEP or FiO₂ on the first day of the baseline period of stability or improvement). Note that the minimum daily PEEP or FiO₂ used for VAE surveillance is the lowest setting during a calendar day that was maintained for > 1 hour (see daily minimum PEEP and FiO₂ definitions for exception to 1 hour requirement).

Period of Worsening Oxygenation: The period of worsening oxygenation is defined as an increase in the daily minimum PEEP values of at least 3 cmH₂O over the daily minimum PEEP of the first day in the baseline period or an increase in the daily minimum FiO₂ of at least 0.20 (20 points) over the daily minimum FiO₂ of the first day in the baseline period, that immediately follows the baseline period and is sustained for at least 2 or more calendar days.

EXAMPLE: In the example below, the baseline period is defined by mechanical ventilation (MV) days 1 through 4 (shaded in light gray), and the period of worsening oxygenation by MV days 5 and 6 (shaded in darker gray), where the daily minimum PEEP is ≥ 3 cmH₂O greater than the daily minimum PEEP of the first day in the baseline period. Note that there is no VAC on MV day 3, because PEEP values 0-5 cmH₂O are considered equivalent for the purposes of this surveillance.

MV Day	Daily minimum PEEP (cmH ₂ O)	Daily minimum FiO ₂ (oxygen concentration, %)	VAE
1	0 (5)	1.00 (100%)	-
2	0 (5)	0.50 (50%)	-
3	5	0.50 (50%)	-
4	5	0.50 (50%)	-
5	8	0.50 (50%)	VAC
6	8	0.50 (50%)	-

EXAMPLE: In the example below, the baseline period is defined by mechanical ventilation (MV) days 1 through 4 (shaded in light gray), and the period of worsening oxygenation by MV days 5 and 6 (shaded in darker gray), where the daily minimum PEEP is ≥ 3 cmH₂O greater than the daily minimum PEEP of the first day in the baseline period. In this example, note that MV days 1-4 are considered a baseline period even though the daily minimum PEEP increases from 0 to 3 to 5 cmH₂O during this time period - because PEEP values from 0-5 cmH₂O are considered equivalent for the purposes of this surveillance.

MV Day	Daily minimum PEEP (cmH ₂ O)	Daily minimum FiO ₂ (oxygen concentration, %)	VAE
1	0 (5)	1.00 (100%)	-
2	0 (5)	0.50 (50%)	-
3	3 (5)	0.50 (50%)	-
4	5	0.50 (50%)	-
5	8	0.50 (50%)	VAC
6	8	0.50 (50%)	-

EXAMPLE: In the example below, the baseline period is defined by mechanical ventilation (MV) days 3 and 4 (shaded in light gray), and the period of worsening oxygenation by MV days 5 and 6 (shaded in darker gray), where the daily minimum FiO₂ is ≥ 0.20 (20 points) over the daily minimum FiO₂ of the first day in the baseline period.

MV Day	Daily minimum PEEP (cmH ₂ O)	Daily minimum FiO ₂ (oxygen concentration, %)	VAE
1	8	1.00 (100%)	
2	6	0.50 (50%)	
3	5	0.40 (40%)	
4	5	0.40 (40%)	
5	6	0.70 (70%)	VAC
6	6	0.70 (70%)	

EXAMPLE: In the example below, there is no VAC, because the FiO₂ on MV day 4 is higher than the FiO₂ on MV day 3 (and therefore not stable or decreasing) – even though the FiO₂ on MV days 3 and 4 meets the 20-point threshold when compared with the daily minimum FiO₂ on MV days 5 and 6.

MV Day	Daily minimum PEEP (cmH ₂ O)	Daily minimum FiO ₂ (oxygen concentration, %)	VAE
1	8	1.0 (100%)	
2	6	0.50 (50%)	
3	5	0.35 (35%)	
4	5	0.40 (40%)	
5	6	0.70 (70%)	No event
6	6	0.70 (70%)	

Date of Event: The date of onset of worsening oxygenation. This is defined as the first calendar day in which the daily minimum PEEP or FiO₂ increases above the thresholds outlined in the VAE definition algorithm (specifically day 1 of the required ≥ 2 -day period of worsening oxygenation following a ≥ 2 -day period of stability or improvement on the ventilator).

The date of event is NOT the date on which all VAE criteria have been met. It is the first day (of a ≥ 2 -day period) on which either of the worsening oxygenation thresholds (for PEEP or FiO₂) is met.

EXAMPLE: A patient is intubated in the Emergency Room for severe community-acquired pneumonia and admitted (day 1) to the medical ICU (MICU). The patient stabilizes and improves on days 2-5, with a daily minimum FiO₂ of 0.35 (35%) on days 4 and 5. On day 6, the patient experiences respiratory deterioration, and requires a minimum FiO₂ of 0.60 (60%) on days 6 and 7, meeting the criteria for a VAC. The VAC date of event is day 6.

VAE Window Period: This is the period of days around the date of event (specifically the day of onset of worsening oxygenation) within which other VAE criteria must be met. It is usually a 5-day period and includes the 2 days before, the day of, and the 2 days after the VAE date of event. There is an exception, however, in which the VAE Window Period is only 3 or 4 days, as follows:

In cases where the VAE date of event corresponds to mechanical ventilation (MV) day 3 or day 4, the window period described above may only be a 3-day or a 4-day window, because it can NOT include any days before the third day of MV. For example, if the VAE date of event is MV day 3, then the window period includes only the VAE date of event and the 2 days after the VAE date of event (because the 2 days before the VAE date of event are before the third day of MV).

14-day Event Period: VAEs are defined by a 14-day period, starting on the day of onset of worsening oxygenation (the date of event, day 1). While patients may have multiple VAEs during a single hospitalization, a new VAE cannot be identified or reported until this 14-day period has elapsed. VAE criteria met during the 14-day period are attributed to the current VAE.

EXAMPLE: Patient is intubated, and mechanical ventilation (MV) is initiated in the MICU (MV day 1). The patient is stable during the following 4 calendar days (MV days 2 through 5). On MV days 6 and 7 the patient's minimum daily PEEP is increased more than 3 cmH₂O over the first day in the baseline period, therefore meeting the VAC PEEP threshold. The VAC episode is defined by the period encompassing MV days 6 through 19 (14 days, starting on day 1 of worsening oxygenation, which in this case is MV day 6). If the patient were to experience a period of stability or improvement on the ventilator on MV days 18 and 19, followed by another 2-day period of worsening on MV days 20 and 21, a new VAE would be reported, since the second

period of worsening oxygenation has occurred more than 14 days after the start of the initial period of worsening oxygenation.

Episode of Mechanical Ventilation: Defined as a period of days during which the patient was mechanically ventilated for some portion of each consecutive day.

A break in mechanical ventilation of at least one full calendar day, followed by reintubation and/or reinitiation of mechanical ventilation during the same hospitalization, defines a new episode of mechanical ventilation.

EXAMPLE: A patient is intubated, and mechanical ventilation is initiated at 23:00 on hospital day 1. The patient remains intubated and mechanically ventilated from hospital days 2-10. The patient is extubated at 09:00 on hospital day 11 and remains extubated on hospital day 12. The patient is reintubated and mechanical ventilation is reinitiated on hospital day 13. The patient remains intubated and mechanically ventilated from hospital day 14-18. This patient has had two episodes of mechanical ventilation (days 1-11 and days 13-18), separated by at least one full calendar day off of mechanical ventilation.

New Antimicrobial Agent: Defined as any agent listed in the [Appendix](#) that is initiated on or after the third calendar day of mechanical ventilation AND in the VAE Window Period (specifically, the period typically defined by the 2 calendar days before, the day of, and the 2 calendar days after the onset date of the VAE). The agent is considered new for the purposes of this definition if it was NOT given to the patient on either of the 2 days preceding the current start date.

EXAMPLE: A patient is intubated and mechanically ventilated on hospital day 1 in the surgical ICU (SICU). Ceftriaxone and azithromycin are started on day 1 and administered daily. After 3 days of improving respiratory status, the patient's oxygenation deteriorates on days 4 and 5, with a daily minimum PEEP that is 4 cmH₂O higher than it was on days 2 and 3. Criteria for the VAC definition are met; the date of the event is hospital day 4. Ceftriaxone is discontinued and meropenem is started on day 5. Azithromycin is continued. In this case, meropenem is a new antimicrobial agent: 1) it was started on day 5 of mechanical ventilation, and 2) within the VAE Window Period (on the day after VAE date of event), and 3) it was not given to the patient on either of the 2 days preceding the current start date. By contrast, ceftriaxone and azithromycin would not be considered new antimicrobial agents since they were started on day 1 of mechanical ventilation and continued daily into the VAE Window Period.

Hosp Day No.	1	2	3	4	5
MV Day No.	1	2	3	4	5
VAE Day		-2	-1	1	2
VAE Criterion	--	Day 1 of stability or improvement	Day 2 of stability or improvement	Day 1 of worsening oxygenation	Day 2 of worsening oxygenation
Antimicrobial agent	Ceftriaxone & Azithromycin	Ceftriaxone & Azithromycin	Ceftriaxone & Azithromycin	Ceftriaxone & Azithromycin	Meropenem & Ceftriaxone

The antimicrobial agent(s) must have been given by one of the routes of administration outlined in [Table 1](#), and therapy with one or more new antimicrobial agents must be continued for at least 4 calendar days (referred to as 4 “qualifying antimicrobial days” or “QADs”). For further guidance on identification of new antimicrobial agents and on how to determine whether the requirement for 4 QADs is met, refer to FAQ nos. 4-7 at the end of this protocol.

Table 1: Definitions of routes of administration

Route of Administration ^a	Definition ^b
Intravenous	An intravascular route that begins with a vein.
Intramuscular	A route that begins within a muscle.
Digestive Tract	A route that begins anywhere in the digestive tract extending from the mouth through rectum.
Respiratory Tract	A route that begins within the respiratory tract, including the oropharynx and nasopharynx.

^aOther routes of administration are excluded (for example, antibiotic locks, intraperitoneal, intraventricular, irrigation, topical).

^bDefinitions per SNOMED Reference Terminology

Qualifying Antimicrobial Day (QAD): A day on which the patient was administered an antimicrobial agent determined to be “new” within the VAE Window Period. Four consecutive QADs are needed to meet the IVAC antimicrobial criterion—starting within the VAE Window Period.

- Days on which a new antimicrobial agent is administered count as QADs.
- Days between administrations of the same new antimicrobial agent also count as QADs as long as there is a gap of no more than 1 calendar day between administrations.
 - For example, if levofloxacin is given on VAE Day 1, has not been given in the 2 preceding calendar days, and is given again on VAE Days 3, 5, and 7, there are 7 QADs - because the days between the levofloxacin doses also count as QADs.

VAE Day	-2	-1	1	2	3	4	5	6	7
Antimicrobial Agent			Levofloxacin		Levofloxacin		Levofloxacin		Levofloxacin
QAD (Y/N)	N	N	Y	Y	Y	Y	Y	Y	Y

- Days between administrations of different new antimicrobial agents do NOT count as QADs.
 - For example, if levofloxacin is given to the patient on VAE Days -2 and -1 only, no antimicrobials are given on VAE Day 1, and meropenem is given only on VAE Day 2 (remember there is no VAE Day 0), then there are not 4 consecutive QADs. VAE Days -2 and -1 count as 2 consecutive QADs, but VAE Day 1 cannot be counted as a QAD because it is a day between different antimicrobial agents.

VAE Day	-2	-1	1	2	3	4
Antimicrobial Agent	Levofloxacin	Levofloxacin		Meropenem		
QAD (Y/N)	Y	Y	N	Y	N	N

For further guidance on identification of new antimicrobial agents and on how to determine whether the requirement for 4 QADs is met, refer to FAQ nos. 4-7 at the end of this protocol.

Purulent Respiratory Secretions: Defined as secretions from the lungs, bronchi, or trachea that contain ≥ 25 neutrophils and ≤ 10 squamous epithelial cells per low power field [lpf, x100].

Some clinical laboratories may use different results reporting formats for direct examinations of respiratory secretions. Additional instructions for using the purulent respiratory secretions criterion are provided in [Table 2](#), below (see also FAQ no. 11 at the end of this protocol).

Table 2: Instructions for using the purulent respiratory secretions criterion, based on laboratory reporting of respiratory secretion direct examination results.

How do I use the purulent respiratory secretions criterion if ...	Instruction
My laboratory reports counts of “white blood cells” or “polymorphonuclear leukocytes” or “leukocytes” rather than counts of “neutrophils”?	Assume that counts of cells identified by these other descriptors (for example, “white blood cells”) are equivalent to counts of neutrophils, unless the laboratory tells you this is not the case.
My laboratory reports semi-quantitative results (not quantitative results) for numbers of neutrophils and squamous epithelial cells?	Check with the laboratory to get information about what quantitative ranges the semi-quantitative reports correspond to.
My laboratory cannot provide additional information on how its semi-quantitative reporting corresponds to quantitative reporting ranges for neutrophils and squamous epithelial cells?	Use the following direct examination results to meet the purulent respiratory secretions criterion: many, heavy, numerous, 4+, or ≥ 25 neutrophils per low power field (lpf) [x100], AND no, rare, occasional, few, 1+ or 2+, or ≤ 10 squamous epithelial cells per lpf [x100] [20].
My laboratory reports <u>only</u> the numbers of neutrophils present, without reporting the number of squamous epithelial cells?	In this situation, the purulent secretions criterion may be met using the specified quantitative and semi-quantitative thresholds for neutrophils alone (specifically many, heavy, numerous, 4+, or ≥ 25 neutrophils per lpf [x100]).
My laboratory uses different reporting thresholds for neutrophils and squamous epithelial cells (for example, maximum report of ≥ 20 neutrophils per low power field [x100], or minimum report of ≤ 15 squamous epithelial cells per low power field [x100])?	In this situation, the purulent secretions criterion may be met using the laboratory’s specified maximum quantitative threshold for neutrophils, and/or minimum quantitative threshold for squamous epithelial cells.
My laboratory processes respiratory specimens such as bronchoalveolar lavage fluid using a centrifugation procedure (for example, “cytospin”), and there is no quantitation or semi-quantitation of neutrophils or white blood cells in the direct examination report?	In this situation, a report indicating the presence of white blood cells, without quantitation, is sufficient to meet the purulent secretions criterion.

Location of Attribution: The inpatient location where the patient was assigned on the VAE date of event, which is further defined as the date of onset of worsening oxygenation.

EXAMPLE: Patient is intubated and ventilated in the Operating Room on hospital day 1, and then is admitted post-operatively to the SICU on hospital day 1, still on the ventilator. On hospital day 3, the patient experiences the onset of worsening oxygenation, manifested by an increase in the daily minimum FiO_2 of ≥ 0.20 (20 points). On hospital day 4 (also day 4 of mechanical ventilation) the patient meets criteria for a VAC. This is reported to NHSN as a VAC for the SICU.

EXCEPTION: **Transfer Rule:** If a VAE develops on the day of transfer or the day following transfer from one inpatient location to another in the same facility or to a new facility (where the day of transfer is day 1), the event is attributed to the transferring location. This is called the Transfer Rule. If the patient was in multiple locations within the transfer rule time frame, attribute the VAE to the first location in which the patient was housed the day before the VAE date of event.

See Transfer Rule examples below.

EXAMPLE: Patient on a ventilator in the SICU who has had stable oxygenation for 3 days is transferred to the MICU, still on the ventilator. On the evening of transfer, after the patient has arrived in the MICU, the patient begins to experience respiratory decompensation, requiring an increase of 0.30 (30 points) in FiO_2 that persists during the following two calendar days. VAC criteria are met on calendar day 3 in the MICU. Because the date of event occurred the day after transfer to the MICU, the VAC event is attributed to the SICU.

SICU Day	MICU Day	Daily Minimum FiO_2 (oxygen concentration, %)	VAE DOE	Location	Location of Attribution
2		0.30 (30%)		SICU	
3	1	0.30 (30%)		SICU -> MICU	
	2	0.60 (60%)	✓	MICU	SICU
	3	0.60 (60%)		MICU	

EXAMPLE: On hospital day 6, the patient is extubated in the MICU and transferred to the stepdown unit. The next day, while in the stepdown unit (hospital day 7), the patient experiences worsening oxygenation and is reintubated and transferred back to the MICU. Criteria for VAC are met the next day (hospital day 8). In this case, the day prior to extubation and the day of extubation (hospital days 5 and 6) count as the required 2-day period of stability or improvement. The day of reintubation (hospital day 7) and the following day (hospital day 8) count as the required 2-day period of worsening oxygenation. Because the date of event occurred on the day following transfer out of the MICU, the event is reported as a VAC for the MICU.

Hospital Day	MV Day	Daily Minimum FiO_2 (oxygen concentration, %)	VAE DOE	Location	Location of Attribution
5	5	0.30 (30%)		MICU	
6	6	0.30 (30%) (extubated at 09:00)		MICU -> Stepdown (transferred at 18:00)	
7	7	0.60 (60%) (reintubated at 10:00)	✓	Stepdown -> MICU (transferred at 10:15)	MICU
8	8	0.60 (60%)		MICU	

EXAMPLE: Patient intubated and mechanically ventilated for 8 days in the SICU of Hospital A. The patient was stable on the ventilator in Hospital A from days 3-6. In the evening on day 7 the patient began to have episodes of desaturation and on day 8 the patient was transferred to Hospital B (day 1 in Hospital B). The patient's respiratory status continues to worsen on the day after transfer (day 2 in Hospital B), and the patient meets criteria for VAC on day 2 in Hospital B. The date of the event, the first day of the period of worsening oxygenation meeting VAE PEEP or FiO₂ thresholds, is day 1 in Hospital B. The infection preventionist (IP) from Hospital B calls the IP from Hospital A to report that this patient was admitted to Hospital B with a VAC. This VAC should be reported by Hospital A and attributed to the Hospital A SICU. No additional ventilator days are reported by Hospital A.

Hospital Day for Hospital A	Hospital Day for Hospital B	Daily Minimum FiO ₂ (oxygen concentration, %)	VAE DOE	Location	Location of Attribution
6		0.30 (30%)		Hospital A	
7		0.30 (30%)		Hospital A	
8	1	0.60 (60%)	✓	Hospital A -> Hospital B	Hospital A
	2	0.60 (60%)		Hospital B	

Reporting Instructions

(additional guidance may be found in the [FAQs](#) at the end of this protocol)

1. Conducting in-plan VAE surveillance means assessing patients for the presence of ALL events included in the algorithm - from VAC to IVAC to PVAP. At this time, a unit conducting in-plan VAE surveillance cannot decide, for example, that only surveillance for VAC (and not for IVAC or PVAP) will be performed.
2. There is a hierarchy of definitions within VAE:
 - a. If a patient meets criteria for VAC and IVAC, report as IVAC.
 - b. If a patient meets criteria for VAC, IVAC, and PVAP, report PVAP.
3. Do not upgrade an event using findings that occur outside the VAE Window Period.
4. If the date of event (date of onset of worsening oxygenation) is on or after the date of documentation of evidence of consent AND the patient is being supported for organ donation purposes, the event should not be reported as a VAE.
5. Pathogens are not reported for VAC or IVAC events.
6. Secondary BSIs are not reported for VAC or IVAC events.
7. Pathogens may be reported for PVAP events, provided they are isolated or identified from appropriate specimen types according to the requirements of the algorithm and are NOT on the list of excluded organisms and culture or non-culture based microbiologic testing method results:
 - a. Excluded organisms and culture or non-culture based microbiologic testing method results that cannot be used to meet the PVAP definition are as follows:
 - i. "Normal respiratory flora," "normal oral flora," "mixed respiratory flora," "mixed oral flora," "altered oral flora" or other similar results indicating isolation of

- commensal flora of the oral cavity or upper respiratory tract. NOTE: A report of “flora” does not exclude the use of an eligible organism isolated or identified from the specimen. Only the “flora” is excluded from use.
- ii. Any *Candida* species or yeast not otherwise specified; any coagulase-negative *Staphylococcus* species; and any *Enterococcus* species, when identified from sputum, endotracheal aspirates, bronchoalveolar lavage, or protected specimen brushings specimens. These organisms can be reported as PVAP pathogens if identified from lung tissue or pleural fluid (where specimen was obtained during thoracentesis or within 24 hours of chest tube placement; pleural fluid specimens collected after a chest tube is repositioned or from a chest tube in place > 24 hours are not eligible for PVAP).
 - b. Additionally, because organisms belonging to the following genera are typically causes of community-associated respiratory infections and are rarely or are not known to be causes of healthcare-associated infections, they are also excluded, and cannot be used to meet the PVAP definition when isolated from any eligible specimen type (to include lung tissue and pleural fluid).
 - **Fungi:** *Blastomyces*, *Histoplasma*, *Coccidioides*, *Paracoccidioides*, *Cryptococcus*, *Pneumocystis*
 - **Vector-borne bacteria:** *Anaplasma* spp., *Ehrlichia* spp., *Borrelia* spp., *Rickettsia* spp.
8. There are three criteria that can be used to meet the PVAP definition ([Figure 1](#)):
- a. Criterion 1: Positive culture meeting specific quantitative or semi-quantitative threshold ([Table 3](#));
 - b. Criterion 2: Purulent respiratory secretions AND identification of organisms NOT meeting the quantitative or semi-quantitative thresholds specified in [Table 3](#);
 - c. Criterion 3: (one of the following)
 - i. Organisms identified from pleural fluid specimen (where specimen was obtained during thoracentesis or within 24 hours of chest tube placement; pleural fluid specimens collected after a chest tube is repositioned or from a chest tube in place > 24 hours are not eligible for PVAP)
 - ii. Positive lung histopathology
 - iii. Lower respiratory specimen cytology findings suggestive of infection
 - iv. Positive diagnostic test for *Legionella* species or selected respiratory viruses
9. See [Table 3](#) for the required quantitative culture thresholds meeting the PVAP definition (Criterion 1). Note that if your laboratory reports semi-quantitative culture results, you should check with your laboratory to confirm that semi-quantitative results match the quantitative thresholds noted in [Table 3](#) (see also FAQ no. 15 at the end of this protocol).

Table 3: Threshold values for cultured specimens used in the PVAP definition

Specimen collection/technique	Values
Lung tissue	$\geq 10^4$ CFU/g tissue*
Bronchoscopically (B) obtained specimens	
Bronchoalveolar lavage (B-BAL)	$\geq 10^4$ CFU/ml*
Protected BAL (B-PBAL)	$\geq 10^4$ CFU/ml*
Protected specimen brushing (B-PSB)	$\geq 10^3$ CFU/ml*
Nonbronchoscopically (NB) obtained (blind) specimens	
NB-BAL	$\geq 10^4$ CFU/ml*
NB-PSB	$\geq 10^3$ CFU/ml*
Endotracheal aspirate (ETA)	$\geq 10^5$ CFU/ml*

CFU = colony forming units, g = gram, ml = milliliter

*Or corresponding semi-quantitative result (see FAQ no. 15 at the end of this protocol)

10. Secondary BSIs may be reported for PVAP events, provided that at least one organism identified from the blood matches an organism isolated from an appropriate respiratory tract specimen (including respiratory secretions, pleural fluid, and lung tissue). The respiratory tract specimen must have been collected on or after the 3rd day of mechanical ventilation and within 2 calendar days before or after the day of onset of worsening oxygenation to be considered for use in meeting the PVAP definition. In addition, the organisms identified from blood must have been collected during the 14-day event period, where day 1 is the day of onset of worsening oxygenation.
- In cases where PVAP is met with only the histopathology criterion and no culture or non-culture based testing is performed on an eligible respiratory specimen, and there is also a positive blood specimen, a secondary BSI is not reported.
 - In cases where a culture or non-culture based testing of respiratory secretions, pleural fluid, or lung tissue is performed and does not identify an organism that matches an organism identified from blood, a secondary BSI is not reported.
 - A matching organism is defined as one of the following:
 - If genus and species are identified in both specimens, they must be the same.
 - EXAMPLE: A blood specimen resulted with *Enterobacter cloacae* and a BAL specimen resulted with *Enterobacter cloacae* are matching organisms.
 - EXAMPLE: A blood specimen resulted with *Enterobacter cloacae* and a BAL specimen resulted with *Enterobacter agglomerans* are NOT matching organisms as the species are different.
 - If the organism is less definitively identified in one specimen than the other, the lesser identified organism must be identified to at least the genus level and at that level the organisms must be the same.
 - EXAMPLE: A BAL resulted with *Pseudomonas spp.* And a blood specimen resulted with *Pseudomonas aeruginosa* are considered a match at the genus level and therefore the BSI can be reported as secondary BSI to VAE.
EXCEPTION: In cases where an organism is identified only as “yeast” or “yeast not otherwise specified,” the organism can be considered a match to

other yeasts, when collected during the required timeframe, whether more fully identified or not.

EXAMPLE: A blood specimen reported as *Candida albicans* and a lung tissue resulted with yeast not otherwise specified are considered to have matching organisms. In this example the two organisms are considered matching organisms because the organisms are complementary (specifically *Candida* is a type of yeast).

NOTE:

This exception is limited to yeast. It does not apply to identification of organisms as Gram positive cocci, Gram negative rods, etc.

Any *Candida* species or yeast not otherwise specified, any coagulase-negative *Staphylococcus* species, and any *Enterococcus* species identified from blood cannot be deemed secondary to a PVAP, unless the organism was also identified from pleural fluid or lung tissue.

Figure 1: Ventilator-Associated Events (VAE) Surveillance Algorithm

Patient has a baseline period of stability or improvement on the ventilator, defined by ≥ 2 calendar days of stable or decreasing daily minimum* FiO_2 or PEEP values. The baseline period is defined as the 2 calendar days immediately preceding the first day of increased daily minimum PEEP or FiO_2 .

*Daily minimum defined by lowest value of FiO_2 or PEEP during a calendar day that is maintained for > 1 hour.

After a period of stability or improvement on the ventilator, the patient has at least one of the following indicators of worsening oxygenation:

- 1) Increase in daily minimum* FiO_2 of ≥ 0.20 (20 points) over the daily minimum FiO_2 of the first day in the baseline period, sustained for ≥ 2 calendar days.
- 2) Increase in daily minimum* PEEP values of ≥ 3 cmH_2O over the daily minimum PEEP of the first day in the baseline period†, sustained for ≥ 2 calendar days.

*Daily minimum defined by lowest value of FiO_2 or PEEP during a calendar day that is maintained for > 1 hour.

†Daily minimum PEEP values of 0-5 cmH_2O are considered equivalent for the purposes of VAE surveillance.

Ventilator-Associated Condition (VAC)

On or after calendar day 3 of mechanical ventilation and within 2 calendar days before or after the onset of worsening oxygenation, the patient meets **both** of the following criteria:

1) Temperature $> 38^\circ\text{C}$ or $< 36^\circ\text{C}$, **OR** white blood cell count $\geq 12,000$ cells/ mm^3 or $\leq 4,000$ cells/ mm^3 .

AND

2) A new antimicrobial agent(s) (see Appendix for eligible antimicrobial agents) is started and is continued for ≥ 4 qualifying antimicrobial days (QAD).

Infection-related Ventilator-Associated Complication (IVAC)

On or after calendar day 3 of mechanical ventilation and within 2 calendar days before or after the onset of worsening oxygenation, **ONE** of the following criteria is met (**taking into account organism exclusions specified in the protocol**):

- 1) Criterion 1: Positive culture of one of the following specimens, meeting quantitative or semi-quantitative thresholds† as outlined in protocol, **without** requirement for purulent respiratory secretions:
 - Endotracheal aspirate, $\geq 10^5$ CFU/ml or corresponding semi-quantitative result
 - Bronchoalveolar lavage, $\geq 10^4$ CFU/ml or corresponding semi-quantitative result
 - Lung tissue, $\geq 10^4$ CFU/g or corresponding semi-quantitative result
 - Protected specimen brush, $\geq 10^3$ CFU/ml or corresponding semi-quantitative result
- 2) Criterion 2: Purulent respiratory secretions (defined as secretions from the lungs, bronchi, or trachea that contain ≥ 25 neutrophils and ≤ 10 squamous epithelial cells per low power field [lpf, $\times 100$])† **PLUS** organism identified from one of the following specimens (to include qualitative culture, or quantitative/semi-quantitative culture without sufficient growth to meet Criterion #1):
 - Sputum
 - Endotracheal aspirate
 - Bronchoalveolar lavage
 - Lung tissue
 - Protected specimen brush
- 3) Criterion 3: One of the following positive tests:
 - Organism identified from pleural fluid (where specimen was obtained during thoracentesis or within 24 hours of chest tube placement; pleural fluid specimens collected after a chest tube is repositioned or from a chest tube in place > 24 hours are not eligible for PVAP)
 - Lung histopathology, defined as: 1) abscess formation or foci of consolidation with intense neutrophil accumulation in bronchioles and alveoli; 2) evidence of lung parenchyma invasion by fungi (hyphae, pseudohyphae, or yeast forms); 3) evidence of infection with the viral pathogens listed below based on results of immunohistochemical assays, cytology, or microscopy performed on lung tissue
 - Diagnostic test for *Legionella* species
 - Diagnostic test on respiratory secretions for influenza virus, respiratory syncytial virus, adenovirus, parainfluenza virus, rhinovirus, human metapneumovirus, coronavirus

† If the laboratory reports semi-quantitative results, those results must correspond to the quantitative thresholds. Refer to Table 2 and 3.

Possible Ventilator-Associated Pneumonia (PVAP)

Numerator and Denominator Data

Numerator Data: The *Ventilator-Associated Event (VAE)* form ([CDC 57.112](#)) is used to collect and report each VAE that is identified during the month selected for surveillance. The [Instructions for Completion of Ventilator-Associated Event Form](#) includes brief instructions for collection and entry of each data element on the form. The VAE form includes patient demographic information and information on the start date and location of initiation of mechanical ventilation. Additional data include the specific criteria met for identifying VAE, whether the patient developed a secondary bloodstream infection, whether the patient died, and, where applicable, the organisms detected and their antimicrobial susceptibilities.

Reporting Instruction: If no VAEs are identified during the month of surveillance, the “*Report No Events*” box must be checked on the appropriate denominator summary screen, for example, Denominators for Intensive Care Unit (ICU)/Other Locations (Not NICU or SCA), etc.

Denominator Data: Device days and patient days are used for denominators (see [Chapter 16 General Key Terms](#)). Ventilator days, which are the numbers of patients managed with ventilatory devices, are collected daily, at the same time each day, according to the chosen location using the appropriate form ([CDC 57.117](#) [Specialty Care Areas] or [57.118](#) [ICU/Other Locations]). These daily counts are summed and only the total for the month is entered into NHSN. Ventilator and patient days are collected for each of the locations monitored. When denominator data are available from electronic sources, these sources may be used as long as the counts are within +/- 5% of manually collected counts, validated for a minimum of 3 consecutive months. Validation of electronic counts should be performed separately for each location conducting VAE surveillance.

All ventilator days are counted, including ventilator days for patients on mechanical ventilation for < 3 days, and patients on high frequency ventilation and other therapies excluded from VAE surveillance. Patients with tracheostomies who are undergoing weaning from mechanical ventilation using tracheostomy collar trials are included in ventilator day counts if they are on mechanical ventilation at the time when the daily ventilator day count is performed. Patients who are not receiving mechanical ventilation via an artificial airway at the time of the daily ventilator day count are not included.

When converting from one electronic counting system to another electronic counting system, the new electronic system should be validated against manual counts as above. If electronic counts for the new electronic system are not within 5% of manual counts, resume manual counting and continue working with IT staff to improve design of electronic denominator data extraction (while reporting manual counts) until concurrent counts are within 5% for 3 consecutive months.

This guideline is important because validating a new electronic counting system against an existing electronic system can magnify errors and result in inaccurate denominator counts.

In addition to the total number of patients on ventilators on each day of surveillance, the number of patients on ventilators who are on the APRV mode of mechanical ventilation or related modes (which is a subset of all patients on ventilators) can optionally be indicated on the appropriate form ([CDC 57.117](#) and [57.118](#)).

Collection of an additional denominator, episodes of mechanical ventilation (EMV), is optionally available for VAE surveillance. The EMV denominator represents the sum of the number of episodes of mechanical ventilation that occurred in that location during the month. A single episode of mechanical ventilation for each patient is to be counted only once per month. Do note, it is possible for a patient to have more than one episode of ventilation occur during a month (for example, discontinuation of mechanical ventilation for greater than 1 calendar day followed by re-initiation of mechanical ventilation).

The EMV denominator is determined by counting all patients in the location who are on mechanical ventilation on the first day of the month regardless of eligibility for inclusion in VAE surveillance. Then, on each subsequent day of the month, count each additional patient that is started on mechanical ventilation. This would include those that are admitted to the location already on mechanical ventilation, those that are newly ventilated, and any previously ventilated patients who have new episodes of mechanical ventilation occurring during the same month. The sum of the count for the first day and each subsequent day of the month is entered in NHSN.

EXAMPLE: On January 1, there are 5 patients on mechanical ventilation in the MICU (2 patients were started on mechanical ventilation on December 24, 2 patients on December 31, and 1 patient on January 1). During the rest of the month, the following are noted: 1 patient is started on mechanical ventilation on January 8; 2 patients are transferred to the MICU on mechanical ventilation on January 15, and 1 patient who was previously ventilated (from January 1 through January 12) goes back on mechanical ventilation on January 20. No other patients are on mechanical ventilation during the month of January. The number of EMV for January is nine. This is calculated as follows: 5 patients (on mechanical ventilation on the first day of the month) + 4 patients who were either started on mechanical ventilation, transferred into the MICU on mechanical ventilation, or re-initiated on mechanical ventilation after being off of the ventilator for at least 1 calendar day = 9 EMV.

Data Analyses

All VAE data entered into NHSN can be analyzed at event (for example, VAE event) or summary level (for example, location or facility level). You can visualize both with descriptive reports (line lists, frequency tables, bar/pie charts, rate tables, and run charts) and with risk-adjusted summary metrics (SIR, SUR).

Before running reports in NHSN, generate data sets. This process freezes your NHSN data at a point in time and copies those data into defined data sets. When you want updates reflected in NHSN reports, regenerate data sets.

Types of VAE Analysis Reports

Standardized Infection Ratio (SIR)

The Standardized Infection Ratio (SIR) is a summary metric used to track HAI incidence over time at a national, state, or local level. The SIR adjusts for various facility and/or patient-level factors that contribute to HAI risk within each facility. In HAI data analysis, the SIR compares the observed (numerator) number of HAIs to the number predicted (denominator), given the standard population (specifically, the NHSN baseline), adjusting for several risk factors that have been found to be significantly associated with differences in infection incidence. The number of predicted VAE events is calculated using negative binomial regression (2015 or 2022 NHSN baselines) to estimate expected counts from facility denominator (specifically, ventilator days) and risk-factor data.

For more information on the SIR, exclusion factors and the VAE parameter estimates, refer to the appropriate SIR guide:

- 2015 Baseline: <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/nhsn-sir-guide.pdf>
- 2022 Baseline: <https://www.cdc.gov/nhsn/2022rebaseline/sir-guide.pdf>

The SIR is calculated by dividing the number of observed infections by the number of predicted infections.

$$\text{SIR} = \frac{\text{Observed (O) HAIs}}{\text{Predicted (P) HAIs}}$$

Note: A SIR will be created for each VAE Category, IVAC Plus*, and Total VAE.

$$\text{Total VAE SIR} = \frac{\text{VAC} + \text{IVAC} + \text{PVAP}}{\text{Num Predicted VAEs}}$$

$$\text{IVAC Plus SIR}^* = \frac{\text{IVAC} + \text{PVAP}}{\text{Num Predicted VAEs}}$$

*IVAC Plus SIR is only available using the 2015 baseline

A SIR greater than 1.0 indicates that more HAIs were observed than predicted; conversely, a SIR less than 1.0 indicates that fewer HAIs were observed than predicted.

NOTE: The SIR will be calculated only if the number of predicted VAEs (numPred) is ≥ 1 to help enforce a minimum precision criterion. This rule was instituted to avoid the calculation and interpretation of statistically imprecise SIRs, which typically have extreme values.

While the VAE SIR can be calculated for single locations, the measure also allows you to summarize your data by multiple locations, adjusting for differences in the incidence of VAEs among the location types. For example, you can calculate one VAE SIR adjusting for all locations reported. Similarly, you can calculate one VAE SIR for all specialty care areas in your facility.

Standardized Utilization Ratio (SUR)

The SUR, or Standardized Utilization Ratio is a summary metric used to track device use at a national, state, local, or facility level over time. The SUR adjusts for various facility and/or location-level factors that contribute to device use. The method of calculating an SUR is similar to the method used to calculate the Standardized Infection Ratio (SIR), a summary metric used in NHSN to track HAIs in device-associated HAI data analysis. The SUR compares the observed (numerator) number of device days reported to what would be predicted (denominator), given the standard population (specifically, the NHSN baseline), adjusting for factors that have been found to be significantly associated with differences in device utilization.

More information regarding the VAE 2015 and 2022 baseline SUR model and the parameter estimates, refer to:

- <https://www.cdc.gov/nhsn/2015rebaseline/index.html>
- <https://www.cdc.gov/nhsn/2022rebaseline/analysis-resources.html>

The SUR is calculated by dividing the number of observed ventilator days by the number of predicted ventilator days.

$$\text{SUR} = \frac{\text{Observed (O) Ventilator Days}}{\text{Predicted (P) Ventilator Days}}$$

A SUR greater than 1.0 indicates that more device days were observed than predicted; conversely, a SUR less than 1.0 indicates that fewer device days were observed than predicted.

VAE Rate

The VAE rate per 1000 ventilator days is calculated by dividing the number of VAEs by the number of ventilator days and multiplying the result by 1000 (ventilator days).

$$\text{VAE Rate per 1000 ventilator days} = \frac{\text{No. of VAEs}}{\text{No. of Ventilator Days}} \cdot 1000$$

The VAE rate per 100 episodes of mechanical ventilation (EMV) is calculated by dividing the number of VAEs by the number of EMV and multiplying the result by 100 (episodes of mechanical ventilation).

$$\text{VAE Rate per 100 EMV} = \frac{\text{No. of VAEs}}{\text{No. of EMV}} \cdot 100$$

Rates and SIRs that may be appropriate for use in public reporting, inter-facility comparisons, and pay-for-reporting/pay-for-performance programs are the overall VAE rate (where the numerator consists of all events meeting at least the VAC definition). Rates and SIRs that may be appropriate for internal use within an individual unit or facility include the “IVAC-plus” rate (where the numerator consists of all events meeting at least the IVAC definition), and rates of specific event types (for example, events meeting only the VAC definition, events meeting only the IVAC definition, events meeting only the PVAP definition).

Device Utilization Ratio (DUR)

The Ventilator or Device Utilization Ratio (DUR) is calculated by dividing the number of ventilator days by the number of patient days. These calculations will be performed separately for the different types of ICUs, SCAs, and other locations in the institution.

$$\text{DUR} = \frac{\text{No. of Ventilator Days}}{\text{No. of Patient Days}}$$

These calculations will be performed separately for the different types of ICUs, specialty care areas, and other locations in the institution. DURs are useful for the purposes of tracking device use over shorter periods of time and for internal trend analyses. Caution should be used when comparing rates.

Descriptive Analysis Output Options

Descriptive analysis output options of numerator and denominator data, such as line listings, frequency tables, and bar and pie charts are available in the NHSN application. SIRs, SURs and VAE rates and run charts are also available. Guides on using NHSN analysis features are available at: www.cdc.gov/nhsn/PS-Analysis-resources/reference-guides.html.

- Line List:
 - <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/linelists.pdf>
- Frequency Table:
 - <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/frequencytables.pdf>
- Bar Chart:
 - <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/BarCharts.pdf>
- Pie Chart:
 - <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/PieChart.pdf>
- Rate Table:
 - <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/ratetables.pdf>

Analysis Resources Links

- Analysis Resources Website:
 - <https://www.cdc.gov/nhsn/ps-analysis-resources/index.html>
- Analysis Quick Reference Guides:
 - <http://www.cdc.gov/nhsn/PS-Analysis-resources/reference-guides.html>
- Reporting of VAE and PedVAE:
 - <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/setup-vae-pedvae-508.pdf>
- VAE Analysis Training:
 - <https://www.cdc.gov/nhsn/training/patient-safety-component/vae.html>

Data Quality Resources Links

- Data Quality Website: <https://www.cdc.gov/nhsn/ps-analysis-resources/data-quality/index.html>
- Data Quality Manual: https://www.cdc.gov/nhsn/pdfs/pscmanual/Instructions_DQ.pdf
- Data Quality Training: <https://www.cdc.gov/nhsn/training/analysis/index.html>

Table 4. VAE Measures Available in NHSN

Measure	Calculation	Application
VAE SIR	$\frac{\text{Observed (O)HAI}}{\text{Predicted (P) HAI}}$	Both location specific and summarized measure
VAE Rates (Ventilator Days)*	$\frac{\text{No. of VAEs}}{\text{No. of Ventilator Days}} \cdot 1000$	Location specific measure only
VAE Rates (EMV)*	$\frac{\text{No. of VAEs}}{\text{No. of EMV}} \cdot 100$	Location specific measure only
Ventilator SUR	$\frac{\text{Observed (O)Ventilator Days}}{\text{Predicted (P) Ventilator Days}}$	Both location specific and summarized measure
DUR	$\frac{\text{No. of Ventilator Days}}{\text{No. of Patient Days}}$	Location specific measure only

*Rates do not account for factors that could contribute to differences in risk between facilities and locations. Therefore, comparing rates should be used with caution.

NHSN Group Analysis

NHSN Group Users can perform the same analysis as facility level users in NHSN. A few helpful tools in NHSN for groups are listed in the resources below. These tools are guides on how to start and join a Group; how to create a template to request data from facilities; how to determine the level of access granted by the facility following the previous steps; and how to analyze the facilities data.

Group Analysis Resources

- NHSN Group Users Page: <https://www.cdc.gov/nhsn/group-users/index.html>
- Group User's Guide to the Membership Rights Report: <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/membership-rights-508.pdf>
- Group User's Guide to the Line Listing- Participation Alerts: <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/group-alerts.pdf>

References

- 1) Behrendt CE. Acute respiratory failure in the United States: incidence and 31-day survival. *Chest* 2000;118:1100-5.
- 2) Kahn JM, Goss CH, Heagerty PJ, et al. Hospital volume and the outcomes of mechanical ventilation. *N Engl J Med* 2006;355:41-50.
- 3) Wunsch H, Linde-Zwirble WT, Angus DC, Hartman ME, Milbrandt EB, Kahn JM. The epidemiology of mechanical ventilation use in the United States. *Crit Care Med* 2010;38:1947-53.
- 4) Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. *N Engl J Med* 2005;353:1685-93.
- 5) Esteban A, Anzueto A, Frutos F, et al. Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28-day international study. *JAMA* 2002;287:345-55.
- 6) Dudeck MA, Weiner LM, Allen-Bridson K, et al. National Healthcare Safety Network (NHSN) Report, Data Summary for 2012, Device-associated Module. *Am J Infect Control* 2013;41:1148-66.
- 7) Klompas M. Does this patient have ventilator-associated pneumonia? *JAMA* 2007;297:1583-93.
- 8) Klompas M. Interobserver variability in ventilator-associated pneumonia surveillance. *Am J Infect Control* 2010;38:237-9.
- 9) Klompas M, Kulldorff M, Platt R. Risk of misleading ventilator-associated pneumonia rates with use of standard clinical and microbiological criteria. *Clin Infect Dis* 2008;46:1443-6.
- 10) Zilberberg MD, Shorr AF. Ventilator-associated pneumonia: the clinical pulmonary infection score as a surrogate for diagnostics and outcome. *Clin Infect Dis* 2010;51 Suppl 1:S131-5.
- 11) Girard T, Kress JP, Fuchs BD, et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a 29andomized controlled trial. *Lancet* 2008;371:126-34.
- 12) Strøm T, Martinussen T, Toft P. A protocol of no sedation for critically ill patients receiving mechanical ventilation. *Lancet* 2010;375:475-80.
- 13) The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. *N Engl J Med* 2000;342:1301-8.
- 14) Schweickert WD, Pohlman MC, Pohlman AS, et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients: a 29andomized controlled trial. *Lancet* 2009;373:1874-82.
- 15) Magill SS, Klompas M, Balk R, et al. Developing a new, national approach to surveillance for ventilator-associated events. *Crit Care Med* 2013;41:2467-75.
- 16) Klompas M, Khan Y, Kleinman K, et al. Multicenter evaluation of a novel surveillance paradigm for complications of mechanical ventilation. *PloS One* 2011;6:e18062.
- 17) Klompas M, Magill S, Robicsek A, et al. Objective surveillance definitions for ventilator-associated pneumonia. *Crit Care Med* 2012;40(12):3154-61.
- 18) Magill SS, Li Q, Gross C, et al. Incidence and characteristics of ventilator-associated events reported to the National Healthcare Safety Network in 2014. *Crit Care Med* 2016;44(12):2154-62.,
- 19) Stedman's medical dictionary. (28th ed). (2005). Philadelphia: Lippincott, Williams, & Wilkins.
- 20) Garcia, LS (Ed.). (2010). Clinical Microbiology Procedures Handbook. Herndon, VA: ASM Press, page 3.2.1.16

Appendix. List of Antimicrobial Agents Eligible for IVAC, PVAP

Antimicrobial Agent
AMIKACIN
AMPHOTERICIN B
AMPHOTERICIN B LIPOSOMAL
AMPICILLIN
AMPICILLIN/SULBACTAM
ANIDULAFUNGIN
AZITHROMYCIN
AZTREONAM
AZTREONAM/AVIBACTAM
BALOXAVIR MARBOXIL
CASPOFUNGIN
CEFAZOLIN
CEFEPIME
CEFEPIME/ENMETAZOBACTAM
CEFIDEROCOL
CEFOTAXIME
CEFOTETAN
CEFOXITIN
CEFTAROLINE
CEFTAZIDIME
CEFTAZIDIME/AVIBACTAM
CEFTOBIPROLE MEDOCARIL
CEFTOLOZANE/TAZOBACTAM
CEFTRIAXONE
CEFUROXIME
CIPROFLOXACIN
CLARITHROMYCIN
CLESROVIMAB
CLINDAMYCIN
COLISTIMETHATE
DALBAVANCIN
DELAFLORACIN
DOXYCYCLINE
ERAVACYCLINE
ERTAPENEM
FLUCONAZOLE

FOSFOMYCIN
GENTAMICIN
IMIPENEM/CILASTATIN
IMIPENEM/CILASTATIN/RELEBACTAM
ISAVUCONAZONIUM
ITRACONAZOLE
LEFAMULIN
LEVOFLOXACIN
LINEZOLID
MEROPENEM
MEROPENEM/VABORBACTAM
METRONIDAZOLE
MICAFUNGIN
MINOCYCLINE
MOLNUPIRAVIR
MOXIFLOXACIN
NAFCILLIN
NIRMATRELVIR (includes NIRMATRELVIR/RITONAVIR)
OMADACYCLINE
ORITAVANCIN
OSELTAMIVIR
OXACILLIN
PENICILLIN G
PERAMIVIR
PIPERACILLIN/TAZOBACTAM
PLAZOMICIN
POLYMYXIN B
POSACONAZOLE
REMDESIVIR
REZAFUNGIN
RIFAMPIN
SULBACTAM/DURLOBACTAM
SULFAMETHOXAZOLE/TRIMETHOPRIM
TEDIZOLID
TELAVANCIN
TETRACYCLINE
TIGECYCLINE
TOBRAMYCIN
VANCOMYCIN, intravenous only
VORICONAZOLE
ZANAMIVIR

VAE Frequently Asked Questions (FAQs)

1) When should I use VAE? Are there circumstances in which I should still use PNEU?

- VAE surveillance is location based and restricted to adult inpatient units only.
- Pediatric and neonatal units are excluded from VAE surveillance (even in circumstances where a pediatric unit may occasionally care for patients who are 18 years of age and older).
- Locations mapped to mixed age CDC location codes are excluded from VAE surveillance.
- Ventilated patients who are 18 years of age and older and who are cared for in pediatric units should be included in any in-plan PedVAP and/or PedVAE surveillance for that location.

It is NOT recommended to include in VAE surveillance young children housed in adult ICU locations who are not thought to be physiologically similar to the location's adult patient population. Facilities may want to evaluate their location mapping to be sure that locations are mapped appropriately to the correct CDC location codes. In circumstances where the populations of adults and children cared for in the same physical location is more mixed (for example, 50% adult patients and 50% pediatric patients), it is recommended that facilities weigh the possibility of establishing a virtual pediatric location for the purposes of surveillance. More information on virtual locations and location mapping can be found here: [Chapter 15 CDC Locations and Descriptions](#)

- While on high frequency ventilation, extracorporeal life support, or paracorporeal membrane oxygenation, patients are EXCLUDED from VAE surveillance.

Patients who are receiving a conventional mode of mechanical ventilation while in the prone position and patients who are receiving a conventional mode of mechanical ventilation while receiving nitric oxide therapy, helium-oxygen mixtures (heliox), or epoprostenol therapy are INCLUDED.

Patients on Airway Pressure Release Ventilation (APRV) and related modes of mechanical ventilation (see FAQ no. 14 are INCLUDED; however, during periods of time while the patient is on APRV, the VAE period of stability or improvement on the ventilator and the period of worsening oxygenation should be determined by changes in FiO₂ only, since changes in PEEP as indicated in this surveillance algorithm may not be applicable to APRV. In addition, patients with VAE who are on APRV or a related mode of mechanical ventilation at the time of VAE onset can be optionally indicated as such on the VAE Form ([CDC 57.112](#)).

- In-plan surveillance for ventilator-associated PNEU may still be conducted for pediatric patients ONLY ("PedVAP" surveillance).
- The PNEU definitions are still available for those units seeking to conduct off-plan PNEU/VAP surveillance for patients of any age and for assignment of a secondary BSI.

2) I am having difficulty visualizing how to arrange the VAE data elements to facilitate easy identification of events. Can you provide some additional guidance?

- For units in which VAE surveillance will be conducted manually, we recommend that you organize the necessary data elements in a table or spreadsheet to assist in identifying VAEs. There are several different ways in which to organize the data – you may consider limiting your spreadsheet to just include the daily minimum PEEP and FiO₂ values, and then, if a VAC event is identified, utilize other data sources to gather information on the data elements included in the IVAC and PVAP definitions. Alternatively, you may choose to include columns for all data elements (from VAC through PVAP) in a single spreadsheet.

For most patients under surveillance for VAE, the only data elements you will need to record are the ventilator days, minimum daily PEEP, and minimum daily FiO₂. The maximum and minimum daily temperatures and white blood cell counts only need to be recorded for those patients who are identified as having met criteria for VAC. The antimicrobial criterion only needs to be assessed for those patients with VAC and with an abnormal temperature or white blood cell count that meets the criteria within the IVAC definition. Microbiology and related data elements included as criteria in the PVAP definition only need to be assessed for those patients who have met the IVAC definition.

EXAMPLE: In the table below, the data elements used to meet VAC, IVAC, and PVAP definition are organized in a fashion that facilitates identification of an event, highlighted in the shaded region. In this example, MV days 3 and 4 constitute the baseline period, with stable daily minimum PEEP of 5 cmH₂O on each day. On MV days 5 and 6, the daily minimum PEEP is 8 cmH₂O, which meets the VAC criterion for worsening oxygenation. If we scan across the table, we can see that the IVAC temperature/white blood cell count criterion is not met (there are no temperatures < 36°C or > 38°C, and no white blood cell counts ≤ 4,000 cells/mm³ or ≥ 12,000 cells/mm³) – so even though the patient was started on a new antimicrobial agent and continued on that agent for 4 calendar days, IVAC is not met. Therefore, this event would be reported as a VAC, with the date of event being MV day 5.

Patient	MV Day	PEEP _{min}	FiO _{2min}	Temp _{min}	Temp _{max}	WBC _{min}	WBC _{max}	Abx	Specimen	Polys / Epis	Organism	VAE
1	1	10	1.0	37.1	37.6	4.3	4.3	None	--	--	--	--
1	2	5	0.60	36.8	37.2	4.6	4.6	None	--	--	--	--
1	3	5	0.40	37.0	37.9	5.4	5.4	None	--	--	--	--
1	4	5	0.40	36.5	37.3	9.2	9.2	Yes	--	--	--	--
1	5	8	0.50	36.3	36.9	8.4	8.4	Yes	ETA	≥ 25 / ≤ 10	<i>S. aureus</i>	VAC
1	6	8	0.40	37.2	37.5	8.5	8.8	Yes	--	--	--	
1	7	5	0.40	37.8	37.9	7.6	7.6	Yes	--	--	--	

MV = mechanical ventilation. PEEP_{min} = Daily minimum PEEP. FiO_{2min} = Daily minimum FiO₂. Temp_{min} = Daily minimum temperature. Temp_{max} = Daily maximum temperature. WBC_{min} = Daily minimum white blood cell count. WBC_{max} = Daily maximum white blood cell count. Abx = antimicrobial agents. Polys / epis = Polymorphonuclear leukocytes and squamous epithelial cells from respiratory specimen.

EXAMPLE: In the table below, by scanning across the data elements, you can see that there are no periods in which there is a stable, 2-day baseline period followed by a 2-day period where the PEEP or FiO₂ are increased 3 cmH₂O or 20 points over the first day in the baseline period. On MV days 2 and 3, the PEEP values are 7 cmH₂O and 6 cmH₂O respectively, and then increase to 9 cmH₂O on MV days 4 and 5 – but the difference between day 4 or day 5 and day 2 is only 2

cmH₂O, rather than the required 3 cmH₂O. Also, the gradual increase in FiO₂ from the time of initiation of mechanical ventilation means that there are not two days on which the FiO₂ is at least 20 points higher than on the 2 previous days. Therefore, although the temperature and white blood cell counts exceed the required thresholds for IVAC on several occasions, and the patient appears to have received a new antimicrobial agent for several days in the setting of a positive blood culture, the VAC definition is not met, and so no VAE is reported.

Patient	MV Day	PEEP _{min}	FiO _{2min}	Temp _{min}	Temp _{max}	WBC _{min}	WBC _{max}	Abx	Specimen	Polys / Epis	Organism	VAE
2	1	5	0.30	37.1	37.6	4.3	4.3	None	--	--	--	--
2	2	7	0.30	36.8	37.2	4.6	4.6	None	--	--	--	--
2	3	6	0.45	37.0	37.9	5.4	5.4	None	--	--	--	--
2	4	9	0.45	36.5	37.3	9.2	9.2	None	--	--	--	--
2	5	9	0.60	36.3	36.9	8.4	8.4	None	ETA	≥ 25 / ≤ 10	<i>S. aureus</i>	--
2	6	8	0.60	37.2	37.5	8.5	8.8	None	--	--	--	--
2	7	6	0.75	37.8	37.9	7.6	7.6	None	--	--	--	--
2	8	6	0.75	38.2	38.4	10.5	11.9	Yes	Blood	--	<i>S. aureus</i>	--
2	9	5	0.80	38.5	38.9	12.7	12.7	Yes	--	--	--	--
2	10	5	0.75	37.4	38.1	12.9	12.9	Yes	--	--	--	--
2	11	5	0.70	37.2	37.9	9.4	9.4	Yes	--	--	--	--
2	12	5	0.60	37.3	37.5	9.5	9.5	Yes	--	--	--	--
2	13	7	0.60	37.2	37.8	8.2	8.2	Yes	--	--	--	--
2	14	8	0.60	37.0	37.7	8.6	8.6	Yes	--	--	--	--

3) Sometimes patients are intubated, extubated, and reintubated several times during a single hospitalization. How do I define an episode of mechanical ventilation, and can a VAE occur in a patient who has recently been extubated?

- An episode of mechanical ventilation is defined as a period of days during which the patient was mechanically ventilated for some portion of each consecutive day during the period.

EXAMPLE: A patient is intubated and mechanically ventilated on hospital day 1. The patient remains on mechanical ventilation from hospital day 2 through 12:00 on hospital day 6. At noon on hospital day 6, the patient is extubated. The patient remains extubated on hospital day 7 and is then reintubated on hospital day 8. In this case, the first episode of mechanical ventilation is defined by hospital days 1 through 6. Since the patient was extubated on hospital day 6 and remained extubated for a full calendar day on hospital day 7, the reintubation of the patient on hospital day 8 defines the start of a second episode of mechanical ventilation. See figure, below.

Hosp Day No.	1	2	3	4	5	6	7	8	9	10
MV Episode	1	1	1	1	1	1	--	2	2	2
MV Day No.	1	2	3	4	5	6—extubated at 12:00	--	1--reintubated	2	3

1 full calendar day off mechanical ventilation, followed by reintubation, defines a new episode of mechanical ventilation.

EXAMPLE: A patient is intubated and mechanically ventilated on hospital day 1. The patient remains on mechanical ventilation from hospital day 2 through hospital day 6 at 12:00. At 12:00

on hospital day 6, the patient is extubated. The patient is reintubated at 21:00 on hospital day 7 and remains intubated and mechanically ventilated till 14:00 on hospital day 10. The patient is extubated at 14:00 on hospital day 10 and remains extubated until hospital discharge on day 15. In this case, there is only a single episode of mechanical ventilation, defined by hospital days 1 through 10, because the patient was extubated on hospital day 6 but reintubated the next calendar day (hospital day 7). See figure, below.

Hosp Day No.	1	2	3	4	5	6	7	8	9	10
MV Episode	1	1	1	1	1	1	1	1	1	1
MV Day No.	1	2	3	4	5	6—extubated at 12:00	7—reintubated at 21:00	8	9	10—extubated at 14:00

Patient was reintubated on the calendar day following extubation (days 6-7). Because there is not 1 calendar day off mechanical ventilation, there is only 1 episode of mechanical ventilation.

- A VAE can occur in a patient who has been extubated and is then reintubated, subject to the amount of time the patient was off the ventilator, as noted in the examples below.

EXAMPLE: A patient is intubated and mechanically ventilated on hospital day 1. The patient remains on mechanical ventilation from hospital day 2 through 12:00 on hospital day 6. At noon on hospital day 6, the patient is extubated. The patient remains extubated on hospital day 7 and is then reintubated on hospital day 8. In this case, because the patient has been extubated for 1 full calendar day (hospital day 7), the “VAE clock” starts over with reintubation on hospital day 8. To meet VAE during this second episode of mechanical ventilation, the patient would have to have at least 2 days of stability or improvement and at least 2 days of worsening oxygenation on the ventilator; therefore, the earliest date on which the patient could meet VAE criteria would be hospital day 11 (stable or improving settings on hospital days 8 and 9, period of worsening oxygenation on hospital days 10 and 11). The VAE date of event would be reported as hospital day 10—the first day of worsening oxygenation meeting VAE criteria. See figure, below.

Hosp Day No.	1	2	3	4	5	6	7	8	9	10	11
MV Episode	1	1	1	1	1	1	--	2	2	2	2
MV Day No.	1	2	3	4	5	6 - extubated at 12:00	--	1 - reintubated	2	3	4
VAE Criterion	--	--	--	--	--	--	--	Day 1 of stability or improvement	Day 2 of stability or improvement	Day 1 of worsening oxygenation	Day 2 of worsening oxygenation

EXAMPLE: A patient is intubated and mechanically ventilated on hospital day 1. The patient remains on mechanical ventilation from hospital day 2 through 12:00 on hospital day 6, when the patient is extubated. The patient is reintubated at 21:00 on hospital day 7. In this case, there is no “new” episode of mechanical ventilation, since there was not a full, ventilator-free calendar day. Therefore, the period of worsening oxygenation may be determined to have started on hospital day 7, the day of reintubation, as long as PEEP or FiO₂ criteria are met. PEEP and FiO₂ data from hospital days 5 and 6 (through the time of extubation) may be used to determine whether a period of stability and improvement occurred, and these data may be compared to PEEP and FiO₂ data obtained from the time of reintubation on hospital day 7 and beyond to determine whether

at least 2 days of worsening oxygenation occurred. The earliest that the patient could meet VAE criteria would be hospital day 8 (assuming stable or improving ventilator settings on hospital days 5 and 6, and two days of worsening oxygenation meeting criteria on hospital days 7 and 8). The VAE date of event would be reported as hospital day 7—the first day of worsening oxygenation meeting VAE criteria. See figure, below.

Hosp Day No.	1	2	3	4	5	6	7	8	9	10
MV Episode	1	1	1	1	1	1	1	1	1	1
MV Day No.	1	2	3	4	5	6 - extubated at 12:00	7 - reintubated at 21:00	8	9	10
VAE Criterion					Day 1 of stability or improvement	Day 2 of stability or improvement	Day 1 of worsening oxygenation	Day 2 of worsening oxygenation		

- A patient may also meet criteria for VAC while intubated and then meet criteria for IVAC (or PVAP) following extubation.

EXAMPLE: A patient is intubated and mechanically ventilated on hospital day 1. The patient remains on mechanical ventilation until 11:00 on hospital day 9, when the patient is extubated. Criteria for VAC are met during the episode of mechanical ventilation, based on 2 days of stability or improvement (MV days 5 and 6) followed by 2 days of worsening oxygenation (MV days 7 and 8). The date of the event is MV day 7, the day of onset of worsening oxygenation. Within the 2 days before and 2 days after the day of onset of worsening oxygenation, the patient has a temperature of 38.4°C, and a new antimicrobial agent is started (meropenem, on MV day 8—see FAQ nos. 4-7). The new antimicrobial agent is continued for at least 4 days (hospital days 8 through 11). Therefore, even though the patient was extubated during the VAE Window Period on hospital day 9 and remained extubated through hospital day 11 (the day on which all IVAC criteria were fulfilled), the event should be reported as an IVAC. Patient extubation does not end a VAE Window Period that has been set by meeting VAC criteria. See figure, below.

Hosp Day No.	4	5	6	7	8	9	10	11
MV Day No.	4	5	6	7	8	9 - extubated at 11:00	--	--
VAE Criterion	--	Day 1 of stability or improvement	Day 2 of stability or improvement	Day 1 of worsening oxygenation	Day 2 of worsening oxygenation	Temp 38.4°C	--	--
Antimicrobial agent	Ceftriaxone	Ceftriaxone	Ceftriaxone	Ceftriaxone	Meropenem	Meropenem	Meropenem	Meropenem

↑
Patient has fulfilled all IVAC criteria, and IVAC should be reported. Date of the IVAC event is hospital day/MV day 7.

4) How do I figure out if an antimicrobial agent is “new” for the IVAC definition?

- A new antimicrobial agent is defined as any agent listed in the [Appendix](#) that is initiated on or after 3 days of mechanical ventilation AND in the VAE Window Period (defined by the two days before, the day of, and the two days after the VAE date of event—as long as all of these days are on or after the 3rd day of mechanical ventilation). The agent is considered new for the purposes of

this definition if it was NOT given to the patient on either of the 2 days preceding the current start date. The agent must be administered via one of the routes listed in [Table 1](#).

See the example in the figure below:

MV Day No.	4	5	6	7	8	9	10	11
VAE Criterion				Day 1 of worsening oxygenation meeting VAE PEEP or FiO ₂ thresholds	Day 2 of worsening oxygenation meeting VAE PEEP or FiO ₂ thresholds			

Example of the 5-day period during which the first dose of a new antimicrobial agent must be given to meet requirements of IVAC definition.

EXAMPLE: A single dose of intravenous vancomycin is given to a patient on the VAE onset date (which is the day of onset of worsening oxygenation meeting VAE criteria, in this case MV day 7), and was not given to the patient during the 2 previous days (MV days 5 and 6). Vancomycin is therefore considered a new antimicrobial agent. See figure, below.

MV Day No.	4	5	6	7	8	9	10
VAE Criterion	--	Day 1 of stability or improvement	Day 2 of stability or improvement	Day 1 of worsening oxygenation	Day 2 of worsening oxygenation		
Antimicrobial agent	None	None	None	Single dose of vancomycin ordered and administered	None	None	Single dose of vancomycin ordered and administered

A single dose of vancomycin is ordered and administered to the patient within the period defined by the two days before, the day of, and the two days after the VAE onset date. Note that no vancomycin was given in the 2 preceding days, and so vancomycin is a "new" antimicrobial agent for the purposes of the VAE definition.

EXAMPLE: If meropenem is given to a patient on the VAE date of event (which is the day of onset of worsening oxygenation meeting VAE criteria, in this case MV day 7), and was not given to the patient during the 2 previous days (MV days 5 and 6), then meropenem is considered a new antimicrobial agent (see figure below). Note that the patient is also receiving ceftriaxone and receives doses during the 5-day period around the onset of worsening oxygenation (first dose during the 5-day period was on MV day 5). However, because ceftriaxone was given to the patient the day before the 5-day period (on MV day 4), ceftriaxone does not count as a new antimicrobial agent for the purposes of the IVAC definition.

MV Day No.	4	5	6	7	8	9	10
VAE Criterion	--	Day 1 of stability or improvement	Day 2 of stability or improvement	Day 1 of worsening oxygenation	Day 2 of worsening oxygenation		
Antimicrobial agent	Ceftriaxone	Ceftriaxone	Ceftriaxone	Meropenem	Meropenem	Meropenem	Meropenem

First dose of meropenem during the 5-day period around the onset of worsening oxygenation. Note that no meropenem was given in the 2 preceding days, and so meropenem is a "new" antimicrobial agent for the purposes of the VAE definition.

5) I have figured out that a new antimicrobial agent was given to the patient. How do I determine whether it was continued for 4 days?

- Make sure you are referencing the Medication Administration Record. You need to know which antimicrobial agents were actually administered to the patient. Antimicrobial orders or dispensing information is not sufficient.
- You do not need to know the dose or frequency of administration.
- Four consecutive Qualifying Antimicrobial Days (QADs)—starting within the VAE Window Period—are needed to meet the IVAC criterion. A QAD is a day on which the patient was administered an antimicrobial agent that was determined to be “new” within the VAE Window Period. Days between administrations of a new antimicrobial agent also count as QADs as long as there is a gap of no more than 1 calendar day between administrations of the same antimicrobial agent. For example, if levofloxacin is given on VAE Day 1, has not been given in the 2 preceding calendar days, and is given again on VAE Days 3, 5, and 7, there are 7 QADs—because the days between levofloxacin doses also count as QADs.
- The requirement for 4 consecutive QADs can be met with 4 days of therapy with the same antimicrobial (with a gap of no more than 1 calendar day between administrations of that antimicrobial)—or it can be met with 4 days of therapy with multiple antimicrobial agents, as long as each antimicrobial was started within the VAE Window Period.
- **EXAMPLE:** In the figure below, meropenem would meet the antimicrobial criterion of the IVAC definition because at least one dose was given on 4 consecutive days.

MV Day No.	1	2	3	4	5	6	7
VAE Criterion	--	Day 1 of Stability or improvement	Day 2 of stability or improvement	Day 1 of worsening oxygenation	Day 2 of worsening oxygenation		
Antimicrobial agent	Ceftriaxone	Ceftriaxone	Ceftriaxone	Meropenem	Meropenem	Meropenem	Meropenem
QAD	No	No	No	Yes	Yes	Yes	Yes

EXAMPLE: In the figure below, the 3 drugs shown in bold lettering all qualify as new antimicrobial agents, and therefore the antimicrobial criterion of IVAC is met, since the patient is given 4 consecutive days of new antimicrobial agents.

MV Day No.	1	2	3	4	5	6	7
VAE Criterion	--	Day 1 of Stability or improvement	Day 2 of stability or improvement	Day 1 of worsening oxygenation	Day 2 of worsening oxygenation		
Antimicrobial agent	Ceftriaxone	Ceftriaxone	Ceftriaxone	Meropenem	Imipenem/Cilastatin	Piperacillin/Tazobactam	Piperacillin/Tazobactam
QAD	No	No	No	Yes	Yes	Yes	Yes

EXAMPLE: In the figure below, levofloxacin is a new antimicrobial agent (it was started during the VAE Window Period, on MV day 3, and was not given in the 2 days preceding the first day of administration). There are gaps of no more than 1 calendar days between days on which levofloxacin is given, and so the intervening days also count as QADs. In this example, there are 5 QADs (MV days 3-7); therefore, the antimicrobial criterion of IVAC is met.

MV Day No.	1	2	3	4	5	6	7
VAE Criterion	--	Day 1 of Stability or improvement	Day 2 of stability or improvement	Day 1 of worsening oxygenation	Day 2 of worsening oxygenation		
Antimicrobial agent			Levofloxacin		Levofloxacin		Levofloxacin
QAD	No	No	Yes	Yes	Yes	Yes	Yes

6) There are many patients in my ICU with renal insufficiency and/or who are receiving hemodialysis. These patients may receive certain antimicrobial agents on an infrequent dosing schedule (for example, every 48 hours). How do I determine whether they have received 4 consecutive days of new antimicrobial therapy?

- See FAQ no. 5 above. You do not need to know the patient's renal function, the dose of the antimicrobial agent, or the frequency of administration. The antimicrobial criterion rules remain the same, regardless of whether patients have renal dysfunction or not.

7) What if the patient is being given one-time doses of intravenous vancomycin? How do I take that into account when using the IVAC surveillance definition?

- The rules for determining whether the antimicrobial criterion is met do not require that you know the dose or frequency of administration.
- Make sure that vancomycin qualifies as a new antimicrobial agent—that it was not given in the 2 days preceding the day on which vancomycin was given during the VAE Window Period.
- Check to see whether there are 4 consecutive QADs with vancomycin; if there are gaps of no more than 1 calendar day between days on which vancomycin is given, the intervening days may be counted as QADs. If there are gaps of longer than 1 calendar day between days of vancomycin therapy, the requirement for 4 consecutive QADs cannot be met using vancomycin alone—but make sure to check whether the 4 consecutive QAD requirement is met by considering any other antimicrobials being administered to the patient. See the example in the figure below.

EXAMPLE: A patient is given a single dose of vancomycin 1 gram IV on MV day 5. Since vancomycin was started on or after day 3 of mechanical ventilation, and no vancomycin was administered on MV days 2, 3, or 4, vancomycin qualifies as a new antimicrobial agent. A second, single dose of vancomycin 1 gram IV is administered on MV day 8. Because there is a gap of more than 1 calendar day between days of vancomycin administration (there is a gap of 2 days in this example), the requirement for 4 consecutive QADs is not met, and therefore the IVAC antimicrobial criterion is not met.

MV Day No.	2	3	4	5	6	7	8	9
VAE Criterion	--	--	Day 1 of Stability or improvement	Day 2 of stability or improvement	Day 1 of worsening oxygenation	Day 2 of worsening oxygenation		
Antimicrobial agent	None	None	None	Vancomycin 1 gram IV x 1 dose	None	None	Vancomycin 1 gram IV x 1 dose	None
QAD	No	No	No	Yes	No	No	Yes	No

8) Can I only report pathogens if they are isolated in cultures of appropriate specimens? What about pathogens identified by non-culture based diagnostic testing?

- PVAP incorporates results of non-culture based microbiological diagnostic testing. For PVAP, pathogens that are grown in culture OR selected pathogens that are identified as a result of other laboratory testing (for example, antigen testing, polymerase chain reaction (PCR), immunohistochemistry, etc.) should be reported. Do not limit reporting to just those organisms isolated in culture. For example, influenza A identified by PCR in a patient meeting PVAP criteria should be reported as a pathogen for that event.

9) The PVAP Criterion 3 includes “positive diagnostic tests” for *Legionella* species and selected viruses. What kinds of diagnostic tests can be used to meet the definition?

- Diagnostic testing practices may vary from facility to facility and change over time as better tests are developed. Listed here are some examples of diagnostic tests for specific pathogens included in the PVAP definition. Positive results of these tests may be used in meeting the PVAP definition. Your facility may use other testing methods; positive results obtained using these methods may also be appropriate for use in meeting the PVAP definition. If you have a question regarding a diagnostic test method, check with your laboratory.
- For *Legionella* species, positive results of any of the following, performed on the appropriate specimen: urinary antigen, *Legionella*-specific respiratory culture, paired serology (4-fold rise in titer between acute and convalescent specimens), direct fluorescent antibody stain, immunohistochemistry stain, or nucleic acid detection assays (such as PCR) performed on a respiratory specimen.
- For respiratory viruses (influenza, respiratory syncytial virus [RSV], parainfluenza viruses, human metapneumovirus, coronaviruses, rhinoviruses and adenovirus), positive results for any of the following:
 - Performed on an appropriate respiratory specimen – molecular tests (for example, PCR, nucleic acid amplification), antigen detection tests (including rapid tests), immunofluorescence tests, viral culture, or
 - Performed on appropriate pathologic specimens – immunohistochemical assays, cytology, microscopy, or
 - Performed on appropriately timed paired sera (acute and convalescent) – serological assays demonstrating seroconversion or a significant rise in antibody titer.

10) What about organisms identified from pleural fluid and lung tissue specimens? Can I report any pathogen identified from a lung tissue, or from a pleural fluid specimen, assuming the specimen was obtained during thoracentesis or within 24 hours of chest tube insertion?

- Any pathogen identified from lung tissue, when that lung tissue was obtained during an open lung biopsy, video-assisted thoracoscopic surgery, or via other transthoracic or transbronchial biopsy approach, may be reported with the exception of the excluded pathogens belonging to the following genera.
 - **Fungi:** *Blastomyces*, *Histoplasma*, *Coccidioides*, *Paracoccidioides*, *Cryptococcus*, *Pneumocystis*
 - **Vector-borne bacteria:** *Anaplasma spp.*, *Ehrlichia spp.*, *Borrelia spp.*, *Rickettsia spp.*

- Any pathogen identified from pleural fluid, when that fluid was obtained during thoracentesis or within 24 hours of chest tube insertion (where there was no repositioning of the chest tube prior to specimen collection), may be reported with the exception of the excluded pathogens belonging to the following genera.
 - Fungi:** *Blastomyces*, *Histoplasma*, *Coccidioides*, *Paracoccidioides*, *Cryptococcus*, *Pneumocystis*
 - Vector-borne bacteria:** *Anaplasma spp.*, *Ehrlichia spp.*, *Borrelia spp.*, *Rickettsia spp.*

11) How are “purulent respiratory secretions” defined?

- Purulent respiratory secretions used to meet Criterion 2 of the PVAP definition are defined as:
 - Secretions from the lungs, bronchi, or trachea with ≥ 25 neutrophils and ≤ 10 squamous epithelial cells per low power field [lpf, x100].
 - If the laboratory reports semi-quantitative results, you should check with your laboratory to be certain that the semi-quantitative results match the quantitative thresholds noted above.
- If your laboratory is not able to provide additional information on how a semi-quantitative reporting system corresponds to quantitative reporting ranges for neutrophils and squamous epithelial cells, here is some guidance from the *Clinical Microbiology Procedures Handbook* (3rd ed., 2010)*:

1+ = occasional or rare = < 1 cell per low power field [lpf, x100]

2+ = few = 1-9 cells per low power field [lpf, x100]

3+ = moderate = 10-25 cells per low power field [lpf, x100]

4+ = heavy = > 25 cells per low power field [lpf, x100]

*Reference: Garcia, LS (Ed.). (2010). *Clinical Microbiology Procedures Handbook*. Herndon, VA: ASM Press, page 3.2.1.16.

- With this range in mind, and in the absence of additional information from your laboratory, “purulent respiratory secretions” are defined as secretions that contain many, heavy, numerous, 4+ or ≥ 25 neutrophils per low power field [lpf, x100] AND no, rare, occasional, few, 1+ or 2+, or ≤ 10 squamous epithelial cells per low power field [lpf, x100].
- If your laboratory uses a different reporting format for results of direct examination of respiratory secretions, you may still be able to use the purulent respiratory secretions in meeting the PVAP definition. See the instructions available in the VAE Protocol, [Table 2](#).

12) What is the definition of “positive lung histopathology” that can be used to meet the PVAP definition?

- If the lung tissue specimen was obtained via open lung biopsy, video-assisted thoracoscopic surgery, or via other transthoracic or transbronchial biopsy approach, it is eligible for consideration in meeting the PVAP definition (Criterion 3).
- Histopathological findings that can be used to meet the PVAP definition include:
 - Abscess formation or foci of consolidation with intense neutrophil accumulation in bronchioles and alveoli;

- Evidence of lung parenchyma invasion by fungi (hyphae, pseudohyphae, or yeast forms);
- Evidence of infection with the viral pathogens listed in FAQ no. 9 (above) based on results of immunohistochemical assays, cytology, or microscopy performed on lung tissue.
- Additionally, lower respiratory specimen cytology findings suggestive of infection are eligible for consideration in meeting the PVAP definition (Criterion 3).

13) I am still having trouble understanding the time frame that defines a VAE. Can you explain what is meant by this statement that appears in the algorithm: “On or after calendar day 3 of mechanical ventilation and within 2 calendar days before or after the onset of worsening oxygenation”?

- The intent of these criteria is to determine whether a VAC is due to an infectious process (IVAC) and/or pneumonia (PVAP) by looking for corroborating inflammatory and infectious signs at the time of VAC onset. The criterion, “on or after calendar day 3” is intended to exclude inflammatory and infectious signs present on the first two days of mechanical ventilation because they are more likely to be due to pre-existing conditions than ventilator-acquired complications. The criterion, “within 2 calendar days before or after the onset of worsening oxygenation,” is intended to identify infectious and inflammatory signs that arise at the same time as VAC and may therefore point to the cause of the VAC.
- The figures below illustrate the time frame that defines a VAE. The date of event is the first day of worsening oxygenation, defined by the PEEP and FiO₂ thresholds outlined in the algorithm. The date of event defines the time frame within which all other criteria must be met. In the examples below, the shaded area defines the VAE Window Period in which IVAC criteria (temperature or white count abnormalities, plus a new antimicrobial agent started and continued for at least 4 days) must be met, and in which a PVAP criterion must be met.

Keep in mind that VAE criteria must be met based on specimens collected or antimicrobial agents started after day 2 of mechanical ventilation.

EXAMPLE 1: When the onset date of the VAE occurs early in the course of mechanical ventilation (for example, day 3 or 4 of mechanical ventilation), the period in which certain inflammatory and infectious criteria are sought for IVAC and PVAP is shorter, because the first 2 days of mechanical ventilation are excluded from the normal 5-day window surrounding the day of increased ventilator support.

MV Day No.	1	2	3	4	5	6	7
Worsening oxygenation	--	Day 1 of Stability or improvement	Day 2 of stability or improvement	Day 1 of worsening oxygenation	Day 2 of worsening oxygenation	-	
Temperature abnormality or white blood cell count abnormality			←An abnormal temperature or white blood cell count, according to the algorithm parameters, must be documented within this shaded period→				
Antimicrobial agent			←New agent must be started on any day within this shaded period, and then continued for at least 4 days→				
Purulent respiratory secretions, positive culture, positive histopathology			←Specimen must be collected on any day within this shaded period→				

EXAMPLE 2: When the onset date of the VAE occurs later in the course of mechanical ventilation, the period in which certain criteria must be met is a day longer, because the patient has already been on mechanical ventilation for more than 3 days and therefore inflammatory and infectious signs arising anywhere in the full 5-day window surrounding the day of increased ventilator settings can count towards IVAC and PVAP.

MV Day No.	10	11	12	13	14	15	16
Worsening oxygenation	--	Day 1 of Stability or improvement	Day 2 of stability or improvement	Day 1 of worsening oxygenation	Day 2 of worsening oxygenation		
Temperature abnormality or white blood cell count abnormality		←An abnormal temperature or white blood cell count, according to the algorithm parameters, must be documented within this shaded period→					
Antimicrobial agent		←New agent must be started on any day within this shaded period, and then continued for at least 4 days→					
Purulent respiratory secretions, positive culture, positive histopathology		←Specimen must be collected on any day within this shaded period→					

14) Providers in my ICU use different types of mechanical ventilation for different patients. Can you explain the circumstances in which mechanically ventilated patients are to be excluded from VAE surveillance and the circumstances in which mechanically ventilated patients should be included in VAE surveillance?

- VAE surveillance is restricted to adult inpatient locations. Patients on mechanical ventilation who are in adult inpatient locations in acute care and long-term acute care hospitals and inpatient rehabilitation facilities are eligible for inclusion in VAE surveillance.
- Patients are excluded from VAE surveillance during periods of time when they are receiving high frequency ventilation, or if they are receiving extracorporeal life support or paracorporeal membrane oxygenation (for example, extracorporeal membrane oxygenation - ECMO). Patients may be on these types of support for a portion of a calendar day, but not for the entire calendar day. In these instances, the patient is eligible for inclusion in VAE surveillance during the portion of the calendar day when the patient was being mechanically ventilated using a conventional type of mechanical ventilation. Ventilator settings documented while on a conventional mode of ventilation are to be used to select daily minimum PEEP and FiO₂ values for the calendar day.
- Patients are included in surveillance if they are on a ventilator (as defined in the VAE surveillance protocol) and are being mechanically ventilated through an endotracheal or tracheostomy tube using a conventional mode of mechanical ventilation (such as volume controlled, pressure controlled, or pressure support mechanical ventilation).
 - Patients on conventional mechanical ventilation who are receiving nitric oxide, helium-oxygen mixtures (heliox), or epoprostenol therapy are included in surveillance.
 - Patients on conventional mechanical ventilation who are being ventilated in the prone position are included in surveillance.
- Patients are also included in surveillance if they are on a ventilator (as defined in the VAE surveillance protocol) and are being mechanically ventilated through an endotracheal or tracheostomy tube using Airway Pressure Release Ventilation (APRV) or related modes. APRV is a mode of mechanical ventilation characterized by continuous application of positive airway pressure with an intermittent pressure release phase. Some terms that are used to indicate APRV or a related mode of mechanical ventilation may include, but are not limited to, BiLevel, Bi Vent,

BiPhasic, PCV+, DuoPAP. NHSN recommends reviewing the [VAE Surveillance Mechanical Ventilation Table](#) on the VAE webpage and additionally consulting with your Respiratory Therapy and/or Critical Care staff to determine if the patient's ventilator mode is APRV or a related mode.

- i. For patients on APRV or related modes the entire calendar day, the period of worsening oxygenation following a period of stability or improvement on the ventilator that is required for identification of a VAE will be defined by the FiO_2 criterion within the VAE surveillance definition algorithm. The PEEP criterion may not be applicable in patients on APRV or related modes of mechanical ventilation.
 - ii. For patients on APRV or related modes for a portion of the calendar day, identification of a VAE can be determined in either the PEEP or FiO_2 parameter. However, only ventilator settings documented during the calendar day while on a conventional mode of ventilation are to be used to select the daily minimum PEEP.
- If you have questions about mechanical ventilation, you should check with the Respiratory Therapy and/or Critical Care departments in your facility.

15) My laboratory only performs semi-quantitative cultures of lower respiratory tract specimens and cannot provide me with additional guidance to help me know what semi-quantitative culture result corresponds to the quantitative thresholds specified in Criterion 1 of the PVAP definition. Can you provide more information?

For the purposes of this surveillance, and in the absence of additional information available from your laboratory, a semi-quantitative result of "moderate" "many" "numerous" or "heavy" growth, or 2+, 3+ or 4+ growth, meets the PVAP definition (Criterion 1).

Pediatric Ventilator-Associated Event (PedVAE)

For use in neonatal and pediatric locations only

Table of Contents

Introduction	1
Settings	3
Inclusion and Exclusion Criteria	3
Definitions	4
Figure 1: Pediatric Ventilator-Associated Events (PedVAE) Surveillance Algorithm	9
Meeting PedVAE Surveillance Algorithm	10
Additional Definitions	11
Reporting Instructions	13
Numerator and Denominator Data	14
Data Analyses	16
Table 1: PedVAE Measures Available in NHSN	18
References	19
Appendix. List of Eligible Antimicrobial Agents	20

Introduction

Mechanical ventilation is an essential, life-saving therapy for patients with critical illness and respiratory failure. Hundreds of thousands of patients receive mechanical ventilation in the United States each year [1-3]. These patients are at high risk for complications and poor outcomes, including death [1-5]. Ventilator-associated pneumonia (VAP), sepsis, acute respiratory distress syndrome (ARDS), pulmonary embolism, barotrauma, and pulmonary edema are among the complications that can occur in patients receiving mechanical ventilation. Such complications can lead to longer duration of mechanical ventilation, longer stays in the intensive care unit (ICU) and hospital, increased healthcare costs, and increased risk of disability and death. In preterm neonates, prolonged mechanical ventilation for respiratory distress syndrome can contribute to the development of chronic lung disease [6]. Prolonged mechanical ventilation in extremely low birthweight infants is also associated with neurodevelopmental delay [7].

Surveillance for ventilator-associated events in the National Healthcare Safety Network (NHSN) prior to 2013 was limited to VAP. Traditional VAP definitions, including the NHSN PNEU definitions (revised in 2002), have well-described limitations [8-11]. These definitions typically require radiographic evidence of pneumonia, although data suggest that chest radiograph findings do not accurately identify VAP. The subjectivity and variability inherent in chest radiograph technique, interpretation, and reporting make chest imaging ill-suited for inclusion in a definition algorithm to be used for the potential purposes of public reporting, inter-facility comparisons, and pay-for-reporting and pay-for-performance programs. Another major limitation of the available VAP definitions is their reliance on specific clinical signs or symptoms, which are subjective and may be poorly or inconsistently documented in the medical record.

The limitations of VAP surveillance definitions have implications for prevention. Valid and reliable surveillance data are necessary for assessing the effectiveness of prevention strategies. It is notable that some effective measures for improving outcomes of patients on mechanical ventilation do not specifically target pneumonia prevention [12-15].

In 2011, CDC organized a working group composed of members of several stakeholder organizations to address the limitations of the NHSN PNEU definitions and propose a new approach to surveillance for Ventilator-Associated Events (VAE) for NHSN, focusing on adult patients [16]. The organizations represented in the working group included the Critical Care Societies Collaborative (the American Association of Critical-Care Nurses, the American College of Chest Physicians, the American Thoracic Society, and the Society for Critical Care Medicine), the American Association for Respiratory Care, the Association of Professionals in Infection Control and Epidemiology, the Council of State and Territorial Epidemiologists, the Healthcare Infection Control Practices Advisory Committee's Surveillance Working Group, the Infectious Diseases Society of America, and the Society for Healthcare Epidemiology of America.

The VAE surveillance definition algorithm developed by the working group was implemented in the NHSN in January 2013 and is available for use in adult locations only. The definition algorithm is based on objective, streamlined, and potentially automatable criteria that identify a broad range of conditions and complications occurring in mechanically ventilated patients in adult locations. Data indicate that streamlined, objective algorithms to detect ventilator-associated events are easily implemented, can make use of electronic health record systems to automate event detection, and identify events that are clinically important and associated with outcomes such as ICU and hospital length of stay and mortality [17, 18]. Research suggests that most VAEs in adult patients are due to pneumonia, ARDS, atelectasis, and pulmonary edema [17]. These are significant clinical conditions that may be preventable. VAE rates and event characteristics in adult inpatient locations reporting data to NHSN in 2014 have been published [19].

VAE surveillance was not initially made available for use in neonatal and pediatric locations, based on the recommendations of a separate working group that CDC organized in 2012 to consider whether the VAE surveillance approach could also be used in neonatal and pediatric inpatient populations. This working group included representatives from the following organizations: the American Academy of Pediatrics (AAP) Committee on the Fetus and Newborn, the AAP Committee on Infectious Diseases, the AAP Section on Critical Care, the AAP Section on Pediatric Pulmonology, the American Association of Critical-Care Nurses, the American College of Chest Physicians Pediatric Chest Medicine Network, the American Thoracic Society Scientific Assembly on Pediatrics, the American Association for Respiratory Care, the Children's Hospital Association, the Association of Professionals in Infection Control and Epidemiology, the Council of State and Territorial Epidemiologists, the Pediatric Infectious Diseases Society, the Pediatric Cardiac Intensive Care Society, the Society for Healthcare Epidemiology of America, the Society of Critical Care Medicine, and the Vermont-Oxford Network. In mid-2013, this working group determined that there were insufficient data to inform development of a pediatric VAE definition. Further working group discussions were postponed until 2015, following publication of the results of a study on pediatric VAE definition criteria [20]. This study demonstrated that events defined by changes in the fraction of inspired oxygen (FiO₂) and mean airway pressure (MAP) were associated with increases in patient length of stay as well as mortality [20]. After additional discussion with the working group, CDC decided to move forward with pediatric VAE (PedVAE) development and implementation in NHSN.

NOTE: The PedVAE definition algorithm is for use in surveillance. It is not a clinical definition algorithm and is not intended for use in the clinical management of patients. Examples provided throughout this protocol are for illustration purposes only and are not intended to represent actual clinical scenarios.

Settings

Inpatient locations eligible to participate in PedVAE surveillance are those neonatal and pediatric locations in acute care hospitals, long term acute care hospitals, and inpatient rehabilitation facilities where denominator data (ventilator and patient days) can be collected for patients. Such locations may include critical/intensive care units (ICU), specialty care areas (SCA), step-down units, and wards. A complete listing of neonatal and pediatric inpatient locations can be found in [Chapter 15 CDC Locations and Descriptions](#).

Non-acute care mapped locations in acute care facilities (chronic care units in acute care facilities) are not eligible to participate in PedVAE surveillance.

It is not required to monitor for PedVAEs after discharge if a patient is transferred to another facility while still on mechanical ventilation. However, if discovered, any PedVAE with a date of event on the day of discharge or the day after discharge is attributed to the discharging location and should be included in any PedVAE reported to NHSN by the discharging location. No additional ventilator days are reported.

Inclusion and Exclusion Criteria

Patients INCLUDED in PedVAE surveillance:

- All patients in the neonatal and pediatric inpatient locations found in Chapter 15, regardless of patient's age
- Patients on a [ventilator](#) (as defined below) who are receiving
 - a conventional mode of mechanical ventilation (for example, synchronized intermittent mandatory ventilation)
 - high-frequency oscillatory or jet ventilation
- Patients on a [ventilator](#) (as defined below) who are receiving a conventional mode of mechanical ventilation or high frequency oscillatory or jet ventilation
 - while in the prone position
 - while receiving surfactant, corticosteroids, nitric oxide therapy, helium-oxygen mixtures (heliox), or epoprostenol therapy

Patients EXCLUDED from PedVAE surveillance:

- All patients in the adult inpatient locations found in Chapter 15, regardless of patient's age
- Patients on extracorporeal life support or paracorporeal membrane oxygenation are excluded from PedVAE surveillance during periods of time when the support is in place for the entire calendar day

Definitions

Ventilator: Any device used to support, assist, or control respiration (inclusive of the weaning period) through the application of positive pressure to the airway when delivered via an artificial airway, specifically an oral/nasal endotracheal or tracheostomy tube.

Ventilation and lung expansion devices that deliver positive pressure to the airway (for example, CPAP, BiPAP, Bi-level, IPPB, and PEEP) via non-invasive means (for example, nasal prongs, nasal mask, full face mask, total mask, etc.) are not considered ventilators unless positive pressure is delivered via an artificial airway (oral/nasal endotracheal or tracheostomy tube).

PedVAE: PedVAEs are identified by deterioration in respiratory status after a period of stability or improvement on the ventilator ([Figure 1](#)).

Patients must be mechanically ventilated for at least 4 calendar days to fulfill PedVAE criteria (where the day of intubation and initiation of mechanical ventilation is day 1).

Mean Airway Pressure (MAP): The average pressure exerted on the airway and lungs from the beginning of inspiration until the beginning of the next inspiration [21]. In patients on mechanical ventilation, MAP is the most powerful influence on oxygenation and is determined by positive end-expiratory pressure (PEEP), peak inspiratory pressure (PIP), inspiratory time, and frequency [22]. A sustained increase in the daily minimum MAP of ≥ 4 cmH₂O following a period of stability or improvement on the ventilator is one of two criteria that can be used in meeting the PedVAE definition.

Fraction of Inspired Oxygen (FiO₂): The fraction of oxygen in inspired gas. For example, the FiO₂ of ambient air is 0.21; the oxygen concentration of ambient air is 21%. In patients on mechanical ventilation, the FiO₂ is one of the key parameters that can be adjusted depending on the patient's oxygenation needs and is typically in the range of 0.21 (oxygen concentration of 21%) to 1.0 (oxygen concentration of 100%). A sustained increase in the daily minimum FiO₂ of ≥ 0.25 (25 points) following a period of stability or improvement on the ventilator is one of the two criteria that can be used in meeting the PedVAE definition.

Daily Minimum MAP: The lowest value of MAP during a calendar day. For the purposes of surveillance:

- When determining the daily minimum MAP value, round MAP values in the following manner: a MAP of 10.00 – 10.49 is rounded to 10 and a MAP of 10.50 – 10.99 is rounded to 11. For example, a patient who is intubated and started on mechanical ventilation at 21:30 on June 1, with a MAP of 10.35 cmH₂O at 21:30 and a MAP of 10.54 cmH₂O at 23:30 would have a daily minimum MAP of 10 cmH₂O on June 1.
- In patients < 30 days old, MAP values of 0-8 cmH₂O are considered equivalent; therefore, any day on which the daily minimum MAP was 0-8 cmH₂O would be assigned a daily minimum value of 8 cmH₂O.
- In patients ≥ 30 days old, MAP values of 0-10 cmH₂O are considered equivalent; therefore, any day on which the daily minimum MAP was 0-10 cmH₂O would be assigned a daily minimum value of 10 cmH₂O.

EXAMPLE: The patient (< 30 days old) is intubated at 18:00. MAP values through the remainder of the calendar day are as follows:

Time	18:00	19:00	20:00	21:00	22:00	23:00
MAP (cmH ₂ O)	12.35	11.15	9.28	9.43	11.42	11.35

In this example, the daily minimum MAP for the purposes of PedVAE surveillance is 9 cmH₂O. MAP readings of 9.28 and 9.43 are rounded to 9.

EXAMPLE: The patient is intubated at 18:00. MAP values are as follows through the remainder of the calendar day:

Time	18:00	19:00	20:00	21:00	22:00	23:00
MAP (cmH ₂ O)	12	12	10	12	10	12

In this example, the daily minimum MAP for the purposes of PedVAE surveillance is 10 cmH₂O. This is the lowest value recorded during the calendar day. When making daily minimum MAP determinations the value does not need to be maintained for > 1 hour.

EXAMPLE: MAP values are as follows through the course of a calendar day for a patient ≥ 30 days old:

Time	01:00	04:00	08:00	12:00	16:00	20:00
MAP (cmH ₂ O)	9 (10)	11	9 (10)	11	11	12

In this example, the daily minimum MAP is 10 cmH₂O. Although 9 cmH₂O is the lowest value recorded, in patients ≥ 30 days old MAP values of 0-10 cmH₂O are considered equivalent; therefore, the daily minimum MAP of 9 cmH₂O at 01:00 and 08:00 would be assigned a daily minimum value of 10 cmH₂O.

EXAMPLE: You are reviewing a < 30-day old patient's ventilator data on Wednesday morning to determine the daily minimum MAP values for Monday and Tuesday. The neonatal ICU (NICU) monitors and records MAP every 30 minutes. You see that the lowest MAP on Monday (9 cmH₂O) was recorded at 23:30 when the episode of mechanical ventilation was initiated for this patient. The patient remained at this MAP for an additional 30 minutes on Tuesday morning and was then at MAP 12 cmH₂O for the rest of the day on Tuesday. What do you record as the daily minimum MAP for Monday and for Tuesday? The lowest (and only) value of 9 cmH₂O is recorded as the daily minimum MAP for Monday. On Tuesday, the daily minimum MAP should also be recorded as 9 cmH₂O, as it is the lowest value recorded on Tuesday.

Day	Time	MAP (cmH ₂ O)
Monday	23:30	9
Tuesday	00:00	9
Tuesday	00:30	9
Tuesday	01:00	12

Day	Time	MAP (cmH ₂ O)
Tuesday	01:30	12
Tuesday	02:00 through 23:30	12

Daily Minimum MAP determinations are made using documented MAP values specific to the calendar day and independently of the MAP values recorded on the previous calendar day or the next calendar day.

EXAMPLE: You are reviewing a < 30-day old patient's ventilator data on Thursday morning to determine the daily minimum MAP values for Tuesday and Wednesday. The neonatal ICU (NICU) monitors and records MAP every 8 hours. You see that the lowest MAP on Tuesday is 8 cmH₂O, last recorded at 23:30. The first recorded MAP on Wednesday, at 07:30, is 12 cmH₂O and the patient remains at that MAP for the remainder of the calendar day on Wednesday. What do you record as the daily minimum MAP for Tuesday and for Wednesday? On Tuesday, the daily minimum MAP is 8 cmH₂O, as it is the lowest value recorded on that calendar day. On Wednesday, the daily minimum MAP is 12 cmH₂O, as it is the lowest value recorded on that calendar day. Only MAP values documented during the given calendar day are taken into consideration when determining the daily minimum MAP for that calendar day.

Day	Time	MAP (cmH ₂ O)
Tuesday	07:30	9
Tuesday	15:30	8
Tuesday	23:30	8
Wednesday	07:30	12
Wednesday	15:30	12
Wednesday	23:30	12

Daily Minimum FiO₂: The lowest value of FiO₂ during a calendar day that is set on the ventilator and *maintained for > 1 hour*. This requirement that the daily minimum FiO₂ be the lowest setting maintained for > 1 hour will ensure that units monitoring and recording FiO₂ settings hourly or more frequently than once per hour are able to apply the PedVAE surveillance FiO₂ criterion in a standardized way.

If ventilator settings are monitored and recorded less frequently than once per hour (for example, every 2 hours or every 4 hours), the daily minimum FiO₂ is simply the lowest value of FiO₂ set on the ventilator during the calendar day.

EXAMPLE: FiO₂ is set at the following values through the course of a calendar day:

Time	00:00	04:00	08:00	12:00	16:00	20:00
FiO ₂	1.0	0.6	0.4	0.5	0.55	0.6

In this example, the daily minimum FiO₂ for the purposes of PedVAE surveillance is 0.4. FiO₂ settings are monitored and recorded every 4 hours. Each setting has been maintained for > 1 hour; therefore, the lowest recorded FiO₂ setting for the calendar day is the daily minimum FiO₂.

If there is no documentation of values maintained for > 1 hour (for example, the lowest value of FiO₂ is set late in the calendar day, mechanical ventilation is discontinued early in the calendar day, FiO₂ settings are changed very frequently throughout the calendar day), the daily minimum FiO₂ will default to the lowest value of FiO₂ set on the ventilator during the calendar day (regardless of how long that setting was maintained).

- For example, a patient who is intubated and started on mechanical ventilation at 23:00 on June 1, with a FiO₂ setting of 0.30 from 23:00 to 00:00, would have a daily minimum FiO₂ of 0.30 on June 1 for the purposes of PedVAE surveillance.

In units tracking FiO₂ settings every hour or more frequently than every hour, there must be sufficient consecutive recordings of a specific FiO₂ setting to meet the minimum required duration of > 1 hour.

- In units tracking FiO₂ every 15 minutes, 5 consecutive recordings of FiO₂ at a certain level would be needed to meet the required > 1 hour minimum duration (for example, 09:00, 09:15, 09:30, 09:45, and 10:00).
- In units tracking FiO₂ every 30 minutes, 3 consecutive recordings of FiO₂ at a certain level would be needed to meet the required > 1 hour minimum duration (for example, 09:00, 09:30, and 10:00).
- In units tracking FiO₂ every hour, 2 consecutive recordings of FiO₂ at a certain level would be needed to meet the required > 1 hour minimum duration (for example, 09:00 and 10:00).

EXAMPLE: The patient is intubated at 18:00. FiO₂ is set at the following values through the remainder of the calendar day:

Time	18:00	19:00	20:00	21:00	22:00	23:00
FiO ₂	1.0	0.8	0.5	0.5	0.8	0.8

In this example, the daily minimum FiO₂ for the purposes of PedVAE surveillance is 0.5. FiO₂ settings are being monitored and recorded every hour. There are two consecutive hours where the FiO₂ setting is noted to be 0.5 (20:00 and 21:00), and therefore the required minimum duration of > 1 hour is met.

EXAMPLE: The patient is intubated at 18:00. FiO₂ is set at the following values through the remainder of the calendar day:

Time	18:00	19:00	20:00	21:00	22:00	23:00
FiO ₂	0.8	0.8	0.5	0.8	0.5	0.8

In this example, the daily minimum FiO₂ for the purposes of PedVAE surveillance is 0.8. FiO₂ settings are being monitored and recorded every hour. Although the lowest FiO₂ is 0.5, it is recorded at two non-consecutive time points only (20:00, and then 22:00), and so the required > 1 hour minimum duration is not met. There are two consecutive hours where the FiO₂ setting is noted to be 0.8 (18:00 and 19:00), and therefore the required minimum duration of > 1 hour is met to allow use of this setting as the daily minimum FiO₂ for PedVAE surveillance.

EXAMPLE: You are reviewing a patient's ventilator settings on Friday morning to determine the daily minimum FiO₂ value for Thursday. The patient was intubated and initiated on mechanical

ventilation at 21:45 hours on Thursday. The pediatric ICU (PICU) monitored and recorded FiO_2 settings for the patient every 15 minutes during the remainder of the day on Thursday. Based on the information recorded in the table below, what should you record as the daily minimum FiO_2 for Thursday? In this example, since there is no setting that is maintained for > 1 hour during the calendar day, the daily minimum FiO_2 for Thursday is 0.70 (70%). This is the lowest value of FiO_2 set on the ventilator during the calendar day.

Day	Time	FiO_2
Thursday	21:45	Intubated; 1.0
	22:00	1.0
	22:15	0.90
	22:30	0.90
	22:45	0.70
	23:00	0.80
	23:15	0.85
	23:30	0.85
	23:45	0.85

Daily Minimum FiO_2 determinations are made using documented FiO_2 values specific to the calendar day and independently of the FiO_2 values recorded on the previous calendar day or the next calendar day.

EXAMPLE: You are reviewing a patient's ventilator data on Thursday morning to determine the daily minimum FiO_2 values for Tuesday and Wednesday. The neonatal ICU (NICU) monitors and records FiO_2 every 8 hours. You see that the lowest FiO_2 on Tuesday is 0.70 (70%), last recorded at 23:30. The first recorded FiO_2 on Wednesday, at 07:30, is 0.95 (95%) and the patient remains at that FiO_2 for the remainder of the calendar day on Wednesday. What do you record as the daily minimum FiO_2 for Tuesday and for Wednesday? On Tuesday, the daily minimum FiO_2 is 0.70 (70%), as it is the lowest value recorded on that calendar day. On Wednesday, the daily minimum FiO_2 is 0.95 (95%), as it is the lowest value recorded on that calendar day. Only FiO_2 values documented during the given calendar day are taken into consideration when determining the daily minimum FiO_2 for that calendar day.


Day	Time	FiO_2
Tuesday	07:30	0.75
Tuesday	15:30	0.70
Tuesday	23:30	0.70
Wednesday	07:30	0.95
Wednesday	15:30	0.95
Wednesday	23:30	0.95

Baseline Period: The baseline period of stability or improvement on the ventilator is defined as the 2 calendar days immediately preceding the first day of increased daily minimum MAP or FiO_2 , and must be characterized by ≥ 2 calendar days of stable or decreasing daily minimum MAP or FiO_2 values (specifically, the daily minimum MAP or FiO_2 on the second day of the baseline period of stability or improvement must be equal to or less than the daily minimum MAP or FiO_2 on the first day of the baseline period of stability

or improvement). Note that the daily minimum MAP is the lowest value documented during a calendar day, and the daily minimum FiO₂ is the lowest value documented during a calendar day that was maintained for > 1 hour (see daily minimum FiO₂ definition for exception to the > 1 hour requirement).

Period of Worsening Oxygenation: The period of worsening oxygenation is defined as an increase in the daily minimum MAP values of at least 4 cmH₂O over the daily minimum MAP of the first day in the baseline period or an increase in the daily minimum FiO₂ of at least 0.25 (25 points) over the daily minimum FiO₂ of the first day in the baseline period, that immediately follows the baseline period and is sustained for at least 2 or more calendar days.

Figure 1: Pediatric Ventilator-Associated Events (PedVAE) Surveillance Algorithm



Meeting PedVAE Surveillance Algorithm

EXAMPLE: In the example below, in a patient < 30 days old, the baseline period is mechanical ventilation (MV) days 1 through 4 (shaded in light gray), and the period of worsening oxygenation is MV days 5 and 6 (shaded in darker gray), where the daily minimum MAP is ≥ 4 cmH₂O greater than the daily minimum MAP during the baseline period (keeping in mind that daily minimum MAP values 0-8 cmH₂O in a patient < 30 days should be considered to be equal to 8 cmH₂O for the purposes of surveillance, and an increase in the daily minimum MAP to at least 12 cmH₂O, sustained for at least 2 calendar days, would be needed to meet the PedVAE definition).

MV Day	Daily minimum MAP (cmH ₂ O)	Daily minimum FiO ₂ (oxygen concentration, %)	PedVAE
1	7 (8)	1.00 (100%)	
2	7 (8)	0.50 (50%)	
3	8	0.50 (50%)	
4	8	0.50 (50%)	
5	12	0.50 (50%)	✓
6	12	0.50 (50%)	

EXAMPLE: In the example below, the baseline period is mechanical ventilation (MV) days 3 and 4 (shaded in light gray), and the period of worsening oxygenation is MV days 5 and 6 (shaded in darker gray), where the daily minimum FiO₂ is ≥ 0.25 (25 points) over the daily minimum FiO₂ during the baseline period.

MV Day	Daily minimum MAP (cmH ₂ O)	Daily minimum FiO ₂ (oxygen concentration, %)	PedVAE
1	12	1.00 (100%)	
2	11	0.50 (50%)	
3	9	0.40 (40%)	
4	9	0.40 (40%)	
5	11	0.70 (70%)	✓
6	11	0.70 (70%)	

EXAMPLE: In the example below, there is no PedVAE because the FiO₂ on MV day 4 is higher than the FiO₂ on MV day 3 (and therefore not stable or decreasing) – even though the FiO₂ on MV days 5 and 6 meets the 25-point threshold when compared with the daily minimum FiO₂ on MV days 3 and 4.

MV Day	Daily minimum MAP (cmH ₂ O)	Daily minimum FiO ₂ (oxygen concentration, %)	PedVAE
1	12	1.00 (100%)	
2	11	0.50 (50%)	
3	9	0.35 (35%)	
4	9	0.40 (40%)	
5	11	0.70 (70%)	No event
6	11	0.70 (70%)	

Additional Definitions

Date of Event: The date of onset of worsening oxygenation. This is defined as the first calendar day in which the daily minimum MAP or FiO₂ increases above the thresholds outlined in the PedVAE definition algorithm (specifically, day 1 of the required ≥ 2 -day period of worsening oxygenation following a ≥ 2 -day period of stability or improvement on the ventilator).

The earliest date of event for PedVAE is day 3 of mechanical ventilation (where the day of intubation and initiation of mechanical ventilation is day 1).

The “date of event” is NOT the date on which all PedVAE criteria have been met. It is the first day (of a ≥ 2 -day period) on which either of the worsening oxygenation thresholds (for MAP or FiO₂) is met.

EXAMPLE: A patient is intubated in the Emergency Room for severe community-acquired pneumonia and admitted to the PICU (day 1). The patient stabilizes and improves on days 2-5, with a daily minimum FiO₂ of 0.35 (35%) on days 4 and 5. On day 6, the patient experiences respiratory deterioration and requires a minimum FiO₂ of 0.60 (60%) on days 6 and 7, meeting the criteria for a PedVAE. The date of the PedVAE event is day 6.

14-day Event Period: PedVAEs are defined by a 14-day period, starting on the day of onset of worsening oxygenation (the date of event, day 1). While patients may have multiple PedVAEs during a single hospitalization, a new PedVAE cannot be identified or reported until this 14-day period has elapsed. The 14-day event period is event date to event date, so a new baseline period of stability or improvement can occur during the previous event period.

EXAMPLE: A patient is intubated and mechanical ventilation (MV) is initiated in the PICU (MV day 1). The patient is stable during the 6 following calendar days (MV days 2-7). On MV days 8 and 9, the patient’s minimum daily MAP is increased more than 4 cmH₂O over the first day in the baseline period, therefore meeting the PedVAE MAP threshold. The PedVAE is defined by the period encompassing MV days 8 through 21 (14 days, starting on day 1 of worsening oxygenation, which in this case is MV day 8). If the patient were to experience a period of stability or improvement on the ventilator on MV days 20 and 21, followed by another 2-day period of worsening on MV days 22 and 23, a new PedVAE would be reported, since the second period of worsening oxygenation occurred more than 14 days after the start of initial period of worsening oxygenation.

Episode of Mechanical Ventilation: Defined as a period of days during which the patient was mechanically ventilated for some portion of each consecutive day.

A break in mechanical ventilation of at least one full calendar day, followed by reintubation and/or reinitiation of mechanical ventilation during the same hospitalization, defines a new episode of mechanical ventilation.

EXAMPLE: A patient is intubated and mechanical ventilation is initiated at 23:00 on hospital day 1. The patient remains intubated and mechanically ventilated from hospital days 2-10. The patient is extubated at 09:00 on hospital day 11 and remains extubated on hospital day 12. The patient is reintubated and mechanical ventilation is reinitiated on hospital day 13. The patient remains

intubated and mechanically ventilated from hospital day 14-18. This patient has had two episodes of mechanical ventilation (days 1-11 and days 13-18), separated by at least one full calendar day off of mechanical ventilation.

Location of Attribution: The inpatient location where the patient was assigned on the PedVAE date of event, which is further defined as the date of onset of worsening oxygenation.

EXAMPLE: Patient is intubated and ventilated in the Operating Room on hospital day 1 and then is admitted post-operatively to the NICU on hospital day 1, still on the ventilator. On hospital day 3, the patient experiences the onset of worsening oxygenation, manifested by an increase in the daily minimum FiO_2 of ≥ 0.25 (25 points). On day 4 (also the 4th day of mechanical ventilation) the patient meets criteria for a PedVAE. This is reported as a PedVAE for the NICU.

EXCEPTION: **Transfer Rule:** If the PedVAE date of event is on the day of transfer or the day following transfer from one inpatient location to another in the same facility or to a new facility (where the day of transfer is day 1), the event is attributed to the transferring location. This is called the Transfer Rule. If the patient was in multiple locations within the transfer rule time frame, attribute the PedVAE to the **first** location in which the patient was housed the day before the PedVAE date of event. See Transfer Rule examples below.

EXAMPLE: On hospital day 6, the patient is extubated in the PICU and transferred to the stepdown unit. The next day, while in the stepdown unit (day 7), the patient experiences worsening oxygenation and is reintubated and transferred back to the PICU. Criteria for PedVAE are met the next day (hospital day 8). In this case, the day prior to extubation and the day of extubation (hospital days 5 and 6) count as the required 2-day period of stability or improvement. The day of reintubation (hospital day 7) and the following day (hospital day 8) count as the required 2-day period of worsening oxygenation. Because the date of event occurred on the day following transfer out of the PICU, the event is reported as a PedVAE for the PICU.

Hospital Day	MV Day	Daily minimum FiO_2 (oxygen concentration, %)	PedVAE DOE	Location	Location of Attribution
5	5	0.30 (30%)		PICU	
6	6	0.30 (30%) (extubated at 09:00)		PICU -> Stepdown (transferred at 18:00)	
7	7	0.60 (60%) (reintubated at 10:00)	✓	Stepdown -> PICU (transferred at 10:15)	PICU
8	8	0.60 (60%)		PICU	

EXAMPLE: Patient intubated and mechanically ventilated for 8 days in the NICU of Hospital A. The patient was stable on the ventilator in Hospital A from days 3-6. In the evening on day 7 the patient began to have episodes of desaturation and on day 8 the patient was transferred to Hospital B (day 1 in Hospital B). The day after transfer (day 2 in Hospital B), the patient meets criteria for PedVAE. The date of the event, the first day of the period of worsening oxygenation meeting PedVAE MAP or FiO_2 thresholds, is day 1 in Hospital B. The infection preventionist (IP) from Hospital B calls the IP at Hospital A to report that this patient was admitted to Hospital B with a PedVAE. This PedVAE should be reported by Hospital A and attributed to the Hospital A NICU. No additional ventilator days are reported by Hospital A.

Hospital Day for Hospital A	Hospital Day for Hospital B	Daily minimum FiO ₂ (oxygen concentration, %)	PedVAE DOE	Location	Location of Attribution
6		0.30 (30%)		Hospital A	
7		0.30 (30%)		Hospital A	
8	1	0.60 (60%)	✓	Hospital A -> Hospital B	Hospital A
	2	0.60 (60%)		Hospital B	

Reporting Instructions

1. Conducting in-plan PedVAE surveillance means monitoring patients for the presence of events meeting the PedVAE definition.
2. If the date of event (date of onset of worsening oxygenation) is on or after the date of documentation of evidence of consent AND the patient is being supported for organ donation purposes, the event should not be reported as a PedVAE.
3. Secondary BSIs are not reported or attributable to a PedVAE.
4. Clinical findings associated with a PedVAE may assist in better understanding the etiology and focusing efforts to prevent PedVAEs [23-25]. Should a facility choose to provide the following information, the PedVAE form includes optional data fields to report:
 - a. Clinical diagnoses or events that were associated with the PedVAE. Note that multiple events may be reported for a single PedVAE.
 - b. Antimicrobial agents listed in the [Appendix](#) that are administered on the date of event or within the 2 days before or 2 days after the event. The name of the specific antimicrobial agent and the administration initiation date may also be reported.
 - c. Pathogens detected by culture or non-culture based microbiological testing of upper or lower respiratory specimens with a specimen collection date on the date of event or within the 2 days before or 2 days after the date of event or in blood with a specimen collection date within the 2 days before the date of event and up to 13 days after the date of event.

NOTE: Because organisms belonging to the following genera are typically causes of community-associated respiratory infections and are rarely or are not known to be causes of healthcare-associated infections, they are excluded and cannot be reported.

- **Fungi:** *Blastomyces*, *Histoplasma*, *Coccidioides*, *Paracoccidioides*, *Cryptococcus*, *Pneumocystis*
 - **Vector-borne bacteria:** *Anaplasma spp.*, *Ehrlichia spp.*, *Borrelia spp.*, *Rickettsia spp.*
- d. *Legionella* or *Streptococcus pneumoniae* detected by urine antigen testing with a date of specimen collection on the date of event or within the 2 days before or 2 days after the event.

Numerator and Denominator Data

Numerator Data: The *Pediatric Ventilator-Associated Event (PedVAE)* form ([CDC 57.113](#)) is used to collect and report each PedVAE that is identified during the month selected for surveillance. The [Instructions for Completion of Pediatric Ventilator-Associated Event PedVAE Form](#) includes brief instructions for collection and entry of each data element on the form. The PedVAE form includes patient demographic information and information on the start date and location of initiation of mechanical ventilation. Additional data include the specific criteria met for identifying PedVAE, information about whether the patient was on antimicrobial drugs or had pathogens detected in culture or non-culture based microbiological testing, whether the patient died, and, where applicable, the organisms detected and their antimicrobial susceptibilities.

Reporting Instruction: If no PedVAEs are identified during the month of surveillance, the “*Report No Events*” box must be checked on the appropriate denominator summary screen, for example, Denominators for Intensive Care Unit (ICU)/Other Locations (Not NICU or SCA), etc.

Denominator Data: Device days and patient days are used for denominators (see [Chapter 16 General Key Terms](#)). Ventilator days, which are the number of patients managed with ventilatory devices, are collected daily, at the same time each day, according to the chosen location using the appropriate form ([CDC 57.116](#) [NICU] or [CDC 57.117](#) [Specialty Care Areas] or [CDC 57.118](#) [ICU/Other Locations]). These daily counts are summed and only the total for the month is reported. Ventilator and patient days are collected for each of the locations monitored.

All ventilator days are counted, including ventilator days for patients on mechanical ventilation for < 3 days, and ventilator days for patients on extracorporeal life support or paracorporeal membrane oxygenation who are excluded from PedVAE surveillance. Patients with tracheostomies who are undergoing weaning from mechanical ventilation using tracheostomy collar trials are included in ventilator day counts if they are on mechanical ventilation at the time when the daily ventilator day count is performed. Patients who are not receiving mechanical ventilation via an artificial airway at the time of the daily ventilator count are not included.

When denominator data are available from electronic sources, these sources may be used as long as the counts are within +/- 5% of manually collected counts, validated for a minimum of 3 consecutive months. Validation of electronic counts should be performed separately for each location conducting PedVAE surveillance.

When converting from one electronic counting system to another electronic counting system, the new electronic system should be validated against manual counts as above. If electronic counts for the new electronic system are not within 5% of manual counts, resume manual counting and continue working with IT staff to improve design of electronic denominator data extraction (while reporting manual counts) until concurrent counts are within 5% for 3 consecutive months.

This guideline is important because validating a new electronic counting system against an existing electronic system can magnify errors and result in inaccurate denominator counts.

Collection of an additional denominator, episodes of mechanical ventilation (EMV), is optionally available for PedVAE surveillance. The EMV denominator represents the sum of the number of episodes

of mechanical ventilation that occurred in that location during the month. A single episode of mechanical ventilation for each patient is to be counted only once per month. Do note, it is possible for a patient to have more than one episode of ventilation occur during a month (for example, discontinuation of mechanical ventilation for greater than 1 calendar day followed by reinitiation of mechanical ventilation).

The EMV denominator is determined by counting all patients in the location who are on mechanical ventilation on the first day of the month regardless of eligibility for inclusion in PedVAE surveillance. Then, on each subsequent day of the month, count each additional patient that is started on mechanical ventilation. This would include those that are admitted to the location already on mechanical ventilation, those that are newly ventilated, and any previously ventilated patients who have new episodes of mechanical ventilation occurring during the same month. The sum of the count for the first day and each subsequent day of the month is reported.

EXAMPLE: On January 1, there are 5 patients on mechanical ventilation in the PICU (2 patients were started on mechanical ventilation on December 24, 2 patients on December 31, and 1 patient on January 1). During the rest of the month, the following are noted: 1 patient is started on mechanical ventilation on January 8; 2 patients are transferred to the PICU on mechanical ventilation on January 15; and 1 patient who was previously ventilated (from January 1 through January 12) goes back on mechanical ventilation on January 20. No other patients are on mechanical ventilation during the month of January. The number of EMV for January is nine. This is calculated as follows: 5 patients (on mechanical ventilation on the first day of the month) + 4 patients who were either started on mechanical ventilation, transferred into the PICU on mechanical ventilation, or reinitiated on mechanical ventilation after being off of the ventilator for at least 1 calendar day = 9 EMV.

Data Analyses

All PedVAE data entered into NHSN can be analyzed at event (specifically, PedVAE event) or summary level (for example, location or facility level). You can visualize both with descriptive reports, such as line lists, frequency tables, bar/pie charts, rate tables, and run charts.

Before running reports in NHSN, generate data sets. This process freezes your NHSN data at a point in time and copies those data into defined data sets. When you want updates reflected in NHSN reports, regenerate data sets.

Types of PedVAE Analysis Reports

Standardized Infection Ratio (SIR)

The Standardized Infection Ratio (SIR) is a summary metric used to track HAI incidence over time at a national, state, or local level. The SIR adjusts for various facility and/or patient-level factors that contribute to HAI risk within each facility. In HAI data analysis, the SIR compares the observed (numerator) number of HAIs to the number predicted (denominator), given the standard population (specifically, the NHSN baseline), adjusting for several risk factors that have been found to be significantly associated with differences in infection incidence. The number of predicted PedVAE events is calculated using negative binomial regression (2022 NHSN baseline) to estimate expected counts from facility denominator (specifically, ventilator days) and risk-factor data.

For more information on the SIR, exclusion factors, and the VAE parameter estimates, refer to the SIR guide:

- 2022 Baseline: <https://www.cdc.gov/nhsn/2022rebaseline/sir-guide.pdf>

The SIR is calculated by dividing the number of observed infections by the number of predicted infections.

$$SIR^* = \frac{\text{Observed (O) HAIs}}{\text{Predicted (P) HAIs}}$$

*PedVAE SIR is only available under the 2022 baseline.

PedVAE Rate

The PedVAE rate per 1000 ventilator days is calculated by dividing the number of PedVAEs by the number of ventilator days and multiplying the result by 1000 (ventilator days).

$$\text{PedVAE Rate per 1000 ventilator days} = \frac{\text{No. of PedVAEs}}{\text{No. of Ventilator Days}} \cdot 1000$$

The PedVAE rate per 100 episodes of mechanical ventilation (EMV) is calculated by dividing the number of PedVAEs by the number of episodes of mechanical ventilation and multiplying the result by 100 (episodes of mechanical ventilation).

$$\text{PedVAE Rate per 100 EMV} = \frac{\text{No. of PedVAEs}}{\text{No. of EMV}} \cdot 100$$

Device Utilization Ratio (DUR)

The Ventilator or Device Utilization Ratio (DUR) is calculated by dividing the number of ventilator days by the number of patient days. These calculations will be performed separately for the different types of ICUs, SCAs, and other locations in the institution.

$$\text{DUR} = \frac{\text{No. of Ventilator Days}}{\text{No. of Patient Days}}$$

Descriptive Analysis Output Options

Descriptive analysis output options of numerator and denominator data, such as line listings, frequency tables, and bar and pie charts are also available in the NHSN application. Guides on using NHSN analysis features are available at: www.cdc.gov/nhsn/PS-Analysis-resources/reference-guides.html.

- Line List: <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/linelists.pdf>
- Frequency Table: <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/frequencytables.pdf>
- Bar Chart: <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/BarCharts.pdf>
- Pie Chart: <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/PieChart.pdf>
- Rate Table: <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/ratetables.pdf>

Analysis Resources Links

- Analysis Resources Website: <https://www.cdc.gov/nhsn/ps-analysis-resources/index.html>
- Analysis Quick Reference Guides: <http://www.cdc.gov/nhsn/PS-Analysis-resources/reference-guides.html>
- Reporting of VAE and PedVAE: <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/setup-vae-pedvae-508.pdf>
- PedVAE Analysis Training: <https://www.cdc.gov/nhsn/training/patient-safety-component/pedvae.html>

Data Quality Resources Links

- Data Quality Website: <https://www.cdc.gov/nhsn/ps-analysis-resources/data-quality/index.html>
- Data Quality Manual: https://www.cdc.gov/nhsn/pdfs/psmanual/Instructions_DQ.pdf
- Data Quality Training: <https://www.cdc.gov/nhsn/training/analysis/index.html>

Table 1: PedVAE Measures Available in NHSN

Measure	Calculation	Application
PedVAE Rates (Ventilator Days)*	$\frac{No}{\text{Denominator}} \cdot 1000$	Location specific measure only
PedVAE Rates (EMV)*	$\frac{No}{\text{Denominator}} \cdot 1000$	Location specific measure only
DUR	$\frac{No. of Ventilator Days}{No. of Patient Days}$	Location specific measure only

*Rates do not adjust for differences in risk factors across locations/facilities; use caution when comparing rates.

NHSN Group Analysis

NHSN Group Users can perform the same analysis as facility level users in NHSN. A few helpful tools in NHSN for groups are listed in the resources below. These tools are guides on how to start and join a Group; how to create a template to request data from facilities; how to determine the level of access granted by the facility following the previous steps; and how to analyze the facilities data.

Group Analysis Resources

- NHSN Group Users Page: <https://www.cdc.gov/nhsn/group-users/index.html>
- Group User's Guide to the Membership Rights Report: <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/membership-rights-508.pdf>
- Group User's Guide to the Line Listing - Participation Alerts: <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/group-alerts.pdf>

References

- 1) Behrendt CE. Acute respiratory failure in the United States: incidence and 31-day survival. *Chest* 2000;118:1100-5.
- 2) Kahn JM, Goss CH, Heagerty PJ, et al. Hospital volume and the outcomes of mechanical ventilation. *N Engl J Med* 2006;355:41-50.
- 3) Wunsch H, Linde-Zwirble WT, Angus DC, Hartman ME, Milbrandt EB, Kahn JM. The epidemiology of mechanical ventilation use in the United States. *Crit Care Med* 2010;38:1947-53.
- 4) Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. *N Engl J Med* 2005;353:1685-93.
- 5) Esteban A, Anzueto A, Frutos F, et al. Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28-day international study. *JAMA* 2002;287:345-55.
- 6) Fraser J, Walls M, McGuire W. Respiratory complications of preterm birth. *BMJ* 2004;329:962-5.
- 7) Walsh MC, Morris BH, Wraga LA, et al. Extremely low birthweight neonates with protracted ventilation: mortality and 18-month neurodevelopmental outcomes. *J Pediatrics* 2005;146:798-804.
- 8) Klompas M. Does this patient have ventilator-associated pneumonia? *JAMA* 2007;297:1583-93.
- 9) Klompas M. Interobserver variability in ventilator-associated pneumonia surveillance. *Am J Infect Control* 2010;38:237-9.
- 10) Klompas M, Kulldorff M, Platt R. Risk of misleading ventilator-associated pneumonia rates with use of standard clinical and microbiological criteria. *Clin Infect Dis* 2008;46:1443-6.
- 11) Zilberberg MD, Shorr AF. Ventilator-associated pneumonia: the clinical pulmonary infection score as a surrogate for diagnostics and outcome. *Clin Infect Dis* 2010;51 Suppl 1:S131-5.
- 12) Girard T, Kress JP, Fuchs BD, et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial. *Lancet* 2008;371:126-34.
- 13) Strøm T, Martinussen T, Toft P. A protocol of no sedation for critically ill patients receiving mechanical ventilation. *Lancet* 2010;375:475-80.
- 14) The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. *N Engl J Med* 2000;342:1301-8.
- 15) Schweickert WD, Pohlman MC, Pohlman AS, et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. *Lancet* 2009;373:1874-82.
- 16) Magill SS, Klompas M, Balk R, et al. Developing a new, national approach to surveillance for ventilator-associated events. *Crit Care Med* 2013;41:2467-75.
- 17) Klompas M, Khan Y, Kleinman K, et al. Multicenter evaluation of a novel surveillance paradigm for complications of mechanical ventilation. *PLoS One* 2011;6:e18062.
- 18) Klompas M, Magill S, Robicsek A, et al. Objective surveillance definitions for ventilator-associated pneumonia. *Crit Care Med* 2012;40(12):3154-61.
- 19) Magill SS, Li Q, Gross C, et al. Incidence and characteristics of ventilator-associated events reported to the National Healthcare Safety Network in 2014. *Crit Care Med* 2016;44(12):2154-62.
- 20) Cocoros NM, Kleinman K, Priebe GP, et al. Ventilator-Associated Events in Neonates and Children--A New Paradigm. *Crit Care Med*. 2016 Jan;44:14-22.
- 21) Heulitt M, Clement KC. (2015). Respiratory Mechanics in the Mechanically Ventilated Patient. In *Pediatric and Neonatal Mechanical Ventilation* (p. 303). Rimensberger PC. New York City, NY: Springer Publishing.
- 22) Donn SM, Sinha SK. (2015). Ventilator Modes. In *Pediatric and Neonatal Mechanical Ventilation* (p. 162). Rimensberger PC. New York City, NY: Springer Publishing.
- 23) Cocoros NM, Priebe GP, Gray JE, et al. Factors Associated with Pediatric Ventilator-Associated Conditions in Six U. S. Hospitals: A Nested Case-Control Study. *Pediatric Crit Care Med* 2017 Nov;18(11):e536-e545.
- 24) Karandikar MV, Coffin SE, Priebe GP, et al. Variability in antimicrobial use in pediatric ventilator-associated events. *Infect Control Hosp Epidemiol*. 2019 Jan;40(1):32-39.
- 25) Vaewpanich J, Akcan-Arikan, A, Coss-Bu, JA, et al. Fluid Overload and Kidney Injury Score as a Predictor for Ventilator-Associated Events. *Front Pediatr*. 2019 May;22:7:204.

Appendix. List of Eligible Antimicrobial Agents

Antimicrobial Agent
AMIKACIN
AMPHOTERICIN B
AMPHOTERICIN B LIPOSOMAL
AMPICILLIN
AMPICILLIN/SULBACTAM
ANIDULAFUNGIN
AZITHROMYCIN
AZTREONAM
AZTREONAM/AVIBACTAM
BALOXAVIR MARBOXIL
CASPOFUNGIN
CEFAZOLIN
CEFEPIME
CEFEPIME/ENMETAZOBACTAM
CEFIDEROCOL
CEFOTAXIME
CEFOTETAN
CEFOXITIN
CEFTAROLINE
CEFTAZIDIME
CEFTAZIDIME/AVIBACTAM
CEFTOBIPROLE MEDOCARIL
CEFTOLOZANE/TAZOBACTAM
CEFTRIAZONE
CEFUROXIME
CIPROFLOXACIN
CLARITHROMYCIN
CLESROVIMAB
CLINDAMYCIN
COLISTIMETHATE
DALBAVANCIN
DELAFLORACIN
DOXYCYCLINE
ERAVACYCLINE
ERTAPENEM
FLUCONAZOLE
FOSFOMYCIN
GENTAMICIN
IMIPENEM/CILASTATIN

IMIPENEM/CILASTATIN/RELABACTAM
ISAVUCONAZONIUM
ITRACONAZOLE
LEFAMULIN
LEVOFLOXACIN
LINEZOLID
MEROPENEM
MEROPENEM/VABORBACTAM
METRONIDAZOLE
MICAFUNGIN
MINOCYCLINE
MOLNUPIRAVIR
MOXIFLOXACIN
NAFCILLIN
NIRMATRELVIR (includes NIRMATRELVIR/RITONAVIR)
OMADACYCLINE
ORITAVANCIN
OSELTAMIVIR
OXACILLIN
PENICILLIN G
PERAMIVIR
PIPERACILLIN/TAZOBACTAM
PLAZOMICIN
POLYMYXIN B
POSACONAZOLE
REMDESIVIR
REZAFUNGIN
RIFAMPIN
SULBACTAM/DURLOBACTAM
SULFAMETHOXAZOLE/TRIMETHOPRIM
TEDIZOLID
TELAVANCIN
TETRACYCLINE
TIGECYCLINE
TOBRAMYCIN
VANCOMYCIN, intravenous only
VORICONAZOLE
ZANAMIVIR

Multidrug-Resistant Organism & *Clostridioides difficile* Infection (MDRO/CDI) Module

Table of Contents

Background	2
Table 1. Core and Supplemental Reporting Choices for MDRO and CDI Module	4
Laboratory-Identified (LabID) Event Reporting	5
1A: MDRO LabID Event Reporting	6
Figure 1. MDRO Test Result Algorithm for All Specimens Laboratory-Identified (LabID) Events	8
Figure 2. MDRO Test Result Algorithm for <i>Blood Specimens Only</i> Laboratory-Identified (LabID) Events	9
Table 2: Reporting Options for the MDRO Module (non-CDI)	10
MDRO Data Analysis	15
1B: <i>Clostridioides difficile</i> (<i>C. difficile</i>) LabID Event Reporting	22
Figure 3. <i>C. difficile</i> Test Result Algorithm for Laboratory Identified (LabID) Events	23
Table 3: Reporting Options for <i>C. difficile</i> LabID Event	24
<i>C. Difficile</i> (CDI) Data Analysis	29
Infection Surveillance Reporting	36
2A. MDRO Infection Surveillance Reporting	37
2B. <i>Clostridioides difficile</i> Infection Surveillance Reporting	38
Section II. Supplemental Reporting	40
1. Prevention Process Measures Surveillance	40
2. Active Surveillance Testing Outcome Measures	44
Appendix 1. Guidance for Handling MDRO and CDI Module Infection Surveillance and LabID Event Reporting When Also Following Other NHSN Modules	47
Appendix 2: FacWideIN Denominator Counts	49
Appendix 3: Differentiating Between LabID Event and Infection Surveillance	53

Background:

Methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant *Enterococcus* spp. (VRE), and certain gram-negative bacilli have increased in prevalence in U.S. hospitals over the last three decades and have important implications for patient safety. There is concern about these multidrug-resistant organisms (MDROs), as options for treating patients with these infections are often extremely limited, and MDRO infections are associated with increased lengths of stay, costs, and mortality. Many of these traits have also been observed for *Clostridioides difficile* infection (CDI). The Healthcare Infection Control Practices Advisory Committee (HICPAC) has approved guidelines for the control of MDROs.¹ These guidelines are available at <https://www.cdc.gov/infection-control/hcp/mdro-management/>). The MDRO and *C. difficile* module of NHSN provides a tool to assist facilities in meeting some of the criteria outlined in the guidelines. In addition, many of the metrics used in this module are consistent with “Recommendations for Metrics for Multidrug-Resistant Organisms in Healthcare Settings: SHEA/HICPAC Position Paper.”²

Clostridioides difficile (*C. difficile*) is responsible for a spectrum of *C. difficile* infections (CDI), including uncomplicated diarrhea, pseudomembranous colitis, and toxic megacolon, which can, in some instances, lead to sepsis and death. Although CDI represents a subset of gastrointestinal tract infections in the current CDC definitions for HAIs, specific standard definitions for CDI³ should be incorporated to obtain a more complete understanding of how *C. difficile* is being transmitted in a healthcare facility.

As outlined in the HICPAC guideline¹, these MDRO and *C. difficile* pathogens may require specialized monitoring to evaluate if intensified infection control efforts are required to reduce the occurrence of these organisms and related infections. The **goal** of this module is to provide a mechanism for facilities to report and analyze data that will inform infection prevention professionals of the impact of targeted prevention efforts.

This module contains two core reporting options for MDRO and *C. difficile* – Laboratory Identified (LabID) Event reporting and Infection Surveillance reporting. These reporting options function as two separate and independent reporting methods - one focused on laboratory-based reporting and the second on infection criteria-based surveillance reporting. Reporting options are summarized in [Table 1](#). Participants may choose either one or both of these reporting options and may also choose to participate in any of the supplemental monitoring methods described in [Table 1](#).

See [Appendix 3: Differentiating Between LabID Event and Infection Surveillance](#) for key differences between the two options.

Reporting Method (must choose to monitor by LabID Event or Infection Surveillance reporting before supplemental methods can also be used for monitoring):

- A: Facility-wide by location.** Report for each location separately and includes all locations in a facility. This reporting method requires the most effort but provides the most detail for local and national statistical data.
- B: Selected locations within the facility (1 or more).** Report separately for one or more specific locations within a facility. This includes reporting individual events and denominator data for each of the selected locations. This reporting method is ideal for use in targeted prevention programs.

Note: MDRO “Blood Specimens Only” monitoring is the only MDRO LabID event reporting option for IRF, ED, and 24-hr Observation locations. For Inpatient locations other than IRF, ED, and 24-hr Observation (examples: IPF, Medical, Surgical, etc.) “All Specimens” monitoring is the only MDRO LabID event reporting option.

- C: Overall facility-wide.** Report individual LabID events from each inpatient location and total denominator counts for the entire facility. Options include:
- (1) Overall Facility-wide Inpatient (FacWideIN) to include all inpatient locations where denominator data are collected. When using FacWideIN reporting, facilities must also include location specific reporting for outpatient emergency department (adult and pediatric) and 24-hr Observation location(s).

Note: When following FacWideIN, facilities must include denominators for all inpatient locations physically located in the hospital. Totals reported should not include facilities affiliated with the hospital that are enrolled separately in NHSN (‘sister’ facilities, facilities with ‘shared’ CCN). Additionally, separate denominator data is required to capture encounters for each mapped emergency department and 24-hr observation location.

- (2) Overall Facility-wide Outpatient (FacWideOUT) to include all outpatient locations affiliated with the facility where encounters are captured. Facilities may choose to monitor FacWideOUT in addition to FacWideIN monitoring.
- D: Overall facility-wide: Blood Specimens Only.** This method is available for MDRO LabID Events only and targets the most invasive events. Report individual LabID events from each inpatient location and total denominator counts for the entire facility. Options include:
- (1) Overall Facility-wide Inpatient (FacWideIN) to include all inpatient locations. Using this option, facilities must also include location specific reporting for each outpatient emergency department (specifically, adult and pediatric) and 24-hr observation location(s).

Note: When following FacWideIN, facilities must enter denominators for all inpatient locations physically located in the hospital, as well as denominators for all inpatient locations minus any inpatient rehabilitation facility (IRF) and inpatient psychiatric facility (IPF) locations with separate CCNs. Totals reported should not include facilities affiliated with the hospital that are enrolled

separately in NHSN. Additionally, separate denominator data will be required to capture encounters for each mapped emergency department and 24-hr observation location.

- (2) Overall Facility-wide Outpatient (FacWideOUT) to include all outpatient locations affiliated with the facility. Facilities may choose to monitor FacWideOUT in addition to FacWideIN monitoring.

Table 1. Core and Supplemental Reporting Choices for MDRO and CDI Module

Reporting Choices	MDRO			CDI
	MRSA or MRSA/MSSA	VRE	CephR-Klebsiella, CRE (<i>E. coli</i> , <i>Enterobacter</i> , <i>Klebsiella</i>), <i>Acinetobacter</i> spp. (MDR)	<i>C. difficile</i>
Core	Method	Method	Method	Method
Proxy Infection Measures LabID Event Choose ≥1 organism	A, B, C, D	A, B, C, D	A, B, C, D	[±] A, B, C
AND/OR				
Infection Surveillance Choose ≥1 organism	A, B	A, B	A, B	[±] A, B
Supplemental	Method	Method	Method	Method
Prevention Process Measures Options:				
• Hand Hygiene Adherence	B	B	B	B
• Gown and Gloves Use Adherence	B	B	B	B
• Active Surveillance Testing (AST) Adherence	B	B	N/A	N/A
AST Outcome Measures • Incident and Prevalent Cases using AST	B	B	N/A	N/A

N/A – not available or contraindicated

[±]No surveillance for *C. difficile* will be performed in Neonatal Intensive Care Units (NICU), Specialty Care Nurseries (SCN), babies in LDRP (Labor, Delivery, Recovery, and Post-partum), well-baby nurseries, or well-baby clinics. If conducting facility-wide monitoring (Method C), the denominator counts (admissions, patient-days and encounters) for these locations must be removed.

Section I: Core Reporting

Laboratory-Identified (LabID) Event Reporting

Introduction: LabID Event reporting option allows laboratory testing data to be used without clinical evaluation of the patient and therefore is a much less labor-intensive method to track MDROs and *C. difficile*. These provide proxy infection measures of MDRO and/or *C. difficile* healthcare acquisition, exposure burden, and infection burden based almost exclusively on laboratory data and limited admission date data, including patient care location. LabID Event reporting is ONLY for collecting and tracking positive laboratory results (for example, positive cultures) that are collected for “clinical” purposes (specifically for diagnosis and treatment). This means the results of laboratory specimens collected for active surveillance testing (AST) purposes only **should not** be reported as LabID Events. Additionally, LabID event reporting is by individual NHSN facility; only positive specimens collected at the single NHSN facility are eligible for reporting by that facility as a LabID event.

Key points for LabID Event Reporting:

- LabID Events can be monitored at the overall facility-wide level for inpatient areas (FacWideIN), and/or at the overall facility-wide level for outpatient areas (FacWideOUT).
- At the Overall facility-wide levels and for IRF, ED, and 24-hour observation, MDROs can be monitored for *All Specimen* types or for *Blood Specimens Only*. All other inpatient and outpatient locations can only monitor for *All Specimen* types.
- LabID Events can be monitored for specific locations and require unique denominator data from each of the specific locations (specifically, facility-wide locations monitored separately [Method A] allowing for both facility-wide and location-specific data, or by selected locations only [Method B]).
- A facility choosing to conduct FacWideIN surveillance for LabID Events must also follow location-specific surveillance for that same organism in each outpatient emergency department (pediatric and adult) and 24-hour observation location(s).
- For NHSN reporting purposes, the ‘date admitted to the facility’ is hospital day (HD) 1. When determining a patient’s admission dates to both the facility and specific inpatient location, the NHSN user must take into account any days spent in an inpatient location, as these days contribute to exposure risk. NHSN defines an inpatient as any patient cared for/housed on an inpatient location. Local status may differ from NHSN definition; all days spent in an inpatient unit, regardless of local admission status and/or billing status are included in the counts of admissions and inpatient days for the facility and specific location; **for NHSN reporting purposes, the date admitted to the facility is the calendar date the patient physically locates to an inpatient location**. For further information on counting patient days and admissions, see [Appendix 2: Determining Patient Days for Summary Data Collection: Observation vs. Inpatients](#).

Laboratory and admission data can be used to calculate a variety of distinct proxy measures including: admission prevalence rate and overall patient prevalence rate (measures of exposure burden), MDRO bloodstream infection incidence rate (measure of infection burden and healthcare acquisition), overall

MDRO infection/colonization incidence rate (measure of healthcare acquisition), and CD incidence rate (measure of infection burden and healthcare acquisition).

Use NHSN forms to collect all required data, using the definitions of each data field as indicated in the Tables of Instructions. When denominator data are available from electronic databases, these sources may be used only after a validation of a minimum 3 consecutive months proves the data to be within 5% (+/-) of the manually conducted once a day counts.

1A: MDRO LabID Event Reporting

Methodology: Facilities may choose to monitor one or more of the following MDROs: MRSA, MRSA and MSSA, VRE, CephR- *Klebsiella*, CRE, and/or multidrug-resistant *Acinetobacter* spp. (see definitions below). For *S. aureus*, both the resistant (MRSA) and the susceptible (MSSA) phenotypes can be tracked to provide concurrent measures of the susceptible pathogens as a comparison to those of the resistant pathogens in a setting of active MRSA prevention efforts.

Note: No Active Surveillance Culture/Testing (ASC/AST) results are to be included in this reporting of individual results. AST tracking should be recorded under Process & Outcome Measures.

MDRO Definitions: MDROs included in this module are defined below.

<u>MRSA:</u>	Includes <i>S. aureus</i> cultured from any specimen that tests oxacillin-resistant, ceftazidime-resistant, or methicillin-resistant by standard susceptibility testing methods, or any laboratory finding of MRSA (includes but not limited to PCR or other molecular based detection methods).
<u>MSSA:</u>	<i>S. aureus</i> cultured from a specimen testing susceptible to oxacillin, ceftazidime, or methicillin by standard susceptibility testing method.
<u>VRE:</u>	<i>Enterococcus faecalis</i>, <i>Enterococcus faecium</i>, or <i>Enterococcus species unspecified</i> (only those not identified to the species level) that is resistant to vancomycin, by standard susceptibility testing methods or a laboratory finding of VRE (includes but not limited to PCR or other molecular based detection methods).
<u>CephR- <i>Klebsiella</i>:</u>	<i>Klebsiella oxytoca</i> or <i>Klebsiella pneumoniae</i> testing non-susceptible (specifically, either resistant or intermediate) to <u>ceftazidime, cefotaxime, ceftriaxone, cefepime, ceftazidime/avibactam, or ceftolozane/tazobactam.</u>
<u>CRE:</u>	Any <i>Escherichia coli</i>, <i>Klebsiella oxytoca</i>, <i>Klebsiella pneumoniae</i>, <i>Klebsiella aerogenes</i> or <i>Enterobacter</i> spp. testing <u>resistant</u> to imipenem, meropenem, doripenem, ertapenem, meropenem/vaborbactam, or imipenem/relebactam by standard susceptibility testing methods (specifically, minimum inhibitory concentrations of ≥ 4 mcg/mL for doripenem, imipenem, meropenem, meropenem/vaborbactam, and imipenem/relebactam or ≥ 2 mcg/mL for ertapenem) OR by production of a

carbapenemase (specifically, KPC, NDM, VIM, IMP, OXA-48) demonstrated using a recognized test (examples: polymerase chain reaction, metallo- β -lactamase test, modified-Hodge test, Carba-NP). **Note:** For in-plan CRE surveillance, facilities must conduct surveillance for all three organisms CRE-*E.coli*, CRE-*Enterobacter*, **and** CRE-*Klebsiella* (*Klebsiella oxytoca*, *Klebsiella aerogenes* and *Klebsiella pneumoniae*).

MDR-*Acinetobacter*: Any ***Acinetobacter*** spp. testing non-susceptible (specifically, either resistant or intermediate) to at least one agent in at least 3 antimicrobial classes of the following 6 antimicrobial classes:

Class	Antimicrobial	Class	Antimicrobial
Aminoglycosides:	Amikacin Gentamicin Tobramycin	β-lactam/β-lactam β-lactamase inhibitor combination:	Piperacillin/tazobactam Sulbactam/Durlobactam
Carbapenems:	Imipenem Meropenem Doripenem	Cephalosporins:	Cefepime Ceftazidime Cefotaxime Ceftriaxone
Fluoroquinolones:	Ciprofloxacin Levofloxacin	Sulbactam:	Ampicillin/sulbactam

Settings: MDRO LabID Event reporting can occur in any location: inpatient or outpatient.

Requirements: Facilities must choose at least one of the reporting methods listed below and report data.

Note: Facilities must indicate each reporting choice for the calendar month on the *Patient Safety Monthly Reporting Plan* ([CDC 57.106](#)).

For each MDRO monitored, all MDRO test results are evaluated using either the algorithm in [Figure 1](#) (*All Specimens*) or [Figure 2](#) (*Blood Specimens only*) to determine reportable LabID events for each calendar month and for each facility location as determined by the reporting method chosen.

If monitoring *All Specimens*, all first MDRO isolates (chronologically) per patient, per month, per location are reported as a LabID event regardless of specimen source [EXCLUDES tests related to active surveillance testing] (Figure 1); if a duplicate MDRO isolate is from blood, or if monitoring *Blood Specimens* only, it is reported as a LabID event only if it represents a unique blood source [specifically, no prior isolation of the MDRO in blood from the same patient and location in less than or equal to 14 days, even across calendar months] (Figures [1](#) & [2](#)).

If monitoring *All Specimens* and a blood isolate is entered as the first specimen of the month, then no *non-blood* specimens can be entered that month for that patient and location. Report each LabID Event individually.

Figure 1. MDRO Test Result Algorithm for All Specimens Laboratory-Identified (LabID) Events




Figure 2. MDRO Test Result Algorithm for *Blood Specimens Only* Laboratory-Identified (LabID) Events




Table 2: Reporting Options for the MDRO Module (non-CDI)

Method	Numerator Data Reporting by Location	Denominator Data Reporting
Facility-wide by location Note: Must monitor <i>All Specimen</i> sources	Enter each MDRO LabID Event reported by location	Report separate denominators for each location in the facility as specified in the NHSN Monthly Reporting Plan
Selected locations Note: Must monitor <i>All Specimen</i> sources with the exception of IRF units, 24-hour observation, and emergency department	Enter each MDRO LabID Event reported by selected locations	Report separate denominators for each selected location(s) monitored as specified in the NHSN Monthly Reporting Plan
Overall Facility-wide Inpatient (FacWideIN), <i>All Specimen</i>	Enter each MDRO LabID Specimen Event from all inpatient locations <u>AND</u> separately for outpatient emergency department, and 24-hour observation location(s)	<u>Report total</u> denominator data for all inpatient locations physically located in the hospital (for example, total number of admissions and total number of patient days), as well as denominators for all inpatient locations minus inpatient rehabilitation facility and inpatient psychiatric facility locations with separate CCNs Separate denominators should be reported for each mapped outpatient emergency department and 24-hour observation location(s)
Overall Facility-wide Outpatient (FacWideOUT), <i>All Specimen</i>	Enter each MDRO LabID Event from all affiliated outpatient locations separately	<u>Report total</u> denominator data for all outpatient locations (for example, total number of encounters, including ED and OBS encounters in addition to other outpatient locations)
Overall Facility-wide Inpatient (FacWideIN), <i>Blood Specimen Only</i>	Enter each MDRO LabID Blood Specimen Event from all inpatient locations <u>AND</u> separately for outpatient emergency department, and 24-hour observation location(s)	<u>Report total</u> denominator data for all inpatient locations physically located in the hospital (for example, total number of admissions and total number of patient days), as well as denominators for all inpatient locations minus inpatient rehabilitation facility and inpatient psychiatric facility locations with separate CCNs Separate denominators should be reported for each mapped outpatient emergency department and 24-hour observation location(s)

Definitions:

MDRO Isolate: Any specimen, obtained for clinical decision making, testing positive for an MDRO ([as defined above](#)). **Note:** Excludes tests related to active surveillance testing.

Duplicate MDRO Isolate: If monitoring *All Specimens*, any subsequent MDRO isolate from the same patient and location after the first isolate of the specific MDRO during a calendar month, regardless of specimen source, except unique blood source ([Figure 1](#)). Reporting is by single facility; therefore, *All Specimens* must be collected/reported from the same NHSN reporting facility.

EXAMPLE: On January 2, a newly admitted ICU patient has a positive MRSA urine culture. The following week, while still in the ICU, the same patient has MRSA cultured from an infected decubitus ulcer. The MRSA wound culture is considered a duplicate MDRO isolate, since it is the second non-blood MRSA isolate collected from the same patient and location during the same calendar month.

For blood isolates:

- Any MDRO blood isolate from the same patient and location, following a previous MDRO blood isolate within 14 days across calendar months and readmission to the same location.
- There should be 14 days with no blood isolates for the patient and specific location before another blood event is entered into NHSN for the patient and location.
- The date of specimen collection is considered Day 1.

Unique Blood Source: A MDRO isolate from blood in a patient with no prior positive blood culture for the same MDRO and location in less than or equal to 14 days, even across calendar months and different facility admissions ([Figure 2](#)). There should be 14 days with no positive blood culture result for the patient, MDRO, and location before another blood specimen LabID Event is entered into NHSN for the patient, MDRO, and location for *Blood Specimen only* monitoring (LabID event 14-day rule). All unique blood source isolates must be reported to NHSN (if your facility chooses this type of surveillance); however, not all unique blood source isolates will be counted in the FacWideIN Standardized Infection Ratio (SIR) and analysis reports. More information about which events are counted in the numerator of the FacWideIN SIR can be found here: https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/mrsacdi_tips.pdf. Additionally, if following *All Specimens*, the first MDRO for the patient, month, and location should be reported. The date of specimen collection is considered Day 1.

Note: NHSN recommends each facility keep an internal line listing log of all positive isolates as a reference in LabID event reporting to ensure the LabID event 14-day rule is applied correctly. The LabID event 14-day timeframe is between positive *specimens* in the location, not 14 days between *events*. The 14-day rule for LabID event reporting is specific to the location and resets each time a patient transfers to a new inpatient location.

EXAMPLE:
Monitoring *Blood Specimens only* with multiple isolates from same location

On January 1, an ICU patient has a positive MRSA urine culture which is **not entered** into NHSN because blood specimens only are being monitored. On January 2, while in the same location (ICU), the same patient has a positive MRSA blood culture which **is entered** into NHSN. This starts the 14-day count. On January 5, while in the same location (ICU), the same patient has another positive MRSA blood culture which is **not entered** into NHSN because it has not been 14 days since the original positive MRSA blood culture while in the same location. The January 5 positive blood culture starts a new 14-day count. On January 19, while in the same location (ICU), the same patient has another positive MRSA blood culture. The January 19 MRSA blood culture **is entered** into NHSN because it has been more than 14 days since the patient's most recent positive blood culture (January 5) while in the **same** location (January 19 is day 15).

Date	Location	Specimen Body Site	Reportable?	
1-Jan	ICU	Urine – MRSA isolate	NO	
2-Jan	ICU	Blood – MRSA isolate	YES	
3-Jan	ICU			
4-Jan	ICU			
5-Jan	ICU	Blood – MRSA isolate	NO	1
6-Jan	ICU			2
7-Jan	ICU			3
8-Jan	ICU			4
9-Jan	ICU			5
10-Jan	ICU			6
11-Jan	ICU			7
12-Jan	ICU			8
13-Jan	ICU			9
14-Jan	ICU			10
15-Jan	ICU			11
16-Jan	ICU			12
17-Jan	ICU			13
18-Jan	ICU			14
19-Jan	ICU	Blood – MRSA isolate	YES	15

Non-blood isolate

<14 days from prior blood isolate -- no new blood isolate can be reported

>14 days -- new blood isolate should be reported

EXAMPLE:
Monitoring *All Specimens* with multiple isolates from same location

On January 1, an ICU patient has positive MRSA urine culture which **is entered** into NHSN because it is the first MDRO isolate of the month for this patient. On January 2, while in the same location (ICU), the same patient has a positive MRSA blood culture which **is entered** into NHSN because it is the first positive MRSA blood isolate for the month. *No other non-blood MRSA isolates should be reported for the month for this patient and location as these would represent duplicate isolates.* Any additional MRSA positive blood isolates for the month should be reported following the same 14-day rule as when reporting *Blood Specimens only*. Subsequent months should be reported in the same manner.

Date	Location	Specimen Body Site	Reportable?	
1-Jan	ICU	Urine – MRSA isolate	YES	
2-Jan	ICU	Blood – MRSA isolate	YES	
3-Jan	ICU			
4-Jan	ICU			
5-Jan	ICU	Blood – MRSA isolate	NO	1
6-Jan	ICU			2
7-Jan	ICU			3
8-Jan	ICU			4
9-Jan	ICU			5
10-Jan	ICU			6
11-Jan	ICU			7
12-Jan	ICU			8
13-Jan	ICU			9
14-Jan	ICU			10
15-Jan	ICU			11
16-Jan	ICU			12
17-Jan	ICU			13
18-Jan	ICU			14
19-Jan	ICU	Blood – MRSA isolate	YES	15

1st MRSA isolate of the month

1st MRSA blood isolate of the month

<14 days from prior blood isolate -- no new blood isolate can be reported

>14 days -- new blood isolate should be reported

Laboratory-Identified (LabID) Event: All non-duplicate MDRO isolates from any specimen source and unique blood source MDRO isolates. [EXCLUDES tests related to active surveillance testing]. Even if reporting at the Facility Wide level (FacWideIN or FacWideOUT), all reporting must follow rules by location for reporting.

Note: A [LabID Event calculator](#) is available on the NHSN website to help with data entry decision making around the 14-day rule, which is location specific.

EXAMPLE #1: Monitoring <i>Blood Specimens only</i> with isolates from ED & inpatient location	If monitoring blood specimens for FacWideIN (which requires surveillance in the emergency department and 24-hour observation locations), a patient has a positive MRSA laboratory isolate while in the emergency department (ED). This specimen represents a MRSA LabID Event and should be entered for the outpatient emergency department. The next calendar day, the same patient is admitted to ICU and three days later, has a second positive MRSA blood specimen. This specimen also represents a unique LabID Event because it is the first positive blood specimen in <i>this location</i> (ICU). Note: while this patient has two LabID Events, the second specimen taken from the ICU will be removed from most analysis reports.
EXAMPLE #2: Monitoring <i>All Specimens</i>	If monitoring <i>all specimens</i> , on January 2, a newly admitted ICU patient with no previous positive laboratory isolates during this admission has a positive MRSA urine culture. This specimen represents a LabID Event since it is the first MRSA isolate for the patient, the location, and the calendar month.
EXAMPLE #3: Monitoring <i>All Specimens</i> with isolates from ED & inpatient location	If monitoring <i>all specimens</i> for FacWideIN surveillance, on January 2, a VRE wound culture is collected from the facility's own ED. The patient is then admitted to 4W the next calendar day. The ED culture result must be entered as an outpatient LabID event for the ED location for January 2, as the ED location is included in FacWideIN surveillance and reporting.
EXAMPLE #4: Monitoring <i>Blood Specimens only</i> with multiple blood isolates	If monitoring <i>blood specimens only</i> , on January 26, a newly admitted ICU patient with no previous positive laboratory isolates during this admission has a positive MRSA urine culture which is not entered as a LabID Event since <i>blood specimens only</i> are being monitored. The following day, while in the same location, the same patient has a positive MRSA blood culture. This specimen represents a LabID Event since it is a unique blood source (the first MRSA blood isolate for the same patient and same location). While remaining in ICU, the same patient has another positive blood culture on February 5. This does not represent a new LabID Event since it has not been more than 14 days since the most recent MRSA positive blood isolate for this patient and location.

Reporting Instructions:

- All LabID Events must be reported by specific unit location.
- LabID event reporting is separate and independent of events reported through MDRO Infection Surveillance reporting and/or HAIs reported through the Device-associated and/or Procedure-associated Modules.
- For instructions on unique reporting scenarios, see [Appendix 1. Guidance for Handling MDRO and CDI Module Infection Surveillance and LabID Event Reporting When Also Following Other NHSN Modules](#).
- For additional reporting information, see [Appendix 3. Differentiating Between LabID Event and Infection Surveillance](#).

Numerator Data: Data is reported using the *Laboratory-identified MDRO or CDI Event* form (CDC [57.128](#)).

Denominator Data: Patient days and admissions (for inpatient locations), and encounters (for outpatient locations) are reported using the *MDRO and CDI Monthly Denominator Form* (CDC [57.127](#)).

Reporting FacWideIN Denominators:

Line 1: Facilities will submit total patient days and total patient admissions to reflect all inpatient locations physically located in the hospital.

Line 2: The second line of denominator data entry should reflect all inpatient locations minus inpatient rehabilitation units (IRF units) and inpatient psychiatric units (IPF units) with a separate CCN.

Line 3: The third line of denominator data entry should reflect all inpatient locations minus inpatient rehabilitation units (IRF units) and inpatient psychiatric units (IPF units) with a separate CCN, and minus baby-based locations (for example, NICU, well baby nursery, etc.). The totals should not include other facility types within the hospital that are enrolled and reporting separately (for example, LTAC). See [Table of Instructions](#) for completion instructions.

Note: All days spent in an inpatient unit, regardless of a patient's local admission status and/or billing status, should be included in the denominator counts of patient days and admissions for FacWideIN and/or the specific location. For acute care hospitals completing FacWideIN surveillance, additional guidance on denominator reporting is available here: <https://www.cdc.gov/nhsn/pdfs/cms/acute-care-mrsa-cdi-labiddenumerator-reporting.pdf>. A quick learn instructional video is available here: <https://www.cdc.gov/nhsn/training/patient-safety-component/cdiff.html>.

FacWideOUT, Emergency Departments, 24-hour observation units observation units, and other outpatient units: monthly denominator data are reported as encounters. An encounter is defined as any patient visit to an outpatient location. Each patient counts once regardless of time spent in the location.


MDRO Data Analysis:

All event and summary (denominator) data that are entered into NHSN can be analyzed. After a user generates analysis datasets in the application, all data entered for the facility up until that time are made available in the analysis reports. The data in NHSN can be visualized and analyzed in various ways. For example, descriptive analysis reports for numerator (LabID Events) and denominator (for example, patient days, admissions) data, such as line lists, frequency tables, and bar and pie charts are available. In addition, measures of MDRO incidence and prevalence are available in rate tables and SIR reports. SIRs are only available for FacWideIN surveillance of MRSA bacteremia and *C. difficile*. Unit-specific SIRs are not available, with the exception of CMS-certified IRF units located within a hospital.

Categorizing MDRO LabID Events

Based on data provided on the LabID Event form, each event will be categorized by NHSN. Refer to the “Onset” variable in the NHSN Line List. Onset is assigned based on the location of specimen collection, the date admitted to facility, and date specimen collected, as applicable.

- Community-Onset (CO): LabID Event specimen collected in an outpatient location or an inpatient location on Hospital Day 1 [day of admission], HD 2 or HD 3.
- Healthcare Facility-Onset (HO): LabID Event specimen collected on or after Hospital Day 4 where HD 1 is day of admission. Thus, all HO LabID Events will have occurred more than 3 calendar days after admission.



Descriptive Analysis Reports

Descriptive analysis report options, such as line listings, frequency tables, and bar and pie charts are available for numerator and denominator data. See the NHSN Analysis website for quick reference guides on how to access, generate and interpret data using any of these report types:

<https://www.cdc.gov/nhsn/ps-analysis-resources/reference-guides.html>

Rate Tables

Rate tables are available for each organism in the MDRO Module. FacWideIN and location-specific rate tables are available for MDROs. Various prevalence and incidence rates can be calculated at the month-level or higher.

Note: Incomplete records in NHSN will trigger an “Alert” on the facility’s homepage. All records identified by an “Alert” will be excluded from the rate tables until the Alert is resolved.

The following section describes the various rates calculated for MDRO LabID event surveillance.

Note: FacWideIN MDRO rates utilize the FacWideIN denominators (patient days and admissions) reported on Line 2 of the FacWideIN denominator record, which excludes admissions and patient days from inpatient rehabilitation facility (IRF) and inpatient psychiatric facility (IPF) locations with unique CCNs. For NHSN reporting purposes, IRFs/IPFs located within a hospital is recognized as an inpatient location for the hospital; therefore, admissions/discharges from those facilities to IRF/IPF and vice versa are considered ‘transfers’, specifically, the hospitalization is considered a ‘continuous’ stay for event reporting.

Proxy Measures for Exposure Burden of MDROs – All specimens:

Inpatient Reporting:

- Admission Prevalence Rate = Number of 1st LabID Events per patient per month identified less than or equal to 3 days after admission to the location (if monitoring by inpatient location), or the facility (if monitoring by overall facility-wide inpatient = FacWideIN) / Number of patient admissions to the location or facility x 100
- Location Percent Admission Prevalence that is Community-Onset = Number of Admission Prevalent LabID Events to a location that are CO / Total number Admission Prevalent LabID Events x 100
- Location Percent Admission Prevalence that is Healthcare Facility-Onset = Number of Admission Prevalent LabID Events to a location that are HO / Total number of Admission Prevalent LabID Events x 100
- Overall Patient Prevalence Rate = Number of 1st LabID Events per patient per month regardless of time spent in location (specifically, prevalent + incident, if monitoring by inpatient location), or facility (specifically, CO + HO, if monitoring by overall facility-wide inpatient = FacWideIN) / Number of patient admissions to the location or facility x 100

Outpatient Reporting:

- Outpatient Prevalence Rate = Number of 1st LabID Events per patient per month for the location (if monitoring by outpatient location), or the facility (if monitoring by overall facility-wide outpatient = FacWideOUT) / Number of patient encounters for the location or facility x 100

Measures for MDRO Bloodstream Infection: Calculated when monitoring either *all specimens* or *blood specimens* only. **Note:** Except for certain locations (specifically, inpatient rehabilitation facilities, emergency departments, and 24-hour observation locations), the *blood specimens only* option can only be used at the FacWideIN and FacWideOUT levels.

Inpatient Reporting:

- MDRO Bloodstream Infection Admission Prevalence Rate = Number of all unique blood source LabID Events per patient per month identified less than or equal to 3 days after admission to the location (if monitoring by inpatient location), or facility (if monitoring by overall FacWideIN) / Number of patient admissions to the location or facility x 100
 - **Note:** For MRSA Bacteremia FacWideIN surveillance, this is the CO rate that is used in the risk adjustment calculations of the MRSA bacteremia SIR. The numerator excludes any event in which the patient had a prior positive event in the previous 14 days.
- MDRO Bloodstream Infection Incidence Rate = Number of all unique blood source LabID Events per patient per month identified more than 3 days after admission to the location (if monitoring by inpatient location), or facility (if monitoring by overall facility-wide inpatient = FacWideIN) / Number of patient admissions to the location or facility x 100
- MDRO Bloodstream Infection Incidence Density Rate = Number of all unique blood source LabID Events per patient per month identified more than 3 days after admission to the location (if monitoring by inpatient location), or facility (if monitoring by overall facility-wide inpatient = FacWideIN) / Number of patient days for the location or facility x 1,000
- MDRO Bloodstream Infection Overall Patient Prevalence Rate = Number of 1st Blood LabID Events per patient per month regardless of time spent in location (specifically, prevalent + incident, if monitoring by inpatient location), or facility (specifically, CO + HO, if monitoring by overall facility-wide inpatient = FacWideIN) / Number of patient admissions to the location or facility x 100

MRSA Bloodstream Reporting for CMS-certified Inpatient Rehabilitation Facilities (IRFs) mapped as units within a hospital:

- Inpatient MRSA Bacteremia Incidence Density Rate for IRF units: Number of all incident blood source MRSA LabID events identified more than 3 days after location admission to an IRF unit and where the patient had no positive MRSA bacteremia LabID Events in the prior 14 days in any CMS-certified IRF unit / Total number of patient days for IRF unit(s) x 1,000

Outpatient Reporting:

- Combined MRSA Bloodstream Infection Outpatient Prevalence Rate for ED and 24-hour Observation Locations = Number of unique blood source MRSA LabID events identified in an ED or 24-hour observation location / Total patient encounters in ED and 24-hour observation location(s) x 100
 - Note: For MRSA Bacteremia FacWideIN surveillance, this outpatient rate is used in the risk adjustment calculations of the MRSA bacteremia SIR. The numerator excludes any event in which the patient had a prior positive event in the previous 14 days in an ED or 24-hour observation location.
- MDRO Bloodstream Infection Outpatient Prevalence Rate = Number of all unique blood source LabID Events per patient per month for the location (if monitoring by outpatient location), or the facility (if monitoring by overall facility-wide outpatient = FacWideOUT) / Number of patient encounters for the location or facility x 100

Measures for MDRO-CRE surveillance: The above incidence and prevalence rates are calculated separately for each species of CRE (specifically, *Klebsiella*, *E.coli*, and *Enterobacter*) as well as for all species combined. The following additional metric is available for CRE LabID event reporting:

- Percent Positive for Carbapenemase: Number of CRE positive for carbapenemase / Number of CRE tested for carbapenemase x 100

Proxy Measures for MDRO Healthcare Acquisition:

- Overall MDRO Infection/Colonization Incidence Rate = Number of 1st LabID Events per patient per month among those with no documented prior evidence of previous infection or colonization with this specific organism type from a previously reported LabID Event, and identified more than 3 days after admission to the location (if monitoring by inpatient location), or facility (if monitoring by overall facility-wide inpatient = FacWideIN) / Number of patient admissions to the location or facility x 100
- Overall MDRO Infection/Colonization Incidence Density Rate = Number of 1st LabID Events per patient per month among those with no documented prior evidence of previous infection or colonization with this specific organism type from a previously reported LabID Event, and identified more than 3 days after admission to the location (if monitoring by inpatient location), or facility (if monitoring by overall facility-wide inpatient = FacWideIN) / Number of patient days for the location or facility x 1,000

MRSA Bacteremia LabID Event SIR Reports

SIRs are only available for FacWideIN surveillance of MRSA bacteremia and *C. difficile*. Unit-specific SIRs are not available, with the exception of CMS-certified IRF units located within a hospital. The section below is specific to the MRSA SIR. Information about the *C. difficile* SIR is available in the [CDI LabID Event SIR Reports](#) section of this protocol.

The standardized infection ratio (SIR) is calculated by dividing the number of observed events by the number of predicted events.

$$SIR = \frac{\text{Observed (O) events}}{\text{Predicted (P) events}}$$

The number of predicted events is calculated using probabilities estimated from statistical models constructed from national NHSN data, which represents the baseline population. P-values and 95% confidence intervals are calculated in NHSN using a mid-P Exact Test to provide a statistical comparison between the number of observed events and the number of predicted events. In the NHSN application, the number of predicted events is referred to as “numPred”. The SIR will be calculated only if the number of predicted events (numPred) is greater than or equal to 1. This is to help enforce a minimum precision criterion.

Note: Incomplete records in NHSN will trigger an “Alert” on the facility’s homepage. All records identified by an “Alert” will be excluded from the SIRs until the Alert is resolved.

SIRs will not be calculated for a quarter until the calendar quarter has passed given the use of quarterly risk factors in some SIR models.

Separate MRSA SIR reports exist in NHSN for each facility type:

For acute care hospitals (ACHs), critical access hospitals (CAHs), long-term acute care hospitals (LTACHs), and PPS-exempt cancer hospitals (PCHs):

- *FacWideIN MRSA Bacteremia SIR* = Number of all unique blood source MRSA LabID Events identified in a non-IRF/IPF inpatient location more than 3 days after admission to the facility (specifically, HO MRSA blood events with no prior MRSA blood event for that patient in the previous 14 days) / Number of predicted HO MRSA blood LabID Events
 - **Notes:** An HO MRSA bacteremia LabID event will *not* be counted in the SIR if the same patient had a prior positive MRSA bacteremia in the previous 14 days. This 14-day de-duplication crosses calendar months. More information about which events are counted in the numerator of the FacWideIN SIR can be found here: https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/mrsacdi_tips.pdf
 - **The CMS Reports folder for LTACHs will not contain any data beyond 2018 Q3. See [Table 4](#) of this protocol for more information.**

For free-standing inpatient rehabilitation facilities (IRFs):

- *FacWideIN MRSA Bacteremia SIR* = Number of all unique blood source MRSA LabID Events identified in a non-IPF location in which specimen collection occurred greater than 3 days after admission to the facility (specifically, HO MRSA blood events with no prior MRSA blood event for that patient in the previous 14 days) / Number of predicted HO MRSA blood LabID Events
 - **Notes:** An HO MRSA bacteremia LabID event will *not* be counted in the SIR if the same patient had a prior positive MRSA bacteremia in the previous 14 days. This 14-day de-duplication crosses calendar months. More information about which events are counted in the numerator of the FacWideIN SIR can be found here: https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/mrsacdi_tips.pdf
 - **The CMS Reports folder for IRFs will not contain any data beyond 2018 Q3. See Table 4 of this protocol for more information.**

For CMS-certified IRF units located within a hospital:

- *MRSA Bacteremia SIR for IRF Units* = Number of all unique blood source MRSA LabID Events identified more than 3 days after location admission to the IRF unit and where the patient had no positive MRSA bacteremia LabID Event in the prior 14 days in any CMS-certified IRF unit / Number of predicted MRSA blood LabID Events in the IRF unit(s)
 - **Notes:** A MRSA bacteremia LabID event from the IRF unit will *not* be counted in the SIR if the same patient had a prior positive MRSA bacteremia in the previous 14 days in an IRF unit. This 14-day de-duplication crosses calendar months. Data from all IRF Units within the hospital are combined. More information about which events are counted in the numerator of the IRF Unit SIR can be found here: https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/mrsacdi_tips.pdf
 - **The CMS Reports folder for IRFs will not contain any data beyond 2018 Q3. See Table 4 of this protocol for more information.**

The CMS IRFQR and LTCHQR Programs no longer require submission of data for MRSA bacteremia starting with 2018 Q4 data. However, IRFs and LTACHs may still be required to report MRSA bacteremia data in response to a state or local reporting mandate or may choose to continue this surveillance voluntarily. The 2015 SIR reports located in the HAI Risk Adjusted Measure Reports (SIRs, SURs) analysis folder will contain all data reported, beyond 2018 Q3. The 2022 SIR reports located in the HAI Risk Adjusted Measure Reports (SIRs, SURs) analysis folder will contain all data reported from 2022 and forward.

Additional notes about MRSA SIRs

Inclusion Notes	2015 Baseline	2022 Baseline
HOSP-PSYCH can calculate an SIR	Yes	No
HOSP-VA can calculate an SIR	Yes	No
SIR can be calculated with missing or undefined (zero admissions) quarterly inpatient community-onset prevalence rate	Yes	No

For additional information on the changes in SIR eligibility rules between the 2015 baseline and 2022 baseline, please see [Implementation Guide and Change Log](#).

Implementation Guide and Change Log: <https://www.cdc.gov/nhsn/pdfs/rebaseline/Implementation-Guide-Change-Log.pdf>

For more information on the 2015 and 2022 Baseline SIRs, methodology, and the MRSA and/or CDI parameter estimates, please see the respective SIR guide.

2015 Baseline SIR guide: <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/nhsn-sir-guide.pdf>.

2022 Baseline SIR guide: <https://www.cdc.gov/nhsn/2022rebaseline/sir-guide.pdf>

NHSN Group Analysis:

NHSN Group Users can perform the same analysis as facility level users in NHSN. A few helpful tools in NHSN for groups are listed in the resources below. These tools are guides on how to start and join a Group; how to create a template to request data from facilities; how to determine the level of access granted by the facility following the previous steps, and how to analyze the facilities data.

Group Analysis Resources:

NHSN Group Users Page: <https://www.cdc.gov/nhsn/group-users/index.html>

Group User's Guide to the Membership Rights Report: <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/GroupAnalysisWebinar.pdf>

Group User's Guide to the Line Listing- Participation Alerts: <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/group-alerts.pdf>

Additional Analysis Resources

- CMS reporting resources (checklists, etc.): <https://www.cdc.gov/nhsn/cms/index.html>
- Keys to Success with NHSN Data: <https://www.cdc.gov/nhsn/ps-analysis-resources/keys-to-success.html>
- NHSN Training Website: <https://www.cdc.gov/nhsn/training/index.html>
- NHSN Analysis Resources: <https://www.cdc.gov/nhsn/ps-analysis-resources/index.html>

1B: *Clostridioides difficile* (*C. difficile*) LabID Event Reporting

Methodology: Facilities may choose to monitor *C. difficile* where *C. difficile* testing in the laboratory is performed routinely only on unformed (specifically, conforming to the shape of the container) stool samples. *C. difficile* LabID events may be monitored from all available inpatient locations, emergency departments, and 24-hour observation locations as well as all available affiliated outpatient locations where care is provided to patients post discharge or prior to admission (for example, outpatient clinics and/or physician offices using the same patient identification system for the patient as the admitting facility).

Settings: *C. difficile* LabID Event reporting can occur in any location: inpatient or outpatient. Surveillance will **NOT** be performed in NICU, SCN, babies in LDRP/PP units, well-baby nurseries, or well-baby clinics. If LDRP/PP locations are being monitored, baby counts must be removed when compiling total facility counts for line 3 of the FacWideIN denominator submission.

Requirements: All *C. difficile* test results are evaluated using the algorithm in Figure 3.

Facilities must choose one or more of the reporting choices listed in Table 3 below and report data accordingly.


Figure 3. *C. difficile* Test Result Algorithm for Laboratory Identified (LabID) Events

Table 3: Reporting Options for *C. difficile* LabID Event

Method	Numerator Data Reporting by Location	Denominator Data Reporting
Facility-wide by location	Submit each <i>C. difficile</i> LabID Event reported by location	<u>Report separate</u> denominators for each location in the facility as specified in the NHSN Monthly Reporting Plan
Selected locations	Submit each <i>C. difficile</i> LabID Event reported by selected locations	<u>Report separate</u> denominators for selected locations monitored as specified in the NHSN Monthly Reporting Plan
Overall Facility-wide Inpatient (FacWideIN)	Submit each <i>C. difficile</i> LabID Event from all inpatient locations <u>AND</u> separately for outpatient emergency department and 24-hour observation location(s)	<u>Report total</u> denominator data for all inpatient locations physically located in the hospital (for example, total number of admissions and total number of patient days), minus inpatient rehabilitation facility and inpatient psychiatric facility locations with unique CCNs Separate denominators should be reported to capture encounters for each mapped outpatient emergency department and 24-hour observation location(s)
Overall Facility-wide Outpatient (FacWideOUT)	Submit each <i>C. difficile</i> LabID Event from all affiliated outpatient locations separately	Report total denominator data for all outpatient locations (for example, total number of encounters including ED and OBS encounters in addition to other outpatient locations)

Note: Facilities must indicate each reporting choice chosen for the calendar month on the *Patient Safety Monthly Reporting Plan* (CDC [57.106](#)).

Definitions:**C. difficile-positive laboratory assay:**

A positive laboratory test result for *C. difficile* toxin A and/or B, (includes molecular assays [PCR] and/or toxin assays) tested on an unformed stool specimen (must conform to the container).

OR

A toxin-producing *C. difficile* organism detected by culture or other laboratory means performed on an unformed stool sample (must conform to the container).

Notes:

- When using a multi-step testing algorithm for CDI on the same unformed stool specimen, the finding of the last test performed on the specimen as shown on the final report in the patient medical record will determine if the CDI positive laboratory assay definition is met.
- Only when the final report has specific test times attached to each of the individual testing methods (for example, antigen/toxin and PCR) can one make a valid determination of which test is performed first and which is performed last. If there are no specific test times/time stamps attached to each individual testing method on the final lab report, consider the tests as performed simultaneously and any positive finding is eligible for use.

Examples of Multi-step Testing Interpretations (does not consider prior positives):

Multi-step Testing Same Specimen	Test Time	Testing Method	Documented Findings	Eligible LabID Event?	Explanation
Example A	1pm	NAAT	Negative	Yes	GDH/EIA is toxin positive and the last test performed. Report LabID Event.
	1:30pm	GDH/EIA	GDH Positive, EIA Positive		
Example B	1pm	NAAT	Negative	No	GDH/EIA is toxin negative and the last test performed. Only toxin positive findings meet the CD positive laboratory assay definition for LabID Events. No LabID Event reported.
	1:10pm	GDH/EIA	GDH Positive, EIA Negative		
Example C	1pm	GDH/EIA	GDH Positive, EIA Negative	Yes	NAAT is positive and the last test performed. Report LabID Event.
	2pm	NAAT	Positive		
Example D	1pm	GDH/EIA	GDH Positive, EIA Positive	No	NAAT is negative and the last test performed. No LabID Event reported.
	1:30pm	NAAT	Negative		

Example E	1pm	NAAT	Positive	Yes
	1pm	GDH/EIA	GDH Negative, EIA Negative	
The test time for each testing method is noted as 1pm. Therefore, the tests are considered as performed simultaneously and any positive finding (the NAAT in this example) is eligible for use. Report LabID Event.				

Duplicate *C. difficile*-positive test:

- Any *C. difficile* toxin-positive laboratory result from the same patient and location, following a previous *C. difficile* toxin-positive laboratory result within 14 days even across calendar months and readmissions to the same facility location.
- There should be 14 days with no *C. difficile* toxin-positive laboratory result for the patient and specific location before another *C. difficile* LabID Event is entered into NHSN for the patient and location.
- The date of specimen collection of a previously submitted *C. difficile* LabID Event is considered Day 1.

Note: NHSN recommends each facility keep an internal line listing log of all positive specimens as a reference in LabID event reporting to ensure the LabID event 14-day rule is applied correctly. The 14-day rule for LabID event reporting is specific to the location and resets each time a patient transfers to a new inpatient location.

EXAMPLE: On January 1, an ICU patient has a *C. difficile* toxin-positive laboratory result which is entered into NHSN. On January 4, while in the same location (ICU), the same patient has another positive *C. difficile* toxin-positive laboratory result which is not entered into NHSN because it is a duplicate for the patient and location (has not been more than 14 days since the original *C. difficile* toxin-positive laboratory result while in the same location). On January 16, while in the same location (ICU), the same patient has another *C. difficile* toxin-positive laboratory result. While it has been more than 14 days since the initial positive *C. difficile* toxin-positive laboratory result was entered into NHSN (January 1) for the same patient and same location, it has not been more than 14 days since the patient's most recent *C. difficile* toxin-positive laboratory result (January 4) while in the same location. Therefore, the *C. difficile* toxin-positive laboratory result for January 16 is **not** entered into NHSN. On January 31, the patient has another *C. difficile* toxin-positive laboratory result while in the same location (ICU). Since it has been more than 14 days since the patient's most recent *C. difficile* toxin-positive laboratory result (January 16) while in the same location, this event is entered into NHSN.

Laboratory-Identified (LabID) Event: All non-duplicate *C. difficile* toxin-positive laboratory results. Even if reporting at the facility-wide level (FacWideIN or FacWideOUT), all reporting must follow rules by location for reporting.

Notes:

- A [LabID Event calculator](#) is available on the NHSN website to help with data entry decision making around the location specific 14-day rule.
- If a facility is participating in FacWideIN surveillance and reporting, the facility must also conduct separate location-specific surveillance in all outpatient emergency department and 24-hour observation locations. This means LabID Events for the same organism and LabID Event type must be reported from these locations even if the patient is not subsequently admitted to an inpatient location during the same encounter.
- All emergency department and 24-hour observation locations must be identified and mapped as outpatient locations within NHSN. For more information about mapping locations, see [Chapter 15](#) in the NHSN manual.

Reporting Instructions: All *C. difficile* LabID Events must be reported by location and separately and independently of events reported using the *C. difficile* Infection Surveillance reporting option and/or HAI reporting.

Numerator: Data is reported using the [Laboratory-Identified MDRO or CDI Event form](#) (CDC 57.128).

Denominator Data: Patient days and admissions (for inpatient locations), and encounters (for outpatient locations) are reported using the [MDRO and CDI Monthly Denominator Form](#) (CDC 57.127).

Reporting FacWideIN Denominators:

Line 1: Facilities will submit total patient days and total patient admissions to reflect all inpatient locations physically located in the hospital. See [Table of Instructions](#) for completion instructions.

Line 2: The second line of denominator data entry should reflect all inpatient locations minus inpatient rehabilitation units (IRF units) and inpatient psychiatric units (IPF units) with a separate CCN. See [Table of Instructions](#) for completion instructions.

Line 3: The third line of denominator data entry should reflect all inpatient locations minus inpatient rehabilitation units (IRF units) and inpatient psychiatric units (IPF units) with a separate CCN minus baby-based locations (for example, NICU, well baby nursery, etc.). See [Table of Instructions](#) for completion instructions.

Note: All days spent in an inpatient unit, regardless of a patient's local admission status and/or billing status, should be included in the denominator counts of patient days and admissions for FacWideIN and/or the specific location. For acute care hospitals completing FacWideIN surveillance, additional guidance on denominator reporting is available here: <https://www.cdc.gov/nhsn/pdfs/cms/acute-care-mrsa-cdi-labiddominator-reporting.pdf>. A quick learn instructional video is available here: <https://www.cdc.gov/nhsn/training/patient-safety-component/cdiff.html>

Standard CDI Test Method:

The response for the standard test method or algorithm used to identify CDI should reflect the testing method standardly performed by the testing laboratory for the quarter. The standard test method is reported on the FacWideIN and CMS-certified IRF unit denominator forms on the third month of each quarter (March, June, September, and December). NHSN doesn't make recommendations for specific test method; however, the third month of each quarter report includes a drop-down selection of common testing options. See below for hypothetical scenarios on how to determine the accurate CDI test method to report to NHSN.

Example 1: At Facility A, the laboratory uses "GDH plus EIA for toxin, followed by NAAT if antigen positive, toxin negative as the routine testing process for specimens during the quarter. The appropriate response for the standard test type for this quarter is "GDH antigen plus EIA for toxin followed by NAAT for discrepant results".

Example 2: At Facility B, the laboratory uses a PCR testing method (NAAT) on all specimens. If the specimen is NAAT positive, a reflex test to EIA for confirmation is performed. The appropriate response for the standard test type for this quarter is "NATT plus EIA, if NATT positive (2-step algorithm)".

Example 3: At Facility C, the laboratory uses EIA antigen/toxin assay as the routine testing process. If the antigen is positive and toxin is negative, the physician may order confirmation testing if desired. The appropriate response for the standard test type for this quarter is "GDH – Glutamate dehydrogenase (GDH) plus EIA for toxin".

FacWideOUT and ED/24-hour Observation locations reporting: Denominator data is provided using encounters. An encounter is defined as a patient visit to an outpatient location for care. Each visit counts as one encounter.

For NHSN reporting purposes, the 'date admitted to the facility' is HD 1. When determining a patient's admission dates to both the facility and specific inpatient location, the NHSN user must take into account any days spent in an inpatient location as these days contribute to exposure risk. NHSN defines an inpatient as any patient cared for/housed in an inpatient location. Local status (such as observation or swing bed patient) may differ from NHSN definition; all days spent in an inpatient unit, regardless of local admission status and/or billing status are included in the counts of admissions and inpatient days for the facility and specific location. **For NHSN reporting purposes, the date admitted to the facility is the calendar date the patient physically locates to an inpatient location.**

For further information on counting patient days and admissions, see [Appendix 2: Determining Patient Days for Summary Data Collection: Observation vs. Inpatients](#)


C. Difficile (CDI) Data Analysis:

All CDI event and summary (denominator) data that are entered into NHSN can be analyzed. After a user generates analysis datasets in the application, all data entered for their facility up until that time are made available in the analysis reports. The data in NHSN can be visualized and analyzed in various ways. For example, descriptive analysis reports for numerator (CDI Events) and denominator (for example, patient days, admissions) data, such as line lists, frequency tables, and bar and pie charts are available. In addition, measures of CDI incidence and prevalence are available in rate tables and SIR reports. SIRs are only available for FacWideIN surveillance of MRSA bacteremia and *C. difficile*. Unit-specific SIRs are not available, with the exception of CMS-certified IRF units located within a hospital.

CDI Event Categorization

Based on data provided on the CDI LabID Event form, each event will be categorized by NHSN. Refer to the “Onset” variable in the NHSN Line List. Onset is assigned based on the location of specimen collection, the date admitted to facility, date of specimen collection, and previous discharge, as applicable.

- Community-Onset (CO): LabID Event meeting one of the following criteria:
 - A) collected in an outpatient location in which the patient was not previously discharged from an inpatient location within the same facility less than or equal to 28 days prior to current date of specimen collection
 - B) collected in an inpatient location on HD 1 [day of admission], HD 2 or HD 3.
- Community-Onset Healthcare Facility-Associated (CO-HCFA): CO LabID Event collected from an inpatient or an outpatient location from a patient who was discharged from the facility less than or equal to 28 days prior to current date of stool specimen collection. The previous discharge must have been from an inpatient location within the same facility (in other words, an outpatient visit does not qualify as “admitted” and therefore is not used to set the timeline for CO-HCFA).
- Healthcare Facility-Onset (HO): LabID Event collected from an inpatient location on or after HD 4 where HD 1 is day of admission.



*Patient discharged from inpatient location within the same facility less than or equal to 28 days prior current event.

Hospital Day (HD)

In addition to the onset categorization, CDI LabID Events are further categorized by NHSN as Incident or Recurrent. Refer to the 'cdiAssay' variable in the NHSN Line List.

- **Incident CDI LabID Event:** Any CDI LabID Event from a specimen obtained more than 56 days after the most recent CDI LabID Event (or with no previous CDI LabID Event documented) for that patient. Note: the date of first specimen collection is considered day 1.
- **Recurrent CDI LabID Event:** Any CDI LabID Event from a specimen obtained more than 14 days and less than or equal to 56 days after the most recent CDI LabID Event for that patient. Note: the date of first specimen collection is considered day 1.
- CdiAssay will be unassigned, or "blank", for any CDI LabID event that was collected less than or equal to 14 days after the most recent CDI LabID event for that patient.

Note: CdiAssay is assigned based on prior events from a patient that occurred in an inpatient location, emergency department, or 24-hour observation location.

Descriptive Analysis Reports

Descriptive analysis report options, such as line listings, frequency tables, and bar and pie charts are available for numerator and denominator data. See the NHSN Analysis website for quick reference guides on how to access, generate and interpret data using any of these report types:

<https://www.cdc.gov/nhsn/ps-analysis-resources/reference-guides.html>

Rate Tables

FacWideIN and location-specific rate tables are available for CDI. Various prevalence and incidence rates can be calculated at the month-level or higher.

Note: Incomplete records in NHSN will trigger an “Alert” on the facility’s homepage. All denominator records identified by an “Alert” will be excluded from the rate tables until the Alert is resolved.

Note: FacWideIN CDI rates utilize the FacWideIN denominators (patient days and admissions) reported on Line 3 of the FacWideIN denominator record, which excludes admissions and patient days from the following: IRF and IPF locations with unique CCNs separate from the reporting facility, neonatal ICUs, special care nurseries, and well-baby locations. For NHSN reporting purposes, IRFs/IPFs located within a hospital is recognized as an inpatient location for the facility; therefore, admissions/discharges from hospitals to IRF/IPF and vice versa are considered ‘transfers’, specifically, the hospitalization is considered a ‘continuous’ stay for event reporting.

The following section describes the various measures calculated for CDI LabID event surveillance.

CDI Prevalence Rates:

- Inpatient Admission Prevalence Rate = Number of non-duplicate CDI LabID Events per patient per month identified less than or equal to 3 days after admission to the location (if monitoring by inpatient location), or facility (if monitoring by overall facility-wide inpatient=FacWideIN) (includes CO and CO-HCFA events) / Number of patient admissions to the location or facility x 100
 - **Note:** See “CDIF_admPrevRate” in the NHSN Rate Tables.
- Community-Onset Admission Prevalence Rate = Number of inpatient CDI LabID events that are CO, per month, in the facility / Number of patient admissions to the facility x 100
 - **Note:** See “CDI_COprevRate” in the NHSN Rate Tables. This calculation is only accurate for overall FacWideIN reporting. For CDI FacWideIN surveillance, this is the CO rate that is used in the risk adjustment calculations of the 2015 CDI SIR.
 - **Note:** See “CDI_COprevRate_bs3” in the NHSN Rate Tables. This calculation is only accurate for overall FacWideIN reporting. For CDI FacWideIN surveillance, this is the CO rate that is used in the risk adjustment calculations of the 2022 CDI SIR.
- Inpatient Percent Admission Prevalence that is Community-Onset = Number of Admission Prevalent LabID Events to a location that are CO / Total number Admission Prevalent LabID Events x 100
 - **Note:** See “CDIF_pctAdmPrevCO” in the NHSN Rate Tables. This percentage is available for unit-specific CDI surveillance and is calculated separately for each applicable unit. The numerator in this formula does not include CDI LabID events labeled as CO-HCFA.
- Inpatient Percent Admission Prevalence that is Community-Onset Healthcare Facility-Associated = Number of Admission Prevalent LabID Events to a location that are CO-HCFA / Total number Admission Prevalent LabID Events x 10
 - **Note:** See “CDIF_pctAdmPrevCOHCFA”. This percentage is available for unit-specific CDI surveillance and is calculated separately for each applicable unit.

- Inpatient Percent Admission Prevalence that is Healthcare Facility-Onset = Number of Admission Prevalent LabID Events to a location that are HO / Total number of Admission Prevalent LabID Events x 100
 - Note: See “CDIF_pctAdmPrevHO” in the NHSN Rate Tables. This percentage is available for unit-specific CDI surveillance and is calculated separately for each applicable unit.
- Inpatient Overall Patient Prevalence Rate = Number of 1st CDI LabID Events per patient per month regardless of time spent in location (specifically, prevalent + incident, if monitoring by inpatient location), or facility (specifically, CO + CO-HCFA + HO, if monitoring by FacWideIN) / Number of patient admissions to the location or facility x 100
 - Note: See “CDIF_prevRate” in the NHSN Rate Tables.
- Outpatient Prevalence Rate = Number of all non-duplicate CDI LabID Events per patient per month for the location (if monitoring by outpatient location), or the facility (if monitoring by overall facility-wide outpatient=FacWideOUT) / Number of patient encounters for the location or facility x 100
- Combined Outpatient Prevalence Rate for ED and 24-hour Observation Locations = Total number of unique CO CDI LabID events identified in an ED or 24- hour observation location / Total patient encounters in ED and 24-hour observation location(s) x 100
 - Note: The numerator excludes any event in which the patient had a prior positive CDI event in the previous 14 days in an ED or 24-hour observation location. Date of first specimen collection is considered “Day 1”.

CDI Incidence Rates

- Inpatient Location CDI Incidence Rate = Number of Incident CDI LabID Events per month identified more than 3 days after admission to the location / Number of patient days for the location x 10,000
 - Note: See “CDIF_incRate” in the NHSN Rate Tables. This rate is only available for location-specific CDI surveillance.
- Inpatient Facility CDI Healthcare Facility-Onset Incidence Rate = Number of all Incident HO CDI LabID Events per month in the facility / Number of patient days for the facility x 10,000
 - Note: See “CDIF_HOIncRate” in the NHSN Rate Tables. (This calculation is only available for FacWideIN reporting.)
- Inpatient Facility CDI Combined Incidence Rate = Number of all Incident HO and CO-HCFA CDI LabID Events per month in the facility / Number of patient days for the facility x 10,000
 - Note: See “CDIF_facIncRate” in the NHSN Rate Tables. (This calculation is only available for FacWideIN reporting.)
- Inpatient CDI Incidence Density Rate for IRF units: Number of all incident CDI LabID events identified more than 3 days after location admission to an IRF unit and where the patient had no positive CDI LabID events in the prior 14 days in any CMS-certified IRF unit / Total number of patient days for IRF units x 10,000

- Note: See “CDIF_IRFIncRate” in the NHSN Rate Tables. This rate is only available for CMS-certified IRF units located within an acute care, critical access, or long-term acute care hospitals

CDI LabID Event SIR Reports

SIRs are only available for FacWideIN surveillance of MRSA bacteremia and *C. difficile*. Unit-specific SIRs are not available, with the exception of CMS-certified IRF units located within a hospital. The section below is specific to the CDI SIR. For more information about the MRSA SIR, refer to the [MRSA Bacteremia Event SIR Reports](#) section of this protocol.

The standardized infection ratio (SIR) is calculated by dividing the number of observed events by the number of predicted events.

$$SIR = \frac{\text{Observed (O) events}}{\text{Predicted (P) events}}$$

The number of predicted events is calculated using probabilities estimated from statistical models constructed from national NHSN data, which represents the baseline population. P-values and 95% confidence intervals are calculated in NHSN using a mid-P Exact Test to provide a statistical comparison between the number of observed events and the number of predicted events. In the NHSN application, the number of predicted events is referred to as “numPred”. The SIR will be calculated only if the number of predicted events (numPred) is greater than or equal to 1. This is to help enforce a minimum precision criterion.

Note: Incomplete records in NHSN will trigger an “Alert” on the facility’s homepage. All records identified by an “Alert” will be excluded from the SIRs until the Alert is resolved.

SIRs will not be calculated for a quarter until the calendar quarter has passed given the use of quarterly risk factors in the SIR models. The risk adjustment model for some facility types utilizes a quarterly community-onset prevalence rate, which requires that all 3 months of data entry are complete in NHSN before an SIR is calculated. Also, some risk adjustment models have another quarterly variable, CDI Test Type. When the FacWideIN or IRF Unit MDRO/CDI denominator form is completed for the last month of each quarter, users are asked to report the standard test method that was used to identify CDI in the hospital for that quarter. That test method is used to derive the CDI Test Type for the quarter and used in the calculation of the FacWideIN or IRF Unit CDI SIR for that quarter.

Separate CDI SIR reports exist in NHSN for each facility type:

For acute care hospitals (ACHs), critical access hospitals (CAHs), long-term acute care hospitals (LTACHs), and PPS-exempt cancer hospitals (PCHs):

- *FacWideIN CDI SIR* = Number of all incident CDI LabID Events identified in a non-IRF/IPF location more than 3 days after admission to the facility / Number of predicted Incident HO CDI LabID Events
 - **Note:** More information about which events are counted in the FacWideIN CDI SIR can be found here: https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/mrsacdi_tips.pdf

For free-standing Inpatient Rehabilitation Facilities:

- *FacWideIN CDI SIR* = Number of all incident CDI LabID Events identified in a non-IPF location more than 3 days after admission to the facility/ Number of predicted Incident HO CDI LabID Events
 - **Note:** More information about which events are counted in the FacWideIN CDI SIR can be found here: https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/mrsacdi_tips.pdf

For CMS-certified Inpatient Rehabilitation Facility Units located within a hospital:

IRF units within a hospital that participate in the CMS Inpatient Rehabilitation Facility Quality Reporting Program will be given a CDI SIR separate from the FacWideIN SIR for the acute care hospital. The SIR will be sent to CMS on behalf of IRF units participating in the CMS IRF Quality Reporting Program.

- *CDI SIR for IRF units:* Number of all CDI LabID events identified more than 3 days after location admission to an IRF unit and where the patient had no positive CDI LabID events in the prior 14 days in any CMS-certified IRF unit / Number of predicted CDI LabID events in the IRF unit(s)
 - **Note:** This SIR is only available for CMS-certified IRF units located within a hospital. SIRs will not be calculated for a quarter until the calendar quarter has passed and the CDI test method has been reported. When the IRF Unit's MDRO denominator form is completed for the last month of each quarter, users are asked to report the standard test method that was used to identify CDI for that quarter. That test method is used to derive the CDI Test Type for the quarter and used in the calculation of the IRF Unit's CDI SIR for that quarter. More information about which events are counted in the IRF Unit's CDI SIR can be found here: https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/mrsacdi_tips.pdf

Additional notes about CDI SIRs

Inclusion Notes	2015 Baseline	2022 Baseline
HOSP-PSYCH can calculate an SIR	Yes	No
HOSP-VA can calculate an SIR	Yes	No
SIR can be calculated with missing or undefined (zero admissions) quarterly inpatient community-onset prevalence rate	Yes	No

For additional information on the changes in SIR eligibility rules between the 2015 baseline and 2022 baseline, please see [Implementation Guide and Change Log](#).

Implementation Guide and Change Log: <https://www.cdc.gov/nhsn/pdfs/rebaseline/Implementation-Guide-Change-Log.pdf>

For more information on the 2015 and 2022 Baseline SIRs, methodology, and the MRSA and/or CDI parameter estimates, please see the respective SIR guide.

2015 Baseline SIR guide: <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/nhsn-sir-guide.pdf>.

2022 Baseline SIR guide: <https://www.cdc.gov/nhsn/2022rebaseline/sir-guide.pdf>.

NHSN Group Analysis:

NHSN Group Users can perform the same analysis as facility level users in NHSN. A few helpful tools in NHSN for groups are listed in the resources below. These tools are guides on how to start and join a Group; how to create a template to request data from facilities; how to determine the level of access granted by the facility following the previous steps, and how to analyze the facilities data.

Group Analysis Resources:

NHSN Group Users Page: <https://www.cdc.gov/nhsn/group-users/index.html>

Group User's Guide to the Membership Rights Report: <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/GroupAnalysisWebinar.pdf>

Group User's Guide to the Line Listing- Participation Alerts: <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/group-alerts.pdf>

Additional Analysis Resources

- CMS reporting resources (checklists, etc.): <https://www.cdc.gov/nhsn/cms/index.html>
- Keys to Success with NHSN Data: <https://www.cdc.gov/nhsn/ps-analysis-resources/keys-to-success.html>
- NHSN Training Website: <https://www.cdc.gov/nhsn/training/index.html>
- NHSN Analysis Resources: <https://www.cdc.gov/nhsn/ps-analysis-resources/index.html>

Table 4: Measures Delivered to CMS For Facilities Participating in Quality Reporting Programs MRSA Bloodstream Infection and *C. difficile* LabID Events

<u>Facility Type</u>	<u>CMS Quality Reporting Program</u>	<u>MRSA Bloodstream Infection LabID Event Measure Sent to CMS</u>	<u><i>C. difficile</i> LabID Event Measure Sent to CMS</u>
General Acute Care Hospitals	Inpatient Quality Reporting Program	FacWideIN MRSA Bacteremia SIR	FacWideIN CDI SIR
Long Term Care Hospitals (referred to as Long Term Acute Care Hospitals in NHSN)	Long Term Care Hospital Quality Reporting Program	None	FacWideIN CDI SIR
Inpatient Rehabilitation Facilities (IRFs)	Inpatient Rehabilitation Facility Quality Reporting Program	IRF units within a hospital: None	IRF units within a hospital: CDI SIR for IRF Units
		Free-standing IRFs: None	Free-standing IRFs: FacWideIN CDI SIR
PPS-Exempt Cancer Hospitals (PCHs)	PPS-Exempt Cancer Hospital Quality Reporting Program	FacWideIN MRSA Bacteremia SIR	FacWideIN CDI SIR

Infection Surveillance Reporting

Introduction: The Infection Surveillance reporting option for MDRO and *C. difficile* infections enables users to utilize the CDC/NHSN healthcare-associated infections definitions for identifying and reporting infections associated with MDROs and/or *C. difficile*. Surveillance must occur from at least one patient care area and requires active, patient-based, prospective surveillance of the chosen MDRO(s) and/or *C. difficile* infections (CDIs) by a trained Infection Preventionist (IP). This means that the IP shall seek to confirm and classify infections caused by the chosen MDRO(s) and/or *C. difficile* for monitoring during a patient's stay in at least one patient care location during the surveillance period. These data will enhance the ability of NHSN to aggregate national data on MDROs and CDIs.

2A. MDRO Infection Surveillance Reporting

Methodology: Facilities may choose to monitor one or more of the following MDROs: MRSA, MRSA and MSSA, VRE, CephR- *Klebsiella*, CRE (CRE-*Klebsiella*, CRE-*E. coli*, and CRE-*Enterobacter*), and multidrug-resistant *Acinetobacter* spp. (See definitions in Section I, Option 1A). For *S. aureus*, both the resistant (MRSA) and the susceptible (MSSA) phenotypes can be tracked to provide concurrent measures of the susceptible pathogens as a comparison to those of the resistant pathogens in a setting of active MRSA prevention efforts. **Note:** No Active Surveillance Culture/Testing (ASC/AST) results are to be included in this reporting of individual results.

Settings: Infection Surveillance can occur in any inpatient location where such infections may be identified and where denominator data can be collected, which may include critical/intensive care units (ICU), specialty care areas (SCA), neonatal units, step-down units, wards, and chronic care units. In Labor, Delivery, Recovery, & Post-partum (LDRP) locations, where mom and babies are housed together, users must count both mom and baby in the denominator. If moms only are being counted, then multiply moms times two to include both mom and baby in denominators.

Requirements: Surveillance for all types of NHSN-defined healthcare-associated infections (HAIs), regardless if HAI is included in “in-plan” or “off- plan” surveillance, of the MDRO selected for monitoring in at least one location in the healthcare facility as indicated in the [Patient Safety Monthly Reporting Plan \(CDC 57.106\)](#).

Definitions: MDROs included in this module are defined in Section I, Option 1A. Refer to [CDC/NHSN Surveillance Definitions for Specific Types of Infections](#) for infection site criteria.

Location of Attribution and Transfer Rule applies – See Identifying HAIs in NHSN ([Chapter 2](#)).

Reporting Instructions: If participating in MDRO/CDI Infection Surveillance and/or LabID Event Reporting, along with the reporting of HAIs through the Device-Associated and/or Procedure-Associated Modules, see [Appendix 1: Guidance for Handling MDRO/CDI Module Infection Surveillance and LabID Event Reporting When Also Following Other NHSN Modules](#) for instructions on unique reporting scenarios.

Numerator Data: Number of healthcare-associated infections, by MDRO type. Infections are reported on the appropriate NHSN forms: *Primary Bloodstream Infection*, *Pneumonia*, *Ventilator-Associated Event*, *Urinary Tract Infection*, *Surgical Site Infection*, or *MDRO or CDI Infection Event* (CDC 57.108, 57.111, 57.112, 57.114, 57.120, and 57.126, respectively.). See the *Table of Instructions*, located in each of the applicable chapters, for completion instructions.

Denominator Data: Number of patient days and admissions. Patient days and admissions are reported by location using the [MDRO and CDI Monthly Denominator Form](#) (CDC 57.127). See [Table of Instructions](#) for completion instructions.

Data Analysis: Data are stratified by time (for example, month, quarter, etc.) and patient care location.
$$\text{MDRO Infection Incidence Rate} = \text{Number of HAIs by MDRO type} / \text{Number of patient days} \times 1000$$

2B. *Clostridioides difficile* Infection Surveillance Reporting

Methodology: *C. difficile* Infection (CDI) Surveillance, reporting on all NHSN-defined healthcare-associated CDIs from at least one patient care area, is one reporting option for *C. difficile* (part of your facility's Monthly Reporting Plan). These data will enhance the ability of NHSN to aggregate national data on CDIs.

Settings: Infection Surveillance will occur in any inpatient location where denominator data can be collected, which may include critical/intensive care units (ICU), specialty care areas (SCA), step-down units, wards, and chronic care units. Surveillance will NOT be performed in Neonatal Intensive Care Units (NICU), Specialty Care Nurseries (SCN), babies in LDRP, or well-baby nurseries. If LDRP locations are being monitored, baby counts must be removed.

Requirements: Surveillance for CDI must be performed in at least one location in the healthcare institution as indicated in the [Patient Safety Monthly Reporting Plan](#) (CDC 57.106).

Definitions: Report all healthcare-associated infections where *C. difficile*, identified by a positive toxin result including toxin producing gene [PCR]), is the associated pathogen, according to the Repeat Infection Timeframe (RIT) rule for HAIs (See [Identifying HAIs in NHSN chapter](#)). Refer to specific definitions in [CDC/NHSN Surveillance Definitions for Specific Types of Infections](#) chapter for *C. difficile* gastrointestinal system infection (GI-CDI).

HAI cases of CDI that meet criteria for a healthcare-associated infection should be reported as *Clostridioides difficile* gastrointestinal system infection (GI-CDI). Report the pathogen as *C. difficile* on the [MDRO or CDI Infection Event form](#) (CDC 57.126). If the patient develops GI-CDI, and GI-GE or GI-GIT, report the GI-CDI and the GI-GE or GI-GIT only if additional enteric organisms are identified and applicable criteria are met. **Note:** CDI laboratory-identified event (LabID Event) categorizations (for example, recurrent CDI assay, incident CDI assay, healthcare facility-onset, community-onset, community-onset healthcare facility-associated) do **not** apply to HAIs including *C. difficile* associated gastrointestinal system infections (GI-CDI). Each new GI-CDI must be reported according to the HAI rules outlined in [Identifying HAIs in NHSN](#) chapter 2.

CDI Complications: CDI in a case patient within 30 days after CDI symptom onset with at least one of the following:

1. Admission to an intensive care unit for complications associated with CDI (for example: for shock that requires vasopressor therapy);
 2. Surgery (for example, colectomy) for toxic megacolon, perforation, or refractory colitis
- AND/OR**
3. Death caused by CDI within 30 days after symptom onset and occurring during the hospital admission.

Location of Attribution and Transfer Rule apply to Infection Surveillance – See [Identifying HAIs in NHSN](#) chapter.

Numerator Data: Number of healthcare-associated *C. difficile* infections. Infections are reported on the [MDRO or CDI Infection Event form](#) (CDC 57.126). See [Tables of Instructions](#) for completion instructions.

Denominator Data: Number of patient days and admissions by location are reported using the *MDRO and CDI Monthly Denominator Form* (CDC 57.127). See [Tables of Instructions](#) for completion instructions.

C. difficile Infections:

Numerator: The total number of HAI CDI cases identified during the surveillance month for a location.

Denominator: The total number of patient days and admissions during the surveillance month for a location.

Data Analysis: Data are stratified by time (for example, month, quarter, etc.) and by patient care location.

C. difficile Infection Incidence Rate = Number of HAI CDI cases / Number of patient days x **10,000**

Section II. Supplemental Reporting

1. Prevention Process Measures Surveillance

a. Monitoring Adherence to Hand Hygiene

Introduction: This option will allow facilities to monitor adherence to hand hygiene after a healthcare worker (HCW) has contact with a patient or inanimate object(s) in the immediate vicinity of the patient. Research studies have reported data suggesting that improved after-contact hand hygiene is associated with reduced MDRO transmission. While there are multiple opportunities for hand hygiene during patient care, for the purpose of this option, only hand hygiene after contact with a patient or inanimate object(s) in the immediate vicinity of the patient will be observed and reported.

(<http://www.cdc.gov/handhygiene/>)

Settings: Surveillance will occur in any location: inpatient or outpatient.

Requirements: Surveillance for adherence to hand hygiene in at least one location in the healthcare institution for at least one calendar month as indicated in the [Patient Safety Monthly Reporting Plan](#) (CDC 57.106). This should be done in patient care locations also selected for Infection Surveillance or LabID Event reporting.

In participating patient care locations, perform at least 30 different unannounced observations after contact with patients for as many individual HCWs as possible. For example, try to observe all types of HCWs performing a variety of patient care tasks during the course of the month, not only nurses, or not only during catheter or wound care. No personal identifiers will be collected or reported.

Definitions:

Antiseptic handwash: Washing hands with water and soap or other detergents containing an antiseptic agent.

Antiseptic hand-rub: Applying an antiseptic hand-rub product to all surfaces of the hands to reduce the number of microorganisms present.

Hand hygiene: A general term that applies to either: handwashing, antiseptic hand wash, antiseptic hand rub, or surgical hand antisepsis.

Handwashing: Washing hands with plain (specifically, non-antimicrobial) soap and water.

Numerator: Hand Hygiene Performed = Total number of observed contacts during which a HCW touched either the patient or inanimate objects in the immediate vicinity of the patient and appropriate hand hygiene was performed.

Denominator: Hand Hygiene Indicated = Total number of observed contacts during which a HCW touched either the patient or inanimate objects in the immediate vicinity of the patient and therefore, appropriate hand hygiene was indicated.

Hand hygiene process measure data are reported using the *MDRO and CDI Monthly Denominator Form* (CDC 57. 127). See Tables of Instructions for completion instructions.

Data Analysis: Data are stratified by time (for example, month, quarter, etc.) and patient care location.

Hand Hygiene Percent Adherence = Number of contacts for which hand hygiene was performed / Number of contacts for which hand hygiene was indicated x 100

b. Monitoring Adherence to Gown and Gloves Use as Part of Contact Precautions

Introduction: This option will allow facilities to monitor adherence to gown and gloves use when a HCW has contact with a patient or inanimate object(s) in the immediate vicinity of the patient, when that patient is on Transmission-based Contact Precautions. While numerous aspects of adherence to Contact Precautions could be monitored, this surveillance option is only focused on the use of gown and gloves. (http://www.cdc.gov/ncidod/dhqp/gl_isolation_contact.html)

Settings: Surveillance can occur in any of 4 types of inpatient locations: (1) intensive care units (ICU), (2) specialty care areas, (3) neonatal intensive care units (NICU), and (4) any other inpatient care location in the institution (for example, surgical wards).

Requirements: Surveillance for adherence to gown and gloves use in at least one location in the healthcare institution for at least 1 calendar month as indicated in the [Patient Safety Monthly Reporting Plan](#) (CDC 57.106). Ideally, this should be done in patient care locations also selected for Infection Surveillance or LabID Event reporting.

Among patients on Transmission-based Contact Precautions in participating patient care locations, perform at least 30 unannounced observations. A total of thirty different contacts must be observed monthly among HCWs of varied occupation types. For example, try to observe all types of HCWs performing a variety of patient care tasks during the course of the month, not only nurses, or not only during catheter or wound care. Both gown and gloves must be donned appropriately prior to contact for compliance. No personal identifiers will be collected or reported.

Definitions:

Gown and gloves use: In the context of Transmission-based Contact Precautions, the donning of both a gown and gloves prior to contact with a patient or inanimate object(s) in the immediate vicinity of the patient. Both a gown and gloves must be donned appropriately prior to contact for compliance.

Numerator: Gown and Gloves Used = Total number of observed contacts between a HCW and a patient or inanimate object(s) in the immediate vicinity of a patient on Transmission-based Contact Precautions for which gown and gloves had been donned appropriately prior to the contact.

Denominator: Gown and Gloves Indicated = Total number of observed contacts between a HCW and a patient on Transmission-based Contact Precautions or inanimate objects in the immediate vicinity of the

patient and therefore, gown and gloves were indicated.

Gown and gloves use process measure data are reported using the [MDRO and CDI Monthly Denominator Form](#) (CDC 57.127). See [Tables of Instructions](#) for completion instructions.

Data Analysis: Data are stratified by time (for example, month, quarter, etc.) and patient care location. *Gown and Glove Use Percent Adherence* = Number of contacts for which gown and gloves were used appropriately / Number of contacts for which gown and gloves were indicated x 100

c. Monitoring Adherence to Active Surveillance Testing

Introduction: This option will allow facilities to monitor adherence to active surveillance testing (AST) of MRSA and/or VRE, using culturing or other methods.

Settings: Surveillance will occur in any of 4 types of inpatient locations: (1) intensive care units (ICU), (2) specialty care areas, (3) neonatal intensive care units (NICU), and (4) any other inpatient care location in the institution (for example, surgical wards).

Requirements: Surveillance of AST adherence in at least one location in the healthcare facility for at least one calendar month as indicated in the [Patient Safety Monthly Reporting Plan](#) (CDC 57.106). A facility may choose to report AST for MRSA and/or VRE in one or multiple patient care locations, as the facility deems appropriate. Ideally, this should be done in patient care locations also selected for Infection Surveillance or LabID Event reporting. To improve standardization of timing rules for AST specimen collection, classify admission specimens as those obtained on day 1 (admission date), day 2, or day 3 (specifically, less than or equal to 3 days). Classify discharge/transfer AST specimens as those collected on or after day 4 (specifically, more than 3 days).

Definitions:

AST Eligible Patients: Choose one of two methods for identifying patients that are eligible for AST:

All = All patients in the selected patient care area regardless of history of MRSA or VRE infection or colonization.

OR

NHx = All patients in the selected patient care area who have NO documented positive MRSA or VRE infection or colonization during the previous 12 months (as ascertained by either a facility's laboratory records or information provided by referring facilities); and no evidence of MRSA or VRE during stay in the patient care location (specifically, they are not in Contact Precautions).

Timing of AST: Choose one of two methods for reporting the timing of AST:

Adm = Specimens for AST obtained less than or equal to 3 days after admission,

OR

Both = Specimens for AST obtained less than or equal to 3 days after admission and, for patients' stays of more than 3 days, at the time of discharge/transfer. Discharge/transfer AST should

include all discharges (including discharges from the facility or to other wards or deaths) and can include the most recent weekly AST if performed more than 3 days after admission to the patient care location. Discharge/transfer AST should not be performed on patients who tested positive on AST admission.

Numerator and Denominator Data: Use the [MDRO and CDI Monthly Denominator Form](#) (CDC 57.127) to indicate: 1) AST was performed during the month for MRSA and/or VRE, 2) AST-eligible patients, and 3) the timing of AST. No personal identifiers will be collected or reported. See Tables of Instructions for completion instructions.

Numerator: For each month during which AST is performed:

Admission AST Performed = Number of patients eligible for admission AST who had a specimen obtained for testing less than or equal to 3 days after admission,
AND/OR

Discharge/Transfer AST Performed = For patients' stays more than 3 days, the number of discharged or transferred patients eligible for AST who had a specimen obtained for testing prior to discharge, not including the admission AST.

Denominator: For each month during which AST is performed:

Admission AST Eligible = Number of patients eligible for admission AST (All or NHx),
AND/OR

Discharge/Transfer AST Eligible = Number of patients eligible for discharge/transfer AST (All or NHx) AND in the facility location more than 3 days AND negative if tested on admission.

Data Analysis: Data are stratified by patient care location and time (for example, month, quarter, etc.), according to AST-eligible patients monitored and the timing of AST.

Admission AST Percent Adherence = Number of patients with admission AST Performed / Number of patients admission AST eligible x 100

Discharge/transfer AST Percent Adherence = Number of patients with discharge/transfer AST performed / Number of patients discharge/transfer AST eligible x 100

2. Active Surveillance Testing Outcome Measures

Introduction: This option will allow facilities to use the results of AST to monitor the prevalent and incident rates of MRSA and/or VRE colonization or infection. This information will assist facilities in assessing the impact of intervention programs on MRSA or VRE transmission.

Settings: Surveillance will occur in any of 4 types of inpatient locations: (1) intensive care units (ICU), (2) specialty care, (3) neonatal intensive care units (NICU), and (4) any other inpatient care location in the institution (for example, surgical wards).

Requirements: Surveillance for prevalent and/or incident MRSA or VRE cases in at least one location in the healthcare facility for at least one calendar month as indicated in the [Patient Safety Monthly Reporting Plan](#) (CDC 57.106). This can be done ONLY in locations where AST adherence is being performed. A minimum AST adherence level will be required for the system to calculate prevalence and incidence. A facility may choose to report AST for MRSA and/or VRE in one or multiple patient care locations, as the facility deems appropriate. Ideally, this should be done in patient care locations also selected for Infection Surveillance or LabID Event reporting. To improve standardization of timing rules for AST specimen collection, classify admission specimens as those obtained on day 1 (admission date), day 2, or day 3 (specifically, less than or equal to 3 days). Classify discharge/transfer AST specimens as those collected on or after day 4 (specifically, more than 3 days). Only the first specimen positive for MRSA or VRE from a given patient in the patient care location is counted, whether obtained for AST or as part of clinical care. If an Admission AST specimen is not collected from an eligible patient, assume the patient has no MRSA or VRE colonization.

Definitions:

AST Admission Prevalent case:

Known Positive = A patient with documentation on admission of MRSA or VRE colonization or infection in the previous 12 months (specifically, patient is known to be colonized or infected as ascertained by either a facility's laboratory records or information provided by referring facilities). (All MRSA or VRE colonized patients currently in a location during the month of surveillance should be considered "Known Positive"),

OR

Admission AST or Clinical Positive = A patient with MRSA or VRE isolated from a specimen collected for AST less than or equal to 3 days after admission or from clinical specimen obtained less than or equal to 3 days after admission (specifically, MRSA or VRE cannot be attributed to this patient care location).

AST Incident case: A patient with a stay more than 3 days:

With no documentation on admission of MRSA or VRE colonization or infection during the previous 12 months (as ascertained either by the facility's laboratory records or information provided by referring facilities); including admission AST or clinical culture obtained less than or equal to 3 days after admission (specifically, patient without positive specimen),

AND

With MRSA or VRE isolated from a specimen collected for AST or clinical reasons more than 3 days after admission to the patient care location or at the time of discharge/transfer from the patient care location (including discharges from the facility or to other locations or deaths).

MRSA colonization: Carriage of MRSA without evidence of infection (for example, nasal swab test positive for MRSA, without signs or symptoms of infection).

AST Eligible Patients: Choose one of two methods for identifying patients' eligible for AST:

All = All patients in the selected patient care area regardless of history of MRSA or VRE infection or colonization,

OR

NHx = All patients in the selected patient care area who have NO documented positive MRSA or VRE infection or colonization during the previous 12 months (as ascertained either by the facility's laboratory records or information provided by referring facilities); and no evidence of MRSA or VRE during stay in the patient care location.

Timing of AST: Choose one of two methods for reporting the timing of AST:

Adm = Specimens for AST obtained less than or equal to 3 days after admission,

OR

Both = Specimens for AST obtained less than or equal to 3 days after admission and, for patients' stays of more than 3 days, at the time of discharge/transfer. Discharge/transfer AST should include all discharges (including discharges from the facility or to other wards or deaths) and can include the most recent weekly AST if performed more than 3 days after admission to the patient care location. Discharge/transfer AST should not be performed on patients who tested positive on AST admission.

Numerator and Denominator Data: Use the [MDRO and CDI Monthly Denominator Form](#) (CDC 57.127) to indicate: 1) AST outcomes monitoring and adherence was performed during the month for MRSA and/or VRE, 2) AST eligible patients, and 3) the timing of AST. No personal identifiers will be collected or reported. See [Tables of Instructions](#) for completion instructions.

If only admission AST is performed, only prevalent cases of MRSA or VRE can be detected in that patient care location. If both admission and discharge/transfer AST are performed, both prevalent and incident cases can be detected. No personal identifiers will be collected or reported.

Admission Prevalent Case:

Numerator Sources: (1) Known Positive; (2) Admission AST or Clinical Positive = Cases less than or equal to 3 days after admission

Denominator Source: Total number of admissions

Incident Case:

Numerator: Discharge/transfer AST or Clinical Positive = Cases more than 3 days after admission and without positive test result(s) on admission

Denominator: Total number of patient days

Note: For research purposes calculating patient-days at risk (specifically, excluding patient-days in which patients were known to be MRSA or VRE colonized or infected) may be a preferable denominator, but for surveillance purposes and ease of aggregating, total number of patient days is required for this module.

Data Analysis: Data are stratified by patient care location and time (for example, month, quarter, etc.) according to the eligible patients monitored and timing of AST.

AST Admission Prevalence rate =

For Eligible patients = All:

Number of admission AST or clinical positive / Number of admissions x 100

For Eligible patients = NHx:

Number of admission AST or clinical positive + Number of known positive / Number of admissions x 100

AST Incidence rate =

Number of discharge/transfer AST or clinical positive / Number of patient days x 1000

¹HICPAC, Management of Multidrug-Resistant Organisms in Healthcare Settings.

<<https://www.cdc.gov/hicpac/index.html>>.

²Cohen AL, et al. *Infection Control and Hospital Epidemiology*. Oct 2008; 29:901-913.

³McDonald LC, Coignard B, Dubberke E, Song X, Horan T, Kutty PK. Recommendations for surveillance of *Clostridium difficile*-associated disease. *Infection Control Hospital Epidemiology* 2007; 28:140-5.

⁴Clinical Practice Guidelines for *Clostridium difficile* Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA); L Clifford McDonald, Dale N Gerding, Stuart Johnson, Johan S Bakken, Karen C Carroll, Susan E Coffin, Erik R Dubberke, Kevin W Garey, Carolyn V Gould, Ciaran Kelly, Vivian Loo, Julia Shaklee Sammons, Thomas J Sandora, Mark H Wilcox; *Clinical Infectious Diseases*, Volume 66, Issue 7, 19 March 2018, Pages 987–994,

Appendix 1. Guidance for Handling MDRO and CDI Module Infection Surveillance and LabID Event Reporting When Also Following Other NHSN Modules

If a facility is monitoring BSI (CLABSI), UTI (CAUTI), PNEU (VAP), or VAE within the Device-Associated Module and/or SSIs within the Procedure-Associated Module and is also monitoring MDROs (for example, MRSA) in the MDRO and CDI Module, then there are a few situations where reporting the infection or LabID event may be confusing. The following scenarios provide guidance to keep the counts and rates consistent throughout your facility and between all of the NHSN Modules.

Device-Associated Module with MDRO and CDI Module

Scenario 1: Facility is following BSI (CLABSI), UTI (CAUTI), PNEU (VAP), or VAE along with MDRO Infection Surveillance and possibly LabID Event Reporting in the same location:

Healthcare-associated Infection identified for this location.

1. Report the infection (BSI, UTI, PNEU, or VAE).
2. Answer “Yes” to the MDRO infection question.

This fulfills the infection reporting requirements of both modules in one entry and lets the NHSN reporting tool know that this infection should be included in both the Device-Associated and the MDRO infection datasets and rates.

3. If following LabID event reporting in the same location, report also (separately) as a LabID Event (if meets the MDRO protocol criteria for LabID event).

Scenario 2: Facility is following BSI (CLABSI), UTI (CAUTI), PNEU (VAP), or VAE along with MDRO Infection Surveillance and possibly LabID Event Reporting in multiple locations:

The event date for the infection is the day of patient transfer from one location (the transferring location) to another location (the new location), or the next day.

1. Report the infection (BSI, UTI, PNEU, and VAE) and attribute to the transferring location, if transferring location was following that Event Type (BSI, UTI, PNEU, VAE) on the day of Event, which occurred on the date of transfer, or the following day.
2. Answer “Yes” to the MDRO infection question, if the transferring location was following that MDRO on the day of Event, which occurred on the date of transfer, or the following day.
3. If, on the date of culture collection, the new location is following LabID event reporting, report also (separately) as a LabID Event and attribute to the new location (if meets the MDRO protocol criteria for LabID event).

Procedure-Associated Module with MDRO and CDI Module

Note: SSIs are associated to a specific procedure and not a patient location; MDRO events are connected with the patient location.

Scenario 3: Facility is following SSI along with MDRO Infection Surveillance and possibly LabID Event Reporting:

Patient has surgery, is transferred to a single unit for the remainder of the stay, and during the current stay acquires an SSI.

1. Report the infection (SSI) and attribute to the post-op location.
2. Answer “Yes” to the MDRO infection question, if the post-op location is following that MDRO during the month of the date of event.
3. If following LabID event reporting in the post-op location, report also (separately) as a LabID Event (if organism meets the MDRO protocol criteria for LabID event).

Scenario 4: Facility is following SSI along with MDRO Infection Surveillance and possibly LabID Event Reporting:

Patient has surgery, is either discharged immediately (outpatient) or transferred to a unit (inpatient), is discharged, and subsequently is readmitted with an SSI.

1. Report the infection (SSI) and attribute to the discharging (post-op) location (not the readmission location).
2. Answer “Yes” to the MDRO infection question, if the discharging (post-op) location was following that MDRO during the Date of Event.
3. If following LabID event reporting in the readmitting location or outpatient clinic where the specimen was collected, report also (separately) as a LabID Event (if organism meets the MDRO protocol criteria for LabID event).

Appendix 2: FacWideIN Denominator Counts

For the purpose of NHSN surveillance and reporting, a 24-hour observation area is mapped as an outpatient unit, and time spent in this type of unit does not contribute to inpatient counts (specifically, patient days, device days, admissions). Stays in such outpatient units represent “encounters” for the purposes of LabID Event monitoring in the MDRO/CDI module.

The NHSN instructions for recording the number of patients in an inpatient unit state that for each day of the month selected, at the same time each day, the number of patients on the unit should be recorded. This procedure should be followed regardless of the patient’s billing status (such as an observation patient or a swing bed patient for example).

Key point: it is the patient’s physical location and NOT the patient’s admission status that determines whether the patient counts for an inpatient location or the 24-hour observation location.

1. Observation patient in **observation location**:

When an observation patient is housed in a location that is mapped as a 24-hr Observation area, they should not be included in any inpatient counts. These areas are considered outpatient locations.

2. Observation patient in **inpatient location**:

a. If an observation patient is transferred to an inpatient location:

LabID event reporting -- Only patient days in the inpatient location are to be included in patient day counts for the location or FacWideIN. These counts should be inclusive of all patients housed in the inpatient location, regardless of their admission status as an observation patient.

b. If an observation patient is admitted to an inpatient location, the patient must be included in all surveillance events designated in the monthly reporting plan and included in patient and device day counts. The patient is being housed, monitored, and cared for in an inpatient location and therefore is at risk for acquisition of an HAI. The facility assignment of the patient as an observation patient or an inpatient has no bearing for the purpose of counting.

Below is an example of attributing patient days to a patient admitted to an inpatient location, regardless of whether the facility considers the patient an observation patient or an inpatient.

The examples show counts taken at: A) 12:00 am and B) 11:00 pm.

A. Count at 12:00 am (midnight):

Date	Mr X Pt Day	Mr Y Pt Day
01/01	Mr X admitted at 8:00 pm Mr X not counted because the count for 01/01 was taken at 12:01 am on 01/01 and he was not yet admitted X	Mr Y admitted at 12:00 am Mr Y is counted because the count for 01/01 was taken at 12:01 am and that is when he was admitted 1
01/02	1	2
01/03	2	3
01/04	3	4
01/05	Mr X discharged at 5:00 pm 4 Counted for 01/05 because he was in the hospital at 12:01 am on 01/05 when the count for that day was taken	Mr Y discharged at 12:01 am 5 Counted for 01/05 because he was in the hospital at 12:01 am on 01/05 when the count for that day was taken
Total	4 patient days	5 patient days

If we use the same admission dates and times for Mr. X, but a different time is selected for the patient day count, for example 11:00 pm, the total number of days in the count will be the same; they will simply be coming from different dates.

When converting from manual data collection to an electronic counting system, the data must be checked to ensure that all appropriate patients are included or excluded from those counts and that, for three consecutive months, your electronic data are within +/- 5% of the number obtained by manual counts. If these counts are more than 5% discrepant, then you will need to evaluate and determine the cause of the discrepancies and methods to address them.

When converting from one electronic counting system to another electronic counting system, the new electronic system should be validated against manual counts as above. If electronic counts for the new electronic system are not within 5% of manual counts, resume manual counting and continue working to improve design of electronic denominator data extraction (while reporting manual counts) until concurrent counts are within 5% for 3 consecutive months.

Note: This guideline is important because validating a new electronic counting system against an existing electronic system can magnify errors and result in inaccurate denominator counts. The main goal is to accurately count patients in the denominators that may contribute to the numerator.

B. Count at 11:00 pm:

Date	Mr X	Pt Day
01/01	Mr X admitted at 8:00 am	Counted because the count for 01/01 is taken at 11:00 pm on 01/01 and he is in the hospital at that time 1
01/02		2
01/03		3
01/04		4
01/05	MR X discharged at 5:00 pm	Not counted for 01/05 because he was not in the hospital at 11:00 pm on 01/05 when the count for that day was taken X
Total		4 patient days

Determining Admission Counts for Summary Data Collection:

Recognizing there are a variety of ways in which patient day and admission counts are obtained for a facility and for specific locations, this guidance is offered to assist with standardization within and across facilities. How you operationalize this guidance will depend on how you are obtaining the data for your counts. It is most important that whatever method is used by a facility, it should be used each and every month for consistency of data and metrics.

1. **Facility-Wide Inpatient Admission Count:** Include any new patients that are assigned to a bed in any inpatient location within the facility regardless of billing status. Qualification as a new patient means that the patient was not present on the previous calendar day. The daily admission counts are summed at the end of the calendar month for a monthly facility-wide inpatient admission count.
2. **Inpatient Location-Specific Admission Count:** Include any new patients that are assigned to a bed in the specific inpatient location. Qualification as a new patient means that the patient was not present in the specific inpatient location on the previous calendar day. The daily admission counts are summed at the end of the calendar month for a monthly inpatient location-specific admission count.

Any patient who meets criteria for new inclusion should be counted, regardless of whether they are coded by the facility as an inpatient or as an observation patient.

Below is an example of manually counting location-specific and facility-wide admission counts related to a patient admitted to an inpatient location and transferred to multiple patient locations during his hospital stay. The example shows counts taken at 11:00 pm.

Example: Counts at 11:00 pm:

Unit	Date/Time Mr. X Placed on Inpatient Unit	Date/Time Mr. X Transferred Out of Inpatient Unit	Inpatient Location-Specific Admission Count	Inpatient Facility-Wide Admission Count
SICU	10/08 – 10:00am (facility admission)	10/13 – 9:00am	1 Adm for SICU	1 Adm for FacWideIN
MICU	10/13 – 9:15am	10/13 – 11:00am	Not present and so not counted	Same Adm, and also not present so not counted
Surgical Ward	10/13 – 11:30am	10/25 – 1:00pm	1 Adm for Surgical Ward	Same Adm so not counted
Medical Ward	10/25 – 1:30pm	10/26 – 10:00am (facility discharge)	1 Adm for Medical Ward	Same Adm so not counted

Appendix 3: Differentiating Between LabID Event and Infection Surveillance

	LabID Event	Infection Surveillance (using HAI surveillance definitions)
Protocol	LabID Event protocol in Chapter 12 of NHSN manual	Infection Surveillance protocol in Chapter 12 of NHSN manual <u>and</u> HAI site-specific definitions in NHSN manual (for example, BSI, UTI, SSI, PNEU, VAE, and GI-CDI and other HAI definitions)
Signs & Symptoms	NONE. Laboratory and admission data, without clinical evaluation of patient	Combination of laboratory data and clinical evaluation of patient (signs/symptoms)
Surveillance Rules	- HAI and POA do NOT apply - Transfer Rule does NOT apply - Location = location of patient at time of specimen collection - Event date = specimen collection date	- HAI and POA do apply - Transfer Rule applies - See NHSN protocol for details regarding location and date of event
Denominator Reporting	- Number of patient days and admissions - Can be reported by specific location or facility-wide, depending on reporting option(s) selected - Inpatient and/or outpatient	- Device days and patient days must be collected separately for each monitored location - Inpatient reporting only
Categorization of Infections	- Events categorized based on inpatient or outpatient location and admission and specimen collection dates - Healthcare Facility-Onset (HO) - Community-Onset (CO) - Community-Onset Healthcare Facility-Associated (CO-HCFA) for <i>C. difficile</i> only - HO, CO, and CO-HCFA (if applicable) LabID Events must be reported to NHSN - Additional categorizations are applied to <i>C. difficile</i>, which include Incident CDI event and Recurrent CDI event. Both must be reported to NHSN.	- HAI protocols used - Events are either HAI or not, <u>therefore LabID Event categorizations do not apply</u> - Only HAIs are reported to NHSN

Antimicrobial Use and Resistance (AUR) Module

Contents

Antimicrobial Use and Resistance (AUR) Module	1
Introduction	1
1. Antimicrobial Use (AU) Option	2
Introduction	2
Requirements	3
Data Analyses	8
Appendix A. Table of Instructions: Antimicrobial Use Option	17
Appendix B. List of Antimicrobials	19
Appendix C. Example Calculations of Antimicrobial Days	23
Appendix D: List of SAARs	26
Appendix E: Antimicrobial Groupings for SAAR Calculations	34
2. Antimicrobial Resistance (AR) Option	40
Introduction	40
Requirements	41
Data Analyses	53
Appendix F. List of Eligible Organisms and Corresponding Antimicrobial Susceptibility Panels for the NHSN AR Option	64
Appendix G. Technical and Isolate Based Report Variables	72
Appendix H. Denominator Data Variables	78
Appendix I. NHSN AR Option Phenotype Definitions	81
Appendix J. List of SRIRs and pSIRs	87
References	88
Change Log	90

Introduction

This module contains two options: one focused on antimicrobial use and the second on antimicrobial resistance. To participate in either option, facility personnel responsible for reporting antimicrobial use (AU) or resistance (AR) data to the National Healthcare Safety Network (NHSN) must coordinate with their pharmacy and/or laboratory information software providers to configure their system to generate standard formatted file(s) to be imported into NHSN. The format provided for data submission follows the [Health Level 7 \(HL7\) Clinical Document Architecture \(CDA\)](#) standard.¹ Manual data entry is not available for the AUR Module.

Purpose

The NHSN AUR Module provides a mechanism for facilities to report and to analyze AU and/or AR data to inform benchmarking, reduce antimicrobial resistant infections through antimicrobial stewardship, and interrupt transmission of resistant pathogens at individual facilities or facility networks.²

1. Antimicrobial Use (AU) Option

Introduction

Antimicrobial resistance rates continue to increase in hospitals across the United States.³ One of the five CDC core actions to combat the spread of antimicrobial resistance is improving the use of antimicrobials.⁴ Studies show that providing timely and reliable feedback of information to clinicians regarding their prescribing practices, such as through antimicrobial usage reports, can improve appropriateness of antimicrobial use.⁵⁻⁷

Objectives: The primary objective of the Antimicrobial Use (AU) Option is to facilitate risk-adjusted inter- and intra-facility antimicrobial use benchmarking. A secondary objective is to evaluate antimicrobial use trends over time at the facility and national levels.

Methodology: The primary antimicrobial use metric reported to the AU Option is antimicrobial days per 1,000 days present. An antimicrobial day (also known as day of therapy) is defined by any amount of a **specific** antimicrobial agent administered in a calendar day to a particular patient as documented in the electronic medication administration record (eMAR) and/or bar coding medication administration (BCMA) system (refer to Numerator Data section starting on page 14-4 for more information); all antimicrobial days for a specific agent administered across a population are summed in aggregate.⁸⁻¹¹ Days present are defined as the aggregate number of patients housed in a patient care location or facility anytime throughout a day during a calendar month (refer to Denominator Data section starting on page 14-6 for more information). For each facility, the numerator (antimicrobial days) is aggregated by month for each patient care location and overall for inpatient areas facility-wide (specifically, facility-wide inpatient or FacWideIN). Similarly, the denominator (days present) is calculated for the corresponding patient care-location-month or facility-wide inpatient-month. A secondary antimicrobial use metric, antimicrobial days per 100 admissions, is reported to the AU Option for facility-wide inpatient (FacWideIN) data.

The numerator and denominators are further defined below and must adhere to the data format specified by the [HL7 CDA Implementation Guide](#) developed by the CDC and HL7.¹ **Manual data entry is not available for the NHSN AU Option.**

Settings: All inpatient facilities enrolled in NHSN and reporting to the Patient Safety Component can participate in the AU Option. This includes facilities enrolled as general acute care hospitals, critical access hospitals, children's hospitals, long term acute care hospitals, pediatric long term acute care hospitals, military and veterans' hospitals, oncology hospitals, orthopedic hospitals, psychiatric hospitals, rehabilitation hospitals, surgical hospitals, women's hospitals, women's and children's hospitals, government and non-government hospitals for public health emergencies. Facilities must have the ability to collect the numerator and denominator data electronically and upload those data into NHSN using the required CDA specifications. NHSN does not currently support the submission of data

into the AU Option from ambulatory surgery centers, long term care facilities (for example, skilled nursing facilities, nursing homes) nor outpatient dialysis facilities.

NHSN strongly encourages the submission of data from all NHSN-defined inpatient locations (including procedural areas like operating rooms), facility-wide inpatient (FacWideIN), and select outpatient acute care settings (specifically, outpatient emergency department [ED], pediatric ED, and 24-hour observation area) from which the numerator and denominator data can be accurately electronically captured. The AU Option does not accept data from other outpatient locations such as outpatient clinics. The FacWideIN record should contain data from all inpatient locations and inpatient procedural areas from which the numerator and denominator can be accurately electronically captured. A comprehensive submission will enable a facility to optimize inter- and/or intra-facility comparisons among specific wards, combined wards, and facility-wide data.

NHSN delineates a CDC-defined designation (CDC Location) for patient care areas/locations where patients have similar disease conditions or are receiving care for similar medical or surgical specialties. Each facility location is “mapped” to one CDC Location within the NHSN facility. The specific CDC Location code is determined by the type of patients cared for in that area according to the NHSN location mapping algorithm for acuity level and service type. The patient care areas include adult, pediatric, and neonatal units as defined by NHSN Codes. See the [NHSN Locations chapter](#) for more information regarding location mapping. Note: facilities should not map a whole separate set locations for AUR reporting (for example, “1 North” and “1 North AUR”). Facilities are encouraged to report data from all inpatient locations which means facilities may report AUR data for more locations than are used for HAI reporting (for example, operating rooms, specialty ward locations like labor and delivery, etc.). Please work with Infection Control/Infection Prevention to determine the correct location mapping for your facility.

Requirements

Each month:

1. The facility must indicate the specific locations from which they plan to submit antimicrobial use data in the [Patient Safety Monthly Reporting Plan](#).
 - a. When reporting AU Option data from inpatient and outpatient locations, list FacWideIN, each individual inpatient location, and each individual outpatient location as separate rows in the plan.
2. The CDA files submitted by the facility contain all data fields outlined in the Table of Instructions ([Appendix A](#)) for each location.
3. The facility uploads data via CDA files for all locations indicated in the Monthly Reporting Plan.
 - a. Submit one file for each individual patient care location as well as a separate file for FacWideIN. As an example, a facility with three patient care locations will upload three separate files for each individual location and one additional file for FacWideIN for a total of four files per month.

NHSN recommends the facility uploads data into NHSN for a given calendar month by the end of the subsequent calendar month.

Numerator Data (Antimicrobial Days):

Antimicrobial Days (also known as Days of Therapy): Defined as the aggregate sum of days for which any amount of a *specific* antimicrobial agent was administered to individual patients as documented in the eMAR and/or BCMA.⁸⁻¹¹ [Appendix B](#) provides the full list of antimicrobial agents collected in the NHSN AU Option. Aggregate antimicrobial days are reported monthly for inpatient locations, FacWideIN, and three select outpatient acute care settings (specifically, outpatient ED, pediatric ED, and 24-hour observation area) for select antimicrobial agents and stratified by route of administration (specifically, intravenous, intramuscular, digestive, and respiratory).

Refer to [Table 1](#) and [Table 2](#) for the definitions of drug-specific antimicrobial days and stratification based on route of administration. Antimicrobials are only counted as an antimicrobial day on the day of administration. For example, when a patient is administered 1 gram Vancomycin intravenously twice daily for three days, three “Vancomycin Days (total)” and three “Vancomycin Days (IV)” are counted when stratified by intravenous route of administration. Please note this rule also applies to antimicrobials that have an extended half-life (such as Dalbavancin, Oritavancin and Rezafungin) and in patients with renal impairment. [Table 3](#) summarizes the data elements for numerator calculation. [Appendix C](#) provides additional examples of antimicrobial day calculation.

A whole number greater than or equal to 0 or “NA” must be reported for every antimicrobial agent and route of administration listed in [Appendix B](#) for every location record for each month. Antimicrobial agents and routes of administration cannot be left blank. Facilities should report “0” (zero) antimicrobial days when no aggregate use occurred during a given reporting period for a specific antimicrobial agent/route (for example, Zanamivir via the respiratory route) **and** that agent/route can be accurately captured in the eMAR or BCMA system.

Please note, facilities should report “NA” (Not Applicable) **only** when the administrations for an agent/route cannot be electronically captured at that facility (specifically, data are not available for a specific antimicrobial agent/route). Furthermore, facilities should consistently report “NA” across all locations and FacWideIN. For example, if a facility was unable to electronically capture Amikacin administered via the respiratory route (in the event of using the IV formulation for inhalation), the facility would report “NA” for the respiratory route of Amikacin for all individual locations and FacWideIN. The same rule also applies to non-formulary agents. If use of non-formulary agents can be accurately electronically captured, no use of those agents in each location/month would be reported as “0” (zero). Additionally, if the total number of antimicrobial days is a numerical value, then none of the individual routes should be marked as N/A.

Table 1. Classification and Definition of Routes of Administration for Antimicrobial Days

Classification: Route of Administration^a	Definition^b
Intravenous (IV)	An intravascular route that begins with a vein.
Intramuscular (IM)	A route that begins within a muscle.
Digestive Tract	A route that begins anywhere in the digestive tract extending from the mouth through rectum. ^c
Respiratory Tract	A route that begins within the respiratory tract, including the oropharynx and nasopharynx.

Table 2. Example Stratification of Antimicrobial Days by Route of Administration

Month/ Year- Location	Antimicrobial Agent	Drug-specific Antimicrobial Days				
		Total^d	IV	IM	Digestive^e	Respiratory
Month/ Year Location	Tobramycin	Tobramycin Days (Total)	Tobramycin Days (IV)	Tobramycin Days (IM)	Tobramycin Days (Digestive)	Tobramycin Days (Respiratory)
01/2022 Med Ward		1	1	0	0	1

^a Other routes of administration are excluded from the AU Option reporting (for example, antibiotic locks, intraperitoneal, intrapleural, intraventricular, irrigation, topical) and should not be included in the total antimicrobial days nor the sub-stratification of the routes of administration.

^b Definitions were drawn from SNOMED qualifier value hierarchy. Refer to the [CDA Antimicrobial Use \(AU\) Toolkit](#) for specific codes corresponding to each route of administration.

^c For example, rectal administration of Vancomycin.

^d Drug-specific antimicrobial days (total) attributes one antimicrobial day for any route of administration. For example, if Tobramycin was administered to a patient intravenously *and* via a respiratory route on the same day, the antimicrobial days would be counted as “one Tobramycin Day (Total)” and the stratification by route of administration would be “one Tobramycin Day (IV)” and “one Tobramycin Day (Respiratory)”.

^e Tobramycin is used for an example of route stratification only and is not FDA approved for administration via the digestive route.

Table 3. Data Elements for Antimicrobial Days

Data Element	Details
Antimicrobial Agents	Defined as select antimicrobial agents and stratified by route of administration (specifically, intravenous, intramuscular, digestive, and respiratory). Refer to Appendix B for a complete list of antimicrobials. The list of select antimicrobials will evolve with time as new agents become commercially available and old agents are removed from the market. <i>Topical antimicrobial agents are not included in the NHSN AU Option.</i>
Data source	Antimicrobial days are derived from antimicrobial administration data documented in the eMAR and/or BCMA only. Usage derived from other data sources (for example, pharmacy orders, doses dispensed, doses billed) <i>cannot</i> be submitted.
Location	Antimicrobial days are aggregated for each inpatient location, facility-wide inpatient, and three select outpatient acute-care settings (specifically, outpatient ED, pediatric ED, and 24-hour observation area) per the NHSN location definitions .
Time Unit	Antimicrobial days for a specific antimicrobial agent and stratification by route of administration are aggregated monthly per location.

Denominator Data (Days Present and Admissions): The numerator will be analyzed against the denominators of days present (all locations) and admissions (for facility-wide inpatient [FacWideIN] only). The denominators are further defined below.

Days present: Days present are defined as the time period during which a given patient is at risk for antimicrobial exposure in each patient location. The definition of days present differs from the definition of patient days used in other NHSN modules. Days present is further defined below in context of calculation for patient care location-specific analyses and facility-wide inpatient analyses. Please note that a separate calculation for days present is required for each patient care location compared to facility-wide inpatient.

For patient care location-specific analyses, days present are calculated as the number of patients who were present, regardless of patient status (for example, inpatient, observation), for any portion of each day during a calendar month for a patient care location. The patient can begin attributing to the days present count in an outpatient location such as an Emergency Department as soon as they have had an initial interaction with a medical professional (for example, the beginning of triage), regardless of when the patient is placed in a bed. The aggregate measure is calculated by summing days present for that location and month. The day of admission, discharge, and transfer to and from locations will be *included* in the days present count. Below are examples that illustrate appropriate days present calculation:

- A patient admitted to the medical ward on Monday and discharged two days later on Wednesday contributes three days present in the medical ward because the patient was present in that specific location at some point during each of the three calendar days (specifically, Monday, Tuesday, and Wednesday).
- On the day a patient is transferred from a medical critical care unit to a medical ward, the patient contributes one day present in the medical critical care unit and one day present in

the medical ward because the patient was present in both locations at some point during that calendar day. Similarly, a patient contributes days present to the operating room or ED if data are submitted from these locations.

- One patient can only contribute one day present for a specific location per calendar day. While a patient cannot contribute more than one day present to any one *unique* location on the same day that patient can contribute a day present to two *different* locations on the same day. For example, a patient transferred from the surgical ward to the operating room and back to the surgical ward in a calendar day contributes one day present to the surgical ward and one day present to the operating room.

For facility-wide inpatient (FacWideIN) analyses, days present are calculated as the number of patients who were present in an *inpatient* location within the facility for any portion of each day during a calendar month. The aggregate measure is calculated by summing up all the days present for facility-wide inpatient for a given month. Thus, a sum of days present from location-specific analyses would be higher than days present for the facility (FacWideIN) because transfers between wards can account for multiple location “days present” for a given patient on a single calendar day. Therefore, it is not permissible to sum the individual days present for location-specific analyses to achieve the facility-wide inpatient (FacWideIN) days present count. The calculation must be a separate summation for facility-wide inpatient analyses.

Please note that only inpatient locations in which both the antimicrobial days (numerator) and the days present (denominator) can be accurately electronically captured should be included in the FacWideIN counts. Additionally, outpatient locations (ED, pediatric ED, and 24-hour observation) should **not** be included in FacWideIN counts.

Admissions: Admissions are defined as the aggregate number of patients admitted to an inpatient location within the facility (facility-wide inpatient) starting on first day of each calendar month through the last day of the calendar month. A patient is counted as an admission when they arrive in an NHSN designated inpatient location regardless of patient status (for example, inpatient, observation). Further, a patient admitted to an inpatient unit would be counted as an admission even if they were discharged that same calendar day. If in the ADT system a patient appears to move from an inpatient to an outpatient ED, pediatric ED or 24-hour observation location then back to an inpatient location, it should be counted as two separate admissions. In the AU Option, admissions are reported only for facility-wide inpatient (FacWideIN). Please note, the definition of admissions used in the AUR Module is different than the definition used in the NHSN MDRO/CDI Module.

Table 4. Location-specific and Facility-wide Inpatient Metrics

Patient Care Location-Specific Analyses
Rate of Antimicrobial Days per 1,000 Days Present $\frac{\text{Drug specific antimicrobial days per patient care location per month}}{\text{Days present per patient care location per month}} \times 1000$ Notes: - One patient can contribute only one day present per calendar day for each specific location. - Summed total may be higher when compared to facility-wide count (reflecting transfers between locations).
Facility-wide Inpatient Analyses
Rate of Antimicrobial Days per 1,000 Days Present $\frac{\text{Drug specific antimicrobial days for all inpatient units in a facility per month}}{\text{Days present per facility wide inpatient per month}} \times 1000$ Notes: - One patient can contribute only one day present per calendar day for a facility. Thus, one denominator is obtained for all inpatient locations in an entire facility. - The days present measure for facility-wide inpatient should be lower when compared to sum total from location-specific comparison. - Only include inpatient units where both the antimicrobial days (numerator) and the days present (denominator) can be accurately electronically captured. - Exclude outpatient locations.
Rate of Antimicrobial Days per 100 Admissions $\frac{\text{Drug specific antimicrobial days for all inpatient units in a facility per month}}{\text{Admissions per facility wide inpatient per month}} \times 100$ Notes: - Only calculate for facility-wide inpatient for the AU Option. - Only include inpatient units where both the antimicrobial days (numerator) and the days present and admissions (denominators) can be accurately electronically captured. - Exclude outpatient locations.

Data Analyses

All AU Option data reported to NHSN can be analyzed immediately after submission to NHSN. After [generating analysis datasets within NHSN](#), users can view reported data using various NHSN analysis reports to visualize and analyze data in more detail. For example, descriptive analysis reports such as line lists and bar charts are available. In addition, measures of antimicrobial use are available in rate tables and Standardized Antimicrobial Administration Ratios (SAAR) reports.

Types of AU Option Analysis Reports

Standardized Antimicrobial Administration Ratio (SAAR):

The Standardized Antimicrobial Administration Ratio (SAAR) is a metric developed by CDC to analyze and report antimicrobial use data in summary form. The SAAR is calculated by dividing observed antimicrobial use by predicted antimicrobial use.

$$SAAR = \frac{\text{Observed Antimicrobial Use}}{\text{Predicted Antimicrobial Use}}$$

The observed antimicrobial use is the number of days of therapy, or antimicrobial days, reported by a facility for a specified category of antimicrobial agents in a specified group of patient care locations. The predicted antimicrobial use is calculated using predictive models developed by CDC and applied to nationally aggregated 2023 adult, pediatric and neonatal AU data reported to NHSN from the same group of patient care location types. Separate predictive models are developed for each specific antimicrobial agent category.

The SAAR can be generated for 22 antimicrobial agent categories (7 adult, 8 pediatric, and 7 neonatal) and 39 specific NHSN location types (26 adult, 9 pediatric, and 4 neonatal), for a total of 282 possible SAARs (see [Appendix D](#)), each of which can serve as a high-value target or high-level indicator for antimicrobial stewardship programs. The antimicrobial agent categories were determined by CDC with input from external adult, pediatric, and neonatal infectious disease physicians and pharmacists. The SAAR agent categories are listed below. The specific antimicrobial agents in each category can be found in [Appendix E](#).

- Adult SAAR antimicrobial agent categories
 - All antibacterial agents
 - Broad spectrum antibacterial agents predominantly used for hospital-onset infections
 - Broad spectrum antibacterial agents predominantly used for community-acquired infections
 - Antibacterial agents predominantly used for resistant gram-positive infections (e.g., MRSA)
 - Narrow spectrum beta-lactam agents
 - Antibacterial agents posing the highest risk for CDI (not mutually exclusive, agents may overlap with other categories)
 - Antifungal agents predominantly used for invasive candidiasis
- Pediatric SAAR antimicrobial agent categories
 - All antibacterial agents
 - Broad spectrum antibacterial agents predominantly used for hospital-onset infections
 - Broad spectrum antibacterial agents predominantly used for community-acquired infections
 - Antibacterial agents predominantly used for resistant gram-positive infections (e.g., MRSA)
 - Narrow spectrum beta-lactam agents
 - Azithromycin
 - Antibacterial agents posing the highest risk for CDI (not mutually exclusive, agents may overlap with other categories)

- Antifungal agents predominantly used for invasive candidiasis
- Neonatal SAAR antimicrobial agent categories
 - All antibacterial agents
 - Vancomycin
 - Broad spectrum gram-negative coverage
 - Third generation Cephalosporins
 - Ampicillin
 - Aminoglycosides
 - Fluconazole

With the 2023 SAAR rebaseline, SAARs are available to facilities that have submitted AU data from one of the 39 eligible adult, pediatric, and neonatal SAAR location types included in [Table 5](#). As an important note, the SAARs generated in NHSN only include the SAAR eligible location types listed in Table 5. None of the SAARs contain AU data from *all* inpatient locations in each facility. Therefore, none of the SAARs would be considered a “facility-wide” SAAR. In the future, as more facilities submit AU data, the NHSN Team plans to develop SAARs for additional location types.

Table 5. Location types able to generate SAARs

CDC Location Type	CDC Location Code	NHSN Healthcare Service Location (HL7) Code
Adult Critical Care Locations		
Burn Critical Care	IN:ACUTE:CC:B	1026-4
Medical Cardiac Critical Care	IN:ACUTE:CC:C	1028-0
Medical Critical Care	IN:ACUTE:CC:M	1027-2
Medical-Surgical Critical Care	IN:ACUTE:CC:MS	1029-8
Neurologic Critical Care	IN:ACUTE:CC:N	1035-5
Neurosurgical Critical Care	IN:ACUTE:CC:NS	1031-4
Surgical Critical Care	IN:ACUTE:CC:S	1030-6
Surgical Cardiothoracic Critical Care	IN:ACUTE:CC:CT	1032-2
Trauma Critical Care	IN:ACUTE:CC:T	1025-6
Adult Ward Locations		
Burn Ward	IN:ACUTE:WARD:B	1052-0
Labor and Delivery Ward	IN:ACUTE:WARD:LD	1058-7
Labor, Delivery, Recovery, Postpartum Suite	IN:ACUTE:WARD:LD_PP	1059-5
Medical Ward	IN:ACUTE:WARD:M	1060-3
Medical-Surgical Ward	IN:ACUTE:WARD:MS	1061-1
Neurology Ward	IN:ACUTE:WARD:N	1062-9
Neurosurgical Ward	IN:ACUTE:WARD:NS	1063-7
Postpartum Ward	IN:ACUTE:WARD:PP	1068-6
Pulmonary Ward	IN:ACUTE:WARD:PULM	1069-4
Surgical Ward	IN:ACUTE:WARD:S	1072-8

CDC Location Type	CDC Location Code	NSHN Healthcare Service Location (HL7) Code
Adult Other Locations		
Adult Mixed Acuity Unit	IN:ACUTE:MIXED:ALL_ADULT	1210-4
Adult Orthopedic Ward	IN:ACUTE:WARD:ORT	1065-2
Adult Orthopedic Trauma Ward	IN:ACUTE:WARD:T_ORT	1066-0
Adult Step Down Unit	IN:ACUTE:STEP	1099-1
ONC General Hematology-Oncology Ward	IN:ACUTE:WARD:ONC_HONC	1232-8
ONC Hematopoietic Stem Cell Transplant Ward	IN:ACUTE:WARD:ONC_HSCT	1231-0
Solid Organ Transplant SCA	IN:ACUTE:SCA:SOTP	1092-6
Pediatric Locations		
Pediatric Medical Critical Care	IN:ACUTE:CC:M_PED	1044-7
Pediatric Medical-Surgical Critical Care	IN:ACUTE:CC:MS_PED	1045-4
Pediatric Surgical Cardiothoracic Critical Care	IN:ACUTE:CC:CT_PED	1043-9
Pediatric Medical Ward	IN:ACUTE:WARD:M_PED	1076-9
Pediatric Medical-Surgical Ward	IN:ACUTE:WARD:MS_PED	1081-9
Pediatric ONC General Hematology/Oncology Ward	IN:ACUTE:WARD:ONC_HONC_PED	1235-1
Pediatric ONC Hematopoietic Stem Cell Transplant Ward	IN:ACUTE:WARD:ONC_HSCT_PED	1234-4
Pediatric Surgical Ward	IN:ACUTE:WARD:S_PED	1086-8
Pediatric Step Down Unit	IN:ACUTE:STEP:PED	1100-7
Neonatal Locations		
Special Care Nursery (Level II)	IN:ACUTE:STEP:NURS	1041-3
Neonatal Critical Care (Level II/III)	IN:ACUTE:CC_STEP:NURS	1039-7
Neonatal Critical Care (Level III)	IN:ACUTE:CC:NURS	1040-5
Neonatal Critical Care (Level IV)	IN:ACUTE:CC:NURS_IV	1269-0

A high SAAR that achieves statistical significance (specifically, a SAAR value statistically significantly larger than 1.0) may indicate antimicrobial overuse. A SAAR that is not statistically different from 1.0 indicates antimicrobial use is equivalent to the referent population's antimicrobial use. A low SAAR that achieves statistical significance may indicate antimicrobial underuse. Please note, a SAAR alone is not a definitive measure of the appropriateness or judiciousness of antimicrobial use, and any SAAR may warrant further investigation. For example, a SAAR above 1.0 that does not achieve statistical significance may be associated with meaningful excess of antimicrobial use and further investigation may be needed. Also, a SAAR that is statistically different from 1.0 does not mean that further investigation will be productive. SAARs were created for hospital reporters to compare their use of antimicrobials in each SAAR category against the national benchmark. The groupings of antimicrobials for SAAR categories were based on expert opinions with a goal to optimize the usefulness for antimicrobial stewardship. Since these conditions are often multifactorial and often lagged in time, higher SAARs are not meant to indicate a definitive and immediate clinical consequence (for example, CDI incidence or specific antimicrobial resistant infection).

SAARs can be produced by month, quarter, half-year, year, or cumulative time periods. The SAAR report can be modified to show SAARs by a specific location or a subset of location types. However, keep in mind that SAARs can only be generated and/or modified to show data for the 39 select location types listed above in [Table 5](#).

Additional details and guidance for the SAARs are available in the resources listed below:

[SAAR Guide](#)

[Keys to Success with the SAAR](#)

[SAAR Table](#)

[SAAR Table – by Location](#)

[SAAR Plot](#)

Targeted Assessment for Antimicrobial Stewardship (TAS):

The Targeted Assessment for Antimicrobial Stewardship (TAS) is a framework for quality improvement developed by the CDC to use NHSN AU Option data for action to optimize AU at facilities. TAS is available to hospitals participating in the NHSN AU Option. TAS can be used by antimicrobial stewards and others focused on optimizing AU within groups, such as health departments and health systems, as well as individual facilities.

The TAS Reports use a metric called the antimicrobial use cumulative attributable difference (AU-CAD). The AU-CAD represents the difference between the observed days and a selected Standardized Antimicrobial Administration Ratio (SAAR) target. The TAS Reports allow for ranking facilities within groups, or location groups and locations within individual facilities, by the AU-CAD, to identify where stewardship efforts may have the greatest impact. Since the SAAR is not a definitive measure of the appropriateness or judiciousness of AU, CDC cannot define SAAR targets for facilities or groups. Facilities and groups, however, can use their information on antibiotic use (for example, a medication use evaluation to assess appropriate courses of therapy) to establish improvement goals that can then be monitored with NHSN AU Option metrics (for example, the AU-CAD and SAAR).

$$\text{AU-CAD} = \text{Observed antimicrobial days} - (\text{Predicted antimicrobial days} \times \text{SAAR target})$$

The AU-CAD is the number of antimicrobial days needed to achieve the desired SAAR target. The higher the AU-CAD value, the greater the number of antimicrobial days that need to be reduced to meet the SAAR target. For example, if a facility has an AU-CAD of 75 when they run a TAS report with a SAAR target of 0.95, the interpretation would be “The facility would have needed 75 fewer antimicrobial days to reach their SAAR target of 0.95 during this time period.”

TAS Reports are located within the Analysis section of NHSN. You’ll notice the TAS Reports have their own subfolder within the Antimicrobial Use and Resistance Module folder. The TAS reports are separated by population (adult, pediatric, or neonatal) and by level of aggregation (group, facility, location group, and location). TAS reports include only those location types that can generate SAARs; in other words, the same locations in the SAAR reports will also be included in the TAS reports.

Table 6. Location types able to generate SAARs and included in TAS reports using the 2023 baseline

Location Group in TAS Reports	CDC Location Type	CDC Location Code	NSHN Healthcare Service Location (HL7) Code
Adult			
General ICU	Medical Critical Care	IN:ACUTE:CC:M	1027-2
General ICU	Surgical Critical Care	IN:ACUTE:CC:S	1030-6
General ICU	Medical-Surgical Critical Care	IN:ACUTE:CC:MS	1029-8
Step Down	Adult Step Down Unit	IN:ACUTE:STEP	1099-1
Mixed Acuity	Adult Mixed Acuity Unit	IN:ACUTE:MIXED:ALL_ADULT	1210-4
General Ward	Medical Ward	IN:ACUTE:WARD:M	1060-3
General Ward	Surgical Ward	IN:ACUTE:WARD:S	1072-8
General Ward	Medical-Surgical Ward	IN:ACUTE:WARD:MS	1061-1
OB	Labor and Delivery Ward	IN:ACUTE:WARD:LD	1058-7
OB	Labor, Delivery, Recovery, Postpartum Suite	IN:ACUTE:WARD:LD_PP	1059-5
OB	Postpartum Ward	IN:ACUTE:WARD:PP	1068-6
Ortho	Adult Orthopedic Ward	IN:ACUTE:WARD:ORT	1065-2
Ortho	Adult Orthopedic Trauma Ward	IN:ACUTE:WARD:T_ORT	1066-0
SOTP	Solid Organ Transplant SCA	IN:ACUTE:SCA:SOTP	1092-6
Oncology	ONC General Hematology-Oncology Ward	IN:ACUTE:WARD:ONC_HONC	1232-8
Oncology	Oncology Hematopoietic Stem Cell Transplant Ward	IN:ACUTE:WARD:ONC_HSCT	1231-0
Pediatric			
General ICU	Pediatric Medical Critical Care	IN:ACUTE:CC:M:PED	1044-7
General ICU	Pediatric Medical-Surgical Critical Care	IN:ACUTE:CC:MS_PED	1045-4
SurgCard ICU	Pediatric Surgical Cardiothoracic Critical Care	IN:ACUTE:CC:CT_PED	1043-9
Step Down	Pediatric Step Down Unit	IN:ACUTE:STEP:PED	1100-7
General Ward	Pediatric Medical Ward	IN:ACUTE:WARD:M_PED	1076-9
General Ward	Pediatric Surgical Ward	IN:ACUTE:WARD:S_PED	1086-8
General Ward	Pediatric Medical-Surgical Ward	IN:ACUTE:WARD:MS_PED	1081-9
Oncology	Pediatric ONC General Hematology/Oncology Ward	IN:ACUTE:WARD:ONC_HONC_PED	1235-1
Oncology	Pediatric ONC Hematopoietic Stem Cell Transplant Ward	IN:ACUTE:WARD:ONC_HSCT_PED	1234-4

Location Group in TAS Reports	CDC Location Type	CDC Location Code	NHSN Healthcare Service Location (HL7) Code
Neonatal			
N/A	Step down Neonatal Nursery	IN:ACUTE:STEP:NURS	1041-3
N/A	Neonatal Critical Care (Level II/III)	IN:ACUTE:CC_STEP:NURS	1039-7
N/A	Neonatal Critical Care (Level III)	IN:ACUTE:CC:NURS	1040-5
N/A	Neonatal Critical Care (Level IV)	IN:ACUTE:CC:NURS_IV	1269-0

The TAS reports are available at different levels of aggregation:

- Group
 - Available only when running the TAS reports within an NHSN Group.
 - One table displays metrics pooled at the group level. All other tables in the Group reports display metrics at the facility level for each member facility in the group by SAAR type.
- Facility
 - Available only when running the TAS reports within an individual facility.
 - The reports display metrics pooled at the facility level for an individual facility.
- Location Group
 - The reports display metrics for a group of patient care locations based on how the locations are mapped in NHSN (see [Table 6](#)).
 - Adult location groups: General ICUs, General Wards, Stepdown, Mixed Acuity, OB, Oncology, Ortho, SOTP
 - Pediatric location groups: General ICUs, General Wards, SurgCard ICU, Oncology, Stepdown
 - Location groups are not available for neonatal TAS reports.
 - Two types of location group reports are available depending on your preferred sort:
 - Location groups (Separated): Rank is based on location group SAAR Type AU-CAD values *within the location group*. In other words, the SAAR Types are ranked based on location group AU-CAD value within that specific location group.
 - Location groups (Combined): Rank is based on location group SAAR Type AU-CAD values among all SAAR Types and location groups. In other words, SAAR Types and location groups are ranked according to the AU-CAD value alone.
- Locations
 - AU-CAD values are provided for each individual location able to generate SAARs (see [Table 6](#)).

Separately, the TAS Dashboard, found on the NHSN Patient Safety Component Home Page or in the Dashboard section of the left-hand navigation menu, allows NHSN facilities to visualize locations with the greatest need for antimicrobial stewardship. The TAS Dashboard displays AU-CADs over time, by quarter, for the most recent complete four calendar quarters at the group, facility, and location level. Unlike the TAS Reports, the time period and level of aggregation displayed by the TAS Dashboard cannot be changed.

Additional detail and guidance for the TAS reports and dashboards are available in the resources listed below:

[TAS Guide](#)

[TAS Report – Facility-level](#)

[TAS Report – Location group-level](#)

[TAS Report – Location-level](#)

[TAS Report – Group-level](#)

[TAS Dashboard – Facility](#)

[TAS Dashboard – Group](#)

Rates:

Users can generate basic rate tables as incidence density rates of antimicrobial days per 1,000 days present stratified by patient care location and facility-wide inpatient. A rate of antimicrobial days per 100 admissions can also be generated for facility-wide inpatient only. Default rate tables can be generated by antimicrobial category (specifically, antibacterial, antifungal, anti-influenza, antiviral) and class (for example, aminoglycosides, carbapenems, cephalosporins) for the most recent month of data submitted or all months of data submitted for FacWideIN or each individual location. Modifications can be made to any rate table to show specific months or locations. Specific rate tables can also be modified to produce a rate per individual antimicrobial, select antimicrobials within the same class, and select antimicrobials within different classes.

[Rate Table – by location](#)

[Rate Table – FacWideIN](#)

Descriptive analysis:

Line Lists: Line lists are the most customizable AU Option analysis report. The default line lists show the total antimicrobial days and the sub-stratification of routes of administration for each antimicrobial as well as the days present and admissions for each month and location of data submitted. Default line lists can be generated for the most recent month of data submitted or all months of data submitted, for FacWideIN or each individual location. Users can modify any line list to show specific months, locations, antimicrobials, and/or routes of administration. The line lists are the most helpful AU Option report when validating the data.

[Line List](#)

Bar Charts: Bar charts provide visualizations of antimicrobial use within a facility. Default bar charts can be generated for the most recent month of data submitted or all months of data submitted for FacWideIN or each individual location. There is also a bar chart that shows selected agent distribution by month.

[Bar Chart](#)

[Bar Chart – Selected drugs](#)

All AU Option data analysis reports can be exported from NHSN in various formats including Excel, CSV, SAS.

NHSN Group Analysis:

NHSN Group users can visualize and analyze AU data shared with them by member facilities using NHSN analysis reports. In addition to the Analysis Quick Reference Guides (QRGs) referenced in each section above and available from in the Antimicrobial Use and Resistance Module Reports section of the [Analysis Quick Reference Guide](#) page, Groups can find Group-specific resources on the [NHSN Group Users](#) page.

Additional Analysis Resources:

Users can find recorded training sessions and Quick Learn videos highlighting AU Option analysis reports on the [AUR Training](#) page.

Appendix A. Table of Instructions: Antimicrobial Use Option

Data Field	Data Field Description
Facility OID ^f	Required. Must be assigned to facility and included in the CDA data file prior to submission to NHSN.
Vendor (Application) OID ^g	Required. Must be assigned to a vendor's software application and included in the AU CDA data file prior to submission to NHSN. The Vendor (Application) OID should be obtained by the software vendor and is distinct from the Facility OID.
SDS Validation ID	Required. The Synthetic Data Set (SDS) Validation ID will be provided to the AU CDA vendor by the AUR Module Team upon confirmation that the AU Summary SDS Excel file passed validation as part of the AU SDS initiative. ^h
Vendor Software Name	Optional. Vendor software name is the name of the software application that generates the AU CDA file. NHSN collects this information to more effectively troubleshoot CDA files when needed.
Software Version	Optional. Software version is the version of the software application that generates the AU CDA file. NHSN collects this information to more effectively troubleshoot CDA files when needed.
Vendor Name	Optional. Vendor name is the name of the vendor that owns the software application that generates the AU CDA file. NHSN collects this information to more effectively troubleshoot CDA files when needed.
Month	Required. Record the 2-digit month during which the data were collected for this location.
Year	Required. Record the 4-digit year during which the data were collected for this location.
Location	Required. The patient care location for which the data are being uploaded.
Numerator: Antimicrobial days per month per location	Required. Antimicrobial days are defined as the aggregate sum of the days of therapy for which a <i>specific</i> antimicrobial was administered. These are required to be extracted from electronic medication administration record (eMAR) and/or bar coding medication administration (BCMA) system. Antimicrobial days are collected for select antimicrobial agents (refer to Appendix B) and stratified by route of administration.

^f Facilities interested in submitting data to NHSN via CDA must obtain a Facility OID (object identifier). More information on how to obtain an OID for your facility can be found on the [CDA Submission Support Portal](#).

^g AU CDA files are required to include a Vendor (Application) OID (object identifier) as part of the AU Option Synthetic Data Set initiative. More information on how to obtain a Vendor (Application) OID can be found on the [Vendor \(Application\) Object Identifier](#) page.

^h More detailed information about the AU Synthetic Data Set validation process can be found on the [AUR Synthetic Data Set Validation](#) page.

Data Field	Data Field Description
Denominator(s):	Required.
Days present	Days present are defined as risk for antimicrobial exposure per each day of the calendar month stratified by location. For patient care location-specific analyses, days present is calculated as the number of patients who were present for any portion of each day during a calendar month for a patient care location. The patient can begin attributing to the days present count in an outpatient location such as an Emergency Department as soon as they have had an initial interaction with a medical professional (for example, the beginning of triage), regardless of when the patient is placed in a bed. For facility-wide inpatient analyses, days present are calculated as the number of patients who were present in an inpatient location within the facility for any portion of each day during a calendar month.
Admissions	Admissions are defined as the aggregate number of patients admitted to an inpatient location within the facility (facility-wide inpatient) starting on first day of each calendar month through the last day of the calendar month. A patient is counted as an admission when they arrive in an NHSN designated inpatient location regardless of patient status (for example, inpatient, observation). Further, a patient admitted to an inpatient unit would be counted as an admission even if they were discharged that same calendar day. If in the ADT system a patient appears to move from an inpatient to an outpatient ED, pediatric ED or 24-hour observation location then back to an inpatient location, it should be counted as two separate admissions. In the AU Option, admissions are only reported for facility-wide inpatient. Please note, the admissions definition used in the AUR Module is different than the definition used in the NHSN MDRO/CDI Module.

Appendix B. List of Antimicrobials

Please note that mapping of standardized terminology (RXNORM) is provided in the Information Data Model (IDM) found in the [Antimicrobial Use Toolkit](#). The list of NHSN drug codes as well as the drug values used for the development of the CDA files can be found here: [Eligible Antimicrobials](#).

Antimicrobial Agent	Antimicrobial Category	Antimicrobial Class ⁱ	Antimicrobial Subclass ^j
AMANTADINE	Anti-influenza	M2 ion channel inhibitors	
AMIKACIN	Antibacterial	Aminoglycosides	
AMIKACIN LIPOSOMAL ^k	Antibacterial	Aminoglycosides	
AMOXICILLIN	Antibacterial	Penicillins	Aminopenicillin
AMOXICILLIN/ CLAVULANATE	Antibacterial	β -lactam/ β -lactamase inhibitor combination	
AMPHOTERICIN B	Antifungal	Polyenes	
AMPHOTERICIN B LIPID COMPLEX	Antifungal	Polyenes	
AMPHOTERICIN B LIPOSOMAL	Antifungal	Polyenes	
AMPICILLIN	Antibacterial	Penicillins	Aminopenicillin
AMPICILLIN/ SULBACTAM	Antibacterial	β -lactam/ β -lactamase inhibitor combination	
ANIDULAFUNGIN	Antifungal	Echinocandins	
AZITHROMYCIN	Antibacterial	Macrolides	
AZTREONAM	Antibacterial	Monobactams	
AZTREONAM/AVIBACTAM	Antibacterial	β -lactam/ β -lactamase inhibitor combination	Monobactam/ β -lactamase inhibitor combination
BALOXAVIR MARBOXIL	Anti-influenza	Polymerase acidic endonuclease inhibitors	
CASPOFUNGIN	Antifungal	Echinocandins	
CEFACLOX	Antibacterial	Cephalosporins	Cephalosporin 2 nd generation
CEFADROXIL	Antibacterial	Cephalosporins	Cephalosporin 1 st generation
CEFAZOLIN	Antibacterial	Cephalosporins	Cephalosporin 1 st generation
CEFDINIR	Antibacterial	Cephalosporins	Cephalosporin 3 rd generation

ⁱ Adapted from CLSI M100¹²

^j Adapted from CLSI M100¹²

^k While reported separately in the CDA file, Amikacin Liposomal will be rolled up and reported in the NHSN AU Option analysis reports with Amikacin.

Antimicrobial Agent	Antimicrobial Category	Antimicrobial Class ⁱ	Antimicrobial Subclass ^j
CEFEPIME	Antibacterial	Cephalosporins	Cephalosporin 4 th generation
CEFEPIME/ ENMETAZOBACTAM	Antibacterial	β -lactam/ β -lactamase inhibitor combination	
CEFIDEROCOL	Antibacterial	Cephalosporins	Siderophore
CEFIXIME	Antibacterial	Cephalosporins	Cephalosporin 3 rd generation
CEFOTAXIME	Antibacterial	Cephalosporins	Cephalosporin 3 rd generation
CEFOTETAN	Antibacterial	Cephalosporins	Cephamecin
CEFOXITIN	Antibacterial	Cephalosporins	Cephamecin
CEFPODOXIME	Antibacterial	Cephalosporins	Cephalosporin 3 rd generation
CEFPROZIL	Antibacterial	Cephalosporins	Cephalosporin 2 nd generation
CEFTAROLINE	Antibacterial	Cephalosporins	Cephalosporins with anti-MRSA activity
CEFTAZIDIME	Antibacterial	Cephalosporins	Cephalosporin 3 rd generation
CEFTAZIDIME/AVIBACTAM	Antibacterial	β -lactam/ β -lactamase inhibitor combination	
CEFTOBIPROLE MEDOCARIL	Antibacterial	Cephalosporins	Cephalosporins with anti-MRSA activity
CEFTOLOZANE/ TAZOBACTAM	Antibacterial	β -lactam/ β -lactamase inhibitor combination	
CEFTRIAZONE	Antibacterial	Cephalosporins	Cephalosporin 3 rd generation
CEFUROXIME	Antibacterial	Cephalosporins	Cephalosporin 2 nd generation
CEPHALEXIN	Antibacterial	Cephalosporins	Cephalosporin 1 st generation
CIPROFLOXACIN	Antibacterial	Fluoroquinolones	
CLARITHROMYCIN	Antibacterial	Macrolides	
CLESROVIMAB	Monoclonal Antibody	Fusion inhibitor	
CLINDAMYCIN	Antibacterial	Lincosamides	
COLISTIMETHATE	Antibacterial	Polymyxins	
COLISTIN ⁱ	Antibacterial	Polymyxins	
DALBAVANCIN	Antibacterial	Glycopeptides	Lipoglycopeptides
DAPTOMYCIN	Antibacterial	Lipopeptides	
DELAFLORACIN	Antibacterial	Fluoroquinolones	
DICLOXACILLIN	Antibacterial	Penicillins	Penicillinase-stable penicillins

ⁱ While reported separately in the CDA file, Colistin will be rolled up and reported in the NHSN AU Option analysis reports with Colistimethate.

Antimicrobial Agent	Antimicrobial Category	Antimicrobial Class ⁱ	Antimicrobial Subclass ^j
DOXYCYCLINE	Antibacterial	Tetracyclines	
ERAVACYCLINE	Antibacterial	Tetracyclines	Fluorocycline
ERTAPENEM	Antibacterial	Carbapenems	
ERYTHROMYCIN	Antibacterial	Macrolides	
FIDAXOMICIN	Antibacterial	Macrocyclic	
FLUCONAZOLE	Antifungal	Azoles	
FOSFOMYCIN	Antibacterial	Fosfomycins	
GENTAMICIN	Antibacterial	Aminoglycosides	
GEPOTIDACIN	Antibacterial	Triazaacenaphthylenes	
IMIPENEM/ CILASTATIN	Antibacterial	Carbapenems	
IMIPENEM/CILASTATIN/ RELEBACTAM	Antibacterial	β -lactam/ β -lactamase inhibitor combination	
ISAVUCONAZONIUM	Antifungal	Azoles	
ITRACONAZOLE	Antifungal	Azoles	
LEFAMULIN	Antibacterial	Pleuromutilins	
LEVOFLOXACIN	Antibacterial	Fluoroquinolones	
LINEZOLID	Antibacterial	Oxazolidinones	
MEROPENEM	Antibacterial	Carbapenems	
MEROPENEM/ VABORBACTAM	Antibacterial	β -lactam/ β -lactamase inhibitor combination	
METRONIDAZOLE	Antibacterial	Nitroimidazoles	
MICAFUNGIN	Antifungal	Echinocandins	
MINOCYCLINE	Antibacterial	Tetracyclines	
MOLNUPIRAVIR	Antiviral	Nucleoside Analog	
MOXIFLOXACIN	Antibacterial	Fluoroquinolones	
NAFCILLIN	Antibacterial	Penicillins	Penicillinase-stable penicillins
NIRMATRELVIR ^m	Antiviral	Protease Inhibitor	
NIRSEVIMAB ⁿ	Monoclonal Antibody	Fusion inhibitor	

^m Per Paxlovid prescribing information, Nirmatrelvir must be co-administered with Ritonavir. However, for public health surveillance, NHSN AU Option will be capturing only administered Nirmatrelvir.

ⁿ Nirsevimab is a long-acting monoclonal antibody for the prevention of respiratory syncytial virus–associated lower respiratory tract infection among infants and children aged <24 months.¹³

Antimicrobial Agent	Antimicrobial Category	Antimicrobial Class ⁱ	Antimicrobial Subclass ^j
NITROFURANTOIN	Antibacterial	Nitrofurans	
OMADACYCLINE	Antibacterial	Tetracyclines	Aminomethylcycline
ORITAVANCIN	Antibacterial	Glycopeptides	Lipoglycopeptides
OSELTAMIVIR	Anti-influenza	Neuraminidase inhibitors	
OXACILLIN	Antibacterial	Penicillins	Penicillinase-stable penicillins
PENICILLIN G	Antibacterial	Penicillins	Penicillin
PENICILLIN V	Antibacterial	Penicillins	Penicillin
PERAMIVIR	Anti-influenza	Neuraminidase inhibitors	
PIPERACILLIN/ TAZOBACTAM	Antibacterial	β -lactam/ β -lactamase inhibitor combination	
PIVMECILLINAM	Antibacterial	Penicillins	
PLAZOMICIN	Antibacterial	Aminoglycosides	
POLYMYXIN B	Antibacterial	Polymyxins	
POSACONAZOLE	Antifungal	Azoles	
REMDESIVIR	Antiviral	Nucleotide Analog	
REZAFUNGIN	Antifungal	Echinocandins	
RIFAMPIN	Antibacterial	Rifampin	
RIMANTADINE	Anti-influenza	M2 ion channel inhibitors	
SULBACTAM/ DURLOBACTAM	Antibacterial	β -lactam/ β -lactamase inhibitor combination	
SULFAMETHOXAZOLE/ TRIMETHOPRIM	Antibacterial	Folate pathway inhibitors	
SULOPENEM/PROBENECID	Antibacterial	Penems	Thiopenem
TEDIZOLID	Antibacterial	Oxazolidinones	
TELAVANCIN	Antibacterial	Glycopeptides	Lipoglycopeptides
TETRACYCLINE	Antibacterial	Tetracyclines	
TIGECYCLINE	Antibacterial	Glycylcyclines	
TINIDAZOLE	Antibacterial	Nitroimidazoles	
TOBRAMYCIN	Antibacterial	Aminoglycosides	
VANCOMYCIN	Antibacterial	Glycopeptides	Glycopeptide
VORICONAZOLE	Antifungal	Azoles	
ZANAMIVIR	Anti-influenza	Neuraminidase inhibitors	

Appendix C. Example Calculations of Antimicrobial Days

Example 1. Example eMAR and Calculation of Antimicrobial Days

This example illustrates the antimicrobial days calculation for a patient receiving 1 gram Meropenem intravenously every 8 hours and 1000mg Amikacin intravenously every 24 hours in the medical ward.

Table 1 provides an example of administered doses for this patient documented in eMAR. Table 2 illustrates the calculation of Meropenem and Amikacin days by antimicrobial (total) and stratified by route of administration based on the administered doses of Meropenem and Amikacin documented in eMAR.

Table 3 illustrates the contribution of this patient's antimicrobial days to the aggregate monthly report per patient care location.

Table 1. Example eMAR for patient housed in Medical Ward

Medical Ward	Monday December 28	Tuesday December 29	Wednesday December 30
Meropenem 1g intravenously every 8 hours	Given: 2300	Given: 0700 Given: 1500 Given: 2300	Given: 0700
Amikacin 1000mg intravenously every 24 hours	Given: 2300	Given: 2300	

Table 2. Example of calculation of antimicrobial days

Calculation	Monday December 28	Tuesday December 29	Wednesday December 30
Drug-specific Antimicrobial Days (total)	Meropenem Days = 1 Amikacin Days = 1	Meropenem Days = 1 Amikacin Days = 1	Meropenem Days = 1 Amikacin Days = 0
Drug-specific Antimicrobial Days Stratified by Route of Administration	Meropenem Days (IV) = 1 Amikacin Days (IV) = 1	Meropenem Days ^o (IV) = 1 Amikacin Days (IV) = 1	Meropenem Days (IV) = 1 Amikacin Days (IV) = 0

Table 3. Example of antimicrobial days per month per patient care location

Month/ Year-Location	Antimicrobial Agent	Drug-specific Antimicrobial Days				
		Total	IV	IM	Digestive	Respiratory
December Medical Ward	Meropenem	3	3	0	0	0
December Medical Ward	Amikacin	2	2	0	0	0

^o Please note, despite receiving three administrations of Meropenem on December 29, the patient only contributed one total Meropenem antimicrobial day per calendar day.

Example 2. Differences in Calculations for Patient Care Location and Facility-Wide Inpatient for a Patient Transferred Between Patient Care Locations

This example illustrates the antimicrobial days calculation for a patient receiving 1 gram Vancomycin every 8 hours that was transferred from the MICU to a medical ward on December 1. Table 1 provides an example of doses documented in eMAR administered to this patient in the MICU and Medical Ward. Table 2 illustrates the calculation of Vancomycin days by antimicrobial (total) and stratified by route of administration based on the administered doses of Vancomycin documented in eMAR. One Vancomycin day is attributed to both the MICU and Medical Ward locations since administrations took place in both units during the calendar day. Further, despite receiving two administrations of Vancomycin in the Medical Ward, the patient only attributes one total Vancomycin antimicrobial day for the Medical Ward per calendar day. Table 3 shows the contribution of this patient's Vancomycin days to the aggregate monthly report per location and facility-wide inpatient. Note that while the patient attributes one total Vancomycin day for both the MICU and the Medical Ward on December 1, only one total Vancomycin day can be attributed to the FacWideIN count that calendar day.

Table 1. Example eMAR for patient transferred from MICU to Medical Ward on December 1

eMAR	Tuesday December 1 Location: MICU	Tuesday December 1 Location: Medical Ward
Vancomycin 1g intravenously every 8 hours	Given: 0700	Given: 1500 Given: 2300

Table 2. Example of calculation of antimicrobial days for December 1

Calculation	Tuesday December 1 Location: MICU	Tuesday December 1 Location: Medical Ward
Drug-specific Antimicrobial Days (total)	Vancomycin Days = 1	Vancomycin Days = 1
Drug-specific Antimicrobial Days Stratified by Route of Administration	Vancomycin Days (IV) = 1	Vancomycin Days (IV) = 1

Table 3. Example of antimicrobial days per month per patient care location and facility-wide inpatient contributed from December 1

Month/ Year-Location	Antimicrobial Agent	Drug-specific Antimicrobial Days				
		Total	IV	IM	Digestive	Respiratory
December MICU	Vancomycin	1	1	0	0	0
December Medical Ward	Vancomycin	1	1	0	0	0
December Facility-wide inpatient	Vancomycin	1	1	0	0	0

Example 3. Calculation of Antimicrobial Days for a Patient Care Location when a Patient Admission extends over Two Different Months

This example illustrates the antimicrobial days calculation for a patient receiving 1 gram Ceftriaxone intravenously every 24 hours for two days in the Surgical Ward (but spanning different months). Table 1 provides an example of administered doses for this patient documented in eMAR. Table 2 illustrates the calculation of Ceftriaxone days by antimicrobial (total) and stratification of route of administration based upon the administered doses of Ceftriaxone documented in eMAR. Table 3 illustrates the contribution of this patient's Ceftriaxone days to the aggregate monthly report per patient care location.

Note: The patient's FacWideIN admission (denominator) would be attributed to the month the patient was first physically located in an inpatient location within the facility. In the scenario highlighted here, the patient would attribute 1 admission to December and no admission to January (specifically, the patient would not be counted in the total January admissions count). The patient would continue to contribute one day present for each day the patient was in the location/facility.

Table 1. Example eMAR for patient housed in Surgical Ward

eMAR	Thursday December 31 Location: Surgical Ward	Friday January 1 Location: Surgical Ward
Ceftriaxone 1g intravenously every 24 hours	Given: 0800	Given: 0800

Table 2. Example of calculation of antimicrobial days

Calculation	Thursday December 31 Location: Surgical Ward	Friday January 1 Location: Surgical Ward
Drug-specific Antimicrobial Days (total)	Ceftriaxone Day = 1	Ceftriaxone Day = 1
Drug-specific Antimicrobial Days Stratified by Route of Administration	Ceftriaxone Day (IV) = 1	Ceftriaxone Day (IV) = 1

Table 3. Example of antimicrobial days per month per patient care location

Month/ Year-Location	Antimicrobial Agent	Drug-specific Antimicrobial Days				
		Total	IV	IM	Digestive	Respiratory
December/ Surgical Ward	Ceftriaxone	1	1	0	0	0
January/ Surgical Ward	Ceftriaxone	1	1	0	0	0

Appendix D: List of SAARs^P

Table 1. Adult SAARs

SAAR Antimicrobial Agent Category	Locations	SAAR Type in NHSN
All antibacterial agents	All Adult SAAR Locations	Adult_All-Antibacterial_All_2023
	Adult Medical, Medical-Surgical, Surgical ICUs; Medical, Medical-Surgical, Surgical Wards; Step Down Units; Mixed Acuity Units; Orthopedic and Orthopedic Trauma Wards; Labor and Delivery, Labor, Delivery, Recovery, Postpartum Suite, Postpartum Wards; Solid Organ Transplant Specialty Care Areas; General Hematology-Oncology, Hematopoietic Stem Cell Transplant Wards	Adult_All-Antibacterial_Select_2023
Broad spectrum antibacterial agents predominantly used for hospital-onset infections	Adult Medical, Medical-Surgical, Surgical ICUs	Adult_BSHO_GeneralICU_2023
	Adult Burn ICUs	Adult_BSHO_BurnICU_2023
	Adult Medical Cardiac ICUs	Adult_BSHO_MedCardICU_2023
	Adult Surgical Cardiothoracic ICUs	Adult_BSHO_SurgCardICU_2023
	Adult Neurologic ICUs	Adult_BSHO_NeuroICU_2023
	Adult Neurosurgical ICUs	Adult_BSHO_NeuroSurgICU_2023
	Adult Trauma ICUs	Adult_BSHO_TraumaICU_2023
	Adult Medical, Medical-Surgical, Surgical Wards	Adult_BSHO_GeneralWard_2023
	Adult Burn Wards	Adult_BSHO_BurnWard_2023
	Adult Neurology Wards	Adult_BSHO_NeuroWard_2023
	Adult Neurosurgical Wards	Adult_BSHO_NeuroSurgWard_2023
	Adult Pulmonary Wards	Adult_BSHO_PulmWard_2023
	Adult Labor and Delivery, Labor, Delivery, Recovery, Postpartum Suite, Postpartum Wards	Adult_BSHO_OB_2023
	Adult Orthopedic, Orthopedic Trauma Wards	Adult_BSHO_ORTHO_2023
	Adult Mixed Acuity Units	Adult_BSHO_MixedAcuity_2023
	Adult Step Down Units	Adult_BSHO_Step_2023

^P Users can find 2014 baseline SAAR details here: <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/aur/saar-2014-508.pdf>. Users can find 2017 and 2018 baseline SAAR details here: <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/aur/saar-2017-2018-508.pdf>.

SAAR Antimicrobial Agent Category	Locations	SAAR Type in NHSN
	Adult Solid Organ Transplant Specialty Care Areas	Adult_BSHO_SOTP_2023
	Adult General Hematology-Oncology, Hematopoietic Stem Cell Transplant Wards	Adult_BSHO_ONC_2023
Broad spectrum antibacterial agents predominantly used for community-acquired infections	Adult Medical, Medical-Surgical, Surgical ICUs	Adult_BSCA_GeneralICU_2023
	Adult Burn ICUs	Adult_BSCA_BurnICU_2023
	Adult Medical Cardiac ICUs	Adult_BSCA_MedCardICU_2023
	Adult Surgical Cardiothoracic ICUs	Adult_BSCA_SurgCardICU_2023
	Adult Neurologic ICUs	Adult_BSCA_NeuroICU_2023
	Adult Neurosurgical ICUs	Adult_BSCA_NeuroSurgICU_2023
	Adult Trauma ICUs	Adult_BSCA_TraumaICU_2023
	Adult Medical, Medical-Surgical, Surgical Wards	Adult_BSCA_GeneralWard_2023
	Adult Burn Wards	Adult_BSCA_BurnWard_2023
	Adult Neurology Wards	Adult_BSCA_NeuroWard_2023
	Adult Neurosurgical Wards	Adult_BSCA_NeuroSurgWard_2023
	Adult Pulmonary Wards	Adult_BSCA_PulmWard_2023
	Adult Labor and Delivery, Labor, Delivery, Recovery, Postpartum Suite, Postpartum Wards	Adult_BSCA_OB_2023
	Adult Orthopedic, Orthopedic Trauma Wards	Adult_BSCA_ORTHO_2023
	Adult Mixed Acuity Units	Adult_BSCA_MixedAcuity_2023
	Adult Step Down Units	Adult_BSCA_Step_2023
	Adult Solid Organ Transplant Specialty Care Areas	Adult_BSCA_SOTP_2023
	Adult General Hematology-Oncology, Hematopoietic Stem Cell Transplant Wards	Adult_BSCA_ONC_2023
Antibacterial agents predominantly used for resistant gram-positive infections (e.g., MRSA)	Adult Medical, Medical-Surgical, Surgical ICUs	Adult_GramPos_GeneralICU_2023
	Adult Burn ICUs	Adult_GramPos_BurnICU_2023
	Adult Medical Cardiac ICUs	Adult_GramPos_MedCardICU_2023
	Adult Surgical Cardiothoracic ICUs	Adult_GramPos_SurgCardICU_2023
	Adult Neurologic ICUs	Adult_GramPos_NeuroICU_2023

SAAR Antimicrobial Agent Category	Locations	SAAR Type in NHSN
	Adult Neurosurgical ICUs	Adult_GramPos_NeuroSurgICU_2023
	Adult Trauma ICUs	Adult_GramPos_TraumaICU_2023
	Adult Medical, Medical-Surgical, Surgical Wards	Adult_GramPos_GeneralWard_2023
	Adult Burn Wards	Adult_GramPos_BurnWard_2023
	Adult Neurology Wards	Adult_GramPos_NeuroWard_2023
	Adult Neurosurgical Wards	Adult_GramPos_NeuroSurgWard_2023
	Adult Pulmonary Wards	Adult_GramPos_PulmWard_2023
	Adult Labor and Delivery, Labor, Delivery, Recovery, Postpartum Suite, Postpartum Wards	Adult_GramPos_OB_2023
	Adult Orthopedic, Orthopedic Trauma Wards	Adult_GramPos_ORTHO_2023
	Adult Mixed Acuity Units	Adult_GramPos_MixedAcuity_2023
	Adult Step Down Units	Adult_GramPos_Step_2023
	Adult Solid Organ Transplant Specialty Care Areas	Adult_GramPos_SOTP_2023
	Adult General Hematology-Oncology, Hematopoietic Stem Cell Transplant Wards	Adult_GramPos_ONC_2023
Narrow spectrum beta-lactam agents	Adult Medical, Medical-Surgical, Surgical ICUs	Adult_NSBL_GeneralICU_2023
	Adult Burn ICUs	Adult_NSBL_BurnICU_2023
	Adult Medical Cardiac ICUs	Adult_NSBL_MedCardICU_2023
	Adult Surgical Cardiothoracic ICUs	Adult_NSBL_SurgCardICU_2023
	Adult Neurologic ICUs	Adult_NSBL_NeuroICU_2023
	Adult Neurosurgical ICUs	Adult_NSBL_NeuroSurgICU_2023
	Adult Trauma ICUs	Adult_NSBL_TraumaICU_2023
	Adult Medical, Medical-Surgical, Surgical Wards	Adult_NSBL_GeneralWard_2023
	Adult Burn Wards	Adult_NSBL_BurnWard_2023
	Adult Neurology Wards	Adult_NSBL_NeuroWard_2023
	Adult Neurosurgical Wards	Adult_NSBL_NeuroSurgWard_2023

SAAR Antimicrobial Agent Category	Locations	SAAR Type in NHSN
	Adult Pulmonary Wards	Adult_NSBL_PulmWard_2023
	Adult Labor and Delivery, Labor, Delivery, Recovery, Postpartum Suite, Postpartum Wards	Adult_NSBL_OB_2023
	Adult Orthopedic, Orthopedic Trauma Wards	Adult_NSBL_ORTHO_2023
	Adult Mixed Acuity Units	Adult_NSBL_MixedAcuity_2023
	Adult Step Down Units	Adult_NSBL_Step_2023
	Adult Solid Organ Transplant Specialty Care Areas	Adult_NSBL_SOTP_2023
	Adult General Hematology-Oncology, Hematopoietic Stem Cell Transplant Wards	Adult_NSBL_ONC_2023
Antibacterial agents posing the highest risk for CDI	Adult Medical, Medical-Surgical, Surgical ICUs	Adult_CDI_GeneralICU_2023
	Adult Burn ICUs	Adult_CDI_BurnICU_2023
	Adult Medical Cardiac ICUs	Adult_CDI_MedCardICU_2023
	Adult Surgical Cardiothoracic ICUs	Adult_CDI_SurgCardICU_2023
	Adult Neurologic ICUs	Adult_CDI_NeuroICU_2023
	Adult Neurosurgical ICUs	Adult_CDI_NeuroSurgICU_2023
	Adult Trauma ICUs	Adult_CDI_TraumaICU_2023
	Adult Medical, Medical-Surgical, Surgical Wards	Adult_CDI_GeneralWard_2023
	Adult Burn Wards	Adult_CDI_BurnWard_2023
	Adult Neurology Wards	Adult_CDI_NeuroWard_2023
	Adult Neurosurgical Wards	Adult_CDI_NeuroSurgWard_2023
	Adult Pulmonary Wards	Adult_CDI_PulmWard_2023
	Adult Labor and Delivery, Labor, Delivery, Recovery, Postpartum Suite, Postpartum Wards	Adult_CDI_OB_2023
	Adult Orthopedic, Orthopedic Trauma Wards	Adult_CDI_ORTHO_2023
	Adult Mixed Acuity Units	Adult_CDI_MixedAcuity_2023
	Adult Step Down Units	Adult_CDI_Step_2023
	Adult Solid Organ Transplant Specialty Care Areas	Adult_CDI_SOTP_2023
	Adult General Hematology-Oncology, Hematopoietic Stem Cell Transplant Wards	Adult_CDI_ONC_2023
Antifungal agents predominantly	Adult Medical, Medical-Surgical, Surgical ICUs	Adult_Antifungal_GeneralICU_2023
	Adult Burn ICUs	Adult_Antifungal_BurnICU_2023

SAAR Antimicrobial Agent Category	Locations	SAAR Type in NHSN
used for invasive candidiasis	Adult Medical Cardiac ICUs	Adult_Antifungal_MedCardICU_2023
	Adult Surgical Cardiothoracic ICUs	Adult_Antifungal_SurgCardICU_2023
	Adult Neurologic ICUs	Adult_Antifungal_NeuroICU_2023
	Adult Neurosurgical ICUs	Adult_Antifungal_NeuroSurgICU_2023
	Adult Trauma ICUs	Adult_Antifungal_TraumaICU_2023
	Adult Medical, Medical-Surgical, Surgical Wards	Adult_Antifungal_GeneralWard_2023
	Adult Burn Wards	Adult_Antifungal_BurnWard_2023
	Adult Neurology Wards	Adult_Antifungal_NeuroWard_2023
	Adult Neurosurgical Wards	Adult_Antifungal_NeuroSurgWard_2023
	Adult Pulmonary Wards	Adult_Antifungal_PulmWard_2023
	Adult Labor and Delivery, Labor, Delivery, Recovery, Postpartum Suite, Postpartum Wards	Adult_Antifungal_OB_2023
	Adult Orthopedic, Orthopedic Trauma Wards	Adult_Antifungal_ORTHO_2023
	Adult Mixed Acuity Units	Adult_Antifungal_MixedAcuity_2023
	Adult Step Down Units	Adult_Antifungal_Step_2023
	Adult Solid Organ Transplant Specialty Care Areas	Adult_Antifungal_SOTP_2023
	Adult General Hematology-Oncology, Hematopoietic Stem Cell Transplant Wards	Adult_Antifungal_ONC_2023

Table 2: Pediatric SAARs

SAAR Antimicrobial Agent Category	Locations	SAAR Type in NHSN
All antibacterial agents	All Pediatric SAAR locations	Ped_All-Antibacterial_2023

SAAR Antimicrobial Agent Category	Locations	SAAR Type in NHSN
Broad spectrum antibacterial agents predominantly used for hospital- onset infections	Pediatric Medical and Medical-Surgical ICUs	Ped_BSHO_GeneralICU_2023
	Pediatric Surgical Cardiothoracic ICUs	Ped_BSHO_SurgCardICU_2023
	Pediatric Medical, Medical-Surgical, Surgical Wards	Ped_BSHO_GeneralWard_2023
	Pediatric Step Down Units	Ped_BSHO_Step_2023
	Pediatric General Hematology-Oncology, Hematopoietic Stem Cell Transplant Wards	Ped_BSHO_ONC_2023
Broad spectrum antibacterial agents predominantly used for community- acquired infections	Pediatric Medical and Medical-Surgical ICUs	Ped_BSCA_GeneralICU_2023
	Pediatric Surgical Cardiothoracic ICUs	Ped_BSCA_SurgCardICU_2023
	Pediatric Medical, Medical-Surgical, Surgical Wards	Ped_BSCA_GeneralWard_2023
	Pediatric Step Down Units	Ped_BSCA_Step_2023
	Pediatric General Hematology-Oncology, Hematopoietic Stem Cell Transplant Wards	Ped_BSCA_ONC_2023
Antibacterial agents predominantly used for resistant gram-positive infections (e.g., MRSA)	Pediatric Medical and Medical-Surgical ICUs	Ped_GramPos_GeneralICU_2023
	Pediatric Surgical Cardiothoracic ICUs	Ped_GramPos_SurgCardICU_2023
	Pediatric Medical, Medical-Surgical, Surgical Wards	Ped_GramPos_GeneralWard_2023
	Pediatric Step Down Units	Ped_GramPos_Step_2023
	Pediatric General Hematology-Oncology, Hematopoietic Stem Cell Transplant Wards	Ped_GramPos_ONC_2023
Narrow spectrum beta-lactam agents	Pediatric Medical and Medical-Surgical ICUs	Ped_NSBL_GeneralICU_2023
	Pediatric Surgical Cardiothoracic ICUs	Ped_NSBL_SurgCardICU_2023
	Pediatric Medical, Medical-Surgical, Surgical Wards	Ped_NSBL_GeneralWard_2023
	Pediatric Step Down Units	Ped_NSBL_Step_2023
	Pediatric General Hematology-Oncology, Hematopoietic Stem Cell Transplant Wards	Ped_NSBL_ONC_2023
Azithromycin	Pediatric Medical and Medical-Surgical ICUs	Ped_Azith_ICU_2023
	Pediatric Surgical Cardiothoracic ICUs	Ped_Azith_SurgCardICU_2023
	Pediatric Medical, Medical-Surgical, Surgical Wards	Ped_Azith_GeneralWard_2023
	Pediatric Step Down Units	Ped_Azith_Step_2023
	Pediatric General Hematology-Oncology, Hematopoietic Stem Cell Transplant Wards	Ped_Azith_ONC_2023

SAAR Antimicrobial Agent Category	Locations	SAAR Type in NHSN
Antibacterial agents posing the highest risk for CDI	Pediatric Medical and Medical-Surgical ICUs	Ped_CDI_ICU_2023
	Pediatric Surgical Cardiothoracic ICUs	Ped_CDI_SurgCardICU_2023
	Pediatric Medical, Medical-Surgical, Surgical Wards	Ped_CDI_GeneralWard_2023
	Pediatric Step Down Units	Ped_CDI_Step_2023
	Pediatric General Hematology-Oncology, Hematopoietic Stem Cell Transplant Wards	Ped_CDI_ONC_2023
Antifungal agents predominantly used for invasive candidiasis	Pediatric Medical and Medical-Surgical ICUs	Ped_Antifungal_ICU_2023
	Pediatric Surgical Cardiothoracic ICUs	Ped_Antifungal_SurgCardICU_2023
	Pediatric Medical, Medical-Surgical, Surgical Wards	Ped_Antifungal_GeneralWard_2023
	Pediatric Step Down Units	Ped_Antifungal_Step_2023
	Pediatric General Hematology-Oncology, Hematopoietic Stem Cell Transplant Wards	Ped_Antifungal_ONC_2023

Table 3: Neonatal SAARs

SAAR Antimicrobial Agent Category	Locations	SAAR Type in NHSN
All antibacterial agents	Special Care Nursery (Level II), Neonatal Critical Care (Level II/III), Neonatal Critical Care (Level III), Neonatal Critical Care (Level IV)	Neo_All-Antibacterial_2023
Vancomycin	Special Care Nursery (Level II), Neonatal Critical Care (Level II/III), Neonatal Critical Care (Level III), Neonatal Critical Care (Level IV)	Neo_Vancomycin_2023
Broad spectrum gram-negative coverage	Special Care Nursery (Level II), Neonatal Critical Care (Level II/III), Neonatal Critical Care (Level III), Neonatal Critical Care (Level IV)	Neo_BSGN_2023
Third generation Cephalosporins	Special Care Nursery (Level II), Neonatal Critical Care (Level II/III), Neonatal Critical Care (Level III), Neonatal Critical Care (Level IV)	Neo_3G-Cephalosporins_2023
Ampicillin	Special Care Nursery (Level II), Neonatal Critical Care (Level II/III), Neonatal Critical	Neo_Ampicillin_2023

SAAR Antimicrobial Agent Category	Locations	SAAR Type in NHSN
	Care (Level III), Neonatal Critical Care (Level IV)	
Aminoglycosides	Special Care Nursery (Level II), Neonatal Critical Care (Level II/III), Neonatal Critical Care (Level III), Neonatal Critical Care (Level IV)	Neo_Aminoglycosides_2023
Fluconazole	Special Care Nursery (Level II), Neonatal Critical Care (Level II/III), Neonatal Critical Care (Level III), Neonatal Critical Care (Level IV)	Neo_Fluconazole_2023

Appendix E: Antimicrobial Groupings for SAAR Calculations^q

Adult SAAR Antimicrobial Agent Categories

Adult All antibacterial agents

All antibacterial agents in the AUR protocol except:

- AMIKACIN LIPOSOME
- AZTREONAM-AVIBACTAM
- GEPOTIDACIN
- SULOPENEM/PROBENECID

Adult Broad spectrum antibacterial agents predominantly used for hospital-onset infections

- AMIKACIN (IV only)
- AZTREONAM (IV only)
- CEFEPIME
- CEFTAZIDIME
- GENTAMICIN (IV only)
- IMIPENEM/CILASTATIN
- MEROPENEM
- PIPERACILLIN/TAZOBACTAM
- TOBRAMYCIN (IV only)

Adult Broad spectrum antibacterial agents predominantly used for community-acquired infections

- CEFACLOR
- CEFDINIR
- CEFIXIME
- CEFOTAXIME
- CEFPODOXIME
- CEFPROZIL
- CEFTRIAXONE
- CEFUROXIME
- CIPROFLOXACIN
- DELAFLOXACIN
- ERTAPENEM
- LEVOFLOXACIN
- MOXIFLOXACIN
- PIVMECILLINAM

^q Users can find 2014 baseline SAAR details here: <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/aur/saar-2014-508.pdf>. Users can find 2017 and 2018 baseline SAAR details here: <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/aur/saar-2017-2018-508.pdf>.

Adult Antibacterial agents predominantly used for resistant gram-positive infections (e.g., MRSA)

- CEFTAROLINE
- CEFTOBIPROLE MEDOCARIL
- DALBAVANCIN
- DAPTOMYCIN
- LINEZOLID
- ORITAVANCIN
- TEDIZOLID
- TELAVANCIN
- VANCOMYCIN (IV only)

Adult Narrow spectrum beta-lactam agents

- AMOXICILLIN
- AMOXICILLIN/CLAVULANATE
- AMPICILLIN
- AMPICILLIN/SULBACTAM
- CEFADROXIL
- CEFAZOLIN
- CEFOTETAN
- CEFOXITIN
- CEPHALEXIN
- DICLOXACILLIN
- NAFCILLIN
- OXACILLIN
- PENICILLIN G
- PENICILLIN V

Adult Antibacterial agents posing the highest risk for CDI

This category contains antimicrobials that are part of other SAAR categories.

- CEFACLOR
- CEFDINIR
- CEFEPIME
- CEFIXIME
- CEFOTAXIME
- CEFOTETAN
- CEFOXITIN
- CEFPODOXIME
- CEFPROZIL
- CEFTAZIDIME
- CEFTAZIDIME/AVIBACTAM
- CEFTRIAXONE

- CEFUROXIME
- CIPROFLOXACIN
- CLINDAMYCIN
- DELAFLOXACIN
- ERTAPENEM
- IMIPENEM/CILASTATIN
- IMIPENEM/CILASTATIN/RELEBACTAM
- LEVOFLOXACIN
- MEROPENEM
- MEROPENEM/VABORBACTAM
- MOXIFLOXACIN

Adult Antifungal agents predominantly used for invasive candidiasis

- ANIDULAFUNGIN
- CASPOFUNGIN
- FLUCONAZOLE
- MICAFUNGIN
- REZAFUNGIN

Pediatric SAAR Antimicrobial Agent Categories**Pediatric All antibacterial agents**

All antibacterial agents in the AUR protocol **except**:

- AMIKACIN LIPOSOME
- AZTREONAM-AVIBACTAM
- GEPOTIDACIN
- SULOPENEM/PROBENECID

Pediatric Broad spectrum antibacterial agents predominantly used for hospital-onset infections

- AMIKACIN (IV only)
- AZTREONAM (IV only)
- CEFEPIME
- CEFTAZIDIME
- CIPROFLOXACIN
- DELAFLOXACIN
- ERTAPENEM
- IMIPENEM/CILASTATIN
- LEVOFLOXACIN
- MEROPENEM
- MOXIFLOXACIN
- PIPERACILLIN/TAZOBACTAM
- TOBRAMYCIN (IV only)

Pediatric Broad spectrum antibacterial agents predominantly used for community-acquired infections

- AMOXICILLIN/CLAVULANATE
- AMPICILLIN/SULBACTAM
- CEFACLOR
- CEFDINIR
- CEFIXIME
- CEFOTAXIME
- CEFPODOXIME
- CEFPROZIL
- CEFTRIAXONE
- CEFUROXIME
- PIVMECILLINAM

Pediatric Antibacterial agents predominantly used for resistant gram-positive infections (e.g., MRSA)

- CEFTAROLINE
- CEFTOBIPROLE MEDOCARIL
- CLINDAMYCIN
- DALBAVANCIN
- DAPTOMYCIN
- LINEZOLID
- ORITAVANCIN
- TEDIZOLID
- TELAVANCIN
- VANCOMYCIN (IV only)

Pediatric Narrow spectrum beta-lactam agents

- AMOXICILLIN
- AMPICILLIN
- CEFADROXIL
- CEFAZOLIN
- CEFOTETAN
- CEFOXITIN
- CEPHALEXIN
- DICLOXACILLIN
- NAFCILLIN
- OXACILLIN
- PENICILLIN G
- PENICILLIN V

Pediatric Azithromycin

- AZITHROMYCIN

Pediatric Antibacterial agents posing the highest risk for CDI

This category contains antimicrobials that are part of other SAAR categories.

- CEFACLOR
- CEFDINIR
- CEFEPIME
- CEFIXIME
- CEFOTAXIME
- CEFOTETAN
- CEFOXITIN
- CEFPODOXIME
- CEFPROZIL
- CEFTAZIDIME
- CEFTAZIDIME/AVIBACTAM
- CEFTRIAXONE
- CEFUROXIME
- CIPROFLOXACIN
- CLINDAMYCIN
- DELAFLOXACIN
- ERTAPENEM
- IMIPENEM/CILASTATIN
- IMIPENEM/CILASTATIN/RELEBACTAM
- LEVOFLOXACIN
- MEROPENEM
- MEROPENEM/VABORBACTAM
- MOXIFLOXACIN

Pediatric Antifungal agents predominantly used for invasive candidiasis

- ANIDULAFUNGIN
- CASPOFUNGIN
- FLUCONAZOLE
- MICAFUNGIN
- REZAFUNGIN

Neonatal SAAR Antimicrobial Agent Categories**Neonatal All antibacterial agents**

All antibacterial agents in the AUR protocol except:

- AMIKACIN LIPOSOME
- AZTREONAM-AVIBACTAM
- GEPOTIDACIN
- SULOPENEM/PROBENECID

Neonatal Vancomycin

- VANCOMYCIN (IV only)

Neonatal Broad spectrum gram-negative coverage

- CEFEPIME (IV only)
- ERTAPENEM (IV only)
- IMIPENEM/CILASTATIN (IV only)
- MEROPENEM (IV only)
- PIPERACILLIN/TAZOBACTAM (IV only)

Neonatal Third generation Cephalosporins

- CEFOTAXIME (IV only)
- CEFTAZIDIME (IV only)
- CEFTRIAXONE (IV only)

Neonatal Ampicillin

- AMPICILLIN (IV and IM only)

Neonatal Aminoglycosides

- AMIKACIN (IV only)
- GENTAMICIN (IV and IM only)
- TOBRAMYCIN (IV only)

Neonatal Fluconazole

- FLUCONAZOLE (IV and oral only)

2. Antimicrobial Resistance (AR) Option

Introduction

The proportion of isolates resistant to specific antimicrobial agents is a common measure of antimicrobial resistance. Proportion susceptible (%S) can aid clinical decision making (hospital antibiograms) and assessing the impact of transmission prevention and antimicrobial stewardship success, although the measure may not be very sensitive to measuring success of short-term efforts. Proportion susceptible also facilitates local or regional assessment of progression or improvement of a particular resistance problem to guide local or regional transmission prevention efforts. Validity of local and regional assessments of the magnitude of a particular resistance phenotype can be improved by using standardized methodology for aggregating proportion resistant.

Objectives:

1. Facilitate antimicrobial resistance data evaluation using a standardized approach to:
 - a. Provide local practitioners with an improved awareness of a variety of antimicrobial resistance problems to aid clinical decision making and prioritize transmission prevention efforts.
 - b. Provide facility-specific measures in context of a regional and national perspective (specifically, benchmarking) that can inform decisions to accelerate transmission prevention efforts and reverse propagation of emerging or established resistant pathogens.
2. Allow regional and national assessment of antimicrobial resistant organisms of public health importance, including ecologic and infection burden assessment.

Methodology:

The AR Option reports antimicrobial resistance data as a proportion.¹⁴ The proportion susceptible is defined as the number of susceptible isolates divided by the number of isolates tested for the specific antimicrobial agent being evaluated. For each facility, the numerator (specifically, number of susceptible isolates) is derived from isolate-level reports submitted. The ultimate source of the isolate data included in these reports is the laboratory information system (LIS). Laboratory results data from the electronic health record system (EHRs) can be used to populate the AR Option numerator records submitted to NHSN in healthcare settings where the LIS is directly connected to the EHRs. The AR Option obtains denominators of patient days and admissions from the ADT system (or similar system that allows for electronic access of required data elements).

Facilities must not employ manual means of data collection to report AR Option data to NHSN. Facilities that do not have access to discrete data elements needed for AR Option reporting are not eligible to participate in the AR Option. For example, facilities receiving results via PDF or fax for eligible organisms and/or required susceptibility results will not be able to participate in the AR Option as those data are not saved as discrete fields. Of note, beginning in January 2025, *Candida* isolates without susceptibility testing or without susceptibility testing results in discrete format are eligible for AR Option reporting. The sections below further define the numerator and denominator, which must adhere to the data

format specified by the Health Level 7 (HL7) [CDA Implementation Guide](#) developed by the CDC and HL7.¹ Manual data entry is not available for the AR Option.

Settings:

All inpatient facilities enrolled in NHSN and using the Patient Safety Component can participate in the AR Option. This includes facilities enrolled as general acute care hospitals, critical access hospitals, children's hospitals, long term acute care hospitals, pediatric long term acute care hospitals, military and veterans' hospitals, oncology hospitals, orthopedic hospitals, psychiatric hospitals, rehabilitation hospitals, surgical hospitals, women's hospitals, women's and children's hospitals, and government and non-government hospitals for public health emergencies. Participating facilities must be able to collect the numerator and denominator data electronically and upload those data into NHSN using the required CDA specifications. NHSN does not currently support AR Option data submission from long term care facilities (for example, skilled nursing facilities and nursing homes) nor outpatient dialysis facilities.

NHSN strongly encourages reporting specimens at each facility from all NHSN-defined inpatient locations (including inpatient procedural areas like operating rooms) and three select outpatient locations: Emergency Department (ED), Pediatric ED, and 24-hour Observation Area from which the numerator data can be accurately electronically captured. The AR Option does not accept specimens collected in other outpatient location types, such as outpatient clinics. The denominators of patient days and admissions are only reported at the facility-wide inpatient level (FacWideIN). As of 2026, hospitals can also report patient days for each individual inpatient location. The denominator of outpatient encounters is reported separately from the three select outpatient location types: ED, Pediatric ED, and 24-hour Observation Area. Previous experience with AUR Module implementation suggests that reporting from all NHSN patient care locations is easier than reporting from selected locations.

Requirements

Each month:

1. The facility must indicate they plan to submit AR Option data on the [Patient Safety Monthly Reporting Plan](#).
 - a. The facility must add FacWideIN to the plan to report AR Option data from inpatient locations.
 - i. Beginning in 2026, facilities can optionally choose to report patient days from each individual inpatient location. Hospitals choosing to report these denominators should add a checkmark in the Antimicrobial Resistance column for each inpatient location for that month.
 - ii. Hospitals choosing not to report patient days for each inpatient unit should not add a checkmark in the Antimicrobial Resistance column for the individual inpatient locations for that month.
 - b. The facility must add each outpatient location separately to report AR Option data from the three select outpatient location types.
2. The facility must report two record types for each month of surveillance.

- a. Create one event file for each isolate-based report.
 - i. Isolate is defined as a population of a single organism observed in a culture obtained from a patient specimen.
 - ii. Each AR Option event file contains the specific location of specimen collection.
 - iii. **Note:** If the facility has no AR Events to report (specifically, there were no isolates that met the AR Option inclusion criteria), the facility can select the box on the NHSN Alert screen to report “No AR Events.” More information can be found here: [Report No AR Events Guide](#). The “No AR Events” check box is available for each individual inpatient location, individual outpatient location and at the FacWideIN level.
- b. Submit one summary file for the FacWideIN denominator data report and one summary file for **each** outpatient location listed in the reporting plan.
 - i. Hospitals choosing to optionally report patient days for each individual inpatient location will also include one summary file for **each** inpatient location.

NHSN recommends AR Option data be submitted to NHSN for a given calendar month by the end of the subsequent calendar month. However, facilities should wait at least seven calendar days following the end of the month before submitting data to ensure the lab completed all susceptibility testing and reported results back to the EHRs.

Isolate-based report

The facility must report all required data each month for each eligible isolate-based report (See [Appendix F](#)). The facility should only consider specimens collected in an inpatient or select outpatient location (ED, pediatric ED, and 24-hour observation) for eligibility. The facility should only report isolates to the AR Option with any antimicrobial susceptibility testing completed regardless of whether the drug is specified as required in the AR Option Protocol. For example, if a facility isolates *Enterococcus* species from a urine specimen but does not perform susceptibility testing on that isolate, the isolate is not eligible for reporting to the AR Option. Antimicrobial susceptibility testing can include phenotypic (for example, MIC, e-test, disk diffusion), molecular (for example, Biofire BCIDII, Luminex Verigene, GenMark Eplex BCID-GP, Cepheid GeneXpert Xpert MRSA/SA BC, etc.), or both methods. However, beginning in January 2025, *Candida* isolates, as well as *Nakaseomyces glabratus* (*Candida glabrata*) and *Pichia kudriavzevii* (*Candida krusei*), without susceptibility testing or access to results are exceptions and can be reported under AR Option.

The facility should report all eligible isolates that meet the reporting guidelines outlined in this protocol to NHSN regardless of the antimicrobial resistance of the isolated organism. This means that even isolates that are susceptible to all required antimicrobials are eligible to be reported to the AR Option. Additionally, isolates in which all the *NHSN-required* antimicrobials were not tested, but at least one non-required drug was tested, are eligible to be reported into NHSN. For example, if a facility tested a *Staphylococcus aureus* isolate for the non-required drug Telithromycin and none of the other 26 NHSN required antimicrobials were tested, that isolate would still be considered eligible for reporting to the AR Option. This is consistent with CLSI M39 Guidance on reporting cumulative susceptibility test

results.¹⁵ Non-culture based organism detection completed on the specimen instead of on a bacterial or fungal isolate (for example, Karius Test) should not be submitted.

Report two distinct events based on specimens obtained in inpatient and select outpatient locations with susceptibility testing performed:

1. **Each** eligible organism isolated from an *invasive* source (blood or cerebrospinal fluid [CSF]) per patient, per 14 day period even across calendar months:
 - a. There should be 14 days with no positive culture result from the laboratory for the patient and specific organism before the facility enters another invasive source AR Event into NHSN for the patient and specific organism. NOTE: The date of specimen collection is considered Day 1.
 - b. After >14 days have passed with no positive culture results for that specific organism, the facility can report another positive culture from an invasive source with that specific organism as an AR Event. For example, if a facility obtained a positive blood culture from a patient on January 1, the earliest another invasive specimen could be reported to NHSN for that same patient and organism would be January 15 (assuming there were no positive blood or CSF cultures in the interim).
2. The **first** eligible organism isolated from any eligible *non-invasive* culture source (lower respiratory, urine, skin, soft tissue, wound and musculoskeletal), per patient, per month.
 - a. Only one AR event is allowed per calendar month for the same patient/organism for lower respiratory, urine, or skin, soft tissue, wound and musculoskeletal specimens.

Note: The AR Option 14-day rule starts with the day of specimen collection and applies *only* to those specimens collected in an inpatient location or select outpatient location (ED, pediatric ED, or 24-hour observation area) in the reporting facility. Outpatient locations other than the ED, pediatric ED, and 24-hour observation area (for example, wound clinic or outpatient laboratory) should not be included in the 14-day rule. Further, cultures obtained while the patient was at *another* healthcare facility should not be included in the 14-day calculations.

A. Eligible organisms

Facilities and vendors should refer to the AR Option Pathogen Roll-up Workbook found in the [Antimicrobial Resistance Toolkit](#) for eligible organisms for AR Option reporting and the complete list of their associated SNOMED codes. All organisms in the Workbook are eligible for reporting. Facilities and vendors should first rollup the eligible organisms using the Pathogen Roll-up Workbook before applying the isolate selection rules and rules for the removal of same day duplicates. When genus level codes are eligible for reporting, remember to report the species level code, if provided by the lab, to prevent over de-duplication of AR Events. Refer to the AR Option Pathogen Roll-up Reference Guide, also found in the AR Toolkit, for guidance using the workbook and determining which SNOMED codes are accepted into NHSN.

Eligible organisms include:

- All *Acinetobacter* species
- All *Candida* species
- *Nakaseomyces glabratus* (*Candida glabrata*)
- *Pichia kudriavzevii* (*Candida krusei*)
- All *Citrobacter* species
- All *Enterobacter* species
- All *Enterococcus* species
- *Escherichia coli*
- All *Klebsiella* species
- *Morganella morganii*
- All *Proteus* species
- *Pseudomonas aeruginosa*
- *Serratia marcescens*
- *Staphylococcus aureus*
- *Stenotrophomonas maltophilia*
- *Streptococcus agalactiae*
- *Streptococcus pneumoniae*
- *Streptococcus pyogenes*

B. Specimen Sources

Eligible specimen source groups include blood, CSF, urine, lower respiratory, skin, soft tissue, wound, and musculoskeletal. Facilities and vendors should refer to the Specimen Source tab of Information Data Model (IDM) found in the [Antimicrobial Resistance Toolkit](#) for the complete list of eligible specimen sources and their associated SNOMED codes. Facilities should only report those SNOMED codes listed in the AR Specimen Source value set on the Specimen Source tab in the IDM. Do not include SNOMED children specimen types unless specifically listed.

1. Eligible invasive specimen sources include cerebrospinal fluid (CSF) and blood specimens. ([Table 1](#))

Note: Report blood or CSF cultures growing the same eligible specific organism (genus and species or genus only if the species has not been identified) *only if* the patient had no positive blood or CSF culture result with that specific organism (genus and species or genus only if the species has not been identified) within the last 14 days, even across calendar months.

2. Eligible non-invasive specimen sources include lower respiratory (for example, sputum, bronchoalveolar lavage), urine, skin, soft tissue, wound, and musculoskeletal specimens.

Table 1: Example of 14-day rule for a specific organism from a single patient in an inpatient location

Date	Lab Result	Reported to NHSN?	Justification
January 1	<i>Staphylococcus aureus</i> isolated from blood culture	Yes	Patient's first blood culture of inpatient admission; <i>Staphylococcus aureus</i> is isolated; facility reports AR Event into NHSN.
January 4	<i>Staphylococcus aureus</i> isolated from blood culture	No	It has been fewer than 14 days since the patient's last invasive culture tested positive for <i>Staphylococcus aureus</i> (January 1).
January 16	<i>Staphylococcus aureus</i> isolated from CSF culture	No	It has been fewer than 14 days since the patient's last invasive culture tested positive for <i>Staphylococcus aureus</i> (January 4).
January 31	<i>Staphylococcus aureus</i> isolated from blood culture	Yes	It has been more than 14 days since the patient's last invasive culture tested positive for <i>Staphylococcus aureus</i> (January 16); facility reports AR Event into NHSN.

The facility should evaluate all isolate test results using either the algorithm in [Figure 1](#) (Invasive specimens) or [Figure 2](#) (Non-invasive specimens) to determine reportable AR events for each calendar month.

- For eligible invasive specimens, there should be 14 days with no positive culture result from the laboratory for the patient and specific organism before the facility enters another invasive source AR Event into NHSN for the patient and specific organism ([Figure 1](#)). Based on the 14-day rule, at a maximum, a patient would have no more than three invasive isolates per specific organism reported per month.
- For eligible non-invasive specimens, the facility should report all first non-invasive isolates (chronologically) per patient, per month, per organism as an AR Event ([Figure 2](#)).

C. Antimicrobial Resistance Gene Markers

Facilities have the option to report molecular test results for specific antimicrobial resistance genes. Some examples of molecular tests include but are not limited to: Biofire BCIDII, Luminex Verigene, GenMark Eplex BCID-GP, and Cepheid GeneXpert Xpert MRSA/SA BC. Facilities and vendors should refer to the AR Genotypic Test tab of the IDM found in the [Antimicrobial Resistance Toolkit](#) for the complete list of eligible resistance gene tests. Facilities should only report those LOINC codes listed in the AR Genotypic Test tab.

Eligible resistance genes include:

- blaCTX-M
- blaIMP
- blaKPC
- blaNDM
- blaOXA
- blaVIM
- MCR
- mecA
- mecC
- MREJ
- SCCmec
- vanA
- vanB

D. Required Data

Required data include data available from the LIS, EHRs, and administrative data systems. The set of variables for each isolate consists of a variable to identify the NHSN facility, specimen-/patient-related data, and antimicrobial susceptibility data as outlined below.

For additional information on each variable please see [Appendix G](#).

- Facility identifier
 - Unique NHSN Facility ID (Object Identifier [OID] is used in the CDA)
- Specimen-/Patient-related data
 - Patient identifier
 - Date of birth
 - Sex
 - Race (optional variable)
 - Ethnicity (optional variable)
 - Whether the patient was admitted to the facility during the encounter (True/False)
 - Date admitted to facility (see details in [Appendix G](#))
 - Specimen collection date
 - Specimen source
 - Location code (mapped to CDC location codes)
 - Isolate identifier (unique isolate ID in the electronic laboratory report based upon the isolate being reported with its own antimicrobial susceptibility testing [AST] results)
 - Organism ([Appendix F](#))
- Antimicrobial susceptibility data
 - Antimicrobial ([Appendix F](#))

- Penicillin-binding protein 2a-agglutination (PBP2a) (required only if using the R3 Implementation Guide [IG] and reporting *Staphylococcus aureus*)
- Polymerase chain reaction (PCR) *mec*-gene (required only if using the R3 IG and reporting *Staphylococcus aureus*)
- E-test sign
- E-test value & unit of measure
- Interpretation of E-test
- Minimum Inhibitory Concentration (MIC) sign
- MIC value & unit of measure
- Interpretation of MIC test
- Disk diffusion (Kirby-Bauer or KB) test sign
- Disk diffusion (KB) test value & unit of measure
- Interpretation of disk diffusion (KB) test
- Final interpretation result
- Rapid molecular detection of antimicrobial resistance gene markers test and result

Notes:

- While many of these fields are required in the CDA report, facilities unable to electronically obtain the results of the individual laboratory tests (specifically, E-test, MIC, Disk diffusion [KB]) may still report AR Option data by using “NA” to indicate “no discrete data available” for these specific tests as long as the final interpretation result can be provided for each antimicrobial tested.
- Only the lab tests listed above can be included in the CDA report. However, if your lab uses additional tests like the ceftioxin screen or inducible clindamycin test and uses the results of the additional test to change/amend the final interpretation for a given drug included in our panel, we’d like you to report the same result you sent to the clinician to NHSN. For example, if the lab updated the result for erythromycin based on the result of the inducible clindamycin test, you should report the changed erythromycin result (same result reported to clinician) to NHSN.
- Facilities reporting data using the R3 IG and unable to electronically obtain the results of the PBP2a-agglutination and/or PCR *mec*-gene tests for *Staphylococcus aureus* may report “Unknown” for these specific tests.
- For each isolate:
 - NHSN requires a specific set of phenotypic drug susceptibility tests (ASTs) (also known as the drug panel) to be included in the CDA file. The required organism/drug panel combinations are listed on the AntiP tab, and the required ASTs for each panel are listed on the AR AST tab in the IDM. If the laboratory does not perform a required AST, the vendor must use “NASK” in the CDA file.
 - Facilities may report results of rapid molecular detection of AR markers in the CDA file. Eligible AR genotypic tests are listed on the AR Genotypic Test tab in the IDM. If no genotypic tests were performed for an isolate, the vendor must include the designated code section in the CDA file to indicate a true zero.
- If a rapid molecular test was performed but the facility is unable to electronically obtain the results, facilities should use “NA” for the given genes to indicate no discrete data available.
- Facilities should not employ manual means of data collection to report AR Option data to NHSN.

E. Reporting Guidelines

- Interpretation of phenotypic test results (E-test, MIC test, Disk diffusion [KB] test) includes the following results:
 - S = Susceptible
 - S-DD = Susceptible-Dose Dependent
 - I = Intermediate
 - R = Resistant
 - NS = Non-Susceptible
 - NA = Not Tested or no discrete data available
 - Note: After upload into NHSN, Not Tested values appear as “N”.
 - Specific to Gentamicin and Streptomycin results for *Enterococcus* testing high-level resistance:
 - S = Susceptible/Synergistic
 - R = Resistant/Not Synergistic
- No molecular test performed
 - If yes/false, indicate the tests performed
 - If no/true, indicate no tests were performed
- If at least one molecular test is performed, interpretation of results includes the following:
 - Detected
 - Not detected
 - Indeterminant
 - Invalid
 - NA = No discrete data available
- In circumstances where a single isolate undergoes additional testing (for example, susceptibility testing for additional drugs, phenotypic testing in addition to molecular AR gene testing, or additional molecular AR gene testing), the results for that single isolate should be combined into one AR Event file.
- Facilities should only report final or corrected susceptibility testing to NHSN. Do not report preliminary laboratory results for NHSN AR Option reporting.
- In circumstances where different breakpoints are required, rely on the specimen source to determine which susceptibility results to report.
 - If the specimen source is CSF, report the meningitis breakpoint susceptibility.
 - If the specimen source is anything other than CSF, report the non-meningitis breakpoint susceptibility.
- Facilities should report results based on clinical, not epidemiological, breakpoints.
- All organisms listed in the AR Option Pathogen Roll-up Workbook found in the [Antimicrobial Resistance Toolkit](#) are eligible for submission. Facilities/vendors should first perform the roll-up of organisms before applying subsequent reporting rules.

F. Removal of Same Day Duplicates

Multiple isolates of the same organism from the same specimen may produce conflicting results. Facilities should only report one isolate to NHSN, retaining the unique nature of the test results. Facilities must follow the rules listed below to ensure removal of duplicate isolate reports.

Duplicates are defined as same species or genus, when identification to species level is not provided, isolated from the same source type (specifically, invasive or non-invasive) from the same patient on the same day. For example, if a patient has a blood specimen and urine specimen collected on the same day and *E.coli* is isolated from both, because the specimens are from two different source types (invasive vs non-invasive), they are not considered duplicates.

Select the isolate to report to NHSN based on these rules (see [Figure 3](#)):

- For invasive source isolate selection, select CSF isolates over blood isolates.
- For non-invasive source isolate selection, select isolates based on the order specified: 1) lower respiratory, 2) urine, 3) skin, soft tissue, wound, and musculoskeletal.
 - If two or more isolates are identified from skin, soft tissue, wound and/or musculoskeletal on the same day, use the [Figure 3](#) flow chart to assess which isolate has higher amount of drug resistance.
- Eliminate isolates on same day with neither phenotypic nor molecular susceptibility test results. Only report isolates with final laboratory test results to NHSN.
- Do not merge test results across multiple isolates (specifically, don't summarize results across different isolates tested on same day).
- Do not consider results from drugs that are outside of the NHSN-specified drug panels when determining which isolate to report.

If there are conflicting results within the AST an individual isolate, follow this guidance before de-duplicating isolates.

- If the lab performs the same test (for example, E-test) on the same isolate but the two tests produce conflicting results, report the final interpretation provided by the lab.
 - If the lab did not provide a final interpretation, then report the most resistant interpretation (NS > R > I > S-DD > S > NA) for that specific antimicrobial.
 - For example, if a facility performs two E-tests for the same drug on the same isolate and one produces "Intermediate" while the other produces "Susceptible," report "Intermediate" as the final interpretation for that specific drug susceptibility.
- If the lab performs specific antimicrobial tests (for example, MIC and E-test) on the same isolate that produce conflicting susceptibility interpretations, and the laboratory did not provide a final summary interpretation, report the most resistant specific test interpretation as the final interpretation (NS > R > I > S-DD > S > NA) for that specific antimicrobial.
 - For example, if drug susceptibility results produced MIC = Resistant and E-Test = Intermediate but the lab did not provide a final interpretation, report "Resistant" as the final interpretation for that specific antimicrobial susceptibility.

After resolving any conflicting results within an individual isolate, compare two or more isolates in the following order until one isolate is selected to be reported as an AR Event:

1. Compare the number of non-susceptible (NS) results.
2. If tied, compare resistant findings, including phenotypic resistant (R) results and detected resistance genes. If the isolates have the same total number of resistant or detected findings, select the isolate with the greater number of **AR genes detected (R)**.
3. If still tied, compare the number of intermediate (I) results.

4. If still tied, compare the number of susceptible-dose dependent (S-DD) results.
5. If still tied, compare susceptible findings, including phenotypic susceptible (S) results and resistance genes reported as not detected. If the isolates have the same total number of resistant findings, select the isolate with the greater number of **phenotypic susceptible (S) results**.
6. If the isolates remain equivalent after all comparisons, report the isolate that was entered first into the laboratory information system (LIS).

Table 2: Examples of same day de-duplication logic

Scenario 1							
	Drug 1	Drug 2	Drug 3	Drug 4	AR Gene 1	AR Gene 2	Justification
Isolate A	NS	I	R	S	detected	not detected	Report Isolate A due to the higher number of phenotypic NS results.
Isolate B	S	I	R	S	NA	not detected	Duplicate. Do not report.
Scenario 2							
	Drug 1	Drug 2	Drug 3	Drug 4	AR Gene 1	AR Gene 2	Justification
Isolate C	R	I	R	S	detected	not detected	Report Isolate C due to the higher number of phenotypic R and genotypic detected results.
Isolate D	R	I	R	S	NA	not detected	Duplicate. Do not report.
Scenario 3							
	Drug 1	Drug 2	Drug 3	Drug 4	AR Gene 1	AR Gene 2	Justification
Isolate E	R	I	R	S	detected	not detected	While equal number of phenotypic R and genotypic detected results, report Isolate E due to higher number of genes detected.
Isolate F	R	R	R	S	NA	not detected	Duplicate. Do not report.

Scenario 4							
	Drug 1	Drug 2	Drug 3	Drug 4	AR Gene 1	AR Gene 2	Justification
Isolate G	R	I	R	S	NA	NA	Duplicate. Do not report.
Isolate H	R	R	R	S	NA	NA	Report Isolate H due to the higher number of phenotypic R and genotypic detected results.
Scenario 5							
	Drug 1	Drug 2	Drug 3	Drug 4	AR Gene 1	AR Gene 2	Justification
Isolate I	S	NA	R	S	not detected	not detected	Duplicate. Do not report.
Isolate J	S	S	R	S	NA	not detected	While equal number of phenotypic S and genotypic not detected results, report Isolate J due to higher number of phenotypic S reported.

Denominator Data

For each month, report combined denominator data for all inpatient locations within the facility (facility-wide inpatient [FacWideIN]): (See [Appendix H](#) for details)

1. Patient Days: Number of patients present in the facility or inpatient location at the same time on each day of the month, summed across all days in the month.
2. Admissions: Number of patients admitted to an inpatient location in the facility each month.
 - a. A patient is counted as an admission when they arrive in an NHSN designated inpatient location regardless of patient status (for example, inpatient, observation).
 - b. A patient admitted to an inpatient unit would be counted as an admission even if they were discharged that same calendar day.
 - c. If in the ADT system a patient appears to move from an inpatient to an outpatient ED, pediatric ED or 24-hour observation location then back to an inpatient location, it should be counted as two separate admissions.
 - d. Please note, the admissions definition used in the AUR Module is different than the definition used in the NHSN MDRO/CDI Module.

Note: Neither the patient days nor admissions denominators should include the counts from outpatient locations (ED, pediatric ED, and 24-hour observation area).

Report patient days for **each** individual inpatient location within the facility. The report will include the number of patients present in that individual location at the same time each day on each day of the month, summed across all days in the month.

Report outpatient encounters for the three select outpatient locations: ED, Pediatric ED, and 24-hour Observation Area:

1. Encounters: A visit to an eligible outpatient location counts as a single encounter. The patient can contribute an encounter as soon as they have had an initial interaction with a medical professional (for example, the beginning of triage). The patient can contribute an encounter regardless of whether the patient is placed in a bed.
 - a. If the patient's stay in any eligible outpatient location continues into subsequent calendar days, that patient should still be counted as 1 encounter. For example:
 - i. If the patient arrives in the ED on Monday and remains in the ED until Wednesday, that patient should be counted as 1 encounter within the ED.
 - b. If the patient transfers from one outpatient location to another within the same facility, that patient should be counted as 1 encounter for the first outpatient location and should not be counted as an encounter for the receiving location (specifically, a patient should not contribute two encounters when transferring between outpatient locations in the same facility). For example:
 - i. If the patient arrives in the ED on Monday, then is transferred to the 24-hour Observation Area on Tuesday, the patient should be counted only as 1 encounter within the ED and zero encounters within the 24-hour Observation Area.
 - c. If the patient is discharged, or leaves, then returns to that outpatient unit during the same calendar day, that patient should be counted as 2 encounters. For example:
 - i. If the patient arrives in the ED at 07:00 on Monday, is discharged at 11:00 on Monday then returns to the ED at 18:00 on Monday, that patient counts as two separate encounters for the ED.
 - d. If the patient transfers from outpatient to inpatient, then to outpatient, the second outpatient stay (assuming it's in an eligible location) would be considered a new encounter because there was time spent in an inpatient location. For example:
 - i. If the patient arrives in the ED on Monday, is admitted or transferred to the medical ICU on Monday then is transferred to the 24-hour Observation Unit on Tuesday and admitted or transferred back to the medical ward on Tuesday, the patient contributes 1 encounter to the ED location and 1 encounter to the 24-hour Observation Unit since there was time spent in an inpatient location (medical ward) in between the outpatient stays.
 - e. If the patient's stay in the facility crosses calendar months, the patient will contribute an encounter to the first month the patient was in an outpatient location. For example:

- i. If patient is in outpatient location on January 31 and February 1 then count as 1 encounter to January and zero to February.
- f. Please note, the encounters count will not be a direct match to the AU Option days present count for these location types.

Minimizing Bias & Bypassing Suppression

The hospital LIS is the ultimate source of antimicrobial susceptibility test results, but in some healthcare facilities not all susceptibility results are readily available in the LIS for reporting to NHSN. Concerted efforts are needed to obtain antimicrobial susceptibility data for the purpose of reporting to NHSN. Due to a practice referred to as selective reporting or cascade reporting, some antimicrobial susceptibility results might be withheld from clinical end users. This practice can serve to control costs or to prevent overuse of some antimicrobial agents, but it also can exert an adverse impact on the completeness of antimicrobial susceptibility results reporting to public health surveillance systems and infection control programs.¹⁶ This can lead to significant biases in the calculation of cumulative antibiograms available for surveillance or infection control. Facilities should make every effort to submit all antimicrobial susceptibility data that meet the NHSN protocol requirements, regardless of whether those data are suppressed from clinical end users.

Data Analyses

Facilities and groups can analyze all AR Option data reported to NHSN immediately after data upload. After [generating analysis datasets within NHSN](#), users can view all reported data in the NHSN analysis reports. The data in NHSN can be visualized and analyzed in many ways. For example, descriptive analysis reports such as line lists and bar charts are available. In addition, measures of antimicrobial resistance are available in rate tables, antibiogram, Standardized Resistant Infection Ratio (SRIR) and Pathogen-specific Standardized Infection Ratio (pSIR) reports.

Types of AR Option Analysis Reports

Standardized Resistant Infection Ratio (SRIR):

The Standardized Resistant Infection Ratio (SRIR) is a metric developed by CDC to enable facilities to compare their rates of hospital-onset (HO) drug-resistant infection events to a national benchmark. The SRIR adjusts for various facility level factors that contribute to AR risk within each facility. It compares the actual number of resistant infections to the number predicted, given the standard population (specifically, the 2019 NHSN baseline), adjusting for several risk factors that have been found to be statistically significantly associated with rates of resistant infections. The SRIR is calculated by dividing the number of observed resistant infections by the number of predicted resistant infections.

$$\text{SRIR} = \frac{\# \text{ Observed Resistant Infections}}{\# \text{ Predicted Resistant Infections}}$$

The observed resistant infections are the number of HO AR Events that meet NHSN-specific resistance definitions (for example, CRE, MRSA, multi-drug resistant *Pseudomonas aeruginosa*). The predicted

resistant infections are calculated using predictive models developed by CDC and applied to nationally aggregated 2019 AR data reported to NHSN. Separate predictive models are developed for each specific resistant organism definition and specimen source (blood, urine, and lower respiratory).

The SRIR can be generated for 7 drug-resistant phenotypes from 3 specimen sources (blood, urine, and lower respiratory), for a total of 21 possible SRIRs (see [Appendix J](#)). The resistant organisms eligible for SRIR calculation were determined by CDC with input from external experts, including adult, pediatric, and neonatal infectious disease physicians and pharmacists. The drug-resistant phenotypes are listed below (see [Appendix I](#) for definitions).

- Carbapenem-resistant Enterobacterales
- Extended-spectrum cephalosporin-resistant Enterobacterales
- Fluoroquinolone-resistant Enterobacterales
- Vancomycin-resistant *Enterococcus*
- Fluoroquinolone-resistant *Pseudomonas aeruginosa*
- Multi-drug-resistant *Pseudomonas aeruginosa*
- Methicillin-resistant *Staphylococcus aureus*

At present, SRIRs are available to facilities that have submitted at least one hospital-onset isolate of the specific organism in the given specimen source during the time period of interest. For example, a Vancomycin-resistant *Enterococcus* blood SRIR can be generated for the facilities that submitted at least one HO *Enterococcus* blood event in the given time period.

A SRIR greater than 1.0 indicates that more resistant infections were observed than predicted. A SRIR less than 1.0 indicates that fewer resistant infections were observed than predicted. An SRIR of 0 indicates a facility reported the organism of interest from the specimen source of interest during the correct time period, but the organism was not resistant to the drug(s) specified. For example, using the example of HO VRE in urine, if a hospital reports 10 hospital-onset *Enterococcus* isolates from urine during the time of interest, and all 10 are reported to be susceptible to vancomycin, the HO VRE SRIR would be 0 because there were 0 observed resistant infection events.

A SRIR value may be missing when no HO isolates of the organism of interest were reported from the given specimen source during the time period, or an HO organism of interest was reported for the specimen source but <0.3 events were predicted (minimum precision criterion was not met). Using the example of HO VRE in urine, a facility would receive a missing value for a SRIR if:

- 1) No HO *Enterococcus* was reported in a urine specimen or,
- 2) HO *Enterococcus* was reported from urine during the correct time period but there were <0.3 HO VRE events predicted for the time period of interest.

SRIRs can be produced by quarter, half-year, year, or cumulative time periods.

[NHSN SRIR/pSIR Guide](#)
[SRIR Report](#)

Pathogen-specific Standardized Infection Ratio (pSIR):

The Pathogen-Specific Standardized Infection Ratio (pSIR) is a metric developed by CDC to enable facilities to compare their rates of HO culture-positive infections of specific pathogen to a national benchmark. It compares the actual number of events (pathogens isolated) to the number predicted, given the standard population (specifically, the 2019 NHSN baseline), adjusting for several risk factors that have been found to be statistically significantly associated with differences in infection incidence. The pSIR is calculated by dividing observed infections of specific pathogens by predicted infections.

$$\text{pSIR} = \frac{\# \text{ Observed Infections of Specific Pathogens}}{\# \text{ Predicted Infections of Specific Pathogens}}$$

The observed infections are the number of HO events reported to NHSN. The predicted infections are calculated using predictive models developed by CDC and applied to nationally aggregated 2019 AR data reported to NHSN. Separate predictive models are developed for each pathogen and specimen source (blood, urine, and lower respiratory).

The pSIR can be generated for 4 pathogens/pathogen groups from 3 specimen sources (blood, urine, and lower respiratory), for a total of 12 possible pSIRs (see [Appendix J](#)).

- Enterobacterales: includes *Escherichia coli*, *Klebsiella aerogenes*, *Klebsiella oxytoca*, *Klebsiella pneumoniae*, or *Enterobacter* spp.
- *Enterococcus*: includes all *Enterococcus* spp.
- *Staphylococcus aureus*
- *Pseudomonas aeruginosa*

At present, pSIRs are available to facilities that have submitted at least one HO pathogen in the correct specimen source during the specified time period of interest.

A pSIR greater than 1.0 indicates that more infections were observed than predicted. A pSIR less than 1.0 indicates that fewer infections were observed than predicted. A pSIR value of 0 indicates a facility reported at least one HO isolate from the specimen source of interest during the correct time period, but the pathogen of interest was not isolated. For example, for hospital-onset *Enterococcus* in urine, if a facility reported one or more HO isolates (any organism) from urine during the time period of interest, but no HO *Enterococcus* was isolated, the facility would receive a pSIR of 0.

A pSIR value may be missing when no positive culture grew reportable AR organisms from the given specimen source during the time period, or an HO organism of interest was reported for the specimen source but <0.3 events were predicted (minimum precision criterion was not met). Using the example of HO *Enterococcus* in urine, a facility would receive a missing value for a pSIR if:

- 1) No HO positive culture from a urine specimen grew Enterobacterales, *Enterococcus*, *Staphylococcus aureus*, or *Pseudomonas aeruginosa*
- 2) At least one HO pathogen of interest was isolated from urine during the correct time period but there were <0.3 HO *Enterococcus* events predicted for that time period

pSIRs can be produced by quarter, half-year, year, or cumulative time periods.

[NHSN SRIR/pSIR Guide](#)
[pSIR Report](#)

Facility-wide Antibigram:

The facility-wide antibiogram table displays the calculated percent susceptible (see [Table 3](#)) for each organism-antimicrobial combination. Users can stratify the antibiogram table by specimen source, time period, and/or by specific antimicrobial or organism. By default, the facility-wide antibiogram will include isolates collected in eligible outpatient locations (ED, pediatric ED and 24-hour observation area) if the facility reports those to NHSN. Note: A facility must have tested and reported the antimicrobial susceptibility results for at least 30 isolates for a specific organism/antimicrobial combination in the given time period for results to appear in the Percent Susceptible table of NHSN antibiogram report.

In addition to the facility-wide antibiogram, within the same report, NHSN creates a table displaying the calculated percent tested (see [Appendix F](#)) for each organism-antimicrobial combination reported from all locations (inpatient and outpatient) to the AR Option.

[Antibiogram and Percent Tested Report](#)

Table 3. Facility-wide Antibiogram

Facility-wide: standard report for facility and group user
% susceptible is calculated for each organism-antimicrobial pairing: $\%S = \frac{\text{Total \# of isolates S}}{\text{Total \# of isolates tested}}$

Antimicrobial Resistance Option (AR) Events

Five reports list all events reported into the NHSN AR Option regardless of susceptibility results.

Line List: Users can generate a line list to show all AR Events reported into NHSN for a given time period. The line list is the most customizable type of AR Option analysis report. The line list is also the most helpful AR Option report for data validation.

[Line List](#)

Bar Chart: Users can generate a bar chart to show all AR Events reported into NHSN for a given time period. By default, the bar chart will show the number of AR Events by organism over the most recent 12-month time period. Users can modify the bar chart to show the number of Antimicrobial Resistant Organisms based on the AR Option phenotype definitions ([Appendix I](#)).

[Bar Chart](#)



Incidence Rate Table: Users can generate an incidence rate table that includes hospital-onset (HO) events by individual specimen type and a combined all specimen type rate for select pathogen groups.

$$\text{HO incidence: } \frac{\# \text{ HO AR Events}}{\# \text{ patient days}} \times 10,000$$

[Incidence Rate Table](#)

Prevalence Rate Table: Users can generate two prevalence rate tables that include community-onset (CO) events by individual specimen type and a combined all specimen type rate for select pathogen groups.

$$\text{CO prevalence: } \frac{\# \text{ CO AR Events from inpt and outpt locations}}{\# \text{ admissions}} \times 10,000$$

$$\text{Outpatient CO prevalence: } \frac{\# \text{ CO AR Events from outpt locations}}{\# \text{ encounters}} \times 10,000$$

Prevalence Rate Tables:

[Inpatient and outpatient report](#)

[Outpatient only report](#)

Antimicrobial Resistant Option (AR) Drug-resistant Organisms (AR Organisms)

Six reports use the AR Option phenotype definitions ([Appendix I](#)) to determine Antimicrobial Resistant Organisms. Specifically, only events with susceptibility results meeting the phenotype definitions will be included in these reports.

Line List: Users can generate a line list to show all AR Organisms that meet the AR Option phenotype definitions for a given time period. The default line list shows each AR Organism reported to NHSN, patient information, specimen collection date, and the location where the specimen was collected.

[AR Organisms Line List](#)

Frequency Table: Users can generate a frequency table to show the number of AR Events meeting the AR Option phenotype definitions in a given time period. While the table default is to display events by month, modifications can be made to display the data by quarter, half-year, year, or cumulative time periods.

[AR Organisms Frequency Table](#)

Rate Table: Users can generate a rate table to display the percent of resistant isolates by AR Option phenotype. The percent resistant is calculated by dividing the number of resistant isolates over the number of isolates tested multiplied by 100.

$$\frac{\# \text{ isolates resistant}}{\# \text{ isolates tested}} \times 100$$

[AR Organisms Rate Table](#)

Incidence Rate Table: Users can generate an incidence rate table that includes hospital-onset (HO) events that meet AR Option phenotype definitions by individual specimen type and a combined all specimen type rate.

$$\text{HO incidence: } \frac{\# \text{ HO AR Events}}{\# \text{ patient days}} \times 10,000$$

[Incidence Rate Table](#)

Prevalence Rate Table: Users can generate two prevalence rate tables that include community-onset (CO) events that meet AR Option phenotype definitions by individual specimen type and a combined all specimen type rate.

$$\text{CO prevalence: } \frac{\# \text{ CO AR Events from inpt and outpt locations}}{\# \text{ admissions}} \times 10,000$$

$$\text{Outpatient CO prevalence: } \frac{\# \text{ CO AR Events from outpt locations}}{\# \text{ encounters}} \times 10,000$$

Prevalence Rate Tables:

[Inpatient and outpatient report](#)

[Outpatient only report](#)

Users can also export AR Option data from NHSN in various formats including Excel, CSV, and SAS.

Additional analysis reports will be available in future releases. Requests for additional reports can be sent to: NHSN@cdc.gov.

NHSN Group Analysis:

NHSN Group users can visualize and analyze AR data shared with them by member facilities using NHSN analysis reports. In addition to the Analysis Quick Reference Guides (QRGs) available in the Antimicrobial Use and Resistance Module Reports section of the [Patient Safety Analysis Quick Reference Guide](#) page. Groups can find Group-specific resources on the [NHSN Group Users](#) page.

Additional Analysis Resources:

Users can also find recorded training sessions and Quick Learn videos highlighting AR Option analysis reports on the [AUR Training](#) page.


Figure 1. Test Result Algorithm for Invasive Specimen Reporting





Figure 2. Test Result Algorithm for Non-Invasive Specimen Reporting

Figure 3. Reporting Algorithm for Same Day Duplicates





Appendix F. List of Eligible Organisms and Corresponding Antimicrobial Susceptibility Panels for the NHSN AR Option

Please note that standardized terminology (SNOMED & LOINC) mappings are provided in the [Antimicrobial Resistance Toolkit](#). Facilities and vendors should refer to the AR Option Pathogen Roll-up Workbook found in the [Antimicrobial Resistance Toolkit](#) for the eligible organisms for AR Option reporting and the complete list of their associated SNOMED codes. The Roll-up Workbook provides a mapping from eligible pathogen terms (those terms that, if identified, should be reported) to accepted pathogen terms (the SNOMED terms accepted by the NHSN application). The toolkit also provides a Quick Reference Guide containing examples of how to use the Roll-up Workbook. Testing methods should follow most recent CLSI guidance as appropriate.

Organism	Specimen Type	Antimicrobial Agents tested for Susceptibility
<i>Acinetobacter</i> (All <i>Acinetobacter</i> species noted in the AR Option Pathogen Roll-up Workbook)	Blood, CSF, Lower Respiratory, Skin, Soft Tissue, Wound, Musculoskeletal, Urine	Amikacin Ampicillin-sulbactam ^r Cefepime Cefiderocol Cefotaxime Ceftazidime Ceftriaxone Ciprofloxacin Colistin Gentamicin Imipenem Levofloxacin Meropenem Minocycline Piperacillin-tazobactam ^f Polymyxin B Sulbactam-durlobactam Tobramycin Trimethoprim-sulfamethoxazole ^f
	Additional Agents for Urine	None
<i>Continued on the next page</i>		

^r When reporting the MIC value of combination agents (for example, ampicillin-sulbactam), report the first value in the lab result as the MIC value since NHSN cannot accept the forward slash in the CDA AR Event file.

Organism	Specimen Type	Antimicrobial Agents tested for Susceptibility
<i>Candida</i> <i>Nakaseomyces glabratus</i> <i>(Candida glabrata)</i> <i>Pichia kudriavzevii (Candida krusei)</i> (All <i>Candida</i> species noted in the AR Option Pathogen Roll-up Workbook)	Blood, CSF, Skin, Soft Tissue, Wound, Musculoskeletal, Urine Note: Lower respiratory will not be collected for <i>Candida</i> spp.	Amphotericin B Anidulafungin Caspofungin Fluconazole Micafungin Posaconazole Rezafungin Voriconazole
	Additional Agents for Urine	None
Continued on the next page		

Organism	Specimen Type	Antimicrobial Agents tested for Susceptibility
<i>Citrobacter</i> (All <i>Citrobacter</i> species noted in the AR Option Pathogen Roll-up Workbook) <i>Enterobacter</i> (All <i>Enterobacter</i> species noted in the AR Option Pathogen Roll-up Workbook) <i>Escherichia coli</i> <i>Klebsiella</i> (All <i>Klebsiella</i> species noted in the AR Option Pathogen Roll-up Workbook) <i>Morganella morganii</i> <i>Proteus</i> (All <i>Proteus</i> species noted in the AR Option Pathogen Roll-up Workbook) <i>Serratia marcescens</i>	Blood, CSF, Lower Respiratory, Skin, Soft Tissue, Wound, Musculoskeletal, Urine	Amikacin Amoxicillin-clavulanic acid ^f Ampicillin Ampicillin-sulbactam ^f Aztreonam Cefazolin (urine or non-urine breakpoints) ^{s t} Cefepime Cefiderocol Cefotaxime Cefotetan Cefoxitin Ceftaroline Ceftazidime Ceftazidime-avibactam ^f Ceftolozane-tazobactam ^f Ceftriaxone Cefuroxime Ciprofloxacin Colistin Ertapenem Gentamicin Imipenem Imipenem-relebactam ^f Levofloxacin Meropenem Meropenem-vaborbactam ^f Piperacillin-tazobactam ^f Plazomicin Tetracycline Trimethoprim-sulfamethoxazole ^f Tobramycin
	Additional Agents for Urine	Ceftibuten Fosfomycin Nitrofurantoin

^s If the LIS produces urine and non-urine breakpoint results, rely on the specimen source to determine which susceptibility results to report. If the specimen source is urine, report the urine breakpoint susceptibility. If the specimen source is blood, CSF, lower respiratory, skin, soft tissue, wound or musculoskeletal report the non-urine breakpoint susceptibility.

^t For Enterobacterales, if the specimen source is urine, report uncomplicated urinary tract infection breakpoints.

Organism	Specimen Type	Antimicrobial Agents tested for Susceptibility
<i>Enterococcus</i> (All <i>Enterococcus</i> species noted in the AR Option Pathogen Roll-up Workbook) <i>Enterococcus faecalis</i> <i>Enterococcus faecium</i>	Blood, CSF, Lower Respiratory, Skin, Soft Tissue, Wound, Musculoskeletal, Urine	Ampicillin Dalbavancin Daptomycin Gentamicin Gentamicin high potency Linezolid Oritavancin Penicillin ^u Streptomycin Streptomycin high potency Tedizolid Telavancin Vancomycin Note: For Gentamicin and Streptomycin only: Synergistic = Susceptible Non-synergistic = Resistant
	Additional Agents for Urine Note: Exclude Gentamicin and Streptomycin	Ciprofloxacin Fosfomycin Levofloxacin Nitrofurantoin Tetracycline

Continued on the next page

^u If the LIS does not differentiate between Penicillin G and Penicillin V, list susceptibility results under Penicillin G and indicate that Penicillin V was not tested (NA).

Organism	Specimen Type	Antimicrobial Agents tested for Susceptibility
<i>Pseudomonas aeruginosa</i>	Blood, CSF, Lower Respiratory, Skin, Soft Tissue, Wound, Musculoskeletal, Urine	Aztreonam Cefepime Cefiderocol Ceftazidime Ceftazidime-avibactam ^f Ceftolozane-tazobactam ^f Ciprofloxacin Colistin Imipenem Imipenem-relebactam ^f Levofloxacin Meropenem Piperacillin-tazobactam ^f Polymyxin B Tobramycin
	Additional Agents for Urine	Amikacin
Continued on the next page		

Organism	Specimen Type	Antimicrobial Agents tested for Susceptibility
<i>Staphylococcus aureus</i>	Blood, CSF, Lower Respiratory, Skin, Soft Tissue, Wound, Musculoskeletal, Urine	Azithromycin Cefoxitin Ceftaroline Ciprofloxacin Clarithromycin Clindamycin Dalbavancin Daptomycin Doxycycline Erythromycin Gentamicin Lefamulin Levofloxacin Linezolid Minocycline Moxifloxacin Oritavancin Oxacillin or Nafcillin [†] Penicillin ^u Rifampin Tedizolid Telavancin Tetracycline Trimethoprim-sulfamethoxazole ^c Vancomycin
	Additional Agents for Urine	Nitrofurantoin
<i>Stenotrophomonas maltophilia</i>	Blood, CSF, Lower Respiratory, Skin, Soft Tissue, Wound, Musculoskeletal, Urine	Cefiderocol Levofloxacin Minocycline Trimethoprim-sulfamethoxazole ^c
	Additional Agents for Urine	None
Continued on the next page		

[†] For *Staphylococcus aureus* susceptibility testing, if the LIS tests Nafcillin instead of Oxacillin, report Nafcillin susceptibility results as Oxacillin.

Organism	Specimen Type	Antimicrobial Agents tested for Susceptibility
<i>Streptococcus agalactiae</i> <i>Streptococcus pyogenes</i>	Blood, CSF, Lower Respiratory, Skin, Soft Tissue, Wound, Musculoskeletal, Urine	Ampicillin Azithromycin Cefepime Cefotaxime Ceftaroline Ceftriaxone Clarithromycin Clindamycin Dalbavancin Daptomycin Erythromycin Levofloxacin Linezolid Oritavancin Penicillin ^u Tedizolid Telavancin Tetracycline Vancomycin
	Additional Agents for Urine	None
Continued on the next page		

Organism	Specimen Type	Antimicrobial Agents tested for Susceptibility
<i>Streptococcus pneumoniae</i>	Blood, CSF, Lower Respiratory, Skin, Soft Tissue, Wound, Musculoskeletal, Urine	Amoxicillin Amoxicillin-clavulanic acid ^f Azithromycin Cefepime (meningitis or non-meningitis breakpoints) ^w Cefotaxime (meningitis or non-meningitis breakpoint) ^w Ceftaroline Ceftriaxone (meningitis or non-meningitis breakpoint) ^w Cefuroxime (parenteral breakpoint) Clarithromycin Clindamycin Doxycycline Ertapenem Erythromycin Imipenem Lefamulin Levofloxacin Linezolid Meropenem Moxifloxacin Penicillin ^u (meningitis or non-meningitis breakpoint) ^w Penicillin V ^u (oral breakpoint) Rifampin Tetracycline Trimethoprim-sulfamethoxazole Vancomycin
	Additional Agents for Urine	None

^w If the LIS produces meningitis and non-meningitis breakpoint results, rely on the specimen source to determine which susceptibility results to report. If the specimen source is CSF, report the meningitis breakpoint susceptibility. If the specimen source is blood, urine, lower respiratory, skin, soft tissue, wound or musculoskeletal report the non-meningitis breakpoint susceptibility.

Appendix G. Technical and Isolate Based Report Variables

Facility, Patient, and Specimen sections

Name	Description of Field	Code Value List	Level of Requirement in CDA file
Facility OID ^x	Must be assigned to facility and included in the importation file prior to submission to NHSN		Required
Vendor (Application) OID ^y	Must be assigned to a vendor's software application and included in the AR CDA data file prior to submission to NHSN. The Vendor (Application) OID should be obtained by the software vendor and is distinct from the Facility OID.		Required
SDS Validation ID ^z	The Synthetic Data Set (SDS) Validation ID will be provided to the AR CDA vendor by the AUR Module Team upon confirmation that the AR SDS Excel files pass validation as part of the AR SDS initiative.		Required
Vendor Software Name	Vendor software name is the name of the software application that generates the AR CDA file. NHSN collects this information to more effectively troubleshoot CDA files when needed.		Optional
Software Version	Software version is the version of the software application that generates the AR CDA file. NHSN collects this information to more effectively troubleshoot CDA files when needed.		Optional
Vendor Name	Vendor name is the name of the vendor that owns the software application that generates the AR CDA file. NHSN collects this information to more effectively troubleshoot CDA files when needed.		Optional
Patient ID	Alphanumeric patient ID assigned by the hospital and may consist of any combination of numbers and/or letters. This ID remains the same for the patient across all visits and admissions for all NHSN reporting.		Required

^x Facilities interested in submitting data to NHSN via CDA must obtain a Facility OID (object identifier). More information on how to obtain an OID for your facility can be found on the [CDA Submission Support Portal](#).

^y AR CDA files are required to include a Vendor (Application) OID (object identifier) as part of the AR Option Synthetic Data Set initiative. More information on how to obtain a Vendor (Application) OID can be found on the Vendor (Application) Object Identifier page.

^z More detailed information about the AR Synthetic Data Set validation process can be found on the [CDA Submission Support Portal's Innovation Tools](#) page.

Name	Description of Field	Code Value List	Level of Requirement in CDA file
Date of Birth	The date of the patient's birth including month, day, and year.		Required
Sex	The sex of the person.	F (Female), M (Male)	Required
Race	The patient's race	American Indian/ Alaska Native, Asian, Black or African American, Native Hawaiian/ Other Pacific Islander, White	Optional
Ethnicity	The patient's ethnicity.	Hispanic or Latino, or Not Hispanic or Not Latino.	Optional
Admission status	Whether the patient was admitted to the facility during the encounter. Notes: • Report True (Yes) if the specimen was collected in an inpatient location. • Report True (Yes) if the specimen was collected in an outpatient location (for example, ED) and the patient was transferred to an inpatient location. • Report True (Yes) if the specimen was collected in an outpatient location and the facility discharges from the ED or 24-hour observation area, then admits to inpatient (<i>instead of transferring</i>), when less than 24 hours between ED or 24-hour observation area discharge and inpatient admit (at the same hospital).	True/False	Required

Name	Description of Field	Code Value List	Level of Requirement in CDA file
	Report False (No) if the specimen was collected in an outpatient location and the patient was transferred to another facility or discharged and did not return within 24 hours.		
Date admitted to facility	The date admitted to the facility is the calendar date that the patient physically locates to an inpatient location. Notes: - If the specimen was collected in an inpatient location, use the date of admission for this field - If the specimen was collected in an outpatient location, use the admission status variable as a guide: - If the admission status variable is True (Yes), then use the date the patient was admitted to the inpatient location for this field - If the admission status variable is False (No), then use the encounter date (the date the patient arrived in the first outpatient location) for this field - If the specimen was collected on day 2 in an outpatient location, report the date of the first day in the outpatient location - If patient is transferred to a subsequent outpatient location and specimen is collected in the second outpatient location, report the date the patient entered the first outpatient location		Required
Specimen collection date	Date the specimen was collected including month, day, and year.		Required
Specimen source	Specimen source from which the isolate was recovered (blood, CSF, urine, lower respiratory, skin, soft tissue, musculoskeletal, wound).	SNOMED CT	Required

Name	Description of Field	Code Value List	Level of Requirement in CDA file
Location	Patient care area where patient was located when the laboratory specimen was collected. Use patient location obtained from administrative data system (ADT).	CDC Location Codes	Required

Organism and Antimicrobial Susceptibility Testing Results sections

Name	Description of Field	Code Value List	Data element required for CDA file?	"NA" allowed?
Isolate identifier	Isolate identifier unique for each isolate within laboratory based upon the isolate being reported with its own AST results. For example, a urine specimen yields an <i>E. coli</i> isolate and a <i>K. pneumoniae</i> isolate and both have AST performed and reported; each isolate should be reported with a unique isolate identifier. Discuss with the facility's lab or LIS personnel to determine which identifier in the LIS can be used as the unique isolate ID for the purposes of AR Option reporting.		Y	N
Organism	Organism identified from specimen (Appendix F).	SNOMED CT	Y	N
Antimicrobial	Antimicrobial(s) tested for susceptibility (Appendix F defines agents by organism and specimen source)	LOINC	Y	N
PBP2a-agglutination	Result for PBP2a-agglutination (only if using the R3 IG to report SA)	Positive, Negative, or Unknown	Y (Required only if using the R3 IG to report <i>Staph aureus</i>)	N

Name	Description of Field	Code Value List	Data element required for CDA file?	"NA" allowed?
PCR mec-gene	Result for PCR mec-gene (only if using the R3 IG to report SA)	Positive, Negative, or Unknown	Y (Required only if using the R3 IG to report <i>Staph aureus</i>)	N
E-test sign ^{aa}	E-test sign Note: Instead of "NA", use "=" to express an exact value.		Y	Y (Recommend reporting sign if test value is reported)
E-test value/units of measure	E-test (Value in micrograms/liter). Use '.' as decimal delimiter, for example, 0.25		Y	Y (Recommend reporting value if test sign is reported)
Interpretation of E-test	Interpretation result of the E-test susceptibility test performed		Y	Y
MIC sign ^{aa}	MIC sign Note: Instead of "NA", use "=" to express an exact value.		Y	Y (Recommend reporting sign if test value is reported)
MIC value/units of measure	MIC (Value in micrograms/liter). Use '.' as decimal delimiter, for example, 0.25		Y	Y (Recommend reporting value if test sign is reported)
Interpretation of MIC test	Interpretation result of the MIC susceptibility test performed		Y	Y
Disk diffusion (KB) sign ^{aa}	Disk diffusion (KB) sign Note: Instead of "NA", use "=" to express an exact value.		Y	Y (Recommend reporting sign if test value is reported)

^{aa} Refer to the HL7 Implementation Guide for specifics on how to code these values in the CDA report.

Note: While many of these specific test results (specifically, E-test, MIC, Disk diffusion [KB]) are required in the CDA report, facilities unable to electronically obtain these results may still participate by using 'NA' to signify 'Not Tested'. Facilities should not employ manual means of data collection.

Name	Description of Field	Code Value List	Data element required for CDA file?	"NA" allowed?
Disk diffusion (KB) value/units of measure	Disk diffusion (KB) value in millimeters		Y	Y (Recommend reporting value if test sign is reported)
Interpretation of Disk diffusion (KB) test	Interpretation result of the disk diffusion (KB) susceptibility test performed		Y	Y
Final Interpretation result	Final interpretation result of all different susceptibility tests performed		Y	Y
Molecular test performed	Whether a molecular test for an AR resistance gene was performed. Notes: Report false (Yes) to indicate at least one molecular test for an AR resistance gene was performed. Report true (No) to indicate no molecular tests for an AR resistance gene were performed.	True/False	Y (if using the R4-D4 IG)	N
Molecular test	Specific AR resistance gene tested for	LOINC	Y (if molecular test performed = False)	N
Molecular test result	Result of the molecular test for an AR resistance gene	SNOMED CT	Y (if molecular test performed = False)	Y

Appendix H. Denominator Data Variables

Name	Description of Field	Level of Requirement
Facility OID ^{bb}	Must be assigned to facility and included in the importation file prior to submission to NHSN.	Required
Vendor (Application) OID ^{cc}	Must be assigned to a vendor's software application and included in the AR CDA data file prior to submission to NHSN. The Vendor (Application) OID should be obtained by the software vendor and is distinct from the Facility OID.	Required
SDS Validation ID ^{dd}	The Synthetic Data Set (SDS) Validation ID will be provided to the AR CDA vendor by the AUR Module Team upon confirmation that the AR SDS Excel files pass validation as part of the AR SDS initiative.	Required
Vendor Software Name	Vendor software name is the name of the software application that generates the AR CDA file. NHSN collects this information to more effectively troubleshoot CDA files when needed.	Optional
Software Version	Software version is the version of the software application that generates the AR CDA file. NHSN collects this information to more effectively troubleshoot CDA files when needed.	Optional
Vendor Name	Vendor name is the name of the vendor that owns the software application that generates the AR CDA file. NHSN collects this information to more effectively troubleshoot CDA files when needed.	Optional
Location	FacWideIN, individual inpatient location, ED, Pediatric ED, 24-hour Observation Area	Required
Month	2-Digit month	Required
Year	4-Digit year	Required
Patient Days	Enter the total number of patient days collected at the same time each day combined for the month. For FacWideIN, all the facility's inpatient acute care locations should be included where denominators can be accurately collected.	Required for FacWideIN and individual

^{bb} Facilities interested in submitting data to NHSN via CDA must obtain a Facility OID (object identifier). More information on how to obtain an OID for your facility can be found on the [CDA Submission Support Portal](#).

^{cc} AR CDA files are required to include a Vendor (Application) OID (object identifier) as part of the AR Option Synthetic Data Set initiative. More information on how to obtain a Vendor (Application) OID can be found on the [Vendor \(Application\) Object Identifier](#) page.

^{dd} More detailed information about the AR Synthetic Data Set validation process can be found on the [CDA Submission Support Portal's Innovation Tools](#) page.

Name	Description of Field	Level of Requirement
		inpatient locations
Admission Count	Enter the total number of admissions for all facility inpatient locations combined for the month. • A patient is counted as an admission when they arrive in an NHSN designated inpatient location regardless of patient status (for example, inpatient, observation). • A patient admitted to an inpatient unit would be counted as an admission even if they were discharged that same calendar day. • If in the ADT system a patient appears to move from an inpatient to an outpatient ED, pediatric ED or 24-hour observation location then back to an inpatient location, it should be counted as two separate admissions. • Please note, the admissions definition used in the AUR Module is different than the definition used in the NHSN MDRO/CDI Module.	Required for FacWideIN
Encounters for outpatient locations	Enter the total number of patient visits to the given outpatient location (specifically, ED, Pediatric ED, 24-hour Observation Area). A visit to an eligible outpatient location counts as a single encounter. The patient can contribute an encounter as soon as they have had an initial interaction with a medical professional (for example, the beginning of triage). The patient can contribute an encounter regardless of whether the patient is placed in a bed. • If the patient's stay in any eligible outpatient location continues into subsequent calendar days, that patient should still be counted as 1 encounter. For example: ○ If the patient arrives in the ED on Monday and remains in the ED until Wednesday, that patient should be counted as 1 encounter within the ED. • If the patient transfers from one outpatient location to another within the same facility, that patient should be counted as 1 encounter for the first outpatient location and should not be counted as an encounter for the receiving location (specifically, a patient should not contribute two encounters when transferring between outpatient locations in the same facility). For example: ○ If the patient arrives in the ED on Monday, then is transferred to the 24-hour Observation Area on Tuesday, the patient should be counted only as 1 encounter within	Required for ED, Pediatric ED, and 24-hour Observation Area

Name	Description of Field	Level of Requirement
	the ED and zero encounters within the 24-hour Observation Area. • If the patient is discharged, or leaves, then returns to that outpatient unit, that patient should be counted as 2 encounters, even when the movements were during the same calendar day. For example: ○ If the patient arrives in the ED at 07:00 on Monday, is discharged at 11:00 on Monday then returns to the ED at 18:00 on Monday, that patient counts as two separate encounters for the ED. • If the patient transfers from outpatient to inpatient, then to outpatient, the second outpatient stay (assuming it's in an eligible location) would be considered a new encounter because there was time spent in an inpatient location. For example: ○ If the patient arrives in the ED on Monday, is admitted or transferred to the medical ICU on Monday then is transferred to the 24-hour Observation Unit on Tuesday and admitted or transferred back to the medical ward on Tuesday, the patient would contribute 2 encounters (the first in the ED and the second to the 24-hour Observation Unit) since there was time spent in an inpatient location (medical ward) in between the outpatient stays. • If the patient's stay in the facility crosses calendar months, the patient will contribute an encounter to the first month the patient was in an outpatient location. For example: ○ If patient is in outpatient location on January 31 and February 1 then count as 1 encounter to January and zero to February. • Please note, the encounters count will not be a direct match to the AU Option days present count for these location types.	

Appendix I. NHSN AR Option Phenotype Definitions

Note: The phenotypes defined here for the AR Option only and may not match phenotype definitions used in other NHSN Modules. Additionally, the drug classes listed below are specific to laboratory testing and, in some cases, do not match the specific class defined in the AU Option. The drugs included in each phenotype definition are specific to those included in the reportable drug panel for that organism. Please refer to [Appendix F](#) of the AUR Module Protocol for the complete list of drug panels for each organism.

Phenotype Name	Phenotype Code	Phenotype Definition ^{ee}
Methicillin-resistant <i>Staphylococcus aureus</i> ^{ff}	MRSA_AR	<i>Staphylococcus aureus</i> that has tested Resistant (R) to at least one of the following: oxacillin or ceftiofloxacin
Carbapenem-resistant Enterobacterales (expanded)	CREexpanded_AR	Any <i>Citrobacter</i> spp., <i>Enterobacter</i> spp., <i>E. coli</i>, <i>Klebsiella</i> spp., and <i>Serratia marcescens</i> that has tested Resistant (R) to at least one of the following: imipenem, meropenem, doripenem^{gg}, ertapenem, meropenem/vaborbactam, or imipenem/relebactam OR Any <i>Proteus</i> spp., and <i>Morganella morganii</i> that has tested Resistant (R) to at least one of the following: meropenem, doripenem^{gg}, ertapenem, or meropenem/vaborbactam Note: Beginning in January 2022, this phenotype was expanded to include meropenem/vaborbactam and imipenem/relebactam. Note: Beginning in January 2023, this phenotype was expanded to add <i>Citrobacter braakii</i>, <i>Citrobacter freundii</i> complex, and <i>Citrobacter youngae</i>. Prior to January 2023, this phenotype only included <i>Citrobacter amalonaticus</i>, <i>Citrobacter freundii</i>, and <i>Citrobacter koseri</i>. Note: Beginning in January 2025, this phenotype was expanded to all species within the <i>Citrobacter</i>, <i>Klebsiella</i>, and <i>Proteus</i> genus.

^{ee} Adapted from CLSI M100

^{ff} A SRIR is available for this phenotype.

^{gg} Beginning in January 2025, the denoted drugs are no longer required to report for the given pathogen and therefore are not considered when determining whether the isolate meets NHSN AR Option phenotype definitions.

Phenotype Name	Phenotype Code	Phenotype Definition ^{ee}
Carbapenem-resistant Enterobacterales ^{ff} (<i>E. coli</i> , <i>Klebsiella</i> , or <i>Enterobacter</i>)	CREall_AR	Any <i>Escherichia coli</i> , <i>Klebsiella aerogenes</i> , <i>Klebsiella oxytoca</i> , <i>Klebsiella pneumoniae</i> , or <i>Enterobacter</i> spp. that has tested Resistant (R) to at least one of the following: imipenem, meropenem, doripenem ^{gg} , ertapenem, meropenem/vaborbactam, or imipenem/relebactam Note: Beginning in January 2022, this phenotype was expanded to include meropenem/vaborbactam and imipenem/relebactam.
Carbapenem-resistant <i>E. coli</i>	CREecoli_AR	Any <i>Escherichia coli</i> that has tested Resistant (R) to at least one of the following: imipenem, meropenem, doripenem ^{gg} , ertapenem, meropenem/vaborbactam, or imipenem/relebactam Note: Beginning in January 2022, this phenotype was expanded to include meropenem/vaborbactam and imipenem/relebactam.
Carbapenem-non-susceptible <i>Pseudomonas aeruginosa</i>	carbNS_PA_AR	<i>Pseudomonas aeruginosa</i> that has tested either Intermediate (I) or Resistant (R) to at least one of the following: imipenem, meropenem, doripenem ^{gg} , or imipenem/relebactam Note: Beginning in January 2022, this phenotype was expanded to include imipenem/relebactam.
Extended-spectrum cephalosporin-resistant Enterobacterales ^{ff}	ESCEall_AR	Any <i>Escherichia coli</i> , <i>Klebsiella aerogenes</i> , <i>Klebsiella oxytoca</i> , <i>Klebsiella pneumoniae</i> , or <i>Enterobacter</i> spp. that has tested Resistant (R) to at least one of the following: cefepime, ceftriaxone, cefotaxime, ceftazidime, ceftazidime-avibactam, or ceftolozane-tazobactam

Phenotype Name	Phenotype Code	Phenotype Definition ^{ee}
Extended-spectrum cephalosporin-resistant <i>E. coli</i>	ESCecoli_AR	Any <i>Escherichia coli</i> that has tested Resistant (R) or Intermediate (I) to at least one of the following: cefepime, ceftriaxone, cefotaxime, ceftazidime, ceftazidime-avibactam, or ceftolozane-tazobactam Note: Beginning in January 2022, this phenotype was expanded to include ceftazidime-avibactam and ceftolozane-tazobactam. Note: Beginning in January 2023, this phenotype was expanded to include isolates testing Intermediate (I) in addition to those testing resistant (R) to align with NHSN HAI phenotypes.
Extended-spectrum cephalosporin-resistant <i>Klebsiella</i> spp.	ESCKlebsiella_AR	Any <i>Klebsiella</i> spp. (except <i>Klebsiella aerogenes</i>) that has tested Resistant (R) or Intermediate (I) to at least one of the following: cefepime, ceftriaxone, cefotaxime, ceftazidime, ceftazidime-avibactam, or ceftolozane-tazobactam Note: Beginning in January 2022, this phenotype was expanded to include ceftazidime-avibactam and ceftolozane-tazobactam. Note: Beginning in January 2023, this phenotype was expanded to include isolates testing Intermediate (I) in addition to those testing resistant (R) to align with NHSN HAI phenotypes. Note: Beginning in January 2025, this phenotype was expanded to include all species within the <i>Klebsiella</i> genus except <i>Klebsiella aerogenes</i>.
Fluoroquinolone-resistant Enterobacterales ^{ff}	FQE_AR	Any <i>Escherichia coli</i> , <i>Klebsiella aerogenes</i> , <i>Klebsiella oxytoca</i> , <i>Klebsiella pneumoniae</i> , or <i>Enterobacter</i> spp. that has tested Resistant (R) to at least one of the following: ciprofloxacin, levofloxacin, or moxifloxacin
Fluoroquinolone-resistant Enterobacterales	FQE_AR_2025	Any <i>Escherichia coli</i> , <i>Klebsiella</i> spp., or <i>Enterobacter</i> spp. that has tested Resistant (R) to at least one of the following: ciprofloxacin, levofloxacin, or moxifloxacin

Phenotype Name	Phenotype Code	Phenotype Definition ^{ee}
Fluoroquinolone-resistant <i>Pseudomonas aeruginosa</i> ^{ff}	FQPA_AR	<i>Pseudomonas aeruginosa</i> that has tested Resistant (R) to at least one of the following: ciprofloxacin or levofloxacin
Multidrug-resistant <i>Pseudomonas aeruginosa</i> ^{ff}	MDR_PA_AR	<i>Pseudomonas aeruginosa</i> that has tested either Intermediate (I) or Resistant (R) to at least one drug in at least three of the following six categories^{hh}: 1. Extended-spectrum cephalosporin (cefepime, ceftazidime, ceftazidime-avibactam, ceftolozane-tazobactam) 2. Fluoroquinolones (ciprofloxacin, levofloxacin) 3. Aminoglycosides (amikacin^{gg}, tobramycin) 4. Carbapenems (imipenem, meropenem, doripenem^{gg}, imipenem/relebactam) 5. Piperacillin/tazobactam 6. Cefiderocol Note: Beginning in January 2022, this phenotype was expanded to include ceftazidime-avibactam, ceftolozane-tazobactam, imipenem/relebactam and cefiderocol. Note: Beginning in May 2026, this phenotype was updated to remove gentamicin. This change will be applied to all historical and future <i>Pseudomonas aeruginosa</i> results.
Carbapenem-non-susceptible <i>Acinetobacter</i> spp.	carbNS_Acine_AR	Any <i>Acinetobacter</i> spp. that has tested either Intermediate (I) or Resistant (R) to at least one of the following: imipenem, meropenem, or doripenem ^{gg}

^{hh} The category names are for grouping purposes and are not inclusive of all drugs in that drug class.

Phenotype Name	Phenotype Code	Phenotype Definition ^{ee}
Multidrug-resistant <i>Acinetobacter</i> spp.	MDR_Acine_AR	Any <i>Acinetobacter</i> spp. that has tested either Intermediate (I) or Resistant (R) to at least one drug in at least three of the following seven categories^{hh}: 1. Extended-spectrum cephalosporin (cefepime, ceftazidime, ceftriaxone, cefotaxime) 2. Fluoroquinolones (ciprofloxacin, levofloxacin) 3. Aminoglycosides (amikacin, gentamicin, tobramycin) 4. Carbapenems (imipenem, meropenem, doripenem^{gg}) 5. Piperacillin/tazobactam 6. Ampicillin/sulbactam 7. Cefiderocol Note: Beginning in January 2022, this phenotype was expanded to include cefiderocol.
Vancomycin-resistant <i>Enterococcus faecalis</i>	VREfaecalis_AR	<i>Enterococcus faecalis</i> that has tested Resistant (R) to vancomycin
Vancomycin-resistant <i>Enterococcus faecium</i>	VREfaecium_AR	<i>Enterococcus faecium</i> that has tested Resistant (R) to vancomycin
Vancomycin-resistant <i>Enterococcus</i> ^{ff}	VREgeneral_AR	Any <i>Enterococcus</i> spp. that has tested Resistant (R) to vancomycin
Fluconazole-resistant <i>Candida</i> spp., <i>Nakaseomyces glabratus</i> (<i>Candida glabrata</i>), <i>Pichia kudriavzevii</i> (<i>Candida krusei</i>)	FR_Candi_AR	Any <i>Candida</i> spp., <i>Nakaseomyces glabratus</i> (<i>Candida glabrata</i>), and <i>Pichia kudriavzevii</i> (<i>Candida krusei</i>) that has tested Resistant (R) to fluconazole Note: Beginning in January 2025, this phenotype was expanded to include all species within the <i>Candida</i> genus and continue to include <i>Nakaseomyces glabratus</i> (<i>Candida glabrata</i>), and <i>Pichia kudriavzevii</i> (<i>Candida krusei</i>). Prior to January 2025, this phenotype only included <i>Candida albicans</i>, <i>Candida auris</i>, <i>Candida glabrata</i>, <i>Candida parapsilosis</i>, and <i>Candida tropicalis</i>.

Phenotype Name	Phenotype Code	Phenotype Definition ^{ee}
Drug-resistant <i>Streptococcus pneumoniae</i>	DR_SP_AR	<i>Streptococcus pneumoniae</i> that has tested either Intermediate (I) or Resistant (R) to at least one of the antimicrobials listed in the NHSN AR Option defined drug panel Note: Beginning in January 2023, this phenotype was expanded to include isolates testing Intermediate (I) in addition to those testing resistant (R) to align with CDC's Antibiotic Threats Report .

Appendix J. List of SRIRs and pSIRs

Table 1. Hospital-onset SRIRs

SRIR	Specimen Source	SRIR Type in NHSN
Hospital-onset Carbapenem-resistant Enterobacterales	Blood	HO_CREall_Blood
	Lower Respiratory Tract	HO_CREall_LRT
	Urine	HO_CREall_Urine
Hospital-onset Extended-spectrum cephalosporin-resistant Enterobacterales	Blood	HO_ESCEall_Blood
	Lower Respiratory Tract	HO_ESCEall_LRT
	Urine	HO_ESCEall_Urine
Hospital-onset Fluoroquinolone-resistant Enterobacterales	Blood	HO_FQE_Blood
	Lower Respiratory Tract	HO_FQE_LRT
	Urine	HO_FQE_Urine
Hospital-onset Vancomycin-resistant <i>Enterococcus</i>	Blood	HO_VRE_Blood
	Lower Respiratory Tract	HO_VRE_LRT
	Urine	HO_VRE_Urine
Hospital-onset Fluoroquinolone-resistant <i>Pseudomonas aeruginosa</i>	Blood	HO_FQPA_Blood
	Lower Respiratory Tract	HO_FQPA_LRT
	Urine	HO_FQPA_Urine
Hospital-onset Multidrug-resistant <i>Pseudomonas aeruginosa</i>	Blood	HO_MDR_PA_Blood
	Lower Respiratory Tract	HO_MDR_PA_LRT
	Urine	HO_MDR_PA_Urine
Hospital-onset Methicillin-resistant <i>Staphylococcus aureus</i>	Blood	HO_MRSA_Blood
	Lower Respiratory Tract	HO_MRSA_LRT
	Urine	HO_MRSA_Urine

Table 2. Hospital-onset pSIRs

pSIR	Specimen Source	pSIR Type in NHSN
Hospital-onset Enterobacterales	Blood	HO_Enterobacterales_Blood
	Lower Respiratory Tract	HO_Enterobacterales_LRT
	Urine	HO_Enterobacterales_Urine
Hospital-onset <i>Enterococcus</i>	Blood	HO_Enterococcus_Blood
	Lower Respiratory Tract	HO_Enterococcus_LRT
	Urine	HO_Enterococcus_Urine
Hospital-onset <i>Staphylococcus aureus</i>	Blood	HO_SA_Blood
	Lower Respiratory Tract	HO_SA_LRT
	Urine	HO_SA_Urine
Hospital-onset <i>Pseudomonas aeruginosa</i>	Blood	HO_PA_Blood
	Lower Respiratory Tract	HO_PA_LRT
	Urine	HO_PA_Urine

References

1. National Healthcare Safety Network (NHSN) Patient Safety Component: Clinical Document Architecture. <http://www.cdc.gov/nhsn/cdaportal/index.html>
2. Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. *Clin Infect Dis*. 2016 May 15;62(10):e51-77. doi: 10.1093/cid/ciw118. Epub 2016 Apr 13. PMID: 27080992; PMCID: PMC5006285.
3. Centers for Disease Control and Prevention. HAI Pathogens and Antimicrobial Resistance Report, 2018 – 2021. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2023. <https://www.cdc.gov/nhsn/hai-report/index.html>
4. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2021-2022. Available at: <https://www.cdc.gov/antimicrobial-resistance/data-research/threats/update-2022.html>
5. Davey P, Marwick CA, Scott CL, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. *Cochrane Database Syst Rev* 2017;2:CD003543.
6. Ansari F, Gray K, Nathwani D, et al. Outcomes of an intervention to improve hospital antibiotic prescribing; interrupted time series with segmented regression analysis. *J Antimicrob Chemother* 2003;52:842-8.
7. Solomon DH, Van Houten L, Glynn RJ. Academic detailing to improve use of broad-spectrum antibiotics at an academic medical center. *Arch Inter Med* 2001;161:1897-902.
8. Schwartz DN, Evans RS, Camins B, et al. Deriving measures of intensive care unit antimicrobial use from computerized pharmacy data: methods, validation, and overcoming barriers. *Infect Control Hosp Epidemiol* 2011;32:472-80.
9. Polk RE, Fox C, Mahoney A, Letcavage J, MacDougall C. Measurement of adult Antibacterial Drug Use in 130 US Hospitals: Comparison of Defined Daily Dose and Days of Therapy. *Clin Infect Dis* 2007;44:664-70.
10. Kuster SP, Ledergerber B, Hintermann A, et al. Quantitative antibiotic use in hospitals: comparison of measurements, literature review, and recommendations for standards of reporting. *Infection* 2008; 6:549-59.
11. Berrington A. Antimicrobial prescribing in hospitals: be careful what you measure. *J Antimicrob Chemother* 2010;65:163-168.
12. CLSI. 2020 Performance standards for antimicrobial susceptibility testing, 30th edition. CLSI document M100-ED20. Wayne, PA: Clinical and Laboratory Standards Institute; 2020.
13. Jones JM, Fleming-Dutra KE, Prill MM, et al. Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023. *MMWR Morb Mortal Wkly Rep* 2023;72:920–925. DOI: <http://dx.doi.org/10.15585/mmwr.mm7234a4>.
14. Schwaber MJ, De-Medina T, and Carmeli Y. Epidemiological interpretation on antibiotic resistance studies – what are we missing? *Nat Rev Microbiol* 2004;2:979-83.
15. CLSI. Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data; Approved Guideline – Third Edition. CLSI document M39-A3. Wayne, PA: Clinical and Laboratory Standards; 2009.

-
16. Council of State and Territorial Epidemiologists (CSTE). Recommendations for strengthening public health surveillance of antimicrobial resistance in the United States. <https://cdn.ymaws.com/www.cste.org/resource/resmgr/PS/13-SI-01.pdf>. Accessed October 1, 2015.

Change Log

The Change Log outlines the changes made to the AUR Module Protocol compared to the previous version.

July 2026

Antimicrobial Use

- Updated and corrected SAAR tables
- Removed reference to SAAR Rate tables

Antimicrobial Resistance

- Addition of molecular tests for antimicrobial resistance genes
- Updated same day de-duplication logic to include genotypic results
- Added Table 2 to demonstrate same day de-duplication logic
- Updated Figure 3 – Reporting algorithm for same day duplicates
- Updated the definition of MDR *Pseudomonas aeruginosa* (Appendix I)

January 2026

Antimicrobial Use

- Updates for required antimicrobials (Appendix B)
 - Add: AZTREONAM/AVIBACTAM, CLESROVIMAB, GEPOTIDACIN, SULOPENEM/PROBENCID
- Updates to SAARs to reflect 2023 baseline updates (Appendices D and E)
- Removed reference to pie charts

Antimicrobial Resistance

- Updates for required antimicrobial susceptibility testing panels (Appendix F)
 - *Acinetobacter*: remove Doxycycline and Tetracycline; add Sulbactam-durlobactam
 - *Acinetobacter* will no longer have a urine-specific panel. All *Acinetobacter* urine isolates will now use the same panel as non-urine isolates.
 - *Candida*: add Rezafungin
- Add reporting of patient day denominator for individual inpatient locations (pages 37-38 and 45 and Appendix H)

Both

- Combined reference sections and moved to the end of the document.

February 2025

- Updated variable name and value set for Patient Sex.

January 2025

Antimicrobial Use

- Updates for required antimicrobials (Appendices B and E)
 - Add: CEFEPIME/ENMETAZOACTAM, CEFTOBIPROLE MEDOCARIL, and PIVMECILLINAM

- Remove: CHLORAMPHENICOL
- Days present definition updated to state the patient can contribute an encounter as soon as they have had an initial interaction with a medical professional (for example, the beginning of triage) when in an eligible outpatient location. (page 6, Appendix A)

Antimicrobial Resistance

- Updates for required organisms (page 40-41, Appendices F and I)
 - Add: genus and all species level terms for *Candida*, *Citrobacter*, *Klebsiella*, and *Proteus*
 - Remember to report the species level code if provided by the lab to prevent over de-duplication of AR Events.
 - Add: *Streptococcus pyogenes* (Group A *Streptococcus*)
 - Updated AR Option Pathogen Roll-up Workbook ([AR CDA Toolkit](#))
- Updates for required specimens (pages 41, 42, 44, 54, 55 and Appendices F and G)
 - Add: skin, soft tissue, wound and musculoskeletal as non-invasive specimens
 - Add: indwelling catheter specimen as non-invasive specimen
- Updates for required antimicrobial susceptibility testing panels (Appendix F)
 - *Acinetobacter* urine and non-urine panels: remove Doripenem
 - *Candida* panel: add Amphotericin B
 - *Enterobacterales* panels:
 - Non-urine panel: add Plazomicin, remove Chloramphenicol, Doripenem, Doxycycline, Minocycline, Polymyxin B
 - Urine panel: add Ceftibuten, Plazomicin, remove Chloramphenicol, Doripenem, Doxycycline, Minocycline, Polymyxin B, Sulfisoxazole, Trimethoprim
 - *Enterococcus* panels urine and non-urine panels: remove Quinupristin-dalfopristin
 - *Pseudomonas aeruginosa* panels:
 - Non-urine panel: remove Amikacin, Doripenem, Gentamicin
 - (New panel) urine panel: add Amikacin, Aztreonam, Cefepime, Cefiderocol, Ceftazidime/Avibactam, Ceftazidime, Ceftolozane/Tazobactam, Ciprofloxacin, Colistin, Imipenem, Imipenem-relebactam, Levofloxacin, Meropenem, Polymyxin B, Piperacillin with Tazobactam and Tobramycin
 - *Staphylococcus aureus* panels:
 - Non-urine panel: remove Chloramphenicol
 - Urine panel: remove Chloramphenicol, Sulfisoxazole, Trimethoprim
 - *Stenotrophomonas maltophilia* panel: remove Ceftazidime, Chloramphenicol
 - *Streptococcus pneumoniae* panel: remove Chloramphenicol, Gemifloxacin
 - *Streptococcus agalactiae* and *Streptococcus pyogenes* panel: add Tetracycline, remove Chloramphenicol
- Updates to phenotype definitions assigned by NHSN for AR Option Events. Added notes to indicate changes in phenotype definitions over time. (Appendix I)
- *Candida* isolates without antimicrobial susceptibility testing are eligible for AR Option reporting. (pages 37 and 39)
- Admission status definition clarified for the scenario referencing transfer to another facility. (Appendix G)

-
- Admission definition updated to match AU Option. Specifically, transfer from an inpatient to an outpatient ED, pediatric ED, or 24-hour observation location then back to an inpatient location is counted as two separate admissions. (Appendix H)
 - Encounter definition updated to state the patient can contribute an encounter as soon as they have had an initial interaction with a medical professional (for example, the beginning of triage). (page 45, Appendix H)

CDC Locations and Descriptions and Instructions for Mapping Patient Care Locations


Table of Contents

Instructions for Mapping Patient Care Locations in NHSN	2
Appendix: Creation and Management of Locations in NHSN	7
Master CDC Locations and Descriptions	9
Inpatient Locations	9
Acute Care Facilities General	9
Adult Critical Care Units.....	9
Pediatric Critical Care Units.....	11
Neonatal Units.....	12
Specialty Care Areas (SCA).....	16
Adult Wards.....	16
Pediatric Wards.....	21
Step Down Units.....	23
Mixed Acuity Units.....	24
Operating Rooms.....	26
Chronic Care Units (Previously named Long Term Care).....	27
Long Term Care Facilities	28
Long Term Acute Care Facilities	29
Inpatient Rehabilitation Facilities	30
Oncology Facilities	31
Inpatient Psychiatric Facilities.....	34
Outpatient Locations	35
Outpatient Ambulatory Surgery Centers	35
Acute Care Facilities General	37
Acute Settings.....	37
Clinic (non-acute) Settings.....	39
Outpatient Dialysis Facilities	39
Facility-Wide Locations	39
Community Locations	40
Non-Patient Care Locations	40


Instructions for Mapping Patient Care Locations in NHSN

NHSN recommends facilities map each patient care area in their facility to a **CDC location code** defined by NHSN in order to report surveillance data collected from these areas. This document functions as a decision-making tool when determining the appropriate CDC location for NHSN surveillance, as defined in the NHSN Manual. This process should be followed when adding any new unit to NHSN for surveillance and should be repeated for any unit when there is a significant change in patient mix (for example, merging of units, taking on a new service).

Step 1: Define the acuity of patient care level for the location (critical care, step-down care, or ward level care)



Step 2: Define the patient population (type of service/patient mix) for the location



Step 3:

Map to the appropriate CDC Location Code. Please see the [CDC Location descriptions](#) or the [HSLOC CODE SYSTEM from the CDA Support Portal](#) for definitions of each CDC Location used for NHSN surveillance.

Location Mapping Definitions

1. NHSN 80% Rule: The 80% rule applies to acuity and patient mix determinations. If 80% of patients are of the same acuity and a certain type (for example, pediatric patients with orthopedic problems), the area is designated as that specific type of location (in this example, an Inpatient Pediatric Orthopedic Ward). The 80% rule does not apply to ward-level medical and surgical patient types. If general medical or surgical patients make up more than 60% of patients in a location, then map to the majority type, specifically medical or surgical.

2. Patient mix/type: When determining the appropriate CDC Location mapping for a unit, facilities should review the patient mix in that unit for the last full calendar year. Options for review include using acuity billing data (if available), admitting service, admission/transfer diagnosis, or facility specific titles (examples: ICU = ICU, NICU = NICU)

- Facilities should use 1 year of data to make this determination.
- If a full year of data is not available, a shorter period of at least 3 months is acceptable, but every effort should be made to collect and analyze greater periods of time in the future.

3. Virtual locations: Virtual locations are created in NHSN when the 80% rule for major specific patient type mapping is not met. The use of virtual locations is recommended for those physical units that are geographically split by patient service, those in which beds are designated by service, or units where denominator data can be collected by patient type/service. For those facilities that use an electronic upload of data to NHSN, discuss mapping of virtual locations in NHSN with your facility's EHR contact to ensure compatibility.

Example: a facility has an ICU – called 5 West – comprised of approximately 50% neurology patients and 50% neurosurgery patients. The neurology patients are housed in beds 1-10 and the neurosurgery patients are housed in beds 11-20. Rather than mapping as a medical/surgical critical care unit, the facility maps two specific type locations in NHSN:

5WEST_N: Neurologic Critical Care (10 beds)

5WEST_NS: Neurosurgical Critical Care (10 beds)

This facility will collect and enter data separately for 5WEST_N and 5WEST_NS which allows NHSN analytics for each major specific patient type. Specifically, the facility will be able to obtain rates and standardized infection ratios (SIRs) for each location separately. Note that the data collected and reported for each virtual location is based on data from the designated 10 beds assigned (specifically, overflow from 5WEST_N into 5WEST_NS will be counted with **5WEST_NS**).

4. Mixed Acuity Unit: This CDC location code is available for adult patient care areas only and is intended for those units comprised of patients with varying levels of acuity; it is designed primarily for facilities employing a “acuity adaptable” or “universal” bed patient care model (the patient stays in the same bed during all phases of care). NOTE: Mapping a location in NHSN to the CDC “Mixed Acuity” designation may have implications on data that your facility reports for CMS Programs and/or your state's reporting

mandate(s). Although a Mixed Acuity location may have ICU beds and ICU patients, it is not considered an ICU location type for the purposes of CMS reporting and therefore is not included in any ICU-specific reporting requirements. Mixed Acuity units are also excluded from ward-specific reporting requirements. For information about how this location designation may impact your facility's compliance with your state mandate (if applicable), please contact your state HAI coordinator. Mapping individual virtual locations by acuity is preferred over mapping a mixed acuity unit for facilities with a means to separate denominator data.

5. Overflow Unit: This location is intended for areas previously not used for inpatient care (which has been repurposed to care for critically or non-critically ill or injured patients on a temporary basis) **OR** for patient care areas designated specifically for inpatient overflow/surge use for extended periods of time.

Examples

Example 1: An ICU that is 85% Burn patients, 15% Trauma

CDC Location: Burn Critical Care (IN:ACUTE:CC:B)

Why? Meets 80% rule for critical care acuity level and 80% rule for specific service (burn)

Example 2: An ICU that is 55% medical and 45% surgical

CDC Location: Medical/Surgical Critical Care (IN:ACUTE:CC:MS)

Why? Meets 80% rule for critical care acuity level and does not meet the 60% rule for designation as either medical or surgical service level alone, therefore, use combined medical/surgical designation

Example 3: A unit that is comprised of 60% medical inpatients and 40% general observation patients

CDC Location: Medical Ward (IN:ACUTE:WARD:M)

Why? This is a special scenario due to the mix of inpatients and outpatients in this unit. A location where at least 51% of the patients have been formally admitted to the facility should be mapped as in inpatient unit, rather than an outpatient observation unit. The 60% rule for general service and the 80% rule for specific service still apply when deciding on the specific type of inpatient location to use; this location met the 60% rule for medical service. All patients housed in this unit should be included in the surveillance efforts for this location regardless of patient status.

Example 4: An ICU that is 40% Neurosurgical, 40% Surgical, and 20% Medical

Option 1 - Single CDC Location: Surgical Critical Care

Why? Meets 80% rule for critical care acuity level and does not meet the 80% rule for a specific service level alone, but when surgical patients are combined, that total does equal 80%.

Option 2 - Multiple CDC Virtual Locations: Neurosurgical Critical Care and Surgical Critical Care, with the medical patients reported with the Surgical Critical Care location since the general surgical designation is the least specific of the two

Why? By splitting this unit into 2 virtual locations, each meets the 80% rule for critical care acuity level, and one meets the 80% rule for designation as Neurosurgical Critical

Care, while the other meets the 60% rule as general surgical service (when combining surgical and medical patients). This option requires denominator data be separated by virtual location.

Example 5: A unit that is comprised of 60% Medical ICU and 40% Step Down patients

Option 1 - Multiple CDC Virtual Locations: Medical Critical Care and Step Down Unit

Why? By splitting this unit into 2 virtual locations, each meets the 80% rule for the appropriate acuity level, and each meets the 80% rule for type of service. Preferred mapping if denominator data can be captured separately for each virtual location.

Option 2 - Single CDC Location: Mixed Acuity Unit

Why? This location is not comprised of at least 80% of the patients of the same acuity level and therefore meets the single location definition of a mixed acuity unit. Note that this location is not considered an ICU location type for the purposes of NHSN reporting and therefore, would not be included in any ICU-specific reporting requirements.

Example 6: A pediatric ward that is comprised of 70% neurosurgical patients and 30% orthopedic patients

Option 1 - Single CDC Location: Pediatric Surgical Ward

Why? Meets 80% rule for ward-level acuity and does not meet the 80% rule for a specific service level alone and meets the 60% rule for general surgical service.

Option 2 - Multiple CDC Virtual Locations: Pediatric Neurosurgical Ward and Pediatric Orthopedic Ward

Why? By splitting this unit into 2 virtual locations, each meets the 80% rule for the appropriate acuity level, and each meets the 80% rule for type of service.

Appendix: Creation and Management of Locations in NHSN

Create New Locations:

Validation of mapped locations for a facility should be conducted annually or when the acuity or patient mix of the unit undergoes a permanent change. If there are operational locations in your hospital that are not already mapped in NHSN, the area(s) will need to be formally mapped for the purposes of NHSN surveillance and reporting.

Locations can be mapped by following these steps:

1. Go to Facility > Locations.
2. On the Locations screen, 4 fields will display for entry – Your code, Your label, CDC location code, and bed size.
3. Start by selecting the appropriate CDC Location Description from the drop-down menu. NOTE: When selecting a CDC Location Description, your location must meet the 80% Rule in order to be assigned as that CDC Location Description.
4. Following the CDC Location description selection, Enter a local location identifier (Your Code) and local location label (Your label). The fields are free text to enable the facility to submit an entry that will match the location designation within the facility EHR.
5. Make sure the Status is set to “Active” and then enter the number of beds that are set up and staffed in that location.
6. Once all information for this new location is entered, click ‘Add’.

Manage Existing Locations:

Facilities should ensure locations with an “Active” status in NHSN are those that are operational units within the facility. The number of beds indicated for each location should also be checked for accuracy and, if necessary, updated to reflect the current number of beds set up and staffed.

Location information can be updated by following these steps:

1. Go to Facility > Locations.
2. On the Locations screen, click ‘Find’.
3. The facility Location Table will populate at the bottom of the screen. Review each mapping including the status of each location, as well as Bed size. Click on the hyperlink within the Location Table to display the individual unit details.
4. If a location’s information needs to be updated, edits are limited to ‘your code’, ‘your label’, status and bed size. Make modification to these fields then click ‘Save’.
5. The CDC location description is not editable; if the CDC location description is inaccurate, change the status of the current location to ‘inactive’ and map a new location using the appropriate CDC location description.

Manage Physically Moved Locations

Units within a facility may physically move to another area of the same facility and be given a different name. If the staff are moving with these locations, and the type of patients remains the same (specifically, the only difference is the geographical location and/or Bed size), it is recommended to change “Your Code” and “Your Label” (and Bed size, if appropriate) on the existing location record. These fields can be updated by following the instructions for “Manage Existing Locations” above. Updating the value of “Your

Code” will also update all previously entered records for the location, allowing for continuous analysis and reporting.

Inaccurate CDC Location Description

Please note that the CDC Location Description cannot be edited after a location is mapped in NHSN. If the CDC Location Description assigned to the existing location is incorrect, there are additional steps you will need to follow, depending on the scenario:

Scenario 1: The patient population in this unit has changed such that the current CDC Location Description, using the 80% rule, is inaccurate.

Solution: Due to patient population change, a new location is created in NHSN and mapped to a CDC Location Description that most accurately reflects the type of patients receiving care in that location, using the 80% rule. The existing location is placed into “Inactive” status. When creating a new location, a different “Your Code” and “Your Label” value must be used. Note: data reported from inactive locations can continue to be analyzed within NHSN for the months during which they appear in the Monthly Reporting Plans. Additionally, data submitted under inactive locations will not be linked to new, active locations.

The Master CDC Locations and Descriptions table (below starting pg. 15-10) is additionally found within the CDA Support Portal under Code System HSLOC:

<https://www.cdc.gov/nhsn/cdaportal/terminology/codesystem/hsloc.html>. Availability of the online mapping tool does NOT mean a facility must ‘remap’ existing locations; the table below will continue to provide reference for ‘new’ unit mappings or ‘remapping’ of existing units.

Master CDC Locations and Descriptions

CDC Location Label	NHSN Healthcare Service Location Code	CDC Location Code	Location Description
INPATIENT LOCATIONS			
ACUTE CARE FACILITIES GENERAL			
Adult Critical Care Units			
Burn Critical Care	1026-4	IN:ACUTE:CC:B	Critical care area for the care of patients with significant/major burns.
Medical Cardiac Critical Care	1028-0	IN:ACUTE:CC:C	Critical care area for the care of patients with serious heart problems that DO NOT require heart surgery.
Medical Critical Care	1027-2	IN:ACUTE:CC:M	Critical care area for the care of patients who are being treated for nonsurgical conditions.
Medical-Surgical Critical Care	1029-8	IN:ACUTE:CC:MS	Critical care area for the care of patients with medical and/or surgical conditions.
Neurologic Critical Care	1035-5	IN:ACUTE:CC:N	Critical care area for the care of patients with life-threatening neurologic diseases.
Neurosurgical Critical Care	1031-4	IN:ACUTE:CC:NS	Critical care area for the surgical management of patients with severe neurologic diseases or those at risk for neurologic injury as a result of surgery.

CDC Location Label	NHSN Healthcare Service Location Code	CDC Location Code	Location Description
Oncology Medical Critical Care	1223-7	IN:ACUTE:CC:ONC_M	Critical care area for the care of oncology patients who are being treated for nonsurgical conditions related to their malignancy.
Oncology Surgical Critical Care	1224-5	IN:ACUTE:CC:ONC_S	Critical care area for the evaluation and management of oncology patients with serious illness before and/or after cancer-related surgery.
Oncology Medical-Surgical Critical Care	1225-2	IN:ACUTE:CC:ONC_MS	Critical care area for the care of oncology patients with medical and/or surgical conditions related to their malignancy.
Onsite Overflow Critical Care	1272-4	IN:ACUTE:CC:OF_ONSITE	Area previously used for non-patient care or an unused patient care area which has been repurposed to care for critically ill or injured patients on a temporary basis OR an ICU acuity patient care area used specifically for overflow/surge critically ill patients formally admitted to the facility.
Prenatal Critical Care	1034-8	IN:ACUTE:CC:PNATL	Critical care area for the care of pregnant women with complex medical or obstetric problems requiring a high level of care to prevent the loss of the fetus and to protect the life of the mother.
Respiratory Critical Care	1033-0	IN:ACUTE:CC:R	Critical care area for the evaluation and treatment of patients with severe respiratory conditions.

CDC Location Label	NHSN Healthcare Service Location Code	CDC Location Code	Location Description
Surgical Cardiothoracic Critical Care	1032-2	IN:ACUTE:CC:CT	Critical care area for the care of patients following cardiac and/or thoracic surgery.
Surgical Critical Care	1030-6	IN:ACUTE:CC:S	Critical care area for the evaluation and management of patients with serious illness before and/or after surgery.
Trauma Critical Care	1025-6	IN:ACUTE:CC:T	Critical care area for the care of patients who require a high level of monitoring and/or intervention following trauma or during critical illness related to trauma.
Pediatric Critical Care Units			
ONC Pediatric Critical Care	1233-6	IN:ACUTE:CC:ONC_PED	Critical care area for the care of oncology patients ≤18 years old who are being treated for surgical or nonsurgical conditions related to their malignancy.
Pediatric Burn Critical Care	1042-1	IN:ACUTE:CC:B_PED	Critical care area for the care of patients ≤18 years old with significant/major burns.
Pediatric Surgical Cardiothoracic Critical Care	1043-9	IN:ACUTE:CC:CT_PED	Critical care area for the care of patients ≤18 years old following cardiac and thoracic surgery.
Pediatric Medical Critical Care	1044-7	IN:ACUTE:CC:M_PED	Critical care area for the care of patients ≤18 years old who are being treated for nonsurgical conditions.
Pediatric Medical-Surgical Critical Care	1045-4	IN:ACUTE:CC:MS_PED	Critical care area for the care of patients ≤18 years old with medical and/or surgical conditions.

CDC Location Label	NHSN Healthcare Service Location Code	CDC Location Code	Location Description
Pediatric Neurosurgical Critical Care	1046-2	IN:ACUTE:CC:NS_PED	Critical care area for the surgical management of patients ≤18 years old with severe neurologic diseases or those at risk for neurologic injury as a result of surgery.
Pediatric Respiratory Critical Care	1047-0	IN:ACUTE:CC:R_PED	Critical care area for the evaluation and treatment of patients ≤18 years old with severe respiratory conditions.
Pediatric Surgical Critical Care	1048-8	IN:ACUTE:CC:S_PED	Critical care area for the evaluation and management of patients ≤18 years old with serious illness before and/or after surgery.
Pediatric Trauma Critical Care	1049-6	IN:ACUTE:CC:T_PED	Critical care area for the care of patients ≤18 years old who require a high level of monitoring and/or intervention following trauma or during critical illness related to trauma.
Neonatal Units			
Well Newborn-- Nursery (Level I)	1038-9	IN:ACUTE:WARD:NURS	Hospital area for evaluation and postnatal care of healthy newborns. May include neonatal resuscitation and stabilization of ill newborns until transfer to a facility at which specialty neonatal care is provided.

CDC Location Label	NHSN Healthcare Service Location Code	CDC Location Code	Location Description
Special Care Nursery (Level II)	1041-3	IN:ACUTE:STEP:NURS	The capabilities of Level II, listed below, are from the American Academy of Pediatrics definitions of levels of neonatal care.¹ <u>Level II special care nursery</u> Level I capabilities plus: • Provide care for infants born ≥ 32 wks. gestation and weighing ≥ 1500 g who have physiologic immaturity or who are moderately ill with problems that are expected to resolve rapidly and are not anticipated to need subspecialty services on an urgent basis • Provide care for infants convalescing after intensive care • Provide mechanical ventilation for brief duration (<24 h) or continuous positive airway pressure or both • Stabilize infants born before 32 wks. gestation and weighing less than 1500 g until transfer to a neonatal intensive care facility

CDC Location Label	NHSN Healthcare Service Location Code	CDC Location Code	Location Description
Neonatal Critical Care (Level II/III)	1039-7	IN:ACUTE:CC_STEP: NURS	Combined nursery housing both Level II and III newborns and infants, as per the NHSN level definitions above and below. This is analogous to a mixed acuity unit specifically for Neonatal Critical Care patients. This location label is only used within the NHSN application.
Neonatal Critical Care (Level III)	1040-5	IN:ACUTE:CC:NURS	A hospital neonatal intensive care unit (NICU) organized with personnel and equipment to provide continuous life support and comprehensive care for extremely high-risk newborn infants and those with complex and critical illness. The capabilities of Level III, listed below, are from the American Academy of Pediatrics definitions of levels of neonatal care.¹ <u>Level III NICU</u> Level II capabilities plus: • Provide sustained life support • Provide comprehensive care for infants born < 32 wks. gestation and weighing <1500 g and infants born at all gestational ages and birth weights with critical illness • Provide prompt and readily available access to a full range of pediatric medical subspecialists, pediatric surgical specialists, pediatric

CDC Location Label	NHSN Healthcare Service Location Code	CDC Location Code	Location Description
			anesthesiologists, and pediatric ophthalmologists • Provide a full range of respiratory support that may include conventional and/or high-frequency ventilation and inhaled nitric oxide • Perform advanced imaging, with interpretation on an urgent basis, including computed tomography, MRI, and echocardiography
Neonatal Critical Care (Level IV)	1269-0	IN:ACUTE:CC:NURS_IV	Critical care area for the care of newborns and infants with serious illness requiring Level IV care; area is supervised by a neonatologist Level IV Level III capabilities plus: • Located within an institution with the capability to provide surgical repair of complex congenital or acquired conditions • Maintain a full range of pediatric medical subspecialists, pediatric surgical subspecialists, and pediatric subspecialists at the site • Facilitate transport and provide outreach education

CDC Location Label	NHSN Healthcare Service Location Code	CDC Location Code	Location Description
Specialty Care Areas (SCA)			
Dialysis Specialty Care Area	1198-1	IN:ACUTE:SCA:DIAL	Specialty care area for the care of patients who require acute dialysis as a temporary measure.
Pediatric Dialysis Specialty Care Area	1091-8	IN:ACUTE:SCA:DIAL_PED	Specialty care area for the care of patients ≤18 years old who require acute dialysis as a temporary measure.
Pediatric Solid Organ Transplant Specialty Care Area	1093-4	IN:ACUTE:SCA:SOTP_PED	Specialty care area for the postoperative care of patients ≤18 years old who have had a solid organ transplant (for example, heart/lung, kidney, liver, pancreas).
Solid Organ Transplant Specialty Care Area	1092-6	IN:ACUTE:SCA:SOTP	Specialty care area for the postoperative care of patients >18 years old who have had a solid organ transplant (for example, heart/lung, kidney, liver, pancreas).
Adult Wards			
Antenatal Care Ward	1205-4	IN:ACUTE:WARD: ANTENAT	Hospital area for observation, evaluation, treatment or surgery of high-risk pregnancy patients.
Behavioral Health/Psych Ward	1051-2	IN:ACUTE:WARD:BHV	Area for the evaluation and treatment of patients with acute psychiatric or behavioral disorders.
Burn Ward	1052-0	IN:ACUTE:WARD:B	Area for the evaluation and treatment of patients who have burns.

CDC Location Label	NHSN Healthcare Service Location Code	CDC Location Code	Location Description
Ear, Nose, Throat Ward	1053-8	IN:ACUTE:WARD:ENT	Area for the evaluation, treatment, or surgery of patients with ear, nose, or throat disorders.
Gastrointestinal Ward	1054-6	IN:ACUTE:WARD:GI	Area for the evaluation, treatment, or surgery of patients with disorders of the gastrointestinal tract.
Genitourinary Ward	1055-3	IN:ACUTE:WARD:GU	Area for the evaluation, treatment, or surgery of patients with disorders of the genitourinary system.
Gerontology Ward	1056-1	IN:ACUTE:WARD:GNT	Area for the evaluation, treatment, or surgery of patients with age-related diseases.
Gynecology Ward	1057-9	IN:ACUTE:WARD:GYN	Area for the evaluation, treatment, or surgery of female patients with reproductive tract disorders.
Jail Unit	1171-8	IN:ACUTE:WARD:JAL	Overnight stay patient care area of a hospital or correctional facility used only for those who are in custody of law enforcement during their treatment.
Labor and Delivery Ward	1058-7	IN:ACUTE:WARD:LD	Area where patients labor and give birth.
Labor, Delivery, Recovery, Postpartum Suite	1059-5	IN:ACUTE:WARD:LD_PP	Suite used for labor, delivery, recovery and postpartum care -- all within the same suite.
Medical Ward	1060-3	IN:ACUTE:WARD:M	Area for the evaluation and treatment of patients with medical conditions or disorders.

CDC Location Label	NHSN Healthcare Service Location Code	CDC Location Code	Location Description
Medical-Surgical Ward	1061-1	IN:ACUTE:WARD:MS	Area for the evaluation of patients with medical and/or surgical conditions.
Neurology Ward	1062-9	IN:ACUTE:WARD:N	Area for the evaluation and treatment of patients with neurologic disorders.
Neurosurgical Ward	1063-7	IN:ACUTE:WARD:NS	Area for the care of patients whose primary reason for admission is to have neurosurgery or to be cared for by a neurosurgeon after head or spinal trauma.
Oncology Leukemia Ward	1226-0	IN:ACUTE:WARD:ONC_LEUK	Area for the evaluation and treatment of patients with leukemia.
Oncology Lymphoma Ward	1228-6	IN:ACUTE:WARD:ONC_LYMPH	Area for the evaluation and treatment of patients with lymphoma.
Oncology Leukemia/Lymphoma Ward	1229-4	IN:ACUTE:WARD:ONC_LL	Area for the evaluation and treatment of patients with leukemia and/or lymphoma.
Oncology Solid Tumor Ward	1230-2	IN:ACUTE:WARD:ONC_ST	Area for the evaluation and treatment of oncology patients with solid tumors.
Oncology Hematopoietic Stem Cell Transplant Ward	1231-0	IN:ACUTE:WARD:ONC_HSCT	Area for the care of patients who undergo stem cell transplant for the treatment of cancers, immune effector cell therapy, and/or blood or immune system disorders.

CDC Location Label	NHSN Healthcare Service Location Code	CDC Location Code	Location Description
Oncology General Hematology-Oncology Ward	1232-8	IN:ACUTE:WARD: ONC_HONC	Area for the evaluation and treatment of patients with cancer and/or blood disorders.
Ophthalmology Ward	1064-5	IN:ACUTE:WARD:OPH	Area for the care of patients whose primary reason for admission is to have eye surgery or to be cared for by an ophthalmologist after eye trauma.
Orthopedic Ward	1065-2	IN:ACUTE:WARD:ORT	Area for the evaluation, treatment, or surgery on bones, joints, and associated structures by an orthopedist.
Orthopedic Trauma Ward	1066-0	IN:ACUTE:WARD:T_ORT	Area for the evaluation and treatment of patients with orthopedic injuries or disorders.
Onsite Overflow Ward	1271-6	IN:ACUTE:WARD:OF_ONSITE	Area previously used for non-patient care which has been repurposed to care for non-critically ill or injured patients on a temporary basis <u>OR</u> a patient care area used specifically for overflow inpatients.
Plastic Surgery Ward	1067-8	IN:ACUTE:WARD:PLS	Area for the care of patients who have reconstructive surgery performed by a plastic surgeon.
Postpartum Ward	1068-6	IN:ACUTE:WARD:PP	Area for the care of patients recovering from childbirth.
Pulmonary Ward	1069-4	IN:ACUTE:WARD:PULM	Area for the evaluation and treatment of patients with respiratory system conditions or disorders.

CDC Location Label	NHSN Healthcare Service Location Code	CDC Location Code	Location Description
Rehabilitation Ward (within Hospital)	1070-2	IN:ACUTE:WARD:REHAB	Area for the evaluation and restoration of function to patients who have lost function due to acute or chronic pain, musculoskeletal problems, stroke, or catastrophic events resulting in complete or partial paralysis.
School Infirmary	1172-6	IN:ACUTE:WARD:IFM	Overnight stay patient care area of a school infirmary or health center (for example, private residential school or college campus).
Stroke (Acute) Ward	1071-0	IN:ACUTE:WARD:STRK	Area for the evaluation, stabilization, and treatment of patients who have experienced an acute stroke.
Surgical Ward	1072-8	IN:ACUTE:WARD:S	Area for the evaluation and treatment of patients who have undergone a surgical procedure.
Telemetry Ward	1208-8	IN:ACUTE:WARD:TEL	Area dedicated to providing evaluation and treatment of cardiac patients with orders for continuous cardiac monitoring.
Vascular Surgery Ward	1073-6	IN:ACUTE:WARD:VS	Area for the evaluation and treatment of patients who have undergone vascular surgery.
Chemical Dependency Ward	1270-8	IN:ACUTE:WARD:CD	Area for the evaluation and treatment of patients with chemical dependency.

CDC Location Label	NHSN Healthcare Service Location Code	CDC Location Code	Location Description
Pediatric Wards			
Adolescent Behavioral Health Ward	1075-1	IN:ACUTE:WARD: BHV_ADOL	Area for the evaluation and treatment of patients 13-18 years old with acute psychiatric or behavioral disorders.
Oncology Pediatric Hematopoietic Stem Cell Transplant Ward	1234-4	IN:ACUTE:WARD: ONC_HSCT_PED	Area for the care of patients ≤18 years old who undergo stem cell transplant for the treatment of cancers and/or blood or immune system disorders.
Oncology Pediatric General Hematology/Oncology Ward	1235-1	IN:ACUTE:WARD: ONC_HONC_PED	Area for the evaluation and treatment of patients ≤18 years old with cancer and/or blood disorders.
Pediatric Behavioral Health Ward	1077-7	IN:ACUTE:WARD:BHV_PED	Area for the evaluation and treatment of patients ≤18 years old with acute psychiatric or behavioral disorders.
Pediatric Burn Ward	1078-5	IN:ACUTE:WARD:B_PED	Area for the evaluation and treatment of patients ≤18 years old who have tissue injury caused by burns.
Pediatric Ear, Nose, Throat Ward	1079-3	IN:ACUTE:WARD: ENT_PED	Area for the evaluation and treatment of patients ≤18 years old with disorders of the ear, nose, and/or throat.
Pediatric Genitourinary Ward	1080-1	IN:ACUTE:WARD: GU_PED	Area for the evaluation and treatment of patients ≤18 years old with disorders of the genitourinary system.
Pediatric Medical Ward	1076-9	IN:ACUTE:WARD:M_PED	Area for the evaluation and treatment of patients ≤18 years old with medical conditions or disorders.

CDC Location Label	NHSN Healthcare Service Location Code	CDC Location Code	Location Description
Pediatric Medical-Surgical Ward	1081-9	IN:ACUTE:WARD: MS_PED	Area for the evaluation and treatment of patients ≤18 years old with medical and/or surgical conditions.
Pediatric Neurology Ward	1082-7	IN:ACUTE:WARD:N_PED	Area for the evaluation and treatment of patients ≤18 years old with neurologic disorders.
Pediatric Neurosurgical Ward	1083-5	IN:ACUTE:WARD:NS_PED	Area for care of patients ≤18 years old whose primary reason for admission is to have neurosurgery or to be cared for by a neurosurgeon after head or spinal trauma.
Pediatric Orthopedic Ward	1084-3	IN:ACUTE:WARD: ORT_PED	Area for the evaluation and treatment of patients ≤18 years old with orthopedic injuries or disorders.
Pediatric Rehabilitation Ward (within Hospital)	1085-0	IN:ACUTE:WARD: REHAB_PED	Area for the evaluation and restoration of function to patients ≤18 years old who have lost function due to acute or chronic pain, musculoskeletal problems, stroke, or catastrophic events resulting in complete or partial paralysis.
Pediatric Surgical Ward	1086-8	IN:ACUTE:WARD:S_PED	Area for the evaluation and treatment of patients ≤18 years old who have undergone a surgical procedure.

CDC Location Label	NHSN Healthcare Service Location Code	CDC Location Code	Location Description
Step Down Units			
Adult Step Down Unit	1099-1	IN:ACUTE:STEP	Area for adult patients who are hemodynamically stable and can benefit from close supervision and monitoring, such as frequent pulmonary toilet, vital signs, and/or neurologic and neurovascular checks.
Oncology Step Down Unit	1227-8	IN:ACUTE:STEP:ONC	Area for oncology patients who are hemodynamically stable and can benefit from close supervision and monitoring, such as frequent pulmonary toilet, vital signs, and/or neurologic and neurovascular checks.
Pediatric Step-Down Unit	1100-7	IN:ACUTE:STEP:PED	Area for patients ≤ 18 years old who are hemodynamically stable and can benefit from close supervision and monitoring, such as frequent pulmonary toilet, vital signs, and/or neurologic and neurovascular checks.

CDC Location Label	NHSN Healthcare Service Location Code	CDC Location Code	Location Description
Mixed Acuity Units			
Adult Mixed Acuity Unit	1210-4	IN:ACUTE:MIXED: ALL_ADULT	Area for the evaluation and treatment of adult patients whose conditions are of varying levels of acuity (for example, critical care, ward-level care, step-down type care). The area may house patients followed by different hospital services (for example, coronary, medical, surgical, etc.). This care area may or may not include "acuity adaptable" or "universal" beds (specifically, this model of patient care allows a patient to stay in same bed during all phases of care, from critical care through lower levels of care).
Pediatric Mixed Acuity Unit	1211-2	IN:ACUTE:MIXED: ALL_PEDS	Area for the evaluation and treatment of pediatric patients whose conditions are of varying levels of acuity (for example, critical care, ward-level care, step down type care). The area may house patients followed by different hospital services (for example, coronary, medical, surgical, etc.). This care area may or may not include "acuity adaptable" or "universal" beds (specifically, this model of patient care allows a patient to stay in the same bed during all phases of care, from critical care through lower levels of care).

CDC Location Label	NHSN Healthcare Service Location Code	CDC Location Code	Location Description
Mixed Age Mixed Acuity Unit	1212-0	IN: ACUTE:MIXED:ALL	Area for the evaluation and treatment of a mixture of adult and pediatric patients whose conditions are of varying levels of acuity (for example, critical care, ward-level care, step-down type care). The area may house patients followed by different hospital services (for example, coronary, medical, surgical, etc.). This care area may or may not include "acuity adaptable" or "universal" beds (specifically, this model of patient care allows a patient to stay in same bed during all phases of care, from critical care through lower levels of care).
Oncology Mixed Acuity Unit (all ages)	1236-9	IN: ACUTE:MIXED:ONC	Area for the evaluation and treatment of a mixture of adult and pediatric oncology patients whose conditions are of varying levels of acuity (for example, critical care, ward-level care, step-down type care). This care area may or may not include "acuity adaptable" or "universal" beds (specifically, this model of patient care allows a patient to stay in the same bed during all phases of care, from critical care through lower levels of care).

CDC Location Label	NHSN Healthcare Service Location Code	CDC Location Code	Location Description
Operating Rooms			
Cardiac Catheterization Room/Suite	1005-8	IN:ACUTE:OR:CATH	A room or rooms in a hospital equipped for the performance of heart catheterizations for diagnostic or therapeutic purposes. Operating Room requirements for air changes, temperature, humidity and surfaces must be met.
Cesarean Section Room/Suite	1095-9	IN:ACUTE:OR:LD	A room or suite in a hospital equipped for the performance of obstetric and gynecologic surgeries and for the care of the neonate immediately after birth. Operating Room requirements for air changes, temperature, humidity and surfaces must be met.
Interventional Radiology	1203-9	IN:ACUTE:OR:RAD	A room where diagnostic or therapeutic radiology procedures are done on outpatients or inpatients. Operating room requirements for air changes, temperature, humidity, and surfaces must be met.
Operating Room/Suite	1096-7	IN:ACUTE:OR	A room or suite in a hospital equipped for the performance of surgical procedures. Requirements for air changes, temperature, humidity, and surfaces must be met.

CDC Location Label	NHSN Healthcare Service Location Code	CDC Location Code	Location Description
Post Anesthesia Care Unit/Recovery Room	1097-5	IN:ACUTE:OR_STEP	Area designated for monitoring patients for immediate effects of anesthesia before either going home or on to an in-patient care area.
Chronic Care Units (within an Acute Care Hospital) NOTE: These location descriptions should only be used to define chronic care units that share a CCN with the affiliated acute care hospital. NHSN does not specifically define “extended periods of time”, which is used to describe many of the chronic care units. NHSN leaves this to the facility’s discretion. Chronic care units are traditionally non-medical wards where dedicated care is given towards those patients with pre-existing or long-term illness, as opposed to acute care which is concerned with short term or severe illness. Skilled nursing facility (SNF) units located within a hospital that have a CCN that is different from the acute care hospital should be enrolled as a separate NHSN facility within the NHSN Long Term Care Facility Component and use the long-term care locations defined on pages 29-30).			
Inpatient Hospice	1165-0	IN:NONACUTE:LTC:HSP	Area where palliative care is provided to the dying patient.
Chronic Alzheimer's Unit	1103-1	IN:NONACUTE:LTC:ALZ	Area where care is provided to persons diagnosed with Alzheimer's syndrome for extended periods of time.
Chronic Behavioral Health/Psych Unit	1104-9	IN:NONACUTE:LTC:BHV	Area where care is provided to patients with psychiatric or behavioral-disorder diagnoses for extended periods of time.

CDC Location Label	NHSN Healthcare Service Location Code	CDC Location Code	Location Description
Chronic Rehabilitation Unit	1105-6	IN:NONACUTE:LTC: REHAB	Area where evaluation and restoration of function is provided to patients who have lost function due to acute or chronic pain, musculoskeletal problems, stroke, or catastrophic events resulting in complete or partial paralysis.
Chronic Care Unit	1102-3	IN:NONACUTE:LTC	Area where care provided for patients with chronic disease or disabilities for extended periods of time.
Ventilator Dependent Unit	1164-3	IN:NONACUTE:LTC:R	Area where care is provided to patients whose respirations depend on the use of a ventilator for extended periods of time.
LONG TERM CARE FACILITIES (Skilled Nursing Facilities, Assisted Living Facilities)			
Long Term Care Facility Inpatient Hospice Unit	1254-2	IN:NONACUTE:LTCF:HSP	A unit or designated area which provides palliative and supportive care services to individuals diagnosed with life limiting (terminal) conditions.
Long Term Care Facility Dementia Unit	1255-9	IN:NONACUTE:LTCF:DEM	A unit or designated area which provides specialized care for individuals diagnosed with dementia or related conditions, including Alzheimer's disease.
Long Term Care Facility Psychiatric Unit	1256-7	IN:NONACUTE:LTCF:PSY	Unit or designated area which provides specialized care for individuals diagnosed with psychiatric or behavioral disorders.

CDC Location Label	NHSN Healthcare Service Location Code	CDC Location Code	Location Description
Long Term Care Facility Skilled Nursing-Short Term Rehabilitation	1257-5	IN:NONACUTE:LTCF: REHAB	A unit or designated area which primarily provides short term (<90 days), medical, skilled nursing or rehabilitation services to individuals requiring restorative care following recent hospitalization.
Long Term Care Facility General Nursing Unit	1258-3	IN:NONACUTE:LTCF:GEN	A unit or designated area which primarily provides nursing, rehabilitative or custodial services to individuals with varying levels of chronic conditions or disability requiring long term (>90 days) support.
Long Term Care Facility Ventilator Dependent Unit	1259-1	IN:NONACUTE:LTCF:VEN	A unit or designated area which provides nursing and respiratory care to individuals who require mechanical ventilation.
Long Term Care Facility Bariatric Unit	1260-9	IN:NONACUTE:LTCF:BAR	A unit or designated area which provides specialized care for individuals who are preparing for or have undergone bariatric surgery.
LONG TERM ACUTE CARE FACILITIES			
Long Term Acute Care Intensive Care Unit	1220-3	IN:ACUTE:CC:LTAC	Critical care area specializing in the evaluation, treatment, and management of patients that require high observance/acuity and/or special care that are suffering medically complex conditions or who have suffered recent catastrophic illness or injury and require and extended stay in an acute care environment.

CDC Location Label	NHSN Healthcare Service Location Code	CDC Location Code	Location Description
Long Term Acute Care Ward	1221-1	IN:ACUTE:WARD:LTAC	Area for the evaluation and treatment of patients suffering medically complex conditions or who have suffered recent catastrophic illness or injury and require an extended stay in an acute care environment.
Long Term Acute Care Intensive Care Unit	1222-9	IN:ACUTE:CC:LTAC_PED	Critical care area specializing in the evaluation, treatment, and management of patients ≤ 18 years old, that require high observation/acuity and/or special care that are suffering medically complex conditions or who have suffered recent catastrophic illness or injury and require an extended stay in an acute care environment.
Long Term Acute Care Pediatric Ward	1214-6	IN:ACUTE:WARD:LTAC_PED	Area for the evaluation and treatment of patients ≤ 18 years old, suffering medically complex conditions or who have suffered recent catastrophic illness or injury, and require an extended stay in an acute care environment
INPATIENT REHABILITATION FACILITIES			
Rehabilitation Ward (within freestanding Inpatient Rehabilitation Facility)	1217-9	IN:ACUTE:IRF	In-Hospital area for evaluation, treatment, and restoration of function to patients have lost function due to acute or chronic pain, musculoskeletal problems, stroke, brain or spinal cord dysfunction, or catastrophic events resulting in complete or partial paralysis.

CDC Location Label	NHSN Healthcare Service Location Code	CDC Location Code	Location Description
Pediatric Rehabilitation Ward (within freestanding Inpatient Rehabilitation Facility)	1218-7	IN:ACUTE:IRF:PED	In-Hospital area for evaluation, treatment, and restoration of function to patients ≤ 18 years old who have lost function due to acute or chronic pain, musculoskeletal problems, stroke, brain or spinal cord dysfunction, or catastrophic events results in complete or partial paralysis.
ONCOLOGY FACILITIES			
Oncology Medical Critical Care	1223-7	IN:ACUTE:CC:ONC_M	Critical care area for the care of oncology patients who are being treated for nonsurgical conditions related to their malignancy.
Oncology Surgical Critical Care	1224-5	IN:ACUTE:CC:ONC_S	Critical care area for the evaluation and management of oncology patients with serious illness before and/or after cancer-related surgery.
Oncology Medical-Surgical Critical Care	1225-2	IN:ACUTE:CC:ONC_MS	Critical care area for the care of oncology patients with medical and/or surgical conditions related to their malignancy.
Oncology Pediatric Critical Care	1233-6	IN:ACUTE:CC:ONC_PED	Critical care area for the care of oncology patients ≤ 18 years old who are being treated for surgical or nonsurgical conditions related to their malignancy.
Oncology Leukemia Ward	1226-0	IN:ACUTE:WARD: ONC_LEUK	Area for the evaluation and treatment of patients with leukemia.

CDC Location Label	NHSN Healthcare Service Location Code	CDC Location Code	Location Description
Oncology Lymphoma Ward	1228-6	IN:ACUTE:WARD:ONC_LYMPH	Area for the evaluation and treatment of patients with lymphoma.
Oncology Leukemia-Lymphoma Ward	1229-4	IN:ACUTE:WARD: ONC_LL	Area for the evaluation and treatment of patients with leukemia and/or lymphoma.
Oncology Solid Tumor Ward	1230-2	IN:ACUTE:WARD:ONC_ST	Area for the evaluation and treatment of oncology patients with solid tumors.
Oncology Hematopoietic Stem Cell Transplant Ward	1231-0	IN:ACUTE:WARD: ONC_HSCT	Area for the care of patients who undergo stem cell transplant for the treatment of cancers and/or blood or immune system disorders.
Oncology General Hematology-Oncology Ward	1232-8	IN:ACUTE:WARD: ONC_HONC	Area for the evaluation and treatment of patients with cancer and/or blood disorders.
Oncology Pediatric Hematopoietic Stem Cell Transplant Ward	1234-4	IN:ACUTE:WARD: ONC_HSCT_PED	Area for the care of patients ≤18 years old who undergo stem cell transplant for the treatment of cancers and/or blood or immune system disorders.
Oncology Pediatric General Hematology-Oncology Ward	1235-1	IN:ACUTE:WARD: ONC_HONC_PED	Area for the evaluation and treatment of patients ≤18 years old with cancer and/or blood disorders.
Oncology Step Down Unit	1227-8	IN:ACUTE:STEP:ONC	Area for oncology patients who are hemodynamically stable and can benefit from close supervision and monitoring, such as frequent pulmonary toilet, vital signs, and/or neurologic and neurovascular checks.

CDC Location Label	NHSN Healthcare Service Location Code	CDC Location Code	Location Description
Oncology Mixed Acuity Unit (all ages)	1236-9	IN:ACUTE:MIXED:ONC	Area for the evaluation and treatment of a mixture of adult and pediatric oncology patients whose conditions are of varying levels of acuity (for example, critical care, ward-level care, step down type care, etc.). This care area may or may not include "acuity adaptable" or "universal" beds (specifically, this model of patient care allows a patient to stay in same bed during all phases of care, from critical care through lower levels of care).
In addition to the 14 ONC specific locations, HOSP-ONC facilities can also use the following locations within NHSN (Location codes and descriptions can be found in the appropriate section of the master location table): Inpatient Locations - Operating Rooms: - Cardiac Catheterization Room/Suite - Interventional Radiology - Inpatient Operating Room/Suite - Post-Anesthesia Care Unit/Recovery Room - Facility-wide Areas: - FACWIDEIN - Miscellaneous Areas: - Pulmonary Function Testing - Treatment Room - Transport Service - Float Outpatient Locations - Acute Care			

CDC Location Label	NHSN Healthcare Service Location Code	CDC Location Code	Location Description
• 24-Hour Observation Area • Ambulatory Surgery Center • Emergency Department • Outpatient Pediatric Surgery Center • Outpatient Plastic Surgery Center • Outpatient Surgery Recovery Room/Post-Anesthesia Care Unit • Pediatric Emergency Department • Clinic (Nonacute) Settings • Infusion Center • Occupational Health Clinic • Outpatient Hematology/Oncology Clinic • Pediatric Hematology/Oncology Clinic • Radiology (includes Nuclear Medicine) • Specimen Collection Area (Healthcare) • Community Locations • Home Care • Home-based Hospice • Location outside facility • All Non-Patient Care Locations as designated on page 40 in the location table			
INPATIENT PSYCHIATRIC FACILITIES			
HOSP-PSYCH facilities can use the following locations within NHSN (Location codes and descriptions can be found in the appropriate section of the master location table): Inpatient Locations • Adult Wards • Behavioral Health /Psych Ward • Jail Unit			

CDC Location Label	NHSN Healthcare Service Location Code	CDC Location Code	Location Description
• Medical Ward • Medical/Surgical Ward • Pediatric Wards • Adolescent Behavioral Health/Psych Ward • Pediatric Behavioral Health/Psych Ward • Mixed Acuity Locations • Adult Mixed Acuity • Pediatric Mixed Acuity • Chronic Care Units • Chronic Alzheimer's Unit • Chronic Behavioral Health/Psych Unit • Facility-wide Areas: • FACWIDEIN • FACWIDEOUT			
OUTPATIENT LOCATIONS			
OUTPATIENT AMBULATORY SURGERY CENTERS			
Ambulatory Surgery Center	1243-5	OUT:ASC:OR	Area that is equipped for the performance of surgical procedures; can be attached to an ACH or free-standing and has a separate ASC CCN. Operating Room requirements for air changes, temperature, humidity and surfaces must be met.

CDC Location Label	NHSN Healthcare Service Location Code	CDC Location Code	Location Description
Ambulatory Surgery Recovery Room	1245-0	OUT:ASC:OR_STEP	Area designated in an ASC for monitoring patients for the immediate effects of anesthesia.
Outpatient Ambulatory Pediatric Surgery Center	1246-8	OUT:ASC:OR:PED	Area, in an ASC, that is equipped for the performance of surgical operations for persons ≤ 18 years old; may be free-standing or part of a hospital. Operating Room requirements for air changes, temperature, humidity, and surfaces must be met. Patients do not stay overnight.
Outpatient Ambulatory Plastic Surgery Center	1247-6	OUT:ASC:OR:PLS	Area, in an ASC, that is equipped for the performance of plastic surgery operations; may be free-standing or part of a hospital. Operating Room requirements for air changes, temperature, humidity and surfaces must be met. Patients do not stay overnight.
Pediatric Outpatient Operating Room/Suite (Attached)	1248-4	OUT:ACUTE:OR:HOPD_A_PED	A room or suite equipped for the performance of pediatric surgical procedures that is physically within the walls of the affiliated ACH. It is considered a hospital outpatient department used for outpatient pediatric surgical procedures. Requirements for air changes, temperature, humidity, and surfaces must be met.

CDC Location Label	NHSN Healthcare Service Location Code	CDC Location Code	Location Description
Pediatric Outpatient Operating Room/Suite (Detached)	1249-2	OUT:ACUTE:OR:HOPD_D_PED	A room or suite equipped for the performance of pediatric surgical operations that is not physically attached to the affiliated ACH (could be on the same campus or miles away). It is considered a hospital outpatient department used for outpatient pediatric surgical procedures. Requirements for air changes, temperature, humidity, and surfaces must be met.
Outpatient Hemodialysis Clinic - Acute Kidney Injury	1268-2	OUT:NONACUTE:CLINIC:DIAL_A KI	An outpatient setting where Acute Kidney Injury patients are evaluated and receive dialysis several times weekly.
ACUTE CARE FACILITIES GENERAL			
Acute Settings			
24-Hour Observation Area	1162-7	OUT:ACUTE:WARD	Area where patients are monitored for suspected or non-life-threatening conditions <u>for 24 hours or less</u> . More than 50% of patients in this location must be outpatients (observation status) who are not expected to be admitted to an inpatient unit.
Emergency Department	1108-0	OUT:ACUTE:ED	Area that provides emergency medical services; top priority is given to those with life-threatening illness or injury.

CDC Location Label	NHSN Healthcare Service Location Code	CDC Location Code	Location Description
Mobile Emergency Services/EMS	1174-2	OUT:ACUTE:MOBILE:UE	Mobile unit that provides clinical and emergency medical services to patients who require them in the pre-hospital setting.
Post-Anesthesia Care Unit	1169-2	OUT:ACUTE:OR_STEP	Area designated for monitoring patients for the immediate effects of anesthesia before being sent home.
Outpatient Operating Room/Suite_(Attached)	1242-7	OUT:ACUTE:OR:HOPD_A	A room or suite equipped for the performance of surgical operations that is physically within the walls of the affiliated ACH. <i>It is considered a hospital outpatient department used for outpatient surgical procedures.</i> Requirements for air changes, temperature, humidity, and surfaces must be met.
Outpatient Operating Room/Suite(Detached)	1244-3	OUT:ACUTE:OR:HOPD_D	A room or suite equipped for the performance of surgical operations that is not physically attached to the affiliated ACH (could be on the same campus or miles away). <i>It is considered a hospital outpatient department used for outpatient surgical procedures.</i> Requirements for air changes, temperature, humidity, and surfaces must be met.
Pediatric Emergency Department	1109-8	OUT:ACUTE:ED:PED	Area that provides emergency medical services to patients ≤18 years old; top priority is given to those with life-threatening illness or injury.

CDC Location Label	NHSN Healthcare Service Location Code	CDC Location Code	Location Description
Urgent Care Center	1160-1	OUT:ACUTE:CLINIC:UE	Area that provides medical care services for illnesses and injuries that are not life-threatening.
Clinic (non-acute) Settings			
Clinic mapping options may be found in the HSLOC online mapping tool: https://www.cdc.gov/nhsn/cdaportal/terminology/codesystem/hsloc.html			
OUTPATIENT DIALYSIS FACILITIES (Available for use in outpatient ambulatory hemodialysis facilities only)			
Outpatient Hemodialysis Clinic	1153-6	OUT:NONACUTE:CLINIC: DIAL	An outpatient setting for maintenance hemodialysis patients where they are evaluated and dialyzed in-center.
Home Hemodialysis	1262-1	COMM:NONACUTE: HOME:DIAL	Hemodialysis performed by an appropriately trained patient (and the patient's caregiver) and at home.
FACILITY-WIDE LOCATIONS (Available only for Laboratory Identified Event Reporting [LABID] and Antimicrobial Use and Resistance [AUR] Module)			
Facility-wide Inpatient (FacWideIN)	1250-0	FACWIDEIN	Facility-wide Inpatient (FacWIDEIn)
Facility-wide Outpatient (FacWideOUT)	1251-8	FACWIDEOUT	Facility-wide Outpatient (FacWIDEOut)

CDC Location Label	NHSN Healthcare Service Location Code	CDC Location Code	Location Description
COMMUNITY LOCATIONS			
Community location mapping options may be found in the HSLOC online mapping tool: https://www.cdc.gov/nhsn/cdaportal/terminology/codesystem/hsloc.html			
NON-PATIENT CARE LOCATIONS			
(Non-Patient Care Areas available for use in Biovigilance or Healthcare Personnel Safety Components only)			
Non-patient care location mapping options may be found in the HSLOC online mapping tool: https://www.cdc.gov/nhsn/cdaportal/terminology/codesystem/hsloc.html			

References

1. American Academy of Pediatrics. Policy Statement Levels of Neonatal Care. *Pediatrics* 2012; 130 (3): 587-597. Reaffirmed 2021

General Key Terms

The definitions included below are general key terms that are included in two or more Patient Safety Component (PSC) protocols. Definitions specific to individual protocols are located in the respective protocol.

Important Note: *These general key terms are intended to be utilized for NHSN surveillance and may not align with clinical or facility specific definitions.*

Term	Definition
Active Surveillance Culture/Testing (ASC/AST)	Active Surveillance Culture/Testing (ASC/AST) refers to testing that is intended to identify the presence/carriage of microorganisms for the purpose of instituting or discontinuing isolation precautions (for example, nasal swab for MRSA, rectal swab for VRE), or monitoring for eradication of a carrier state/colonization. ASC/AST does NOT include identification of microorganisms with cultures or tests performed for diagnosis and treatment purposes (for example, specimens collected from sterile body sites including blood specimens). Also, see Surveillance cultures.
Apnea	See Vital Signs .
Aseptically obtained	Specimen obtained in a manner to prevent introduction of organisms from the surrounding tissues.
Birthweight	Weight of the infant at the time of birth. Birthweight should not be changed as the infant gains weight. The NHSN birthweight categories are as follows: • A = ≤750 g • B = 751-1000 g • C = 1001-1500 g • D = 1501-2500 g • E = >2500 g
Calendar day	A calendar day is midnight (00:00) to 11:59pm.
Clinical correlation	Physician or physician designee documentation of antimicrobial treatment for site-specific infection related to equivocal findings (not clearly identified) of infection on imaging test. See Physician/Physician Designee .

Term	Definition
	For example, when applying intraabdominal infection (IAB) criterion “3b”, the finding of ‘fluid collection seen in the lower abdominal cavity’ on an imaging test, may or may not represent an infection. This finding is not clearly identified as an infection and should be confirmed with clinical evidence that an infection is present. In the case of IAB criterion “3b”, the clinical evidence that is required, is physician documentation of antimicrobial therapy for treating the intraabdominal infection.
Date of event (DOE)	The date the first element used to meet an NHSN site-specific infection criterion occurs for the first time within the seven-day infection window period. • Synonyms: infection date, date of infection, event date. Note: Rules for DOE do not apply to SSI, VAE, PedVAE, or LabID Events. See respective protocols.
Days present	The denominator “days present” is only used in the AUR Module. See Antimicrobial Use and Resistance (AUR) Module .
Device-associated infection	An infection meeting the HAI definition is considered a device-associated HAI (for example, associated with the use of a ventilator, central line, or indwelling urinary catheter) if the device was in place for >2 calendar days on the date of event, and was also in place on the date of event or the day before the event (with date of insertion and date of removal counted as a Device Day). If the device was in place for >2 calendar days and then removed, the date of event must be the day of device discontinuation or the next day to be device associated. • For a patient who has a central line in place on hospital admission, day of first inpatient access is considered Device Day 1. • For a patient who has a ventilator or indwelling urinary catheter in place prior to inpatient admission, the device day count that determines device–association begins with the admission date to the first inpatient location.
Device days	A count of the number of patients with a specific device in place in a patient care location during a time period. This count can be determined electronically or manually by a daily

Term	Definition
	count, or weekly sampling. See Denominator Data section within individual protocols for further details.
Died	The patient died during the current facility admission.
Event contributed to death	The event either directly caused death or exacerbated an existing disease condition that then led to death as evidenced by available documentation (for example, death/discharge note, autopsy report, etc.).
Equivocal imaging	Findings from medical imaging studies that do not definitively identify an infection or infectious process. Equivocal imaging findings must be clinically correlated specifically physician documentation of antimicrobial therapy treating the infection or infectious process. Clinical correlation verifies the presence of an infection by physician documentation of antimicrobial treatment for that specific infection. • Example of definitive imaging: abscess visualized in the right lower quadrant. • Example of equivocal imaging: fluid collection visualized in the right lower quadrant.
Fever	For NHSN surveillance purposes fever is defined as >38 degrees Celsius (°C), or >100.4 degrees Fahrenheit (°F) documented in the medical record. Conversions for different collection sources or methodologies are not applied.
Gross anatomical exam	Gross anatomic evidence of infection is evidence of infection elicited or visualized on physical examination or observed during an invasive procedure. This includes findings elicited on physical examination of a patient during admission or subsequent assessments of the patient and may include findings noted during a medical/invasive procedure, dependent upon the location of the infection as well as the NHSN infection criterion. For examples and additional detail please see Chapter 9 .
Healthcare-associated infection (HAI)	An infection is considered a HAI if the date of event of the NHSN site-specific infection criterion occurs on or after the 3rd calendar day of admission to an inpatient location where day of admission to an inpatient location is calendar day 1. See Identifying HAIs chapter .

Term	Definition
	Note: Rules for HAI do not apply to SSI, VAE, PedVAE, or LabID Events.
Hypotension	See Vital signs .
Infant	A patient who is ≤ 1 year (≤ 365 days) of age.
Infection window period (IWP)	The 7 days during which all site-specific infection criteria must be met. It includes the date the first positive diagnostic test that is used as an element of the site-specific infection criterion was obtained, the 3 calendar days before, and the 3 calendar days after. Note: Rules for IWP do not apply to SSI, VAE, PedVAE, or LabID Events.
In-plan surveillance	The NHSN surveillance protocol(s) is used, in its entirety for the full month, for that particular HAI, SSI, VAE, PedVAE, or LabID event type as outlined in the NHSN Monthly Reporting Plan (MRP). Only in-plan data are submitted to CMS in accordance with CMS's Quality Reporting Programs and are included in NHSN annual reports or other NHSN publications.
Intensive care unit (ICU)	Also known as a Critical Care Unit, the ICU is a nursing care area that provides intensive observation, diagnostic and therapeutic procedures for adults and/or children who are critically ill. An ICU excludes nursing areas that provide step-down, intermediate care or telemetry only. The type of ICU is determined by the type of patients cared for in that unit according to the 80% Rule –which means 80% of the patients in a location are of a certain type.
Location	The patient care area to which a patient is assigned while receiving care in the healthcare facility. Note: Only mapped inpatient locations where denominator data are collected can be used for attribution and reporting infection events via the Device-associated Module. Operating rooms (including cardiac catheter labs, C-section rooms, and interventional radiology), emergency departments and outpatient locations are not valid locations for attribution of healthcare -associated infection (HAI) events.

Term	Definition
Location of attribution (LOA)	The inpatient location where the patient was assigned on the date of event (see also Date of Event and Transfer Rule terms). Non-bedded patient locations, (for example, PACU or OR) are not eligible for assignment of location of attribution for HAI events. Location of attribution must be a location where denominator data can be collected. See individual HAI protocol(s) for additional details.
Neonate	A patient who is ≤ 30 days of age.
Non-bedded patient location	A patient care location that does not house patients overnight; therefore, for NHSN reporting purposes, a device-associated HAI event cannot be attributed to this type of location. No patient or device day counts are collected in non-bedded patient locations. Note: There are non-bedded locations that are considered inpatient non-bedded locations such as the OR, inpatient dialysis, interventional radiology, or the cardiac catheterization lab.
Non-culture based microbiologic testing	Identification of microorganisms using a method of testing other than a culture. Culture based testing requires inoculation of a specimen to culture media, incubation, and observation for actual growth of microorganisms. Depending on the organism identified, culture based testing can take several days to weeks for a final report. In contrast, non-culture based testing methods generally provide faster results, which can assist with early diagnosis and tailoring of antimicrobial therapy. Examples of non-culture based testing include but are not limited to PCR (polymerase chain reaction) and ELISA (Enzyme-linked immunosorbent assay). With the exception of Active Surveillance Culture/Testing (ASC/AST), any test methodology (culture or non-culture based) that provides a final laboratory report in the medical record and identifies an organism, is eligible for use in meeting an NHSN infection definition.
Off-plan surveillance	Facility has not indicated in their NHSN Monthly Reporting Plan that the NHSN surveillance protocol(s) will be used, in its entirety, for a particular HAI event type. Off-plan data are not submitted to CMS in accordance with CMS's Quality Reporting Programs and are not included in NHSN annual reports or other NHSN publications.

Term	Definition
Patient days	A count of the number of patients in a patient care location during a defined time period. This count can be determined electronically or manually by a daily count or, depending on the location type, weekly sampling. See Denominator Data section within individual protocols.
Physician/Physician Designee	The term physician for the purpose of application of the NHSN criteria may be interpreted to mean a surgeon, infectious disease physician, emergency physician, other physician on the case, or physician's designee (Advanced Practice Nurse [APN], Physician's Assistant [PA]).
Present on admission (POA)	An infection meeting an NHSN site-specific infection criterion with a date of event that occurs on the day of admission to an inpatient location (calendar day 1), the 2 days before admission, or the calendar day after admission (POA time period). See Identifying HAIs in NHSN . Note: Rules for POA do not apply to SSI, VAE, PedVAE, or LabID Events.
Repeat infection timeframe (RIT)	The 14-day timeframe during which no new infections of the same type are reported. See Identifying HAIs in NHSN . Note: Rules for the RIT do not apply to SSI, VAE, PedVAE, or LabID Events.
Secondary BSI attribution period (SBAP)	The period in which a blood specimen must be collected for a secondary bloodstream infection to be attributed to a primary site infection. This period includes the Infection Window Period (IWP) combined with the Repeat Infection Timeframe (RIT). The SBAP is 14-17 days in length depending upon the date of event. Note: - Secondary BSI Attribution Period does not apply to VAE, PedVAE, or LabID Events. - The Secondary BSI Attribution Period for SSI is a 17-day period that includes the date of event of the SSI, 3 days prior to the date of event, and 13 days after the SSI date of event.
Standardized infection ratio (SIR)	Summary measure used to track HAIs over time. It compares the number of reported HAIs to the number of predicted HAIs, based on NHSN baseline data. The SIR adjusts for several

Term	Definition
	factors that may impact the risk of acquiring an HAI. See the SIR Guide for more information.
Standardized utilization ratio (SUR)	Summary measure used to track device use over time. It compares the number of reported device days to the number of predicted device days, based on NHSN baseline data. The SUR adjusts for several factors that have been found to be significantly associated with differences in device utilization. See the SUR Guide for more information.
Surveillance cultures	Those cultures reported as part of a facility's infection prevention and control surveillance are not used in patient diagnosis and treatment. Surveillance cultures include but are not limited to stool cultures for vancomycin-resistant <i>Enterococci</i> (VRE) and/or nasal swabs for methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) surveillance. These cultures are also called active surveillance cultures or testing (ASC/AST). Note: Positive cultures collected from sterile body sites including blood specimens are not surveillance cultures and are eligible for use in meeting NHSN HAI, LabID, VAE, and SSI event criteria. Also, see Active Surveillance Culture/Testing (ASC/AST).
Surveillance period for SSI	The timeframe following an NHSN operative procedure for monitoring and identifying an SSI event. The surveillance period is determined by the NHSN operative procedure category (for example, COLO has a 30-day SSI surveillance period and KPRO has a 90-day SSI surveillance period, see Table 2 within the SSI protocol). Superficial incisional SSIs are only followed for a 30-day period for all procedure types. Secondary incisional SSIs are only followed for a 30-day period regardless of the surveillance period for the primary site.
Temperature	See Fever .
Temperature instability	See Vital signs .
Transfer rule	The process of assigning location of attribution when the date of event is on the date of transfer or discharge, or the next day, the infection is attributed to the transferring/discharging location. If the patient was housed in multiple locations within the transfer rule time frame, attribute the infection to the first location in which the patient was housed the day before the infection's date of event.

Term	Definition
	Note: The transfer rule for HAI does not apply to LabID Events.
Vital signs	Clinical measurements used to assess a patient's essential body functions. If a specific vital sign parameter is <u>not</u> stated in a CDC/NHSN HAI definition or criterion (for example, hypotension and temperature instability) the facility should use the vital sign parameter(s) as stated in its policies and procedures for clinical practices. Note: For apnea in ventilated patients < 1 year of age, apnea <u>cannot</u> be determined by changes /adjustments in ventilator settings or by worsening oxygenation.

CDC/NHSN Surveillance Definitions for Specific Types of Infections

Introduction

This chapter contains the CDC/NHSN surveillance definitions and criteria for all specific types of infections. This chapter also provides additional required criteria for the specific infection types that constitute organ space surgical site infections (Refer to Chapter 9 Appendix for specific event types available for organ space SSI attribution for each [NHSN operative procedure category](#)). **Comments and reporting instructions that follow the site-specific criteria provide further explanation and are integral to the correct application of the criteria.** Refer to [Chapter 2 \(Identifying HAIs in NHSN\)](#) for specific guidance for making HAI determinations.

Infection criteria contained in this chapter may be necessary for determining whether a positive blood specimen represents a primary bloodstream infection (BSI) or is secondary to a different type of infection (see Appendix B [Secondary Bloodstream Infection \(BSI\) Guide](#)). A BSI that is identified as secondary to another site of infection must meet one of the infection criteria detailed in this chapter or an eligible infection criterion in the Patient Safety manual and meet other requirements. Secondary BSIs are not reported as Laboratory Confirmed Bloodstream Infections in NHSN, nor can they be associated with the use of a central line.

Not all positive blood specimens are eligible for use as an element in Chapter 17 definitions (specifically for secondary BSI attribution). For example, a single common commensal blood specimen does not meet an LCBI criterion (two matching common commensals along with an eligible symptom) and therefore cannot be used to meet a site-specific criterion nor can it be considered a secondary BSI.

NOTES:

1. See individual protocol chapters for infection criteria for urinary tract infections ([UTI](#)), bloodstream infections ([BSI](#)), pneumonia ([PNEU](#)), ventilator-associated infections ([VAE](#)), and surgical site infections ([SSI](#)).
2. The term physician for the purpose of application of the NHSN criteria may be interpreted to mean a surgeon, infectious disease physician, emergency physician, other physician on the case, or physician's designee (Advanced Practice Nurse [APN], Physician's Assistant [PA]).
3. Examples of "suspected infection" include but are not limited to the following:
 - a. Physician documentation of the suspected infection
 - b. Physician documentation of antimicrobial therapy for a specified infection
 - c. Imaging tests performed on the suspected infection location
 - d. Site-specific specimen collection

4. Organisms identified from implanted devices by culture or non-culture based microbiologic testing methods are eligible for use to meet applicable definitions.
Examples include:
 - a. Vascular graft explanted from a vessel and culture positive can be used to meet VASC 1.
 - b. Screws or other fixation devices removed from bone and culture positive can be used to meet BONE 1.
 - c. Explanted ventricular shunt device and culture positive may be used to meet MEN 1.
 - d. Explanted joint prosthesis that is culture positive may be used to meet PJI element.
5. For NHSN reporting purposes, the term “organism(s)” in this chapter includes viruses.
6. Organisms that primarily cause community-associated infections and are not known to (or rarely) cause healthcare-associated infections, are excluded and cannot be used to meet any NHSN definition.
 - **Fungi:** *Blastomyces*, *Histoplasma*, *Coccidioides*, *Paracoccidioides*, *Cryptococcus*, *Pneumocystis*
 - **Vector-borne bacteria:** *Anaplasma spp.*, *Ehrlichia spp.*, *Borrelia spp.*, *Rickettsia spp.*
7. Antibigrams of the blood and isolates from potential primary sites of infection do not have to match for purposes of determining the source of BSIs (see “matching organisms” below).
8. A **matching organism** is defined as one of the following:
 - a. If genus and species are identified in both specimens, they must be the same.
Example 1: An intraabdominal specimen is used as an element to meet an IAB definition and is growing *Enterobacter cloacae*. A blood specimen with a collection date in the IAB secondary BSI attribution period is reported to be growing *Enterobacter cloacae*. These are considered matching organisms.
Example 2: An intraabdominal specimen is used as an element to meet IAB definition and is growing *Enterococcus faecium*. A blood specimen with a collection date in the IAB secondary BSI attribution period is reported to be growing *Enterococcus faecalis*. These are **NOT** considered matching organisms as the species are different.
 - b. If the organism is less definitively identified in one specimen than the other, the lesser identified organism must be identified to at least the genus level and at that level, the organisms must be the same.
Example 1: A surgical wound growing *Pseudomonas* species is used to meet deep incisional SSI criteria and a blood specimen growing *Pseudomonas aeruginosa* is collected in the SSI secondary BSI attribution period. The organisms are considered matching at the genus level and therefore the BSI is secondary to the SSI.
Example 2: PCR identifying *Enterococcus faecalis* in CSF meets the MEN definition. A subsequent blood culture collected in the MEN secondary BSI attribution period is

identified as *Enterococcus* species. The organisms are considered to be matching and therefore the BSI is secondary to MEN.

- c. There are two exceptions to the definition that involve infections **meeting LCBI 2** criteria with *Staphylococcus* or *Streptococcus*:

Example 1 - (*Staphylococcus*): A patient has a fever and a previous chest tube site is reddened, swollen, and a culture is collected from the soft tissue. The chest tube site culture is reported positive for *Staphylococcus* species. SST/ST definition is met. The next day 2 blood culture sets are collected. The blood cultures are both positive for coagulase-negative *Staphylococcus*. The organisms are NOT considered matching, because *Staphylococcus* species could represent a coagulase-negative or a coagulase-positive *Staphylococcus*. Therefore, the BSI would not be considered secondary to SST/ST.

Example 2 - (*Streptococcus*): A patient has a fever and a previous chest tube is reddened, swollen, and a culture is collected from the soft tissue. The chest tube site culture is reported positive for *Streptococcus* species. SST/ST definition is met. The next day, two blood culture sets are collected. The blood cultures are both positive for *Streptococcus*, viridans group. The organisms are NOT considered matching because *Streptococcus* species could represent a *Streptococcus*, viridans group or non- *Streptococcus*, viridans group. Therefore, the BSI would not be considered secondary to SST/ST.

- d. In cases where an organism is identified only as “yeast” or “yeast not otherwise specified”, the organism can be considered a match to other yeasts, when collected during the required timeframe, whether more fully identified or not.

Example 1: A culture of tissue from the ulcer margin of a decubiti reported positive for yeast is used as an element to meet DECU definition. A blood specimen collected in the secondary BSI attribution period of the DECU is reported as *Candida albicans*. In this example, the two organisms are considered matching organisms as the organisms are complementary (specifically, *Candida* is a type of yeast) and because yeasts isolated from non-sterile sites are commonly not identified to the genus or genus and species level.

NOTE: This exception is limited to yeast. It does not apply to identification of organisms as Gram positive cocci, Gram negative rods, etc.

Example 2: A culture of tissue from ulcer margin of a decubiti reported positive for Gram negative rod is used as an element to meet DECU definition. A blood specimen collected in the secondary BSI attribution period of the DECU is reported as *E. coli*. In this example the two organisms are NOT considered matching organisms.

Examples for Determining Matching Organisms (correct selection for NHSN reporting is bolded)

Identification # 1	Identification # 2	Matching Organisms Yes or No
<i>Bacteroides vulgatus</i>	<i>Bacteroides fragilis</i>	No
<i>Enterococcus faecalis</i>	<i>Enterococcus</i>	Yes
<i>Enterococcus faecium</i>	<i>Enterococcus faecalis</i>	No
<i>Pseudomonas</i> species	<i>Pseudomonas aeruginosa</i>	Yes
Coagulase-negative Staphylococcus	<i>Staphylococcus aureus</i>	No
<i>Staphylococcus epidermidis</i>	Coagulase-negative Staphylococcus	Yes
<i>Staphylococcus</i> species	Coagulase-positive Staphylococcus	No
<i>Streptococcus</i> species	<i>Streptococcus</i> Viridans Group	No
Yeast	<i>Candida</i> species	Yes

Infection criteria used for NHSN healthcare-associated infection surveillance have been grouped into 14 major types with some further categorized into specific infection types. For example, there are three specific types of central nervous system infections (intracranial infection, meningitis or ventriculitis, and spinal abscess/infection) that are grouped under the major type of CNS—Central Nervous System.

Infection criteria are listed in alphabetical order, according to their (abbreviated) major codes, and the criteria for each of the specific types of infection follow it.

Table of Contents

BJ – Bone and Joint Infection	7
BONE – Osteomyelitis	7
DISC – Disc space infection	8
JNT – Joint or bursa infection (not for use as Organ/Space SSI after HPRO or KPRO procedures)	9
PJI – Periprosthetic Joint Infection (for use as Organ/Space SSI following HPRO and KPRO only)	9
CNS – Central Nervous System Infection	10
IC – Intracranial infection (brain abscess, subdural or epidural infection, encephalitis)	10
MEN – Meningitis or ventriculitis	11
SA – Spinal abscess/infection (spinal abscess, spinal subdural or epidural infection)	12
CVS – Cardiovascular System Infection	13
CARD – Myocarditis or pericarditis	13
ENDO – Endocarditis	13
MED – Mediastinitis	13
VASC – Arterial or venous infection excluding infections involving vascular access devices with organisms identified in the blood	14
EENT – Eye, Ear, Nose, Throat, or Mouth Infection	15
CONJ – Conjunctivitis	15
EAR – Ear, mastoid infection	15
EYE – Eye infection, other than conjunctivitis	16
ORAL – Oral cavity infection (mouth, tongue, or gums)	17
SINU – Sinusitis	17
UR – Upper respiratory tract infection, pharyngitis, laryngitis, epiglottitis	18
GI – Gastrointestinal System Infection	18
CDI – <i>Clostridioides difficile</i> Infection	18
GE – Gastroenteritis (excluding <i>C. difficile</i> infections)	19
GIT – Gastrointestinal tract infection (esophagus, stomach, small and large bowel, and rectum) excluding gastroenteritis, appendicitis, and <i>C. difficile</i> infection	20
IAB – Intraabdominal infection, not specified elsewhere, including gallbladder, bile ducts, liver (excluding viral hepatitis), spleen, pancreas, peritoneum, retroperitoneal, subphrenic or subdiaphragmatic space, or other intraabdominal tissue or area not specified elsewhere	21
NEC – Necrotizing enterocolitis	22
LRI – Lower Respiratory System Infection, Other Than Pneumonia	22

LUNG – Other infection of the lower respiratory tract and pleural cavity	22
REPR – Reproductive Tract Infection	23
EMET – Endometritis	23
EPIS – Episiotomy infection	23
OREP – Deep pelvic tissue infection or other infection of the male or female reproductive tract (for example, epididymis, testes, prostate, vagina, ovaries, uterus) including chorioamnionitis, but excluding vaginitis, endometritis or vaginal cuff infections	23
VCUF – Vaginal cuff infection	24
SST-Skin and Soft Tissue Infection	24
BRST – Breast infection or mastitis	24
BURN – Burn infection	25
CIRC – Newborn circumcision infection	25
DECU – Decubitus ulcer infection (also known as pressure injury infection), including both superficial and deep infections	26
SKIN – Skin infection (skin and /or subcutaneous) excluding decubitus ulcers, burns, and infections at vascular access sites	26
ST – Soft tissue infection (muscle and/or fascia [for example, necrotizing fasciitis, infectious gangrene, necrotizing cellulitis, infectious myositis, lymphadenitis, lymphangitis, or parotitis]) excluding decubitus ulcers, burns, and infections at vascular access sites	27
UMB – Omphalitis	27
USI – Urinary System Infection (kidney, ureter, bladder, urethra, or perinephric space excluding UTI [see Chapter 7].)	28

BJ-BONE AND JOINT INFECTION

BONE-Osteomyelitis

When meeting the Osteomyelitis (BONE) definition:

- The BONE Infection Window Period is defined as the 21 days during which all site-specific infection criteria must be met. It includes the date the first positive diagnostic test that is used as an element of the BONE criterion was obtained, the 10 calendar days before, and the 10 calendar days after. The Infection Window Period is lengthened for this event to accommodate the extended diagnostic timeframe that is frequently required to reach a clinical determination of osteomyelitis and the extended antimicrobial treatment timeframes associated with the condition.
- The RIT for Osteomyelitis (BONE) is extended to include the remainder of the patient's current admission.
- When meeting the Osteomyelitis (BONE) definition, the secondary BSI attribution period includes the 21-day infection window period and all subsequent days of the patient's current admission.
 - As a result of this lengthy secondary BSI attribution period, secondary BSI pathogen assignment for BONE is limited to organism(s) identified in blood specimen that match the organism(s) used to meet the BONE definition.
 - If the BONE definition was met using a site-specific specimen (bone culture) or using a blood specimen with *Pseudomonas aeruginosa* as the identified organism and subsequently a blood specimen collected during the BONE secondary BSI attribution period is positive for *Pseudomonas aeruginosa* and *E. coli*, while *Pseudomonas aeruginosa* can be assigned to the BONE event, it cannot be assumed the *E. coli* can be assigned as a secondary BSI pathogen. The blood organism (*E. coli*) does not match the organism (*Pseudomonas aeruginosa*) used to meet BONE definition. If the blood specimen can be used to meet a BONE definition criterion both organisms can be assigned. Otherwise, the *E. coli* will need to be investigated as a separate BSI and identified as a secondary BSI to another site-specific infection or determined to be a primary BSI.

Osteomyelitis must meet at least **one** of the following criteria:

1. Patient has organism(s) identified from bone by culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis and treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
2. Patient has evidence of osteomyelitis on [gross anatomic](#) or histopathologic exam.
3. Patient has at least **two** of the following localized signs or symptoms: fever (>38.0°C), swelling*, pain or tenderness*, heat*, or drainage*

And at least one of the following:

- a. organism(s) identified from blood by culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis and treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).

AND

- imaging test evidence definitive for infection (for example, x-ray, CT scan, MRI, radiolabel scan [gallium, technetium, etc.]), which if equivocal is supported by clinical correlation, specifically, physician or physician designee documentation of antimicrobial treatment for osteomyelitis.
- b. imaging test evidence definitive for infection (for example, x-ray, CT scan, MRI, radiolabel scan [gallium, technetium, etc.]), which if equivocal is supported by clinical correlation, specifically, physician or physician designee documentation of antimicrobial treatment for osteomyelitis.
 - c. physician or physician designee diagnosis of osteomyelitis with documentation of antimicrobial treatment.

** With no other recognized cause*

Reporting Instructions

- Report mediastinitis following cardiac surgery that is accompanied by osteomyelitis as SSI-MED rather than SSI-BONE.
- If a patient meets both organ space JNT and BONE report the SSI as BONE.
- After an HPRO or a KPRO if a patient meets both organ space PJI and BONE report the SSI as BONE.

DISC-Disc space infection

Vertebral disc space infection must meet at least **one** of the following criteria:

1. Patient has organism(s) identified from vertebral disc space by culture or non-culture based microbiologic testing method, which is performed for purposes of clinical diagnosis and treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
2. Patient has evidence of vertebral disc space infection on gross anatomic or histopathologic exam.
3. Patient has at least **one** of the following signs or symptoms: fever (>38.0°C) or pain* at the involved vertebral disc space.

And at least one of the following:

- a. organism(s) identified from blood by culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis and treatment, for example, not Active Surveillance Culture/Testing (ASC/AST)

AND

imaging test evidence definitive for infection (for example, x-ray, CT scan, MRI, radiolabel scan [gallium, technetium, etc.]), which if equivocal is supported by clinical correlation, specifically, physician or physician designee documentation of antimicrobial treatment for vertebral disc space infection.

- b. imaging test evidence definitive for infection (for example, x-ray, CT scan, MRI, radiolabel scan [gallium, technetium, etc.]), which if equivocal is supported by clinical correlation, specifically, physician or physician designee documentation of antimicrobial treatment for vertebral disc space infection.

** With no other recognized cause*

JNT-Joint or bursa infection (not for use as Organ/Space SSI after HPRO or KPRO procedures)

Joint or bursa infections must meet at least **one** of the following criteria:

1. Patient has organism(s) identified from joint fluid or synovial biopsy by culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis and treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
2. Patient has evidence of joint or bursa infection on gross anatomic or histopathologic exam.
3. Patient has a suspected joint or bursa infection and at least two of the following signs or symptoms: swelling*, pain* or tenderness*, heat*, evidence of effusion*, or limitation of motion*.

And at least one of the following:

- a. elevated joint fluid white blood cell count (per reporting laboratory's reference range) **OR** positive leukocyte esterase test strip of joint fluid.
- b. organism(s) and white blood cells seen on Gram stain of joint fluid.
- c. organism(s) identified from blood by culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis and treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
- d. imaging test evidence definitive for infection (for example, x-ray, CT scan, MRI, radiolabel scan [gallium, technetium, etc.]), which if equivocal is supported by clinical correlation, specifically, physician or physician designee documentation of antimicrobial treatment for joint or bursa infection.

* With no other recognized cause

Reporting Instruction

- If a patient meets both organ space JNT and BONE report the SSI as BONE.

PJI – Periprosthetic Joint Infection (for use as Organ/Space SSI following HPRO and KPRO only)

Periprosthetic joint or bursa infections must meet at least **one** of the following criteria:

1. **Two** positive periprosthetic specimens (*tissue or fluid*) with at least one matching organism, identified by culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis and treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
2. A sinus tract* communicating with the joint, purulence, or other gross anatomic evidence of infection.
3. Having **three** of the following minor criteria:
 - a. elevated serum C-reactive protein (CRP; >100 mg/L) **and** erythrocyte sedimentation rate (ESR; >30 mm/hr.)
 - b. elevated synovial fluid white blood cell (WBC; >10,000 cells/μL) count **OR** “++” (*or greater*) change on leukocyte esterase test strip of synovial fluid.
 - c. elevated synovial fluid polymorphonuclear neutrophil percentage (PMN% >90%)
 - d. positive histological analysis of periprosthetic tissue (>5 neutrophils (PMNs) per high power field).

- e. organism(s) identified from a single positive periprosthetic specimen (*tissue or fluid*) by culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis and treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
- f. Synovial fluid alpha-defensin positive.
- g. Physician diagnosis of periprosthetic joint infection.

* A sinus tract is defined as a narrow opening or passageway that can extend in any direction through soft tissue and results in dead space with potential for abscess formation.

Comments:

- A matching organism is defined on page 17-1. Organism(s) identified from hip or knee hardware can be used to meet criterion 1 or a single hardware organism for criterion 3e.

Reporting Instruction

- After an HPRO or a KPRO if a patient meets both organ space PJI and BONE report the SSI as BONE.

CNS-CENTRAL NERVOUS SYSTEM INFECTION

IC-Intracranial infection (brain abscess, subdural or epidural infection, encephalitis)

Intracranial infection must meet at least **one** of the following criteria:

1. Patient has organism(s) identified from brain tissue or dura by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
2. Patient has an abscess or evidence of intracranial infection on gross anatomic or histopathologic exam.
3. Patient has at least **two** of the following signs or symptoms: headache*, dizziness*, fever (>38.0°C), localizing neurologic signs*, changing level of consciousness*, or confusion. *

And at least **one** of the following:

- a. organism(s) seen on microscopic examination of brain or abscess tissue obtained by needle aspiration or during an invasive procedure or autopsy.
 - b. imaging test evidence definitive for infection (for example, ultrasound, CT scan, MRI, radionuclide brain scan, or arteriogram), which if equivocal is supported by clinical correlation, specifically, physician or physician designee documentation of antimicrobial treatment for intracranial infection.
 - c. diagnostic single antibody titer (IgM) or ≥4-fold increase in paired sera (IgG) for organism.
4. Patient ≤1 year of age has at least **two** of the following signs or symptoms: fever (>38.0°C), hypothermia (<36.0°C), apnea*, bradycardia*, localizing neurologic signs*, or changing level of consciousness*, for example, irritability, poor feeding, lethargy.

And at least **one** of the following:

- a. organism(s) seen on microscopic examination of brain or abscess tissue obtained by needle aspiration or during an invasive procedure or autopsy.
- b. imaging test evidence definitive for infection, (for example, ultrasound, CT scan, MRI, radionuclide brain scan, or arteriogram), which if equivocal is supported by clinical correlation,

specifically, physician or physician designee documentation of antimicrobial treatment for intracranial infection.

- c. diagnostic single antibody titer (IgM) or ≥ 4 -fold increase in paired sera (IgG) for organism.

** With no other recognized cause*

Reporting Instructions

- Report as MEN if meningitis (MEN) and encephalitis (IC) are present together.
- Report as IC if meningitis (MEN) and a brain abscess (IC) are present together after operation.
- Report as SA if meningitis (MEN) and spinal abscess/infection (SA) are present together.

MEN-Meningitis or ventriculitis

Meningitis or ventriculitis must meet at least **one** of the following criteria:

1. Patient has organism(s) identified from cerebrospinal fluid (CSF) by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment for example, not Active Surveillance Culture/Testing (ASC/AST).
2. Patient has suspected meningitis or ventriculitis and at least **two** of the following:
 - i. fever ($>38.0^{\circ}\text{C}$) or headache (Note: Elements of “i” alone may not be used to meet the two required elements)
 - ii. meningeal sign(s)*
 - iii. cranial nerve sign(s)*

And at least one of the following:

- a. increased white cells, elevated protein, and decreased glucose in CSF (per reporting laboratory’s reference range).
 - b. organism(s) seen on Gram stain of CSF.
 - c. organism(s) identified from blood by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
 - d. diagnostic single antibody titer (IgM) or ≥ 4 -fold increase in paired sera (IgG) for organism.
3. Patient ≤ 1 year of age has suspected meningitis or ventriculitis and at least **two** of the following elements:
 - i. fever ($>38.0^{\circ}\text{C}$), hypothermia ($<36.0^{\circ}\text{C}$), apnea*, bradycardia*, or irritability* (Note: Elements of “i” alone may not be used to meet the required two elements).
 - ii. meningeal signs*
 - iii. cranial nerve signs*

And at least one of the following:

- a. increased white cells, elevated protein, and decreased glucose in CSF (per reporting laboratory’s reference range).
- b. organism(s) seen on Gram stain of CSF.
- c. organism(s) identified from blood by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
- d. diagnostic single antibody titer (IgM) or ≥ 4 -fold increase in paired sera (IgG) for organism.

** With no other recognized cause*

Reporting Instructions

- Organisms identified from explanted ventricular shunts are eligible for MEN 1.
- Seizures does not meet the cranial nerve sign element for MEN 2 or MEN 3.
- Report CSF shunt infection as SSI-MEN if it occurs within 90 days of placement; if later or after manipulation/access, it is considered CNS-MEN but is not reportable as an SSI.
- Report as MEN if meningitis (MEN) and encephalitis (IC) are present together.
- Report as IC if meningitis (MEN) and a brain abscess (IC) are present together after operation.
- Report as SA if meningitis (MEN) and spinal abscess/infection (SA) are present together.

SA-Spinal abscess/infection (spinal abscess, spinal subdural or epidural infection)

Spinal abscess/infection must meet at least **one** of the following criteria:

1. Patient has organism(s) identified from abscess or from purulent material found in the spinal epidural or subdural space by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
2. Patient has an abscess or other evidence of spinal infection on gross anatomic or histopathologic exam.
3. Patient has at least **one** of the following localized signs or symptoms: fever (>38.0°C), back pain* or tenderness*, radiculitis*, paraparesis*, or paraplegia*

And at least one of the following:

- a. organism(s) identified from blood by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST)

AND

imaging test evidence definitive for spinal abscess/infection, which if equivocal is supported by clinical correlation, specifically, physician or physician designee documentation of antimicrobial treatment for spinal abscess/infection.

- b. imaging test evidence definitive for a spinal abscess/infection (for example, myelography, ultrasound, CT scan, MRI, or other scans [gallium, technetium, etc.]) which if equivocal is supported by clinical correlation, specifically, physician or physician designee documentation of antimicrobial treatment for spinal abscess/infection.

** With no other recognized cause*

Reporting Instruction

- Report as SA if meningitis (MEN) and spinal abscess/infection (SA) are present together after operation.

CVS-CARDIOVASCULAR SYSTEM INFECTION

CARD-Myocarditis or pericarditis

Myocarditis or pericarditis must meet at least **one** of the following criteria:

1. Patient has organism(s) identified from pericardial tissue or fluid by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
2. Patient has at least **two** of the following signs or symptoms: fever ($>38.0^{\circ}\text{C}$), chest pain*, paradoxical pulse*, or increased heart size*

And at least one of the following:

- a. abnormal EKG consistent with myocarditis or pericarditis.
 - b. evidence of myocarditis or pericarditis on histologic exam of heart tissue.
 - c. ≥ 4 -fold rise in paired sera from IgG antibody titer.
 - d. pericardial effusion identified by echocardiogram, CT scan, MRI, or angiography.
3. Patient ≤ 1 year of age has at least **two** of the following signs or symptoms: fever ($>38.0^{\circ}\text{C}$), hypothermia ($<36.0^{\circ}\text{C}$), apnea*, bradycardia*, paradoxical pulse*, or increased heart size*

And at least one of the following:

- a. abnormal EKG consistent with myocarditis or pericarditis.
- b. histologic examination of heart tissue shows evidence of myocarditis or pericarditis.
- c. ≥ 4 -fold rise in paired sera from IgG antibody titer.
- d. pericardial effusion identified by echocardiogram, CT scan, MRI, or angiography.

* With no other recognized cause

ENDO-Endocarditis – Please see [ENDO Appendix](#)

MED-Mediastinitis

Mediastinitis must meet at least **one** of the following criteria:

1. Patient has organism(s) identified from mediastinal tissue or mediastinal fluid by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
2. Patient has evidence of mediastinitis on gross anatomic or histopathologic exam.
3. Patient has at least **one** of the following signs or symptoms: fever ($>38.0^{\circ}\text{C}$), chest pain*, or sternal instability*.

And at least one of the following:

- a. purulent drainage from mediastinal area
 - b. mediastinal widening on imaging test
4. Patient ≤ 1 year of age has at least **one** of the following signs or symptoms: fever ($>38.0^{\circ}\text{C}$), hypothermia ($<36.0^{\circ}\text{C}$), apnea*, bradycardia*, or sternal instability*

And at least one of the following:

- a. purulent drainage from mediastinal area.
- b. mediastinal widening on imaging test.

* *With no other recognized cause*

Comment:

- The mediastinal space is the area under the sternum and in front of the vertebral column, containing the heart and its large vessels, trachea, esophagus, thymus, lymph nodes, and other structures and tissues. It is divided into anterior, middle, posterior, and superior regions.

Reporting Instruction

- Report mediastinitis (MED) following cardiac surgery that is accompanied by osteomyelitis as SSI-MED rather than SSI-BONE.
- MED 4b: Mediastinal stranding, mediastinal fluid collection, mediastinal edema, and mediastinal abscess are eligible imaging findings to meet the “mediastinal widening on imaging test” element.

VASC-Arterial or venous infection excluding infections involving vascular access devices with organisms identified in the blood

Note: If a patient meets the criteria for an LCBI in the presence of an arterial or vascular infection (VASC) report as an LCBI not as a VASC. **

Arterial or venous infection must meet at least **one** of the following criteria:

1. Patient has organism(s) from extracted arteries or veins identified by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
2. Patient has evidence of arterial or venous infection on gross anatomic or histopathologic exam.
3. Patient has at least **one** of the following signs or symptoms: fever (>38.0°C), pain*, erythema*, or heat at involved vascular site*

AND

More than 15 colonies cultured from intravascular cannula tip using semi-quantitative culture method.

4. Patient has purulent drainage at involved vascular site.
5. Patient ≤1 year of age has at least **one** of the following signs or symptoms: fever (>38.0°C), hypothermia (<36.0°C), apnea*, bradycardia*, lethargy*, pain*, erythema*, or heat at involved vascular site*

AND

More than 15 colonies cultured from intravascular cannula tip using semi-quantitative culture method.

* *With no other recognized cause*

Reporting Instructions

- Report infections of an arteriovenous graft, shunt, fistula, or intravascular cannulation site without organism(s) identified from blood as CVS-VASC.
- Report Organ Space VASC infections as an SSI and not an LCBI when you have an SSI with secondary BSI.
- Report intravascular infections with organism(s) identified from the blood and meeting the LCBI criteria, as BSI-LCBI.

** Occasionally, a patient with both an eligible central line and another vascular access device will have pus at the other access site. If there is pus at the site of one of the following vascular access devices and a specimen collected from that site has at least one matching organism to an organism identified in the blood during the BSI IWP, report such events marking the “pus at the vascular access site” field as “Yes.” Vascular access devices included in this exception are limited to:

- Arterial catheters unless in the pulmonary artery, aorta or umbilical artery
- Arteriovenous fistulae
- Arteriovenous grafts
- Hemodialysis reliable outflow (HERO) dialysis catheters
- Intra-aortic balloon pump (IABP) devices
- Non-accessed CL (those neither inserted nor used during current admission)
- Peripheral IV or Midlines

EENT-EYE, EAR, NOSE, THROAT, OR MOUTH INFECTION

CONJ-Conjunctivitis

1. Patient has at least **one** of the following signs or symptoms: pain, erythema, or swelling of conjunctiva or around eye.

And at least one of the following:

- a. Patient has organism(s) identified from conjunctival scraping or purulent exudate obtained from the conjunctiva or contiguous tissues, (for example, eyelid, cornea, meibomian glands, or lacrimal glands) by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
- b. WBCs and organism(s) seen on Gram stain of exudate.
- c. purulent exudate.
- d. multinucleated giant cells seen on microscopic examination of conjunctival exudate or scrapings.
- e. diagnostic single antibody titer (IgM) or ≥ 4 -fold increase in paired sera (IgG) for organism.

Reporting Instructions

- Report other infections of the eye as EYE.
- Do not report chemical conjunctivitis, caused by silver nitrate (AgNO_3), as a healthcare-associated infection.
- Do not report a separate case of conjunctivitis (CONJ) that occurs as a part of another viral illness (for example, UR).

EAR-Ear, mastoid infection

Ear and mastoid infections must meet at least **one** of the following criteria:

Otitis externa must meet at least **one** of the following criteria:

1. Patient has organism(s) identified from purulent drainage from ear canal by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).

2. Patient has at least **one** of the following: fever ($>38.0^{\circ}\text{C}$), pain*, or erythema*
AND
Organism(s) seen on Gram stain of purulent drainage from ear canal.

Otitis media must meet at least **one** of the following criteria:

3. Patient has organism(s) identified from fluid from middle ear obtained during an invasive procedure (for example, tympanocentesis) by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
4. Patient has at least **two** of the following: fever ($>38.0^{\circ}\text{C}$), pain *, inflammation*, retraction* or decreased mobility of eardrum*, or fluid behind eardrum*.

Otitis interna (labyrinthitis) must meet at least **one** of the following criteria:

5. Patient has organism(s) identified from fluid from inner ear obtained during an invasive procedure by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
6. Patient has a physician or physician designee diagnosis of inner ear infection.

Mastoiditis must meet at least **one** of the following criteria:

7. Patient has organism(s) identified from fluid or tissue from mastoid by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example not Active Surveillance Culture/Testing (ASC/AST).
8. Patient has at least **two** of the following: fever ($>38.0^{\circ}\text{C}$), pain or tenderness*, post auricular swelling*, erythema*, headache*, or facial paralysis*.
And at least one of the following:
 - a. organism(s) seen on Gram stain of fluid or tissue from mastoid.
 - b. imaging test evidence definitive for infection (for example, CT scan), which if equivocal is supported by clinical correlation, specifically, physician or physician designee documentation of antimicrobial treatment for mastoid infection.

** With no other recognized cause*

EYE-Eye infection, other than conjunctivitis

An infection of the eye, other than conjunctivitis, must meet at least **one** of the following criteria:

1. Patient has organism(s) identified from anterior or posterior chamber or vitreous fluid by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
2. Patient has at least **two** of the following signs or symptoms with no other recognized cause: eye pain*, visual disturbance*, or hypopyon*

AND

Physician or physician designee initiates antimicrobial therapy within **two** days of onset or worsening of symptoms.

** With no other recognized cause*

ORAL-Oral cavity infection (mouth, tongue, or gums)

Oral cavity infections must meet at least **one** of the following criteria:

1. Patient has organism(s) identified from abscess or purulent material from tissues of oral cavity by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
2. Patient has an abscess or other evidence of oral cavity infection found on invasive procedure, gross anatomic exam, or histopathologic exam.
3. Patient has at least **one** of the following signs or symptoms with no other recognized cause: ulceration, raised white patches on inflamed mucosa, or plaques on oral mucosa.

And at least one of the following:

- a. virus identified from mucosal scrapings or exudate by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST)
- b. multinucleated giant cells seen on microscopic examination of mucosal scrapings or exudate
- c. diagnostic single antibody titer (IgM) or ≥ 4 -fold increase in paired sera (IgG) for organism.
- d. fungal elements seen on microscopic exam of mucosal scrapings or exudate (for example, Gram stain, KOH).
- e. Physician or physician designee initiates antimicrobial therapy within 2 days of onset or worsening of symptoms.

Reporting Instruction

- Report healthcare-associated primary herpes simplex infections of the oral cavity as ORAL; recurrent herpes infections are not healthcare associated.

SINU-Sinusitis

Sinusitis must meet at least **one** of the following criteria:

1. Patient has organism(s) identified from fluid or tissue from the sinus cavity obtained during an invasive procedure by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
2. Patient has at least **one** of the following signs or symptoms: fever ($>38.0^{\circ}\text{C}$), pain or tenderness over the involved sinus*, headache*, purulent exudate*, or nasal obstruction*

AND

Imaging test evidence of sinusitis (for example, x-ray, CT scan).

* With no other recognized cause

UR-Upper respiratory tract infection, pharyngitis, laryngitis, epiglottitis

Upper respiratory tract infections must meet at least **one** of the following criteria:

1. Patient has at least **two** of the following signs or symptoms: fever ($>38.0^{\circ}\text{C}$), erythema of pharynx*, sore throat*, cough*, hoarseness*, tachypnea*, nasal discharge*, or purulent exudate in throat*
And at least one of the following:
 - a. organism(s) identified from upper respiratory site (specifically: nasal cavity, larynx, nasopharynx, pharynx, and epiglottis) by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST). Note: excludes sputum and tracheal aspirate because these are not upper respiratory specimens.
 - b. diagnostic single antibody titer (IgM) or ≥ 4 -fold increase in paired sera (IgG) for organism.
 - c. Physician or physician designee diagnosis of an upper respiratory infection.
2. Patient has an abscess on gross anatomical or histopathologic exam or imaging test.
3. Patient ≤ 1 year of age has at least **two** of the following signs or symptoms: fever ($>38.0^{\circ}\text{C}$), hypothermia ($<36.0^{\circ}\text{C}$), apnea*, bradycardia*, nasal discharge*, or purulent exudate in throat*
And at least one of the following:
 - a. organism(s) identified from upper respiratory site (specifically: nasal cavity, larynx, nasopharynx, pharynx, and epiglottis) by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST). Note: excludes sputum and tracheal aspirate because they are not upper respiratory specimens.
 - b. diagnostic single antibody titer (IgM) or ≥ 4 -fold increase in paired sera (IgG) for organism.
 - c. physician or physician designee diagnosis of an upper respiratory infection.

* With no other recognized cause

GI-GASTROINTESTINAL SYSTEM INFECTION

CDI- *Clostridioides difficile* Infection

Clostridioides difficile infection must meet at least **one** of the following criteria:

1. Positive test for toxin-producing *C. difficile* on an unformed stool specimen (conforms to the shape of the container).
2. Patient has evidence of pseudomembranous colitis on gross anatomic (includes endoscopic exams) or histopathologic exam.

Note:

- When using a multi-testing methodology for CD identification, the result of the last test finding, which is placed onto the patient medical record, will determine if GI-CDI criterion 1 is met.

Comments:

- The date of event for CDI criterion 1 will always be the specimen collection date of the unformed stool, specifically, not the date of onset of unformed stool.

- A positive test for toxin-producing *C. difficile* and an unformed stool specimen is a single element, and both are required to meet criterion.

Reporting Instructions

- Report the CDI and the GE or GIT if additional enteric organism(s) are identified and criteria are met for GE or GIT.
- Report each new GI-CDI according to the Repeat Infection Timeframe (RIT) rule for HAIs (see NHSN HAI definitions in [Chapter 2](#) for further details and guidance).
- CDI laboratory-identified event (LabID Event) categorizations (for example, recurrent CDI assay, incident CDI assay, healthcare facility-onset, community-onset, community-onset healthcare facility-associated) do **not** apply to HAIs, including *C. difficile* associated gastrointestinal infections (GI-CDI).

GE-Gastroenteritis (excluding *C. difficile* infections)

Gastroenteritis must meet at least one of the following criteria:

1. Patient has an acute onset of diarrhea (liquid stools for > 12 hours) with no likely noninfectious cause (for example, diagnostic tests, therapeutic regimen other than antimicrobial agents, acute exacerbation of a chronic condition, or psychological stress information).
2. Patient has at least two of the following signs or symptoms: nausea*, vomiting*, abdominal pain*, fever (>38.0°C), or headache*

And at least one of the following:

- a. an enteric pathogen is identified from a stool or rectal swab by culture or a non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
- b. an enteric pathogen is detected by microscopy on stool.
- c. diagnostic single antibody titer (IgM) or ≥4-fold increase in paired sera (IgG) for organism.

* With no other recognized cause

Comment:

- The reference to “enteric pathogens” describes pathogens that are not considered to be normal flora of the intestinal tract. Enteric pathogens identified on culture or with the use of other diagnostic laboratory tests include *Salmonella*, *Shigella*, *Yersinia*, *Campylobacter*, *Listeria*, *Vibrio*, STEC: Shiga toxin-producing *E. coli*, ETEC: Enterotoxigenic *E. coli*, EPEC: Enteropathogenic *E. coli*, EIEC: Enteroinvasive *E. coli*, EAEC: Enteroaggregative *E. coli*, DAEC: Diffusely adherent *E. coli*, or *Giardia*.

Reporting Instruction

- Report only GI-GIT using the event date as that of GI-GIT if the patient meets criteria for both GI-GE and GI-GIT.

GIT-Gastrointestinal tract infection (esophagus, stomach, small and large bowel, and rectum) excluding gastroenteritis, appendicitis, and *C. difficile* infection

Gastrointestinal tract infections, excluding gastroenteritis and appendicitis, must meet at least **one** of the following criteria:

1. Patient has one of the following:

- a. an abscess or other evidence of gastrointestinal tract infection on gross anatomic or histopathologic exam.
- b. abscess or other evidence of gastrointestinal tract infection on gross anatomic or histopathologic exam (See Reporting Instructions)

AND

organism(s) identified from blood by a culture or non-culture based microbiologic testing method, which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST). The organism(s) identified in the blood must contain at least one MBI organism from the [NHSN Terminology Browser](#).

2. Patient has at least **two** of the following signs or symptoms compatible with infection of the organ or tissue involved: fever (>38.0°C), nausea*, vomiting*, pain* or tenderness*, odynophagia*, or dysphagia*

And at least one of the following:

- a. organism(s) identified from drainage or tissue obtained during an invasive procedure or from drainage from an aseptically placed drain by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
- b. organism(s) seen on Gram stain or fungal elements seen on KOH stain or multinucleated giant cells seen on microscopic examination of drainage or tissue obtained during an invasive procedure or from drainage from an aseptically placed drain.
- c. organism(s) identified from blood by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST). The organism(s) identified in the blood must contain at least one MBI organism from the [NHSN Terminology Browser](#).

AND

imaging test evidence definitive for gastrointestinal infection (for example, endoscopic exam, MRI, CT scan), which if equivocal is supported by clinical correlation, specifically, physician or physician designee documentation of antimicrobial treatment for gastrointestinal tract infection.

- d. imaging test evidence definitive for gastrointestinal infection (for example, endoscopic exam, MRI, CT scan), which if equivocal is supported by clinical correlation, specifically, physician or physician designee documentation of antimicrobial treatment for gastrointestinal tract infection.

* With no other recognized cause

Reporting Instructions

- Report only GI-GIT using the event date as that of GI-GIT if the patient meets criteria for both GI-GE and GI-GIT.
- For GIT 1b: If an organism is identified on histopathologic exam, the blood specimen must contain a matching organism.
- In patients > 1 year, pneumatosis intestinalis is considered an equivocal imaging finding for a gastrointestinal tract infection (GIT). For patients ≤ 1 year, please review the NEC criteria.

IAB-Intraabdominal infection, not specified elsewhere, including gallbladder, bile ducts, liver (excluding viral hepatitis), spleen, pancreas, peritoneum, retroperitoneal, subphrenic or subdiaphragmatic space, or other intraabdominal tissue or area not specified elsewhere

Intraabdominal infections must meet at least **one** of the following criteria:

1. Patient has organism(s) identified from an abscess or from purulent material from intraabdominal space by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
2. Patient has at least one of the following:
 - a. abscess or other evidence of intraabdominal infection on gross anatomic or histopathologic exam.
 - b. abscess or other evidence of intraabdominal infection on gross anatomic or histopathologic exam. (See Reporting Instructions)
3. Patient has at least **two** of the following signs or symptoms: fever (>38.0°C), hypotension, nausea*, vomiting*, abdominal pain or tenderness*, elevated transaminase level(s)*, or jaundice*

AND

organism(s) identified from blood by a culture or non-culture based microbiologic testing method, which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST). The organism(s) identified in the blood must contain at least one MBI organism from the [NHSN Terminology Browser](#).

And at least one of the following:

- a. organism(s) seen on Gram stain and/or identified from intraabdominal fluid or tissue obtained during invasive procedure or from an aseptically-placed drain in the intraabdominal space (for example, closed suction drainage system, open drain, T-tube drain, CT guided drainage) by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
- b. organism(s) identified from blood by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST). The organism(s) identified in the blood must contain at least one MBI organism from the [NHSN Terminology Browser](#).

AND

imaging test evidence definitive for infection (for example, ultrasound, CT scan, MRI, ERCP, radiolabel scans [gallium, technetium, etc.] or on abdominal x-ray), which if equivocal is supported by clinical correlation, specifically, physician or physician designee documentation of antimicrobial treatment for intraabdominal infection. [†]

* With no other recognized cause

Reporting Instructions

- †Biliary ductal dilatation is considered an equivocal finding for cholangitis.
- For IAB 2b: If an organism is identified on histopathologic exam, the blood specimen must contain a matching organism to the organism identified on histopathologic exam.
- Do not report pancreatitis (an inflammatory syndrome characterized by abdominal pain, nausea, and vomiting associated with high serum levels of pancreatic enzymes) unless it is determined to be infectious in origin.
- Eligible laboratory results that represent transaminase levels include: serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), alanine transaminase (ALT) or aspartate transaminase (AST). Consider the requirement for elevated transaminase level(s) met if at least one is elevated as per the normal range provided by the laboratory.

NEC-Necrotizing enterocolitis (*See Chapter 4*)

Necrotizing enterocolitis (NEC) criteria include neither a site-specific specimen nor organism identified from blood specimen. The pathophysiology of NEC is multifactorial. NEC definitions are provided to facilitate the provision of an exception for assigning a BSI secondary to NEC and should not be used for HAI surveillance as they are not designed, tested, or intended for this purpose.

LRI- LOWER RESPIRATORY INFECTION, OTHER THAN PNEUMONIA

LUNG-Other infection of the lower respiratory tract and pleural cavity

Other infections of the lower respiratory tract must meet at least **one** of the following criteria:

1. Patient has organism(s) seen on Gram stain of lung tissue or pleural fluid or identified from lung tissue or pleural fluid* (when pleural fluid was obtained during thoracentesis or within 24 hours of chest tube placement) by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
2. Patient has a lung abscess or other evidence of infection (for example, empyema) on gross anatomic or histopathologic exam.
3. Patient has imaging test evidence of abscess or infection (excludes imaging test evidence of pneumonia) which if equivocal is supported by clinical correlation, specifically, physician or physician designee documentation of antimicrobial treatment for lung infection).

Reporting Instruction

- If patient meets LUNG and PNEU report as PNEU only, unless the LUNG is a surgical site organ/space infection, in which case, report both PNEU and SSI-LUNG.
- Lung tissue or pleural fluid are the only specimens eligible for LUNG.
- Lower respiratory tract secretions (such as sputum, endotracheal/tracheal aspirate, bronchoalveolar lavage) **are not** eligible for LUNG.

*If a pleural fluid specimen is collected after a chest tube is repositioned **OR** after 24 hours of chest tube placement, this pleural fluid specimen is not eligible for LUNG 1. Repositioning must be documented in the patient record by a healthcare professional.

REPR-REPRODUCTIVE TRACT INFECTION

EMET-Endometritis

Endometritis must meet at least **one** of the following criteria:

1. Patient has organism(s) identified from endometrial fluid or tissue by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
2. Patient has **suspected endometritis** with at least **two** of the following signs or symptoms: fever (>38.0°C), pain or tenderness (uterine or abdominal) *, or purulent drainage from uterus.

** With no other recognized cause*

Reporting Instructions

- Do not report an HAI chorioamnionitis as EMET (see OREP).
- Do not report subsequent postpartum endometritis after a vaginal delivery as an HAI if a patient is admitted with POA chorioamnionitis (OREP). (See next bullet for endometritis following a C-section).
- Report as an organ space SSI-EMET if a C-section was performed on a patient with chorioamnionitis and the patient later develops endometritis.

EPIS-Episiotomy infection

Episiotomy infections must meet at least **one** of the following criteria:

1. Postvaginal delivery patient has purulent drainage from the episiotomy site.
2. Postvaginal delivery patient has an episiotomy abscess.

OREP- Pelvic tissue/space infection or other infection of the male or female reproductive tract (for example, epididymis, testes, prostate, vagina, ovaries, uterus) including chorioamnionitis, but excluding vaginitis, endometritis or vaginal cuff infections

Other infections of the male or female reproductive tract must meet at least **one** of the following criteria:

1. Patient has organism(s) identified from tissue or fluid from one of the specified OREP sites (excludes urine and vaginal swabs) by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).

2. Patient has an abscess or other evidence of infection of affected site on gross anatomic or histopathologic exam.
3. Patient has **suspected infection** of one of the listed OREP sites and **two** of the following localized signs or symptoms: fever (>38.0°C), nausea*, vomiting*, pain or tenderness*, or dysuria*

And at least one of the following:

- a. organism(s) identified from blood by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
- b. physician or physician designee initiates antimicrobial therapy within **two** days of onset or worsening of symptoms.

** With no other recognized cause*

Reporting Instructions

- Report endometritis as EMET.
- Report vaginal cuff infections as VCUF.
- If the patient meets for an OREP (HAI or organ/space SSI) and UTI criterion, report both events.

VCUF-Vaginal cuff infection (following HYST and VHYS procedures ONLY)

Vaginal cuff infections must meet at least **one** of the following criteria:

1. Purulent drainage from the vaginal cuff on gross anatomic exam.
2. Abscess or other evidence of infection at the vaginal cuff on gross anatomic exam.
3. Organism(s) identified from fluid or tissue obtained from the vaginal cuff by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).

Reporting Instruction

- Report vaginal cuff infections as SSI-VCUF.

SST-SKIN AND SOFT TISSUE INFECTION

BRST-Breast infection or mastitis

A breast abscess or mastitis must meet at least **one** of the following criteria:

1. Patient has organism(s) identified from affected breast tissue or fluid obtained by invasive procedure or from drainage from an aseptically-placed drain by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
2. Patient has a breast abscess or other evidence of infection on gross anatomic or histopathologic exam.
3. Patient has fever (>38.0°C) and local inflammation of the breast,

AND

Physician or physician designee initiates antimicrobial therapy within 2 days of onset or worsening of symptoms.

Reporting Instructions

- For SSI after a BRST procedure: if the infection is in the subcutaneous region report as a superficial incisional SSI, and if the infection involves the muscle/fascial level report as a deep incisional SSI.
- BRST Criterion '3' is not eligible as an Organ/Space SSI following a BRST procedure.

BURN-Burn infection

Burn infections must meet the following criteria:

1. Patient has a change in burn wound appearance or character such as rapid eschar separation, or dark brown, black, or violaceous discoloration of the eschar,

AND

Organism(s) identified from blood by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).

Reporting Instructions

- Report BURN in the setting of an infected burn covered with a temporary graft or dressing.
- In the setting of a permanent skin graft (autograft) over a burn wound, use the SKIN or ST criteria.

CIRC-Newborn circumcision infection

Circumcision infection in a newborn (≤ 30 days old) must meet at least one of the following criteria:

1. Newborn has purulent drainage from circumcision site.
2. Newborn has at least one of the following signs or symptoms at circumcision site: erythema*, swelling*, or tenderness*,

AND

Pathogen identified from circumcision site by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).

3. Newborn has at least one of the following signs or symptoms at circumcision site: erythema*, swelling*, or tenderness*,

AND

Common commensal is identified from circumcision site by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST),

AND

Physician or physician designee initiates antimicrobial therapy within two days of onset or worsening of symptoms.

* With no other recognized cause

DECU-Decubitus ulcer infection (also known as pressure injury infection), including both superficial and deep infections

Decubitus ulcer infections must meet the following criterion:

1. Patient has at least **two** of the following signs or symptoms: erythema*, tenderness*, or swelling of decubitus wound edges*,

AND

Organism(s) identified from needle aspiration of fluid or biopsy of tissue from decubitus ulcer margin by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).

** With no other recognized cause*

SKIN-Skin infection (skin and/or subcutaneous) excluding decubitus ulcers, burns, and infections at vascular access sites (See [VASC](#)).

Skin infections must meet at least **one** of the following criteria:

1. Patient has at least **one** of the following:
 - purulent drainage
 - pustules
 - vesicles
 - boils (excluding acne)
2. Patient has at least **two** of the following localized signs or symptoms: pain* or tenderness*, swelling*, erythema*, or heat*

And at least one of the following:

- a. organism(s) identified from aspirate or drainage from affected site by a culture or non-culture based testing method which is performed for purposes of clinical diagnosis and treatment for example, not Active Surveillance Culture/Testing (ASC/AST). Identification of two or more common commensal organisms without a recognized pathogen is not eligible for use. Common commensal organisms include, but not are not limited to, diphtheroids (*Corynebacterium* spp. not *C. diphtheria*), *Bacillus* spp. (not *B. anthracis*), *Propionibacterium* spp., coagulase-negative staphylococci (including *S. epidermidis*), viridans group streptococci, *Aerococcus* spp., *Micrococcus* spp., and *Rhodococcus* spp. Common commensals can be accessed from the [NHSN Terminology Browser](#).
- b. multinucleated giant cells seen on microscopic examination of affected tissue.
- c. diagnostic single antibody titer (IgM) or ≥4-fold increase in paired sera (IgG) for organism.

** With no other recognized cause*

Reporting Instructions

- Do not report acne as a skin/soft tissue HAI.
- Report SKIN or ST criteria in the setting of a permanent skin graft (autograft) over a burn wound.
- Apply the site-specific definition (not SKIN) for the following:
 - Report omphalitis in infants as UMB.

- Report infections of the circumcision site in newborns as CIRC.
- For decubitus ulcers, apply the DECU infection.
- Report infected burns as BURN.
- Report a burn covered with a temporary graft or dressing that is infected as BURN.
- Report breast abscesses or mastitis as HAI BRST. If a breast infection is identified after an NHSN operative procedure, assess for an SSI.
- Report localized infection at a vascular access site as a VASC unless there is an organism identified from blood, meeting LCBI criteria, which should instead be reported as an LCBI (see VASC definition).

ST-Soft tissue infection (muscle and/or fascia [for example, necrotizing fasciitis, infectious gangrene, necrotizing cellulitis, infectious myositis, lymphadenitis, lymphangitis, or parotitis]) excluding decubitus ulcers, burns, and infections at vascular access sites (See [VASC](#)).

Soft tissue infections must meet at least **one** of the following criteria:

1. Patient has organism(s) identified from tissue or drainage from affected site by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
2. Patient has purulent drainage at affected site.
3. Patient has an abscess or other evidence of infection on gross anatomic or histopathologic exam.

Reporting Instructions

- Report SKIN or ST criteria in the setting of a permanent skin graft (autograft) over a burn wound.
- Apply the site-specific definitions identified below (not ST) for the following:
 - Report infected decubitus ulcers as DECU.
 - Report infected burns as BURN. Report a burn covered with a temporary graft or dressing that is infected as BURN.
 - Report breast abscesses or mastitis as BRST. If a breast infection is identified after an NHSN operative procedure, assess for an SSI.
 - Report infection of deep pelvic tissues as OREP.
 - Report localized infection at a vascular access site as a VASC unless there is an organism identified from blood, then it should be reported as an LCBI (see [VASC](#) definition).

UMB-Omphalitis

Omphalitis in a newborn (≤ 30 days old) must meet at least **one** of the following criteria:

1. Patient has erythema or drainage from umbilicus.

And at least one of the following:

- a. organism(s) identified from drainage or needle aspirate by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST)
- b. organism(s) identified from blood by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).

2. Patient has erythema and purulence at the umbilicus.

Reporting instruction

- Report infection of the umbilical artery or vein related to umbilical catheterization as VASC if there is no accompanying organism identified from blood specimen. However, if the patient meets criteria for LCBI, report as a LCBI (see [VASC](#)).
- Catheterized umbilical venous catheter (UVC) or umbilical arterial catheter (UAC) sites are not eligible for UMB criteria.

USI – URINARY SYSTEM INFECTION (kidney, ureter, bladder, urethra, or perinephric space excluding UTI [see Chapter 7].)

Urinary system infections must meet at least one of the following criteria:

1. Patient has organism(s) identified from fluid (not urine) or tissue from affected site by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST)
2. Patient has an abscess or other evidence of infection on gross anatomical exam, during invasive procedure, or on histopathologic exam.
3. Patient has one of the following signs or symptoms:

- fever ($>38.0^{\circ}\text{C}$)
- localized pain or tenderness*

And at least one of the following:

- a. purulent drainage from affected site
- b. organism(s) identified from blood by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).

AND

imaging test evidence definitive for infection, for example, ultrasound, CT scan, magnetic resonance imaging [MRI], or radiolabel scan [gallium, technetium]), which if equivocal is supported by clinical correlation, specifically, physician or physician designee documentation of antimicrobial treatment for urinary system infection.

4. Patient ≤ 1 year of age has at least one of the following signs or symptoms:

- fever ($>38.0^{\circ}\text{C}$)
- hypothermia ($<36.0^{\circ}\text{C}$)
- apnea*
- bradycardia*
- lethargy*
- vomiting*

And at least one of the following:

- a. purulent drainage from affected site
- b. organism(s) identified from blood by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).

AND

imaging test evidence definitive for infection, for example, ultrasound, CT scans, magnetic resonance imaging [MRI], or radiolabel scan [gallium, technetium]), which if equivocal is supported by clinical correlation, specifically, physician or physician designee documentation of antimicrobial treatment for urinary system infection.

** With no other recognized cause*

Reporting Instructions

- Report infections following circumcision in newborns as SST-CIRC.

ENDO Appendix

ENDO - Endocarditis

When meeting the Endocarditis (ENDO) definition:

- *The ENDO Infection Window Period is defined as the 21 days during which all site-specific infection criteria must be met. It includes the date the first positive diagnostic test that is used as an element of the ENDO criterion was obtained, the 10 calendar days before, and the 10 calendar days after. The Infection Window Period is lengthened for this event to accommodate the extended diagnostic timeframe that is frequently required to reach a clinical determination of endocarditis.*
- *The RIT for Endocarditis (ENDO) is extended to include the remainder of the patient's current admission.*
- *When meeting the Endocarditis (ENDO) definition, the secondary BSI attribution period includes the 21-day infection window period **and all subsequent days of the patient's current admission.***
 - *As a result of this lengthy secondary BSI attribution period, secondary BSI pathogen assignment for ENDO is limited to organism(s) identified in blood specimen that match the organism(s) used to meet the ENDO definition.*
 - *Example: If the ENDO definition was met using a site-specific specimen (for example, cardiac vegetation) or using a blood specimen with *S. aureus* as the identified organism, if a blood specimen collected during the ENDO secondary BSI attribution period is positive for *S. aureus* and *E. coli*, while the *S. aureus* can be assigned to the ENDO event, it cannot be assumed the *E. coli* can be assigned as a secondary BSI pathogen. The blood organism (*E. coli*) does not match the organism (*S. aureus*) used to meet the ENDO definition. If the blood specimen can be used to meet an ENDO definition criterion both organisms can be assigned. Otherwise, the *E. coli* will need to be investigated as a separate BSI and identified as a secondary BSI to another site-specific infection or determined to be a primary BSI.*

Endocarditis of a natural or prosthetic heart valve must meet at least **one** of the following criteria:

ENDO 1 ¹		
Organism(s) identified from cardiac vegetation ² , cardiac tissue, explanted prosthetic valve or sewing ring, ascending aortic graft (with evidence of valve involvement ³), endovascular intracardiac implantable electronic device (CIED), or arterial embolus by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).		
ENDO 2		
Endocarditis ⁴ seen on histopathologic examination of cardiac vegetation, cardiac tissue, explanted prosthetic valve, or sewing ring, ascending aortic graft (with evidence of valve involvement ³), endovascular intracardiac implantable electronic device (CIED), or embolus by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).		
ENDO 3		
Intraoperative evidence of endocarditis on gross anatomical exam during a cardiac operative procedure.		
ENDO 4		
At least <u>one</u> of the following echocardiographic or cardiac CT imaging test evidence of endocarditis ⁵ :		At least <u>one</u> of the following 18 F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) imaging test(s) shows evidence of endocarditis ⁵ :
i. vegetation on cardiac valve or supporting structures² ii. valvular/leaflet perforation iii. valvular/leaflet aneurysm iv. perivalvular or peri graft abscess v. pseudoaneurysm vi. intracardiac fistula vii. significant new valvular regurgitation as compared with previous imaging (on echocardiography only)⁶ viii. new partial dehiscence of prosthetic valve (compared with previous imaging)	<u>OR</u>	ix. abnormal metabolic activity involving a native or prosthetic valve⁷, ascending aortic graft (with evidence of valve involvement), intracardiac device leads or other intracardiac prosthetic material >3 months after cardiac surgery. x. abnormal metabolic activity ≤3 months after implantation of prosthetic valve⁷, ascending aortic graft (with evidence of valve involvement), intracardiac device leads or other intracardiac prosthetic material.

AND

At least <u>one</u> of the following:	
a. typical infectious endocarditis organism(s): <i>Staphylococcus aureus</i> , <i>Staphylococcus lugdunensis</i> , <i>Enterococcus faecalis</i> , all streptococcal species (except for <i>Streptococcus pneumoniae</i> and <i>Streptococcus pyogenes</i>), <i>Granulicatella</i> spp., <i>Abiotrophia</i> spp., <i>Gemella</i> spp., HACEK group microorganisms (<i>Haemophilus</i> species, <i>Aggregatibacter actinomycetemcomitans</i> , <i>Cardiobacterium hominis</i> , <i>Eikenella corrodens</i> , and <i>Kingella kingae</i>) identified from ≥2 matching blood collections drawn on separate occasions with no more than 1 calendar day between specimen collection by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).	

- b. typical infectious endocarditis organism(s) in the presence of prosthetic material: *coagulase-negative Staphylococci*, *Corynebacterium striatum*, *Corynebacterium jeikeium*, *Serratia marcescens*, *Pseudomonas aeruginosa*, *Cutibacterium acnes*, non-tuberculous mycobacteria, and *Candida* spp. identified from ≥ 2 matching blood collections drawn on separate occasions with no more than 1 calendar day between specimen collection by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
- c. non-typical infectious endocarditis organism(s) identified from ≥ 3 matching blood collections drawn on separate occasions with no more than 1 calendar day between specimen collection by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
- d. *Coxiella burnetii* identified by anti-phase I IgG antibody titer $>1:800$ or identified from a single blood by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
- e. indirect immunofluorescence assays (IFA) for detection of IgM and IgG antibodies to *Bartonella henselae* or *Bartonella quintana* with IgG titer $\geq 1:800$.
- f. *Coxiella burnetii*, *Bartonella* species, or *Tropheryma whippelii* identified in blood by PCR or other non-culture-based testing method.

ENDO 5

At least **three** of the following (**Note: Meaning one element from i, ii, iii, iv, or v and only one condition within each element can be used.**)

- i. prior endocarditis, prosthetic valve, previous valve repair, endovascular cardiac implantable electronic devices (CIED), uncorrected congenital heart disease⁸, more than mild valvular regurgitation or valvular stenosis of any etiology, hypertrophic obstructive cardiomyopathy, or known IV drug use⁹.
- ii. fever ($>38.0^{\circ}\text{C}$)
- iii. new valvular regurgitation on auscultation (when an echocardiogram is not available).
- iv. vascular phenomena: major arterial emboli (specifically, embolic stroke, renal infarct, splenic abscess, cerebral abscess, digital ischemic/gangrene from embolic source), septic pulmonary infarcts, mycotic aneurysm (documented by imaging, seen in surgery, or described in gross pathological specimen), intracranial hemorrhage, conjunctival hemorrhages, or Janeway's lesions documented.
- v. immunologic phenomena: immune complex-mediated glomerulonephritis¹⁰ (documented in medical record), Osler's nodes, Roth's spots, or positive rheumatoid factor.

AND

At least **one** of the following:

- a. typical infectious endocarditis organism(s): *Staphylococcus aureus*, *Staphylococcus lugdunensis*, *Enterococcus faecalis*, all Streptococcal species (except for *Streptococcus pneumoniae* and *Streptococcus pyogenes*), *Granulicatella* spp., *Abiotrophia* spp., *Gemella* spp., HACEK microorganisms group (*Haemophilus* species, *Aggregatibacter actinomycetemcomitans*, *Cardiobacterium hominis*, *Eikenella corrodens*, and *Kingella kingae*) identified from ≥ 2 matching blood collections drawn on separate occasions with no more than 1 calendar day between specimens by a culture or non-culture based microbiologic testing method which is performed

for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST). b. typical infectious endocarditis organism(s) in the presence of prosthetic material: <i>coagulase negative staphylococci</i>, <i>Corynebacterium striatum</i>; <i>C. jeikeium</i>, <i>Serratia marcescens</i>, <i>Pseudomonas aeruginosa</i>, <i>Cutibacterium acnes</i>, <i>non-tuberculous mycobacteria</i>, and <i>Candida spp.</i> identified from ≥ 2 matching blood collections drawn on separate occasions with no more than 1 calendar day between specimens by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST). c. non-typical infectious endocarditis organism(s) identified from ≥ 3 matching blood collections drawn on separate occasions with no more than 1 calendar day between specimen collections by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST). d. <i>Coxiella burnetii</i> identified by anti-phase I IgG antibody titer $>1:800$ or identified from blood by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST). e. indirect immunofluorescence assays (IFA) for detection of IgM and IgG antibodies to <i>Bartonella henselae</i> or <i>Bartonella quintana</i> with IgG titer $>1:800$. f. <i>Coxiella burnetii</i>, <i>Bartonella</i> species, or <i>Tropheryma whippelii</i> identified in blood by PCR or other non-culture-based testing method.
--

ENDO 6

At least <u>one</u> of the following echocardiographic or cardiac CT imaging test evidence of endocarditis⁵: i. vegetation on cardiac valve or supporting structures² ii. perivalvular or peri graft abscess iii. new partial dehiscence of prosthetic valve iv. valvular/leaflet perforation v. valvular/leaflet aneurysm vi. pseudoaneurysm vii. intracardiac fistula viii. significant new valvular regurgitation as compared with previous imaging (on echocardiography only)⁶	OR	At least <u>one</u> of the following 18 F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) imaging test evidence of endocarditis⁵: ix. abnormal metabolic activity involving a native or prosthetic valve⁷, ascending aortic graft (with accompanying evidence of valve involvement), intracardiac device leads or other intracardiac prosthetic material >3 months after cardiac surgery. x. abnormal metabolic activity ≤ 3 months implantation of prosthetic valve⁷, ascending aortic graft (with evidence of valve involvement), intracardiac device leads or other intracardiac prosthetic material.
---	-----------	--

AND

At least <u>one</u> condition from three of the following elements (Note: Meaning one element from a, b, c, d, or e and only one condition within each element can be used.): a. prior endocarditis, prosthetic valve, previous valve repair, endovascular cardiac implantable electronic devices (CIED), uncorrected congenital heart disease⁸, more than mild valvular regurgitation or valvular stenosis of any etiology, hypertrophic obstructive cardiomyopathy, or known IV drug use⁹ b. fever ($>38.0^{\circ}\text{C}$)
--

- c. vascular phenomena: major arterial emboli (specifically, embolic stroke, renal infarct, splenic abscess, cerebral abscess, digital ischemic/gangrene from embolic source), septic pulmonary infarcts, mycotic aneurysm (documented by imaging, seen in surgery, or described in gross pathological specimen), intracranial hemorrhage, conjunctival hemorrhages, or Janeway's lesions documented.
- d. immunologic phenomena: immune complex-mediated glomerulonephritis¹⁰ (documented in medical record), Osler's nodes, Roth's spots, or positive rheumatoid factor.
- e. identification of organism(s) from the blood by at least **one** of the following methods:
 - recognized pathogen(s) identified from blood by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
 - same common commensal organism(s) identified from ≥ 2 blood collections drawn on separate occasions on the same or consecutive days by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).

ENDO 7

One condition from each of the following elements (a, b, c, d, e, and f):

- a. prior endocarditis, prosthetic valve, previous valve repair, endovascular cardiac implantable electronic devices (CIED), uncorrected congenital heart disease⁸, more than mild valvular regurgitation or valvular stenosis of any etiology, hypertrophic obstructive cardiomyopathy, or known IV drug use⁹.
- b. fever ($>38.0^{\circ}\text{C}$)
- c. new valvular regurgitation on auscultation (when an echocardiogram is not available).
- d. vascular phenomena: major arterial emboli (specifically, embolic stroke, renal infarct, splenic abscess, cerebral abscess, digital ischemic/gangrene from embolic source), septic pulmonary infarcts, mycotic aneurysm (documented by imaging, seen in surgery, or described in gross pathological specimen), intracranial hemorrhage, conjunctival hemorrhages, or Janeway's lesions documented.
- e. immunologic phenomena: immune complex-mediated glomerulonephritis¹⁰ (documented in medical record), Osler's nodes, Roth's spots, or positive rheumatoid factor.
- f. identification of organism(s) from the blood by at least **one** of the following methods:
 - recognized pathogen(s) identified from blood by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).
 - same common commensal organism(s) identified from ≥ 2 blood collections drawn on separate occasions on the same or consecutive days by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment, for example, not Active Surveillance Culture/Testing (ASC/AST).

ENDO Footnotes

1. The following are also eligible to ENDO 1:
 - Positive culture from a pacemaker/defibrillator lead or ventricular assist device (VAD) components within the heart.
2. Cardiac vegetation can be found on a cardiac valve, endovascular CIED (including pacemaker/defibrillator leads), explanted prosthetic valve or sewing ring, or ventricular assist device (VAD) components within the heart.
3. “with evidence of valve involvement” is defined as **one** of the following:
 - Echocardiography and/or cardiac CT showing aortic valve vegetation, valvular/leaflet perforation, valvular/leaflet aneurysm.
 - Significant new aortic valve regurgitation on echocardiography as compared with previous imaging.
 - New partial dehiscence of prosthetic aortic valve as compared with previous imaging.
 - Positron emission computed tomography with 18F-FDG: abnormal metabolic activity involving prosthetic aortic valve (implanted >3 months ago) or involving native aortic valve.
 - Aortic valve vegetation, valvular/leaflet perforation, valvular/leaflet aneurysm, or partial dehiscence of prosthetic aortic valve documented by direct inspection during heart surgery.
4. Endocarditis is defined as:
 - Active endocarditis—vegetations, leaflet destruction, or adjacent tissue of native or prosthetic valves showing variable degrees of inflammatory cell infiltrates and healing.
 - Acute endocarditis—vegetations or cardiac/aortic tissue lesions of native or prosthetic valves showing active inflammation without significant healing or organizational change.
 - Subacute/chronic endocarditis—vegetations or cardiac/aortic tissue lesions of native or prosthetic valves demonstrating evidence of healing or attempted healing: maturing granulation tissue and fibrosis showing variable mononuclear cell infiltration and/or calcification.
5. Which if equivocal is supported by clinical correlation (specifically, physician or physician designee documentation of antimicrobial treatment for endocarditis).
6. “Significant new valvular regurgitation” is defined as moderate or severe valvular regurgitation. This imaging finding is valve-specific and cannot be pre-existing. Worsening of this condition is **not** eligible for use (ex. mild to moderate tricuspid regurgitation).
7. For prosthetic valve endocarditis (PVE): intense, focal/multifocal, or heterogeneous FDG uptake patterns; for native valve endocarditis and cardiac device leads, any abnormal uptake pattern.
8. Includes cyanotic CHD (tetralogy of Fallot, univentricular heart, complete transposition, truncus arteriosus, hypoplastic left heart); endocardial cushion defects; ventricular septal defect; left-sided lesions (bicuspid aortic valve; aortic stenosis and insufficiency, mitral valve prolapse, mitral stenosis and insufficiency); right-sided lesions (Ebstein anomaly, anomalies of the pulmonary valve, congenital tricuspid valve disease); patent ductus arteriosus; and other congenital anomalies, with or without repair.
9. Elements of 5i, 6a and 7a documented during the current admission:
 - May be documented outside of the ENDO infection window period or SSI surveillance period.

- Should not be used to set the ENDO date of event.

10. Immune complex-mediated glomerulonephritis is defined as **one** of the following:

- a. Unexplained presence of either acute kidney injury (new reduction of estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m²)

OR

- b. Unexplained acute on chronic kidney injury (for example: from “moderately decreased” to “severely decreased”; or from “severely decreased” to “kidney failure.” (Interpretive ranges for eGFR: normal ≥ 60 mL/min/1.73 m²; moderately decreased 30–59 mL/min/1.73 m²; severely decreased 15–29 mL/min/1.73 m²; kidney failure)

AND

Two of the following: hematuria, proteinuria, cellular casts on inspection of urinary sediment, hypocomplementemia, cryoglobulinemia, and/or presence of circulating immune complexes.

- c. Renal biopsy consistent with immune complex-mediated renal disease.

Reference

1. Fowler VG, Durack DT, Selton-Suty C, et al. The 2023 Duke-International Society for Cardiovascular Infectious Diseases criteria for infective endocarditis: Updating the modified Duke Criteria. *Clin Infect Dis.* 2023;77(4):518-526. doi:10.1093/cid/ciad271